{"iqvdataToc": "\"{\\\"index\\\": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226, 227, 228, 229, 230, 231, 232, 233, 234, 235, 236, 237, 238, 239, 240, 241, 242, 243, 244, 245, 246, 247, 248, 249, 250, 251, 252, 253, 254, 255, 256, 257, 258, 259, 260, 261, 262, 263, 264, 265, 266, 267, 268, 269, 270, 271, 272, 273, 274, 275, 276, 277, 278, 279, 280, 281, 282, 283, 284, 285, 286, 287, 288, 289, 290, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, 304, 305, 306, 307, 308, 309, 310, 311, 312, 313, 314, 315, 316, 317, 318, 319, 320, 321, 322, 323, 324, 325, 326, 327, 328, 329, 330, 331, 332, 333, 334, 335, 336, 337, 338, 339, 340, 341, 342, 343, 344, 345, 346, 347, 348, 349, 350, 351, 352, 353, 354, 355, 356, 357, 358, 359, 360, 361, 362, 363, 364, 365, 366, 367, 368, 369, 370, 371, 372, 373, 374, 375, 376, 377, 378, 379, 380, 381, 382, 383, 384, 385, 386, 387, 388, 389, 390, 391, 392, 393, 394, 395, 396, 397, 398, 399, 400, 401, 402, 403, 404, 405, 406, 407, 408, 409, 410, 411, 412, 413, 414, 415, 416, 417, 418, 419, 420, 421, 422, 423, 424, 425, 426, 427, 428, 429, 430, 431, 432, 433, 434, 435, 436, 437, 438, 439, 440, 441, 442, 443, 444, 445, 446, 447, 448, 449, 450, 451, 452, 453, 454, 455, 456, 457, 458, 459, 460, 461, 462, 463, 464, 465, 466, 467, 468, 469, 470, 471, 472, 473, 474, 475, 476, 477, 478, 479, 480, 481, 482, 483, 484, 485, 486, 487, 488, 489, 490, 491, 492, 493, 494, 495, 496, 497, 498, 499, 500, 501, 502, 503, 504, 505, 506, 507, 508, 509, 510, 511, 512, 513, 514, 515, 516, 517, 518, 519, 520, 521, 522, 523, 524, 525, 526, 527, 528, 529, 530, 531, 532, 533, 534, 535, 536, 537, 538, 539, 540, 541, 542, 543, 544, 545, 546, 547, 548, 549, 550, 551, 552, 553, 554, 555, 556, 557, 558, 559, 560, 561, 562, 563, 564, 565, 566, 567, 568, 569, 570, 571, 572, 573, 574, 575, 576, 577, 578, 579, 580, 581, 582, 583, 584, 585, 586, 587, 588, 589, 590, 591, 592, 593, 594, 595, 596, 597, 598, 599, 600, 601, 602, 603, 604, 605, 606, 607, 608, 609, 610, 611, 612, 613, 614, 615, 616, 617, 618, 619, 620, 621, 622, 623, 624, 625, 626, 627, 628, 629, 630, 631, 632, 633, 634, 635, 636, 637, 638, 639, 640, 641, 642, 643, 644, 645, 646, 647, 648, 649, 650, 651, 652, 653, 654, 655, 656, 657, 658, 659, 660, 661, 662, 663, 664, 665, 666, 667, 668, 669, 670, 671, 672, 673, 674, 675, 676, 677, 678, 679, 680, 681, 682, 683, 684, 685, 686, 687, 688, 689, 690, 691, 692, 693, 694, 695, 696, 697, 698, 699, 700, 701, 702, 703, 704, 705, 706, 707, 708, 709, 710, 711, 712, 713, 714, 715, 716, 717, 718, 719, 720, 721, 722, 723, 724, 725, 726, 727, 728, 729, 730, 731, 732, 733, 734, 735, 736, 737, 738, 739, 740, 741, 742, 743, 744, 745, 746, 747, 748, 749, 750, 751, 752, 753, 754, 755, 756, 757, 758, 759, 760, 761, 762, 763, 764, 765, 766, 767, 768, 769, 770, 771, 772, 773, 774, 775, 776, 777, 778, 779, 780, 781, 782, 783, 784, 785, 786, 787, 788, 789, 790, 791, 792, 793, 794, 795, 796, 797, 798, 799, 800, 801, 802, 803, 804, 805, 806, 807, 808, 809, 810, 811, 812, 813, 814, 815, 816, 817, 818, 819, 820, 821, 822, 823, 824, 825, 826, 827, 828, 829, 830, 831, 832, 833, 834, 835, 836, 837, 838, 839, 840, 841, 842, 843, 844, 845, 846, 847, 848, 849, 850, 851, 852, 853, 854, 855, 856, 857, 858, 859, 860, 861, 862, 863, 864, 865, 866, 867, 868, 869, 870, 871, 872, 873, 874, 875, 876, 877, 878, 879, 880, 881, 882, 883, 884, 885, 886, 887, 888, 889, 890, 891, 892, 893, 894, 895, 896, 897, 898, 899, 900, 901, 902, 903, 904, 905, 906, 907, 908, 909, 910, 911, 912, 913, 914, 915, 916, 917, 918, 919, 920, 921, 922, 923, 924, 925, 926, 927, 928, 929, 930, 931, 932, 933, 934, 935, 936, 937, 938, 939, 940, 941, 942, 943, 944, 945, 946, 947, 948, 949, 950, 951, 952, 953, 954, 955, 956, 957, 958, 959, 960, 961, 962, 963, 964, 965, 966, 967, 968, 969, 970, 971, 972, 973, 974, 975, 976, 977, 978, 979, 980, 981, 982, 983, 984, 985, 986, 987, 988, 989, 990, 991, 992, 993, 994, 995, 996, 997, 998, 999, 1000, 1001, 1002, 1003, 1004, 1005, 1006, 1007, 1008, 1009, 1010, 1011, 1012, 1013, 1014, 1015, 1016, 1017, 1018, 1019, 1020, 1021, 1022, 1023, 1024, 1025, 1026, 1027, 1028, 1029, 1030, 1031, 1032, 1033, 1034, 1035, 1036, 1037, 1038, 1039, 1040, 1041, 1042, 1043, 1044, 1045, 1046, 1047, 1048, 1049, 1050, 1051, 1052, 1053, 1054, 1055, 1056, 1057, 1058, 1059, 1060, 1061, 1062, 1063, 1064, 1065, 1066, 1067, 1068, 1069, 1070, 1071, 1072, 1073, 1074, 1075, 1076, 1077, 1078, 1079, 1080, 1081, 1082, 1083, 1084, 1085, 1086, 1087, 1088, 1089, 1090, 1091, 1092, 1093, 1094, 1095, 1096, 1097, 1098, 1099, 1100, 1101, 1102, 1103, 1104, 1105, 1106, 1107, 1108, 1109, 1110, 1111, 1112, 1113, 1114, 1115, 1116, 1117, 1118, 1119, 1120, 1121, 1122, 1123, 1124, 1125, 1126, 1127, 1128, 1129, 1130, 1131, 1132, 1133, 1134, 1135, 1136, 1137, 1138, 1139, 1140, 1141, 1142, 1143, 1144, 1145, 1146, 1147, 1148, 1149, 1150, 1151, 1152, 1153, 1154, 1155, 1156, 1157, 1158, 1159, 1160, 1161, 1162, 1163, 1164, 1165, 1166, 1167, 1168, 1169, 1170, 1171, 1172, 1173, 1174, 1175, 1176, 1177, 1178, 1179, 1180, 1181, 1182, 1183, 1184, 1185, 1186, 1187, 1188, 1189, 1190, 1191, 1192, 1193, 1194, 1195, 1196, 1197, 1198, 1199, 1200, 1201, 1202, 1203, 1204, 1205, 1206, 1207, 1208, 1209, 1210, 1211, 1212, 1213, 1214, 1215, 1216, 1217, 1218, 1219, 1220, 1221, 1222, 1223, 1224, 1225, 1226, 1227, 1228, 1229, 1230, 1231, 1232, 1233, 1234, 1235, 1236, 1237, 1238, 1239, 1240, 1241, 1242, 1243, 1244, 1245, 1246, 1247, 1248, 1249, 1250, 1251, 1252, 1253, 1254, 1255, 1256, 1257, 1258, 1259, 1260, 1261, 1262, 1263, 1264, 1265, 1266, 1267, 1268, 1269, 1270, 1271, 1272, 1273, 1274, 1275, 1276, 1277, 1278, 1279, 1280, 1281, 1282, 1283, 1284, 1285, 1286, 1287, 1288, 1289, 1290, 1291, 1292, 1293, 1294, 1295, 1296, 1297, 1298, 1299, 1300, 1301, 1302, 1303, 1304, 1305, 1306, 1307, 1308, 1309, 1310, 1311, 1312, 1313, 1314, 1315, 1316, 1317, 1318, 1319, 1320, 1321, 1322, 1323, 1324, 1325, 1326, 1327, 1328, 1329, 1330, 1331, 1332, 1333, 1334, 1335, 1336, 1337, 1338, 1339, 1340, 1341, 1342, 1343, 1344, 1345, 1346, 1347, 1348, 1349, 1350, 1351, 1352, 1353, 1354, 1355, 1356, 1357, 1358, 1359, 1360, 1361, 1362, 1363, 1364, 1365, 1366, 1367, 1368, 1369, 1370, 1371, 1372, 1373, 1374, 1375, 1376, 1377, 1378, 1379, 1380, 1381, 1382, 1383, 1384, 1385, 1386, 1387, 1388, 1389, 1390, 1391, 1392, 1393, 1394, 1395, 1396, 1397, 1398, 1399, 1400, 1401, 1402, 1403, 1404, 1405, 1406, 1407, 1408, 1409, 1410, 1411, 1412, 1413, 1414, 1415, 1416, 1417, 1418, 1419, 1420, 1421, 1422, 1423, 1424, 1425, 1426, 1427, 1428, 1429, 1430, 1431, 1432, 1433, 1434, 1435, 1436, 1437, 1438, 1439, 1440, 1441, 1442, 1443, 1444, 1445, 1446, 1447, 1448, 1449, 1450, 1451, 1452, 1453, 1454, 1455, 1456, 1457, 1458, 1459, 1460, 1461, 1462, 1463, 1464, 1465, 1466, 1467, 1468, 1469, 1470, 1471, 1472, 1473, 1474, 1475, 1476, 1477, 1478, 1479, 1480, 1481, 1482, 1483, 1484, 1485, 1486, 1487, 1488, 1489, 1490, 1491, 1492, 1493, 1494, 1495, 1496, 1497, 1498, 1499, 1500, 1501, 1502, 1503, 1504, 1505, 1506, 1507, 1508, 1509, 1510, 1511, 1512, 1513, 1514, 1515, 1516, 1517, 1518, 1519, 1520, 1521, 1522, 1523, 1524, 1525, 1526, 1527, 1528, 1529, 1530, 1531, 1532, 1533, 1534, 1535, 1536, 1537, 1538, 1539, 1540, 1541, 1542, 1543, 1544, 1545, 1546, 1547, 1548, 1549, 1550, 1551, 1552, 1553, 1554, 1555, 1556, 1557, 1558, 1559, 1560, 1561, 1562, 1563, 1564, 1565, 1566, 1567, 1568, 1569, 1570, 1571, 1572, 1573, 1574, 1575, 1576, 1577, 1578, 1579, 1580, 1581, 1582, 1583, 1584, 1585, 1586, 1587, 1588, 1589, 1590, 1591, 1592, 1593, 1594, 1595, 1596, 1597, 1598, 1599, 1600, 1601, 1602, 1603, 1604, 1605, 1606, 1607, 1608, 1609, 1610, 1611, 1612, 1613, 1614, 1615, 1616, 1617, 1618, 1619, 1620, 1621, 1622, 1623, 1624, 1625, 1626, 1627, 1628, 1629, 1630, 1631, 1632, 1633, 1634, 1635, 1636, 1637, 1638, 1639, 1640, 1641, 1642, 1643, 1644, 1645, 1646, 1647, 1648, 1649, 1650, 1651, 1652, 1653, 1654, 1655, 1656, 1657, 1658, 1659, 1660, 1661, 1662, 1663, 1664, 1665, 1666, 1667, 1668, 1669, 1670, 1671, 1672, 1673, 1674, 1675, 1676, 1677, 1678, 1679, 1680, 1681, 1682, 1683, 1684, 1685, 1686, 1687, 1688, 1689, 1690, 1691, 1692, 1693, 1694, 1695, 1696, 1697, 1698, 1699, 1700, 1701, 1702, 1703, 1704, 1705, 1706, 1707, 1708, 1709, 1710, 1711, 1712, 1713, 1714, 1715, 1716, 1717, 1718, 1719, 1720, 1721, 1722, 1723, 1724, 1725, 1726, 1727, 1728, 1729, 1730, 1731, 1732, 1733, 1734, 1735, 1736, 1737, 1738, 1739, 1740, 1741, 1742, 1743, 1744, 1745, 1746, 1747, 1748, 1749, 1750, 1751, 1752, 1753, 1754, 1755, 1756, 1757, 1758, 1759, 1760, 1761, 1762, 1763, 1764, 1765, 1766, 1767, 1768, 1769, 1770, 1771, 1772, 1773, 1774, 1775, 1776, 1777, 1778, 1779, 1780, 1781, 1782, 1783, 1784, 1785, 1786, 1787, 1788, 1789, 1790, 1791, 1792, 1793, 1794, 1795, 1796, 1797, 1798, 1799, 1800, 1801, 1802, 1803, 1804, 1805, 1806, 1807, 1808, 1809, 1810, 1811, 1812, 1813, 1814, 1815, 1816, 1817, 1818, 1819, 1820, 1821, 1822, 1823, 1824, 1825, 1826, 1827, 1828, 1829, 1830, 1831, 1832, 1833, 1834, 1835, 1836, 1837, 1838, 1839, 1840, 1841, 1842, 1843, 1844, 1845, 1846, 1847, 1848, 1849, 1850, 1851, 1852, 1853, 1854, 1855, 1856, 1857, 1858, 1859, 1860, 1861, 1862, 1863, 1864, 1865, 1866, 1867, 1868, 1869, 1870, 1871, 1872, 1873, 1874, 1875, 1876, 1877, 1878, 1879, 1880, 1881, 1882, 1883, 1884, 1885, 1886, 1887, 1888, 1889, 1890, 1891, 1892, 1893, 1894, 1895, 1896, 1897, 1898, 1899, 1900, 1901, 1902, 1903, 1904, 1905, 1906, 1907, 1908, 1909, 1910, 1911, 1912, 1913, 1914, 1915, 1916, 1917, 1918, 1919, 1920, 1921, 1922, 1923, 1924, 1925, 1926, 1927, 1928, 1929, 1930, 1931, 1932, 1933, 1934, 1935, 1936, 1937, 1938, 1939, 1940, 1941, 1942, 1943, 1944, 1945, 1946, 1947, 1948, 1949, 1950, 1951, 1952, 1953, 1954, 1955, 1956, 1957, 1958, 1959, 1960, 1961, 1962, 1963, 1964, 1965, 1966, 1967, 1968, 1969, 1970, 1971, 1972, 1973, 1974, 1975, 1976, 1977, 1978, 1979, 1980, 1981, 1982, 1983, 1984, 1985, 1986, 1987, 1988, 1989, 1990, 1991, 1992, 1993, 1994, 1995, 1996, 1997, 1998, 1999, 2000, 2001, 2002, 2003, 2004, 2005, 2006, 2007, 2008, 2009, 2010, 2011, 2012, 2013, 2014, 2015, 2016, 2017, 2018, 2019, 2020, 2021, 2022, 2023, 2024, 2025, 2026, 2027, 2028, 2029, 2030, 2031, 2032, 2033, 2034, 2035, 2036, 2037, 2038, 2039, 2040, 2041, 2042, 2043, 2044, 2045, 2046, 2047, 2048, 2049, 2050, 2051, 2052, 2053, 2054, 2055, 2056, 2057, 2058, 2059, 2060, 2061, 2062, 2063, 2064, 2065, 2066, 2067, 2068, 2069, 2070, 2071, 2072, 2073, 2074, 2075, 2076, 2077, 2078, 2079, 2080, 2081, 2082, 2083, 2084, 2085, 2086, 2087, 2088, 2089, 2090, 2091, 2092, 2093, 2094, 2095, 2096, 2097, 2098, 2099, 2100, 2101, 2102, 2103, 2104, 2105, 2106, 2107, 2108, 2109, 2110, 2111, 2112, 2113, 2114, 2115, 2116, 2117, 2118, 2119, 2120, 2121, 2122, 2123, 2124, 2125, 2126, 2127, 2128, 2129, 2130, 2131, 2132, 2133, 2134, 2135, 2136, 2137, 2138, 2139, 2140, 2141, 2142, 2143, 2144, 2145, 2146, 2147, 2148, 2149, 2150, 2151, 2152, 2153, 2154, 2155, 2156, 2157, 2158, 2159, 2160, 2161, 2162, 2163, 2164, 2165, 2166, 2167, 2168, 2169, 2170, 2171, 2172, 2173, 2174, 2175, 2176, 2177, 2178, 2179, 2180, 2181, 2182, 2183, 2184, 2185, 2186, 2187, 2188, 2189, 2190, 2191, 2192, 2193, 2194, 2195, 2196, 2197, 2198, 2199, 2200, 2201, 2202, 2203, 2204, 2205, 2206, 2207, 2208, 2209, 2210, 2211, 2212, 2213, 2214, 2215, 2216, 2217, 2218, 2219, 2220, 2221, 2222, 2223, 2224, 2225, 2226, 2227, 2228, 2229, 2230, 2231, 2232, 2233, 2234, 2235, 2236, 2237, 2238, 2239, 2240, 2241, 2242, 2243, 2244, 2245, 2246, 2247, 2248, 2249, 2250, 2251, 2252, 2253, 2254, 2255, 2256, 2257, 2258, 2259, 2260, 2261, 2262, 2263, 2264, 2265, 2266, 2267, 2268, 2269, 2270, 2271, 2272, 2273, 2274, 2275, 2276, 2277, 2278, 2279, 2280, 2281, 2282, 2283, 2284, 2285, 2286, 2287, 2288, 2289, 2290, 2291, 2292, 2293, 2294, 2295, 2296, 2297, 2298, 2299, 2300, 2301, 2302, 2303, 2304, 2305, 2306, 2307, 2308, 2309, 2310, 2311, 2312, 2313, 2314, 2315, 2316, 2317, 2318, 2319, 2320, 2321, 2322, 2323, 2324, 2325, 2326, 2327, 2328, 2329, 2330, 2331, 2332, 2333, 2334, 2335, 2336, 2337, 2338, 2339, 2340, 2341, 2342, 2343, 2344, 2345, 2346, 2347, 2348, 2349, 2350, 2351, 2352, 2353, 2354, 2355, 2356, 2357, 2358, 2359, 2360, 2361, 2362, 2363, 2364, 2365, 2366, 2367, 2368, 2369, 2370, 2371, 2372, 2373, 2374, 2375, 2376, 2377, 2378, 2379, 2380, 2381, 2382, 2383, 2384, 2385, 2386, 2387, 2388, 2389, 2390, 2391, 2392, 2393, 2394, 2395, 2396, 2397, 2398, 2399, 2400, 2401, 2402, 2403, 2404, 2405, 2406, 2407, 2408, 2409, 2410, 2411, 2412, 2413, 2414, 2415, 2416, 2417, 2418, 2419, 2420, 2421, 2422, 2423, 2424, 2425, 2426, 2427, 2428, 2429, 2430, 2431, 2432, 2433, 2434, 2435, 2436, 2437, 2438, 2439, 2440, 2441, 2442, 2443, 2444, 2445, 2446, 2447, 2448, 2449, 2450, 2451, 2452, 2453, 2454, 2455, 2456, 2457, 2458, 2459, 2460, 2461, 2462, 2463, 2464, 2465, 2466, 2467, 2468, 2469, 2470, 2471, 2472, 2473, 2474, 2475, 2476, 2477, 2478, 2479, 2480, 2481, 2482, 2483, 2484, 2485, 2486, 2487, 2488, 2489, 2490, 2491, 2492, 2493, 2494, 2495, 2496, 2497, 2498, 2499, 2500, 2501, 2502, 2503, 2504, 2505, 2506, 2507, 2508, 2509, 2510, 2511, 2512, 2513, 2514, 2515, 2516, 2517, 2518, 2519, 2520, 2521, 2522, 2523, 2524, 2525, 2526, 2527, 2528, 2529, 2530, 2531, 2532, 2533, 2534, 2535, 2536, 2537, 2538, 2539, 2540, 2541, 2542, 2543, 2544, 2545, 2546, 2547, 2548, 2549, 2550, 2551, 2552, 2553, 2554, 2555, 2556, 2557, 2558, 2559, 2560, 2561, 2562, 2563, 2564, 2565, 2566, 2567, 2568, 2569, 2570, 2571, 2572, 2573, 2574, 2575, 2576, 2577, 2578, 2579, 2580, 2581, 2582, 2583, 2584, 2585, 2586, 2587, 2588, 2589, 2590, 2591, 2592, 2593, 2594, 2595, 2596, 2597, 2598, 2599, 2600, 2601, 2602, 2603, 2604, 2605, 2606, 2607, 2608, 2609, 2610, 2611, 2612, 2613, 2614, 2615, 2616, 2617, 2618, 2619, 2620, 2621, 2622, 2623, 2624, 2625, 2626, 2627, 2628, 2629, 2630, 2631, 2632, 2633, 2634, 2635, 2636, 2637, 2638, 2639, 2640, 2641, 2642, 2643, 2644, 2645, 2646, 2647, 2648, 2649, 2650, 2651, 2652, 2653, 2654, 2655, 2656, 2657, 2658, 2659, 2660, 2661, 2662, 2663, 2664, 2665, 2666, 2667, 2668, 2669, 2670, 2671, 2672, 2673, 2674, 2675, 2676, 2677, 2678, 2679, 2680, 2681, 2682, 2683, 2684, 2685, 2686, 2687, 2688, 2689, 2690, 2691, 2692, 2693, 2694, 2695, 2696, 2697, 2698, 2699, 2700, 2701, 2702, 2703, 2704, 2705, 2706, 2707, 2708, 2709, 2710, 2711, 2712, 2713, 2714, 2715, 2716, 2717, 2718, 2719, 2720, 2721, 2722, 2723, 2724, 2725, 2726, 2727, 2728, 2729, 2730, 2731, 2732, 2733, 2734, 2735, 2736, 2737, 2738, 2739, 2740, 2741, 2742, 2743, 2744, 2745, 2746, 2747, 2748, 2749, 2750, 2751, 2752, 2753, 2754, 2755, 2756, 2757, 2758, 2759, 2760, 2761, 2762, 2763, 2764, 2765, 2766, 2767, 2768, 2769, 2770, 2771, 2772, 2773, 2774, 2775, 2776, 2777, 2778, 2779, 2780, 2781, 2782, 2783, 2784, 2785, 2786, 2787, 2788, 2789, 2790, 2791, 2792, 2793, 2794, 2795, 2796, 2797, 2798, 2799, 2800, 2801, 2802, 2803, 2804, 2805, 2806, 2807, 2808, 2809, 2810, 2811, 2812, 2813, 2814, 2815, 2816, 2817, 2818, 2819, 2820, 2821, 2822, 2823, 2824, 2825, 2826, 2827, 2828, 2829, 2830, 2831, 2832, 2833, 2834, 2835, 2836, 2837, 2838, 2839, 2840, 2841, 2842, 2843, 2844, 2845, 2846, 2847, 2848, 2849, 2850, 2851, 2852, 2853, 2854, 2855, 2856, 2857, 2858, 2859, 2860, 2861, 2862, 2863, 2864, 2865, 2866, 2867, 2868, 2869, 2870, 2871, 2872, 2873, 2874, 2875, 2876, 2877, 2878, 2879, 2880, 2881, 2882, 2883, 2884, 2885, 2886, 2887, 2888, 2889, 2890, 2891, 2892, 2893, 2894, 2895, 2896, 2897, 2898, 2899, 2900, 2901, 2902, 2903, 2904, 2905, 2906, 2907, 2908, 2909, 2910, 2911, 2912, 2913, 2914, 2915, 2916, 2917, 2918, 2919, 2920, 2921, 2922, 2923, 2924, 2925, 2926, 2927, 2928, 2929, 2930, 2931, 2932, 2933, 2934, 2935, 2936, 2937, 2938, 2939, 2940, 2941, 2942, 2943, 2944, 2945, 2946, 2947, 2948, 2949, 2950, 2951, 2952, 2953, 2954, 2955, 2956, 2957, 2958, 2959, 2960, 2961, 2962, 2963, 2964, 2965, 2966, 2967, 2968, 2969, 2970, 2971, 2972, 2973, 2974, 2975, 2976, 2977, 2978, 2979, 2980, 2981, 2982, 2983, 2984, 2985, 2986, 2987, 2988, 2989, 2990, 2991, 2992, 2993, 2994, 2995, 2996, 2997, 2998, 2999, 3000, 3001, 3002, 3003, 3004, 3005, 3006, 3007, 3008, 3009, 3010, 3011, 3012, 3013, 3014, 3015, 3016, 3017, 3018, 3019, 3020, 3021, 3022, 3023, 3024, 3025, 3026, 3027, 3028, 3029, 3030, 3031, 3032, 3033, 3034, 3035, 3036, 3037, 3038, 3039, 3040, 3041, 3042, 3043, 3044, 3045, 3046, 3047, 3048, 3049, 3050, 3051, 3052, 3053, 3054, 3055, 3056, 3057, 3058, 3059, 3060, 3061, 3062, 3063, 3064, 3065, 3066, 3067, 3068, 3069, 3070, 3071, 3072, 3073, 3074, 3075, 3076, 3077, 3078, 3079, 3080, 3081, 3082, 3083, 3084, 3085, 3086, 3087, 3088, 3089, 3090, 3091, 3092, 3093, 3094, 3095, 3096, 3097, 3098, 3099, 3100, 3101, 3102, 3103, 3104, 3105, 3106, 3107, 3108, 3109, 3110, 3111, 3112, 3113, 3114, 3115, 3116, 3117, 3118, 3119, 3120, 3121, 3122, 3123, 3124, 3125, 3126, 3127, 3128, 3129, 3130, 3131, 3132, 3133, 3134, 3135, 3136, 3137, 3138, 3139, 3140, 3141, 3142, 3143, 3144, 3145, 3146, 3147, 3148, 3149, 3150, 3151, 3152, 3153, 3154, 3155, 3156, 3157, 3158, 3159, 3160, 3161, 3162, 3163, 3164, 3165, 3166, 3167, 3168, 3169, 3170, 3171, 3172, 3173, 3174, 3175, 3176, 3177, 3178, 3179, 3180, 3181, 3182, 3183, 3184, 3185, 3186, 3187, 3188, 3189, 3190, 3191, 3192, 3193, 3194, 3195, 3196, 3197, 3198, 3199, 3200, 3201, 3202, 3203, 3204, 3205, 3206, 3207, 3208, 3209, 3210, 3211, 3212, 3213, 3214, 3215, 3216, 3217, 3218, 3219, 3220, 3221, 3222, 3223, 3224, 3225, 3226, 3227, 3228, 3229, 3230, 3231, 3232, 3233, 3234, 3235, 3236, 3237, 3238, 3239, 3240, 3241, 3242, 3243, 3244, 3245, 3246, 3247, 3248, 3249, 3250, 3251, 3252, 3253, 3254, 3255, 3256, 3257, 3258, 3259, 3260, 3261, 3262, 3263, 3264, 3265, 3266, 3267, 3268, 3269, 3270, 3271, 3272, 3273, 3274, 3275, 3276, 3277, 3278, 3279, 3280, 3281, 3282, 3283, 3284, 3285, 3286, 3287, 3288, 3289, 3290, 3291, 3292, 3293, 3294, 3295, 3296, 3297, 3298, 3299, 3300, 3301, 3302, 3303, 3304, 3305, 3306, 3307, 3308, 3309, 3310, 3311, 3312, 3313, 3314, 3315, 3316, 3317, 3318, 3319, 3320, 3321, 3322, 3323, 3324, 3325, 3326, 3327, 3328, 3329, 3330, 3331, 3332, 3333, 3334, 3335, 3336, 3337, 3338, 3339, 3340, 3341, 3342, 3343, 3344, 3345, 3346, 3347, 3348, 3349, 3350, 3351, 3352, 3353, 3354, 3355, 3356, 3357, 3358, 3359, 3360, 3361, 3362, 3363, 3364, 3365, 3366, 3367, 3368, 3369, 3370, 3371, 3372, 3373, 3374, 3375, 3376, 3377, 3378, 3379, 3380, 3381, 3382, 3383, 3384, 3385, 3386, 3387, 3388, 3389, 3390, 3391, 3392, 3393, 3394, 3395, 3396, 3397, 3398, 3399, 3400, 3401, 3402, 3403, 3404, 3405, 3406, 3407, 3408, 3409, 3410, 3411, 3412, 3413, 3414, 3415, 3416, 3417, 3418, 3419, 3420, 3421, 3422, 3423, 3424, 3425, 3426, 3427, 3428, 3429, 3430, 3431, 3432, 3433, 3434, 3435, 3436, 3437, 3438, 3439, 3440, 3441, 3442, 3443, 3444, 3445, 3446, 3447, 3448, 3449, 3450, 3451, 3452, 3453, 3454, 3455, 3456, 3457, 3458, 3459, 3460, 3461, 3462, 3463, 3464, 3465, 3466, 3467, 3468, 3469, 3470, 3471, 3472, 3473, 3474, 3475, 3476, 3477, 3478, 3479, 3480, 3481, 3482, 3483, 3484, 3485, 3486, 3487, 3488, 3489, 3490, 3491, 3492, 3493, 3494, 3495, 3496, 3497, 3498, 3499, 3500, 3501, 3502, 3503, 3504, 3505, 3506, 3507, 3508, 3509, 3510, 3511, 3512, 3513, 3514, 3515, 3516, 3517, 3518, 3519, 3520, 3521, 3522, 3523, 3524, 3525, 3526, 3527, 3528, 3529, 3530, 3531, 3532, 3533, 3534, 3535, 3536, 3537, 3538, 3539, 3540, 3541, 3542, 3543, 3544, 3545, 3546, 3547, 3548, 3549, 3550, 3551, 3552, 3553, 3554, 3555, 3556, 3557, 3558, 3559, 3560, 3561, 3562, 3563, 3564, 3565, 3566, 3567, 3568, 3569, 3570, 3571, 3572, 3573, 3574, 3575, 3576, 3577, 3578, 3579, 3580, 3581, 3582, 3583, 3584, 3585, 3586, 3587, 3588, 3589, 3590, 3591, 3592, 3593, 3594, 3595, 3596, 3597, 3598, 3599, 3600, 3601, 3602, 3603, 3604, 3605, 3606, 3607, 3608, 3609, 3610, 3611, 3612, 3613, 3614, 3615, 3616, 3617, 3618, 3619, 3620, 3621, 3622, 3623, 3624, 3625, 3626, 3627, 3628, 3629, 3630, 3631, 3632, 3633, 3634, 3635, 3636, 3637, 3638, 3639, 3640, 3641, 3642, 3643, 3644, 3645, 3646, 3647, 3648, 3649, 3650, 3651, 3652, 3653, 3654, 3655, 3656, 3657, 3658, 3659, 3660, 3661, 3662, 3663, 3664, 3665, 3666, 3667, 3668, 3669, 3670, 3671, 3672, 3673, 3674, 3675, 3676, 3677, 3678, 3679, 3680, 3681, 3682, 3683, 3684, 3685, 3686, 3687, 3688, 3689, 3690, 3691, 3692, 3693, 3694, 3695, 3696, 3697, 3698, 3699, 3700, 3701, 3702, 3703, 3704, 3705, 3706, 3707, 3708, 3709, 3710, 3711, 3712, 3713, 3714, 3715, 3716, 3717, 3718, 3719, 3720, 3721, 3722, 3723, 3724, 3725, 3726, 3727, 3728, 3729, 3730, 3731, 3732, 3733, 3734, 3735, 3736, 3737, 3738, 3739, 3740, 3741, 3742, 3743, 3744, 3745, 3746, 3747, 3748, 3749, 3750, 3751, 3752, 3753, 3754, 3755, 3756, 3757, 3758, 3759, 3760, 3761, 3762, 3763, 3764, 3765, 3766, 3767, 3768, 3769, 3770, 3771, 3772, 3773, 3774, 3775, 3776, 3777, 3778, 3779, 3780, 3781, 3782, 3783, 3784, 3785, 3786, 3787, 3788, 3789, 3790, 3791, 3792, 3793, 3794, 3795, 3796, 3797, 3798, 3799, 3800, 3801, 3802, 3803, 3804, 3805, 3806, 3807, 3808, 3809, 3810, 3811, 3812, 3813, 3814, 3815, 3816, 3817, 3818, 3819, 3820, 3821, 3822, 3823, 3824, 3825, 3826, 3827, 3828, 3829, 3830, 3831, 3832, 3833, 3834, 3835, 3836, 3837, 3838, 3839, 3840, 3841, 3842, 3843, 3844, 3845, 3846, 3847, 3848, 3849, 3850, 3851, 3852, 3853, 3854, 3855, 3856, 3857, 3858, 3859, 3860, 3861, 3862, 3863, 3864, 3865, 3866, 3867, 3868, 3869, 3870, 3871, 3872, 3873, 3874, 3875, 3876, 3877, 3878, 3879, 3880, 3881, 3882, 3883, 3884, 3885, 3886, 3887, 3888, 3889, 3890, 3891, 3892, 3893, 3894, 3895, 3896, 3897, 3898, 3899, 3900, 3901, 3902, 3903, 3904, 3905, 3906, 3907, 3908, 3909, 3910, 3911, 3912, 3913, 3914, 3915, 3916, 3917, 3918, 3919, 3920, 3921, 3922, 3923, 3924, 3925, 3926, 3927, 3928, 3929, 3930, 3931, 3932, 3933, 3934, 3935, 3936, 3937, 3938, 3939, 3940, 3941, 3942, 3943, 3944, 3945, 3946, 3947, 3948, 3949, 3950, 3951, 3952, 3953, 3954, 3955, 3956, 3957, 3958, 3959, 3960, 3961, 3962, 3963, 3964, 3965, 3966, 3967, 3968, 3969, 3970, 3971, 3972, 3973, 3974, 3975, 3976, 3977, 3978, 3979, 3980, 3981, 3982, 3983, 3984, 3985, 3986, 3987, 3988, 3989, 3990, 3991, 3992, 3993, 3994, 3995, 3996, 3997, 3998, 3999, 4000, 4001, 4002, 4003, 4004, 4005, 4006, 4007, 4008, 4009, 4010, 4011, 4012, 4013, 4014, 4015, 4016, 4017, 4018, 4019, 4020, 4021, 4022, 4023, 4024, 4025, 4026, 4027, 4028, 4029, 4030, 4031, 4032, 4033, 4034, 4035, 4036, 4037, 4038, 4039, 4040, 4041, 4042, 4043, 4044, 4045, 4046, 4047, 4048, 4049, 4050, 4051, 4052, 4053, 4054, 4055, 4056, 4057, 4058, 4059, 4060, 4061, 4062, 4063, 4064, 4065, 4066, 4067, 4068, 4069, 4070, 4071, 4072, 4073, 4074, 4075, 4076, 4077, 4078, 4079, 4080, 4081, 4082, 4083, 4084, 4085, 4086, 4087, 4088, 4089, 4090, 4091, 4092, 4093, 4094, 4095, 4096, 4097, 4098, 4099, 4100, 4101, 4102, 4103, 4104, 4105, 4106, 4107, 4108, 4109, 4110, 4111, 4112, 4113, 4114, 4115, 4116, 4117, 4118, 4119, 4120, 4121, 4122, 4123, 4124, 4125, 4126, 4127, 4128, 4129, 4130, 4131, 4132, 4133, 4134, 4135, 4136, 4137, 4138, 4139, 4140, 4141, 4142, 4143, 4144, 4145, 4146, 4147, 4148, 4149, 4150, 4151, 4152, 4153, 4154, 4155, 4156, 4157, 4158, 4159, 4160, 4161, 4162, 4163, 4164, 4165, 4166, 4167, 4168, 4169, 4170, 4171, 4172, 4173, 4174, 4175, 4176, 4177, 4178, 4179, 4180, 4181, 4182, 4183, 4184, 4185, 4186, 4187, 4188, 4189, 4190, 4191, 4192, 4193, 4194, 4195, 4196, 4197, 4198, 4199, 4200, 4201, 4202, 4203, 4204, 4205, 4206, 4207, 4208, 4209, 4210, 4211, 4212, 4213, 4214, 4215, 4216, 4217, 4218, 4219, 4220, 4221, 4222, 4223, 4224, 4225, 4226, 4227, 4228, 4229, 4230, 4231, 4232, 4233, 4234, 4235, 4236, 4237, 4238, 4239, 4240, 4241, 4242, 4243, 4244, 4245, 4246, 4247, 4248, 4249, 4250, 4251, 4252, 4253, 4254, 4255, 4256, 4257, 4258, 4259, 4260, 4261, 4262, 4263, 4264, 4265, 4266, 4267, 4268, 4269, 4270, 4271, 4272, 4273, 4274, 4275, 4276, 4277, 4278, 4279, 4280, 4281, 4282, 4283, 4284, 4285, 4286, 4287, 4288, 4289, 4290, 4291, 4292, 4293, 4294, 4295, 4296, 4297, 4298, 4299, 4300, 4301, 4302, 4303, 4304, 4305, 4306, 4307, 4308, 4309, 4310, 4311, 4312, 4313, 4314, 4315, 4316, 4317, 4318, 4319, 4320, 4321, 4322, 4323, 4324, 4325, 4326, 4327, 4328, 4329, 4330, 4331, 4332, 4333, 4334, 4335, 4336, 4337, 4338, 4339, 4340, 4341, 4342, 4343, 4344, 4345, 4346, 4347, 4348, 4349, 4350, 4351, 4352, 4353, 4354, 4355, 4356, 4357, 4358, 4359, 4360, 4361, 4362, 4363, 4364, 4365, 4366, 4367, 4368, 4369, 4370, 4371, 4372, 4373, 4374, 4375, 4376, 4377, 4378, 4379, 4380, 4381, 4382, 4383, 4384, 4385, 4386, 4387, 4388, 4389, 4390, 4391, 4392, 4393, 4394, 4395, 4396, 4397, 4398, 4399, 4400, 4401, 4402, 4403, 4404, 4405, 4406, 4407, 4408, 4409, 4410, 4411, 4412, 4413, 4414, 4415, 4416, 4417, 4418, 4419, 4420, 4421, 4422, 4423, 4424, 4425, 4426, 4427, 4428, 4429, 4430, 4431, 4432, 4433, 4434, 4435, 4436, 4437, 4438, 4439, 4440, 4441, 4442, 4443, 4444, 4445, 4446, 4447, 4448, 4449, 4450, 4451, 4452, 4453, 4454, 4455, 4456, 4457, 4458, 4459, 4460, 4461, 4462, 4463, 4464, 4465, 4466, 4467, 4468, 4469, 4470, 4471, 4472, 4473, 4474, 4475, 4476, 4477], \\\"columns\\\": [\\\"section_level\\\", \\\"CPT_section\\\", \\\"type\\\", \\\"content\\\", \\\"font_info\\\", \\\"level_1_CPT_section\\\", \\\"file_section\\\", \\\"file_section_num\\\", \\\"file_section_level\\\", \\\"seq_num\\\"], \\\"data\\\": [[\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"TITLE\\\", \\\"\\\", 1, 1], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"~REDACTED~\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"TAKEDA PHARMACEUTICALS\\\", \\\"\\\", \\\"1\\\", 2], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"PROTOCOL\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"TAKEDA PHARMACEUTICALS\\\", \\\"\\\", \\\"1\\\", 3], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"A Randomized, Double-blind, Placebo-Controlled Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Doses of TAK-861 in\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading8\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"TAKEDA PHARMACEUTICALS\\\", \\\"\\\", \\\"1\\\", 4], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Healthy Adult and Elderly Subjects and Subjects With Narcolepsy Type 1\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"TAKEDA PHARMACEUTICALS\\\", \\\"\\\", \\\"1\\\", 5], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Study Identifier:\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": 22, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 22, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"TAKEDA PHARMACEUTICALS\\\", \\\"\\\", \\\"1\\\", 6], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": 22, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 22, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"TAKEDA PHARMACEUTICALS\\\", \\\"\\\", \\\"1\\\", 7], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"TAK-861-1001\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 22, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 22, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"TAKEDA PHARMACEUTICALS\\\", \\\"\\\", \\\"1\\\", 8], [\\\"\\\", \\\"Unmapped\\\", \\\"table\\\", {\\\"Table\\\": \\\"<table border=\\\\\\\"1\\\\\\\" class=\\\\\\\"dataframe\\\\\\\">\\\\n  <thead>\\\\n    <tr style=\\\\\\\"text-align: right;\\\\\\\">\\\\n      <th></th>\\\\n      <th>1.0</th>\\\\n      <th>2.0</th>\\\\n      <th>3.0</th>\\\\n    </tr>\\\\n  </thead>\\\\n  <tbody>\\\\n    <tr>\\\\n      <th>0</th>\\\\n      <td>Compound:</td>\\\\n      <td>TAK-861</td>\\\\n      <td></td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>1</th>\\\\n      <td>Date:</td>\\\\n      <td>16 March 2021</td>\\\\n      <td></td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>2</th>\\\\n      <td>Version/Amendment Number: Amendment History :</td>\\\\n      <td>Amendment 2</td>\\\\n      <td></td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>3</th>\\\\n      <td>Date</td>\\\\n      <td>Amendment Number</td>\\\\n      <td>Region</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>4</th>\\\\n      <td>16 March 2021</td>\\\\n      <td>Amendment 2</td>\\\\n      <td>Global</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>5</th>\\\\n      <td>12 February 2021</td>\\\\n      <td>Amendment 1</td>\\\\n      <td>Global</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>6</th>\\\\n      <td>15 December 2020</td>\\\\n      <td>Initial version</td>\\\\n      <td>Global</td>\\\\n    </tr>\\\\n  </tbody>\\\\n</table>\\\", \\\"SectionHeaderPrintPage\\\": \\\"0\\\", \\\"TableIndex\\\": \\\"1\\\", \\\"TableName\\\": \\\"TITLE PAGE\\\", \\\"Header\\\": [0, 1, 2, 3]}, {\\\"IsBold\\\": true, \\\"font_size\\\": 22, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 22, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"TAKEDA PHARMACEUTICALS\\\", \\\"\\\", \\\"1\\\", 9], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"TAKEDA PHARMACEUTICALS\\\", \\\"\\\", \\\"1\\\", 10], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"TAKEDA PHARMACEUTICALS\\\", \\\"\\\", \\\"1\\\", 11], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"TAKEDA PHARMACEUTICALS\\\", \\\"\\\", \\\"1\\\", 12], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"CONFIDENTIAL PROPERTY OF ~REDACTED~\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 20, \\\"font_style\\\": \\\"Heading9\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 20, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"TAKEDA PHARMACEUTICALS\\\", \\\"\\\", \\\"1\\\", 13], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"This document is a confidential communication of ~REDACTED~.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 20, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 20, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"TAKEDA PHARMACEUTICALS\\\", \\\"\\\", \\\"1\\\", 14], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Acceptance of this document constitutes the agreement by the recipient that no information contained herein will be published or disclosed without written authorization from ~REDACTED~ except to the extent necessary to obtain informed consent from those persons to whom the drug may be administered.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 20, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 20, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"TAKEDA PHARMACEUTICALS\\\", \\\"\\\", \\\"1\\\", 15], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Furthermore, the information is only meant for review and compliance by the recipient, his or her staff, and applicable institutional review committee and regulatory agencies to enable conduct of the study.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 20, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 20, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"TAKEDA PHARMACEUTICALS\\\", \\\"\\\", \\\"1\\\", 16], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"TABLE OF CONTENTS\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading8\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 17], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"1.0 STUDY SUMMARY 10\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 18], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"1.1 Protocol Amendment 2 Summary of Changes 19\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 19], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"2.0 STUDY SCHEMATIC 20\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 20], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"3.0 SCHEDULE OF STUDY PROCEDURES 21\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 21], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"3.1 Part A 21\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 22], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"3.2 Part B and Part C 27\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 23], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"3.3 Part D 32\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 24], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"3.4 Part E 38\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 25], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"3.5 Part F 43\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 26], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"4.0 INTRODUCTION 48\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 27], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"4.1 Background 48\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 28], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"4.1.1 Summary of Nonclinical Data 49\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 29], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"4.1.2 Summary of Effects in Humans 52\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 30], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"4.2 Rationale for the Proposed Study 52\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 31], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"4.3 Benefit-Risk Profile 53\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 32], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"5.0 STUDY OBJECTIVES AND ENDPOINTS 5 4\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 33], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"5.1 Study Objectives 54\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 34], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"5.1.1 Study Primary Objective 54\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 35], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"5.1.2 Study Secondary Objectives 54\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 36], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"5.1.3 Study Additional/Exploratory Objectives 55\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 37], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"5.2 End points 56\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 38], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"5.2.1 Primary Endpoint 56\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 39], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"5.2.2 Secondary Endpoints 56\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 40], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"5.2.3 Additional/Exploratory Endpoints 56\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 41], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"6.0 STUDY DESIGN AND DESCRIPTION 58\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 42], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"6.1 Study Design 58\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 43], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"6.1.1 Part A: SRD in Japanese Healthy Adults 60\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 44], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"6.1.2 Part B: MRD in Japanese Healthy Adults 61\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 45], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"6.1.3 Part C: Multiple Dose in Healthy Japanese Elderly Subjects 61\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 46], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"6.1.4 Part D: Japanese Subjects With NT1 62\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 47], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"6.1.5 Part E: SRD/MRD in Healthy Non-Japanese Subjects 63\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 48], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"6.1.6 Part F: ~REDACTED~ and Biomarker Evaluation in Health y Non-Japanese Subjects 64\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 49], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"6.2 Dose Escalation 65\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 50], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"6.2.1 Dose Selection Rules 65\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 51], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"6.2.2 Data Review and Interim Analysis 67\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 52], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"6.3 Rationale for Study Design, Dose, and Endpoints 67\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 53], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"6.3.1 Rationale for Study Population 67\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 54], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"6.3.1.1 Healthy Subjects 67\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 55], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"6.3.1.2 Subjects With NT1 67\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 56], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"6.3.2 Rationa le of Study Design 68\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 57], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"6.3.2.1 Parts A, B, C, E, and F 68\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 58], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"6.3.2.2 Part D 69\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 59], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"6.3.3 Rationale for Dose 70\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 60], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"6.3.3.1 Startin g Dose for This Study 70\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 61], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"6.3.4 Maximum Dose/Exposure for This Study 71\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 62], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"6.3.5 Rationale for Endpoints 71\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 63], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"6.3.5.1 Safety Endpoints 71\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 64], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"6.3.5.2 PK Endpoints 72\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 65], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"6.3.5.3 PD Endpoints 72\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 66], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"6.3.6 Critical Procedures Based on Study Objectives: Timing of Procedures 72\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 67], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"6.4 Study Design/Dosing/Procedures Modifications Permitted Within P rotocol\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 68], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Parameters 73\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 69], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"6.5 Study Beginning and End/Completion 74\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 70], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"6.5.1 Definition of Beginning of the Study 74\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 71], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"6.5.2 Definition of End of the Study 74\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 72], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"6.5.3 Definition of Study C ompletion 74\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 73], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"6.5.4 Definition of Study Discontinuation 74\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 74], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"6.5.5 Criteria for Premature Termination or Suspension of the Study 74\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 75], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"6.5.5.1 Criteria for Premature Termination or Suspension of Study 74\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 76], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"6.5.5.2 Stopping Criteria for Individual Cohort 75\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 77], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"6.5.5.3 Procedures for Premature Termination or Suspension of the Study 75\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 78], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"6.5.6 Criteria for Premature Termination or Suspension of a Site 76\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 79], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"6.5.6.1 Criteria for Premature Termination or Suspension of a Site 76\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 80], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"6.5 .6.2 Procedures for Premature Termination or Suspension of a Site 76\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 81], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"7.0 SELECTION AND DISCONTINUATION/WITHDRAWAL OF SUBJECTS 76\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 82], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"7.1 Inclusion Criteria 76\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 83], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"7.2 Exclusion Criteria 79\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 84], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"7.3 Excluded Medi cations, Supplements, Dietary Products 83\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 85], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"7.3.1 Subjects With NT1 (Part D) 84\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 86], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"7.3.2 Concomitant Medications 86\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 87], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"7.3.3 Fruit Juice 87\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 88], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"7.3.4 ~REDACTED~ 87\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 89], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"7.3.5 ~REDACTED~ 87\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 90], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"7.3.6 Smoking 88\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 91], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"7.4 Dosing Instructions and Activity 88\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 92], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"7.4 .1 Diet and Fluid 88\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 93], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"7.4.2 Activity 90\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 94], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"7.4.3 Criteria for Discontinuation or Withdrawal of a Subject 90\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 95], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"7.5 Procedures for Discontinuation or Withdrawal of a Subject 91\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 96], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"7.6 Subject Replacement 92\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 97], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"8.0 CLINICAL STUDY MATERIAL MANAGEMENT 92\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 98], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"8.1 Clinical Study Drug 92\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 99], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"8.1.1 Suspension Formulation 92\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 100], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"8.1.2 Table t Formulation 92\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 101], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"8.1.3 Clinical Study Drug Labeling 92\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 102], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"8.1.3.1 Suspension Formulation 92\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 103], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"8.1.3.2 Tablet Formulation 92\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 104], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"8.1.4 Clinical Study Drug Inventory and Storage 93\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 105], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"8.1.5 C linical Study Drug Blinding 93\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 106], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"8.1.6 Randomization Code Creation and Storage 93\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 107], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"8.1.7 Clinical Study Blind Maintenance/Unblinding Procedure 93\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 108], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"8.1.8 Accountability and Destruction of Sponsor-Supplied Drugs 93\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 109], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"9.0 STUDY PROCEDURES 94\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 110], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"9.1 Administrative Procedures 94\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 111], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"9.1.1 Alternative Approaches to Study Procedures and Data Collection Due to\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 112], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"COVID-19 or Other Unavoidable Circumstances 94\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 113], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"9.1.2 Informed Consent Procedure 96\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 114], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"9.1.2.1 Assignment of Subject Numbers 96\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 115], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"9.1.2.2 Study Drug Assignment and Randomization Number 96\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 116], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"9.1.3 Inclusion and Exclusion 96\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 117], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"9.1.4 Medical History/Demography 96\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 118], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"9.1.5 Concomitant Medications 97\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 119], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"9.2 Clinical Procedures and Assessments 97\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 120], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"9.2.1 Physical Examination 97\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 121], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"9.2.2 Height and Weight 97\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 122], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"9.2.3 BMI 97\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 123], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"9.2.4 Vital Signs 98\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 124], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"9.2.5 ECGs 98\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 125], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"9.2.5.1 12-Lead ECG 98\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 126], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"9.2 .5.2 Holter ECGs 99\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 127], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"9.2.6 ABPM 99\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 128], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"9.2.7 C-SSRS 99\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 129], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"9.2.8 Overactive Bladder Condition 99\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 130], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"9.2.9 Study Drug Administration 99\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 131], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"9.2.10 Urine Input/Output Collection 100\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 132], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"9.2.11 AE Monitoring 100\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 133], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"9.2.12 Laboratory Procedures and Assessments 100\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 134], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"9.2.12.1 Clinical Laboratory Tests 100\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 135], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"9.2.12.2 Diagnostic Screening 102\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 136], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"9.3 Biomarker, PK, PD, and Pharmacogenomics Samples 103\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 137], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"9.3.1 PK Measurements 103\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 138], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"9.3.1.1 Plasma for PK Measurements 105\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 139], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"9.3.1.2 Urine for PK Measurements 105\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 140], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"9.3.1.3 ~REDACTED~ for PK Measurement 105\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 141], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"9.3.1.4 PK Sa mple Analysis 105\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 142], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"9.3.2 PD Measurements 106\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 143], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"9.3.2.1 MWT 106\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 144], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"9.3.2.2 ESS 106\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 145], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"9.3.2.3 Clinical Global Impression Scales (CGI-S and CGI-I) 106\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 146], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"9.3.2.4 Patient Global Impression Scales (PGI-I and PGI-S) 107\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 147], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"9.3.2.5 nPSG 107\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 148], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"9.3.2.6 Wearable EEG Device 107\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 149], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"9.3.2.7 Accelerometry (Actigraphy) 108\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 150], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"9.3.2.8 Assessment of Cataplexy and Other Narcolepsy Symptoms 108\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 151], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"9.3.2.9 KSS 109\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 152], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"9.3.2.10 Cognitive Assessments 109\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 153], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"9.3.2.11 Pilot NT1 Items 110\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 154], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"9.3.2.12 EQ-5D-5L Health-Related QOL Utility Scale 110\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 155], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"9.3.3 Exploratory Biomarker Research 110\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 156], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"9.3.3.1 Exploratory Plasma Biomarker Research 110\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 157], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"9.3.3.2 ~REDACTED~ OX Measurements 110\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 158], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"9.3.3.3 Future Biomedical Research (Unplanned Exploratory Biomarker Researc h) 111\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 159], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"9.3.3.4 DNA Analysis Measurements 111\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 160], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"9.3.4 Confinement 111\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 161], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"10.0 ADVERSE EVENTS 111\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 162], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"10.1 Definitions and Elements of AEs 111\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 163], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"10.1.1 SAEs 113\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 164], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"10.1.2 Special Interest AEs 114\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 165], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"10.2 AE Procedures 115\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 166], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"10.2.1 Assigning Severity/Intensity of AEs 115\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 167], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"10.2.2 Assigning Causality of AEs 115\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 168], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"10.2.3 Assigning Causality of AEs to Study Procedure 115\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 169], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"10.2. 4 Start Date 115\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 170], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"10.2.5 End Date 116\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 171], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"10.2.6 Pattern of AE (Frequency) 116\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 172], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"10.2. 7 Action Taken With Study Treatment 116\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 173], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"10.2.8 Outcome 116\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 174], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"10.2.9 Collection and Reporting of AEs, SAEs, Special Interest AEs, and Abnormal LFTs 117\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 175], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"10.2.9. 1 Collection Period 117\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 176], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"10.2.9.2 Reporting AEs 117\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 177], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"10.2.9.3 Reporting SAEs 118\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 178], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"10.2.9.4 Reporting of Abnormal LFTs 118\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 179], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"10.2.10 Safety Reporting to Investigators, IRBs or IECs, and Regulatory Authorities 119\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 180], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"11.0 STATISTICAL METHODS 119\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 181], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"11.1 Statistical and Analytical Plans 119\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 182], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"11.1.1 Analysis Sets 119\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 183], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"11.1.1.1 Safety Set 119\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 184], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"11.1.1.2 PK Set 119\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 185], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"11.1.1.3 PD Set 120\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 186], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"11.1.1.4 Full Analysis Set 120\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 187], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"11.1.2 Analysis of Demography and Other Baseline Characteristics 120\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 188], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"11.1.3 PK Analysis 120\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 189], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"11.1.4 PD Analysis 121\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 190], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"11.1.5 PK/PD Analysis 121\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 191], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"11.1.6 Safety Analyses 121\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 192], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"11.1.6.1 Clinical Laboratory Evaluation 122\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 193], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"11.1. 6.2 Vital Signs and ECG 122\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 194], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"11.1.6.3 Holter ECG 123\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 195], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"11.1.6.4 Other Safety Parameters 123\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 196], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"11.1. 7 Pharmacogenomics (DNA) Measurement 123\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 197], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"11.2 Interim Analysis and Criteria for Early Termination 123\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 198], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"11.3 Determination of Sample Size 123\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 199], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"12.0 QUALITY CONT ROL AND QUALITY ASSURANCE 124\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 200], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"12.1 Study-Site Monitoring Visits 124\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 201], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"12.2 Protocol Deviations 124\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 202], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"12.3 Quality Assurance Audits and Regulatory Agency Inspections 124\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 203], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"13.0 ETHICAL ASPECTS OF THE STUDY 124\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 204], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"13.1 IRB and/or IEC Approval 125\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 205], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"13.2 Subject Informatio n, Informed Consent, and Subject Authorization 125\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 206], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"13.3 Subject Confidentiality 127\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 207], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"13.4 Publication, Disclosure, and Clinical Study Registration Policy 127\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 208], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"13.4.1 Publication and Disclosure 127\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 209], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"13.4.2 Clinical Study Registration 128\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 210], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"13.4.3 Clinical Study Results Disclosure 128\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 211], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"13.5 Insurance and Compensation for Injury 128\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 212], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"14.0 ADMINISTRATIVE AND REFERENCE INFORMATION 129\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 213], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"14.1 Administrative Information 129\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 214], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"14.1.1 Study Contact Information 129\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 215], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"14.1.2 INVESTIGATOR AGREEMENT 130\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 216], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"14.1.3 Study-Related Responsibilities 131\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 217], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"14.1.4 List of Abbreviations 131\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 218], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"15.0 DATA HANDLING AND RECORDKEEPING 134\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 219], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"15.1 eCRFs 134\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 220], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"15.2 Record Retention 134\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 221], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"16.0 REFERENCES 135\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 222], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"1 7.0 APPENDICES 137\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 223], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"OF CONTENTS\\\", \\\"TABLE\\\", \\\"1\\\", 224], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"LIST OF IN-TEXT TABLES\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"LIST OF IN-TEXT TABLES\\\", \\\"\\\", \\\"1\\\", 225], [\\\"\\\", \\\"Unmapped\\\", \\\"table\\\", {\\\"Table\\\": \\\"<table border=\\\\\\\"1\\\\\\\" class=\\\\\\\"dataframe\\\\\\\">\\\\n  <thead>\\\\n    <tr style=\\\\\\\"text-align: right;\\\\\\\">\\\\n      <th></th>\\\\n      <th>1.0</th>\\\\n      <th>2.0</th>\\\\n    </tr>\\\\n  </thead>\\\\n  <tbody>\\\\n    <tr>\\\\n      <th>0</th>\\\\n      <td>Table 3.a</td>\\\\n      <td>Schedule of Study Procedures for Part A (SRD in Healthy Adults) ....................21</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>1</th>\\\\n      <td>Table 3.b</td>\\\\n      <td>Schedule of Study Procedures for Part A (Food Effect Cohorts).........................23</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>2</th>\\\\n      <td>Table 3.c</td>\\\\n      <td>Detailed Schedule for Part A..............................................................................25</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>3</th>\\\\n      <td>Table 3.d</td>\\\\n      <td>Detailed Schedule for Cohorts A3 and  <span class=\\\\\\\"redact\\\\\\\"> ~REDACTED~ </span>  (SRD Food Effect)..........................26</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>4</th>\\\\n      <td>Table 3.e</td>\\\\n      <td>Schedule of Study Procedures for Part B and Part C (MRD in Healthy Adults/Elderly) ..................................................................................................27</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>5</th>\\\\n      <td>Table 3.f</td>\\\\n      <td>Detailed Schedule for Part B and C....................................................................30</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>6</th>\\\\n      <td>Table 3.g</td>\\\\n      <td>Schedule of Study Procedures for Part D (Subjects With NT1)...........................32</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>7</th>\\\\n      <td>Table 3.h</td>\\\\n      <td>Detailed Schedule for Part D..............................................................................36</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>8</th>\\\\n      <td>Table 3.i</td>\\\\n      <td>Schedule of Study Procedures for Part E: Non-Japanese Cohort.........................38</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>9</th>\\\\n      <td>Table 3.j</td>\\\\n      <td>Detailed Schedule for Part E (MRD Healthy Non-Japanese Adult Subjects).......41</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>10</th>\\\\n      <td>Table 3.k</td>\\\\n      <td>Schedule of Study Procedures for Part F:  <span class=\\\\\\\"redact\\\\\\\"> ~REDACTED~ </span>  Cohorts ......................................43</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>11</th>\\\\n      <td>Table 3.l</td>\\\\n      <td>Detailed Schedule for Part F ( <span class=\\\\\\\"redact\\\\\\\"> ~REDACTED~ </span>  Cohorts in Healthy Non-Japanese Adult subjects).............................................................................................................46</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>12</th>\\\\n      <td>Table 6.a</td>\\\\n      <td>Study Schedule: Part A ......................................................................................61</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>13</th>\\\\n      <td>Table 6.b</td>\\\\n      <td>Study Schedule: Part A (Food Effect Cohorts) ...................................................61</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>14</th>\\\\n      <td>Table 6.c</td>\\\\n      <td>Study Schedule: Part B and Part C .....................................................................62</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>15</th>\\\\n      <td>Table 6.d</td>\\\\n      <td>Study Schedule - Part D.....................................................................................63</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>16</th>\\\\n      <td>Table 6.e</td>\\\\n      <td>Study Schedule: Part E, Non-Japanese Cohort....................................................64</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>17</th>\\\\n      <td>Table 6.f</td>\\\\n      <td>Study Schedule: Part F,  <span class=\\\\\\\"redact\\\\\\\"> ~REDACTED~ </span>  Cohort...................................................................65</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>18</th>\\\\n      <td>Table 6.g</td>\\\\n      <td>Predicted TAK-861 Exposures in Humans and Calculated Safety Margins.........66</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>19</th>\\\\n      <td>Table 7.a</td>\\\\n      <td>Excluded Medications, Supplements, and Dietary Products (Healthy Subjects)..84</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>20</th>\\\\n      <td>Table 7.b</td>\\\\n      <td>Excluded Medications and Supplements.............................................................85</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>21</th>\\\\n      <td>Table 9.a</td>\\\\n      <td>Primary Specimen Collections .........................................................................103</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>22</th>\\\\n      <td>Table 10.a</td>\\\\n      <td><span class=\\\\\\\"redact\\\\\\\"> ~REDACTED~ </span>  class=\\\\\\\"redact\\\\\\\"> ~REDACTED~ </span>  Medically Significant AE List..............................................................114</td>\\\\n    </tr>\\\\n  </tbody>\\\\n</table>\\\", \\\"SectionHeaderPrintPage\\\": \\\"7\\\", \\\"TableIndex\\\": \\\"2\\\", \\\"TableName\\\": \\\"LIST OF IN-TEXT TABLES\\\", \\\"Header\\\": []}, {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"LIST OF IN-TEXT TABLES\\\", \\\"\\\", \\\"1\\\", 226], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"LIST OF IN-TEXT FIGURES\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading8\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"LIST OF IN-TEXT FIGURES\\\", \\\"\\\", \\\"1\\\", 227], [\\\"\\\", \\\"Unmapped\\\", \\\"table\\\", {\\\"Table\\\": \\\"<table border=\\\\\\\"1\\\\\\\" class=\\\\\\\"dataframe\\\\\\\">\\\\n  <thead>\\\\n    <tr style=\\\\\\\"text-align: right;\\\\\\\">\\\\n      <th></th>\\\\n      <th>1.0</th>\\\\n      <th>2.0</th>\\\\n    </tr>\\\\n  </thead>\\\\n  <tbody>\\\\n    <tr>\\\\n      <th>0</th>\\\\n      <td>Figure 2.a</td>\\\\n      <td>Study Diagram NT1 (Part D)..............................................................................20</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>1</th>\\\\n      <td>Figure 6.a</td>\\\\n      <td>Overall Design and Planned Dose Levels of TAK-861.......................................59</td>\\\\n    </tr>\\\\n  </tbody>\\\\n</table>\\\", \\\"SectionHeaderPrintPage\\\": \\\"7\\\", \\\"TableIndex\\\": \\\"3\\\", \\\"TableName\\\": \\\"LIST OF IN-TEXT FIGURES\\\", \\\"Header\\\": []}, {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"LIST OF IN-TEXT FIGURES\\\", \\\"\\\", \\\"1\\\", 228], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"LIST OF APPENDICES\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading8\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"LIST OF APPENDICES\\\", \\\"\\\", \\\"1\\\", 229], [\\\"\\\", \\\"Unmapped\\\", \\\"table\\\", {\\\"Table\\\": \\\"<table border=\\\\\\\"1\\\\\\\" class=\\\\\\\"dataframe\\\\\\\">\\\\n  <thead>\\\\n    <tr style=\\\\\\\"text-align: right;\\\\\\\">\\\\n      <th></th>\\\\n      <th>1.0</th>\\\\n      <th>2.0</th>\\\\n    </tr>\\\\n  </thead>\\\\n  <tbody>\\\\n    <tr>\\\\n      <th>0</th>\\\\n      <td>Appendix A</td>\\\\n      <td>Responsibilities of the Investigator...................................................................137</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>1</th>\\\\n      <td>Appendix B</td>\\\\n      <td>Elements of the Subject Informed Consent.......................................................139</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>2</th>\\\\n      <td>Appendix C</td>\\\\n      <td>Investigator Consent to the Use of Personal Information ..................................142</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>3</th>\\\\n      <td>Appendix D</td>\\\\n      <td>Pregnancy and Contraception...........................................................................143</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>4</th>\\\\n      <td>Appendix E</td>\\\\n      <td>ICSD-3 Diagnostic Criteria for NT1.................................................................148</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>5</th>\\\\n      <td>Appendix F</td>\\\\n      <td>List of Inhibitors and Inducers of CYP3A and the Substrates of CYP3A4 and OATP1B1........................................................................................................149</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>6</th>\\\\n      <td>Appendix G</td>\\\\n      <td>Protocol History...............................................................................................150</td>\\\\n    </tr>\\\\n  </tbody>\\\\n</table>\\\", \\\"SectionHeaderPrintPage\\\": \\\"8\\\", \\\"TableIndex\\\": \\\"4\\\", \\\"TableName\\\": \\\"LIST OF APPENDICES\\\", \\\"Header\\\": []}, {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"LIST OF APPENDICES\\\", \\\"\\\", \\\"1\\\", 230], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"LIST OF APPENDICES\\\", \\\"\\\", \\\"1\\\", 231], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"1.0 STUDY SUMMARY\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading1\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"STUDY SUMMARY\\\", \\\"1.0\\\", \\\"1\\\", 232], [\\\"\\\", \\\"Unmapped\\\", \\\"table\\\", {\\\"Table\\\": \\\"<table border=\\\\\\\"1\\\\\\\" class=\\\\\\\"dataframe\\\\\\\">\\\\n  <thead>\\\\n    <tr style=\\\\\\\"text-align: right;\\\\\\\">\\\\n      <th></th>\\\\n      <th>1.0</th>\\\\n      <th>2.0</th>\\\\n    </tr>\\\\n  </thead>\\\\n  <tbody>\\\\n    <tr>\\\\n      <th>0</th>\\\\n      <td>Name of Sponsor: Takeda Development Center Americas, Inc. 95 Hayden Avenue Lexington, MA 02421 United States Takeda Pharmaceutical Company Limited 1-1, Doshomachi 4-chome Chuo-ku, Osaka 540-8645, Japan</td>\\\\n      <td>Compound: TAK-861</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>1</th>\\\\n      <td>Study Identifier: TAK-861-1001</td>\\\\n      <td>Phase: 1/1b</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>2</th>\\\\n      <td>Protocol Title: A Randomized, Double-blind, Placebo-Controlled Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Doses of TAK-861 in Healthy Adult and Elderly Subjects and Subjects With Narcolepsy Type 1</td>\\\\n      <td>Protocol Title: A Randomized, Double-blind, Placebo-Controlled Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Doses of TAK-861 in Healthy Adult and Elderly Subjects and Subjects With Narcolepsy Type 1</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>3</th>\\\\n      <td>Study Design: This is a first-in-human (FIH), phase 1/1b, double-blind, safety, tolerability, pharmacokinetic (PK), and pharmacodynamic (PD) study of single-rising doses (SRD) and multiple-rising doses (MRD) of TAK-861 in healthy adult subjects, healthy elderly (HE) subjects, and subjects with narcolepsy type 1 (NT1). Parts A to D will be conducted in Japan while Parts E and F will be conducted in the United States. This study consists of 6 parts. Part A: a randomized, double-blind, placebo-controlled, SRD part to assess the safety, tolerability, and PK of TAK-861 administered orally as a suspension or tablet to healthy subjects. The effect of food on the PK of the TAK-861 tablet will also be evaluated. Part B: a randomized, double-blind, placebo-controlled, MRD part to assess the safety, tolerability, PK, and PD of TAK-861 administered orally to healthy subjects. Part C: a randomized, double-blind, placebo-controlled, MRD part to assess the safety, tolerability, PK, and PD of TAK-861 administered orally to HE subjects. Part D: a randomized, double-blind, placebo-controlled, MRD part to assess the safety, tolerability, PK, and PD of TAK-861 administered orally to subjects with NT1. Part E: a randomized, double-blind, placebo-controlled, SRD/MRD part to assess the safety, tolerability, PK and PD of TAK-861 administered orally to healthy subjects of non-Japanese origin. Part F: a randomized, double-blind, placebo-controlled, part to assess the PD and PK of TAK-861 in cerebrospinal fluid (CSF) in healthy subjects of non-Japanese origin. Up to approximately 80 healthy adult Japanese subjects in Part A; 48 healthy adult Japanese subjects in Part B; 8 elderly Japanese subjects in Part C; 18 Japanese subjects with NT1 in Part D; 32 healthy adult non-Japanese subjects in Part E; and 10 healthy adult non-Japanese subjects in Part F will be enrolled. If needed, some cohorts in Part E may include both non-Japanese and Japanese subjects to evaluate ethnobridging in certain dose levels. TAK-861 or matching placebo will be administered orally as a tablet or oral suspension formulation and will be dispensed in a blinded fashion by qualified study site personnel. All cohorts will include serial blood sampling for TAK-861 PK. Urine PK samples will be collected from all cohorts in all parts except Parts D and F. The conduct of the CSF cohort is optional and may be determined on the basis of the PD results from Part D. In selected MRD study parts (ie, Parts B, C, D, and E), additional blood samples will be collected before dose on prespecified days for measurement of the 4\\\\u03b2-hydroxycholesterol/cholesterol ratio to assess cytochrome P450 (CYP)3A4/5 activity. Separately, in selected MRD study parts (ie, B and E), additional blood samples will be collected at designated time points for measurement of coproporphyrin (CP) I and CPIII to assess organic anion transporting polypeptide (OATP)1B1/3 activity.</td>\\\\n      <td>Study Design: This is a first-in-human (FIH), phase 1/1b, double-blind, safety, tolerability, pharmacokinetic (PK), and pharmacodynamic (PD) study of single-rising doses (SRD) and multiple-rising doses (MRD) of TAK-861 in healthy adult subjects, healthy elderly (HE) subjects, and subjects with narcolepsy type 1 (NT1). Parts A to D will be conducted in Japan while Parts E and F will be conducted in the United States. This study consists of 6 parts. Part A: a randomized, double-blind, placebo-controlled, SRD part to assess the safety, tolerability, and PK of TAK-861 administered orally as a suspension or tablet to healthy subjects. The effect of food on the PK of the TAK-861 tablet will also be evaluated. Part B: a randomized, double-blind, placebo-controlled, MRD part to assess the safety, tolerability, PK, and PD of TAK-861 administered orally to healthy subjects. Part C: a randomized, double-blind, placebo-controlled, MRD part to assess the safety, tolerability, PK, and PD of TAK-861 administered orally to HE subjects. Part D: a randomized, double-blind, placebo-controlled, MRD part to assess the safety, tolerability, PK, and PD of TAK-861 administered orally to subjects with NT1. Part E: a randomized, double-blind, placebo-controlled, SRD/MRD part to assess the safety, tolerability, PK and PD of TAK-861 administered orally to healthy subjects of non-Japanese origin. Part F: a randomized, double-blind, placebo-controlled, part to assess the PD and PK of TAK-861 in cerebrospinal fluid (CSF) in healthy subjects of non-Japanese origin. Up to approximately 80 healthy adult Japanese subjects in Part A; 48 healthy adult Japanese subjects in Part B; 8 elderly Japanese subjects in Part C; 18 Japanese subjects with NT1 in Part D; 32 healthy adult non-Japanese subjects in Part E; and 10 healthy adult non-Japanese subjects in Part F will be enrolled. If needed, some cohorts in Part E may include both non-Japanese and Japanese subjects to evaluate ethnobridging in certain dose levels. TAK-861 or matching placebo will be administered orally as a tablet or oral suspension formulation and will be dispensed in a blinded fashion by qualified study site personnel. All cohorts will include serial blood sampling for TAK-861 PK. Urine PK samples will be collected from all cohorts in all parts except Parts D and F. The conduct of the CSF cohort is optional and may be determined on the basis of the PD results from Part D. In selected MRD study parts (ie, Parts B, C, D, and E), additional blood samples will be collected before dose on prespecified days for measurement of the 4\\\\u03b2-hydroxycholesterol/cholesterol ratio to assess cytochrome P450 (CYP)3A4/5 activity. Separately, in selected MRD study parts (ie, B and E), additional blood samples will be collected at designated time points for measurement of coproporphyrin (CP) I and CPIII to assess organic anion transporting polypeptide (OATP)1B1/3 activity.</td>\\\\n    </tr>\\\\n  </tbody>\\\\n</table>\\\", \\\"SectionHeaderPrintPage\\\": \\\"9\\\", \\\"TableIndex\\\": \\\"5\\\", \\\"TableName\\\": \\\"1.0 STUDY SUMMARY\\\", \\\"Header\\\": [0, 3]}, {\\\"IsBold\\\": true, \\\"font_size\\\": 20, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 20, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"STUDY SUMMARY\\\", \\\"1.0\\\", \\\"1\\\", 233], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"STUDY SUMMARY\\\", \\\"1.0\\\", \\\"1\\\", 234], [\\\"\\\", \\\"Unmapped\\\", \\\"table\\\", {\\\"Table\\\": \\\"<table border=\\\\\\\"1\\\\\\\" class=\\\\\\\"dataframe\\\\\\\">\\\\n  <thead>\\\\n    <tr style=\\\\\\\"text-align: right;\\\\\\\">\\\\n      <th></th>\\\\n      <th>1.0</th>\\\\n    </tr>\\\\n  </thead>\\\\n  <tbody>\\\\n    <tr>\\\\n      <th>0</th>\\\\n      <td>Primary Objective: To investigate the safety and tolerability of TAK-861 when single and/or multiple oral doses are administered to healthy adults, HE subjects, and subjects with NT1. Secondary Objectives: To investigate the PK of TAK-861 when single and/or multiple oral doses of suspension and/or tablet formulation are administered to healthy adults. To investigate the PK of TAK-861 when multiple oral doses of tablet formulation are administered to HE subjects and subjects with NT1. To assess the effect of food on the PK of the TAK-861 tablet. Additional/Exploratory Objectives: To identify if subjects are experiencing any bladder related discomfort during the study period. To explore TAK-861 effects on concentrations of endogenous biomarkers (CPI and CPIII) for OATP1B1 and OATP1B3 activities. To explore TAK-861 effects on 4\\\\u03b2-hydroxycholesterol/cholesterol ratio for CYP3A4/5 inductive activity. The exploratory objectives in Part B through F: To evaluate accelerometry (actigraphy) for usefulness to evaluate daytime activity and sleep. To investigate the effect of TAK-861 on daytime sleepiness, as assessed by the Karolinska Sleepiness Scale (KSS). The exploratory objectives in Part D: To investigate the PD of TAK-861, as assessed by Maintenance of Wakefulness Test (MWT). To investigate the PD of TAK-861, as assessed by the Epworth Sleepiness Scale (ESS). To investigate the PD of TAK-861, as assessed by weekly cataplexy rate (WCR). To assess the effect of TAK-861 on daytime sleepiness, cataplexy, and overall narcolepsy symptoms as measured by Patient Global Impression of Improvement (PGI-I), Clinician Global Impression of Improvement (CGI-I), Patient Global Impression of Severity (PGI-S), and Clinician Global Impression of Severity (CGI-S) scales. To assess the effects of TAK-861 on rapid eye movement (REM) sleep-related abnormalities, including hypnagogic/hypnopompic hallucination, sleep paralysis, and nocturnal awakenings, as reported by the subject. To assess the effects of TAK-861 on sleep metrics by polysomnography (PSG) measures and/or portable electroencephalography (EEG). To assess the effects of TAK-861 on attention, vigilance, and memory, as measured by the cognitive tests (SART and CPAL). To investigate the impact of TAK-861 on overall narcolepsy symptoms and daily functioning of subjects, as assessed by the Pilot NT1 Items questionnaire. To investigate the impact of TAK-861 on quality of life of subjects, as assessed by the EuroQoL-5 Dimensions-5 Levels (EQ-5D-5L) scale. To assess the PK-PD relationship of TAK-861 for selected efficacy measures in subjects with NT1. The exploratory objectives in Part F: To assess orexin (OX) levels. The additional safety objectives: To assess the effects of TAK-861 on blood pressure (BP), pulse rate, and electrocardiogram (ECG) parameters (all parts). To assess the effect of TAK-861 on Holter ECG parameters (only collected in Parts A, B, C, and E).</td>\\\\n    </tr>\\\\n  </tbody>\\\\n</table>\\\", \\\"SectionHeaderPrintPage\\\": \\\"9\\\", \\\"TableIndex\\\": \\\"6\\\", \\\"TableName\\\": \\\"1.0 STUDY SUMMARY\\\", \\\"Header\\\": [0]}, {\\\"IsBold\\\": true, \\\"font_size\\\": 20, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 20, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"STUDY SUMMARY\\\", \\\"1.0\\\", \\\"1\\\", 235], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"STUDY SUMMARY\\\", \\\"1.0\\\", \\\"1\\\", 236], [\\\"\\\", \\\"Unmapped\\\", \\\"table\\\", {\\\"Table\\\": \\\"<table border=\\\\\\\"1\\\\\\\" class=\\\\\\\"dataframe\\\\\\\">\\\\n  <thead>\\\\n    <tr style=\\\\\\\"text-align: right;\\\\\\\">\\\\n      <th></th>\\\\n      <th>1.0</th>\\\\n      <th>2.0</th>\\\\n      <th>3.0</th>\\\\n      <th>4.0</th>\\\\n      <th>5.0</th>\\\\n    </tr>\\\\n  </thead>\\\\n  <tbody>\\\\n    <tr>\\\\n      <th>0</th>\\\\n      <td>Study Subject Population: Approximate number of subjects planned to be included in each part is as follows: 80 healthy adult Japanese subjects in Part A. 48 healthy adult Japanese subjects in Part B. 8 elderly Japanese subjects in Part C. 18 Japanese subjects with NT1 in Part D. 32 healthy adult non-Japanese subjects in Part E. 10 healthy adult non-Japanese subjects in Part F.</td>\\\\n      <td>Study Subject Population: Approximate number of subjects planned to be included in each part is as follows: 80 healthy adult Japanese subjects in Part A. 48 healthy adult Japanese subjects in Part B. 8 elderly Japanese subjects in Part C. 18 Japanese subjects with NT1 in Part D. 32 healthy adult non-Japanese subjects in Part E. 10 healthy adult non-Japanese subjects in Part F.</td>\\\\n      <td>Study Subject Population: Approximate number of subjects planned to be included in each part is as follows: 80 healthy adult Japanese subjects in Part A. 48 healthy adult Japanese subjects in Part B. 8 elderly Japanese subjects in Part C. 18 Japanese subjects with NT1 in Part D. 32 healthy adult non-Japanese subjects in Part E. 10 healthy adult non-Japanese subjects in Part F.</td>\\\\n      <td>Study Subject Population: Approximate number of subjects planned to be included in each part is as follows: 80 healthy adult Japanese subjects in Part A. 48 healthy adult Japanese subjects in Part B. 8 elderly Japanese subjects in Part C. 18 Japanese subjects with NT1 in Part D. 32 healthy adult non-Japanese subjects in Part E. 10 healthy adult non-Japanese subjects in Part F.</td>\\\\n      <td></td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>1</th>\\\\n      <td>Planned Number of Subjects: Approximately 196 male and female subjects, including 18 subjects with NT1.</td>\\\\n      <td>Planned Number of Sites: Approximately 15 sites.</td>\\\\n      <td>Planned Number of Sites: Approximately 15 sites.</td>\\\\n      <td>Planned Number of Sites: Approximately 15 sites.</td>\\\\n      <td></td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>2</th>\\\\n      <td>Dose Levels: Maximum dose level that can be tested in this study will be 800 mg/d/man. Part A Starting dose: 1 mg (single dose) Subsequent dose levels: To be determined by emerging safety, tolerability, and PK data. Part B Part C Part D Part E Part F Subsequent single and multiple (once daily [QD] up to 14 days) dose levels: To be determined by emerging safety, tolerability, and PK data.</td>\\\\n      <td>Route of Administration: Oral (tablets and suspension formulations).</td>\\\\n      <td>Route of Administration: Oral (tablets and suspension formulations).</td>\\\\n      <td>Route of Administration: Oral (tablets and suspension formulations).</td>\\\\n      <td></td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>3</th>\\\\n      <td>Duration of Treatment: Part A: single dose Part A (food effect): single dose on Day 1 and Day 15, washout from Day 7 to 14 Part B: 14 days of dosing (QD) Part C: 14 days of dosing (QD) Part D: 14 days of dosing (QD) Part E: single dose and 14 days of dosing (QD) Part F: 10 days of dosing (QD)</td>\\\\n      <td>Study Duration: Screening and baseline: Up to 28 days (Part A, B, C) Up to 35 days (Part E and F) Up to 45 days (Part D)</td>\\\\n      <td>Study Duration: Screening and baseline: Up to 28 days (Part A, B, C) Up to 35 days (Part E and F) Up to 45 days (Part D)</td>\\\\n      <td>Study Duration: Screening and baseline: Up to 28 days (Part A, B, C) Up to 35 days (Part E and F) Up to 45 days (Part D)</td>\\\\n      <td></td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>4</th>\\\\n      <td></td>\\\\n      <td>Treatment period:</td>\\\\n      <td>Treatment period:</td>\\\\n      <td>Treatment period:</td>\\\\n      <td></td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>5</th>\\\\n      <td></td>\\\\n      <td>Part</td>\\\\n      <td>Dosing Day Assessments</td>\\\\n      <td>Sample Collection Days</td>\\\\n      <td>Washout</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>6</th>\\\\n      <td></td>\\\\n      <td>A</td>\\\\n      <td>Day 1</td>\\\\n      <td>Days 1 to 6</td>\\\\n      <td>NA</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>7</th>\\\\n      <td></td>\\\\n      <td>A (food effect)</td>\\\\n      <td>Day 1, Day 15</td>\\\\n      <td>Days 1 to 6, Days 15-20</td>\\\\n      <td>Days 2 to 14 (\\\\u00b12 days)</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>8</th>\\\\n      <td></td>\\\\n      <td>B</td>\\\\n      <td>Day 1 to Day 14</td>\\\\n      <td>Day 1 to Day 18</td>\\\\n      <td>NA</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>9</th>\\\\n      <td></td>\\\\n      <td>C</td>\\\\n      <td>Day 1 to Day 14</td>\\\\n      <td>Day 1 to Day 18</td>\\\\n      <td>NA</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>10</th>\\\\n      <td></td>\\\\n      <td>D</td>\\\\n      <td>Day 1 to Day 14</td>\\\\n      <td>Day 1 to Day 15</td>\\\\n      <td>NA</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>11</th>\\\\n      <td></td>\\\\n      <td>E</td>\\\\n      <td>Day 1; Days 6 through 19</td>\\\\n      <td>Day 1 to Day 23</td>\\\\n      <td>Days 2 to 5</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>12</th>\\\\n      <td></td>\\\\n      <td>F</td>\\\\n      <td>Day 1 to Day 10</td>\\\\n      <td>Day 1 to Day 14</td>\\\\n      <td>NA</td>\\\\n    </tr>\\\\n  </tbody>\\\\n</table>\\\", \\\"SectionHeaderPrintPage\\\": \\\"9\\\", \\\"TableIndex\\\": \\\"7\\\", \\\"TableName\\\": \\\"1.0 STUDY SUMMARY\\\", \\\"Header\\\": [0, 1, 2, 3]}, {\\\"IsBold\\\": true, \\\"font_size\\\": 20, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 20, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"STUDY SUMMARY\\\", \\\"1.0\\\", \\\"1\\\", 237], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"STUDY SUMMARY\\\", \\\"1.0\\\", \\\"1\\\", 238], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"STUDY SUMMARY\\\", \\\"1.0\\\", \\\"1\\\", 239], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"STUDY SUMMARY\\\", \\\"1.0\\\", \\\"1\\\", 240], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"STUDY SUMMARY\\\", \\\"1.0\\\", \\\"1\\\", 241], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"STUDY SUMMARY\\\", \\\"1.0\\\", \\\"1\\\", 242], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"STUDY SUMMARY\\\", \\\"1.0\\\", \\\"1\\\", 243], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"STUDY SUMMARY\\\", \\\"1.0\\\", \\\"1\\\", 244], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"STUDY SUMMARY\\\", \\\"1.0\\\", \\\"1\\\", 245], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"STUDY SUMMARY\\\", \\\"1.0\\\", \\\"1\\\", 246], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"STUDY SUMMARY\\\", \\\"1.0\\\", \\\"1\\\", 247], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"STUDY SUMMARY\\\", \\\"1.0\\\", \\\"1\\\", 248], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"STUDY SUMMARY\\\", \\\"1.0\\\", \\\"1\\\", 249], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"STUDY SUMMARY\\\", \\\"1.0\\\", \\\"1\\\", 250], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"STUDY SUMMARY\\\", \\\"1.0\\\", \\\"1\\\", 251], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"STUDY SUMMARY\\\", \\\"1.0\\\", \\\"1\\\", 252], [\\\"\\\", \\\"Unmapped\\\", \\\"table\\\", {\\\"Table\\\": \\\"<table border=\\\\\\\"1\\\\\\\" class=\\\\\\\"dataframe\\\\\\\">\\\\n  <thead>\\\\n    <tr style=\\\\\\\"text-align: right;\\\\\\\">\\\\n      <th></th>\\\\n      <th>1.0</th>\\\\n    </tr>\\\\n  </thead>\\\\n  <tbody>\\\\n    <tr>\\\\n      <th>0</th>\\\\n      <td>Main Criteria for Inclusion: To be eligible for study participation, subjects must: All subjects The subject must understand the study procedures and agree to participate by providing written informed consent. The subject must be willing and able to comply with all study procedures and restrictions. The subject must be judged to be in good health by the investigator to participate in the study, based on clinical evaluations including laboratory safety tests, medical history, physical examination, 12-lead ECG, and vital sign measurements performed at the screening visit and before the first dose of study drug or first study assessment. Note: Screening laboratory assessments may be repeated for all parts; consultation with the sponsor or designee is encouraged for Part D. Healthy Adult Subjects for Part A, B, C, E, and F The subject must be a current nonsmoker who has not used tobacco- or nicotine-containing products (eg, nicotine patch) for at least 6 months before the first dose of study drug or first study assessment. The subject must have a body mass index (BMI) \\\\u226518.0 and \\\\u226430.0 kg/m <sup>2</sup> at the screening visit. Healthy Adult Subjects (Parts A, B, E, and F) The subject must be aged 18 to 55 years, inclusive, at the screening visit.  The subject must have a body weight \\\\u226550 kg at the screening visit. Healthy Adult Subjects (Part E and F) The subject must be of non-Japanese origin. In the case that a subject of Japanese origin will be included in Part E, the criteria below will be applied: The subject must have been born in Japan to a Japanese mother and father and have maternal and paternal Japanese grandparents. The subject must have not been away from Japan for more than 10 years at the screening visit. In the opinion of the investigator, the subject must have a lifestyle that has not changed significantly since relocation from Japan. HE Subjects (Part C) The subject must be aged \\\\u226565 years, inclusive, at the time of informed consent at the screening visit. The subject must have a body weight \\\\u226540 kg at the screening visit. Subjects with NT1 (Part D) The subject must be aged 18 to 65 years, inclusive, at the time of informed consent. The subject must have a diagnosis of NT1 by polysomnography (PSG)/multiple sleep latency test (MSLT) performed within the past 10 years meeting the minimal acceptable criteria for the proper performance of PSG/MSLT as outlined by the International Classification of Sleep Disorders, 3rd Edition (ICSD-3) criteria. Note: If there is a potential subject with a NT1 whose diagnostic nocturnal polysomnography (nPSG)/MSLT was performed more than 10 years ago or is not available, special exemptions, that is, ability of the site to repeat the diagnostic PSG/MSLT will be considered on a case-by-case basis after discussions between the investigator and the sponsor or designee. If the subject is diagnosed as having NT1 based on ICSD-3 criteria without nPSG/MSLT data but by CSF OX measurement, the subject may be enrolled with the sponsor or its designee\\\\u2019s agreement. Note: for subjects who present with results from CSF test indicating an OX/hypocretin-1 concentration of \\\\u2264110 pg/mL, or less than one-third of the mean values obtained in normal subjects, with the same standardized assay, and the subject presents with cataplexy, the PSG/MSLT requirement may be waived after a discussion with the sponsor or designee. The subject\\\\u2019s ESS score must be \\\\u226510 at Day -1. The subject must be willing to discontinue all medications used for the treatment of NT1. The human leukocyte antigen (HLA) genotype result should be positive for HLA-DQB1*06:02 (positive results for either homozygous or heterozygous alleles will be considered \\\\u201cpositive\\\\u201d and acceptable). Note: Subjects testing negative for HLA-DQB1*06:02 but who present with results from CSF testing indicating</td>\\\\n    </tr>\\\\n  </tbody>\\\\n</table>\\\", \\\"SectionHeaderPrintPage\\\": \\\"9\\\", \\\"TableIndex\\\": \\\"8\\\", \\\"TableName\\\": \\\"1.0 STUDY SUMMARY\\\", \\\"Header\\\": [0]}, {\\\"IsBold\\\": true, \\\"font_size\\\": 20, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 20, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"STUDY SUMMARY\\\", \\\"1.0\\\", \\\"1\\\", 253], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"STUDY SUMMARY\\\", \\\"1.0\\\", \\\"1\\\", 254], [\\\"\\\", \\\"Unmapped\\\", \\\"table\\\", {\\\"Table\\\": \\\"<table border=\\\\\\\"1\\\\\\\" class=\\\\\\\"dataframe\\\\\\\">\\\\n  <thead>\\\\n    <tr style=\\\\\\\"text-align: right;\\\\\\\">\\\\n      <th></th>\\\\n      <th>1.0</th>\\\\n    </tr>\\\\n  </thead>\\\\n  <tbody>\\\\n    <tr>\\\\n      <th>0</th>\\\\n      <td>the subject\\\\u2019s CSF OX/hypocretin-1 concentration is <110 pg/mL, or <1/3 of the mean values obtained in normal subjects with the same standardized assay, may be considered for enrollment into Parts D after a discussion with the sponsor or designee. During the screening period, the subject must have \\\\u22654 partial or complete episodes of cataplexy/week (WCR), averaged over 2 weeks (14 consecutive days) minimum. WCR recording between 7 days after washout of anticataplexy medications and Day -2 will be considered for study eligibility. Subjects must fill out self-reported cataplexy questions in the electronic diary for at least 11 out of 14 days, to be considered compliance. The eligibility criteria pertaining to WCR must be met prior to check in on Day -2. In cases where the ePRO diary becomes unavailable, the study site may employ alternative methods to collect these data with approval from the sponsor or designee. The subject must have a BMI \\\\u226518.0 and \\\\u226440 kg/m <sup>2</sup> at the screening visit. Healthy Adult Subjects for Part F The subject must have regular sleep-wake habits (eg, routinely spending 6.5 to 8 hours sleeping nightly, not oversleeping by more than 3 hours on weekends [ie, total sleep not more than 11 hours]) as determined by investigator interviews and confirmed in approximately 10-day actigraphy records with sleep diary record and the subject must regularly fall asleep between 9:30 PM and 12:00 AM and willing to keep the similar sleep/wake pattern throughout the study period.</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>1</th>\\\\n      <td>Main Criteria for Exclusion: The subject must be excluded from participating in the study if: All Subjects The subject has a history of cancer (does not apply to subjects with carcinoma in situ that has been resolved without further treatment or basal cell cancer; these subjects may be included after approval by the medical monitor). The subject has a known hypersensitivity to any component of the formulation of TAK 861 or related compounds. The subject has a current or prior history of substance abuse disorder per the Diagnostic and Statistical Manual of Mental Disorders, 5th Edition criteria. For subjects with NT1 for Part D, history beyond 12 months before baseline may be allowed after consultation with the Medical Monitor. The subject\\\\u2019s renal creatinine clearance (Cockcroft-Gault Equation) is \\\\u226460 mL/min at screening. The subject has a risk of suicide according to endorsement of Item 4 or 5 of the screening/baseline visit Columbia\\\\u2013Suicide Severity Rating Scale or has made a suicide attempt in the previous 6 months. The subject has past or current epilepsy or seizure, tremor, or disorders of related symptoms. Subjects with single febrile seizure episode in childhood will be allowed for Part D. The subject has a lifetime history of major psychiatric disorder, such as bipolar disorder or schizophrenia. Subjects who have history of major depressive disorder (MDD) may be included, but subjects who have current active MDD or who have had active MDD in the past 6 months are excluded. The subject has a clinically significant history of head injury or head trauma. The subject has a history of cerebral ischemia, transient ischemic attack, intracranial aneurysm, or arteriovenous malformation. The subject has known coronary artery disease, a history of myocardial infarction, angina, cardiac rhythm abnormality, or heart failure. The subject has a resting heart rate outside of the range of 45 to 100 beats per minute at screening, confirmed on repeat testing within a maximum of 30 minutes. For subjects with NT1 for Part D, a range of 40 to 100 beats per minute at screening will be applied. The subject has a medical condition (other than narcolepsy for subjects with NT1 in Part D), such as medically significant unstable cardiovascular, pulmonary, hepatic, renal, or gastrointestinal disease, that would preclude enrollment in the view of the investigator. The subject has current or recent (within 6 months) gastrointestinal disease that is expected to influence the absorption of drugs (ie, a history of malabsorption, esophageal reflux, peptic ulcer disease, erosive esophagitis, frequent [more than once per week] occurrence of heartburn, or any surgical intervention). Any history of</td>\\\\n    </tr>\\\\n  </tbody>\\\\n</table>\\\", \\\"SectionHeaderPrintPage\\\": \\\"9\\\", \\\"TableIndex\\\": \\\"9\\\", \\\"TableName\\\": \\\"1.0 STUDY SUMMARY\\\", \\\"Header\\\": [1]}, {\\\"IsBold\\\": false, \\\"font_size\\\": 20, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [{\\\"start_idx\\\": 14, \\\"end_idx\\\": 16, \\\"standard_entity_name\\\": \\\"Molecule\\\", \\\"subcategory\\\": \\\"Molecule\\\", \\\"confidence\\\": 37.0, \\\"text\\\": \\\"CSF\\\"}], \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 20, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"STUDY SUMMARY\\\", \\\"1.0\\\", \\\"1\\\", 255], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"STUDY SUMMARY\\\", \\\"1.0\\\", \\\"1\\\", 256], [\\\"\\\", \\\"Unmapped\\\", \\\"table\\\", {\\\"Table\\\": \\\"<table border=\\\\\\\"1\\\\\\\" class=\\\\\\\"dataframe\\\\\\\">\\\\n  <thead>\\\\n    <tr style=\\\\\\\"text-align: right;\\\\\\\">\\\\n      <th></th>\\\\n      <th>1.0</th>\\\\n    </tr>\\\\n  </thead>\\\\n  <tbody>\\\\n    <tr>\\\\n      <th>0</th>\\\\n      <td>Roux-en-Y gastric bypass is considered exclusionary and any other surgical intervention that may influence the absorption of drugs should be discussed and approved by the sponsor or designee before enrolling the subject. The subject has liver function test (LFT) values (alanine aminotransferase, aspartate aminotransferase) higher than 1.5 times the upper limit of normal at screening. Healthy Adult Subjects for Parts A, B, C, E, and F The subject has a history of alcohol consumption exceeding 2 standard drinks per day on average (1 glass is approximately equivalent to the following: beer [354 mL/12 oz], wine [118 mL/4 oz], or distilled spirits [29.5 mL/1 oz] per day). Healthy Adult Subjects in Cohorts A3 and A10  The subject is lactose intolerant. Subjects With NT1 for Part D The subject used NT1 medication within at least 7 days or 5 times the elimination half-lives whichever is longer as defined in the protocol section about excluded medications. The subject is an excessive (>600 mg/day) caffeine user 1 week before the study screening. The subject has a medical disorder, other than narcolepsy, associated with excessive daytime sleepiness (EDS). This includes clinically significant moderate to severe obstructive sleep apnea wi th or without treatment with mandibular advanced device hypoglossal nerve stimulation and/or positive airway pressure (PAP) therapy, and/or restless legs syndrome (RLS)/periodic limb movement disorder that has a significant impact on daytime sleepiness. This is evidenced by a clinical history of sleep apnea syndrome (loud snoring with observed respiratory pauses in the absence of nPSG) and/or RLS causing historical sleep onset/maintenance insomnia with resultant insufficient sleep as evaluated during the clinical interview at screening. Or any past PSG data demonstrating any of the following sleep disturbances: apnea-hypopnea index \\\\u226515 or apnea index \\\\u226510, oxygen saturation of < 80 for > 10 seconds, periodic leg movement arousal index of \\\\u226515/h, should be considered exclusionary unless, based on a clinical evaluation by the investigator, a meaningful change in clinical status has occurred that would not impact the results. Because nPSG data is obtained on Day -2, subjects may fail screening if criteria are not meet on the Day -2 nPSG. The subject has any other medical condition, such as anxiety, depression, heart disease, or significant hepatic, pulmonary, or renal disease, that requires the subject to take excluded medications or at the time of screening the subject is being treated with nasal/oro-nasal PAP for any reason. Subjects Who Undergo CSF Sampling (Part D as Optional and Cohort F as Mandatory) Note: For subjects in Part D, a subject who meets the criteria below can still participate in the study if the subject will not undergo optional CSF sampling. The subject has undergone CSF collection within 30 days before check-in. The subject has significant vertebral deformities (scoliosis or kyphosis) that, in the opinion of the investigator, may interfere with the lumbar puncture procedure. The subject has a history of major back (lumbar) surgery, clinically significant back pain, and/or injury, in the opinion of the investigator. The subject has developed signs of lumbar radiculopathy, including lower extremity pain and paresthesia. The subject has any known focal neurological deficit that might suggest an increase in intracranial pressure. The subject has a bleeding abnormality or history of bleeding abnormalities. The subject has thrombocytopenia or other suspected bleeding tendencies noted. The subject is taking an anticoagulant or has abnormal coagulation tests (prothrombin time/international normalized ratio, activated partial thromboplastin time) at screening (1 tablet per day of low dose aspirin [81 mg] is allowed for subjects for Part D). Healthy Adult Subjects for Part F  Have excessive sleepiness, defined by a self-reported ESS score at screening >10; irregular work hours; or routine night-shift work within 1 month before randomization. Have a history of or currently is experiencing any known/suspected sleep disorder (including obstructive sleep</td>\\\\n    </tr>\\\\n  </tbody>\\\\n</table>\\\", \\\"SectionHeaderPrintPage\\\": \\\"9\\\", \\\"TableIndex\\\": \\\"10\\\", \\\"TableName\\\": \\\"1.0 STUDY SUMMARY\\\", \\\"Header\\\": []}, {\\\"IsBold\\\": false, \\\"font_size\\\": 20, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 20, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"STUDY SUMMARY\\\", \\\"1.0\\\", \\\"1\\\", 257], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"STUDY SUMMARY\\\", \\\"1.0\\\", \\\"1\\\", 258], [\\\"\\\", \\\"Unmapped\\\", \\\"table\\\", {\\\"Table\\\": \\\"<table border=\\\\\\\"1\\\\\\\" class=\\\\\\\"dataframe\\\\\\\">\\\\n  <thead>\\\\n    <tr style=\\\\\\\"text-align: right;\\\\\\\">\\\\n      <th></th>\\\\n      <th>1.0</th>\\\\n    </tr>\\\\n  </thead>\\\\n  <tbody>\\\\n    <tr>\\\\n      <th>0</th>\\\\n      <td>apnea and RLS), any disorder associated with EDS. At the time of screening, be receiving treatment with nasal/oronasal PAP for any reason. Have traveled across 2 or more time zones within the 2 weeks before screening.</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>1</th>\\\\n      <td>Main Criteria for Evaluation and Analyses: The primary endpoints of the study are: Number of subjects with at least 1 treatment-emergent adverse event (TEAE) postdose. Number of subjects with at least 1 markedly abnormal value (MAV) for laboratory assessments postdose. Number of subjects with at least 1 MAVs for vital signs postdose. Number of subjects with at least 1 MAVs for ECGs postdose. The secondary endpoints will be assessed through evaluation of the following parameters: PK parameters of TAK-861 in healthy subjects (Parts A, B, C, E, and F) after a single dose (Day 1 [fasted] or Day 15 [fed]: maximum observed plasma concentration [C max ], time of first occurrence of C max [t max ], area under the plasma concentration-time from time 0 to time of the last quantifiable concentration [AUC last ], area under the plasma concentration-time curve from time 0 to infinity [AUC \\\\u221e ], and terminal disposition phase half-life). PK parameters of TAK-861 in healthy subjects (Parts B, C, E and F) after multiple doses (Day 10 or Day 14 or Day 19: C max t max area under the plasma concentration-time curve during a dosing interval [AUC \\\\u03c4 ], and accumulation ratio). PK parameters of TAK-861 in subjects with NT1 (Part D) after single dose (Day 1: C max t max AUC last ) and multiple doses (Day 14: C max t max AUC \\\\u03c4 ). The exploratory endpoints of the study are Additional PK parameters of TAK-861 from plasma, urine, and CSF. Change from baseline in overactive bladder\\\\u2013related symptom bother as evaluated by a checklist. For Parts B and E: The concentration of CPI and CPIII and their PK parameters. For Parts B through E: The change of 4\\\\u03b2-hydroxycholesterol/cholesterol ratio after repeated dosing. For Parts B through F: Parameters on sleep and wakefulness from wearable devices used in the study. Parameters from continuous accelerometry (actigraphy) monitoring from screening through dosing period. Subjective daytime sleepiness using the KSS. For Part D only: Change from baseline in mean sleep latency from 4 trials of MWT to Days 1 and 14. Change from baseline in the total score of subjective daytime sleepiness scale, ESS. Change from baseline in the WCR as reported in the patient-reported sleep diary. PGI-I and CGI-I scores. Change from baseline on scores of PGI-S and CGI-S scales. Change in weekly frequency of REM sleep-related abnormalities, including hypnagogic/hypnopompic hallucination, sleep paralysis, and nocturnal awakenings, from baseline as reported in the patient-reported daily sleep diary. Change in various sleep metrics obtained from nocturnal polysomnography (nPSG) and/or portable EEG, including nocturnal awakenings, from baseline. Change in various measures captured on cognitive tests (SART and CPAL), including attention, vigilance, and memory, from baseline. Change in scores from baseline to Day 15 on Pilot NT1 Items. Change in scores from baseline to Day 15 EQ-5D-5L scales.</td>\\\\n    </tr>\\\\n  </tbody>\\\\n</table>\\\", \\\"SectionHeaderPrintPage\\\": \\\"9\\\", \\\"TableIndex\\\": \\\"11\\\", \\\"TableName\\\": \\\"1.0 STUDY SUMMARY\\\", \\\"Header\\\": [1]}, {\\\"IsBold\\\": false, \\\"font_size\\\": 20, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 20, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"STUDY SUMMARY\\\", \\\"1.0\\\", \\\"1\\\", 259], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"STUDY SUMMARY\\\", \\\"1.0\\\", \\\"1\\\", 260], [\\\"\\\", \\\"Unmapped\\\", \\\"table\\\", {\\\"Table\\\": \\\"<table border=\\\\\\\"1\\\\\\\" class=\\\\\\\"dataframe\\\\\\\">\\\\n  <thead>\\\\n    <tr style=\\\\\\\"text-align: right;\\\\\\\">\\\\n      <th></th>\\\\n      <th>1.0</th>\\\\n    </tr>\\\\n  </thead>\\\\n  <tbody>\\\\n    <tr>\\\\n      <th>0</th>\\\\n      <td>For Part F only: OX levels in CSF. The additional exploratory endpoints: Time-matched change in clinic BP and pulse rate from baseline to postdose on Days 1, 7, 10, or 14 in applicable study parts. Change in ambulatory BP and pulse rate parameters from baseline to the steady state, in applicable study parts. Holter ECG parameters for assessment of the effect of TAK-861 on QT intervals (on Days 1 and 14 postdose, in applicable study parts) The safety endpoints of the study are: Safety and tolerability: adverse events (AEs), vital signs, 12-lead ECG, and clinical laboratory tests.</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>1</th>\\\\n      <td>Statistical Considerations: Safety Analysis: All data analyses and summaries will be performed separately for each study part. All AEs will be coded by System Organ Class and Preferred Term using the Medical Dictionary for Regulatory Activities. TEAEs will be summarized in each study part by treatment, for TAK-861 overall, and for each study part, the placebo subjects from each cohort will be pooled together in summery statistics and data analysis. Where appropriate, safety laboratory assessments, vital signs, ECGs, and Holter ECG parameters (N, mean, SD, median, minimum, and maximum) will be summarized for baseline, postdose, and change from baseline (or change from time-matched baseline to postdose, if appropriate) by treatment. Subjects meeting markedly abnormal criteria will be listed and summarized. Linear mixed-effect models for the repeated measures will be performed to evaluate the drug effect on clinic BP and pulse rate. In these analyses, change from time-matched baseline will be the response and baseline, treatment, time point, and the treatment by time point interaction will be the fixed effects. The relationships between TAK-861 exposure and selected safety measures will be explored graphically, as data permit. Ambulatory BP parameters will be summarized at baseline and scheduled postdose days. Change from baseline will also be summarized. Analysis of covariance or linear mixed-effect model for repeated measures will be used to analyze the drug effect on change from baseline in the ambulatory BP parameters. PK Analyses: Individual concentrations of TAK-861 in the plasma and CSF will be presented in a data listing and summarized by study part, dose level and dosage form, day, and nominal sampling time point using descriptive statistics (arithmetic mean, SD, coefficient of variation, median, minimum, maximum, geometric mean, and coefficient variation for geometric mean), as deemed appropriate. Dose proportionality will be assessed graphically by dosage form if data permit (dose-normalized C max and area under the plasma concentration-time curve [AUC] vs dose). To assess dose proportionality after single and multiple dosing, a power model or analysis of variance (ANOVA) model will be used. Trough plasma concentrations measured in the MRD cohorts will be summarized to assess steady state. For the food effect cohorts in Part A, concentrations of TAK-861 in the plasma will be summarized by regimen (fasted or fed) and nominal sampling time using descriptive statistics. The plasma PK parameters will be summarized for the fasting and fed (standard meal, high-fat meal) conditions. Additionally, exposure parameters (C max and AUC) may be dose-normalized as deemed necessary. Individual concentration data and PK parameters will be presented in data listings. A 1-way ANOVA will be performed on the natural logarithms of TAK-861 C max and AUC (AUC includes AUC last and AUC \\\\u221e or any other AUC as data permits for this evaluation), with values normalized to dose if deemed necessary. The effect of food on the TAK-861 tablet formulation will be evaluated by the ratio and 90% CI of TAK-861 exposure in the fed versus fasted state. For the multiple dose parts, an ANOVA model may be used to assess time dependency in the kinetics of plasma TAK-861 after single and 7 to 14 days of dosing. As data permit, time invariance will be assessed by comparing the AUC \\\\u03c4 after 7 to 14 days of dosing to the AUC \\\\u221e for Day 1, separately for each study part and dose level. The model will include dose, day, and the interaction of dose level by day as factors with the natural logarithmic AUCs as the</td>\\\\n    </tr>\\\\n  </tbody>\\\\n</table>\\\", \\\"SectionHeaderPrintPage\\\": \\\"9\\\", \\\"TableIndex\\\": \\\"12\\\", \\\"TableName\\\": \\\"1.0 STUDY SUMMARY\\\", \\\"Header\\\": [0, 1]}, {\\\"IsBold\\\": false, \\\"font_size\\\": 20, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": true, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 20, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"STUDY SUMMARY\\\", \\\"1.0\\\", \\\"1\\\", 261], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"STUDY SUMMARY\\\", \\\"1.0\\\", \\\"1\\\", 262], [\\\"\\\", \\\"Unmapped\\\", \\\"table\\\", {\\\"Table\\\": \\\"<table border=\\\\\\\"1\\\\\\\" class=\\\\\\\"dataframe\\\\\\\">\\\\n  <thead>\\\\n    <tr style=\\\\\\\"text-align: right;\\\\\\\">\\\\n      <th></th>\\\\n      <th>1.0</th>\\\\n    </tr>\\\\n  </thead>\\\\n  <tbody>\\\\n    <tr>\\\\n      <th>0</th>\\\\n      <td>response. For Parts B through E, the intrinsic CYP3A4/5 activity will be evaluated by the ratio of 4\\\\u03b2 hydroxycholesterol versus cholesterol concentrations. The ratio of hydroxycholesterol over cholesterol will be summarized by dose and day. For Parts B and E, the intrinsic OATP1B1/3 activity will be evaluated by the change in C max or AUC last of CPI or CPIII from the baseline. The change of CPI and CPIII from the baseline will be summarized by dose and day. Individual TAK-861 urinary excretion data by collection interval will be presented in a data listing. The amount of TAK-861 excreted in urine will be summarized by dose level at each scheduled sampling interval using descriptive statistics. Urine PK parameters will be tabulated and summarized descriptively. PD Analyses: For Part D, observed MWT, KSS, ESS, WCR, and other PD endpoints, and change from baseline (or shift tables) will be summarized by treatment and overall. Placebo subjects from different cohorts will be pooled together as 1 placebo group. Change from baseline in MWT and ESS scores will be analyzed using linear mixed-effect models for repeated measures. Baseline will be included as a covariate, treatment, time, and treatment by time interaction will be included as fixed factors. Other PD measures will use a similar model if deemed appropriate for the type of data. Bayesian posterior probability of the true drug effect on MWT of >8 minutes, on ESS of >4 points reduction will be calculated given the data from Part D.</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>1</th>\\\\n      <td>Sample Size Justification: The sample size for each cohort (for Parts A, B, C, E, and F; 8-10 subjects per cohort: 6 active and 2-4 placebo) is typical for FIH SRD/MRD studies investigating safety, tolerability, PK, and PD in healthy subjects. For Part D, 9 subjects each in Cohorts D1 and D2 will be enrolled to evaluate the safety, tolerability, PK, and PD effects of TAK-861 when multiple doses of TAK-861 are administered orally to subjects with NT1. These sample sizes are not based on any effect size or obtained by the MWT statistical evidence.</td>\\\\n    </tr>\\\\n  </tbody>\\\\n</table>\\\", \\\"SectionHeaderPrintPage\\\": \\\"9\\\", \\\"TableIndex\\\": \\\"13\\\", \\\"TableName\\\": \\\"1.0 STUDY SUMMARY\\\", \\\"Header\\\": [0, 1]}, {\\\"IsBold\\\": false, \\\"font_size\\\": 20, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 20, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"STUDY SUMMARY\\\", \\\"1.0\\\", \\\"1\\\", 263], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"1.1 Protocol Amendment 2 Summary of Changes\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading2\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Protocol Amendment 2 Summary of Changes\\\", \\\"1.1\\\", \\\"2\\\", 264], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Protocol Amendment 2 Summary and Rationale:\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Protocol Amendment 2 Summary of Changes\\\", \\\"1.1\\\", \\\"2\\\", 265], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"This section describes the changes in reference to the protocol incorporating Amendment 2.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Protocol Amendment 2 Summary of Changes\\\", \\\"1.1\\\", \\\"2\\\", 266], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"The primary reasons for this amendment are to:\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Protocol Amendment 2 Summary of Changes\\\", \\\"1.1\\\", \\\"2\\\", 267], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\\u2022 Clarify maximum dose levels and exposure.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Protocol Amendment 2 Summary of Changes\\\", \\\"1.1\\\", \\\"2\\\", 268], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\\u2022 Update study exclusion criterion based on recent surgery or blood donation.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Protocol Amendment 2 Summary of Changes\\\", \\\"1.1\\\", \\\"2\\\", 269], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"In this amendment, minor grammatical, editorial, formatting, and administrative changes not affecting the conduct of the study are included for clarification and administrative purposes only.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Protocol Amendment 2 Summary of Changes\\\", \\\"1.1\\\", \\\"2\\\", 270], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Protocol Amendment 2 Summary of Changes\\\", \\\"1.1\\\", \\\"2\\\", 271], [\\\"\\\", \\\"Unmapped\\\", \\\"table\\\", {\\\"Table\\\": \\\"<table border=\\\\\\\"1\\\\\\\" class=\\\\\\\"dataframe\\\\\\\">\\\\n  <thead>\\\\n    <tr style=\\\\\\\"text-align: right;\\\\\\\">\\\\n      <th></th>\\\\n      <th>1.0</th>\\\\n      <th>2.0</th>\\\\n      <th>3.0</th>\\\\n      <th>4.0</th>\\\\n    </tr>\\\\n  </thead>\\\\n  <tbody>\\\\n    <tr>\\\\n      <th>0</th>\\\\n      <td></td>\\\\n      <td>Protocol Amendment 2</td>\\\\n      <td>Protocol Amendment 2</td>\\\\n      <td>Protocol Amendment 2</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>1</th>\\\\n      <td></td>\\\\n      <td>Summary of Changes Since the Last Version of the Approved Protocol</td>\\\\n      <td>Summary of Changes Since the Last Version of the Approved Protocol</td>\\\\n      <td>Summary of Changes Since the Last Version of the Approved Protocol</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>2</th>\\\\n      <td>Change Number</td>\\\\n      <td>Sections Affected by Change</td>\\\\n      <td>Description of Each Change and Rationale</td>\\\\n      <td>Description of Each Change and Rationale</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>3</th>\\\\n      <td></td>\\\\n      <td>Location</td>\\\\n      <td>Description</td>\\\\n      <td>Rationale</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>4</th>\\\\n      <td>1</td>\\\\n      <td>Section 1.0 STUDY SUMMARY; Section 6.3.4 Maximum Dose/Exposure for This Study</td>\\\\n      <td>Maximum dose exposure for the study has been specified.</td>\\\\n      <td>Clarification.</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>5</th>\\\\n      <td>2</td>\\\\n      <td>Section 6.1.1 Part A: SRD in Japanese Healthy Adults</td>\\\\n      <td>To make sentinel dosing execution possible in all Part A cohorts.</td>\\\\n      <td>Revision.</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>6</th>\\\\n      <td>3</td>\\\\n      <td>Section 6.2.1 Dose Selection Rules</td>\\\\n      <td>Dose selection rule section has been clarified.</td>\\\\n      <td>Clarification.</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>7</th>\\\\n      <td>4</td>\\\\n      <td>Section 7.2 Exclusion Criteria</td>\\\\n      <td>Exclusion criteria based on recent surgery or blood donation has been revised.</td>\\\\n      <td>Revision of the criteria based on local regulation.</td>\\\\n    </tr>\\\\n  </tbody>\\\\n</table>\\\", \\\"SectionHeaderPrintPage\\\": \\\"18\\\", \\\"TableIndex\\\": \\\"14\\\", \\\"TableName\\\": \\\"1.1 Protocol Amendment 2 Summary of Changes\\\", \\\"Header\\\": [0, 1, 2, 3]}, {\\\"IsBold\\\": true, \\\"font_size\\\": 20, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 20, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Protocol Amendment 2 Summary of Changes\\\", \\\"1.1\\\", \\\"2\\\", 272], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Protocol Amendment 2 Summary of Changes\\\", \\\"1.1\\\", \\\"2\\\", 273], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Protocol Amendment 2 Summary of Changes\\\", \\\"1.1\\\", \\\"2\\\", 274], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Protocol Amendment 2 Summary of Changes\\\", \\\"1.1\\\", \\\"2\\\", 275], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"2.0 STUDY SCHEMATIC\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading1\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"STUDY SCHEMATIC\\\", \\\"2.0\\\", \\\"1\\\", 276], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Study diagrams for Part A, B, C, E, and F can be found in Section 6.1.\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"STUDY SCHEMATIC\\\", \\\"2.0\\\", \\\"1\\\", 277], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Figure 2.a\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"STUDY SCHEMATIC\\\", \\\"2.0\\\", \\\"1\\\", 278], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"STUDY SCHEMATIC\\\", \\\"2.0\\\", \\\"1\\\", 279], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Study Diagram NT1 (Part D)\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"STUDY SCHEMATIC\\\", \\\"2.0\\\", \\\"1\\\", 280], [\\\"\\\", \\\"Unmapped\\\", \\\"table\\\", {\\\"Table\\\": \\\"<table border=\\\\\\\"1\\\\\\\" class=\\\\\\\"dataframe\\\\\\\">\\\\n  <thead>\\\\n    <tr style=\\\\\\\"text-align: right;\\\\\\\">\\\\n      <th></th>\\\\n      <th>1.0</th>\\\\n      <th>3.0</th>\\\\n      <th>4.0</th>\\\\n      <th>6.0</th>\\\\n    </tr>\\\\n  </thead>\\\\n  <tbody>\\\\n    <tr>\\\\n      <th>0</th>\\\\n      <td>Screening (Day -45 to -3)</td>\\\\n      <td>Baseline (Day -2 to -1)</td>\\\\n      <td>Treatment Period: 14 days of study drug (Days 1 to 15)</td>\\\\n      <td>Follow-up (Day 21 \\\\u00b1 2)</td>\\\\n    </tr>\\\\n  </tbody>\\\\n</table>\\\", \\\"SectionHeaderPrintPage\\\": \\\"19\\\", \\\"TableIndex\\\": \\\"15\\\", \\\"TableName\\\": \\\"2.0 STUDY SCHEMATIC\\\", \\\"Header\\\": [0]}, {\\\"IsBold\\\": true, \\\"font_size\\\": 12, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 12, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"STUDY SCHEMATIC\\\", \\\"2.0\\\", \\\"1\\\", 281], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"STUDY SCHEMATIC\\\", \\\"2.0\\\", \\\"1\\\", 282], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"STUDY SCHEMATIC\\\", \\\"2.0\\\", \\\"1\\\", 283], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"ePRO: cataplexy, sleep diary parameters\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": 12, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 12, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"STUDY SCHEMATIC\\\", \\\"2.0\\\", \\\"1\\\", 284], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Accelerometry (actigraphy) (Screening to Day 14)\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": 12, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 12, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"STUDY SCHEMATIC\\\", \\\"2.0\\\", \\\"1\\\", 285], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Days - to 45-3Days - to 2-11-23-56-78-1213-1415\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": 12, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 12, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"STUDY SCHEMATIC\\\", \\\"2.0\\\", \\\"1\\\", 286], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Safety, Exp EndptsSafety, Exp EndptsSafety, Exp KEndpts, PSafety, Exp Endpts, PK\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 12, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 12, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"STUDY SCHEMATIC\\\", \\\"2.0\\\", \\\"1\\\", 287], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"NT1 meds washout (up to Day -1)MWTMWT\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": 12, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 12, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"STUDY SCHEMATIC\\\", \\\"2.0\\\", \\\"1\\\", 288], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Optional orexin ~REDACTED~ before Day-14Outpt ABPMhr 24nPSGDay -2\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 12, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 12, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"STUDY SCHEMATIC\\\", \\\"2.0\\\", \\\"1\\\", 289], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"DischargeDay15\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": 12, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 12, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"STUDY SCHEMATIC\\\", \\\"2.0\\\", \\\"1\\\", 290], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"nPSGDay 13Outpt ABPMSafety Follow-up on Day 21\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 12, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 12, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"STUDY SCHEMATIC\\\", \\\"2.0\\\", \\\"1\\\", 291], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\\u00b1\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 12, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Courier New\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 12, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"STUDY SCHEMATIC\\\", \\\"2.0\\\", \\\"1\\\", 292], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"2Outpt ABPMhr 24\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 12, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 12, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"STUDY SCHEMATIC\\\", \\\"2.0\\\", \\\"1\\\", 293], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"MWTPortable EEG (Baseline to Follow-up)\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": 12, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 12, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"STUDY SCHEMATIC\\\", \\\"2.0\\\", \\\"1\\\", 294], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Days - to 45-3Days - to 2-11-23-56-78-1213-1415\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": 12, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Times New Roman\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 12, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"STUDY SCHEMATIC\\\", \\\"2.0\\\", \\\"1\\\", 295], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Safety, Exp EndptsSafety, Exp EndptsSafety, Exp KEndpts, PSafety, Exp Endpts, PK\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 12, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 12, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"STUDY SCHEMATIC\\\", \\\"2.0\\\", \\\"1\\\", 296], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"NT1 meds washout (up to Day -1)MWTMWT\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": 12, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Times New Roman\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 12, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"STUDY SCHEMATIC\\\", \\\"2.0\\\", \\\"1\\\", 297], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Optional orexin ~REDACTED~ before Day-14Outpt ABPMhr 24nPSGDay -2\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 12, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 12, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"STUDY SCHEMATIC\\\", \\\"2.0\\\", \\\"1\\\", 298], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"DischargeDay15\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": 12, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Times New Roman\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 12, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"STUDY SCHEMATIC\\\", \\\"2.0\\\", \\\"1\\\", 299], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"nPSGDay 13Outpt ABPMSafety Follow-up on Day 21\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 12, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 12, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"STUDY SCHEMATIC\\\", \\\"2.0\\\", \\\"1\\\", 300], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\\u00b1\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 12, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Courier New\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 12, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"STUDY SCHEMATIC\\\", \\\"2.0\\\", \\\"1\\\", 301], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"2Outpt ABPMhr 24\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 12, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 12, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"STUDY SCHEMATIC\\\", \\\"2.0\\\", \\\"1\\\", 302], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"MWTPortable EEG (Baseline to Follow-up)\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": 12, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Times New Roman\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 12, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"STUDY SCHEMATIC\\\", \\\"2.0\\\", \\\"1\\\", 303], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Days\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": 12, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 12, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"STUDY SCHEMATIC\\\", \\\"2.0\\\", \\\"1\\\", 304], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"-\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": 12, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 12, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"STUDY SCHEMATIC\\\", \\\"2.0\\\", \\\"1\\\", 305], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"to\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": 12, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 12, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"STUDY SCHEMATIC\\\", \\\"2.0\\\", \\\"1\\\", 306], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"45\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": 12, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 12, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"STUDY SCHEMATIC\\\", \\\"2.0\\\", \\\"1\\\", 307], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"-\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": 12, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 12, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"STUDY SCHEMATIC\\\", \\\"2.0\\\", \\\"1\\\", 308], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"3\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": 12, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 12, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"STUDY SCHEMATIC\\\", \\\"2.0\\\", \\\"1\\\", 309], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Days\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": 12, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 12, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"STUDY SCHEMATIC\\\", \\\"2.0\\\", \\\"1\\\", 310], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"-\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": 12, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 12, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"STUDY SCHEMATIC\\\", \\\"2.0\\\", \\\"1\\\", 311], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"to\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": 12, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 12, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"STUDY SCHEMATIC\\\", \\\"2.0\\\", \\\"1\\\", 312], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"2\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": 12, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 12, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"STUDY SCHEMATIC\\\", \\\"2.0\\\", \\\"1\\\", 313], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"-\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": 12, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 12, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"STUDY SCHEMATIC\\\", \\\"2.0\\\", \\\"1\\\", 314], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"1\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": 12, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 12, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"STUDY SCHEMATIC\\\", \\\"2.0\\\", \\\"1\\\", 315], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"1\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": 12, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 12, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"STUDY SCHEMATIC\\\", \\\"2.0\\\", \\\"1\\\", 316], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"-\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": 12, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 12, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"STUDY SCHEMATIC\\\", \\\"2.0\\\", \\\"1\\\", 317], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"2\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": 12, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 12, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"STUDY SCHEMATIC\\\", \\\"2.0\\\", \\\"1\\\", 318], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"3\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": 12, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 12, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"STUDY SCHEMATIC\\\", \\\"2.0\\\", \\\"1\\\", 319], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"-\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": 12, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 12, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"STUDY SCHEMATIC\\\", \\\"2.0\\\", \\\"1\\\", 320], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"5\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": 12, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 12, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"STUDY SCHEMATIC\\\", \\\"2.0\\\", \\\"1\\\", 321], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"6\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": 12, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 12, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"STUDY SCHEMATIC\\\", \\\"2.0\\\", \\\"1\\\", 322], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"-\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": 12, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 12, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"STUDY SCHEMATIC\\\", \\\"2.0\\\", \\\"1\\\", 323], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"7\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": 12, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 12, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"STUDY SCHEMATIC\\\", \\\"2.0\\\", \\\"1\\\", 324], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"8\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": 12, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 12, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"STUDY SCHEMATIC\\\", \\\"2.0\\\", \\\"1\\\", 325], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"-\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": 12, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 12, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"STUDY SCHEMATIC\\\", \\\"2.0\\\", \\\"1\\\", 326], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"12\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": 12, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 12, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"STUDY SCHEMATIC\\\", \\\"2.0\\\", \\\"1\\\", 327], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"13\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": 12, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 12, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"STUDY SCHEMATIC\\\", \\\"2.0\\\", \\\"1\\\", 328], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"-\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": 12, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 12, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"STUDY SCHEMATIC\\\", \\\"2.0\\\", \\\"1\\\", 329], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"14\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": 12, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 12, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"STUDY SCHEMATIC\\\", \\\"2.0\\\", \\\"1\\\", 330], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"15\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": 12, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 12, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"STUDY SCHEMATIC\\\", \\\"2.0\\\", \\\"1\\\", 331], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Safety, Exp\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 12, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 12, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"STUDY SCHEMATIC\\\", \\\"2.0\\\", \\\"1\\\", 332], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Endpts\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 12, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 12, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"STUDY SCHEMATIC\\\", \\\"2.0\\\", \\\"1\\\", 333], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Safety,\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 12, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 12, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"STUDY SCHEMATIC\\\", \\\"2.0\\\", \\\"1\\\", 334], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Exp Endpts\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 12, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 12, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"STUDY SCHEMATIC\\\", \\\"2.0\\\", \\\"1\\\", 335], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Safety, Ex\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 12, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 12, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"STUDY SCHEMATIC\\\", \\\"2.0\\\", \\\"1\\\", 336], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"p\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 12, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 12, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"STUDY SCHEMATIC\\\", \\\"2.0\\\", \\\"1\\\", 337], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"K\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 12, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 12, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"STUDY SCHEMATIC\\\", \\\"2.0\\\", \\\"1\\\", 338], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Endpts, P\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 12, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 12, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"STUDY SCHEMATIC\\\", \\\"2.0\\\", \\\"1\\\", 339], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Safety, Exp\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 12, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 12, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"STUDY SCHEMATIC\\\", \\\"2.0\\\", \\\"1\\\", 340], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Endpts, PK\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 12, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 12, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"STUDY SCHEMATIC\\\", \\\"2.0\\\", \\\"1\\\", 341], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"NT1 meds washout\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": 12, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 12, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"STUDY SCHEMATIC\\\", \\\"2.0\\\", \\\"1\\\", 342], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"(\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": 12, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 12, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"STUDY SCHEMATIC\\\", \\\"2.0\\\", \\\"1\\\", 343], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"up to Day\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": 12, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 12, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"STUDY SCHEMATIC\\\", \\\"2.0\\\", \\\"1\\\", 344], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"-\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": 12, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 12, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"STUDY SCHEMATIC\\\", \\\"2.0\\\", \\\"1\\\", 345], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"1)\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": 12, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 12, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"STUDY SCHEMATIC\\\", \\\"2.0\\\", \\\"1\\\", 346], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"MWT\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": 12, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 12, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"STUDY SCHEMATIC\\\", \\\"2.0\\\", \\\"1\\\", 347], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"MWT\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": 12, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 12, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"STUDY SCHEMATIC\\\", \\\"2.0\\\", \\\"1\\\", 348], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Optional orexin ~REDACTED~ before Day\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 12, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 12, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"STUDY SCHEMATIC\\\", \\\"2.0\\\", \\\"1\\\", 349], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"-\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 12, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 12, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"STUDY SCHEMATIC\\\", \\\"2.0\\\", \\\"1\\\", 350], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"14\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 12, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 12, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"STUDY SCHEMATIC\\\", \\\"2.0\\\", \\\"1\\\", 351], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Outpt ABPM\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 12, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 12, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"STUDY SCHEMATIC\\\", \\\"2.0\\\", \\\"1\\\", 352], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"hr\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 12, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 12, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"STUDY SCHEMATIC\\\", \\\"2.0\\\", \\\"1\\\", 353], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"24\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 12, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 12, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"STUDY SCHEMATIC\\\", \\\"2.0\\\", \\\"1\\\", 354], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"nPSG\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 12, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 12, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"STUDY SCHEMATIC\\\", \\\"2.0\\\", \\\"1\\\", 355], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Day\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 12, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 12, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"STUDY SCHEMATIC\\\", \\\"2.0\\\", \\\"1\\\", 356], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"-\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 12, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 12, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"STUDY SCHEMATIC\\\", \\\"2.0\\\", \\\"1\\\", 357], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"2\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 12, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 12, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"STUDY SCHEMATIC\\\", \\\"2.0\\\", \\\"1\\\", 358], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Discharge\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": 12, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 12, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"STUDY SCHEMATIC\\\", \\\"2.0\\\", \\\"1\\\", 359], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Day15\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": 12, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 12, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"STUDY SCHEMATIC\\\", \\\"2.0\\\", \\\"1\\\", 360], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"nPSG\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 12, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 12, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"STUDY SCHEMATIC\\\", \\\"2.0\\\", \\\"1\\\", 361], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Day 13\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 12, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 12, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"STUDY SCHEMATIC\\\", \\\"2.0\\\", \\\"1\\\", 362], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Outpt ABPM\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 12, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 12, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"STUDY SCHEMATIC\\\", \\\"2.0\\\", \\\"1\\\", 363], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Safety Follow\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 12, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 12, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"STUDY SCHEMATIC\\\", \\\"2.0\\\", \\\"1\\\", 364], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"-\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 12, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 12, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"STUDY SCHEMATIC\\\", \\\"2.0\\\", \\\"1\\\", 365], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"up on Day\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 12, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 12, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"STUDY SCHEMATIC\\\", \\\"2.0\\\", \\\"1\\\", 366], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"21\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 12, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 12, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"STUDY SCHEMATIC\\\", \\\"2.0\\\", \\\"1\\\", 367], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\\u00b1\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 12, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Courier New\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 12, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"STUDY SCHEMATIC\\\", \\\"2.0\\\", \\\"1\\\", 368], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"2\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 12, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 12, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"STUDY SCHEMATIC\\\", \\\"2.0\\\", \\\"1\\\", 369], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Outpt ABPM\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 12, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 12, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"STUDY SCHEMATIC\\\", \\\"2.0\\\", \\\"1\\\", 370], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"hr\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 12, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 12, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"STUDY SCHEMATIC\\\", \\\"2.0\\\", \\\"1\\\", 371], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"24\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 12, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 12, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"STUDY SCHEMATIC\\\", \\\"2.0\\\", \\\"1\\\", 372], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"MWT\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": 12, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 12, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"STUDY SCHEMATIC\\\", \\\"2.0\\\", \\\"1\\\", 373], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Portable EEG (Baseline to\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": 12, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 12, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"STUDY SCHEMATIC\\\", \\\"2.0\\\", \\\"1\\\", 374], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Follow\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": 12, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 12, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"STUDY SCHEMATIC\\\", \\\"2.0\\\", \\\"1\\\", 375], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"-\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": 12, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 12, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"STUDY SCHEMATIC\\\", \\\"2.0\\\", \\\"1\\\", 376], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"up\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": 12, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 12, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"STUDY SCHEMATIC\\\", \\\"2.0\\\", \\\"1\\\", 377], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\")\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": 12, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 12, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"STUDY SCHEMATIC\\\", \\\"2.0\\\", \\\"1\\\", 378], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"STUDY SCHEMATIC\\\", \\\"2.0\\\", \\\"1\\\", 379], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"STUDY SCHEMATIC\\\", \\\"2.0\\\", \\\"1\\\", 380], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"STUDY SCHEMATIC\\\", \\\"2.0\\\", \\\"1\\\", 381], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"STUDY SCHEMATIC\\\", \\\"2.0\\\", \\\"1\\\", 382], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"STUDY SCHEMATIC\\\", \\\"2.0\\\", \\\"1\\\", 383], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"STUDY SCHEMATIC\\\", \\\"2.0\\\", \\\"1\\\", 384], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"STUDY SCHEMATIC\\\", \\\"2.0\\\", \\\"1\\\", 385], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"STUDY SCHEMATIC\\\", \\\"2.0\\\", \\\"1\\\", 386], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"STUDY SCHEMATIC\\\", \\\"2.0\\\", \\\"1\\\", 387], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"STUDY SCHEMATIC\\\", \\\"2.0\\\", \\\"1\\\", 388], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"STUDY SCHEMATIC\\\", \\\"2.0\\\", \\\"1\\\", 389], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"STUDY SCHEMATIC\\\", \\\"2.0\\\", \\\"1\\\", 390], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"STUDY SCHEMATIC\\\", \\\"2.0\\\", \\\"1\\\", 391], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"STUDY SCHEMATIC\\\", \\\"2.0\\\", \\\"1\\\", 392], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"STUDY SCHEMATIC\\\", \\\"2.0\\\", \\\"1\\\", 393], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"STUDY SCHEMATIC\\\", \\\"2.0\\\", \\\"1\\\", 394], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"STUDY SCHEMATIC\\\", \\\"2.0\\\", \\\"1\\\", 395], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"STUDY SCHEMATIC\\\", \\\"2.0\\\", \\\"1\\\", 396], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"STUDY SCHEMATIC\\\", \\\"2.0\\\", \\\"1\\\", 397], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"STUDY SCHEMATIC\\\", \\\"2.0\\\", \\\"1\\\", 398], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"STUDY SCHEMATIC\\\", \\\"2.0\\\", \\\"1\\\", 399], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"STUDY SCHEMATIC\\\", \\\"2.0\\\", \\\"1\\\", 400], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"STUDY SCHEMATIC\\\", \\\"2.0\\\", \\\"1\\\", 401], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"STUDY SCHEMATIC\\\", \\\"2.0\\\", \\\"1\\\", 402], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"STUDY SCHEMATIC\\\", \\\"2.0\\\", \\\"1\\\", 403], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"STUDY SCHEMATIC\\\", \\\"2.0\\\", \\\"1\\\", 404], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"STUDY SCHEMATIC\\\", \\\"2.0\\\", \\\"1\\\", 405], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"STUDY SCHEMATIC\\\", \\\"2.0\\\", \\\"1\\\", 406], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"STUDY SCHEMATIC\\\", \\\"2.0\\\", \\\"1\\\", 407], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"STUDY SCHEMATIC\\\", \\\"2.0\\\", \\\"1\\\", 408], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"STUDY SCHEMATIC\\\", \\\"2.0\\\", \\\"1\\\", 409], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"STUDY SCHEMATIC\\\", \\\"2.0\\\", \\\"1\\\", 410], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"STUDY SCHEMATIC\\\", \\\"2.0\\\", \\\"1\\\", 411], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"STUDY SCHEMATIC\\\", \\\"2.0\\\", \\\"1\\\", 412], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"STUDY SCHEMATIC\\\", \\\"2.0\\\", \\\"1\\\", 413], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"STUDY SCHEMATIC\\\", \\\"2.0\\\", \\\"1\\\", 414], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"STUDY SCHEMATIC\\\", \\\"2.0\\\", \\\"1\\\", 415], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"STUDY SCHEMATIC\\\", \\\"2.0\\\", \\\"1\\\", 416], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"STUDY SCHEMATIC\\\", \\\"2.0\\\", \\\"1\\\", 417], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"STUDY SCHEMATIC\\\", \\\"2.0\\\", \\\"1\\\", 418], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"STUDY SCHEMATIC\\\", \\\"2.0\\\", \\\"1\\\", 419], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"STUDY SCHEMATIC\\\", \\\"2.0\\\", \\\"1\\\", 420], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"STUDY SCHEMATIC\\\", \\\"2.0\\\", \\\"1\\\", 421], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"STUDY SCHEMATIC\\\", \\\"2.0\\\", \\\"1\\\", 422], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"STUDY SCHEMATIC\\\", \\\"2.0\\\", \\\"1\\\", 423], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"STUDY SCHEMATIC\\\", \\\"2.0\\\", \\\"1\\\", 424], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"STUDY SCHEMATIC\\\", \\\"2.0\\\", \\\"1\\\", 425], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"STUDY SCHEMATIC\\\", \\\"2.0\\\", \\\"1\\\", 426], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"STUDY SCHEMATIC\\\", \\\"2.0\\\", \\\"1\\\", 427], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"STUDY SCHEMATIC\\\", \\\"2.0\\\", \\\"1\\\", 428], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"STUDY SCHEMATIC\\\", \\\"2.0\\\", \\\"1\\\", 429], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"STUDY SCHEMATIC\\\", \\\"2.0\\\", \\\"1\\\", 430], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"STUDY SCHEMATIC\\\", \\\"2.0\\\", \\\"1\\\", 431], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"STUDY SCHEMATIC\\\", \\\"2.0\\\", \\\"1\\\", 432], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"STUDY SCHEMATIC\\\", \\\"2.0\\\", \\\"1\\\", 433], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"STUDY SCHEMATIC\\\", \\\"2.0\\\", \\\"1\\\", 434], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"STUDY SCHEMATIC\\\", \\\"2.0\\\", \\\"1\\\", 435], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"STUDY SCHEMATIC\\\", \\\"2.0\\\", \\\"1\\\", 436], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"STUDY SCHEMATIC\\\", \\\"2.0\\\", \\\"1\\\", 437], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"STUDY SCHEMATIC\\\", \\\"2.0\\\", \\\"1\\\", 438], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"STUDY SCHEMATIC\\\", \\\"2.0\\\", \\\"1\\\", 439], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"STUDY SCHEMATIC\\\", \\\"2.0\\\", \\\"1\\\", 440], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"STUDY SCHEMATIC\\\", \\\"2.0\\\", \\\"1\\\", 441], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"STUDY SCHEMATIC\\\", \\\"2.0\\\", \\\"1\\\", 442], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"STUDY SCHEMATIC\\\", \\\"2.0\\\", \\\"1\\\", 443], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"STUDY SCHEMATIC\\\", \\\"2.0\\\", \\\"1\\\", 444], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"STUDY SCHEMATIC\\\", \\\"2.0\\\", \\\"1\\\", 445], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"STUDY SCHEMATIC\\\", \\\"2.0\\\", \\\"1\\\", 446], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"STUDY SCHEMATIC\\\", \\\"2.0\\\", \\\"1\\\", 447], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"STUDY SCHEMATIC\\\", \\\"2.0\\\", \\\"1\\\", 448], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"STUDY SCHEMATIC\\\", \\\"2.0\\\", \\\"1\\\", 449], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"STUDY SCHEMATIC\\\", \\\"2.0\\\", \\\"1\\\", 450], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"STUDY SCHEMATIC\\\", \\\"2.0\\\", \\\"1\\\", 451], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"STUDY SCHEMATIC\\\", \\\"2.0\\\", \\\"1\\\", 452], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"STUDY SCHEMATIC\\\", \\\"2.0\\\", \\\"1\\\", 453], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"ABPM: ambulatory blood pressure monitoring; ~REDACTED~: cerebrospinal fluid; EEG: electroencephalography; ePRO: electronic patient-reported outcomes; Exp Endpts: exploratory endpoints; meds: medications; MWT: Maintenance of Wakefulness Test; nPSG: nocturnal polysomnography; NT1: narcolepsy type 1 (narcolepsy with cataplexy); Outpt: outpatient; PK: pharmacokinetic(s).\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 20, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 20, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"STUDY SCHEMATIC\\\", \\\"2.0\\\", \\\"1\\\", 454], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Red indicates outpatient status; purple indicates inpatient status.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 20, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 20, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"STUDY SCHEMATIC\\\", \\\"2.0\\\", \\\"1\\\", 455], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"3.0 SCHEDULE OF STUDY PROCEDURES\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading1\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"SCHEDULE OF STUDY PROCEDURES\\\", \\\"3.0\\\", \\\"1\\\", 456], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"3.1 Part A\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading2\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part A\\\", \\\"3.1\\\", \\\"2\\\", 457], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"Table 3.a Schedule of Study Procedures for Part A (SRD in Healthy Adults)\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading8\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part A\\\", \\\"3.1\\\", \\\"2\\\", 458], [\\\"\\\", \\\"Unmapped\\\", \\\"table\\\", {\\\"Table\\\": \\\"<table border=\\\\\\\"1\\\\\\\" class=\\\\\\\"dataframe\\\\\\\">\\\\n  <thead>\\\\n    <tr style=\\\\\\\"text-align: right;\\\\\\\">\\\\n      <th></th>\\\\n      <th>1.0</th>\\\\n      <th>2.0</th>\\\\n      <th>3.0</th>\\\\n      <th>4.0</th>\\\\n      <th>5.0</th>\\\\n      <th>6.0</th>\\\\n      <th>7.0</th>\\\\n      <th>8.0</th>\\\\n      <th>9.0</th>\\\\n      <th>10.0</th>\\\\n    </tr>\\\\n  </thead>\\\\n  <tbody>\\\\n    <tr>\\\\n      <th>0</th>\\\\n      <td>Procedures</td>\\\\n      <td>Screening Days -28 to -2</td>\\\\n      <td>Day -1</td>\\\\n      <td>Predose Day 1</td>\\\\n      <td>Postdose Day 1</td>\\\\n      <td>Day 2</td>\\\\n      <td>Day 3 to 5</td>\\\\n      <td>Day 6 <sup>i</sup> Discharge</td>\\\\n      <td>ET</td>\\\\n      <td>Day 9\\\\u00b12 Follow-up Visit</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>1</th>\\\\n      <td>Administrative Procedures</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>2</th>\\\\n      <td>Informed consent</td>\\\\n      <td>X</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>3</th>\\\\n      <td>Inclusion/exclusion criteria</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>4</th>\\\\n      <td>Medical history/demographics</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>5</th>\\\\n      <td>Prior and concomitant medication review (continuous review)</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>6</th>\\\\n      <td>Clinical Procedures/Assessments</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>7</th>\\\\n      <td>Full physical examination</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>8</th>\\\\n      <td>Height, body mass index calculation</td>\\\\n      <td>X</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>9</th>\\\\n      <td>Weight</td>\\\\n      <td>X</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td></td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>10</th>\\\\n      <td>Vital signs (BP [supine], PR [supine], RR, and BT) (see Table 3.c) <sup>a</sup></td>\\\\n      <td>X</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>11</th>\\\\n      <td>Orthostatic BP and pulse rate measurements (see Table 3.c) <sup>b</sup></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>12</th>\\\\n      <td>12-lead ECG standard (see Table 3.c)</td>\\\\n      <td>X</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>13</th>\\\\n      <td>Holter ECG <sup>c</sup></td>\\\\n      <td></td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>14</th>\\\\n      <td>C-SSRS</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td></td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>15</th>\\\\n      <td>Bladder condition checklist</td>\\\\n      <td>X</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>X</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>16</th>\\\\n      <td>TAK-861/placebo administration <sup>d</sup></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>X</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>17</th>\\\\n      <td>AE monitoring (continuous monitoring)</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n    </tr>\\\\n  </tbody>\\\\n</table>\\\", \\\"SectionHeaderPrintPage\\\": \\\"20\\\", \\\"TableIndex\\\": \\\"16\\\", \\\"TableName\\\": \\\"3.1 Part A(Schedule of Assessment)\\\", \\\"Header\\\": [0, 1]}, {\\\"IsBold\\\": true, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part A\\\", \\\"3.1\\\", \\\"2\\\", 459], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part A\\\", \\\"3.1\\\", \\\"2\\\", 460], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part A\\\", \\\"3.1\\\", \\\"2\\\", 461], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part A\\\", \\\"3.1\\\", \\\"2\\\", 462], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part A\\\", \\\"3.1\\\", \\\"2\\\", 463], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part A\\\", \\\"3.1\\\", \\\"2\\\", 464], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part A\\\", \\\"3.1\\\", \\\"2\\\", 465], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part A\\\", \\\"3.1\\\", \\\"2\\\", 466], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part A\\\", \\\"3.1\\\", \\\"2\\\", 467], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part A\\\", \\\"3.1\\\", \\\"2\\\", 468], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part A\\\", \\\"3.1\\\", \\\"2\\\", 469], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part A\\\", \\\"3.1\\\", \\\"2\\\", 470], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part A\\\", \\\"3.1\\\", \\\"2\\\", 471], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part A\\\", \\\"3.1\\\", \\\"2\\\", 472], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part A\\\", \\\"3.1\\\", \\\"2\\\", 473], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part A\\\", \\\"3.1\\\", \\\"2\\\", 474], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part A\\\", \\\"3.1\\\", \\\"2\\\", 475], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part A\\\", \\\"3.1\\\", \\\"2\\\", 476], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part A\\\", \\\"3.1\\\", \\\"2\\\", 477], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part A\\\", \\\"3.1\\\", \\\"2\\\", 478], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part A\\\", \\\"3.1\\\", \\\"2\\\", 479], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part A\\\", \\\"3.1\\\", \\\"2\\\", 480], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part A\\\", \\\"3.1\\\", \\\"2\\\", 481], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part A\\\", \\\"3.1\\\", \\\"2\\\", 482], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part A\\\", \\\"3.1\\\", \\\"2\\\", 483], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part A\\\", \\\"3.1\\\", \\\"2\\\", 484], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part A\\\", \\\"3.1\\\", \\\"2\\\", 485], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part A\\\", \\\"3.1\\\", \\\"2\\\", 486], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part A\\\", \\\"3.1\\\", \\\"2\\\", 487], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part A\\\", \\\"3.1\\\", \\\"2\\\", 488], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part A\\\", \\\"3.1\\\", \\\"2\\\", 489], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part A\\\", \\\"3.1\\\", \\\"2\\\", 490], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part A\\\", \\\"3.1\\\", \\\"2\\\", 491], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part A\\\", \\\"3.1\\\", \\\"2\\\", 492], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part A\\\", \\\"3.1\\\", \\\"2\\\", 493], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part A\\\", \\\"3.1\\\", \\\"2\\\", 494], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part A\\\", \\\"3.1\\\", \\\"2\\\", 495], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part A\\\", \\\"3.1\\\", \\\"2\\\", 496], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part A\\\", \\\"3.1\\\", \\\"2\\\", 497], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part A\\\", \\\"3.1\\\", \\\"2\\\", 498], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part A\\\", \\\"3.1\\\", \\\"2\\\", 499], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part A\\\", \\\"3.1\\\", \\\"2\\\", 500], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part A\\\", \\\"3.1\\\", \\\"2\\\", 501], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part A\\\", \\\"3.1\\\", \\\"2\\\", 502], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part A\\\", \\\"3.1\\\", \\\"2\\\", 503], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part A\\\", \\\"3.1\\\", \\\"2\\\", 504], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part A\\\", \\\"3.1\\\", \\\"2\\\", 505], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part A\\\", \\\"3.1\\\", \\\"2\\\", 506], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part A\\\", \\\"3.1\\\", \\\"2\\\", 507], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part A\\\", \\\"3.1\\\", \\\"2\\\", 508], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part A\\\", \\\"3.1\\\", \\\"2\\\", 509], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part A\\\", \\\"3.1\\\", \\\"2\\\", 510], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part A\\\", \\\"3.1\\\", \\\"2\\\", 511], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part A\\\", \\\"3.1\\\", \\\"2\\\", 512], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part A\\\", \\\"3.1\\\", \\\"2\\\", 513], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part A\\\", \\\"3.1\\\", \\\"2\\\", 514], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part A\\\", \\\"3.1\\\", \\\"2\\\", 515], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part A\\\", \\\"3.1\\\", \\\"2\\\", 516], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part A\\\", \\\"3.1\\\", \\\"2\\\", 517], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part A\\\", \\\"3.1\\\", \\\"2\\\", 518], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part A\\\", \\\"3.1\\\", \\\"2\\\", 519], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part A\\\", \\\"3.1\\\", \\\"2\\\", 520], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part A\\\", \\\"3.1\\\", \\\"2\\\", 521], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part A\\\", \\\"3.1\\\", \\\"2\\\", 522], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part A\\\", \\\"3.1\\\", \\\"2\\\", 523], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part A\\\", \\\"3.1\\\", \\\"2\\\", 524], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part A\\\", \\\"3.1\\\", \\\"2\\\", 525], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part A\\\", \\\"3.1\\\", \\\"2\\\", 526], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part A\\\", \\\"3.1\\\", \\\"2\\\", 527], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part A\\\", \\\"3.1\\\", \\\"2\\\", 528], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part A\\\", \\\"3.1\\\", \\\"2\\\", 529], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part A\\\", \\\"3.1\\\", \\\"2\\\", 530], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part A\\\", \\\"3.1\\\", \\\"2\\\", 531], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part A\\\", \\\"3.1\\\", \\\"2\\\", 532], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part A\\\", \\\"3.1\\\", \\\"2\\\", 533], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part A\\\", \\\"3.1\\\", \\\"2\\\", 534], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part A\\\", \\\"3.1\\\", \\\"2\\\", 535], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part A\\\", \\\"3.1\\\", \\\"2\\\", 536], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part A\\\", \\\"3.1\\\", \\\"2\\\", 537], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part A\\\", \\\"3.1\\\", \\\"2\\\", 538], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part A\\\", \\\"3.1\\\", \\\"2\\\", 539], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part A\\\", \\\"3.1\\\", \\\"2\\\", 540], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part A\\\", \\\"3.1\\\", \\\"2\\\", 541], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part A\\\", \\\"3.1\\\", \\\"2\\\", 542], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part A\\\", \\\"3.1\\\", \\\"2\\\", 543], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part A\\\", \\\"3.1\\\", \\\"2\\\", 544], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part A\\\", \\\"3.1\\\", \\\"2\\\", 545], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part A\\\", \\\"3.1\\\", \\\"2\\\", 546], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part A\\\", \\\"3.1\\\", \\\"2\\\", 547], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part A\\\", \\\"3.1\\\", \\\"2\\\", 548], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part A\\\", \\\"3.1\\\", \\\"2\\\", 549], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part A\\\", \\\"3.1\\\", \\\"2\\\", 550], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part A\\\", \\\"3.1\\\", \\\"2\\\", 551], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part A\\\", \\\"3.1\\\", \\\"2\\\", 552], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part A\\\", \\\"3.1\\\", \\\"2\\\", 553], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part A\\\", \\\"3.1\\\", \\\"2\\\", 554], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part A\\\", \\\"3.1\\\", \\\"2\\\", 555], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part A\\\", \\\"3.1\\\", \\\"2\\\", 556], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part A\\\", \\\"3.1\\\", \\\"2\\\", 557], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part A\\\", \\\"3.1\\\", \\\"2\\\", 558], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part A\\\", \\\"3.1\\\", \\\"2\\\", 559], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part A\\\", \\\"3.1\\\", \\\"2\\\", 560], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part A\\\", \\\"3.1\\\", \\\"2\\\", 561], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part A\\\", \\\"3.1\\\", \\\"2\\\", 562], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part A\\\", \\\"3.1\\\", \\\"2\\\", 563], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part A\\\", \\\"3.1\\\", \\\"2\\\", 564], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part A\\\", \\\"3.1\\\", \\\"2\\\", 565], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part A\\\", \\\"3.1\\\", \\\"2\\\", 566], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"Table 3.a Schedule of Study Procedures for Part A (SRD in Healthy Adults)\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading8\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"a  Schedule of Study Procedures for Part A (SRD in Healthy Adults)\\\", \\\"Table 3.\\\", \\\"2\\\", 567], [\\\"\\\", \\\"Unmapped\\\", \\\"table\\\", {\\\"Table\\\": \\\"<table border=\\\\\\\"1\\\\\\\" class=\\\\\\\"dataframe\\\\\\\">\\\\n  <thead>\\\\n    <tr style=\\\\\\\"text-align: right;\\\\\\\">\\\\n      <th></th>\\\\n      <th>1.0</th>\\\\n      <th>2.0</th>\\\\n      <th>3.0</th>\\\\n      <th>4.0</th>\\\\n      <th>5.0</th>\\\\n      <th>6.0</th>\\\\n      <th>7.0</th>\\\\n      <th>8.0</th>\\\\n      <th>9.0</th>\\\\n      <th>10.0</th>\\\\n      <th>11.0</th>\\\\n    </tr>\\\\n  </thead>\\\\n  <tbody>\\\\n    <tr>\\\\n      <th>0</th>\\\\n      <td>Procedures</td>\\\\n      <td>Screening Days -28 to -2</td>\\\\n      <td>Day -1</td>\\\\n      <td></td>\\\\n      <td>Predose Day 1</td>\\\\n      <td>Postdose Day 1</td>\\\\n      <td>Day 2</td>\\\\n      <td>Day 3 to 5</td>\\\\n      <td>Day 6 <sup>i</sup> Discharge</td>\\\\n      <td>ET</td>\\\\n      <td>Day 9\\\\u00b12 Follow-up Visit</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>1</th>\\\\n      <td>Laboratory Procedures/Assessments</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>2</th>\\\\n      <td>Hematology and blood chemistry <sup>e</sup></td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td></td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>3</th>\\\\n      <td>FSH assessment (optional; for postmenopausal women) <sup>f</sup></td>\\\\n      <td>X</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>4</th>\\\\n      <td>Urinalysis</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>X</td>\\\\n      <td></td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>5</th>\\\\n      <td><span class=\\\\\\\"redact\\\\\\\"> ~REDACTED~ </span>  screening and urine drug screen</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>6</th>\\\\n      <td>Hepatitis and HIV screen</td>\\\\n      <td>X</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>7</th>\\\\n      <td>Blood for retained samples and pharmacogenomics <sup>g</sup></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>8</th>\\\\n      <td>PK Evaluations</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>9</th>\\\\n      <td>Blood sample for PK TAK-861 (See Table 3.c)</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>10</th>\\\\n      <td>Urine sample for PK TAK-861 (See Table 3.c)</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>11</th>\\\\n      <td>Other</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>12</th>\\\\n      <td>Check-in <sup>h</sup></td>\\\\n      <td>X</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>13</th>\\\\n      <td>Confinement</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td></td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td></td>\\\\n    </tr>\\\\n  </tbody>\\\\n</table>\\\", \\\"SectionHeaderPrintPage\\\": \\\"20\\\", \\\"TableIndex\\\": \\\"17\\\", \\\"TableName\\\": \\\"Table 3.a Schedule of Study Procedures for Part A (SRD in Healthy Adults)(Schedule of Assessment)\\\", \\\"AttachmentEntities\\\": [{\\\"content\\\": \\\"Administrative Procedures Informed consent X\\\", \\\"entities\\\": []}, {\\\"content\\\": \\\"Clinical Procedures/Assessments\\\", \\\"entities\\\": []}, {\\\"content\\\": \\\"Height, body mass index calculation X\\\", \\\"entities\\\": []}, {\\\"content\\\": \\\"Vital signs (BP [supine], PR [supine], RR, and BT) (see X Table 3.c) a\\\", \\\"entities\\\": []}, {\\\"content\\\": \\\"Orthostatic BP and pulse rate measurements (see Table 3.c) b\\\", \\\"entities\\\": []}, {\\\"content\\\": \\\"12-lead ECG standard (see Table 3.c) X\\\", \\\"entities\\\": []}, {\\\"content\\\": \\\"TAK-861/placebo administration d X\\\", \\\"entities\\\": []}, {\\\"content\\\": \\\"AE: adverse event; BP: blood pressure; BT: body temperature; C-SSRS: ColumbiaSuicide Severity Rating Scale; ECG: electrocardiogram; ET: early termination; FSH:\\\", \\\"entities\\\": []}, {\\\"content\\\": \\\"follicle-stimulating hormone; PK: pharmacokinetic(s); PR: pulse rate; RR: respiratory rate; SRD: single-rising dose.\\\", \\\"entities\\\": [{\\\"start_idx\\\": 0, \\\"end_idx\\\": 27, \\\"standard_entity_name\\\": \\\"Molecule\\\", \\\"subcategory\\\": \\\"Molecule\\\", \\\"confidence\\\": 87.0, \\\"text\\\": \\\"follicle-stimulating hormone\\\"}]}, {\\\"content\\\": \\\"a BP will be checked (single measurement) with the subject resting for a minimum of 5 minutes lying in a bed with the head of the bed at 30 degrees.\\\", \\\"entities\\\": []}, {\\\"content\\\": \\\"b Orthostatic BP and pulse rate will also be checked, with the subject standing for 1 minute and 5 minutes.\\\", \\\"entities\\\": []}, {\\\"content\\\": \\\"c 12-lead, 24-h continuous Holter monitoring. Additional details may be found in the training manual.\\\", \\\"entities\\\": []}, {\\\"content\\\": \\\"d Drug administration on Day 1 after an overnight fast of at least 10 h; subjects must remain fasted until 4 h postdose. Detailed guidance of drug administration with diet and fluid\\\", \\\"entities\\\": []}, {\\\"content\\\": \\\"requirements can be found in Section 7.4.1.\\\", \\\"entities\\\": []}, {\\\"content\\\": \\\"e Hematology (complete blood count) and blood chemistry on Day 1 will be done at 8 h postdose; on all other days, blood draws will be done at the relative Day 1 predose time.\\\", \\\"entities\\\": []}, {\\\"content\\\": \\\"f FSH is mandatory for postmenopausal subjects.\\\", \\\"entities\\\": []}, {\\\"content\\\": \\\"g Blood samples for pharmacogenomics are collected before the initiation of study drug administration on Day 1. Will be performed once only in each subject during the study period.\\\", \\\"entities\\\": []}, {\\\"content\\\": \\\"h Subjects are to check in in the afternoon or evening of Day -2 at the latest. Some of the assessments (eg, C-SSRS and alcohol and drug screen) can be done at check-in time.\\\", \\\"entities\\\": [{\\\"start_idx\\\": 118, \\\"end_idx\\\": 124, \\\"standard_entity_name\\\": \\\"Molecule\\\", \\\"subcategory\\\": \\\"Molecule\\\", \\\"confidence\\\": 75.0, \\\"text\\\": \\\"alcohol\\\"}]}, {\\\"content\\\": \\\"i Some of the Day 6 study assessments may not be performed based on the emerging data from initial cohorts.\\\", \\\"entities\\\": []}], \\\"FootnoteText_0\\\": \\\" Administrative Procedures Informed consent X\\\", \\\"FootnoteText_1\\\": \\\" Clinical Procedures/Assessments\\\", \\\"FootnoteText_2\\\": \\\" Height, body mass index calculation X\\\", \\\"FootnoteText_3\\\": \\\" Vital signs (BP [supine], PR [supine], RR, and BT) (see X Table 3.c) a\\\", \\\"FootnoteText_4\\\": \\\" Orthostatic BP and pulse rate measurements (see Table 3.c) b\\\", \\\"FootnoteText_5\\\": \\\" 12-lead ECG standard (see Table 3.c) X\\\", \\\"FootnoteText_6\\\": \\\" TAK-861/placebo administration d X\\\", \\\"FootnoteText_7\\\": \\\" AE: adverse event; BP: blood pressure; BT: body temperature; C-SSRS: ColumbiaSuicide Severity Rating Scale; ECG: electrocardiogram; ET: early termination; FSH:\\\", \\\"FootnoteText_8\\\": \\\" follicle-stimulating hormone; PK: pharmacokinetic(s); PR: pulse rate; RR: respiratory rate; SRD: single-rising dose.\\\", \\\"FootnoteText_9\\\": \\\"a BP will be checked (single measurement) with the subject resting for a minimum of 5 minutes lying in a bed with the head of the bed at 30 degrees.\\\", \\\"FootnoteText_10\\\": \\\"b Orthostatic BP and pulse rate will also be checked, with the subject standing for 1 minute and 5 minutes.\\\", \\\"FootnoteText_11\\\": \\\"c 12-lead, 24-h continuous Holter monitoring. Additional details may be found in the training manual.\\\", \\\"FootnoteText_12\\\": \\\"d Drug administration on Day 1 after an overnight fast of at least 10 h; subjects must remain fasted until 4 h postdose. Detailed guidance of drug administration with diet and fluid\\\", \\\"FootnoteText_13\\\": \\\" requirements can be found in Section 7.4.1.\\\", \\\"FootnoteText_14\\\": \\\"e Hematology (complete blood count) and blood chemistry on Day 1 will be done at 8 h postdose; on all other days, blood draws will be done at the relative Day 1 predose time.\\\", \\\"FootnoteText_15\\\": \\\"f FSH is mandatory for postmenopausal subjects.\\\", \\\"FootnoteText_16\\\": \\\"g Blood samples for pharmacogenomics are collected before the initiation of study drug administration on Day 1. Will be performed once only in each subject during the study period.\\\", \\\"FootnoteText_17\\\": \\\"h Subjects are to check in in the afternoon or evening of Day -2 at the latest. Some of the assessments (eg, C-SSRS and alcohol and drug screen) can be done at check-in time.\\\", \\\"FootnoteText_18\\\": \\\"i Some of the Day 6 study assessments may not be performed based on the emerging data from initial cohorts.\\\", \\\"Header\\\": [0, 1]}, {\\\"IsBold\\\": true, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"a  Schedule of Study Procedures for Part A (SRD in Healthy Adults)\\\", \\\"Table 3.\\\", \\\"2\\\", 568], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"a  Schedule of Study Procedures for Part A (SRD in Healthy Adults)\\\", \\\"Table 3.\\\", \\\"2\\\", 569], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"a  Schedule of Study Procedures for Part A (SRD in Healthy Adults)\\\", \\\"Table 3.\\\", \\\"2\\\", 570], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"a  Schedule of Study Procedures for Part A (SRD in Healthy Adults)\\\", \\\"Table 3.\\\", \\\"2\\\", 571], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"a  Schedule of Study Procedures for Part A (SRD in Healthy Adults)\\\", \\\"Table 3.\\\", \\\"2\\\", 572], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"a  Schedule of Study Procedures for Part A (SRD in Healthy Adults)\\\", \\\"Table 3.\\\", \\\"2\\\", 573], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"a  Schedule of Study Procedures for Part A (SRD in Healthy Adults)\\\", \\\"Table 3.\\\", \\\"2\\\", 574], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"a  Schedule of Study Procedures for Part A (SRD in Healthy Adults)\\\", \\\"Table 3.\\\", \\\"2\\\", 575], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"a  Schedule of Study Procedures for Part A (SRD in Healthy Adults)\\\", \\\"Table 3.\\\", \\\"2\\\", 576], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"a  Schedule of Study Procedures for Part A (SRD in Healthy Adults)\\\", \\\"Table 3.\\\", \\\"2\\\", 577], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"a  Schedule of Study Procedures for Part A (SRD in Healthy Adults)\\\", \\\"Table 3.\\\", \\\"2\\\", 578], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"a  Schedule of Study Procedures for Part A (SRD in Healthy Adults)\\\", \\\"Table 3.\\\", \\\"2\\\", 579], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"a  Schedule of Study Procedures for Part A (SRD in Healthy Adults)\\\", \\\"Table 3.\\\", \\\"2\\\", 580], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"a  Schedule of Study Procedures for Part A (SRD in Healthy Adults)\\\", \\\"Table 3.\\\", \\\"2\\\", 581], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"a  Schedule of Study Procedures for Part A (SRD in Healthy Adults)\\\", \\\"Table 3.\\\", \\\"2\\\", 582], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"a  Schedule of Study Procedures for Part A (SRD in Healthy Adults)\\\", \\\"Table 3.\\\", \\\"2\\\", 583], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"a  Schedule of Study Procedures for Part A (SRD in Healthy Adults)\\\", \\\"Table 3.\\\", \\\"2\\\", 584], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"a  Schedule of Study Procedures for Part A (SRD in Healthy Adults)\\\", \\\"Table 3.\\\", \\\"2\\\", 585], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"a  Schedule of Study Procedures for Part A (SRD in Healthy Adults)\\\", \\\"Table 3.\\\", \\\"2\\\", 586], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"a  Schedule of Study Procedures for Part A (SRD in Healthy Adults)\\\", \\\"Table 3.\\\", \\\"2\\\", 587], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"a  Schedule of Study Procedures for Part A (SRD in Healthy Adults)\\\", \\\"Table 3.\\\", \\\"2\\\", 588], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"a  Schedule of Study Procedures for Part A (SRD in Healthy Adults)\\\", \\\"Table 3.\\\", \\\"2\\\", 589], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"a  Schedule of Study Procedures for Part A (SRD in Healthy Adults)\\\", \\\"Table 3.\\\", \\\"2\\\", 590], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"a  Schedule of Study Procedures for Part A (SRD in Healthy Adults)\\\", \\\"Table 3.\\\", \\\"2\\\", 591], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"a  Schedule of Study Procedures for Part A (SRD in Healthy Adults)\\\", \\\"Table 3.\\\", \\\"2\\\", 592], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"a  Schedule of Study Procedures for Part A (SRD in Healthy Adults)\\\", \\\"Table 3.\\\", \\\"2\\\", 593], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"a  Schedule of Study Procedures for Part A (SRD in Healthy Adults)\\\", \\\"Table 3.\\\", \\\"2\\\", 594], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"a  Schedule of Study Procedures for Part A (SRD in Healthy Adults)\\\", \\\"Table 3.\\\", \\\"2\\\", 595], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"a  Schedule of Study Procedures for Part A (SRD in Healthy Adults)\\\", \\\"Table 3.\\\", \\\"2\\\", 596], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"a  Schedule of Study Procedures for Part A (SRD in Healthy Adults)\\\", \\\"Table 3.\\\", \\\"2\\\", 597], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"a  Schedule of Study Procedures for Part A (SRD in Healthy Adults)\\\", \\\"Table 3.\\\", \\\"2\\\", 598], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"a  Schedule of Study Procedures for Part A (SRD in Healthy Adults)\\\", \\\"Table 3.\\\", \\\"2\\\", 599], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"a  Schedule of Study Procedures for Part A (SRD in Healthy Adults)\\\", \\\"Table 3.\\\", \\\"2\\\", 600], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"a  Schedule of Study Procedures for Part A (SRD in Healthy Adults)\\\", \\\"Table 3.\\\", \\\"2\\\", 601], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"a  Schedule of Study Procedures for Part A (SRD in Healthy Adults)\\\", \\\"Table 3.\\\", \\\"2\\\", 602], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"a  Schedule of Study Procedures for Part A (SRD in Healthy Adults)\\\", \\\"Table 3.\\\", \\\"2\\\", 603], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"a  Schedule of Study Procedures for Part A (SRD in Healthy Adults)\\\", \\\"Table 3.\\\", \\\"2\\\", 604], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"a  Schedule of Study Procedures for Part A (SRD in Healthy Adults)\\\", \\\"Table 3.\\\", \\\"2\\\", 605], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"a  Schedule of Study Procedures for Part A (SRD in Healthy Adults)\\\", \\\"Table 3.\\\", \\\"2\\\", 606], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"a  Schedule of Study Procedures for Part A (SRD in Healthy Adults)\\\", \\\"Table 3.\\\", \\\"2\\\", 607], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"a  Schedule of Study Procedures for Part A (SRD in Healthy Adults)\\\", \\\"Table 3.\\\", \\\"2\\\", 608], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"a  Schedule of Study Procedures for Part A (SRD in Healthy Adults)\\\", \\\"Table 3.\\\", \\\"2\\\", 609], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"a  Schedule of Study Procedures for Part A (SRD in Healthy Adults)\\\", \\\"Table 3.\\\", \\\"2\\\", 610], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"a  Schedule of Study Procedures for Part A (SRD in Healthy Adults)\\\", \\\"Table 3.\\\", \\\"2\\\", 611], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"a  Schedule of Study Procedures for Part A (SRD in Healthy Adults)\\\", \\\"Table 3.\\\", \\\"2\\\", 612], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"a  Schedule of Study Procedures for Part A (SRD in Healthy Adults)\\\", \\\"Table 3.\\\", \\\"2\\\", 613], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"a  Schedule of Study Procedures for Part A (SRD in Healthy Adults)\\\", \\\"Table 3.\\\", \\\"2\\\", 614], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"a  Schedule of Study Procedures for Part A (SRD in Healthy Adults)\\\", \\\"Table 3.\\\", \\\"2\\\", 615], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"a  Schedule of Study Procedures for Part A (SRD in Healthy Adults)\\\", \\\"Table 3.\\\", \\\"2\\\", 616], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"a  Schedule of Study Procedures for Part A (SRD in Healthy Adults)\\\", \\\"Table 3.\\\", \\\"2\\\", 617], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"a  Schedule of Study Procedures for Part A (SRD in Healthy Adults)\\\", \\\"Table 3.\\\", \\\"2\\\", 618], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"a  Schedule of Study Procedures for Part A (SRD in Healthy Adults)\\\", \\\"Table 3.\\\", \\\"2\\\", 619], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"a  Schedule of Study Procedures for Part A (SRD in Healthy Adults)\\\", \\\"Table 3.\\\", \\\"2\\\", 620], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"a  Schedule of Study Procedures for Part A (SRD in Healthy Adults)\\\", \\\"Table 3.\\\", \\\"2\\\", 621], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"a  Schedule of Study Procedures for Part A (SRD in Healthy Adults)\\\", \\\"Table 3.\\\", \\\"2\\\", 622], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"a  Schedule of Study Procedures for Part A (SRD in Healthy Adults)\\\", \\\"Table 3.\\\", \\\"2\\\", 623], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"a  Schedule of Study Procedures for Part A (SRD in Healthy Adults)\\\", \\\"Table 3.\\\", \\\"2\\\", 624], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"a  Schedule of Study Procedures for Part A (SRD in Healthy Adults)\\\", \\\"Table 3.\\\", \\\"2\\\", 625], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"a  Schedule of Study Procedures for Part A (SRD in Healthy Adults)\\\", \\\"Table 3.\\\", \\\"2\\\", 626], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"a  Schedule of Study Procedures for Part A (SRD in Healthy Adults)\\\", \\\"Table 3.\\\", \\\"2\\\", 627], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"a  Schedule of Study Procedures for Part A (SRD in Healthy Adults)\\\", \\\"Table 3.\\\", \\\"2\\\", 628], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"a  Schedule of Study Procedures for Part A (SRD in Healthy Adults)\\\", \\\"Table 3.\\\", \\\"2\\\", 629], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"a  Schedule of Study Procedures for Part A (SRD in Healthy Adults)\\\", \\\"Table 3.\\\", \\\"2\\\", 630], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"a  Schedule of Study Procedures for Part A (SRD in Healthy Adults)\\\", \\\"Table 3.\\\", \\\"2\\\", 631], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"a  Schedule of Study Procedures for Part A (SRD in Healthy Adults)\\\", \\\"Table 3.\\\", \\\"2\\\", 632], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"a  Schedule of Study Procedures for Part A (SRD in Healthy Adults)\\\", \\\"Table 3.\\\", \\\"2\\\", 633], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"a  Schedule of Study Procedures for Part A (SRD in Healthy Adults)\\\", \\\"Table 3.\\\", \\\"2\\\", 634], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"a  Schedule of Study Procedures for Part A (SRD in Healthy Adults)\\\", \\\"Table 3.\\\", \\\"2\\\", 635], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"a  Schedule of Study Procedures for Part A (SRD in Healthy Adults)\\\", \\\"Table 3.\\\", \\\"2\\\", 636], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"a  Schedule of Study Procedures for Part A (SRD in Healthy Adults)\\\", \\\"Table 3.\\\", \\\"2\\\", 637], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"a  Schedule of Study Procedures for Part A (SRD in Healthy Adults)\\\", \\\"Table 3.\\\", \\\"2\\\", 638], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"a  Schedule of Study Procedures for Part A (SRD in Healthy Adults)\\\", \\\"Table 3.\\\", \\\"2\\\", 639], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"a  Schedule of Study Procedures for Part A (SRD in Healthy Adults)\\\", \\\"Table 3.\\\", \\\"2\\\", 640], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"a  Schedule of Study Procedures for Part A (SRD in Healthy Adults)\\\", \\\"Table 3.\\\", \\\"2\\\", 641], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"a  Schedule of Study Procedures for Part A (SRD in Healthy Adults)\\\", \\\"Table 3.\\\", \\\"2\\\", 642], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"a  Schedule of Study Procedures for Part A (SRD in Healthy Adults)\\\", \\\"Table 3.\\\", \\\"2\\\", 643], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"a  Schedule of Study Procedures for Part A (SRD in Healthy Adults)\\\", \\\"Table 3.\\\", \\\"2\\\", 644], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"a  Schedule of Study Procedures for Part A (SRD in Healthy Adults)\\\", \\\"Table 3.\\\", \\\"2\\\", 645], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"a  Schedule of Study Procedures for Part A (SRD in Healthy Adults)\\\", \\\"Table 3.\\\", \\\"2\\\", 646], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"a  Schedule of Study Procedures for Part A (SRD in Healthy Adults)\\\", \\\"Table 3.\\\", \\\"2\\\", 647], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"a  Schedule of Study Procedures for Part A (SRD in Healthy Adults)\\\", \\\"Table 3.\\\", \\\"2\\\", 648], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"a  Schedule of Study Procedures for Part A (SRD in Healthy Adults)\\\", \\\"Table 3.\\\", \\\"2\\\", 649], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"a  Schedule of Study Procedures for Part A (SRD in Healthy Adults)\\\", \\\"Table 3.\\\", \\\"2\\\", 650], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"a  Schedule of Study Procedures for Part A (SRD in Healthy Adults)\\\", \\\"Table 3.\\\", \\\"2\\\", 651], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"a  Schedule of Study Procedures for Part A (SRD in Healthy Adults)\\\", \\\"Table 3.\\\", \\\"2\\\", 652], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"a  Schedule of Study Procedures for Part A (SRD in Healthy Adults)\\\", \\\"Table 3.\\\", \\\"2\\\", 653], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"a  Schedule of Study Procedures for Part A (SRD in Healthy Adults)\\\", \\\"Table 3.\\\", \\\"2\\\", 654], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"a  Schedule of Study Procedures for Part A (SRD in Healthy Adults)\\\", \\\"Table 3.\\\", \\\"2\\\", 655], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"a  Schedule of Study Procedures for Part A (SRD in Healthy Adults)\\\", \\\"Table 3.\\\", \\\"2\\\", 656], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"a  Schedule of Study Procedures for Part A (SRD in Healthy Adults)\\\", \\\"Table 3.\\\", \\\"2\\\", 657], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"a  Schedule of Study Procedures for Part A (SRD in Healthy Adults)\\\", \\\"Table 3.\\\", \\\"2\\\", 658], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"a  Schedule of Study Procedures for Part A (SRD in Healthy Adults)\\\", \\\"Table 3.\\\", \\\"2\\\", 659], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"a  Schedule of Study Procedures for Part A (SRD in Healthy Adults)\\\", \\\"Table 3.\\\", \\\"2\\\", 660], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"a  Schedule of Study Procedures for Part A (SRD in Healthy Adults)\\\", \\\"Table 3.\\\", \\\"2\\\", 661], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"a  Schedule of Study Procedures for Part A (SRD in Healthy Adults)\\\", \\\"Table 3.\\\", \\\"2\\\", 662], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"a  Schedule of Study Procedures for Part A (SRD in Healthy Adults)\\\", \\\"Table 3.\\\", \\\"2\\\", 663], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"a  Schedule of Study Procedures for Part A (SRD in Healthy Adults)\\\", \\\"Table 3.\\\", \\\"2\\\", 664], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"a  Schedule of Study Procedures for Part A (SRD in Healthy Adults)\\\", \\\"Table 3.\\\", \\\"2\\\", 665], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"a  Schedule of Study Procedures for Part A (SRD in Healthy Adults)\\\", \\\"Table 3.\\\", \\\"2\\\", 666], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"a  Schedule of Study Procedures for Part A (SRD in Healthy Adults)\\\", \\\"Table 3.\\\", \\\"2\\\", 667], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"a  Schedule of Study Procedures for Part A (SRD in Healthy Adults)\\\", \\\"Table 3.\\\", \\\"2\\\", 668], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"a  Schedule of Study Procedures for Part A (SRD in Healthy Adults)\\\", \\\"Table 3.\\\", \\\"2\\\", 669], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"a  Schedule of Study Procedures for Part A (SRD in Healthy Adults)\\\", \\\"Table 3.\\\", \\\"2\\\", 670], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"a  Schedule of Study Procedures for Part A (SRD in Healthy Adults)\\\", \\\"Table 3.\\\", \\\"2\\\", 671], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"Table 3.b Schedule of Study Procedures for Part A (Food Effect Cohorts)\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading8\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"b  Schedule of Study Procedures for Part A (Food Effect Cohorts)\\\", \\\"Table 3.\\\", \\\"2\\\", 672], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"b  Schedule of Study Procedures for Part A (Food Effect Cohorts)\\\", \\\"Table 3.\\\", \\\"2\\\", 673], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"AE: adverse event; BP: blood pressure; BT: body temperature; C-SSRS: Columbia\\\\u2013Suicide Severity Rating Scale; ECG: electrocardiogram; ET: early termination; FSH: ~REDACTED~; PK: pharmacokinetic(s); PR: pulse rate; RR: respiratory rate.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 17, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 17, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"b  Schedule of Study Procedures for Part A (Food Effect Cohorts)\\\", \\\"Table 3.\\\", \\\"2\\\", 674], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"a\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 11, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 11, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"b  Schedule of Study Procedures for Part A (Food Effect Cohorts)\\\", \\\"Table 3.\\\", \\\"2\\\", 675], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"BP will be checked (single measurement) with the subject resting for a minimum of 5 minutes lying in a bed with the head of the bed at 30 degrees.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 17, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 17, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"b  Schedule of Study Procedures for Part A (Food Effect Cohorts)\\\", \\\"Table 3.\\\", \\\"2\\\", 676], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"b\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 11, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 11, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"b  Schedule of Study Procedures for Part A (Food Effect Cohorts)\\\", \\\"Table 3.\\\", \\\"2\\\", 677], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Orthostatic BP and pulse rate will also be checked, with the subject standing for 1 minute and 5 minutes.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 17, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 17, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"b  Schedule of Study Procedures for Part A (Food Effect Cohorts)\\\", \\\"Table 3.\\\", \\\"2\\\", 678], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"c\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 11, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 11, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"b  Schedule of Study Procedures for Part A (Food Effect Cohorts)\\\", \\\"Table 3.\\\", \\\"2\\\", 679], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"12-lead, 24-h continuous Holter monitoring.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 17, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 17, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"b  Schedule of Study Procedures for Part A (Food Effect Cohorts)\\\", \\\"Table 3.\\\", \\\"2\\\", 680], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Additional details may be found in the training manual.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 17, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 17, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"b  Schedule of Study Procedures for Part A (Food Effect Cohorts)\\\", \\\"Table 3.\\\", \\\"2\\\", 681], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"d\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 11, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 11, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"b  Schedule of Study Procedures for Part A (Food Effect Cohorts)\\\", \\\"Table 3.\\\", \\\"2\\\", 682], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Drug administration on Day 1 after an overnight fast of at least 10 h; subjects must remain fasted until 4 h postdose.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 17, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 17, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"b  Schedule of Study Procedures for Part A (Food Effect Cohorts)\\\", \\\"Table 3.\\\", \\\"2\\\", 683], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"On Day 15, subjects will receive a high-fat and high-calorie breakfast (Cohort A3) or a standardized non\\\\u2013high-fat breakfast (Cohort ~REDACTED~) after an overnight fast of at least 10 h.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 17, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 17, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"b  Schedule of Study Procedures for Part A (Food Effect Cohorts)\\\", \\\"Table 3.\\\", \\\"2\\\", 684], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"The meal must be consumed within 30 minutes and drug administration within 5 minutes after the end of the meal.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 17, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 17, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"b  Schedule of Study Procedures for Part A (Food Effect Cohorts)\\\", \\\"Table 3.\\\", \\\"2\\\", 685], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Detailed guidance of drug administration with diet and fluid requirements can be found in Section 7.4.1.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 17, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 17, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"b  Schedule of Study Procedures for Part A (Food Effect Cohorts)\\\", \\\"Table 3.\\\", \\\"2\\\", 686], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"e\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 11, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 11, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"b  Schedule of Study Procedures for Part A (Food Effect Cohorts)\\\", \\\"Table 3.\\\", \\\"2\\\", 687], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Hematology (complete blood count) and blood chemistry on Day 1 and 15 will be done at 8 h postdose; on all other days, blood draws are at the relative Day 1 predose time.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 17, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 17, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"b  Schedule of Study Procedures for Part A (Food Effect Cohorts)\\\", \\\"Table 3.\\\", \\\"2\\\", 688], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"On Day 14 the assessment may be done after subject checked-in in the afternoon but with at least 8 hours fasting condition.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 17, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 17, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"b  Schedule of Study Procedures for Part A (Food Effect Cohorts)\\\", \\\"Table 3.\\\", \\\"2\\\", 689], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"f\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 11, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 11, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"b  Schedule of Study Procedures for Part A (Food Effect Cohorts)\\\", \\\"Table 3.\\\", \\\"2\\\", 690], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"FSH is mandatory for postmenopausal subjects.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 17, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 17, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"b  Schedule of Study Procedures for Part A (Food Effect Cohorts)\\\", \\\"Table 3.\\\", \\\"2\\\", 691], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"g\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 11, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 11, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"b  Schedule of Study Procedures for Part A (Food Effect Cohorts)\\\", \\\"Table 3.\\\", \\\"2\\\", 692], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Blood samples for pharmacogenomics are collected before the initiation of study drug administration on Day 1.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 17, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 17, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"b  Schedule of Study Procedures for Part A (Food Effect Cohorts)\\\", \\\"Table 3.\\\", \\\"2\\\", 693], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Will be performed once only in each subject during the study period.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 17, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 17, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"b  Schedule of Study Procedures for Part A (Food Effect Cohorts)\\\", \\\"Table 3.\\\", \\\"2\\\", 694], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"h\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 11, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 11, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"b  Schedule of Study Procedures for Part A (Food Effect Cohorts)\\\", \\\"Table 3.\\\", \\\"2\\\", 695], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Subjects are to check in in the afternoon or evening of Day -2 at the latest.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 17, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 17, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"b  Schedule of Study Procedures for Part A (Food Effect Cohorts)\\\", \\\"Table 3.\\\", \\\"2\\\", 696], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Some of the assessments (eg, C-SSRS, ~REDACTED~ and drug screen) can be done at check-in time.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 17, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 17, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"b  Schedule of Study Procedures for Part A (Food Effect Cohorts)\\\", \\\"Table 3.\\\", \\\"2\\\", 697], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"i\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 11, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 11, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"b  Schedule of Study Procedures for Part A (Food Effect Cohorts)\\\", \\\"Table 3.\\\", \\\"2\\\", 698], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Some of the Day 6 and Day 20 study assessments may not be performed based on the emerging data from initial cohorts.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 17, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 17, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"b  Schedule of Study Procedures for Part A (Food Effect Cohorts)\\\", \\\"Table 3.\\\", \\\"2\\\", 699], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"Table 3.c Detailed Schedule for Part A\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading8\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"c  Detailed Schedule for Part A\\\", \\\"Table 3.\\\", \\\"2\\\", 700], [\\\"\\\", \\\"Unmapped\\\", \\\"table\\\", {\\\"Table\\\": \\\"<table border=\\\\\\\"1\\\\\\\" class=\\\\\\\"dataframe\\\\\\\">\\\\n  <thead>\\\\n    <tr style=\\\\\\\"text-align: right;\\\\\\\">\\\\n      <th></th>\\\\n      <th>1.0</th>\\\\n      <th>2.0</th>\\\\n      <th>3.0</th>\\\\n      <th>4.0</th>\\\\n      <th>5.0</th>\\\\n      <th>6.0</th>\\\\n      <th>7.0</th>\\\\n      <th>8.0</th>\\\\n      <th>9.0</th>\\\\n      <th>10.0</th>\\\\n      <th>11.0</th>\\\\n    </tr>\\\\n  </thead>\\\\n  <tbody>\\\\n    <tr>\\\\n      <th>0</th>\\\\n      <td>Procedure</td>\\\\n      <td>Predose</td>\\\\n      <td>Predose</td>\\\\n      <td>Dosing</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>Postdose</td>\\\\n      <td>Postdose</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>Follow-up</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>1</th>\\\\n      <td>Day</td>\\\\n      <td>-1</td>\\\\n      <td>1</td>\\\\n      <td>1</td>\\\\n      <td>2</td>\\\\n      <td>3</td>\\\\n      <td>4</td>\\\\n      <td>5</td>\\\\n      <td>6 <sup>a</sup> Discharge</td>\\\\n      <td>ET</td>\\\\n      <td>9 (\\\\u00b12 days)</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>2</th>\\\\n      <td>Blood sample for TAK-861 PK</td>\\\\n      <td></td>\\\\n      <td>Pre</td>\\\\n      <td>0.25, 0.5, 1, 2, 3, 4, 6, 8, and 12 h Post</td>\\\\n      <td>24 and 36 h Post</td>\\\\n      <td>48 h Post</td>\\\\n      <td>72 h Post</td>\\\\n      <td>96 h Post</td>\\\\n      <td>120 h Post</td>\\\\n      <td>X <sup>b</sup></td>\\\\n      <td></td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>3</th>\\\\n      <td>Urine sample for TAK-861 PK <sup>c</sup></td>\\\\n      <td></td>\\\\n      <td>Spot: Pre</td>\\\\n      <td>Pooled: 0-6 and 6-12 h Post</td>\\\\n      <td>Pooled: 12-24 h Post</td>\\\\n      <td>Pooled: 24-48 h Post</td>\\\\n      <td>Pooled: 48-72 h Post</td>\\\\n      <td>Pooled: 72-96 h Post</td>\\\\n      <td>Pooled: 96-120 h Post</td>\\\\n      <td>X<sup> c</sup></td>\\\\n      <td></td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>4</th>\\\\n      <td>Supine BP and pulse rate measurements</td>\\\\n      <td>Approximately 0700 and then at 0.5, 1, 2, 3, 4, 6, 8, and 12 h later relative to the initial measurement (matched to the time assessment schedule of Day 1)</td>\\\\n      <td>Pre</td>\\\\n      <td>0.5, 1, 2, 3, 4, 6, 8, and 12 h Post</td>\\\\n      <td>24 and 36 h Post</td>\\\\n      <td>48 h Post</td>\\\\n      <td>72 h Post <sup>e</sup></td>\\\\n      <td>96 h Post</td>\\\\n      <td>120 h Post</td>\\\\n      <td>X <sup>d</sup></td>\\\\n      <td>X</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>5</th>\\\\n      <td>Orthostatic BP and pulse rate measurements</td>\\\\n      <td></td>\\\\n      <td>Pre</td>\\\\n      <td>1, 2, and 6 h Post</td>\\\\n      <td>24 h Post</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>X<sup> d, e</sup></td>\\\\n      <td></td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>6</th>\\\\n      <td>Respiratory rate and body temperature</td>\\\\n      <td></td>\\\\n      <td>1 h Pre</td>\\\\n      <td>1, 2, 4, and 6 h Post</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>120 h Post</td>\\\\n      <td>X<sup> d</sup></td>\\\\n      <td>X</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>7</th>\\\\n      <td>Standard 12-lead ECGs</td>\\\\n      <td>X</td>\\\\n      <td>Pre</td>\\\\n      <td>1, 2, 4, 6, and 12 h Post</td>\\\\n      <td>24 h Post</td>\\\\n      <td>48 h Post</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>120 h Post</td>\\\\n      <td>X<sup> d</sup></td>\\\\n      <td>X</td>\\\\n    </tr>\\\\n  </tbody>\\\\n</table>\\\", \\\"SectionHeaderPrintPage\\\": \\\"24\\\", \\\"TableIndex\\\": \\\"18\\\", \\\"TableName\\\": \\\"Table 3.c Detailed Schedule for Part A(Schedule of Assessment)\\\", \\\"Header\\\": [0, 1]}, {\\\"IsBold\\\": true, \\\"font_size\\\": 17, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 17, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"c  Detailed Schedule for Part A\\\", \\\"Table 3.\\\", \\\"2\\\", 701], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"c  Detailed Schedule for Part A\\\", \\\"Table 3.\\\", \\\"2\\\", 702], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"c  Detailed Schedule for Part A\\\", \\\"Table 3.\\\", \\\"2\\\", 703], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"c  Detailed Schedule for Part A\\\", \\\"Table 3.\\\", \\\"2\\\", 704], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"c  Detailed Schedule for Part A\\\", \\\"Table 3.\\\", \\\"2\\\", 705], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"c  Detailed Schedule for Part A\\\", \\\"Table 3.\\\", \\\"2\\\", 706], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"c  Detailed Schedule for Part A\\\", \\\"Table 3.\\\", \\\"2\\\", 707], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"c  Detailed Schedule for Part A\\\", \\\"Table 3.\\\", \\\"2\\\", 708], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"c  Detailed Schedule for Part A\\\", \\\"Table 3.\\\", \\\"2\\\", 709], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"c  Detailed Schedule for Part A\\\", \\\"Table 3.\\\", \\\"2\\\", 710], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"c  Detailed Schedule for Part A\\\", \\\"Table 3.\\\", \\\"2\\\", 711], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"c  Detailed Schedule for Part A\\\", \\\"Table 3.\\\", \\\"2\\\", 712], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"c  Detailed Schedule for Part A\\\", \\\"Table 3.\\\", \\\"2\\\", 713], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"c  Detailed Schedule for Part A\\\", \\\"Table 3.\\\", \\\"2\\\", 714], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"c  Detailed Schedule for Part A\\\", \\\"Table 3.\\\", \\\"2\\\", 715], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"c  Detailed Schedule for Part A\\\", \\\"Table 3.\\\", \\\"2\\\", 716], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"c  Detailed Schedule for Part A\\\", \\\"Table 3.\\\", \\\"2\\\", 717], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"c  Detailed Schedule for Part A\\\", \\\"Table 3.\\\", \\\"2\\\", 718], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"c  Detailed Schedule for Part A\\\", \\\"Table 3.\\\", \\\"2\\\", 719], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"c  Detailed Schedule for Part A\\\", \\\"Table 3.\\\", \\\"2\\\", 720], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"c  Detailed Schedule for Part A\\\", \\\"Table 3.\\\", \\\"2\\\", 721], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"c  Detailed Schedule for Part A\\\", \\\"Table 3.\\\", \\\"2\\\", 722], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"BP: blood pressure; ECG: electrocardiogram; ET: early termination; PK: pharmacokinetic(s); Post: postdose; Pre: predose; SRD: single-rising dose.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 17, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 17, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"c  Detailed Schedule for Part A\\\", \\\"Table 3.\\\", \\\"2\\\", 723], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"a\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 11, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 11, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"c  Detailed Schedule for Part A\\\", \\\"Table 3.\\\", \\\"2\\\", 724], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Discharge Day 6 study assessments may not be performed based on the emerging data from initial cohorts.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 17, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 17, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"c  Detailed Schedule for Part A\\\", \\\"Table 3.\\\", \\\"2\\\", 725], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"b\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 11, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 11, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"c  Detailed Schedule for Part A\\\", \\\"Table 3.\\\", \\\"2\\\", 726], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"At ET visit, blood sample for TAK-861 PK to be collected at the time of subject discontinuation (before discharge).\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 17, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 17, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"c  Detailed Schedule for Part A\\\", \\\"Table 3.\\\", \\\"2\\\", 727], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"c\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 11, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 11, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"c  Detailed Schedule for Part A\\\", \\\"Table 3.\\\", \\\"2\\\", 728], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Urine PK will be done in the fasted portion of A3 and ~REDACTED~, but will not be done in the fed portion for subjects in cohorts A3 and ~REDACTED~.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 17, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 17, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"c  Detailed Schedule for Part A\\\", \\\"Table 3.\\\", \\\"2\\\", 729], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Urine sample for TAK-861 PK to be collected at ET; this is a spot sample that will be pooled with the collection interval at the time of subject discontinuation (before discharge).\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 17, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 17, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"c  Detailed Schedule for Part A\\\", \\\"Table 3.\\\", \\\"2\\\", 730], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"d\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 11, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 11, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"c  Detailed Schedule for Part A\\\", \\\"Table 3.\\\", \\\"2\\\", 731], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"ET assessment to be conducted before discharge.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 17, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 17, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"c  Detailed Schedule for Part A\\\", \\\"Table 3.\\\", \\\"2\\\", 732], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"e\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 11, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 11, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"c  Detailed Schedule for Part A\\\", \\\"Table 3.\\\", \\\"2\\\", 733], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"If ET occurs after 24 h postdose, this assessment is not required.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 17, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 17, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"c  Detailed Schedule for Part A\\\", \\\"Table 3.\\\", \\\"2\\\", 734], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"Table 3.d Detailed Schedule for Cohorts A3 and ~REDACTED~ (SRD Food Effect)\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading8\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"d  Detailed Schedule for Cohorts A3 and A10 (SRD Food Effect)\\\", \\\"Table 3.\\\", \\\"2\\\", 735], [\\\"\\\", \\\"Unmapped\\\", \\\"table\\\", {\\\"Table\\\": \\\"<table border=\\\\\\\"1\\\\\\\" class=\\\\\\\"dataframe\\\\\\\">\\\\n  <thead>\\\\n    <tr style=\\\\\\\"text-align: right;\\\\\\\">\\\\n      <th></th>\\\\n      <th>1.0</th>\\\\n      <th>2.0</th>\\\\n      <th>3.0</th>\\\\n      <th>4.0</th>\\\\n      <th>5.0</th>\\\\n      <th>6.0</th>\\\\n      <th>7.0</th>\\\\n      <th>8.0</th>\\\\n      <th>9.0</th>\\\\n      <th>10.0</th>\\\\n      <th>11.0</th>\\\\n      <th>12.0</th>\\\\n      <th>13.0</th>\\\\n      <th>14.0</th>\\\\n      <th>15.0</th>\\\\n      <th>16.0</th>\\\\n    </tr>\\\\n  </thead>\\\\n  <tbody>\\\\n    <tr>\\\\n      <th>0</th>\\\\n      <td>Procedure</td>\\\\n      <td>Predose</td>\\\\n      <td>Predose</td>\\\\n      <td>Postdose</td>\\\\n      <td>Postdose</td>\\\\n      <td>Postdose</td>\\\\n      <td>Postdose</td>\\\\n      <td>Washout (7\\\\u00b12 days)</td>\\\\n      <td>Predose</td>\\\\n      <td>Predose</td>\\\\n      <td></td>\\\\n      <td>Postdose</td>\\\\n      <td>Postdose</td>\\\\n      <td>Postdose</td>\\\\n      <td>Postdose</td>\\\\n      <td>Follow-up</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>1</th>\\\\n      <td>Day</td>\\\\n      <td>-1</td>\\\\n      <td>1</td>\\\\n      <td>1</td>\\\\n      <td>2</td>\\\\n      <td>3-5</td>\\\\n      <td>6 <sup>d</sup></td>\\\\n      <td></td>\\\\n      <td>14</td>\\\\n      <td>15</td>\\\\n      <td>15</td>\\\\n      <td>16</td>\\\\n      <td>17-19</td>\\\\n      <td>20 <sup>a</sup></td>\\\\n      <td>ET</td>\\\\n      <td>23 (\\\\u00b12 days)</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>2</th>\\\\n      <td>Blood sample for TAK-861 PK</td>\\\\n      <td></td>\\\\n      <td>Pre</td>\\\\n      <td>0.25, 0.5, 1, 2, 3, 4, 6, 8, and 12 h Post</td>\\\\n      <td>24 and 36 h Post</td>\\\\n      <td>48, 72, and 96 h Post</td>\\\\n      <td>120 h Post</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>Pre</td>\\\\n      <td>0.25, 0.5, 1, 2, 3, 4, 6, 8, and 12 h Post</td>\\\\n      <td>24 and 36 h Post</td>\\\\n      <td>48, 72, and 96 h Post</td>\\\\n      <td>120 h Post</td>\\\\n      <td>X <sup>b</sup></td>\\\\n      <td></td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>3</th>\\\\n      <td>Urine sample for TAK-861 PK</td>\\\\n      <td></td>\\\\n      <td>Spot: Pre</td>\\\\n      <td>Pooled: 0-6 and 6-12 h Post</td>\\\\n      <td>Pooled: 12-24 h Post</td>\\\\n      <td>Pooled: 24-48, 48-72, 72-96 h Post</td>\\\\n      <td>Pooled: 96-120 h Post</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>4</th>\\\\n      <td>Supine BP and pulse rate measurements</td>\\\\n      <td>At approximately 0700 and at 0.5, 1, 2, 3, 4, 6, 8, and 12 h later relative to initial measurement (matched to Day 1 assessment schedule)</td>\\\\n      <td>Pre</td>\\\\n      <td>0.5, 1, 2, 3, 4, 6, 8, and 12 h Post</td>\\\\n      <td>24 and 36 h Post</td>\\\\n      <td>48, 72 and 96 h Post</td>\\\\n      <td>120 h Post</td>\\\\n      <td></td>\\\\n      <td>X</td>\\\\n      <td>Pre</td>\\\\n      <td>0.5, 1, 2, 3, 4, 6, 8, and 12 h Post</td>\\\\n      <td>24 and 36 h Post</td>\\\\n      <td>48, 72, and 96 h Post</td>\\\\n      <td>120 h Post</td>\\\\n      <td>X <sup>c</sup></td>\\\\n      <td>X</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>5</th>\\\\n      <td>Orthostatic BP and pulse rate measurements</td>\\\\n      <td></td>\\\\n      <td>Pre</td>\\\\n      <td>1, 2, and 6 h Post</td>\\\\n      <td>24 h Post</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>Pre</td>\\\\n      <td>1, 2, and 6 h Post</td>\\\\n      <td>24 h Post</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>X<sup> c, d</sup></td>\\\\n      <td></td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>6</th>\\\\n      <td>Respiratory rate and body temperature</td>\\\\n      <td></td>\\\\n      <td>1 h Pre</td>\\\\n      <td>1, 2, 4, and 6 h Post</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>120 h Post</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>1 h Pre</td>\\\\n      <td>1, 2, 4, and 6 h Post</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>120 h Post</td>\\\\n      <td>X <sup>c</sup></td>\\\\n      <td>X</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>7</th>\\\\n      <td>Standard 12-lead ECGs</td>\\\\n      <td>X</td>\\\\n      <td>Pre</td>\\\\n      <td>1, 2, 4, 6, and 12 h Post</td>\\\\n      <td>24 h Post</td>\\\\n      <td>48 h Post</td>\\\\n      <td>120 h Post</td>\\\\n      <td></td>\\\\n      <td>X</td>\\\\n      <td>Pre</td>\\\\n      <td>1, 2, 4, 6, and 12 h Post</td>\\\\n      <td>24 h Post</td>\\\\n      <td>48 h Post</td>\\\\n      <td>120 h Post</td>\\\\n      <td>X <sup>c</sup></td>\\\\n      <td>X</td>\\\\n    </tr>\\\\n  </tbody>\\\\n</table>\\\", \\\"SectionHeaderPrintPage\\\": \\\"25\\\", \\\"TableIndex\\\": \\\"19\\\", \\\"TableName\\\": \\\"Table 3.d Detailed Schedule for Cohorts A3 and A10 (SRD Food Effect)(Schedule of Assessment)\\\", \\\"AttachmentEntities\\\": [{\\\"content\\\": \\\"BP: blood pressure; ECG: electrocardiogram; ET: early termination; PK: pharmacokinetic(s); Post: postdose; Pre: predose; SRD: single-rising dose.\\\", \\\"entities\\\": []}, {\\\"content\\\": \\\"a All or some of the Day 6 or Day 20 study assessments may not be performed based on the emerging data from initial cohorts.\\\", \\\"entities\\\": []}, {\\\"content\\\": \\\"b At ET visit, blood sample for TAK-861 PK to be collected at the time of subject discontinuation (before discharge).\\\", \\\"entities\\\": []}, {\\\"content\\\": \\\"c Assessment at ET visit to be conducted before discharge.\\\", \\\"entities\\\": []}, {\\\"content\\\": \\\"d If ET occurs later than 24 h postdose, this assessment is not required.\\\", \\\"entities\\\": []}], \\\"FootnoteText_0\\\": \\\" BP: blood pressure; ECG: electrocardiogram; ET: early termination; PK: pharmacokinetic(s); Post: postdose; Pre: predose; SRD: single-rising dose.\\\", \\\"FootnoteText_1\\\": \\\"a All or some of the Day 6 or Day 20 study assessments may not be performed based on the emerging data from initial cohorts.\\\", \\\"FootnoteText_2\\\": \\\"b At ET visit, blood sample for TAK-861 PK to be collected at the time of subject discontinuation (before discharge).\\\", \\\"FootnoteText_3\\\": \\\"c Assessment at ET visit to be conducted before discharge.\\\", \\\"FootnoteText_4\\\": \\\"d If ET occurs later than 24 h postdose, this assessment is not required.\\\", \\\"Header\\\": [0, 1]}, {\\\"IsBold\\\": true, \\\"font_size\\\": 17, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 17, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"d  Detailed Schedule for Cohorts A3 and A10 (SRD Food Effect)\\\", \\\"Table 3.\\\", \\\"2\\\", 736], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"d  Detailed Schedule for Cohorts A3 and A10 (SRD Food Effect)\\\", \\\"Table 3.\\\", \\\"2\\\", 737], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"d  Detailed Schedule for Cohorts A3 and A10 (SRD Food Effect)\\\", \\\"Table 3.\\\", \\\"2\\\", 738], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"d  Detailed Schedule for Cohorts A3 and A10 (SRD Food Effect)\\\", \\\"Table 3.\\\", \\\"2\\\", 739], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"d  Detailed Schedule for Cohorts A3 and A10 (SRD Food Effect)\\\", \\\"Table 3.\\\", \\\"2\\\", 740], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"d  Detailed Schedule for Cohorts A3 and A10 (SRD Food Effect)\\\", \\\"Table 3.\\\", \\\"2\\\", 741], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"d  Detailed Schedule for Cohorts A3 and A10 (SRD Food Effect)\\\", \\\"Table 3.\\\", \\\"2\\\", 742], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"d  Detailed Schedule for Cohorts A3 and A10 (SRD Food Effect)\\\", \\\"Table 3.\\\", \\\"2\\\", 743], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"d  Detailed Schedule for Cohorts A3 and A10 (SRD Food Effect)\\\", \\\"Table 3.\\\", \\\"2\\\", 744], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"d  Detailed Schedule for Cohorts A3 and A10 (SRD Food Effect)\\\", \\\"Table 3.\\\", \\\"2\\\", 745], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"d  Detailed Schedule for Cohorts A3 and A10 (SRD Food Effect)\\\", \\\"Table 3.\\\", \\\"2\\\", 746], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"d  Detailed Schedule for Cohorts A3 and A10 (SRD Food Effect)\\\", \\\"Table 3.\\\", \\\"2\\\", 747], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"d  Detailed Schedule for Cohorts A3 and A10 (SRD Food Effect)\\\", \\\"Table 3.\\\", \\\"2\\\", 748], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"d  Detailed Schedule for Cohorts A3 and A10 (SRD Food Effect)\\\", \\\"Table 3.\\\", \\\"2\\\", 749], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"d  Detailed Schedule for Cohorts A3 and A10 (SRD Food Effect)\\\", \\\"Table 3.\\\", \\\"2\\\", 750], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"d  Detailed Schedule for Cohorts A3 and A10 (SRD Food Effect)\\\", \\\"Table 3.\\\", \\\"2\\\", 751], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"d  Detailed Schedule for Cohorts A3 and A10 (SRD Food Effect)\\\", \\\"Table 3.\\\", \\\"2\\\", 752], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"d  Detailed Schedule for Cohorts A3 and A10 (SRD Food Effect)\\\", \\\"Table 3.\\\", \\\"2\\\", 753], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"d  Detailed Schedule for Cohorts A3 and A10 (SRD Food Effect)\\\", \\\"Table 3.\\\", \\\"2\\\", 754], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"d  Detailed Schedule for Cohorts A3 and A10 (SRD Food Effect)\\\", \\\"Table 3.\\\", \\\"2\\\", 755], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"d  Detailed Schedule for Cohorts A3 and A10 (SRD Food Effect)\\\", \\\"Table 3.\\\", \\\"2\\\", 756], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"d  Detailed Schedule for Cohorts A3 and A10 (SRD Food Effect)\\\", \\\"Table 3.\\\", \\\"2\\\", 757], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"d  Detailed Schedule for Cohorts A3 and A10 (SRD Food Effect)\\\", \\\"Table 3.\\\", \\\"2\\\", 758], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"d  Detailed Schedule for Cohorts A3 and A10 (SRD Food Effect)\\\", \\\"Table 3.\\\", \\\"2\\\", 759], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"d  Detailed Schedule for Cohorts A3 and A10 (SRD Food Effect)\\\", \\\"Table 3.\\\", \\\"2\\\", 760], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"d  Detailed Schedule for Cohorts A3 and A10 (SRD Food Effect)\\\", \\\"Table 3.\\\", \\\"2\\\", 761], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"d  Detailed Schedule for Cohorts A3 and A10 (SRD Food Effect)\\\", \\\"Table 3.\\\", \\\"2\\\", 762], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"d  Detailed Schedule for Cohorts A3 and A10 (SRD Food Effect)\\\", \\\"Table 3.\\\", \\\"2\\\", 763], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"d  Detailed Schedule for Cohorts A3 and A10 (SRD Food Effect)\\\", \\\"Table 3.\\\", \\\"2\\\", 764], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"d  Detailed Schedule for Cohorts A3 and A10 (SRD Food Effect)\\\", \\\"Table 3.\\\", \\\"2\\\", 765], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"d  Detailed Schedule for Cohorts A3 and A10 (SRD Food Effect)\\\", \\\"Table 3.\\\", \\\"2\\\", 766], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"d  Detailed Schedule for Cohorts A3 and A10 (SRD Food Effect)\\\", \\\"Table 3.\\\", \\\"2\\\", 767], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"d  Detailed Schedule for Cohorts A3 and A10 (SRD Food Effect)\\\", \\\"Table 3.\\\", \\\"2\\\", 768], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"d  Detailed Schedule for Cohorts A3 and A10 (SRD Food Effect)\\\", \\\"Table 3.\\\", \\\"2\\\", 769], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"3.2 Part B and Part C\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading2\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 770], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"Table 3.e Schedule of Study Procedures for Part B and Part C (MRD in Healthy Adults/Elderly)\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading8\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 771], [\\\"\\\", \\\"Unmapped\\\", \\\"table\\\", {\\\"Table\\\": \\\"<table border=\\\\\\\"1\\\\\\\" class=\\\\\\\"dataframe\\\\\\\">\\\\n  <thead>\\\\n    <tr style=\\\\\\\"text-align: right;\\\\\\\">\\\\n      <th></th>\\\\n      <th>1.0</th>\\\\n      <th>2.0</th>\\\\n      <th>3.0</th>\\\\n      <th>4.0</th>\\\\n      <th>5.0</th>\\\\n      <th>6.0</th>\\\\n      <th>7.0</th>\\\\n      <th>8.0</th>\\\\n      <th>9.0</th>\\\\n      <th>10.0</th>\\\\n      <th>11.0</th>\\\\n      <th>12.0</th>\\\\n      <th>13.0</th>\\\\n      <th>14.0</th>\\\\n      <th>15.0</th>\\\\n      <th>16.0</th>\\\\n      <th>17.0</th>\\\\n      <th>18.0</th>\\\\n      <th>19.0</th>\\\\n      <th>20.0</th>\\\\n      <th>21.0</th>\\\\n      <th>22.0</th>\\\\n      <th>23.0</th>\\\\n    </tr>\\\\n  </thead>\\\\n  <tbody>\\\\n    <tr>\\\\n      <th>0</th>\\\\n      <td>Day</td>\\\\n      <td>Screening Days -28 to -2</td>\\\\n      <td>Day -1</td>\\\\n      <td>Predose Day 1</td>\\\\n      <td>1</td>\\\\n      <td>2</td>\\\\n      <td>3</td>\\\\n      <td>4</td>\\\\n      <td>5</td>\\\\n      <td>6</td>\\\\n      <td>7</td>\\\\n      <td>8</td>\\\\n      <td>9</td>\\\\n      <td>10</td>\\\\n      <td>11</td>\\\\n      <td>12</td>\\\\n      <td>13</td>\\\\n      <td>14</td>\\\\n      <td>15</td>\\\\n      <td>16, 17</td>\\\\n      <td>Day 18 <sup>m</sup> Discharge</td>\\\\n      <td>ET</td>\\\\n      <td>Day 21\\\\u00b12 Follow-up Visit</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>1</th>\\\\n      <td>Administrative Procedures</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>2</th>\\\\n      <td>Informed consent</td>\\\\n      <td>X</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>3</th>\\\\n      <td>Inclusion/exclusion criteria</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>4</th>\\\\n      <td>Medical history/demographics</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>5</th>\\\\n      <td>Prior and concomitant medication review (continuous review)</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>6</th>\\\\n      <td>Clinical Procedures/ Assessments</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>7</th>\\\\n      <td>Full physical examination</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>8</th>\\\\n      <td>Height, BMI calculation</td>\\\\n      <td>X</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>9</th>\\\\n      <td>Weight</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td></td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>10</th>\\\\n      <td>Vital signs BP [ supine] PR [ supine] RR, and BT) (see Table a 3.f)</td>\\\\n      <td>X</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>11</th>\\\\n      <td>Orthostatic BP, pulse rate <sup>b</sup> (see Table 3.f)</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>12</th>\\\\n      <td>ABPM (Part B only) <sup>c</sup></td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td></td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td></td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>13</th>\\\\n      <td>12-lead ECG standard(see Table 3.f)</td>\\\\n      <td>X</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>14</th>\\\\n      <td>Holter ECG <sup>d</sup></td>\\\\n      <td></td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>15</th>\\\\n      <td>C-SSRS</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>X</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>X</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>X</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>X</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>X</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>16</th>\\\\n      <td>Bladder condition checklist</td>\\\\n      <td>X</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>X</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>X</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>X</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>X</td>\\\\n      <td></td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>17</th>\\\\n      <td>NSF Sleep Diary\\\\u2013Morning</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td></td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>18</th>\\\\n      <td>KSS <sup>e</sup> (See Table 3.f)</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>19</th>\\\\n      <td>Accelerometry <sup>f</sup></td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>20</th>\\\\n      <td>TAK-861/placebo administration <sup>g</sup></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>21</th>\\\\n      <td>AE monitoring (continuous monitoring)</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>22</th>\\\\n      <td>Hematology and blood chemistry <sup>h</sup></td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td></td>\\\\n      <td>X</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>X</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>X</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>X</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>X</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>23</th>\\\\n      <td>Plasma fluoride (see Table 3.f)</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>24</th>\\\\n      <td>FSH assessment (optional; for postmenopausal women) <sup>i</sup></td>\\\\n      <td>X</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>25</th>\\\\n      <td>Urinalysis</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>X</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>X</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>26</th>\\\\n      <td>24-hour urine input/output collection</td>\\\\n      <td></td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>27</th>\\\\n      <td><span class=\\\\\\\"redact\\\\\\\"> ~REDACTED~ </span>  screening and urine drug screen</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>28</th>\\\\n      <td>Hepatitis and HIV screen</td>\\\\n      <td>X</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>29</th>\\\\n      <td>Blood for retained samples and pharmacogenomics <sup>j</sup></td>\\\\n      <td></td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>30</th>\\\\n      <td>Blood sample for CYP3A4/5 activity (see Table 3.f)</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>31</th>\\\\n      <td>Blood samples for OATP1B1/3 activity, Part B (see Table 3.f)</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>32</th>\\\\n      <td>Blood for exosome research <sup>k</sup></td>\\\\n      <td></td>\\\\n      <td>X</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>X</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>X</td>\\\\n      <td></td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>33</th>\\\\n      <td>PK Evaluations</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>34</th>\\\\n      <td>Blood sample for PK TAK-861 (See Table 3.f)</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>35</th>\\\\n      <td>Urine sample for PK TAK-861 (See Table 3.f)</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>36</th>\\\\n      <td>Check-in <sup>l</sup></td>\\\\n      <td>X</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>37</th>\\\\n      <td>Confinement</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td></td>\\\\n    </tr>\\\\n  </tbody>\\\\n</table>\\\", \\\"SectionHeaderPrintPage\\\": \\\"26\\\", \\\"TableIndex\\\": \\\"20\\\", \\\"TableName\\\": \\\"3.2 Part B and Part C(Schedule of Assessment)\\\", \\\"AttachmentEntities\\\": [{\\\"content\\\": \\\"Administrative Procedures Informed consent X\\\", \\\"entities\\\": []}, {\\\"content\\\": \\\"review (continuous review) Clinical Procedures/\\\", \\\"entities\\\": []}, {\\\"content\\\": \\\"Height, BMI calculation X\\\", \\\"entities\\\": []}, {\\\"content\\\": \\\"Vital signs BP [ supine] , PR X\\\", \\\"entities\\\": []}, {\\\"content\\\": \\\"[ supine] , RR, and BT) (see Table 3.f) a\\\", \\\"entities\\\": []}, {\\\"content\\\": \\\"Orthostatic BP, pulse rate b (see Table 3.f)\\\", \\\"entities\\\": []}, {\\\"content\\\": \\\"12-lead ECG standard (see X Table 3.f)\\\", \\\"entities\\\": []}, {\\\"content\\\": \\\"KSS e (See Table 3.f)\\\", \\\"entities\\\": []}, {\\\"content\\\": \\\"(continuous monitoring)\\\", \\\"entities\\\": []}, {\\\"content\\\": \\\"Laboratory Procedures/\\\", \\\"entities\\\": []}, {\\\"content\\\": \\\"Plasma fluoride (see Table 3.f)\\\", \\\"entities\\\": []}, {\\\"content\\\": \\\"FSH assessment (optional; for X\\\", \\\"entities\\\": []}, {\\\"content\\\": \\\"postmenopausal women) i\\\", \\\"entities\\\": []}, {\\\"content\\\": \\\"Hepatitis and HIV screen X\\\", \\\"entities\\\": []}, {\\\"content\\\": \\\"Blood for retained samples and X pharmacogenomics j X\\\", \\\"entities\\\": []}, {\\\"content\\\": \\\"activity (see Table 3.f)\\\", \\\"entities\\\": []}, {\\\"content\\\": \\\"ABPM: ambulatory blood pressure monitoring; AE: adverse event; BMI: body mass index; BP: blood pressure; BT: body temperature; C-SSRS: ColumbiaSuicide Severity Rating Scale; CYP:\\\", \\\"entities\\\": []}, {\\\"content\\\": \\\"cytochrome P450; ECG: electrocardiogram; ET: early termination; FSH: follicle-stimulating hormone; KSS: Karolinska Sleepiness Scale; MRD: multiple-rising dose; NSF: National Sleep\\\", \\\"entities\\\": [{\\\"start_idx\\\": 69, \\\"end_idx\\\": 96, \\\"standard_entity_name\\\": \\\"Molecule\\\", \\\"subcategory\\\": \\\"Molecule\\\", \\\"confidence\\\": 87.0, \\\"text\\\": \\\"follicle-stimulating hormone\\\"}]}, {\\\"content\\\": \\\"Foundation; OATP: organic anion transporting polypeptide; PK: pharmacokinetic(s); PR: pulse rate; RR: respiratory rate.\\\", \\\"entities\\\": []}, {\\\"content\\\": \\\"a BP will be checked (single measurement) with the subject resting for a minimum of 5 minutes lying in a bed with the head of the bed at 30 degrees.\\\", \\\"entities\\\": []}, {\\\"content\\\": \\\"b Orthostatic BP and pulse rate will also be checked, with the subject standing for 1 minute and 5 minutes.\\\", \\\"entities\\\": []}, {\\\"content\\\": \\\"c Twenty-four hour ABPM starts on Days -2, 3, 6, 10 and 13 in the morning before dosing time of the day.\\\", \\\"entities\\\": []}, {\\\"content\\\": \\\"d 12-lead, 24-h continuous Holter monitoring. Additional details may be found in the training manual.\\\", \\\"entities\\\": []}, {\\\"content\\\": \\\"e If subject is sleeping, please refer to Section 9.3.2.9 regarding how to rate KSS.\\\", \\\"entities\\\": []}, {\\\"content\\\": \\\"f Subjects will wear accelerometer for approximately 10 consecutive days during the screening period and throughout the study.\\\", \\\"entities\\\": []}, {\\\"content\\\": \\\"g Drug will be administered as a single dose after an overnight fast of at least 10 h. Subjects will continue to fast for an additional 4 h after dosing on serial PK collection days or 2 h after dosing\\\", \\\"entities\\\": []}, {\\\"content\\\": \\\"on nonintense PK collection days. Detailed guidance of drug administration with diet and fluid requirements can be found in Section 7.4.1.\\\", \\\"entities\\\": []}, {\\\"content\\\": \\\"h Hematology (complete blood count) and blood chemistry on Day 1 will be done at 8 h postdose. On all other days, blood draws are predose or at the relative Day 1 predose time.\\\", \\\"entities\\\": []}, {\\\"content\\\": \\\"i FSH is mandatory for postmenopausal subjects.\\\", \\\"entities\\\": []}, {\\\"content\\\": \\\"j Blood samples for pharmacogenomics are collected before the initiation of study drug administration on Day 1. Will be performed once only in each subject during the study period.\\\", \\\"entities\\\": []}, {\\\"content\\\": \\\"k The exploratory assay may include exploratory assessment of orexin-related biomarkers in plasma neuronally derived exosomes (exosome research).\\\", \\\"entities\\\": []}, {\\\"content\\\": \\\"l Subjects to check in in the afternoon or evening of Day -2 at the latest. For Part B, subjects may need to check in on Day -3 evening time to start ABPM in the morning time of Day -2. Some\\\", \\\"entities\\\": []}, {\\\"content\\\": \\\"of the assessments (eg. C-SSRS, alcohol, and drug screen) can be done at check-in time.\\\", \\\"entities\\\": [{\\\"start_idx\\\": 32, \\\"end_idx\\\": 38, \\\"standard_entity_name\\\": \\\"Molecule\\\", \\\"subcategory\\\": \\\"Molecule\\\", \\\"confidence\\\": 75.0, \\\"text\\\": \\\"alcohol\\\"}]}, {\\\"content\\\": \\\"m Day 18 study assessments may not be performed based on the emerging data from initial cohorts.\\\", \\\"entities\\\": []}], \\\"FootnoteText_0\\\": \\\" Administrative Procedures Informed consent X\\\", \\\"FootnoteText_1\\\": \\\" review (continuous review) Clinical Procedures/\\\", \\\"FootnoteText_2\\\": \\\" Height, BMI calculation X\\\", \\\"FootnoteText_3\\\": \\\" Vital signs BP [ supine] , PR X\\\", \\\"FootnoteText_4\\\": \\\"[ supine] , RR, and BT) (see Table 3.f) a\\\", \\\"FootnoteText_5\\\": \\\" Orthostatic BP, pulse rate b (see Table 3.f)\\\", \\\"FootnoteText_6\\\": \\\" 12-lead ECG standard (see X Table 3.f)\\\", \\\"FootnoteText_7\\\": \\\"KSS e (See Table 3.f)\\\", \\\"FootnoteText_8\\\": \\\" (continuous monitoring)\\\", \\\"FootnoteText_9\\\": \\\" Laboratory Procedures/\\\", \\\"FootnoteText_10\\\": \\\" Plasma fluoride (see Table 3.f)\\\", \\\"FootnoteText_11\\\": \\\" FSH assessment (optional; for X\\\", \\\"FootnoteText_12\\\": \\\" postmenopausal women) i\\\", \\\"FootnoteText_13\\\": \\\" Hepatitis and HIV screen X\\\", \\\"FootnoteText_14\\\": \\\" Blood for retained samples and X pharmacogenomics j X\\\", \\\"FootnoteText_15\\\": \\\" activity (see Table 3.f)\\\", \\\"FootnoteText_16\\\": \\\" ABPM: ambulatory blood pressure monitoring; AE: adverse event; BMI: body mass index; BP: blood pressure; BT: body temperature; C-SSRS: ColumbiaSuicide Severity Rating Scale; CYP:\\\", \\\"FootnoteText_17\\\": \\\" cytochrome P450; ECG: electrocardiogram; ET: early termination; FSH: follicle-stimulating hormone; KSS: Karolinska Sleepiness Scale; MRD: multiple-rising dose; NSF: National Sleep\\\", \\\"FootnoteText_18\\\": \\\" Foundation; OATP: organic anion transporting polypeptide; PK: pharmacokinetic(s); PR: pulse rate; RR: respiratory rate.\\\", \\\"FootnoteText_19\\\": \\\"a BP will be checked (single measurement) with the subject resting for a minimum of 5 minutes lying in a bed with the head of the bed at 30 degrees.\\\", \\\"FootnoteText_20\\\": \\\"b Orthostatic BP and pulse rate will also be checked, with the subject standing for 1 minute and 5 minutes.\\\", \\\"FootnoteText_21\\\": \\\"c Twenty-four hour ABPM starts on Days -2, 3, 6, 10 and 13 in the morning before dosing time of the day.\\\", \\\"FootnoteText_22\\\": \\\"d 12-lead, 24-h continuous Holter monitoring. Additional details may be found in the training manual.\\\", \\\"FootnoteText_23\\\": \\\"e If subject is sleeping, please refer to Section 9.3.2.9 regarding how to rate KSS.\\\", \\\"FootnoteText_24\\\": \\\"f Subjects will wear accelerometer for approximately 10 consecutive days during the screening period and throughout the study.\\\", \\\"FootnoteText_25\\\": \\\"g Drug will be administered as a single dose after an overnight fast of at least 10 h. Subjects will continue to fast for an additional 4 h after dosing on serial PK collection days or 2 h after dosing\\\", \\\"FootnoteText_26\\\": \\\" on nonintense PK collection days. Detailed guidance of drug administration with diet and fluid requirements can be found in Section 7.4.1.\\\", \\\"FootnoteText_27\\\": \\\"h Hematology (complete blood count) and blood chemistry on Day 1 will be done at 8 h postdose. On all other days, blood draws are predose or at the relative Day 1 predose time.\\\", \\\"FootnoteText_28\\\": \\\"i FSH is mandatory for postmenopausal subjects.\\\", \\\"FootnoteText_29\\\": \\\"j Blood samples for pharmacogenomics are collected before the initiation of study drug administration on Day 1. Will be performed once only in each subject during the study period.\\\", \\\"FootnoteText_30\\\": \\\"k The exploratory assay may include exploratory assessment of orexin-related biomarkers in plasma neuronally derived exosomes (exosome research).\\\", \\\"FootnoteText_31\\\": \\\"l Subjects to check in in the afternoon or evening of Day -2 at the latest. For Part B, subjects may need to check in on Day -3 evening time to start ABPM in the morning time of Day -2. Some\\\", \\\"FootnoteText_32\\\": \\\" of the assessments (eg. C-SSRS, alcohol, and drug screen) can be done at check-in time.\\\", \\\"FootnoteText_33\\\": \\\"m Day 18 study assessments may not be performed based on the emerging data from initial cohorts.\\\", \\\"Header\\\": [0, 1, 0]}, {\\\"IsBold\\\": true, \\\"font_size\\\": 17, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 17, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 772], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 773], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 774], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 775], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 776], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 777], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 778], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 779], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 780], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 781], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 782], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 783], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 784], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 785], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 786], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 787], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 788], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 789], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 790], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 791], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 792], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 793], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 794], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 795], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 796], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 797], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 798], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 799], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 800], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 801], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 802], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 803], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 804], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 805], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 806], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 807], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 808], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 809], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 810], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 811], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 812], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 813], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 814], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 815], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 816], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 817], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 818], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 819], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 820], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 821], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 822], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 823], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 824], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 825], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 826], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 827], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 828], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 829], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 830], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 831], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 832], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 833], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 834], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 835], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 836], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 837], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 838], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 839], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 840], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 841], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 842], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 843], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 844], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 845], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 846], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 847], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 848], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 849], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 850], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 851], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 852], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 853], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 854], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 855], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 856], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 857], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 858], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 859], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 860], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 861], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 862], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 863], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 864], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 865], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 866], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 867], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 868], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 869], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 870], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 871], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 872], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 873], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 874], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 875], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 876], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 877], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 878], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 879], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 880], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 881], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 882], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 883], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 884], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 885], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 886], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 887], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 888], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 889], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 890], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 891], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 892], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 893], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 894], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 895], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 896], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 897], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 898], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 899], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 900], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 901], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 902], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 903], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 904], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 905], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 906], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 907], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 908], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 909], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 910], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 911], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 912], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 913], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 914], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 915], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 916], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 917], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 918], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 919], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 920], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 921], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 922], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 923], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 924], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 925], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 926], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 927], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 928], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 929], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 930], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 931], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 932], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 933], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 934], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 935], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 936], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 937], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 938], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 939], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 940], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 941], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 942], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 943], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 944], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 945], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 946], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 947], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 948], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 949], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 950], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 951], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 952], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 953], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 954], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 955], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 956], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 957], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 958], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 959], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 960], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 961], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 962], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 963], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 964], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 965], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 966], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 967], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 968], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 969], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 970], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 971], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 972], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 973], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 974], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 975], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 976], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 977], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 978], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 979], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 980], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 981], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 982], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 983], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 984], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 985], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 986], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 987], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 988], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 989], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 990], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 991], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 992], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 993], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 994], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 995], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 996], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 997], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 998], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 999], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1000], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1001], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1002], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1003], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1004], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1005], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1006], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1007], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1008], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1009], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1010], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1011], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1012], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1013], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1014], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1015], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1016], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1017], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1018], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1019], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1020], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1021], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1022], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1023], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1024], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1025], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1026], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1027], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1028], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1029], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1030], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1031], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1032], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1033], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1034], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1035], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1036], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1037], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1038], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1039], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1040], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1041], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1042], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1043], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1044], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1045], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1046], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1047], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1048], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1049], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1050], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1051], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1052], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1053], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1054], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1055], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1056], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1057], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1058], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1059], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1060], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1061], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1062], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1063], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1064], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1065], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1066], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1067], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1068], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1069], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1070], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1071], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1072], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1073], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1074], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1075], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1076], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1077], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1078], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1079], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1080], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1081], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1082], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1083], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1084], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"Table 3.e Schedule of Study Procedures for Part B and Part C (MRD in Healthy Adults/Elderly)\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading8\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1085], [\\\"\\\", \\\"Unmapped\\\", \\\"table\\\", \\\"\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": 17, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 17, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1086], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1087], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1088], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1089], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1090], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1091], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1092], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1093], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1094], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1095], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1096], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1097], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1098], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1099], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1100], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1101], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1102], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1103], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1104], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1105], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1106], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1107], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1108], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1109], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1110], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1111], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1112], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1113], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1114], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1115], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1116], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1117], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1118], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1119], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1120], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1121], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1122], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1123], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1124], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1125], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1126], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1127], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1128], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1129], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1130], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1131], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1132], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1133], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1134], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1135], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1136], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1137], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1138], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1139], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1140], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1141], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1142], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1143], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1144], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1145], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1146], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1147], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1148], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1149], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1150], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1151], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1152], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1153], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1154], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1155], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1156], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1157], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1158], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1159], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1160], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1161], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1162], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1163], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1164], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1165], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1166], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1167], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1168], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1169], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1170], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1171], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1172], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1173], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1174], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1175], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1176], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1177], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1178], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1179], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1180], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1181], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1182], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1183], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1184], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1185], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1186], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1187], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1188], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1189], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1190], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1191], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1192], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1193], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1194], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1195], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1196], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1197], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1198], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1199], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1200], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1201], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1202], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1203], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1204], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1205], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1206], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1207], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1208], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1209], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1210], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1211], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1212], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1213], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1214], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1215], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1216], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1217], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1218], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1219], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1220], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1221], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1222], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1223], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1224], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1225], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1226], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1227], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1228], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1229], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1230], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1231], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1232], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1233], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1234], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1235], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1236], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1237], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1238], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1239], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1240], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1241], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1242], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1243], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1244], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1245], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1246], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1247], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1248], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1249], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1250], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1251], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1252], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1253], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1254], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1255], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1256], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1257], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1258], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1259], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1260], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1261], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1262], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1263], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1264], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1265], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1266], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1267], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1268], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1269], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1270], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1271], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1272], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1273], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1274], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1275], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1276], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1277], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1278], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1279], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1280], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1281], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1282], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1283], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1284], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1285], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1286], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1287], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1288], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1289], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1290], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1291], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1292], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1293], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1294], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1295], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1296], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1297], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1298], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1299], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1300], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1301], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1302], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1303], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1304], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1305], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1306], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1307], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1308], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1309], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1310], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1311], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1312], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1313], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1314], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1315], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1316], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1317], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1318], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1319], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1320], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1321], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1322], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1323], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1324], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1325], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1326], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1327], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1328], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1329], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1330], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1331], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1332], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1333], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1334], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1335], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1336], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1337], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1338], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1339], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1340], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1341], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1342], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1343], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1344], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1345], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1346], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1347], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1348], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1349], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1350], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1351], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1352], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1353], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1354], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1355], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1356], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1357], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1358], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1359], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1360], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1361], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1362], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1363], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1364], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1365], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1366], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1367], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1368], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1369], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1370], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1371], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1372], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1373], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1374], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1375], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1376], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1377], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1378], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1379], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1380], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1381], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1382], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1383], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1384], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1385], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1386], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1387], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1388], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1389], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1390], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1391], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part B and Part C\\\", \\\"3.2\\\", \\\"2\\\", 1392], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"Table 3.e Schedule of Study Procedures for Part B and Part C (MRD in Healthy Adults/Elderly)\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading8\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"e  Schedule of Study Procedures for Part B and Part C (MRD in Healthy Adults/Elderly)\\\", \\\"Table 3.\\\", \\\"2\\\", 1393], [\\\"\\\", \\\"Unmapped\\\", \\\"table\\\", \\\"\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": 17, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 17, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"e  Schedule of Study Procedures for Part B and Part C (MRD in Healthy Adults/Elderly)\\\", \\\"Table 3.\\\", \\\"2\\\", 1394], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"e  Schedule of Study Procedures for Part B and Part C (MRD in Healthy Adults/Elderly)\\\", \\\"Table 3.\\\", \\\"2\\\", 1395], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"e  Schedule of Study Procedures for Part B and Part C (MRD in Healthy Adults/Elderly)\\\", \\\"Table 3.\\\", \\\"2\\\", 1396], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"e  Schedule of Study Procedures for Part B and Part C (MRD in Healthy Adults/Elderly)\\\", \\\"Table 3.\\\", \\\"2\\\", 1397], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"e  Schedule of Study Procedures for Part B and Part C (MRD in Healthy Adults/Elderly)\\\", \\\"Table 3.\\\", \\\"2\\\", 1398], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"e  Schedule of Study Procedures for Part B and Part C (MRD in Healthy Adults/Elderly)\\\", \\\"Table 3.\\\", \\\"2\\\", 1399], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"e  Schedule of Study Procedures for Part B and Part C (MRD in Healthy Adults/Elderly)\\\", \\\"Table 3.\\\", \\\"2\\\", 1400], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"e  Schedule of Study Procedures for Part B and Part C (MRD in Healthy Adults/Elderly)\\\", \\\"Table 3.\\\", \\\"2\\\", 1401], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"e  Schedule of Study Procedures for Part B and Part C (MRD in Healthy Adults/Elderly)\\\", \\\"Table 3.\\\", \\\"2\\\", 1402], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"e  Schedule of Study Procedures for Part B and Part C (MRD in Healthy Adults/Elderly)\\\", \\\"Table 3.\\\", \\\"2\\\", 1403], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"e  Schedule of Study Procedures for Part B and Part C (MRD in Healthy Adults/Elderly)\\\", \\\"Table 3.\\\", \\\"2\\\", 1404], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"e  Schedule of Study Procedures for Part B and Part C (MRD in Healthy Adults/Elderly)\\\", \\\"Table 3.\\\", \\\"2\\\", 1405], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"e  Schedule of Study Procedures for Part B and Part C (MRD in Healthy Adults/Elderly)\\\", \\\"Table 3.\\\", \\\"2\\\", 1406], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"e  Schedule of Study Procedures for Part B and Part C (MRD in Healthy Adults/Elderly)\\\", \\\"Table 3.\\\", \\\"2\\\", 1407], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"e  Schedule of Study Procedures for Part B and Part C (MRD in Healthy Adults/Elderly)\\\", \\\"Table 3.\\\", \\\"2\\\", 1408], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"e  Schedule of Study Procedures for Part B and Part C (MRD in Healthy Adults/Elderly)\\\", \\\"Table 3.\\\", \\\"2\\\", 1409], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"e  Schedule of Study Procedures for Part B and Part C (MRD in Healthy Adults/Elderly)\\\", \\\"Table 3.\\\", \\\"2\\\", 1410], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"e  Schedule of Study Procedures for Part B and Part C (MRD in Healthy Adults/Elderly)\\\", \\\"Table 3.\\\", \\\"2\\\", 1411], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"e  Schedule of Study Procedures for Part B and Part C (MRD in Healthy Adults/Elderly)\\\", \\\"Table 3.\\\", \\\"2\\\", 1412], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"e  Schedule of Study Procedures for Part B and Part C (MRD in Healthy Adults/Elderly)\\\", \\\"Table 3.\\\", \\\"2\\\", 1413], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"e  Schedule of Study Procedures for Part B and Part C (MRD in Healthy Adults/Elderly)\\\", \\\"Table 3.\\\", \\\"2\\\", 1414], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"e  Schedule of Study Procedures for Part B and Part C (MRD in Healthy Adults/Elderly)\\\", \\\"Table 3.\\\", \\\"2\\\", 1415], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"e  Schedule of Study Procedures for Part B and Part C (MRD in Healthy Adults/Elderly)\\\", \\\"Table 3.\\\", \\\"2\\\", 1416], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"e  Schedule of Study Procedures for Part B and Part C (MRD in Healthy Adults/Elderly)\\\", \\\"Table 3.\\\", \\\"2\\\", 1417], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"e  Schedule of Study Procedures for Part B and Part C (MRD in Healthy Adults/Elderly)\\\", \\\"Table 3.\\\", \\\"2\\\", 1418], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"e  Schedule of Study Procedures for Part B and Part C (MRD in Healthy Adults/Elderly)\\\", \\\"Table 3.\\\", \\\"2\\\", 1419], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"e  Schedule of Study Procedures for Part B and Part C (MRD in Healthy Adults/Elderly)\\\", \\\"Table 3.\\\", \\\"2\\\", 1420], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"e  Schedule of Study Procedures for Part B and Part C (MRD in Healthy Adults/Elderly)\\\", \\\"Table 3.\\\", \\\"2\\\", 1421], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"e  Schedule of Study Procedures for Part B and Part C (MRD in Healthy Adults/Elderly)\\\", \\\"Table 3.\\\", \\\"2\\\", 1422], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"e  Schedule of Study Procedures for Part B and Part C (MRD in Healthy Adults/Elderly)\\\", \\\"Table 3.\\\", \\\"2\\\", 1423], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"e  Schedule of Study Procedures for Part B and Part C (MRD in Healthy Adults/Elderly)\\\", \\\"Table 3.\\\", \\\"2\\\", 1424], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"e  Schedule of Study Procedures for Part B and Part C (MRD in Healthy Adults/Elderly)\\\", \\\"Table 3.\\\", \\\"2\\\", 1425], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"e  Schedule of Study Procedures for Part B and Part C (MRD in Healthy Adults/Elderly)\\\", \\\"Table 3.\\\", \\\"2\\\", 1426], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"e  Schedule of Study Procedures for Part B and Part C (MRD in Healthy Adults/Elderly)\\\", \\\"Table 3.\\\", \\\"2\\\", 1427], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"e  Schedule of Study Procedures for Part B and Part C (MRD in Healthy Adults/Elderly)\\\", \\\"Table 3.\\\", \\\"2\\\", 1428], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"e  Schedule of Study Procedures for Part B and Part C (MRD in Healthy Adults/Elderly)\\\", \\\"Table 3.\\\", \\\"2\\\", 1429], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"e  Schedule of Study Procedures for Part B and Part C (MRD in Healthy Adults/Elderly)\\\", \\\"Table 3.\\\", \\\"2\\\", 1430], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"e  Schedule of Study Procedures for Part B and Part C (MRD in Healthy Adults/Elderly)\\\", \\\"Table 3.\\\", \\\"2\\\", 1431], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"e  Schedule of Study Procedures for Part B and Part C (MRD in Healthy Adults/Elderly)\\\", \\\"Table 3.\\\", \\\"2\\\", 1432], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"e  Schedule of Study Procedures for Part B and Part C (MRD in Healthy Adults/Elderly)\\\", \\\"Table 3.\\\", \\\"2\\\", 1433], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"e  Schedule of Study Procedures for Part B and Part C (MRD in Healthy Adults/Elderly)\\\", \\\"Table 3.\\\", \\\"2\\\", 1434], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"e  Schedule of Study Procedures for Part B and Part C (MRD in Healthy Adults/Elderly)\\\", \\\"Table 3.\\\", \\\"2\\\", 1435], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"e  Schedule of Study Procedures for Part B and Part C (MRD in Healthy Adults/Elderly)\\\", \\\"Table 3.\\\", \\\"2\\\", 1436], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"e  Schedule of Study Procedures for Part B and Part C (MRD in Healthy Adults/Elderly)\\\", \\\"Table 3.\\\", \\\"2\\\", 1437], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"e  Schedule of Study Procedures for Part B and Part C (MRD in Healthy Adults/Elderly)\\\", \\\"Table 3.\\\", \\\"2\\\", 1438], [\\\"\\\", \\\"Unmapped\\\", \\\"table\\\", {\\\"Table\\\": \\\"<table border=\\\\\\\"1\\\\\\\" class=\\\\\\\"dataframe\\\\\\\">\\\\n  <thead>\\\\n    <tr style=\\\\\\\"text-align: right;\\\\\\\">\\\\n      <th></th>\\\\n      <th>1.0</th>\\\\n      <th>2.0</th>\\\\n      <th>3.0</th>\\\\n      <th>4.0</th>\\\\n      <th>5.0</th>\\\\n      <th>6.0</th>\\\\n      <th>7.0</th>\\\\n      <th>8.0</th>\\\\n      <th>9.0</th>\\\\n      <th>10.0</th>\\\\n      <th>11.0</th>\\\\n      <th>12.0</th>\\\\n      <th>13.0</th>\\\\n      <th>14.0</th>\\\\n      <th>15.0</th>\\\\n      <th>16.0</th>\\\\n      <th>17.0</th>\\\\n      <th>18.0</th>\\\\n      <th>19.0</th>\\\\n    </tr>\\\\n  </thead>\\\\n  <tbody>\\\\n    <tr>\\\\n      <th>0</th>\\\\n      <td>Procedure</td>\\\\n      <td>Predose</td>\\\\n      <td>Treatment Period</td>\\\\n      <td>Treatment Period</td>\\\\n      <td>Treatment Period</td>\\\\n      <td>Treatment Period</td>\\\\n      <td>Treatment Period</td>\\\\n      <td>Treatment Period</td>\\\\n      <td>Treatment Period</td>\\\\n      <td>Treatment Period</td>\\\\n      <td>Treatment Period</td>\\\\n      <td>Treatment Period</td>\\\\n      <td>Treatment Period</td>\\\\n      <td>Treatment Period</td>\\\\n      <td>Treatment Period</td>\\\\n      <td>Treatment Period</td>\\\\n      <td>Postdose/Follow-up</td>\\\\n      <td>Postdose/Follow-up</td>\\\\n      <td>Postdose/Follow-up</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>1</th>\\\\n      <td>Day</td>\\\\n      <td>-1</td>\\\\n      <td>1</td>\\\\n      <td>2</td>\\\\n      <td>3</td>\\\\n      <td>4</td>\\\\n      <td>5</td>\\\\n      <td>6</td>\\\\n      <td>7</td>\\\\n      <td>8</td>\\\\n      <td>9</td>\\\\n      <td>10</td>\\\\n      <td>11</td>\\\\n      <td>12</td>\\\\n      <td>13</td>\\\\n      <td>14-17</td>\\\\n      <td>18 <sup>a</sup></td>\\\\n      <td>ET</td>\\\\n      <td>21 (\\\\u00b12 days)</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>2</th>\\\\n      <td>Blood sample for TAK-861 PK</td>\\\\n      <td></td>\\\\n      <td>Pre and 0.25, 0.5, 1, 2, 3, 4, 6, 8, and 12 h Post</td>\\\\n      <td>24 h after Day 1  dose (must be collected before Day 2 dose)</td>\\\\n      <td></td>\\\\n      <td>Pre</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>Pre</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>Pre</td>\\\\n      <td></td>\\\\n      <td>Pre</td>\\\\n      <td>Pre and 0.25, 0.5, 1, 2, 3, 4, 6, 8 12, 24, 36, 48, and 72 h after Day 14 dose</td>\\\\n      <td>96 h after Day 14 dose</td>\\\\n      <td>X <sup>b</sup></td>\\\\n      <td></td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>3</th>\\\\n      <td>Blood sample for CYP3A4/5 activity</td>\\\\n      <td></td>\\\\n      <td>Pre</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>Pre</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>Predose on Day 14</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>4</th>\\\\n      <td>Blood sample for OATP1B1/3 activity, Part B only</td>\\\\n      <td></td>\\\\n      <td>Pre, 1, 2, 6, and 12 h</td>\\\\n      <td>Pre</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>Pre, 1, 2, 6, 12, 24 h after Day 14 dose</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>5</th>\\\\n      <td>Blood sample for plasma fluoride</td>\\\\n      <td></td>\\\\n      <td>Pre</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>2 and 12 h after Day 14 dose</td>\\\\n      <td>96 h after Day 14 dose</td>\\\\n      <td>X <sup>b</sup></td>\\\\n      <td></td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>6</th>\\\\n      <td>Urine sample for TAK-861 PK (selected cohorts only)</td>\\\\n      <td></td>\\\\n      <td>Spot: Pre Pooled: 0-6 and 6-12 h Post</td>\\\\n      <td>Pooled: 12-24 h after Day 1 dose</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>Pooled: 0-6, 6-12, and 12-24 h after Day 14 dose</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>7</th>\\\\n      <td>Supine BP and pulse rate measurements</td>\\\\n      <td>Approximately before morning dose time on Day 1 and 0.5, 1, 2, 3, 4, 6, 8, and 12 h later relative to initial measurement (matched to the time assessment schedule of Day 1)</td>\\\\n      <td>Pre and 0.5, 1, 2, 3, 4, 6, 8, and 12 h Post</td>\\\\n      <td>24 h after Day 1 dose</td>\\\\n      <td>Pre</td>\\\\n      <td>Pre</td>\\\\n      <td>Pre</td>\\\\n      <td>Pre</td>\\\\n      <td>Pre and 3, 6, and 12 h Post</td>\\\\n      <td>Pre</td>\\\\n      <td>Pre</td>\\\\n      <td>Pre</td>\\\\n      <td>Pre</td>\\\\n      <td>Pre</td>\\\\n      <td>Pre</td>\\\\n      <td>Pre and 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 36, 48, and 72 h after Day 14 dose</td>\\\\n      <td>96 h after Day 14 dose <sup>c</sup></td>\\\\n      <td>X <sup>c</sup></td>\\\\n      <td>X</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>8</th>\\\\n      <td>Orthostatic BP and pulse rate measurements</td>\\\\n      <td>X<sup> (relative Pre time)</sup></td>\\\\n      <td>Pre, 1, 2, and 6 h Post</td>\\\\n      <td>24 h Post</td>\\\\n      <td></td>\\\\n      <td>Pre</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>Pre</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>Pre</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>Pre, 1, 2, and 6 h after Day 14 dose</td>\\\\n      <td>96 h after Day 14 dose</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>9</th>\\\\n      <td>Respiratory rate</td>\\\\n      <td></td>\\\\n      <td>Pre and 1, 2, 4, and 6 h Post</td>\\\\n      <td>Pre</td>\\\\n      <td></td>\\\\n      <td>Pre</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>Pre</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>Pre</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>Pre dose on Day 14</td>\\\\n      <td>96 h after Day 14 dose</td>\\\\n      <td>X<sup> c</sup></td>\\\\n      <td>X</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>10</th>\\\\n      <td>Body temperature</td>\\\\n      <td></td>\\\\n      <td>Pre</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>Pre</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>Pre</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>Pre</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>Pre dose on Day 14</td>\\\\n      <td>96 h after Day 14 dose</td>\\\\n      <td>X<sup> c</sup></td>\\\\n      <td>X</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>11</th>\\\\n      <td>Standard 12-lead ECGs</td>\\\\n      <td>X</td>\\\\n      <td>Pre and 1, 2, 4, 6, and 12 h Post</td>\\\\n      <td>Pre</td>\\\\n      <td></td>\\\\n      <td>Pre</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>Pre</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>Pre</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>Pre dose on Day 14</td>\\\\n      <td>96 h after Day 14 dose</td>\\\\n      <td>X<sup> c</sup></td>\\\\n      <td>X</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>12</th>\\\\n      <td>KSS <sup>d</sup></td>\\\\n      <td>Pre (relative to planned Day 1 dose time) and 1, 2, 4, 8, 12, and 14 h relative to initial measurement</td>\\\\n      <td>16 and 24 h after initial  Day -1 measurement</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>Pre and 1, 2, 4, 8, 12, and 14 h Post</td>\\\\n      <td>16 and 24 h after Day 7 dose</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>Pre and 1, 2, 4, 8, 12, 16, and 24 h after Day 14 dose</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n    </tr>\\\\n  </tbody>\\\\n</table>\\\", \\\"SectionHeaderPrintPage\\\": \\\"26\\\", \\\"TableIndex\\\": \\\"23\\\", \\\"TableName\\\": \\\"Table 3.e Schedule of Study Procedures for Part B and Part C (MRD in Healthy Adults/Elderly)(Schedule of Assessment)\\\", \\\"AttachmentEntities\\\": [{\\\"content\\\": \\\"activity, Part B (see Table 3.f)\\\", \\\"entities\\\": []}, {\\\"content\\\": \\\"Blood sample for PK TAK-861 (See Table 3.f)\\\", \\\"entities\\\": []}, {\\\"content\\\": \\\"TAK-861 (See Table 3.f)\\\", \\\"entities\\\": []}], \\\"FootnoteText_0\\\": \\\" activity, Part B (see Table 3.f)\\\", \\\"FootnoteText_1\\\": \\\" Blood sample for PK TAK-861 (See Table 3.f)\\\", \\\"FootnoteText_2\\\": \\\" TAK-861 (See Table 3.f)\\\", \\\"Header\\\": [0, 1]}, {\\\"IsBold\\\": true, \\\"font_size\\\": 16, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 16, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"e  Schedule of Study Procedures for Part B and Part C (MRD in Healthy Adults/Elderly)\\\", \\\"Table 3.\\\", \\\"2\\\", 1439], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"e  Schedule of Study Procedures for Part B and Part C (MRD in Healthy Adults/Elderly)\\\", \\\"Table 3.\\\", \\\"2\\\", 1440], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"e  Schedule of Study Procedures for Part B and Part C (MRD in Healthy Adults/Elderly)\\\", \\\"Table 3.\\\", \\\"2\\\", 1441], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"e  Schedule of Study Procedures for Part B and Part C (MRD in Healthy Adults/Elderly)\\\", \\\"Table 3.\\\", \\\"2\\\", 1442], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"e  Schedule of Study Procedures for Part B and Part C (MRD in Healthy Adults/Elderly)\\\", \\\"Table 3.\\\", \\\"2\\\", 1443], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"e  Schedule of Study Procedures for Part B and Part C (MRD in Healthy Adults/Elderly)\\\", \\\"Table 3.\\\", \\\"2\\\", 1444], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"e  Schedule of Study Procedures for Part B and Part C (MRD in Healthy Adults/Elderly)\\\", \\\"Table 3.\\\", \\\"2\\\", 1445], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"e  Schedule of Study Procedures for Part B and Part C (MRD in Healthy Adults/Elderly)\\\", \\\"Table 3.\\\", \\\"2\\\", 1446], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"e  Schedule of Study Procedures for Part B and Part C (MRD in Healthy Adults/Elderly)\\\", \\\"Table 3.\\\", \\\"2\\\", 1447], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"e  Schedule of Study Procedures for Part B and Part C (MRD in Healthy Adults/Elderly)\\\", \\\"Table 3.\\\", \\\"2\\\", 1448], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"e  Schedule of Study Procedures for Part B and Part C (MRD in Healthy Adults/Elderly)\\\", \\\"Table 3.\\\", \\\"2\\\", 1449], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"e  Schedule of Study Procedures for Part B and Part C (MRD in Healthy Adults/Elderly)\\\", \\\"Table 3.\\\", \\\"2\\\", 1450], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"e  Schedule of Study Procedures for Part B and Part C (MRD in Healthy Adults/Elderly)\\\", \\\"Table 3.\\\", \\\"2\\\", 1451], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"e  Schedule of Study Procedures for Part B and Part C (MRD in Healthy Adults/Elderly)\\\", \\\"Table 3.\\\", \\\"2\\\", 1452], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"e  Schedule of Study Procedures for Part B and Part C (MRD in Healthy Adults/Elderly)\\\", \\\"Table 3.\\\", \\\"2\\\", 1453], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"e  Schedule of Study Procedures for Part B and Part C (MRD in Healthy Adults/Elderly)\\\", \\\"Table 3.\\\", \\\"2\\\", 1454], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"e  Schedule of Study Procedures for Part B and Part C (MRD in Healthy Adults/Elderly)\\\", \\\"Table 3.\\\", \\\"2\\\", 1455], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"e  Schedule of Study Procedures for Part B and Part C (MRD in Healthy Adults/Elderly)\\\", \\\"Table 3.\\\", \\\"2\\\", 1456], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"e  Schedule of Study Procedures for Part B and Part C (MRD in Healthy Adults/Elderly)\\\", \\\"Table 3.\\\", \\\"2\\\", 1457], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"e  Schedule of Study Procedures for Part B and Part C (MRD in Healthy Adults/Elderly)\\\", \\\"Table 3.\\\", \\\"2\\\", 1458], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"e  Schedule of Study Procedures for Part B and Part C (MRD in Healthy Adults/Elderly)\\\", \\\"Table 3.\\\", \\\"2\\\", 1459], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"e  Schedule of Study Procedures for Part B and Part C (MRD in Healthy Adults/Elderly)\\\", \\\"Table 3.\\\", \\\"2\\\", 1460], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"e  Schedule of Study Procedures for Part B and Part C (MRD in Healthy Adults/Elderly)\\\", \\\"Table 3.\\\", \\\"2\\\", 1461], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"e  Schedule of Study Procedures for Part B and Part C (MRD in Healthy Adults/Elderly)\\\", \\\"Table 3.\\\", \\\"2\\\", 1462], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"e  Schedule of Study Procedures for Part B and Part C (MRD in Healthy Adults/Elderly)\\\", \\\"Table 3.\\\", \\\"2\\\", 1463], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"e  Schedule of Study Procedures for Part B and Part C (MRD in Healthy Adults/Elderly)\\\", \\\"Table 3.\\\", \\\"2\\\", 1464], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"e  Schedule of Study Procedures for Part B and Part C (MRD in Healthy Adults/Elderly)\\\", \\\"Table 3.\\\", \\\"2\\\", 1465], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"e  Schedule of Study Procedures for Part B and Part C (MRD in Healthy Adults/Elderly)\\\", \\\"Table 3.\\\", \\\"2\\\", 1466], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"e  Schedule of Study Procedures for Part B and Part C (MRD in Healthy Adults/Elderly)\\\", \\\"Table 3.\\\", \\\"2\\\", 1467], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"e  Schedule of Study Procedures for Part B and Part C (MRD in Healthy Adults/Elderly)\\\", \\\"Table 3.\\\", \\\"2\\\", 1468], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"e  Schedule of Study Procedures for Part B and Part C (MRD in Healthy Adults/Elderly)\\\", \\\"Table 3.\\\", \\\"2\\\", 1469], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"e  Schedule of Study Procedures for Part B and Part C (MRD in Healthy Adults/Elderly)\\\", \\\"Table 3.\\\", \\\"2\\\", 1470], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"e  Schedule of Study Procedures for Part B and Part C (MRD in Healthy Adults/Elderly)\\\", \\\"Table 3.\\\", \\\"2\\\", 1471], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"e  Schedule of Study Procedures for Part B and Part C (MRD in Healthy Adults/Elderly)\\\", \\\"Table 3.\\\", \\\"2\\\", 1472], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"e  Schedule of Study Procedures for Part B and Part C (MRD in Healthy Adults/Elderly)\\\", \\\"Table 3.\\\", \\\"2\\\", 1473], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"e  Schedule of Study Procedures for Part B and Part C (MRD in Healthy Adults/Elderly)\\\", \\\"Table 3.\\\", \\\"2\\\", 1474], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"e  Schedule of Study Procedures for Part B and Part C (MRD in Healthy Adults/Elderly)\\\", \\\"Table 3.\\\", \\\"2\\\", 1475], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"e  Schedule of Study Procedures for Part B and Part C (MRD in Healthy Adults/Elderly)\\\", \\\"Table 3.\\\", \\\"2\\\", 1476], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"e  Schedule of Study Procedures for Part B and Part C (MRD in Healthy Adults/Elderly)\\\", \\\"Table 3.\\\", \\\"2\\\", 1477], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"e  Schedule of Study Procedures for Part B and Part C (MRD in Healthy Adults/Elderly)\\\", \\\"Table 3.\\\", \\\"2\\\", 1478], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"e  Schedule of Study Procedures for Part B and Part C (MRD in Healthy Adults/Elderly)\\\", \\\"Table 3.\\\", \\\"2\\\", 1479], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"e  Schedule of Study Procedures for Part B and Part C (MRD in Healthy Adults/Elderly)\\\", \\\"Table 3.\\\", \\\"2\\\", 1480], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"e  Schedule of Study Procedures for Part B and Part C (MRD in Healthy Adults/Elderly)\\\", \\\"Table 3.\\\", \\\"2\\\", 1481], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"e  Schedule of Study Procedures for Part B and Part C (MRD in Healthy Adults/Elderly)\\\", \\\"Table 3.\\\", \\\"2\\\", 1482], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"e  Schedule of Study Procedures for Part B and Part C (MRD in Healthy Adults/Elderly)\\\", \\\"Table 3.\\\", \\\"2\\\", 1483], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"e  Schedule of Study Procedures for Part B and Part C (MRD in Healthy Adults/Elderly)\\\", \\\"Table 3.\\\", \\\"2\\\", 1484], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"e  Schedule of Study Procedures for Part B and Part C (MRD in Healthy Adults/Elderly)\\\", \\\"Table 3.\\\", \\\"2\\\", 1485], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"e  Schedule of Study Procedures for Part B and Part C (MRD in Healthy Adults/Elderly)\\\", \\\"Table 3.\\\", \\\"2\\\", 1486], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"e  Schedule of Study Procedures for Part B and Part C (MRD in Healthy Adults/Elderly)\\\", \\\"Table 3.\\\", \\\"2\\\", 1487], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"e  Schedule of Study Procedures for Part B and Part C (MRD in Healthy Adults/Elderly)\\\", \\\"Table 3.\\\", \\\"2\\\", 1488], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"e  Schedule of Study Procedures for Part B and Part C (MRD in Healthy Adults/Elderly)\\\", \\\"Table 3.\\\", \\\"2\\\", 1489], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"e  Schedule of Study Procedures for Part B and Part C (MRD in Healthy Adults/Elderly)\\\", \\\"Table 3.\\\", \\\"2\\\", 1490], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"e  Schedule of Study Procedures for Part B and Part C (MRD in Healthy Adults/Elderly)\\\", \\\"Table 3.\\\", \\\"2\\\", 1491], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"e  Schedule of Study Procedures for Part B and Part C (MRD in Healthy Adults/Elderly)\\\", \\\"Table 3.\\\", \\\"2\\\", 1492], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"e  Schedule of Study Procedures for Part B and Part C (MRD in Healthy Adults/Elderly)\\\", \\\"Table 3.\\\", \\\"2\\\", 1493], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"e  Schedule of Study Procedures for Part B and Part C (MRD in Healthy Adults/Elderly)\\\", \\\"Table 3.\\\", \\\"2\\\", 1494], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"e  Schedule of Study Procedures for Part B and Part C (MRD in Healthy Adults/Elderly)\\\", \\\"Table 3.\\\", \\\"2\\\", 1495], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"e  Schedule of Study Procedures for Part B and Part C (MRD in Healthy Adults/Elderly)\\\", \\\"Table 3.\\\", \\\"2\\\", 1496], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"e  Schedule of Study Procedures for Part B and Part C (MRD in Healthy Adults/Elderly)\\\", \\\"Table 3.\\\", \\\"2\\\", 1497], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"e  Schedule of Study Procedures for Part B and Part C (MRD in Healthy Adults/Elderly)\\\", \\\"Table 3.\\\", \\\"2\\\", 1498], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"e  Schedule of Study Procedures for Part B and Part C (MRD in Healthy Adults/Elderly)\\\", \\\"Table 3.\\\", \\\"2\\\", 1499], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"e  Schedule of Study Procedures for Part B and Part C (MRD in Healthy Adults/Elderly)\\\", \\\"Table 3.\\\", \\\"2\\\", 1500], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"e  Schedule of Study Procedures for Part B and Part C (MRD in Healthy Adults/Elderly)\\\", \\\"Table 3.\\\", \\\"2\\\", 1501], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"e  Schedule of Study Procedures for Part B and Part C (MRD in Healthy Adults/Elderly)\\\", \\\"Table 3.\\\", \\\"2\\\", 1502], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"e  Schedule of Study Procedures for Part B and Part C (MRD in Healthy Adults/Elderly)\\\", \\\"Table 3.\\\", \\\"2\\\", 1503], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"e  Schedule of Study Procedures for Part B and Part C (MRD in Healthy Adults/Elderly)\\\", \\\"Table 3.\\\", \\\"2\\\", 1504], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"e  Schedule of Study Procedures for Part B and Part C (MRD in Healthy Adults/Elderly)\\\", \\\"Table 3.\\\", \\\"2\\\", 1505], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"e  Schedule of Study Procedures for Part B and Part C (MRD in Healthy Adults/Elderly)\\\", \\\"Table 3.\\\", \\\"2\\\", 1506], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"e  Schedule of Study Procedures for Part B and Part C (MRD in Healthy Adults/Elderly)\\\", \\\"Table 3.\\\", \\\"2\\\", 1507], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"e  Schedule of Study Procedures for Part B and Part C (MRD in Healthy Adults/Elderly)\\\", \\\"Table 3.\\\", \\\"2\\\", 1508], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"e  Schedule of Study Procedures for Part B and Part C (MRD in Healthy Adults/Elderly)\\\", \\\"Table 3.\\\", \\\"2\\\", 1509], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"e  Schedule of Study Procedures for Part B and Part C (MRD in Healthy Adults/Elderly)\\\", \\\"Table 3.\\\", \\\"2\\\", 1510], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"e  Schedule of Study Procedures for Part B and Part C (MRD in Healthy Adults/Elderly)\\\", \\\"Table 3.\\\", \\\"2\\\", 1511], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"e  Schedule of Study Procedures for Part B and Part C (MRD in Healthy Adults/Elderly)\\\", \\\"Table 3.\\\", \\\"2\\\", 1512], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"e  Schedule of Study Procedures for Part B and Part C (MRD in Healthy Adults/Elderly)\\\", \\\"Table 3.\\\", \\\"2\\\", 1513], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"e  Schedule of Study Procedures for Part B and Part C (MRD in Healthy Adults/Elderly)\\\", \\\"Table 3.\\\", \\\"2\\\", 1514], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"e  Schedule of Study Procedures for Part B and Part C (MRD in Healthy Adults/Elderly)\\\", \\\"Table 3.\\\", \\\"2\\\", 1515], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"e  Schedule of Study Procedures for Part B and Part C (MRD in Healthy Adults/Elderly)\\\", \\\"Table 3.\\\", \\\"2\\\", 1516], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"e  Schedule of Study Procedures for Part B and Part C (MRD in Healthy Adults/Elderly)\\\", \\\"Table 3.\\\", \\\"2\\\", 1517], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"Table 3.f Detailed Schedule for Part B and C\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading8\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"f  Detailed Schedule for Part B and C\\\", \\\"Table 3.\\\", \\\"2\\\", 1518], [\\\"\\\", \\\"Unmapped\\\", \\\"table\\\", \\\"\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": 16, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 16, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"f  Detailed Schedule for Part B and C\\\", \\\"Table 3.\\\", \\\"2\\\", 1519], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"f  Detailed Schedule for Part B and C\\\", \\\"Table 3.\\\", \\\"2\\\", 1520], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"f  Detailed Schedule for Part B and C\\\", \\\"Table 3.\\\", \\\"2\\\", 1521], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"f  Detailed Schedule for Part B and C\\\", \\\"Table 3.\\\", \\\"2\\\", 1522], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"f  Detailed Schedule for Part B and C\\\", \\\"Table 3.\\\", \\\"2\\\", 1523], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"f  Detailed Schedule for Part B and C\\\", \\\"Table 3.\\\", \\\"2\\\", 1524], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"f  Detailed Schedule for Part B and C\\\", \\\"Table 3.\\\", \\\"2\\\", 1525], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"f  Detailed Schedule for Part B and C\\\", \\\"Table 3.\\\", \\\"2\\\", 1526], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"f  Detailed Schedule for Part B and C\\\", \\\"Table 3.\\\", \\\"2\\\", 1527], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"f  Detailed Schedule for Part B and C\\\", \\\"Table 3.\\\", \\\"2\\\", 1528], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"f  Detailed Schedule for Part B and C\\\", \\\"Table 3.\\\", \\\"2\\\", 1529], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"f  Detailed Schedule for Part B and C\\\", \\\"Table 3.\\\", \\\"2\\\", 1530], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"f  Detailed Schedule for Part B and C\\\", \\\"Table 3.\\\", \\\"2\\\", 1531], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"f  Detailed Schedule for Part B and C\\\", \\\"Table 3.\\\", \\\"2\\\", 1532], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"f  Detailed Schedule for Part B and C\\\", \\\"Table 3.\\\", \\\"2\\\", 1533], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"f  Detailed Schedule for Part B and C\\\", \\\"Table 3.\\\", \\\"2\\\", 1534], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"f  Detailed Schedule for Part B and C\\\", \\\"Table 3.\\\", \\\"2\\\", 1535], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"f  Detailed Schedule for Part B and C\\\", \\\"Table 3.\\\", \\\"2\\\", 1536], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"f  Detailed Schedule for Part B and C\\\", \\\"Table 3.\\\", \\\"2\\\", 1537], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"f  Detailed Schedule for Part B and C\\\", \\\"Table 3.\\\", \\\"2\\\", 1538], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"f  Detailed Schedule for Part B and C\\\", \\\"Table 3.\\\", \\\"2\\\", 1539], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"f  Detailed Schedule for Part B and C\\\", \\\"Table 3.\\\", \\\"2\\\", 1540], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"f  Detailed Schedule for Part B and C\\\", \\\"Table 3.\\\", \\\"2\\\", 1541], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"f  Detailed Schedule for Part B and C\\\", \\\"Table 3.\\\", \\\"2\\\", 1542], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"f  Detailed Schedule for Part B and C\\\", \\\"Table 3.\\\", \\\"2\\\", 1543], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"f  Detailed Schedule for Part B and C\\\", \\\"Table 3.\\\", \\\"2\\\", 1544], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"f  Detailed Schedule for Part B and C\\\", \\\"Table 3.\\\", \\\"2\\\", 1545], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"f  Detailed Schedule for Part B and C\\\", \\\"Table 3.\\\", \\\"2\\\", 1546], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"f  Detailed Schedule for Part B and C\\\", \\\"Table 3.\\\", \\\"2\\\", 1547], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"f  Detailed Schedule for Part B and C\\\", \\\"Table 3.\\\", \\\"2\\\", 1548], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"f  Detailed Schedule for Part B and C\\\", \\\"Table 3.\\\", \\\"2\\\", 1549], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"f  Detailed Schedule for Part B and C\\\", \\\"Table 3.\\\", \\\"2\\\", 1550], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"f  Detailed Schedule for Part B and C\\\", \\\"Table 3.\\\", \\\"2\\\", 1551], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"f  Detailed Schedule for Part B and C\\\", \\\"Table 3.\\\", \\\"2\\\", 1552], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"f  Detailed Schedule for Part B and C\\\", \\\"Table 3.\\\", \\\"2\\\", 1553], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"f  Detailed Schedule for Part B and C\\\", \\\"Table 3.\\\", \\\"2\\\", 1554], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"f  Detailed Schedule for Part B and C\\\", \\\"Table 3.\\\", \\\"2\\\", 1555], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"f  Detailed Schedule for Part B and C\\\", \\\"Table 3.\\\", \\\"2\\\", 1556], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"f  Detailed Schedule for Part B and C\\\", \\\"Table 3.\\\", \\\"2\\\", 1557], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"f  Detailed Schedule for Part B and C\\\", \\\"Table 3.\\\", \\\"2\\\", 1558], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"f  Detailed Schedule for Part B and C\\\", \\\"Table 3.\\\", \\\"2\\\", 1559], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"f  Detailed Schedule for Part B and C\\\", \\\"Table 3.\\\", \\\"2\\\", 1560], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"f  Detailed Schedule for Part B and C\\\", \\\"Table 3.\\\", \\\"2\\\", 1561], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"f  Detailed Schedule for Part B and C\\\", \\\"Table 3.\\\", \\\"2\\\", 1562], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"f  Detailed Schedule for Part B and C\\\", \\\"Table 3.\\\", \\\"2\\\", 1563], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"f  Detailed Schedule for Part B and C\\\", \\\"Table 3.\\\", \\\"2\\\", 1564], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"f  Detailed Schedule for Part B and C\\\", \\\"Table 3.\\\", \\\"2\\\", 1565], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"f  Detailed Schedule for Part B and C\\\", \\\"Table 3.\\\", \\\"2\\\", 1566], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"f  Detailed Schedule for Part B and C\\\", \\\"Table 3.\\\", \\\"2\\\", 1567], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"f  Detailed Schedule for Part B and C\\\", \\\"Table 3.\\\", \\\"2\\\", 1568], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"f  Detailed Schedule for Part B and C\\\", \\\"Table 3.\\\", \\\"2\\\", 1569], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"BP: blood pressure; ECG: electrocardiogram; ET: early termination; KSS: Karolinska Sleepiness Scale; OATP: organic anion transporting polypeptide; PK: pharmacokinetic(s); Post: postdose; Pre:\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 16, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 16, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"f  Detailed Schedule for Part B and C\\\", \\\"Table 3.\\\", \\\"2\\\", 1570], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"predose.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 16, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 16, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"f  Detailed Schedule for Part B and C\\\", \\\"Table 3.\\\", \\\"2\\\", 1571], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"a\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 10, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 10, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"f  Detailed Schedule for Part B and C\\\", \\\"Table 3.\\\", \\\"2\\\", 1572], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"All or some of the Day 18 study assessments may not be performed based on the emerging data from initial cohorts.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 16, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 16, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"f  Detailed Schedule for Part B and C\\\", \\\"Table 3.\\\", \\\"2\\\", 1573], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"b\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 10, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 10, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"f  Detailed Schedule for Part B and C\\\", \\\"Table 3.\\\", \\\"2\\\", 1574], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Blood sample for TAK-861 PK and plasma fluoride testing to be collected at the time of subject discontinuation (before discharge).\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 16, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 16, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"f  Detailed Schedule for Part B and C\\\", \\\"Table 3.\\\", \\\"2\\\", 1575], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"c\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 10, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 10, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"f  Detailed Schedule for Part B and C\\\", \\\"Table 3.\\\", \\\"2\\\", 1576], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Assessment to be conducted before discharge.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 16, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 16, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"f  Detailed Schedule for Part B and C\\\", \\\"Table 3.\\\", \\\"2\\\", 1577], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"d\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 10, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 10, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"f  Detailed Schedule for Part B and C\\\", \\\"Table 3.\\\", \\\"2\\\", 1578], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"If subject is sleeping, please refer to Section 9.3.2.9 regarding how to rate KSS.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 16, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 16, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"f  Detailed Schedule for Part B and C\\\", \\\"Table 3.\\\", \\\"2\\\", 1579], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"3.3 Part D\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading2\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part D\\\", \\\"3.3\\\", \\\"2\\\", 1580], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"Table 3.g Schedule of Study Procedures for Part D (Subjects With NT1)\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading8\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"g  Schedule of Study Procedures for Part D (Subjects With NT1)\\\", \\\"Table 3.\\\", \\\"2\\\", 1581], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"g  Schedule of Study Procedures for Part D (Subjects With NT1)\\\", \\\"Table 3.\\\", \\\"2\\\", 1582], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"g  Schedule of Study Procedures for Part D (Subjects With NT1)\\\", \\\"Table 3.\\\", \\\"2\\\", 1583], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"g  Schedule of Study Procedures for Part D (Subjects With NT1)\\\", \\\"Table 3.\\\", \\\"2\\\", 1584], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"g  Schedule of Study Procedures for Part D (Subjects With NT1)\\\", \\\"Table 3.\\\", \\\"2\\\", 1585], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"ABPM: ambulatory blood pressure monitoring; AE: adverse event; aPPT: activated partial thromboplastin time; BMI: body mass index; BP: blood pressure; BT: body temperature; CGI-I: Clinical Global\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 16, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 16, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"g  Schedule of Study Procedures for Part D (Subjects With NT1)\\\", \\\"Table 3.\\\", \\\"2\\\", 1586], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Impression of Improvement; CGI-S: Clinical Global Impression of Severity; CPAL: ~REDACTED~ ~REDACTED~ Learning; ~REDACTED~: cerebrospinal fluid; C-SSRS: Columbia-Suicide Severity Rating Scale;\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 16, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 16, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"g  Schedule of Study Procedures for Part D (Subjects With NT1)\\\", \\\"Table 3.\\\", \\\"2\\\", 1587], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"CYP: cytochrome P450; ECG: electrocardiogram; EEG: electroencephalography; ePRO: electronic patient-reported outcome; EQ-5D-5L: EuroQoL-5 Dimensions-5 Levels; ESS: Epworth Sleepiness\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 16, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 16, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"g  Schedule of Study Procedures for Part D (Subjects With NT1)\\\", \\\"Table 3.\\\", \\\"2\\\", 1588], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Scale; ET: early termination; FSH: ~REDACTED~; ~REDACTED~: ~REDACTED~; HLA: human leukocyte antigen; ICSD-3: International Classification of Sleep Disorders, 3rd edition; INR: international normalized ratio; KSS: Karolinska Sleepiness Scale; LP: lumbar puncture; MSLT: multiple sleep latency test; MWT: Maintenance of Wakefulness Test; nPSG: nocturnal polysomnography; NT1: narcolepsy type 1 (narcolepsy with cataplexy); PD: pharmacodynamic(s); PGI-I: Patient Global Impression of Improvement; PGI-S: Patient Global Impression of Severity; PR: pulse rate; PSG: polysomnography; PK: pharmacokinetic(s); PT: prothrombin time; RR: respiratory rate; SART: Sustained Attention to Response Test. In-clinic periods are indicated by clear cells, allows a \\\\u00b11-day window.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 16, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 16, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"g  Schedule of Study Procedures for Part D (Subjects With NT1)\\\", \\\"Table 3.\\\", \\\"2\\\", 1589], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Outpatient periods are marked with light gray cells.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 16, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 16, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"g  Schedule of Study Procedures for Part D (Subjects With NT1)\\\", \\\"Table 3.\\\", \\\"2\\\", 1590], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"a\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 10, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 10, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"g  Schedule of Study Procedures for Part D (Subjects With NT1)\\\", \\\"Table 3.\\\", \\\"2\\\", 1591], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Informed consent may be performed by e-consent.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 16, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 16, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"g  Schedule of Study Procedures for Part D (Subjects With NT1)\\\", \\\"Table 3.\\\", \\\"2\\\", 1592], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"b\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 10, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 10, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"g  Schedule of Study Procedures for Part D (Subjects With NT1)\\\", \\\"Table 3.\\\", \\\"2\\\", 1593], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"If no PSG/MSLT has been performed within the past 10 years, meeting the minimal acceptance criteria as outlined by the ICSD-3 criteria, special exemptions, ie, ability of the site to repeat the diagnostic PSG/MSLT, will be considered on a case-by-case basis after discussions between the investigator and the sponsor or designee.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 16, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 16, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"g  Schedule of Study Procedures for Part D (Subjects With NT1)\\\", \\\"Table 3.\\\", \\\"2\\\", 1594], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"c\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 10, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 10, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"g  Schedule of Study Procedures for Part D (Subjects With NT1)\\\", \\\"Table 3.\\\", \\\"2\\\", 1595], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"NT1 medication washout before baseline (minimum of 7 days or 5 half-lives for NT1 medications, whichever is longer).\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 16, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 16, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"g  Schedule of Study Procedures for Part D (Subjects With NT1)\\\", \\\"Table 3.\\\", \\\"2\\\", 1596], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"d\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 10, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 10, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"g  Schedule of Study Procedures for Part D (Subjects With NT1)\\\", \\\"Table 3.\\\", \\\"2\\\", 1597], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Physical examination will occur at indicated time point.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 16, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 16, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"g  Schedule of Study Procedures for Part D (Subjects With NT1)\\\", \\\"Table 3.\\\", \\\"2\\\", 1598], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"e\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 10, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 10, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"g  Schedule of Study Procedures for Part D (Subjects With NT1)\\\", \\\"Table 3.\\\", \\\"2\\\", 1599], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Fundoscopic examination will be performed only in those who elect ~REDACTED~ collection and will be evaluated before ~REDACTED~ collection.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 16, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 16, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"g  Schedule of Study Procedures for Part D (Subjects With NT1)\\\", \\\"Table 3.\\\", \\\"2\\\", 1600], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Coagulation laboratory tests for subjects participating in the optional ~REDACTED~ collection (for orexin); a ~REDACTED~ sample should be taken before Day -14 via LP.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 16, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 16, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"g  Schedule of Study Procedures for Part D (Subjects With NT1)\\\", \\\"Table 3.\\\", \\\"2\\\", 1601], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Subjects will be required to meet all specified protocol eligibility requirements.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 16, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 16, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"g  Schedule of Study Procedures for Part D (Subjects With NT1)\\\", \\\"Table 3.\\\", \\\"2\\\", 1602], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Before any LP can be performed, the results of the most recent coagulation panel must be reviewed by the investigator and must indicate that the LP can be performed safely.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 16, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 16, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"g  Schedule of Study Procedures for Part D (Subjects With NT1)\\\", \\\"Table 3.\\\", \\\"2\\\", 1603], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"f\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 10, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 10, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"g  Schedule of Study Procedures for Part D (Subjects With NT1)\\\", \\\"Table 3.\\\", \\\"2\\\", 1604], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"BP will be checked (single measurement) with the subject resting for a minimum of 5 minutes lying in a bed with the head of the bed at 30 degrees.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 16, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 16, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"g  Schedule of Study Procedures for Part D (Subjects With NT1)\\\", \\\"Table 3.\\\", \\\"2\\\", 1605], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Refer to Section 9.2.4 for details.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 16, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 16, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"g  Schedule of Study Procedures for Part D (Subjects With NT1)\\\", \\\"Table 3.\\\", \\\"2\\\", 1606], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"a Orthostatic BP may not be performed based on the emerging data from initial cohorts.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 16, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 16, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"g  Schedule of Study Procedures for Part D (Subjects With NT1)\\\", \\\"Table 3.\\\", \\\"2\\\", 1607], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Orthostatic BP and pulse rate will be checked, with the subject standing for 1 minute and 5 minutes.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 16, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 16, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"g  Schedule of Study Procedures for Part D (Subjects With NT1)\\\", \\\"Table 3.\\\", \\\"2\\\", 1608], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"b ABPM readings will be obtained over approximately 24 hours at home (if patient stayed in clinic, it is allowed to do it on site), starting on Day -4 and ending on Day -3 (to avoid overlap with nPSG).\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 16, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 16, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"g  Schedule of Study Procedures for Part D (Subjects With NT1)\\\", \\\"Table 3.\\\", \\\"2\\\", 1609], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Additional ABPM readings will be obtained over 24 hours at home, starting no later than the morning of Day 6 (or Day 5) and Day 12.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 16, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 16, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"g  Schedule of Study Procedures for Part D (Subjects With NT1)\\\", \\\"Table 3.\\\", \\\"2\\\", 1610], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Refer to Section 9.2.6 for further details.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 16, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 16, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"g  Schedule of Study Procedures for Part D (Subjects With NT1)\\\", \\\"Table 3.\\\", \\\"2\\\", 1611], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"i\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 10, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 10, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"g  Schedule of Study Procedures for Part D (Subjects With NT1)\\\", \\\"Table 3.\\\", \\\"2\\\", 1612], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Drug will be taken in the morning on awakening as close to 8AM as possible after an overnight fast of at least 8 h (after completion of predose assessments if in the unit).\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 16, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 16, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"g  Schedule of Study Procedures for Part D (Subjects With NT1)\\\", \\\"Table 3.\\\", \\\"2\\\", 1613], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"At home, subjects are encouraged to take study drug at approximately the same time/manner each day in the morning.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 16, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 16, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"g  Schedule of Study Procedures for Part D (Subjects With NT1)\\\", \\\"Table 3.\\\", \\\"2\\\", 1614], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Detailed guidance of drug administration with diet and fluid requirements can be found in Section 7.4.1.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 16, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 16, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"g  Schedule of Study Procedures for Part D (Subjects With NT1)\\\", \\\"Table 3.\\\", \\\"2\\\", 1615], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"j\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 10, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 10, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"g  Schedule of Study Procedures for Part D (Subjects With NT1)\\\", \\\"Table 3.\\\", \\\"2\\\", 1616], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"nPSG consisting of 8-hour nighttime polysomnography will be obtained.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 16, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 16, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"g  Schedule of Study Procedures for Part D (Subjects With NT1)\\\", \\\"Table 3.\\\", \\\"2\\\", 1617], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"k\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 13, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 13, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"g  Schedule of Study Procedures for Part D (Subjects With NT1)\\\", \\\"Table 3.\\\", \\\"2\\\", 1618], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"ePRO diary measures (including self-report assessments of cataplexy, sleep paralysis, and hypnagogic/hypnopompic hallucinations, self-reported sleep parameters, and naps) will be obtained starting after\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 16, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 16, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"g  Schedule of Study Procedures for Part D (Subjects With NT1)\\\", \\\"Table 3.\\\", \\\"2\\\", 1619], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"successful initial screening visit.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 16, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 16, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"g  Schedule of Study Procedures for Part D (Subjects With NT1)\\\", \\\"Table 3.\\\", \\\"2\\\", 1620], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"See Section 9.3.2.8 for additional details.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 16, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 16, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"g  Schedule of Study Procedures for Part D (Subjects With NT1)\\\", \\\"Table 3.\\\", \\\"2\\\", 1621], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"l\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 10, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 10, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"g  Schedule of Study Procedures for Part D (Subjects With NT1)\\\", \\\"Table 3.\\\", \\\"2\\\", 1622], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Accelerometry (actigraphy) will be collected from screening (following signed consent) for a minimum of 14 consecutive days, after which subjects will ship the device back to the site in a prepaid/prelabeled shipping box.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 16, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 16, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"g  Schedule of Study Procedures for Part D (Subjects With NT1)\\\", \\\"Table 3.\\\", \\\"2\\\", 1623], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"After this baseline accelerometry period, subjects will not wear the device again until Day -2.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 16, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 16, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"g  Schedule of Study Procedures for Part D (Subjects With NT1)\\\", \\\"Table 3.\\\", \\\"2\\\", 1624], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Subjects will then wear the device continuously from Day -2 to Day 14.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 16, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 16, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"g  Schedule of Study Procedures for Part D (Subjects With NT1)\\\", \\\"Table 3.\\\", \\\"2\\\", 1625], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"m\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 13, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 13, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"g  Schedule of Study Procedures for Part D (Subjects With NT1)\\\", \\\"Table 3.\\\", \\\"2\\\", 1626], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Nighttime only, including nights combined with nPSG.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 16, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 16, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"g  Schedule of Study Procedures for Part D (Subjects With NT1)\\\", \\\"Table 3.\\\", \\\"2\\\", 1627], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Portable EEG may not be included, depending on sponsor\\\\u2019s discretion, see Section 9.3.2.6.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 16, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 16, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"g  Schedule of Study Procedures for Part D (Subjects With NT1)\\\", \\\"Table 3.\\\", \\\"2\\\", 1628], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"n\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 10, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 10, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"g  Schedule of Study Procedures for Part D (Subjects With NT1)\\\", \\\"Table 3.\\\", \\\"2\\\", 1629], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Hematology and blood chemistry procedures should occur after at least 8 hours of fasting and predose.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 16, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 16, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"g  Schedule of Study Procedures for Part D (Subjects With NT1)\\\", \\\"Table 3.\\\", \\\"2\\\", 1630], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"o\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 10, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 10, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"g  Schedule of Study Procedures for Part D (Subjects With NT1)\\\", \\\"Table 3.\\\", \\\"2\\\", 1631], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Pregnancy test is required for women of childbearing potential only.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 16, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 16, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"g  Schedule of Study Procedures for Part D (Subjects With NT1)\\\", \\\"Table 3.\\\", \\\"2\\\", 1632], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Serum pregnancy test will be done at screening and before final discharge.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 16, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 16, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"g  Schedule of Study Procedures for Part D (Subjects With NT1)\\\", \\\"Table 3.\\\", \\\"2\\\", 1633], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"At all other time points, urine ~REDACTED~ testing will be done.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 16, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 16, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"g  Schedule of Study Procedures for Part D (Subjects With NT1)\\\", \\\"Table 3.\\\", \\\"2\\\", 1634], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Predose ~REDACTED~ testing will be done within approximately 24 hours before first study drug administration on Day -1 and predose at check-in for all other scheduled times.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 16, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 16, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"g  Schedule of Study Procedures for Part D (Subjects With NT1)\\\", \\\"Table 3.\\\", \\\"2\\\", 1635], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Pregnancy testing can be repeated at any time at the investigator\\\\u2019s discretion.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 16, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 16, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"g  Schedule of Study Procedures for Part D (Subjects With NT1)\\\", \\\"Table 3.\\\", \\\"2\\\", 1636], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"p\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 10, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 10, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"g  Schedule of Study Procedures for Part D (Subjects With NT1)\\\", \\\"Table 3.\\\", \\\"2\\\", 1637], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"FSH is mandatory for postmenopausal subjects.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 16, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 16, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"g  Schedule of Study Procedures for Part D (Subjects With NT1)\\\", \\\"Table 3.\\\", \\\"2\\\", 1638], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"q\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 10, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 10, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"g  Schedule of Study Procedures for Part D (Subjects With NT1)\\\", \\\"Table 3.\\\", \\\"2\\\", 1639], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Urinalysis will include specific gravity.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 16, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 16, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"g  Schedule of Study Procedures for Part D (Subjects With NT1)\\\", \\\"Table 3.\\\", \\\"2\\\", 1640], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"r\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 10, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 10, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"g  Schedule of Study Procedures for Part D (Subjects With NT1)\\\", \\\"Table 3.\\\", \\\"2\\\", 1641], [\\\"\\\", \\\"Unmapped\\\", \\\"table\\\", {\\\"Table\\\": \\\"<table border=\\\\\\\"1\\\\\\\" class=\\\\\\\"dataframe\\\\\\\">\\\\n  <thead>\\\\n    <tr style=\\\\\\\"text-align: right;\\\\\\\">\\\\n      <th></th>\\\\n      <th>1.0</th>\\\\n      <th>2.0</th>\\\\n      <th>3.0</th>\\\\n      <th>4.0</th>\\\\n      <th>5.0</th>\\\\n      <th>6.0</th>\\\\n      <th>7.0</th>\\\\n      <th>8.0</th>\\\\n      <th>9.0</th>\\\\n      <th>10.0</th>\\\\n      <th>11.0</th>\\\\n      <th>12.0</th>\\\\n      <th>13.0</th>\\\\n      <th>14.0</th>\\\\n      <th>15.0</th>\\\\n      <th>16.0</th>\\\\n    </tr>\\\\n  </thead>\\\\n  <tbody>\\\\n    <tr>\\\\n      <th>0</th>\\\\n      <td>Day</td>\\\\n      <td>Screening -45 to -3</td>\\\\n      <td>Check-in/ Baseline -2</td>\\\\n      <td>Baseline -1</td>\\\\n      <td>1 Predose</td>\\\\n      <td>1 Postdose</td>\\\\n      <td>2</td>\\\\n      <td>3-5 Outpatient</td>\\\\n      <td>6</td>\\\\n      <td>7</td>\\\\n      <td>8-12 Outpatient</td>\\\\n      <td>13</td>\\\\n      <td>14</td>\\\\n      <td>15 Discharge</td>\\\\n      <td>ET</td>\\\\n      <td>Day 21 \\\\u00b12 Follow-up Visit</td>\\\\n    </tr>\\\\n  </tbody>\\\\n</table>\\\", \\\"SectionHeaderPrintPage\\\": \\\"31\\\", \\\"TableIndex\\\": \\\"25\\\", \\\"TableName\\\": \\\"Table 3.g Schedule of Study Procedures for Part D (Subjects With NT1)\\\", \\\"Header\\\": [0]}, {\\\"IsBold\\\": true, \\\"font_size\\\": 16, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 16, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"g  Schedule of Study Procedures for Part D (Subjects With NT1)\\\", \\\"Table 3.\\\", \\\"2\\\", 1642], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"At screening visit, ~REDACTED~ screening will be done initially with a breathalyzer and if positive, a serum ~REDACTED~ level will be obtained.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 16, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 16, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"g  Schedule of Study Procedures for Part D (Subjects With NT1)\\\", \\\"Table 3.\\\", \\\"2\\\", 1643], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"For all other time points a breathalyzer will be done at every check-in time.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 16, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 16, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"g  Schedule of Study Procedures for Part D (Subjects With NT1)\\\", \\\"Table 3.\\\", \\\"2\\\", 1644], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"s\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 10, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 10, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"g  Schedule of Study Procedures for Part D (Subjects With NT1)\\\", \\\"Table 3.\\\", \\\"2\\\", 1645], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Urine drug screen: May be repeated at any time at the investigator\\\\u2019s discretion.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 16, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 16, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"g  Schedule of Study Procedures for Part D (Subjects With NT1)\\\", \\\"Table 3.\\\", \\\"2\\\", 1646], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"t\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 13, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 13, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"g  Schedule of Study Procedures for Part D (Subjects With NT1)\\\", \\\"Table 3.\\\", \\\"2\\\", 1647], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Blood samples for pharmacogenomics are collected before the initiation of study drug administration on Day 1.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 16, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 16, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"g  Schedule of Study Procedures for Part D (Subjects With NT1)\\\", \\\"Table 3.\\\", \\\"2\\\", 1648], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Will be performed once only in each subject during the study period.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 16, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 16, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"g  Schedule of Study Procedures for Part D (Subjects With NT1)\\\", \\\"Table 3.\\\", \\\"2\\\", 1649], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"u\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 13, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 13, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"g  Schedule of Study Procedures for Part D (Subjects With NT1)\\\", \\\"Table 3.\\\", \\\"2\\\", 1650], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"The exploratory assay may include exploratory assessment of orexin-related biomarkers in plasma neuronally derived exosomes (exosome research).\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 16, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 16, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"g  Schedule of Study Procedures for Part D (Subjects With NT1)\\\", \\\"Table 3.\\\", \\\"2\\\", 1651], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"v\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 13, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 13, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"g  Schedule of Study Procedures for Part D (Subjects With NT1)\\\", \\\"Table 3.\\\", \\\"2\\\", 1652], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Check-in should occur in the afternoon at the latest on Days -2, 6 (optional), and 13; otherwise, check-in should occur in the morning if optional stay does not occur on night of Day 6.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 16, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 16, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"g  Schedule of Study Procedures for Part D (Subjects With NT1)\\\", \\\"Table 3.\\\", \\\"2\\\", 1653], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"If the patient does not stay overnight on Day 6, the scheduled in-clinic assessment on Day 6 will be done before the Day 7 dose occurs and subject must not have anything by mouth past midnight, before they arrive at the clinic on the next day, and assessments planned in the unit should occur once the subject has checked in.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 16, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 16, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"g  Schedule of Study Procedures for Part D (Subjects With NT1)\\\", \\\"Table 3.\\\", \\\"2\\\", 1654], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"w\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 13, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 13, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"g  Schedule of Study Procedures for Part D (Subjects With NT1)\\\", \\\"Table 3.\\\", \\\"2\\\", 1655], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"For the first 4 subjects of the first cohort of Part D, subjects need to stay in the clinic from Day -2 to Day 7.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 16, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 16, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"g  Schedule of Study Procedures for Part D (Subjects With NT1)\\\", \\\"Table 3.\\\", \\\"2\\\", 1656], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Discharge days are the last day of each confinement period.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 16, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 16, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"g  Schedule of Study Procedures for Part D (Subjects With NT1)\\\", \\\"Table 3.\\\", \\\"2\\\", 1657], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"g  Schedule of Study Procedures for Part D (Subjects With NT1)\\\", \\\"Table 3.\\\", \\\"2\\\", 1658], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"Table 3.h Detailed Schedule for Part D\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading8\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"g  Schedule of Study Procedures for Part D (Subjects With NT1)\\\", \\\"Table 3.\\\", \\\"2\\\", 1659], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"g  Schedule of Study Procedures for Part D (Subjects With NT1)\\\", \\\"Table 3.\\\", \\\"2\\\", 1660], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"Table 3.h Detailed Schedule for Part D\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading8\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"h  Detailed Schedule for Part D\\\", \\\"Table 3.\\\", \\\"2\\\", 1661], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"h  Detailed Schedule for Part D\\\", \\\"Table 3.\\\", \\\"2\\\", 1662], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Approx: approximately; BP: blood pressure; CPAL: ~REDACTED~ ~REDACTED~ Learning; CYP: cytochrome P450; ECG: electrocardiogram; ET: early termination; KSS: Karolinska Sleepiness Scale; MWT: Maintenance of Wakefulness Test; PD: pharmacodynamic(s); PK: pharmacokinetic(s); Post: postdose; Pre: predose; SART: Sustained Attention to Response Test.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 16, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 16, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"h  Detailed Schedule for Part D\\\", \\\"Table 3.\\\", \\\"2\\\", 1663], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"a\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 10, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 10, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"h  Detailed Schedule for Part D\\\", \\\"Table 3.\\\", \\\"2\\\", 1664], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"At ET, the assessments indicated as (X) will be done whenever possible, if subject visits the site soon after decision of ET.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 16, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 16, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"h  Detailed Schedule for Part D\\\", \\\"Table 3.\\\", \\\"2\\\", 1665], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"b\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 10, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 10, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"h  Detailed Schedule for Part D\\\", \\\"Table 3.\\\", \\\"2\\\", 1666], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"PK is to be done closest to the specified time.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 16, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 16, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"h  Detailed Schedule for Part D\\\", \\\"Table 3.\\\", \\\"2\\\", 1667], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"c\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 10, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 10, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"h  Detailed Schedule for Part D\\\", \\\"Table 3.\\\", \\\"2\\\", 1668], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"ECG, BP, and pulse should be done near specified times before the PK if there is overlap.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 16, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 16, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"h  Detailed Schedule for Part D\\\", \\\"Table 3.\\\", \\\"2\\\", 1669], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"On Days 6 and 13, vital signs (pulse rate, BP) will be taken in the unit between the time the subject checks in to the site and before the subject goes to bed.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 16, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 16, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"h  Detailed Schedule for Part D\\\", \\\"Table 3.\\\", \\\"2\\\", 1670], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"If subject does not come in for the Day 6 optional visit, the assessments indicated as (x) can be skipped.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 16, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 16, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"h  Detailed Schedule for Part D\\\", \\\"Table 3.\\\", \\\"2\\\", 1671], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"d\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 10, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 10, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"h  Detailed Schedule for Part D\\\", \\\"Table 3.\\\", \\\"2\\\", 1672], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"KSS will be done at closest time for each assessment point just before MWT will start.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 16, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 16, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"h  Detailed Schedule for Part D\\\", \\\"Table 3.\\\", \\\"2\\\", 1673], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"If subject is sleeping, please refer to Section 9.3.2.9 regarding how to rate KSS.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 16, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 16, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"h  Detailed Schedule for Part D\\\", \\\"Table 3.\\\", \\\"2\\\", 1674], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"e\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 10, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 10, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"h  Detailed Schedule for Part D\\\", \\\"Table 3.\\\", \\\"2\\\", 1675], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"The cognitive assessment will include SART and CPAL.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 16, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 16, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"h  Detailed Schedule for Part D\\\", \\\"Table 3.\\\", \\\"2\\\", 1676], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"3.4 Part E\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading2\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"h  Detailed Schedule for Part D\\\", \\\"Table 3.\\\", \\\"2\\\", 1677], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"Table 3.i Schedule of Study Procedures for Part E: Non-Japanese Cohort\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading8\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"h  Detailed Schedule for Part D\\\", \\\"Table 3.\\\", \\\"2\\\", 1678], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"h  Detailed Schedule for Part D\\\", \\\"Table 3.\\\", \\\"2\\\", 1679], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"Table 3.i Schedule of Study Procedures for Part E: Non-Japanese Cohort\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading8\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"h  Detailed Schedule for Part D\\\", \\\"Table 3.\\\", \\\"2\\\", 1680], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"h  Detailed Schedule for Part D\\\", \\\"Table 3.\\\", \\\"2\\\", 1681], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"Table 3.i Schedule of Study Procedures for Part E: Non-Japanese Cohort\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading8\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"i  Schedule of Study Procedures for Part E: Non-Japanese Cohort\\\", \\\"Table 3.\\\", \\\"2\\\", 1682], [\\\"\\\", \\\"Unmapped\\\", \\\"table\\\", {\\\"Table\\\": \\\"<table border=\\\\\\\"1\\\\\\\" class=\\\\\\\"dataframe\\\\\\\">\\\\n  <thead>\\\\n    <tr style=\\\\\\\"text-align: right;\\\\\\\">\\\\n      <th></th>\\\\n      <th>1.0</th>\\\\n      <th>2.0</th>\\\\n      <th>3.0</th>\\\\n      <th>4.0</th>\\\\n      <th>5.0</th>\\\\n      <th>6.0</th>\\\\n      <th>7.0</th>\\\\n      <th>8.0</th>\\\\n      <th>9.0</th>\\\\n      <th>10.0</th>\\\\n      <th>11.0</th>\\\\n      <th>12.0</th>\\\\n      <th>13.0</th>\\\\n      <th>14.0</th>\\\\n      <th>15.0</th>\\\\n      <th>16.0</th>\\\\n      <th>17.0</th>\\\\n      <th>18.0</th>\\\\n      <th>19.0</th>\\\\n      <th>20.0</th>\\\\n    </tr>\\\\n  </thead>\\\\n  <tbody>\\\\n    <tr>\\\\n      <th>0</th>\\\\n      <td>Procedures</td>\\\\n      <td>Predose</td>\\\\n      <td>Predose</td>\\\\n      <td>Dosing</td>\\\\n      <td>After First Dose and Before MRD Dosing</td>\\\\n      <td>After First Dose and Before MRD Dosing</td>\\\\n      <td>MRD Dosing</td>\\\\n      <td>MRD Dosing</td>\\\\n      <td>MRD Dosing</td>\\\\n      <td>MRD Dosing</td>\\\\n      <td>MRD Dosing</td>\\\\n      <td>MRD Dosing</td>\\\\n      <td>MRD Dosing</td>\\\\n      <td>MRD Dosing</td>\\\\n      <td>MRD Dosing</td>\\\\n      <td>MRD Dosing</td>\\\\n      <td>MRD Dosing</td>\\\\n      <td>Discharge/ ET</td>\\\\n      <td>Discharge/ ET</td>\\\\n      <td>Follow-up</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>1</th>\\\\n      <td>Day</td>\\\\n      <td>-1</td>\\\\n      <td>1</td>\\\\n      <td>1</td>\\\\n      <td>2-5</td>\\\\n      <td>6</td>\\\\n      <td>6</td>\\\\n      <td>7</td>\\\\n      <td>8</td>\\\\n      <td>9</td>\\\\n      <td>10-11</td>\\\\n      <td>12</td>\\\\n      <td>13-15</td>\\\\n      <td>16</td>\\\\n      <td>17</td>\\\\n      <td>18</td>\\\\n      <td>19-22</td>\\\\n      <td>23 <sup>b</sup></td>\\\\n      <td>E T</td>\\\\n      <td>26 (\\\\u00b12 days)</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>2</th>\\\\n      <td>Blood sample for TAK-861 PK</td>\\\\n      <td></td>\\\\n      <td>Pre</td>\\\\n      <td>0.25, 0.5, 1, 2, 3, 4, 6, 8, and 12 h Post</td>\\\\n      <td>24, 36, 48, 72, and 96 h after Day 1 dose</td>\\\\n      <td>120 h after Day 1 dose (before Day 6 dose)</td>\\\\n      <td>0.25, 0.5, 1, 2, 3, 4, 6, 8, and 12 h Post</td>\\\\n      <td>24 h after Day 6 dose</td>\\\\n      <td></td>\\\\n      <td>Pre</td>\\\\n      <td></td>\\\\n      <td>Pre</td>\\\\n      <td></td>\\\\n      <td>Pre</td>\\\\n      <td></td>\\\\n      <td>Pre</td>\\\\n      <td>Pre and 0.25, 0.5, 1, 2, 3, 4, 6, 8 12, 24, 36, 48, and 72 h after Day 19 dose</td>\\\\n      <td>96 h after Day 19 dose <sup>c</sup></td>\\\\n      <td>X <sup>a</sup></td>\\\\n      <td></td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>3</th>\\\\n      <td>Urine sample for TAK-861 PK</td>\\\\n      <td></td>\\\\n      <td>Spot: Pre</td>\\\\n      <td>Pooled: 0-6 and 6-12 h Post</td>\\\\n      <td>Pooled: 12-24, 24-48, 48-72, and 72-96 h after Day 1 dose</td>\\\\n      <td>Pooled: 96-120 h after Day 1 dose (or to before Day 6 dose)</td>\\\\n      <td>Pooled: 0-6 and 6-12 h Post</td>\\\\n      <td>Pooled: 12-24 h after Day 6 dose</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>Pooled: 0-6, 6-12, and 12-24 h after Day 19 dose</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>4</th>\\\\n      <td>Blood sample for OATP1B1/3 activity</td>\\\\n      <td></td>\\\\n      <td>Pre</td>\\\\n      <td>1, 2, 6, and 12 h</td>\\\\n      <td>Pre on Day 2</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>Pre, 1, 2, 6, 12, 24 h after Day 19 dose</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>5</th>\\\\n      <td>Blood sample for CYP3A4/5 activity</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>Pre</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>Pre</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>Pre</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>6</th>\\\\n      <td>Blood sample for plasma fluoride</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>Pre</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>2 and 12 h postdose</td>\\\\n      <td>72 h after Day 19 dose</td>\\\\n      <td>X <sup>a</sup></td>\\\\n      <td></td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>7</th>\\\\n      <td>BP and pulse rate measurements</td>\\\\n      <td>Approximately 0700 and then at 0.5, 1, 2, 3, 4, 6, 8, and 12 h later relative to the initial measurement (matched to the time assessment schedule of Day 1)</td>\\\\n      <td>Pre</td>\\\\n      <td>0.5, 1, 2, 3, 4, 6, 8, and 12 h Post</td>\\\\n      <td>24, 36, 48, 72 and 96 h after Day 1 dose</td>\\\\n      <td>Before Day 6 dose</td>\\\\n      <td>0.5, 1, 2, 3, 4, 6, 8, and 12 h Post</td>\\\\n      <td>24 h after Day 6 dose</td>\\\\n      <td>Pre</td>\\\\n      <td>Pre</td>\\\\n      <td>Pre</td>\\\\n      <td>Pre and 3, 6, and 12 h Post</td>\\\\n      <td>Pre</td>\\\\n      <td>Pre</td>\\\\n      <td>Pre</td>\\\\n      <td>Pre</td>\\\\n      <td>Pre and 0.5, 1, 2, 3, 4, 6, 8 12, 24, 36, 48, and 72 h after Day 19 dose</td>\\\\n      <td>96 h after Day 19 dose</td>\\\\n      <td>X <sup>c</sup></td>\\\\n      <td>X</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>8</th>\\\\n      <td>Orthostatic BP and pulse rate measurements</td>\\\\n      <td></td>\\\\n      <td>Pre</td>\\\\n      <td>1, 2, and 6 h Post</td>\\\\n      <td>24 h Post</td>\\\\n      <td>Pre</td>\\\\n      <td>1, 2, and 6 h Post</td>\\\\n      <td>24 h Post</td>\\\\n      <td></td>\\\\n      <td>Pre</td>\\\\n      <td></td>\\\\n      <td>Pre</td>\\\\n      <td></td>\\\\n      <td>Pre</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>Pre, 1, 2, and 6 h Post</td>\\\\n      <td>96 h after Day 19 dose</td>\\\\n      <td>X <sup>c</sup></td>\\\\n      <td></td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>9</th>\\\\n      <td>Respiratory rate</td>\\\\n      <td></td>\\\\n      <td>1 h Pre</td>\\\\n      <td>1, 2, 4, and 6 h Post</td>\\\\n      <td></td>\\\\n      <td>Pre</td>\\\\n      <td>1, 2, 4, and 6 h Post</td>\\\\n      <td>Pre</td>\\\\n      <td></td>\\\\n      <td>Pre</td>\\\\n      <td></td>\\\\n      <td>Pre</td>\\\\n      <td></td>\\\\n      <td>Pre</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>Pre</td>\\\\n      <td>96 h after Day 19 dose</td>\\\\n      <td>X<sup> c</sup></td>\\\\n      <td>X</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>10</th>\\\\n      <td>Body temperature</td>\\\\n      <td></td>\\\\n      <td>1 h Pre</td>\\\\n      <td>1, 2, 4, and 6 h Post</td>\\\\n      <td></td>\\\\n      <td>Pre</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>Pre</td>\\\\n      <td></td>\\\\n      <td>Pre</td>\\\\n      <td></td>\\\\n      <td>Pre</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>Pre</td>\\\\n      <td>96 h after Day 19 dose</td>\\\\n      <td>X<sup> c</sup></td>\\\\n      <td>X</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>11</th>\\\\n      <td>Standard 12-lead ECGs</td>\\\\n      <td>X</td>\\\\n      <td>Pre</td>\\\\n      <td>1, 2, 4, 6, and 12 h Post</td>\\\\n      <td>24 and 48 h Post</td>\\\\n      <td>Pre</td>\\\\n      <td>1, 2, 4, 6, and 12 h Post</td>\\\\n      <td>Pre</td>\\\\n      <td></td>\\\\n      <td>Pre</td>\\\\n      <td></td>\\\\n      <td>Pre</td>\\\\n      <td></td>\\\\n      <td>Pre</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>Pre</td>\\\\n      <td>96 h after Day 19 dose</td>\\\\n      <td>X<sup> c</sup></td>\\\\n      <td>X</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>12</th>\\\\n      <td>KSS <sup>d</sup></td>\\\\n      <td>Pre (relative to planned Day 1 dose time) and 1, 2, 4, 8, 12, 14, 16, and 24 h relative to initial measurement</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>Pre and 1, 2, 4, 8, 12, 14, 16, and 24 h Post</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n    </tr>\\\\n  </tbody>\\\\n</table>\\\", \\\"SectionHeaderPrintPage\\\": \\\"37\\\", \\\"TableIndex\\\": \\\"26\\\", \\\"TableName\\\": \\\"Table 3.i Schedule of Study Procedures for Part E: Non-Japanese Cohort\\\", \\\"AttachmentEntities\\\": [{\\\"content\\\": \\\"Administrative Procedures Informed consent X\\\", \\\"entities\\\": []}, {\\\"content\\\": \\\"Height, BMI calculation X\\\", \\\"entities\\\": []}, {\\\"content\\\": \\\"Vital signs (BP [ supine] , PR X\\\", \\\"entities\\\": []}, {\\\"content\\\": \\\"[ supine] , RR, and BT) a (see Table 3.j)\\\", \\\"entities\\\": []}, {\\\"content\\\": \\\"Orthostatic BP and rate b (see Table 3.j)\\\", \\\"entities\\\": []}, {\\\"content\\\": \\\"12-lead ECG standard (see X Table 3.j)\\\", \\\"entities\\\": []}, {\\\"content\\\": \\\"Laboratory Procedures/\\\", \\\"entities\\\": []}, {\\\"content\\\": \\\"Plasma fluoride (see Table 3.j)\\\", \\\"entities\\\": []}, {\\\"content\\\": \\\"FSH assessment (optional; for X\\\", \\\"entities\\\": []}, {\\\"content\\\": \\\"postmenopausal women) g\\\", \\\"entities\\\": []}, {\\\"content\\\": \\\"Hepatitis and HIV screen X\\\", \\\"entities\\\": []}, {\\\"content\\\": \\\"Blood for retained samples and X pharmacogenomics h\\\", \\\"entities\\\": []}, {\\\"content\\\": \\\"activity (see Table 3.j)\\\", \\\"entities\\\": []}, {\\\"content\\\": \\\"Blood samples for OATP1B1/3\\\", \\\"entities\\\": []}, {\\\"content\\\": \\\"Blood sample for PK TAK-861 (see Table 3.j)\\\", \\\"entities\\\": []}, {\\\"content\\\": \\\"Urine sample for PK TAK-861 (see Table 3.j)\\\", \\\"entities\\\": []}, {\\\"content\\\": \\\"ABPM: ambulatory blood pressure monitoring; AE: adverse event; BMI: body mass index; BP: blood pressure; BT: body temperature; C-SSRS: ColumbiaSuicide Severity Rating Scale; CYP:\\\", \\\"entities\\\": []}, {\\\"content\\\": \\\"cytochrome P450; ECG: electrocardiogram; ET: early termination; FSH: follicle-stimulating hormone; KSS: Karolinska Sleepiness Scale; NSF: National Sleep Foundation; OATP: organic anion\\\", \\\"entities\\\": [{\\\"start_idx\\\": 138, \\\"end_idx\\\": 162, \\\"standard_entity_name\\\": \\\"ANY: Organization\\\", \\\"subcategory\\\": \\\"ANY: Organization\\\", \\\"confidence\\\": 87.0, \\\"text\\\": \\\"National Sleep Foundation\\\"}, {\\\"start_idx\\\": 69, \\\"end_idx\\\": 96, \\\"standard_entity_name\\\": \\\"Molecule\\\", \\\"subcategory\\\": \\\"Molecule\\\", \\\"confidence\\\": 87.0, \\\"text\\\": \\\"follicle-stimulating hormone\\\"}]}, {\\\"content\\\": \\\"transporting polypeptide; PK: pharmacokinetic(s); PR: pulse rate; RR: respiratory rate.\\\", \\\"entities\\\": []}, {\\\"content\\\": \\\"a BP will be checked (single measurement) with the subject resting for a minimum of 5 minutes lying in a bed with the head of the bed at 30 degrees.\\\", \\\"entities\\\": []}, {\\\"content\\\": \\\"b Orthostatic BP and pulse rate will also be checked, with the subject standing for 1 minute and 5 minutes.\\\", \\\"entities\\\": []}, {\\\"content\\\": \\\"c T wenty-four hour ABPM starts on Days -2, 8, 11, 15 and 18 in the morning before dosing time of the day. Refer to Section 9.2.6 for further details.\\\", \\\"entities\\\": []}, {\\\"content\\\": \\\"d 12-lead, 24-h continuous Holter monitoring. Additional details may be found in the training manual.\\\", \\\"entities\\\": []}, {\\\"content\\\": \\\"e Drug will be administered as a single dose after an overnight fast of at least 10 h on Day 1, followed by a washout period through Day 5. On Day 6, study drug will be administered in the morning after a\\\", \\\"entities\\\": []}, {\\\"content\\\": \\\"fast of at least 10 h. Subjects will continue to fast for an additional 4 h after dosing on serial PK collection days or 2 h after dosing on nonintense PK collection days. Detailed guidance of drug administration\\\", \\\"entities\\\": []}, {\\\"content\\\": \\\"with diet and fluid requirements can be found in Section 7.4.1.\\\", \\\"entities\\\": []}, {\\\"content\\\": \\\"f Hematology (complete blood count) and blood chemistry on Day 1 will be done at 8 h postdose. On all other days, blood draws are predose or at the relative Day 1 predose time.\\\", \\\"entities\\\": []}, {\\\"content\\\": \\\"g FSH is mandatory for postmenopausal subjects.\\\", \\\"entities\\\": []}, {\\\"content\\\": \\\"h Blood samples for pharmacogenomics are collected before the initiation of study drug administration on Day 1. Will be performed once only in each subject during the study period.\\\", \\\"entities\\\": []}, {\\\"content\\\": \\\"i The exploratory assay may include exploratory assessment of OX-related biomarkers in the plasma (exosome research).\\\", \\\"entities\\\": []}, {\\\"content\\\": \\\"j Subjects may need to check in on Day -3 evening time to start ABPM in the morning time of Day -2.\\\", \\\"entities\\\": []}, {\\\"content\\\": \\\"k Day 23 study assessments may not be performed based on the emerging data from initial cohorts.\\\", \\\"entities\\\": []}], \\\"FootnoteText_0\\\": \\\" Administrative Procedures Informed consent X\\\", \\\"FootnoteText_1\\\": \\\" Height, BMI calculation X\\\", \\\"FootnoteText_2\\\": \\\" Vital signs (BP [ supine] , PR X\\\", \\\"FootnoteText_3\\\": \\\"[ supine] , RR, and BT) a (see Table 3.j)\\\", \\\"FootnoteText_4\\\": \\\" Orthostatic BP and rate b (see Table 3.j)\\\", \\\"FootnoteText_5\\\": \\\" 12-lead ECG standard (see X Table 3.j)\\\", \\\"FootnoteText_6\\\": \\\" Laboratory Procedures/\\\", \\\"FootnoteText_7\\\": \\\" Plasma fluoride (see Table 3.j)\\\", \\\"FootnoteText_8\\\": \\\" FSH assessment (optional; for X\\\", \\\"FootnoteText_9\\\": \\\" postmenopausal women) g\\\", \\\"FootnoteText_10\\\": \\\" Hepatitis and HIV screen X\\\", \\\"FootnoteText_11\\\": \\\" Blood for retained samples and X pharmacogenomics h\\\", \\\"FootnoteText_12\\\": \\\" activity (see Table 3.j)\\\", \\\"FootnoteText_13\\\": \\\" Blood samples for OATP1B1/3\\\", \\\"FootnoteText_14\\\": \\\" Blood sample for PK TAK-861 (see Table 3.j)\\\", \\\"FootnoteText_15\\\": \\\" Urine sample for PK TAK-861 (see Table 3.j)\\\", \\\"FootnoteText_16\\\": \\\" ABPM: ambulatory blood pressure monitoring; AE: adverse event; BMI: body mass index; BP: blood pressure; BT: body temperature; C-SSRS: ColumbiaSuicide Severity Rating Scale; CYP:\\\", \\\"FootnoteText_17\\\": \\\" cytochrome P450; ECG: electrocardiogram; ET: early termination; FSH: follicle-stimulating hormone; KSS: Karolinska Sleepiness Scale; NSF: National Sleep Foundation; OATP: organic anion\\\", \\\"FootnoteText_18\\\": \\\" transporting polypeptide; PK: pharmacokinetic(s); PR: pulse rate; RR: respiratory rate.\\\", \\\"FootnoteText_19\\\": \\\"a BP will be checked (single measurement) with the subject resting for a minimum of 5 minutes lying in a bed with the head of the bed at 30 degrees.\\\", \\\"FootnoteText_20\\\": \\\"b Orthostatic BP and pulse rate will also be checked, with the subject standing for 1 minute and 5 minutes.\\\", \\\"FootnoteText_21\\\": \\\"c T wenty-four hour ABPM starts on Days -2, 8, 11, 15 and 18 in the morning before dosing time of the day. Refer to Section 9.2.6 for further details.\\\", \\\"FootnoteText_22\\\": \\\"d 12-lead, 24-h continuous Holter monitoring. Additional details may be found in the training manual.\\\", \\\"FootnoteText_23\\\": \\\"e Drug will be administered as a single dose after an overnight fast of at least 10 h on Day 1, followed by a washout period through Day 5. On Day 6, study drug will be administered in the morning after a\\\", \\\"FootnoteText_24\\\": \\\" fast of at least 10 h. Subjects will continue to fast for an additional 4 h after dosing on serial PK collection days or 2 h after dosing on nonintense PK collection days. Detailed guidance of drug administration\\\", \\\"FootnoteText_25\\\": \\\" with diet and fluid requirements can be found in Section 7.4.1.\\\", \\\"FootnoteText_26\\\": \\\"f Hematology (complete blood count) and blood chemistry on Day 1 will be done at 8 h postdose. On all other days, blood draws are predose or at the relative Day 1 predose time.\\\", \\\"FootnoteText_27\\\": \\\"g FSH is mandatory for postmenopausal subjects.\\\", \\\"FootnoteText_28\\\": \\\"h Blood samples for pharmacogenomics are collected before the initiation of study drug administration on Day 1. Will be performed once only in each subject during the study period.\\\", \\\"FootnoteText_29\\\": \\\"i The exploratory assay may include exploratory assessment of OX-related biomarkers in the plasma (exosome research).\\\", \\\"FootnoteText_30\\\": \\\"j Subjects may need to check in on Day -3 evening time to start ABPM in the morning time of Day -2.\\\", \\\"FootnoteText_31\\\": \\\"k Day 23 study assessments may not be performed based on the emerging data from initial cohorts.\\\", \\\"Header\\\": [0, 1]}, {\\\"IsBold\\\": true, \\\"font_size\\\": 16, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 16, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"i  Schedule of Study Procedures for Part E: Non-Japanese Cohort\\\", \\\"Table 3.\\\", \\\"2\\\", 1683], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"i  Schedule of Study Procedures for Part E: Non-Japanese Cohort\\\", \\\"Table 3.\\\", \\\"2\\\", 1684], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"i  Schedule of Study Procedures for Part E: Non-Japanese Cohort\\\", \\\"Table 3.\\\", \\\"2\\\", 1685], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"i  Schedule of Study Procedures for Part E: Non-Japanese Cohort\\\", \\\"Table 3.\\\", \\\"2\\\", 1686], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"i  Schedule of Study Procedures for Part E: Non-Japanese Cohort\\\", \\\"Table 3.\\\", \\\"2\\\", 1687], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"i  Schedule of Study Procedures for Part E: Non-Japanese Cohort\\\", \\\"Table 3.\\\", \\\"2\\\", 1688], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"i  Schedule of Study Procedures for Part E: Non-Japanese Cohort\\\", \\\"Table 3.\\\", \\\"2\\\", 1689], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"i  Schedule of Study Procedures for Part E: Non-Japanese Cohort\\\", \\\"Table 3.\\\", \\\"2\\\", 1690], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"i  Schedule of Study Procedures for Part E: Non-Japanese Cohort\\\", \\\"Table 3.\\\", \\\"2\\\", 1691], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"i  Schedule of Study Procedures for Part E: Non-Japanese Cohort\\\", \\\"Table 3.\\\", \\\"2\\\", 1692], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"i  Schedule of Study Procedures for Part E: Non-Japanese Cohort\\\", \\\"Table 3.\\\", \\\"2\\\", 1693], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"i  Schedule of Study Procedures for Part E: Non-Japanese Cohort\\\", \\\"Table 3.\\\", \\\"2\\\", 1694], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"i  Schedule of Study Procedures for Part E: Non-Japanese Cohort\\\", \\\"Table 3.\\\", \\\"2\\\", 1695], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"i  Schedule of Study Procedures for Part E: Non-Japanese Cohort\\\", \\\"Table 3.\\\", \\\"2\\\", 1696], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"i  Schedule of Study Procedures for Part E: Non-Japanese Cohort\\\", \\\"Table 3.\\\", \\\"2\\\", 1697], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"i  Schedule of Study Procedures for Part E: Non-Japanese Cohort\\\", \\\"Table 3.\\\", \\\"2\\\", 1698], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"i  Schedule of Study Procedures for Part E: Non-Japanese Cohort\\\", \\\"Table 3.\\\", \\\"2\\\", 1699], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"i  Schedule of Study Procedures for Part E: Non-Japanese Cohort\\\", \\\"Table 3.\\\", \\\"2\\\", 1700], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"i  Schedule of Study Procedures for Part E: Non-Japanese Cohort\\\", \\\"Table 3.\\\", \\\"2\\\", 1701], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"i  Schedule of Study Procedures for Part E: Non-Japanese Cohort\\\", \\\"Table 3.\\\", \\\"2\\\", 1702], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"i  Schedule of Study Procedures for Part E: Non-Japanese Cohort\\\", \\\"Table 3.\\\", \\\"2\\\", 1703], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"i  Schedule of Study Procedures for Part E: Non-Japanese Cohort\\\", \\\"Table 3.\\\", \\\"2\\\", 1704], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"i  Schedule of Study Procedures for Part E: Non-Japanese Cohort\\\", \\\"Table 3.\\\", \\\"2\\\", 1705], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"i  Schedule of Study Procedures for Part E: Non-Japanese Cohort\\\", \\\"Table 3.\\\", \\\"2\\\", 1706], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"i  Schedule of Study Procedures for Part E: Non-Japanese Cohort\\\", \\\"Table 3.\\\", \\\"2\\\", 1707], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"i  Schedule of Study Procedures for Part E: Non-Japanese Cohort\\\", \\\"Table 3.\\\", \\\"2\\\", 1708], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"i  Schedule of Study Procedures for Part E: Non-Japanese Cohort\\\", \\\"Table 3.\\\", \\\"2\\\", 1709], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"i  Schedule of Study Procedures for Part E: Non-Japanese Cohort\\\", \\\"Table 3.\\\", \\\"2\\\", 1710], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"i  Schedule of Study Procedures for Part E: Non-Japanese Cohort\\\", \\\"Table 3.\\\", \\\"2\\\", 1711], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"i  Schedule of Study Procedures for Part E: Non-Japanese Cohort\\\", \\\"Table 3.\\\", \\\"2\\\", 1712], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"i  Schedule of Study Procedures for Part E: Non-Japanese Cohort\\\", \\\"Table 3.\\\", \\\"2\\\", 1713], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"i  Schedule of Study Procedures for Part E: Non-Japanese Cohort\\\", \\\"Table 3.\\\", \\\"2\\\", 1714], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"i  Schedule of Study Procedures for Part E: Non-Japanese Cohort\\\", \\\"Table 3.\\\", \\\"2\\\", 1715], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"i  Schedule of Study Procedures for Part E: Non-Japanese Cohort\\\", \\\"Table 3.\\\", \\\"2\\\", 1716], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"i  Schedule of Study Procedures for Part E: Non-Japanese Cohort\\\", \\\"Table 3.\\\", \\\"2\\\", 1717], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"i  Schedule of Study Procedures for Part E: Non-Japanese Cohort\\\", \\\"Table 3.\\\", \\\"2\\\", 1718], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"i  Schedule of Study Procedures for Part E: Non-Japanese Cohort\\\", \\\"Table 3.\\\", \\\"2\\\", 1719], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"i  Schedule of Study Procedures for Part E: Non-Japanese Cohort\\\", \\\"Table 3.\\\", \\\"2\\\", 1720], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"i  Schedule of Study Procedures for Part E: Non-Japanese Cohort\\\", \\\"Table 3.\\\", \\\"2\\\", 1721], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"i  Schedule of Study Procedures for Part E: Non-Japanese Cohort\\\", \\\"Table 3.\\\", \\\"2\\\", 1722], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"i  Schedule of Study Procedures for Part E: Non-Japanese Cohort\\\", \\\"Table 3.\\\", \\\"2\\\", 1723], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"i  Schedule of Study Procedures for Part E: Non-Japanese Cohort\\\", \\\"Table 3.\\\", \\\"2\\\", 1724], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"i  Schedule of Study Procedures for Part E: Non-Japanese Cohort\\\", \\\"Table 3.\\\", \\\"2\\\", 1725], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"i  Schedule of Study Procedures for Part E: Non-Japanese Cohort\\\", \\\"Table 3.\\\", \\\"2\\\", 1726], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"i  Schedule of Study Procedures for Part E: Non-Japanese Cohort\\\", \\\"Table 3.\\\", \\\"2\\\", 1727], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"i  Schedule of Study Procedures for Part E: Non-Japanese Cohort\\\", \\\"Table 3.\\\", \\\"2\\\", 1728], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"i  Schedule of Study Procedures for Part E: Non-Japanese Cohort\\\", \\\"Table 3.\\\", \\\"2\\\", 1729], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"i  Schedule of Study Procedures for Part E: Non-Japanese Cohort\\\", \\\"Table 3.\\\", \\\"2\\\", 1730], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"i  Schedule of Study Procedures for Part E: Non-Japanese Cohort\\\", \\\"Table 3.\\\", \\\"2\\\", 1731], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"i  Schedule of Study Procedures for Part E: Non-Japanese Cohort\\\", \\\"Table 3.\\\", \\\"2\\\", 1732], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"i  Schedule of Study Procedures for Part E: Non-Japanese Cohort\\\", \\\"Table 3.\\\", \\\"2\\\", 1733], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"i  Schedule of Study Procedures for Part E: Non-Japanese Cohort\\\", \\\"Table 3.\\\", \\\"2\\\", 1734], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"i  Schedule of Study Procedures for Part E: Non-Japanese Cohort\\\", \\\"Table 3.\\\", \\\"2\\\", 1735], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"i  Schedule of Study Procedures for Part E: Non-Japanese Cohort\\\", \\\"Table 3.\\\", \\\"2\\\", 1736], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"i  Schedule of Study Procedures for Part E: Non-Japanese Cohort\\\", \\\"Table 3.\\\", \\\"2\\\", 1737], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"i  Schedule of Study Procedures for Part E: Non-Japanese Cohort\\\", \\\"Table 3.\\\", \\\"2\\\", 1738], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"i  Schedule of Study Procedures for Part E: Non-Japanese Cohort\\\", \\\"Table 3.\\\", \\\"2\\\", 1739], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"i  Schedule of Study Procedures for Part E: Non-Japanese Cohort\\\", \\\"Table 3.\\\", \\\"2\\\", 1740], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"i  Schedule of Study Procedures for Part E: Non-Japanese Cohort\\\", \\\"Table 3.\\\", \\\"2\\\", 1741], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"i  Schedule of Study Procedures for Part E: Non-Japanese Cohort\\\", \\\"Table 3.\\\", \\\"2\\\", 1742], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"i  Schedule of Study Procedures for Part E: Non-Japanese Cohort\\\", \\\"Table 3.\\\", \\\"2\\\", 1743], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"i  Schedule of Study Procedures for Part E: Non-Japanese Cohort\\\", \\\"Table 3.\\\", \\\"2\\\", 1744], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"i  Schedule of Study Procedures for Part E: Non-Japanese Cohort\\\", \\\"Table 3.\\\", \\\"2\\\", 1745], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"i  Schedule of Study Procedures for Part E: Non-Japanese Cohort\\\", \\\"Table 3.\\\", \\\"2\\\", 1746], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"i  Schedule of Study Procedures for Part E: Non-Japanese Cohort\\\", \\\"Table 3.\\\", \\\"2\\\", 1747], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"Table 3.j Detailed Schedule for Part E (MRD Healthy Non-Japanese Adult Subjects)\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading8\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"j  Detailed Schedule for Part E (MRD Healthy Non-Japanese Adult Subjects)\\\", \\\"Table 3.\\\", \\\"2\\\", 1748], [\\\"\\\", \\\"Unmapped\\\", \\\"table\\\", \\\"\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": 16, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 16, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"j  Detailed Schedule for Part E (MRD Healthy Non-Japanese Adult Subjects)\\\", \\\"Table 3.\\\", \\\"2\\\", 1749], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"j  Detailed Schedule for Part E (MRD Healthy Non-Japanese Adult Subjects)\\\", \\\"Table 3.\\\", \\\"2\\\", 1750], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"j  Detailed Schedule for Part E (MRD Healthy Non-Japanese Adult Subjects)\\\", \\\"Table 3.\\\", \\\"2\\\", 1751], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"j  Detailed Schedule for Part E (MRD Healthy Non-Japanese Adult Subjects)\\\", \\\"Table 3.\\\", \\\"2\\\", 1752], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"j  Detailed Schedule for Part E (MRD Healthy Non-Japanese Adult Subjects)\\\", \\\"Table 3.\\\", \\\"2\\\", 1753], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"j  Detailed Schedule for Part E (MRD Healthy Non-Japanese Adult Subjects)\\\", \\\"Table 3.\\\", \\\"2\\\", 1754], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"j  Detailed Schedule for Part E (MRD Healthy Non-Japanese Adult Subjects)\\\", \\\"Table 3.\\\", \\\"2\\\", 1755], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"j  Detailed Schedule for Part E (MRD Healthy Non-Japanese Adult Subjects)\\\", \\\"Table 3.\\\", \\\"2\\\", 1756], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"j  Detailed Schedule for Part E (MRD Healthy Non-Japanese Adult Subjects)\\\", \\\"Table 3.\\\", \\\"2\\\", 1757], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"j  Detailed Schedule for Part E (MRD Healthy Non-Japanese Adult Subjects)\\\", \\\"Table 3.\\\", \\\"2\\\", 1758], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"j  Detailed Schedule for Part E (MRD Healthy Non-Japanese Adult Subjects)\\\", \\\"Table 3.\\\", \\\"2\\\", 1759], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"j  Detailed Schedule for Part E (MRD Healthy Non-Japanese Adult Subjects)\\\", \\\"Table 3.\\\", \\\"2\\\", 1760], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"j  Detailed Schedule for Part E (MRD Healthy Non-Japanese Adult Subjects)\\\", \\\"Table 3.\\\", \\\"2\\\", 1761], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"j  Detailed Schedule for Part E (MRD Healthy Non-Japanese Adult Subjects)\\\", \\\"Table 3.\\\", \\\"2\\\", 1762], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"j  Detailed Schedule for Part E (MRD Healthy Non-Japanese Adult Subjects)\\\", \\\"Table 3.\\\", \\\"2\\\", 1763], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"j  Detailed Schedule for Part E (MRD Healthy Non-Japanese Adult Subjects)\\\", \\\"Table 3.\\\", \\\"2\\\", 1764], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"j  Detailed Schedule for Part E (MRD Healthy Non-Japanese Adult Subjects)\\\", \\\"Table 3.\\\", \\\"2\\\", 1765], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"j  Detailed Schedule for Part E (MRD Healthy Non-Japanese Adult Subjects)\\\", \\\"Table 3.\\\", \\\"2\\\", 1766], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"j  Detailed Schedule for Part E (MRD Healthy Non-Japanese Adult Subjects)\\\", \\\"Table 3.\\\", \\\"2\\\", 1767], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"j  Detailed Schedule for Part E (MRD Healthy Non-Japanese Adult Subjects)\\\", \\\"Table 3.\\\", \\\"2\\\", 1768], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"j  Detailed Schedule for Part E (MRD Healthy Non-Japanese Adult Subjects)\\\", \\\"Table 3.\\\", \\\"2\\\", 1769], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"j  Detailed Schedule for Part E (MRD Healthy Non-Japanese Adult Subjects)\\\", \\\"Table 3.\\\", \\\"2\\\", 1770], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"j  Detailed Schedule for Part E (MRD Healthy Non-Japanese Adult Subjects)\\\", \\\"Table 3.\\\", \\\"2\\\", 1771], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"j  Detailed Schedule for Part E (MRD Healthy Non-Japanese Adult Subjects)\\\", \\\"Table 3.\\\", \\\"2\\\", 1772], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"j  Detailed Schedule for Part E (MRD Healthy Non-Japanese Adult Subjects)\\\", \\\"Table 3.\\\", \\\"2\\\", 1773], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"j  Detailed Schedule for Part E (MRD Healthy Non-Japanese Adult Subjects)\\\", \\\"Table 3.\\\", \\\"2\\\", 1774], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"j  Detailed Schedule for Part E (MRD Healthy Non-Japanese Adult Subjects)\\\", \\\"Table 3.\\\", \\\"2\\\", 1775], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"j  Detailed Schedule for Part E (MRD Healthy Non-Japanese Adult Subjects)\\\", \\\"Table 3.\\\", \\\"2\\\", 1776], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"j  Detailed Schedule for Part E (MRD Healthy Non-Japanese Adult Subjects)\\\", \\\"Table 3.\\\", \\\"2\\\", 1777], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"j  Detailed Schedule for Part E (MRD Healthy Non-Japanese Adult Subjects)\\\", \\\"Table 3.\\\", \\\"2\\\", 1778], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"j  Detailed Schedule for Part E (MRD Healthy Non-Japanese Adult Subjects)\\\", \\\"Table 3.\\\", \\\"2\\\", 1779], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"j  Detailed Schedule for Part E (MRD Healthy Non-Japanese Adult Subjects)\\\", \\\"Table 3.\\\", \\\"2\\\", 1780], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"j  Detailed Schedule for Part E (MRD Healthy Non-Japanese Adult Subjects)\\\", \\\"Table 3.\\\", \\\"2\\\", 1781], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"j  Detailed Schedule for Part E (MRD Healthy Non-Japanese Adult Subjects)\\\", \\\"Table 3.\\\", \\\"2\\\", 1782], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"j  Detailed Schedule for Part E (MRD Healthy Non-Japanese Adult Subjects)\\\", \\\"Table 3.\\\", \\\"2\\\", 1783], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"j  Detailed Schedule for Part E (MRD Healthy Non-Japanese Adult Subjects)\\\", \\\"Table 3.\\\", \\\"2\\\", 1784], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"j  Detailed Schedule for Part E (MRD Healthy Non-Japanese Adult Subjects)\\\", \\\"Table 3.\\\", \\\"2\\\", 1785], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"j  Detailed Schedule for Part E (MRD Healthy Non-Japanese Adult Subjects)\\\", \\\"Table 3.\\\", \\\"2\\\", 1786], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"j  Detailed Schedule for Part E (MRD Healthy Non-Japanese Adult Subjects)\\\", \\\"Table 3.\\\", \\\"2\\\", 1787], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"j  Detailed Schedule for Part E (MRD Healthy Non-Japanese Adult Subjects)\\\", \\\"Table 3.\\\", \\\"2\\\", 1788], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"j  Detailed Schedule for Part E (MRD Healthy Non-Japanese Adult Subjects)\\\", \\\"Table 3.\\\", \\\"2\\\", 1789], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"j  Detailed Schedule for Part E (MRD Healthy Non-Japanese Adult Subjects)\\\", \\\"Table 3.\\\", \\\"2\\\", 1790], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"j  Detailed Schedule for Part E (MRD Healthy Non-Japanese Adult Subjects)\\\", \\\"Table 3.\\\", \\\"2\\\", 1791], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"j  Detailed Schedule for Part E (MRD Healthy Non-Japanese Adult Subjects)\\\", \\\"Table 3.\\\", \\\"2\\\", 1792], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"j  Detailed Schedule for Part E (MRD Healthy Non-Japanese Adult Subjects)\\\", \\\"Table 3.\\\", \\\"2\\\", 1793], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"j  Detailed Schedule for Part E (MRD Healthy Non-Japanese Adult Subjects)\\\", \\\"Table 3.\\\", \\\"2\\\", 1794], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"j  Detailed Schedule for Part E (MRD Healthy Non-Japanese Adult Subjects)\\\", \\\"Table 3.\\\", \\\"2\\\", 1795], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"j  Detailed Schedule for Part E (MRD Healthy Non-Japanese Adult Subjects)\\\", \\\"Table 3.\\\", \\\"2\\\", 1796], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"j  Detailed Schedule for Part E (MRD Healthy Non-Japanese Adult Subjects)\\\", \\\"Table 3.\\\", \\\"2\\\", 1797], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"j  Detailed Schedule for Part E (MRD Healthy Non-Japanese Adult Subjects)\\\", \\\"Table 3.\\\", \\\"2\\\", 1798], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"BP: blood pressure; CYP: cytochrome P450; ECG: electrocardiogram; ET: early termination; KSS: Karolinska Sleepiness Scale; MRD: multiple-rising dose; OATP: organic anion transporting polypeptide; PK: pharmacokinetic(s); Post: postdose; Pre: predose.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 16, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 16, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"j  Detailed Schedule for Part E (MRD Healthy Non-Japanese Adult Subjects)\\\", \\\"Table 3.\\\", \\\"2\\\", 1799], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"a\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 10, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 10, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"j  Detailed Schedule for Part E (MRD Healthy Non-Japanese Adult Subjects)\\\", \\\"Table 3.\\\", \\\"2\\\", 1800], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"At ET, blood sample to be collected at the time of subject discontinuation (before discharge).\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 16, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 16, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"j  Detailed Schedule for Part E (MRD Healthy Non-Japanese Adult Subjects)\\\", \\\"Table 3.\\\", \\\"2\\\", 1801], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"b\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 10, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 10, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"j  Detailed Schedule for Part E (MRD Healthy Non-Japanese Adult Subjects)\\\", \\\"Table 3.\\\", \\\"2\\\", 1802], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"All or some of the Day 23 study assessments may not be performed based on the emerging data from initial cohorts.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 16, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 16, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"j  Detailed Schedule for Part E (MRD Healthy Non-Japanese Adult Subjects)\\\", \\\"Table 3.\\\", \\\"2\\\", 1803], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"c\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 10, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 10, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"j  Detailed Schedule for Part E (MRD Healthy Non-Japanese Adult Subjects)\\\", \\\"Table 3.\\\", \\\"2\\\", 1804], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Assessment to be conducted before discharge.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 16, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 16, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"j  Detailed Schedule for Part E (MRD Healthy Non-Japanese Adult Subjects)\\\", \\\"Table 3.\\\", \\\"2\\\", 1805], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"d\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 10, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 10, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"j  Detailed Schedule for Part E (MRD Healthy Non-Japanese Adult Subjects)\\\", \\\"Table 3.\\\", \\\"2\\\", 1806], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"KSS will be done at closest time for each assessment point just before MWT will start.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 16, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 16, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"j  Detailed Schedule for Part E (MRD Healthy Non-Japanese Adult Subjects)\\\", \\\"Table 3.\\\", \\\"2\\\", 1807], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"If subject is sleeping, please refer to Section 9.3.2.9 regarding how to rate KSS.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 16, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 16, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"j  Detailed Schedule for Part E (MRD Healthy Non-Japanese Adult Subjects)\\\", \\\"Table 3.\\\", \\\"2\\\", 1808], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"3.5 Part F\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading2\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part F\\\", \\\"3.5\\\", \\\"2\\\", 1809], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"Table 3.k Schedule of Study Procedures for Part F: ~REDACTED~ Cohorts\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading8\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part F\\\", \\\"3.5\\\", \\\"2\\\", 1810], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part F\\\", \\\"3.5\\\", \\\"2\\\", 1811], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"Table 3.k Schedule of Study Procedures for Part F: ~REDACTED~ Cohorts\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading8\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part F\\\", \\\"3.5\\\", \\\"2\\\", 1812], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Part F\\\", \\\"3.5\\\", \\\"2\\\", 1813], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"Table 3.k Schedule of Study Procedures for Part F: ~REDACTED~ Cohorts\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading8\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"k  Schedule of Study Procedures for Part F: CSF Cohorts\\\", \\\"Table 3.\\\", \\\"2\\\", 1814], [\\\"\\\", \\\"Unmapped\\\", \\\"table\\\", {\\\"Table\\\": \\\"<table border=\\\\\\\"1\\\\\\\" class=\\\\\\\"dataframe\\\\\\\">\\\\n  <thead>\\\\n    <tr style=\\\\\\\"text-align: right;\\\\\\\">\\\\n      <th></th>\\\\n      <th>1.0</th>\\\\n      <th>2.0</th>\\\\n      <th>3.0</th>\\\\n      <th>4.0</th>\\\\n      <th>5.0</th>\\\\n      <th>6.0</th>\\\\n      <th>7.0</th>\\\\n      <th>8.0</th>\\\\n      <th>9.0</th>\\\\n      <th>10.0</th>\\\\n      <th>11.0</th>\\\\n      <th>12.0</th>\\\\n      <th>13.0</th>\\\\n      <th>14.0</th>\\\\n      <th>15.0</th>\\\\n      <th>16.0</th>\\\\n      <th>17.0</th>\\\\n      <th>18.0</th>\\\\n    </tr>\\\\n  </thead>\\\\n  <tbody>\\\\n    <tr>\\\\n      <th>0</th>\\\\n      <td>Day</td>\\\\n      <td>Screening Days -35 to -2</td>\\\\n      <td>Baseline Day -1</td>\\\\n      <td>Day 1 Pre</td>\\\\n      <td>Day 1</td>\\\\n      <td>Day 2</td>\\\\n      <td>Day 3</td>\\\\n      <td>Day 4</td>\\\\n      <td>Day 5</td>\\\\n      <td>Day 6</td>\\\\n      <td>Day 7</td>\\\\n      <td>Day 8</td>\\\\n      <td>Day 9</td>\\\\n      <td>Day 10</td>\\\\n      <td>Day 11</td>\\\\n      <td>Day 12 -13</td>\\\\n      <td>Day 14 Discharge/ ET <sup>j</sup></td>\\\\n      <td>Day 17\\\\u00b12 Follow-up Visit</td>\\\\n    </tr>\\\\n  </tbody>\\\\n</table>\\\", \\\"SectionHeaderPrintPage\\\": \\\"42\\\", \\\"TableIndex\\\": \\\"28\\\", \\\"TableName\\\": \\\"Table 3.k Schedule of Study Procedures for Part F: CSF Cohorts\\\", \\\"Header\\\": [0]}, {\\\"IsBold\\\": true, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"k  Schedule of Study Procedures for Part F: CSF Cohorts\\\", \\\"Table 3.\\\", \\\"2\\\", 1815], [\\\"\\\", \\\"Unmapped\\\", \\\"table\\\", {\\\"Table\\\": \\\"<table border=\\\\\\\"1\\\\\\\" class=\\\\\\\"dataframe\\\\\\\">\\\\n  <thead>\\\\n    <tr style=\\\\\\\"text-align: right;\\\\\\\">\\\\n      <th></th>\\\\n      <th>1.0</th>\\\\n      <th>2.0</th>\\\\n      <th>3.0</th>\\\\n      <th>4.0</th>\\\\n      <th>5.0</th>\\\\n      <th>6.0</th>\\\\n      <th>7.0</th>\\\\n      <th>8.0</th>\\\\n      <th>9.0</th>\\\\n      <th>10.0</th>\\\\n      <th>11.0</th>\\\\n      <th>12.0</th>\\\\n      <th>13.0</th>\\\\n    </tr>\\\\n  </thead>\\\\n  <tbody>\\\\n    <tr>\\\\n      <th>0</th>\\\\n      <td>Procedures</td>\\\\n      <td>Baseline</td>\\\\n      <td>Treatment Period</td>\\\\n      <td>Treatment Period</td>\\\\n      <td>Treatment Period</td>\\\\n      <td>Treatment Period</td>\\\\n      <td>Treatment Period</td>\\\\n      <td>Treatment Period</td>\\\\n      <td>Treatment Period</td>\\\\n      <td>Treatment Period</td>\\\\n      <td>Postdose/Follow-up</td>\\\\n      <td>Postdose/Follow-up</td>\\\\n      <td>Postdose/Follow-up</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>1</th>\\\\n      <td>Day</td>\\\\n      <td>-1</td>\\\\n      <td>1</td>\\\\n      <td>2</td>\\\\n      <td>3</td>\\\\n      <td>4</td>\\\\n      <td>5-6</td>\\\\n      <td>7</td>\\\\n      <td>8-9</td>\\\\n      <td>10-13</td>\\\\n      <td>14 <sup>c</sup></td>\\\\n      <td>ET</td>\\\\n      <td>17 (\\\\u00b12 days)</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>2</th>\\\\n      <td>Blood sample for TAK-861 PK</td>\\\\n      <td></td>\\\\n      <td>Pre and 0.25, 0.5, 1, 2, 3, 4, 6, 8, and 12 h Post</td>\\\\n      <td>24 h after Day 1 dose</td>\\\\n      <td></td>\\\\n      <td>Pre</td>\\\\n      <td></td>\\\\n      <td>Pre</td>\\\\n      <td></td>\\\\n      <td>Pre on Day 10 and 0.25, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 36, 48, and 72 h after last dose</td>\\\\n      <td>96 h after last dose</td>\\\\n      <td>X <sup>a</sup></td>\\\\n      <td></td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>3</th>\\\\n      <td><span class=\\\\\\\"redact\\\\\\\"> ~REDACTED~ </span>  sample for TAK-861 PK</td>\\\\n      <td>X<sup> (relative 1 hour postdose time when Day 10 dose may happen)</sup></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>Pre on Day 10 and 1, 2, 4, 8, 12, 16, 20, and 24 h after last dose</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>4</th>\\\\n      <td>CSF sample for TAK-861 orexin levels</td>\\\\n      <td>X<sup> (relative 1 hour postdose time when Day 10 dose may happen)</sup></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>Pre on Day 10 and 1, 2, 4, 8, 12, 16, 20, and 24 h after last dose</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>5</th>\\\\n      <td>Supine BP and supine pulse rate measurements</td>\\\\n      <td>Approximately before morning dose on Day 1 and 0.5, 1, 2, 3, 4, 6, 8, and 12 h later relative to initial measurement (matched to the time assessment schedule of Day 1)</td>\\\\n      <td>Pre and 0.5, 1, 2, 3, 4, 6, 8, and 12 h Post</td>\\\\n      <td>24 h after Day 1 dose</td>\\\\n      <td>Pre</td>\\\\n      <td>Pre</td>\\\\n      <td>Pre</td>\\\\n      <td>Pre and 3, 6, and 12 h Post</td>\\\\n      <td>Pre</td>\\\\n      <td>Pre and 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 36, 48, and 72 h after last dose</td>\\\\n      <td>96 h after last dose</td>\\\\n      <td>X <sup>b</sup></td>\\\\n      <td>X</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>6</th>\\\\n      <td>Standing Orthostatic BP and pulse rate measurements</td>\\\\n      <td>X<sup> (relative Pre)</sup></td>\\\\n      <td>Pre, 1, 2, and 6 h Post</td>\\\\n      <td>24 h after Day 1 dose</td>\\\\n      <td></td>\\\\n      <td>Pre</td>\\\\n      <td></td>\\\\n      <td>Pre</td>\\\\n      <td></td>\\\\n      <td>Pre, 1, 2, and 6 h Post</td>\\\\n      <td>96 h after last dose</td>\\\\n      <td>X <sup>b</sup></td>\\\\n      <td></td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>7</th>\\\\n      <td>Respiratory rate</td>\\\\n      <td></td>\\\\n      <td>Pre and 1, 2, 4, and 6 h Post</td>\\\\n      <td>Pre</td>\\\\n      <td></td>\\\\n      <td>Pre</td>\\\\n      <td></td>\\\\n      <td>Pre</td>\\\\n      <td></td>\\\\n      <td>Pre</td>\\\\n      <td>96 h after last dose</td>\\\\n      <td>X <sup>b</sup></td>\\\\n      <td>X</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>8</th>\\\\n      <td>Body temperature</td>\\\\n      <td></td>\\\\n      <td>Pre</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>Pre</td>\\\\n      <td></td>\\\\n      <td>Pre</td>\\\\n      <td></td>\\\\n      <td>Pre</td>\\\\n      <td>96 h after last dose <sup>c</sup></td>\\\\n      <td>X <sup>b</sup></td>\\\\n      <td>X</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>9</th>\\\\n      <td>Standard 12-lead ECGs</td>\\\\n      <td>X</td>\\\\n      <td>Pre and 1, 2, 4, 6, and 12 h Post</td>\\\\n      <td>Pre</td>\\\\n      <td></td>\\\\n      <td>Pre</td>\\\\n      <td></td>\\\\n      <td>Pre</td>\\\\n      <td></td>\\\\n      <td>Pre</td>\\\\n      <td>96 h after last dose <sup>c</sup></td>\\\\n      <td>X <sup>b</sup></td>\\\\n      <td>X</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>10</th>\\\\n      <td>KSS</td>\\\\n      <td>Pre (relative to planned Day 1 dose) and 1, 2, 4, 8, 12, 14 and 15, 16, 24 h relative to initial measurement <sup>d</sup></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>Pre and 1, 2, 4, 8, 12, 14, 15, 16, and 24 h Post</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n    </tr>\\\\n  </tbody>\\\\n</table>\\\", \\\"SectionHeaderPrintPage\\\": \\\"42\\\", \\\"TableIndex\\\": \\\"29\\\", \\\"TableName\\\": \\\"Table 3.k Schedule of Study Procedures for Part F: CSF Cohorts(Schedule of Assessment)\\\", \\\"AttachmentEntities\\\": [{\\\"content\\\": \\\"Administrative Procedures Informed consent X\\\", \\\"entities\\\": []}, {\\\"content\\\": \\\"medication review (continuous review)\\\", \\\"entities\\\": []}, {\\\"content\\\": \\\"Procedures/Assessments\\\", \\\"entities\\\": []}, {\\\"content\\\": \\\"Height, BMI calculation X\\\", \\\"entities\\\": []}, {\\\"content\\\": \\\"Vital signs a, b (see Table 3.l) X\\\", \\\"entities\\\": []}, {\\\"content\\\": \\\"12-lead ECG standard (See X Table 3.l)\\\", \\\"entities\\\": []}, {\\\"content\\\": \\\"(continuous monitoring)\\\", \\\"entities\\\": []}, {\\\"content\\\": \\\"Laboratory Procedures/\\\", \\\"entities\\\": []}, {\\\"content\\\": \\\"count) and blood chemistry e FSH assessment f X\\\", \\\"entities\\\": []}, {\\\"content\\\": \\\"Hepatitis and HIV screen X\\\", \\\"entities\\\": []}, {\\\"content\\\": \\\"Blood for retained samples and X pharmacogenomics g\\\", \\\"entities\\\": []}, {\\\"content\\\": \\\"Blood sample for PK TAK-861 (See Table 3.l)\\\", \\\"entities\\\": []}, {\\\"content\\\": \\\"CSF sample for PK and OX (see Table 3.l)\\\", \\\"entities\\\": [{\\\"start_idx\\\": 0, \\\"end_idx\\\": 2, \\\"standard_entity_name\\\": \\\"Molecule\\\", \\\"subcategory\\\": \\\"Molecule\\\", \\\"confidence\\\": 37.0, \\\"text\\\": \\\"CSF\\\"}]}, {\\\"content\\\": \\\"ESS (only for determining X eligibility)\\\", \\\"entities\\\": []}, {\\\"content\\\": \\\"AE: adverse event; aPTT: activated partial thromboplastin time; BMI: body mass index; BP: blood pressure; CSF: cerebrospinal fluid; C-SSRS: ColumbiaSuicide\\\", \\\"entities\\\": [{\\\"start_idx\\\": 106, \\\"end_idx\\\": 108, \\\"standard_entity_name\\\": \\\"Molecule\\\", \\\"subcategory\\\": \\\"Molecule\\\", \\\"confidence\\\": 37.0, \\\"text\\\": \\\"CSF\\\"}]}, {\\\"content\\\": \\\"Severity Rating Scale; ECG: electrocardiogram; ESS: Epworth Sleepiness Scale; ET: early termination; FSH: follicle-stimulating hormone; INR: international\\\", \\\"entities\\\": [{\\\"start_idx\\\": 106, \\\"end_idx\\\": 133, \\\"standard_entity_name\\\": \\\"Molecule\\\", \\\"subcategory\\\": \\\"Molecule\\\", \\\"confidence\\\": 87.0, \\\"text\\\": \\\"follicle-stimulating hormone\\\"}]}, {\\\"content\\\": \\\"normalized ratio; KSS: Karolinska Sleepiness Scale; NSF: National Sleep Foundation; PK: pharmacokinetic(s); PT: prothrombin time.\\\", \\\"entities\\\": [{\\\"start_idx\\\": 57, \\\"end_idx\\\": 81, \\\"standard_entity_name\\\": \\\"ANY: Organization\\\", \\\"subcategory\\\": \\\"ANY: Organization\\\", \\\"confidence\\\": 87.0, \\\"text\\\": \\\"National Sleep Foundation\\\"}]}, {\\\"content\\\": \\\"a BP will be checked (single measurement) with the subject resting for a minimum of 5 minutes lying in a bed with the head of the bed at 30 degrees.\\\", \\\"entities\\\": []}, {\\\"content\\\": \\\"b Orthostatic BP and pulse rate will also be checked, with the subject standing for 1 minute and 5 minutes.\\\", \\\"entities\\\": []}, {\\\"content\\\": \\\"c Subject will start recording sleep diary and start wearing accelerometry on Day -11 and subject will continue wearing accelerometry until discharge. Additional subject behavior\\\", \\\"entities\\\": []}, {\\\"content\\\": \\\"information collecting system may be also collected during Day -11 through discharge.\\\", \\\"entities\\\": []}, {\\\"content\\\": \\\"d Drug will be administered as a single dose after an overnight fast of at least 10 h. Subjects will continue to fast for an additional 4 h after dosing on serial PK collection days or 2 h\\\", \\\"entities\\\": []}, {\\\"content\\\": \\\"after dosing on nonintense PK collection days. Detailed guidance of drug administration with diet and fluid requirements can be found in Section 7.4.1.\\\", \\\"entities\\\": []}, {\\\"content\\\": \\\"e Hematology (complete blood count) and blood chemistry on Day 1 will be done at 8 h postdose. On all other days, blood draws are predose or at the relative Day 1 predose time.\\\", \\\"entities\\\": []}, {\\\"content\\\": \\\"f FSH is mandatory for postmenopausal subjects.\\\", \\\"entities\\\": []}, {\\\"content\\\": \\\"g Blood samples for pharmacogenomics are collected before the initiation of study drug administration on Day1. Will be performed once only in each subject during the study period.\\\", \\\"entities\\\": []}, {\\\"content\\\": \\\"h The exploratory assay may include exploratory assessment of OX-related biomarkers in plasma neuronally derived exosomes (exosome research).\\\", \\\"entities\\\": []}, {\\\"content\\\": \\\"i Subjects to check in in the afternoon or evening of Day -2 at the latest.\\\", \\\"entities\\\": []}, {\\\"content\\\": \\\"j Day 12 study assessments may not be performed based on the emerging data from initial cohorts.\\\", \\\"entities\\\": []}, {\\\"content\\\": \\\"6, 8, and 12 h 36, 48, and 72 h after last Post dose\\\", \\\"entities\\\": []}, {\\\"content\\\": \\\"initial measurement (matched to Post\\\", \\\"entities\\\": []}, {\\\"content\\\": \\\"the time assessment schedule of Day 1)\\\", \\\"entities\\\": []}, {\\\"content\\\": \\\"temperature last dose c\\\", \\\"entities\\\": []}, {\\\"content\\\": \\\"dose) and 1, 2, 4, 8, 12, 14 and 15, 16, and 24 h Post\\\", \\\"entities\\\": []}, {\\\"content\\\": \\\"15, 16, 24 h relative to initial measurement d\\\", \\\"entities\\\": []}, {\\\"content\\\": \\\"BP: blood pressure; CSF: cerebrospinal fluid; ECG: electrocardiogram; KSS: Karolinska Sleepiness Scale; MRD: multiple-rising dose; PK: pharmacokinetic(s); Post: postdose; Pre: predose.\\\", \\\"entities\\\": [{\\\"start_idx\\\": 20, \\\"end_idx\\\": 22, \\\"standard_entity_name\\\": \\\"Molecule\\\", \\\"subcategory\\\": \\\"Molecule\\\", \\\"confidence\\\": 37.0, \\\"text\\\": \\\"CSF\\\"}]}, {\\\"content\\\": \\\"a At ET, blood sample to be collected at the time of subject discontinuation (before discharge).\\\", \\\"entities\\\": []}, {\\\"content\\\": \\\"b ET assessment to be conducted before discharge.\\\", \\\"entities\\\": []}, {\\\"content\\\": \\\"c All or some of the Day 14 study assessments may not be performed based on the emerging data from initial cohorts.\\\", \\\"entities\\\": []}, {\\\"content\\\": \\\"d If subject is sleeping, please refer to Section 9.3.2.9 regarding how to rate KSS.\\\", \\\"entities\\\": []}], \\\"FootnoteText_0\\\": \\\" Administrative Procedures Informed consent X\\\", \\\"FootnoteText_1\\\": \\\" medication review (continuous review)\\\", \\\"FootnoteText_2\\\": \\\" Procedures/Assessments\\\", \\\"FootnoteText_3\\\": \\\" Height, BMI calculation X\\\", \\\"FootnoteText_4\\\": \\\" Vital signs a, b (see Table 3.l) X\\\", \\\"FootnoteText_5\\\": \\\" 12-lead ECG standard (See X Table 3.l)\\\", \\\"FootnoteText_6\\\": \\\" (continuous monitoring)\\\", \\\"FootnoteText_7\\\": \\\" Laboratory Procedures/\\\", \\\"FootnoteText_8\\\": \\\" count) and blood chemistry e FSH assessment f X\\\", \\\"FootnoteText_9\\\": \\\" Hepatitis and HIV screen X\\\", \\\"FootnoteText_10\\\": \\\" Blood for retained samples and X pharmacogenomics g\\\", \\\"FootnoteText_11\\\": \\\" Blood sample for PK TAK-861 (See Table 3.l)\\\", \\\"FootnoteText_12\\\": \\\" CSF sample for PK and OX (see Table 3.l)\\\", \\\"FootnoteText_13\\\": \\\" ESS (only for determining X eligibility)\\\", \\\"FootnoteText_14\\\": \\\" AE: adverse event; aPTT: activated partial thromboplastin time; BMI: body mass index; BP: blood pressure; CSF: cerebrospinal fluid; C-SSRS: ColumbiaSuicide\\\", \\\"FootnoteText_15\\\": \\\" Severity Rating Scale; ECG: electrocardiogram; ESS: Epworth Sleepiness Scale; ET: early termination; FSH: follicle-stimulating hormone; INR: international\\\", \\\"FootnoteText_16\\\": \\\" normalized ratio; KSS: Karolinska Sleepiness Scale; NSF: National Sleep Foundation; PK: pharmacokinetic(s); PT: prothrombin time.\\\", \\\"FootnoteText_17\\\": \\\"a BP will be checked (single measurement) with the subject resting for a minimum of 5 minutes lying in a bed with the head of the bed at 30 degrees.\\\", \\\"FootnoteText_18\\\": \\\"b Orthostatic BP and pulse rate will also be checked, with the subject standing for 1 minute and 5 minutes.\\\", \\\"FootnoteText_19\\\": \\\"c Subject will start recording sleep diary and start wearing accelerometry on Day -11 and subject will continue wearing accelerometry until discharge. Additional subject behavior\\\", \\\"FootnoteText_20\\\": \\\" information collecting system may be also collected during Day -11 through discharge.\\\", \\\"FootnoteText_21\\\": \\\"d Drug will be administered as a single dose after an overnight fast of at least 10 h. Subjects will continue to fast for an additional 4 h after dosing on serial PK collection days or 2 h\\\", \\\"FootnoteText_22\\\": \\\" after dosing on nonintense PK collection days. Detailed guidance of drug administration with diet and fluid requirements can be found in Section 7.4.1.\\\", \\\"FootnoteText_23\\\": \\\"e Hematology (complete blood count) and blood chemistry on Day 1 will be done at 8 h postdose. On all other days, blood draws are predose or at the relative Day 1 predose time.\\\", \\\"FootnoteText_24\\\": \\\"f FSH is mandatory for postmenopausal subjects.\\\", \\\"FootnoteText_25\\\": \\\"g Blood samples for pharmacogenomics are collected before the initiation of study drug administration on Day1. Will be performed once only in each subject during the study period.\\\", \\\"FootnoteText_26\\\": \\\"h The exploratory assay may include exploratory assessment of OX-related biomarkers in plasma neuronally derived exosomes (exosome research).\\\", \\\"FootnoteText_27\\\": \\\"i Subjects to check in in the afternoon or evening of Day -2 at the latest.\\\", \\\"FootnoteText_28\\\": \\\"j Day 12 study assessments may not be performed based on the emerging data from initial cohorts.\\\", \\\"FootnoteText_29\\\": \\\" 6, 8, and 12 h 36, 48, and 72 h after last Post dose\\\", \\\"FootnoteText_30\\\": \\\" initial measurement (matched to Post\\\", \\\"FootnoteText_31\\\": \\\" the time assessment schedule of Day 1)\\\", \\\"FootnoteText_32\\\": \\\" temperature last dose c\\\", \\\"FootnoteText_33\\\": \\\" dose) and 1, 2, 4, 8, 12, 14 and 15, 16, and 24 h Post\\\", \\\"FootnoteText_34\\\": \\\" 15, 16, 24 h relative to initial measurement d\\\", \\\"FootnoteText_35\\\": \\\" BP: blood pressure; CSF: cerebrospinal fluid; ECG: electrocardiogram; KSS: Karolinska Sleepiness Scale; MRD: multiple-rising dose; PK: pharmacokinetic(s); Post: postdose; Pre: predose.\\\", \\\"FootnoteText_36\\\": \\\"a At ET, blood sample to be collected at the time of subject discontinuation (before discharge).\\\", \\\"FootnoteText_37\\\": \\\"b ET assessment to be conducted before discharge.\\\", \\\"FootnoteText_38\\\": \\\"c All or some of the Day 14 study assessments may not be performed based on the emerging data from initial cohorts.\\\", \\\"FootnoteText_39\\\": \\\"d If subject is sleeping, please refer to Section 9.3.2.9 regarding how to rate KSS.\\\", \\\"Header\\\": [0, 1]}, {\\\"IsBold\\\": true, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"k  Schedule of Study Procedures for Part F: CSF Cohorts\\\", \\\"Table 3.\\\", \\\"2\\\", 1816], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"k  Schedule of Study Procedures for Part F: CSF Cohorts\\\", \\\"Table 3.\\\", \\\"2\\\", 1817], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"k  Schedule of Study Procedures for Part F: CSF Cohorts\\\", \\\"Table 3.\\\", \\\"2\\\", 1818], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"k  Schedule of Study Procedures for Part F: CSF Cohorts\\\", \\\"Table 3.\\\", \\\"2\\\", 1819], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"k  Schedule of Study Procedures for Part F: CSF Cohorts\\\", \\\"Table 3.\\\", \\\"2\\\", 1820], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"k  Schedule of Study Procedures for Part F: CSF Cohorts\\\", \\\"Table 3.\\\", \\\"2\\\", 1821], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"k  Schedule of Study Procedures for Part F: CSF Cohorts\\\", \\\"Table 3.\\\", \\\"2\\\", 1822], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"k  Schedule of Study Procedures for Part F: CSF Cohorts\\\", \\\"Table 3.\\\", \\\"2\\\", 1823], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"k  Schedule of Study Procedures for Part F: CSF Cohorts\\\", \\\"Table 3.\\\", \\\"2\\\", 1824], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"k  Schedule of Study Procedures for Part F: CSF Cohorts\\\", \\\"Table 3.\\\", \\\"2\\\", 1825], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"k  Schedule of Study Procedures for Part F: CSF Cohorts\\\", \\\"Table 3.\\\", \\\"2\\\", 1826], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"k  Schedule of Study Procedures for Part F: CSF Cohorts\\\", \\\"Table 3.\\\", \\\"2\\\", 1827], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"k  Schedule of Study Procedures for Part F: CSF Cohorts\\\", \\\"Table 3.\\\", \\\"2\\\", 1828], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"k  Schedule of Study Procedures for Part F: CSF Cohorts\\\", \\\"Table 3.\\\", \\\"2\\\", 1829], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"k  Schedule of Study Procedures for Part F: CSF Cohorts\\\", \\\"Table 3.\\\", \\\"2\\\", 1830], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"k  Schedule of Study Procedures for Part F: CSF Cohorts\\\", \\\"Table 3.\\\", \\\"2\\\", 1831], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"k  Schedule of Study Procedures for Part F: CSF Cohorts\\\", \\\"Table 3.\\\", \\\"2\\\", 1832], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"k  Schedule of Study Procedures for Part F: CSF Cohorts\\\", \\\"Table 3.\\\", \\\"2\\\", 1833], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"k  Schedule of Study Procedures for Part F: CSF Cohorts\\\", \\\"Table 3.\\\", \\\"2\\\", 1834], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"k  Schedule of Study Procedures for Part F: CSF Cohorts\\\", \\\"Table 3.\\\", \\\"2\\\", 1835], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"k  Schedule of Study Procedures for Part F: CSF Cohorts\\\", \\\"Table 3.\\\", \\\"2\\\", 1836], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"k  Schedule of Study Procedures for Part F: CSF Cohorts\\\", \\\"Table 3.\\\", \\\"2\\\", 1837], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"k  Schedule of Study Procedures for Part F: CSF Cohorts\\\", \\\"Table 3.\\\", \\\"2\\\", 1838], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"k  Schedule of Study Procedures for Part F: CSF Cohorts\\\", \\\"Table 3.\\\", \\\"2\\\", 1839], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"k  Schedule of Study Procedures for Part F: CSF Cohorts\\\", \\\"Table 3.\\\", \\\"2\\\", 1840], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"k  Schedule of Study Procedures for Part F: CSF Cohorts\\\", \\\"Table 3.\\\", \\\"2\\\", 1841], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"k  Schedule of Study Procedures for Part F: CSF Cohorts\\\", \\\"Table 3.\\\", \\\"2\\\", 1842], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"k  Schedule of Study Procedures for Part F: CSF Cohorts\\\", \\\"Table 3.\\\", \\\"2\\\", 1843], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"k  Schedule of Study Procedures for Part F: CSF Cohorts\\\", \\\"Table 3.\\\", \\\"2\\\", 1844], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"k  Schedule of Study Procedures for Part F: CSF Cohorts\\\", \\\"Table 3.\\\", \\\"2\\\", 1845], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"k  Schedule of Study Procedures for Part F: CSF Cohorts\\\", \\\"Table 3.\\\", \\\"2\\\", 1846], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"k  Schedule of Study Procedures for Part F: CSF Cohorts\\\", \\\"Table 3.\\\", \\\"2\\\", 1847], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"k  Schedule of Study Procedures for Part F: CSF Cohorts\\\", \\\"Table 3.\\\", \\\"2\\\", 1848], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"k  Schedule of Study Procedures for Part F: CSF Cohorts\\\", \\\"Table 3.\\\", \\\"2\\\", 1849], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"k  Schedule of Study Procedures for Part F: CSF Cohorts\\\", \\\"Table 3.\\\", \\\"2\\\", 1850], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"k  Schedule of Study Procedures for Part F: CSF Cohorts\\\", \\\"Table 3.\\\", \\\"2\\\", 1851], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"k  Schedule of Study Procedures for Part F: CSF Cohorts\\\", \\\"Table 3.\\\", \\\"2\\\", 1852], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"k  Schedule of Study Procedures for Part F: CSF Cohorts\\\", \\\"Table 3.\\\", \\\"2\\\", 1853], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"k  Schedule of Study Procedures for Part F: CSF Cohorts\\\", \\\"Table 3.\\\", \\\"2\\\", 1854], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"k  Schedule of Study Procedures for Part F: CSF Cohorts\\\", \\\"Table 3.\\\", \\\"2\\\", 1855], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"k  Schedule of Study Procedures for Part F: CSF Cohorts\\\", \\\"Table 3.\\\", \\\"2\\\", 1856], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"k  Schedule of Study Procedures for Part F: CSF Cohorts\\\", \\\"Table 3.\\\", \\\"2\\\", 1857], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"k  Schedule of Study Procedures for Part F: CSF Cohorts\\\", \\\"Table 3.\\\", \\\"2\\\", 1858], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"k  Schedule of Study Procedures for Part F: CSF Cohorts\\\", \\\"Table 3.\\\", \\\"2\\\", 1859], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"k  Schedule of Study Procedures for Part F: CSF Cohorts\\\", \\\"Table 3.\\\", \\\"2\\\", 1860], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"k  Schedule of Study Procedures for Part F: CSF Cohorts\\\", \\\"Table 3.\\\", \\\"2\\\", 1861], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"k  Schedule of Study Procedures for Part F: CSF Cohorts\\\", \\\"Table 3.\\\", \\\"2\\\", 1862], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"k  Schedule of Study Procedures for Part F: CSF Cohorts\\\", \\\"Table 3.\\\", \\\"2\\\", 1863], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"k  Schedule of Study Procedures for Part F: CSF Cohorts\\\", \\\"Table 3.\\\", \\\"2\\\", 1864], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"k  Schedule of Study Procedures for Part F: CSF Cohorts\\\", \\\"Table 3.\\\", \\\"2\\\", 1865], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"k  Schedule of Study Procedures for Part F: CSF Cohorts\\\", \\\"Table 3.\\\", \\\"2\\\", 1866], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"k  Schedule of Study Procedures for Part F: CSF Cohorts\\\", \\\"Table 3.\\\", \\\"2\\\", 1867], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"Table 3.l Detailed Schedule for Part F (~REDACTED~ Cohorts in Healthy Non-Japanese Adult subjects)\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading8\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"l  Detailed Schedule for Part F (CSF Cohorts in Healthy Non-Japanese Adult subjects)\\\", \\\"Table 3.\\\", \\\"2\\\", 1868], [\\\"\\\", \\\"Unmapped\\\", \\\"table\\\", \\\"\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"l  Detailed Schedule for Part F (CSF Cohorts in Healthy Non-Japanese Adult subjects)\\\", \\\"Table 3.\\\", \\\"2\\\", 1869], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"l  Detailed Schedule for Part F (CSF Cohorts in Healthy Non-Japanese Adult subjects)\\\", \\\"Table 3.\\\", \\\"2\\\", 1870], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"l  Detailed Schedule for Part F (CSF Cohorts in Healthy Non-Japanese Adult subjects)\\\", \\\"Table 3.\\\", \\\"2\\\", 1871], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"l  Detailed Schedule for Part F (CSF Cohorts in Healthy Non-Japanese Adult subjects)\\\", \\\"Table 3.\\\", \\\"2\\\", 1872], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"l  Detailed Schedule for Part F (CSF Cohorts in Healthy Non-Japanese Adult subjects)\\\", \\\"Table 3.\\\", \\\"2\\\", 1873], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"l  Detailed Schedule for Part F (CSF Cohorts in Healthy Non-Japanese Adult subjects)\\\", \\\"Table 3.\\\", \\\"2\\\", 1874], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"l  Detailed Schedule for Part F (CSF Cohorts in Healthy Non-Japanese Adult subjects)\\\", \\\"Table 3.\\\", \\\"2\\\", 1875], [\\\"1\\\", \\\"Introduction\\\", \\\"header\\\", \\\"4.0 INTRODUCTION\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading1\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"INTRODUCTION\\\", \\\"4.0\\\", \\\"1\\\", 1876], [\\\"2\\\", \\\"Background\\\", \\\"header\\\", \\\"4.1 Background\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading2\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"Background\\\", \\\"4.1\\\", \\\"2\\\", 1877], [\\\"2\\\", \\\"Background\\\", \\\"text\\\", \\\"The orexinergic system is a major wake-promoting system of the brain.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"Background\\\", \\\"4.1\\\", \\\"2\\\", 1878], [\\\"2\\\", \\\"Background\\\", \\\"text\\\", \\\"It is comprised of 2 types of wake promoting orexin (OX, also known as hypocretin) neurons, localized in a specific region of the lateral and posterior hypothalamus and have excitatory projections to wide areas of the central nervous system (CNS) including the basal forebrain and brainstem nuclei involved in maintaining wakefulness (ie, cholinergic neurons if the reticular activating system, histaminergic tuberomammillary nucleus, noradrenergic locus ~REDACTED~, ~REDACTED~ ventral lateral area, and the serotonergic dorsal raphe nucleus).\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"Background\\\", \\\"4.1\\\", \\\"2\\\", 1879], [\\\"2\\\", \\\"Background\\\", \\\"text\\\", \\\"The OX system acts to coordinate and synchronize the wake-promoting centers of the brain and when absent (ie, in patients with narcolepsy type 1 [NT1]), sleep/wake instability results.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"Background\\\", \\\"4.1\\\", \\\"2\\\", 1880], [\\\"2\\\", \\\"Background\\\", \\\"text\\\", \\\"The orexinergic system is also involved in several other functions, such as feeding, reward, and sympathetic activity.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"Background\\\", \\\"4.1\\\", \\\"2\\\", 1881], [\\\"2\\\", \\\"Background\\\", \\\"text\\\", \\\"OX is a neuropeptide, and the orexinergic system is a major wake-promoting system of the brain.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"Background\\\", \\\"4.1\\\", \\\"2\\\", 1882], [\\\"2\\\", \\\"Background\\\", \\\"text\\\", \\\"Two orexinergic neuropeptides, OX-A and OX-B, have been identified to date.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"Background\\\", \\\"4.1\\\", \\\"2\\\", 1883], [\\\"2\\\", \\\"Background\\\", \\\"text\\\", \\\"The OXs exert effects via 2 types of receptors, the orexin type-1 receptor (OX1R) and the orexin type-2 receptor (OX2R).\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"Background\\\", \\\"4.1\\\", \\\"2\\\", 1884], [\\\"2\\\", \\\"Background\\\", \\\"text\\\", \\\"OX-A has a high affinity for the OX1R and OX2R, and OX-B has a high affinity for the OX2R.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"Background\\\", \\\"4.1\\\", \\\"2\\\", 1885], [\\\"2\\\", \\\"Background\\\", \\\"text\\\", \\\"These 2 OX receptors make distinct contributions to the regulation of arousal.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"Background\\\", \\\"4.1\\\", \\\"2\\\", 1886], [\\\"2\\\", \\\"Background\\\", \\\"text\\\", \\\"OX2Rs in the tuberomammillary nucleus are essential for the maintenance of wakefulness, whereas both receptor types are required for the inhibition of rapid eye movement (REM) sleep [1].\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"Background\\\", \\\"4.1\\\", \\\"2\\\", 1887], [\\\"2\\\", \\\"Background\\\", \\\"text\\\", \\\"OX receptors are G protein\\\\u2013coupled receptors and on activation, OX1R and OX2R couple with Gq protein to increase intracellular calcium ion concentration.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"Background\\\", \\\"4.1\\\", \\\"2\\\", 1888], [\\\"2\\\", \\\"Background\\\", \\\"text\\\", \\\"The pathological loss of orexinergic neurons is associated with the development of NT1 [2].\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"Background\\\", \\\"4.1\\\", \\\"2\\\", 1889], [\\\"2\\\", \\\"Background\\\", \\\"text\\\", \\\"Narcolepsy with cataplexy, or NT1, has been defined by International Classification of Sleep\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"Background\\\", \\\"4.1\\\", \\\"2\\\", 1890], [\\\"2\\\", \\\"Background\\\", \\\"text\\\", \\\"Disorders, 3rd Edition (ICSD-3) criteria [3] as having low levels of OX in the cerebrospinal fluid (~REDACTED~) (\\\\u2264110 pg/mL, or less than one-third of normal levels), resulting from the nearly complete loss of OX-producing neurons.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"Background\\\", \\\"4.1\\\", \\\"2\\\", 1891], [\\\"2\\\", \\\"Background\\\", \\\"text\\\", \\\"In contrast, narcolepsy is characterized by the absence of cataplexy.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"Background\\\", \\\"4.1\\\", \\\"2\\\", 1892], [\\\"2\\\", \\\"Background\\\", \\\"text\\\", \\\"The pathophysiology of NT1 has a presumed, although unproven, autoimmune basis in individuals with a specific genetic predisposition, the most common of which is the human leukocyte antigen (HLA) DQB1*06:02 [4,5].\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"Background\\\", \\\"4.1\\\", \\\"2\\\", 1893], [\\\"2\\\", \\\"Background\\\", \\\"text\\\", \\\"Narcolepsy is a rare, acquired, chronic neurologic disorder that alters sleep-state stability.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"Background\\\", \\\"4.1\\\", \\\"2\\\", 1894], [\\\"2\\\", \\\"Background\\\", \\\"text\\\", \\\"The cardinal symptom of narcolepsy is excessive daytime sleepiness (EDS), described as a sudden overpowering need to sleep during the day normal periods of alertness.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"Background\\\", \\\"4.1\\\", \\\"2\\\", 1895], [\\\"2\\\", \\\"Background\\\", \\\"text\\\", \\\"Intrusion of REM sleep phenomena into wakefulness can also occur.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"Background\\\", \\\"4.1\\\", \\\"2\\\", 1896], [\\\"2\\\", \\\"Background\\\", \\\"text\\\", \\\"These REM-like phenomena may include cataplexy (sudden loss of muscle tone triggered by strong emotions), hypnagogic/hypnopompic hallucinations (hallucinatory phenomenon that can include mental, auditory, tactile or uncinate events typically occurring during at the transitions into and out of sleep), and sleep paralysis (similar to cataplexy, ie, acute onset of muscle atonia accompanied by a somatic feeling of general paralysis, usually occurring during the transition from wakefulness into sleep).\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"Background\\\", \\\"4.1\\\", \\\"2\\\", 1897], [\\\"2\\\", \\\"Background\\\", \\\"text\\\", \\\"Disturbed nighttime sleep (DNS) is a common narcolepsy-related symptom, with difficulty maintaining continuous nocturnal sleep manifested by frequent awakenings with prompt return back into sleep.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"Background\\\", \\\"4.1\\\", \\\"2\\\", 1898], [\\\"2\\\", \\\"Background\\\", \\\"text\\\", \\\"Together, these 5 clinical features (EDS, cataplexy, hypnagogic/hypnopompic hallucinations, sleep paralysis, and DNS) comprise the narcolepsy symptom pentad.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"Background\\\", \\\"4.1\\\", \\\"2\\\", 1899], [\\\"2\\\", \\\"Background\\\", \\\"text\\\", \\\"It has been estimated that only 20% to 30% of patients have all components of the pentad at any one time.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"Background\\\", \\\"4.1\\\", \\\"2\\\", 1900], [\\\"2\\\", \\\"Background\\\", \\\"text\\\", \\\"On the basis of the aforementioned data demonstrating that partial or complete OX deficiency plays an important role in the development of EDS, OX replacement therapy is expected to improve EDS through a pathophysiology-directed mechanism of action.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"Background\\\", \\\"4.1\\\", \\\"2\\\", 1901], [\\\"2\\\", \\\"Background\\\", \\\"text\\\", \\\"A novel drug that acts to help address the deficiency of OX may address the spectrum of narcolepsy symptoms and may have greater efficacy than currently approved drugs for EDS and cataplexy.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"Background\\\", \\\"4.1\\\", \\\"2\\\", 1902], [\\\"2\\\", \\\"Background\\\", \\\"text\\\", \\\"TAK-861 is an orally available, highly selective OX2R agonist being developed by ~REDACTED~ for the treatment of narcolepsy.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"Background\\\", \\\"4.1\\\", \\\"2\\\", 1903], [\\\"2\\\", \\\"Background\\\", \\\"text\\\", \\\"The purpose of this first-in-human (FIH) study is to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamic (PD) of single and multiple oral doses of TAK-861 in healthy non-Japanese and Japanese subjects, healthy elderly (HE) subjects, and subjects with NT1.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"Background\\\", \\\"4.1\\\", \\\"2\\\", 1904], [\\\"2\\\", \\\"Background\\\", \\\"text\\\", \\\"The proposed dose range of TAK-861 to be explored in this FIH study is anticipated to achieve a sufficient range of plasma exposures, with a margin above the predicted pharmacologically active exposures in both healthy and narcolepsy conditions.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"Background\\\", \\\"4.1\\\", \\\"2\\\", 1905], [\\\"2\\\", \\\"Background\\\", \\\"text\\\", \\\"The study includes assessment of TAK-861 ~REDACTED~ concentrations to evaluate CNS penetration relative to systemic exposure in support of dose selection.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"Background\\\", \\\"4.1\\\", \\\"2\\\", 1906], [\\\"2\\\", \\\"Background\\\", \\\"text\\\", \\\"This FIH study also includes a PD/efficacy evaluation in subjects with NT1.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"Background\\\", \\\"4.1\\\", \\\"2\\\", 1907], [\\\"2\\\", \\\"Background\\\", \\\"text\\\", \\\"Overall, the safety and tolerability, PK, and PD information generated in this study will be used to inform the design and dosing regimen selection of subsequent clinical studies of TAK-861.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"Background\\\", \\\"4.1\\\", \\\"2\\\", 1908], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"4.1.1 Summary of Nonclinical Data\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading4\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"Summary of Nonclinical Data\\\", \\\"4.1.1\\\", \\\"3\\\", 1909], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"In an in vitro study using Chinese hamster ovary (CHO)-K1 cells expressing recombinant human OX2R, TAK-861 increased intracellular calcium ion levels in a concentration-dependent manner with half-maximal effective concentration (EC50) of 0.0025 \\\\u00b5mol/L.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"Summary of Nonclinical Data\\\", \\\"4.1.1\\\", \\\"3\\\", 1910], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"In an in vitro study using CHO-K1 cells expressing recombinant human OX1R, TAK-861 showed an agonist activity on human OX1R with an EC50 of 7.5 \\\\u00b5mol/L.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"Summary of Nonclinical Data\\\", \\\"4.1.1\\\", \\\"3\\\", 1911], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"The results of in vitro pharmacology studies showed that TAK-861 is a potent and selective agonist of OX2R with 3000-fold selectivity over OX1R.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"Summary of Nonclinical Data\\\", \\\"4.1.1\\\", \\\"3\\\", 1912], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"TAK-861 was studied in wild type (WT) mice, OX2R KO mice, narcolepsy model OX/ataxin-3 transgenic (TG) mice, and cynomolgus monkeys.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"Summary of Nonclinical Data\\\", \\\"4.1.1\\\", \\\"3\\\", 1913], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"TAK-861 (oral) showed significant arousal effect in OX/ataxin-3 TG mice and their littermate non-TG mice in sleep phase with minimum effective doses of <0.03 and 1 mg/kg, respectively.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"Summary of Nonclinical Data\\\", \\\"4.1.1\\\", \\\"3\\\", 1914], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"The sensitivity of OX/ataxin-3 TG mice for TAK-861 may be more than 30-fold higher compared with that of non-TG mice based on the minimum effective dose.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"Summary of Nonclinical Data\\\", \\\"4.1.1\\\", \\\"3\\\", 1915], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"However, it should be noted that the dose of TAK-861 to induce the same level of wakefulness was demonstrated to be approximately 10-fold lower in OX/ataxin-3 TG mice than in non-TG mice.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"Summary of Nonclinical Data\\\", \\\"4.1.1\\\", \\\"3\\\", 1916], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Importantly, TAK-861 at 10 mg/kg (oral) did not affect wakefulness time in OX2R KO mice in sleep phase.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"Summary of Nonclinical Data\\\", \\\"4.1.1\\\", \\\"3\\\", 1917], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Thus, these results suggest that TAK-861 shows arousal effect through OX2R activation in mice.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"Summary of Nonclinical Data\\\", \\\"4.1.1\\\", \\\"3\\\", 1918], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Moreover, TAK-861 ameliorated the narcolepsy-like symptoms in OX/ataxin-3 TG mice in active phase; TAK-861 at 0.3 and 1 mg/kg (oral) significantly improved fragmentation of wakefulness, and TAK-861 at 1 mg/kg significantly suppressed cataplexy-like episodes in OX/ataxin-3 TG mice.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"Summary of Nonclinical Data\\\", \\\"4.1.1\\\", \\\"3\\\", 1919], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Mice are nocturnal animals with polyphasic sleep/wakefulness structure, whereas nonhuman primates such as cynomolgus monkeys are diurnal animals whose sleep/wake structure is monophasic.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"Summary of Nonclinical Data\\\", \\\"4.1.1\\\", \\\"3\\\", 1920], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"TAK-861 at 1 mg/kg (oral) showed significant arousal effect in cynomolgus monkeys in sleep phase.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"Summary of Nonclinical Data\\\", \\\"4.1.1\\\", \\\"3\\\", 1921], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"These results suggest that TAK-861 shows arousal effect not only in nocturnal mice but also in diurnal nonhuman primates with normal OX levels during their sleep phase.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"Summary of Nonclinical Data\\\", \\\"4.1.1\\\", \\\"3\\\", 1922], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"By restoring OX neurotransmission at the OX2R in the brain, TAK-861 may treat a broader range of symptoms in individuals with NT1.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"Summary of Nonclinical Data\\\", \\\"4.1.1\\\", \\\"3\\\", 1923], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Moreover, arousal effects were also seen in WT mice and nonhuman primates with presumed normal levels of OX, indicating the potential for TAK-861 to also provide clinical benefit for EDS in individuals with narcolepsy type 2 or other disorders associated with EDS for which the needed exposures could be safely reached.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"Summary of Nonclinical Data\\\", \\\"4.1.1\\\", \\\"3\\\", 1924], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"TAK-861 at 10 \\\\u00b5mol/L did not show significant activity on any receptors, ion channels, and enzymes (102 targets in total) in in vitro assays, with the exceptions of cannabinoid CB1 and ~REDACTED~ PR-B (58% and 62% inhibition, respectively).\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"Summary of Nonclinical Data\\\", \\\"4.1.1\\\", \\\"3\\\", 1925], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"In addition, to identify off-target activity profiles, functional activities of TAK-861 on receptors, ion channels, and enzymes (47 targets in total) were evaluated.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"Summary of Nonclinical Data\\\", \\\"4.1.1\\\", \\\"3\\\", 1926], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"TAK-861 did not show significant activity (defined as 50% inhibitory concentration [IC\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"Summary of Nonclinical Data\\\", \\\"4.1.1\\\", \\\"3\\\", 1927], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"50\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"subscript\\\"}, \\\"Introduction\\\", \\\"Summary of Nonclinical Data\\\", \\\"4.1.1\\\", \\\"3\\\", 1928], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"] or EC\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"Summary of Nonclinical Data\\\", \\\"4.1.1\\\", \\\"3\\\", 1929], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"50\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"subscript\\\"}, \\\"Introduction\\\", \\\"Summary of Nonclinical Data\\\", \\\"4.1.1\\\", \\\"3\\\", 1930], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\\u226410 \\\\u03bcmol/L) on any receptors, ion channels, or enzymes tested except for cannabinoid CB1 antagonistic activity (IC\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"Summary of Nonclinical Data\\\", \\\"4.1.1\\\", \\\"3\\\", 1931], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"50\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"subscript\\\"}, \\\"Introduction\\\", \\\"Summary of Nonclinical Data\\\", \\\"4.1.1\\\", \\\"3\\\", 1932], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"of 3.2 \\\\u03bcmol/L).\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"Summary of Nonclinical Data\\\", \\\"4.1.1\\\", \\\"3\\\", 1933], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"In the evaluation of CNS function in rats, TAK-861 increased body temperature at 20 and 100 mg/kg and decreased at 1000 mg/kg.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"Summary of Nonclinical Data\\\", \\\"4.1.1\\\", \\\"3\\\", 1934], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"It has been reported that OX-A, endogenous peptide ligand, induces both hypothermia and hyperthermia, and OX-B induces hyperthermia in rats [6].\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"Summary of Nonclinical Data\\\", \\\"4.1.1\\\", \\\"3\\\", 1935], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Thus, the changes in body temperature may be related to pharmacological action of TAK-861.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"Summary of Nonclinical Data\\\", \\\"4.1.1\\\", \\\"3\\\", 1936], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Hyperactivity was observed in rats at 20, 100, and 1000 mg/kg.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"Summary of Nonclinical Data\\\", \\\"4.1.1\\\", \\\"3\\\", 1937], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"The hyperactivity is considered to be due to the pharmacological actions of TAK-861, since OX2R agonists have been reported to increase locomotor activity in rats [7].\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"Summary of Nonclinical Data\\\", \\\"4.1.1\\\", \\\"3\\\", 1938], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"The no-observed-effect level (NOEL) on the CNS function in male rats was not determined [8].\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"Summary of Nonclinical Data\\\", \\\"4.1.1\\\", \\\"3\\\", 1939], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"In in vitro cardiovascular assessments, TAK-861 showed no inhibition of human ether-\\\\u00e0-go-go\\\\u2013 related gene current at \\\\u22643 \\\\u00b5g/mL, and the IC\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"Summary of Nonclinical Data\\\", \\\"4.1.1\\\", \\\"3\\\", 1940], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"50\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"subscript\\\"}, \\\"Introduction\\\", \\\"Summary of Nonclinical Data\\\", \\\"4.1.1\\\", \\\"3\\\", 1941], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"value was estimated to be >3 \\\\u00b5g/mL.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"Summary of Nonclinical Data\\\", \\\"4.1.1\\\", \\\"3\\\", 1942], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"In in vivo cardiovascular studies, systolic, diastolic, and mean blood pressure (BP) and left ventricular systolic pressure were increased at \\\\u22653 mg/kg in conscious telemeterized male monkeys.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"Summary of Nonclinical Data\\\", \\\"4.1.1\\\", \\\"3\\\", 1943], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"At 300 mg/kg, increases in LV dP/dt\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"Summary of Nonclinical Data\\\", \\\"4.1.1\\\", \\\"3\\\", 1944], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"max\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"subscript\\\"}, \\\"Introduction\\\", \\\"Summary of Nonclinical Data\\\", \\\"4.1.1\\\", \\\"3\\\", 1945], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"(maximal left ventricular pressure rise) and heart rate (HR) were noted in 1 animal.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"Summary of Nonclinical Data\\\", \\\"4.1.1\\\", \\\"3\\\", 1946], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"These findings were considered nonadverse.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"Summary of Nonclinical Data\\\", \\\"4.1.1\\\", \\\"3\\\", 1947], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"These increases were attributed to the pharmacological action of TAK-861 at OX2R in the CNS, since it has been reported that intracerebroventricular administrations of OX increased arterial BP and HR in rats mainly via OX2R [9].\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"Summary of Nonclinical Data\\\", \\\"4.1.1\\\", \\\"3\\\", 1948], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"A decrease in LV dP/dt\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"Summary of Nonclinical Data\\\", \\\"4.1.1\\\", \\\"3\\\", 1949], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"max\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"subscript\\\"}, \\\"Introduction\\\", \\\"Summary of Nonclinical Data\\\", \\\"4.1.1\\\", \\\"3\\\", 1950], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"was also noted at 300 mg/kg.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"Summary of Nonclinical Data\\\", \\\"4.1.1\\\", \\\"3\\\", 1951], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Although mechanisms for this change was not clear, there were no effects on the other hemodynamic parameters (systemic BP or HR) at the same time points.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"Summary of Nonclinical Data\\\", \\\"4.1.1\\\", \\\"3\\\", 1952], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Therefore, the decreased LV dP/dt\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"Summary of Nonclinical Data\\\", \\\"4.1.1\\\", \\\"3\\\", 1953], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"max\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"subscript\\\"}, \\\"Introduction\\\", \\\"Summary of Nonclinical Data\\\", \\\"4.1.1\\\", \\\"3\\\", 1954], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"was considered to be nonadverse.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"Summary of Nonclinical Data\\\", \\\"4.1.1\\\", \\\"3\\\", 1955], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"In the evaluation of respiratory function in rats, TAK-861 increased respiratory rate (RR) at 20 and 100 mg/kg and minute volume (MV) at 100 mg/kg in rats.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"Summary of Nonclinical Data\\\", \\\"4.1.1\\\", \\\"3\\\", 1956], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"At 1000 mg/kg, no effects were observed on the respiratory system in rats.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"Summary of Nonclinical Data\\\", \\\"4.1.1\\\", \\\"3\\\", 1957], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Increased activity, which is considered due to the pharmacological action of an OX2R agonist, may have induced the increases in RR and MV.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"Summary of Nonclinical Data\\\", \\\"4.1.1\\\", \\\"3\\\", 1958], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"However, it has been reported that OX-A, which acts on both OX receptor types 1 and 2 [8], elicits cardiovascular and respiratory excitation, and administration of OX into the lateral ventricles of the brain induces a rise in RR and tidal volume in urethane-anesthetized mice [10].\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"Summary of Nonclinical Data\\\", \\\"4.1.1\\\", \\\"3\\\", 1959], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Therefore, the increase in RR and MV may relate to the direct pharmacological action of TAK-861 via the CNS.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"Summary of Nonclinical Data\\\", \\\"4.1.1\\\", \\\"3\\\", 1960], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"The NOEL on the respiratory system in male rats was not determined.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"Summary of Nonclinical Data\\\", \\\"4.1.1\\\", \\\"3\\\", 1961], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"TAK-861 has absolute bioavailability of 320.3% at 10 mg/kg in rats and 32.3% at 1 mg/kg in monkeys.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"Summary of Nonclinical Data\\\", \\\"4.1.1\\\", \\\"3\\\", 1962], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"The terminal phase half-life after IV administration was 0.7 hours in rats and 3.5 hours in monkeys.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"Summary of Nonclinical Data\\\", \\\"4.1.1\\\", \\\"3\\\", 1963], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"TAK-861 has high permeability and is not a substrate for P-glycoprotein and breast cancer resistance protein.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"Summary of Nonclinical Data\\\", \\\"4.1.1\\\", \\\"3\\\", 1964], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Plasma protein binding of [3H]TAK-861 was 96.2% to 97.8% and was concentration-independent in monkeys and humans and slightly concentration-dependent in rats.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"Summary of Nonclinical Data\\\", \\\"4.1.1\\\", \\\"3\\\", 1965], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"An in vitro study with human hepatocytes showed that TAK-861 was metabolized by cytochrome P450 (CYP)s with 100.0% of relative contribution ratio.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"Summary of Nonclinical Data\\\", \\\"4.1.1\\\", \\\"3\\\", 1966], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"In addition, an in vitro metabolism study with CYP-expressing microsomes (CYP1A2, 2B6, 2C8, 2C9, 2C19, 2D6, and 3A4) showed that TAK-861 was mainly metabolized by CYP3A4 and to a lesser degree by CYP2C9 and 2D6.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"Summary of Nonclinical Data\\\", \\\"4.1.1\\\", \\\"3\\\", 1967], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Therefore, TAK-861 is predominantly metabolized by CYP3A4 in human hepatocytes.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"Summary of Nonclinical Data\\\", \\\"4.1.1\\\", \\\"3\\\", 1968], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"The potential exists for drug-drug interactions (DDIs) when TAK-861 is coadministered with drugs that are inhibitors or inducers of CYP3A.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"Summary of Nonclinical Data\\\", \\\"4.1.1\\\", \\\"3\\\", 1969], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"In the in vitro induction assay, TAK-861 was an inducer for CYP1A2, 2B6, 2C8, 2C9, and 3A4.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"Summary of Nonclinical Data\\\", \\\"4.1.1\\\", \\\"3\\\", 1970], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"The mean fold changes in the gene expression of CYP1A2, 2B6, 2C8, 2C9, 3A4 at a TAK-861 concentration of 30 \\\\u00b5mol/L were 2.55, 4.47, 4.42, 2.78, and 36.3, respectively.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"Summary of Nonclinical Data\\\", \\\"4.1.1\\\", \\\"3\\\", 1971], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"TAK-861 directly inhibited CYP2C8, 2C9, 2C19, 2D6, and 3A4/5 (~REDACTED~ 1'-hydroxylation) with IC\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"Summary of Nonclinical Data\\\", \\\"4.1.1\\\", \\\"3\\\", 1972], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"50\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"subscript\\\"}, \\\"Introduction\\\", \\\"Summary of Nonclinical Data\\\", \\\"4.1.1\\\", \\\"3\\\", 1973], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"s of 21, 18, 13, 4.6, and 18 \\\\u00b5mol/L, respectively.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"Summary of Nonclinical Data\\\", \\\"4.1.1\\\", \\\"3\\\", 1974], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"TAK-861 did not show direct inhibition of CYP1A2, 2B6, and 3A4 (~REDACTED~ 6\\\\u03b2-hydroxylation) (IC\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"Summary of Nonclinical Data\\\", \\\"4.1.1\\\", \\\"3\\\", 1975], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"50\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"subscript\\\"}, \\\"Introduction\\\", \\\"Summary of Nonclinical Data\\\", \\\"4.1.1\\\", \\\"3\\\", 1976], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"of >30 \\\\u00b5mol/L).\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"Summary of Nonclinical Data\\\", \\\"4.1.1\\\", \\\"3\\\", 1977], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"For CYP3A4/5, the maximal inactivation rate constant (k\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"Summary of Nonclinical Data\\\", \\\"4.1.1\\\", \\\"3\\\", 1978], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"inact\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"subscript\\\"}, \\\"Introduction\\\", \\\"Summary of Nonclinical Data\\\", \\\"4.1.1\\\", \\\"3\\\", 1979], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\") and 50% of the k\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"Summary of Nonclinical Data\\\", \\\"4.1.1\\\", \\\"3\\\", 1980], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"inact\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"subscript\\\"}, \\\"Introduction\\\", \\\"Summary of Nonclinical Data\\\", \\\"4.1.1\\\", \\\"3\\\", 1981], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"values were 0.05079 min-1 and 11.83 \\\\u03bcmol/L respectively.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"Summary of Nonclinical Data\\\", \\\"4.1.1\\\", \\\"3\\\", 1982], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"These results indicate that TAK-861 had both direct inhibitory effects and time-dependent inhibitory effects on CYP3A4/5 activity and direct inhibitory effects on CYP2C8, 2C9, 2C19, and 2D6 activity.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"Summary of Nonclinical Data\\\", \\\"4.1.1\\\", \\\"3\\\", 1983], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"In vitro transporter inhibition studies were also conducted.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"Summary of Nonclinical Data\\\", \\\"4.1.1\\\", \\\"3\\\", 1984], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"TAK-861 inhibited organic anion transporting polypeptide (OATP)1B1 and OATP1B3 (IC\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"Summary of Nonclinical Data\\\", \\\"4.1.1\\\", \\\"3\\\", 1985], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"50\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"subscript\\\"}, \\\"Introduction\\\", \\\"Summary of Nonclinical Data\\\", \\\"4.1.1\\\", \\\"3\\\", 1986], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"s of 0.910 and 37.7 \\\\u00b5mol/L) and IC\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"Summary of Nonclinical Data\\\", \\\"4.1.1\\\", \\\"3\\\", 1987], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"50\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"subscript\\\"}, \\\"Introduction\\\", \\\"Summary of Nonclinical Data\\\", \\\"4.1.1\\\", \\\"3\\\", 1988], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"values were shifted with preincubation conditions (IC\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"Summary of Nonclinical Data\\\", \\\"4.1.1\\\", \\\"3\\\", 1989], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"50\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"subscript\\\"}, \\\"Introduction\\\", \\\"Summary of Nonclinical Data\\\", \\\"4.1.1\\\", \\\"3\\\", 1990], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"s of 0.372 and 18.0 \\\\u00b5mol/L).\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"Summary of Nonclinical Data\\\", \\\"4.1.1\\\", \\\"3\\\", 1991], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Considering the highest predicted dose and exposure for the efficacy and the DDI potentials evaluated in in vitro assay, TAK-861 may interact with drugs that are substrates of CYP3A4 and OATP1B1.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"Summary of Nonclinical Data\\\", \\\"4.1.1\\\", \\\"3\\\", 1992], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"A definitive 4-week oral gavage toxicity and TK study was conducted in rats at dose levels of 0, 20, 100, and 1000 mg/kg.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"Summary of Nonclinical Data\\\", \\\"4.1.1\\\", \\\"3\\\", 1993], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"All TAK-861 findings noted at all dose levels were considered nonadverse, such as transiently suppressed body weight gain with decreased food consumption, changes in hematology and clinical chemistry parameters with no microscopic correlates, minimal degeneration of ameloblasts in the incisors, microscopic changes in the liver and thyroid indicative of induction of drug-metabolizing enzymes, increased vacuolation in the adrenal cortex, and minimal vacuolation in the interstitial cells of the ovary.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"Summary of Nonclinical Data\\\", \\\"4.1.1\\\", \\\"3\\\", 1994], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"The no-observed-adverse-effect level (NOAEL) was 1000 mg/kg with mean maximum observed plasma concentration (C\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"Summary of Nonclinical Data\\\", \\\"4.1.1\\\", \\\"3\\\", 1995], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"max\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"subscript\\\"}, \\\"Introduction\\\", \\\"Summary of Nonclinical Data\\\", \\\"4.1.1\\\", \\\"3\\\", 1996], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\") and area under the plasma concentration-time curve from time 0 to 24 hours (AUC\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"Summary of Nonclinical Data\\\", \\\"4.1.1\\\", \\\"3\\\", 1997], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"24\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"subscript\\\"}, \\\"Introduction\\\", \\\"Summary of Nonclinical Data\\\", \\\"4.1.1\\\", \\\"3\\\", 1998], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\") values of TAK-861 at the NOAEL on Day 28 were 16,000 ng/mL and 203,000 h*ng/mL (males) and 32,200 ng/mL and 537,000 h*ng/mL (females), respectively.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"Summary of Nonclinical Data\\\", \\\"4.1.1\\\", \\\"3\\\", 1999], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"A definitive 4-week oral gavage toxicity and TK study was conducted in monkeys at dose levels of 0, 30, 100, and 300 mg/kg.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"Summary of Nonclinical Data\\\", \\\"4.1.1\\\", \\\"3\\\", 2000], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Although several TAK-861\\\\u2013related findings, such as increased white blood cell, neutrophil, and basophil counts in 1 male, increased triglyceride, and hepatic changes indicative of induction of drug-metabolizing enzymes, were noted, they were considered to be nonadverse.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"Summary of Nonclinical Data\\\", \\\"4.1.1\\\", \\\"3\\\", 2001], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Therefore, it was concluded that the NOAEL was 300 mg/kg.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"Summary of Nonclinical Data\\\", \\\"4.1.1\\\", \\\"3\\\", 2002], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"The dose was associated with mean C\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"Summary of Nonclinical Data\\\", \\\"4.1.1\\\", \\\"3\\\", 2003], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"max\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"subscript\\\"}, \\\"Introduction\\\", \\\"Summary of Nonclinical Data\\\", \\\"4.1.1\\\", \\\"3\\\", 2004], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"and AUC\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"Summary of Nonclinical Data\\\", \\\"4.1.1\\\", \\\"3\\\", 2005], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"24\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"subscript\\\"}, \\\"Introduction\\\", \\\"Summary of Nonclinical Data\\\", \\\"4.1.1\\\", \\\"3\\\", 2006], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"values of TAK-861 on Day 28 of 15,700 ng/mL and 181,000 h*ng/mL (males) and 23,100 ng/mL and 306,000 h*ng/mL (females), respectively.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"Summary of Nonclinical Data\\\", \\\"4.1.1\\\", \\\"3\\\", 2007], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"TAK-861 is a fluoride-containing molecule, and defluorinated metabolites have been detected in vitro.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"Summary of Nonclinical Data\\\", \\\"4.1.1\\\", \\\"3\\\", 2008], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"It is known that an excess of fluoride can cause impairment of tooth enamel formation by acting on ameloblasts and in 4-week toxicity studies in rats and monkeys plasma fluoride levels were increased dose dependently.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"Summary of Nonclinical Data\\\", \\\"4.1.1\\\", \\\"3\\\", 2009], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"TAK-861 was not mutagenic or genotoxic in a bacterial reversion assay.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"Summary of Nonclinical Data\\\", \\\"4.1.1\\\", \\\"3\\\", 2010], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"TAK-861 was considered to have genotoxic potential to induce micronucleus in vitro after the frequencies of micronucleate cells were increased following continuous treatment at 60 \\\\u00b5g/mL without metabolic activation.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"Summary of Nonclinical Data\\\", \\\"4.1.1\\\", \\\"3\\\", 2011], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"However, genotoxic effects were not observed in vivo following a bone marrow micronucleus assay and a comet assay in the liver in male rats (2-day administration, dose levels of 0, 250, 500, 1000, and 2000 mg/kg).\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"Summary of Nonclinical Data\\\", \\\"4.1.1\\\", \\\"3\\\", 2012], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"TAK-861 absorption of UV-visible light at 290 to 700 nm was below the threshold for direct phototoxicity; thus, no direct phototoxicity is anticipated.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"Summary of Nonclinical Data\\\", \\\"4.1.1\\\", \\\"3\\\", 2013], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"For more information on TAK-861, please refer to the investigator\\\\u2019s brochure.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"Summary of Nonclinical Data\\\", \\\"4.1.1\\\", \\\"3\\\", 2014], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"4.1.2 Summary of Effects in Humans\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading4\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"Summary of Effects in Humans\\\", \\\"4.1.2\\\", \\\"3\\\", 2015], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"TAK-861 has not been studied in humans before this study.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"Summary of Effects in Humans\\\", \\\"4.1.2\\\", \\\"3\\\", 2016], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"4.2 Rationale for the Proposed Study\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading2\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"Rationale for the Proposed Study\\\", \\\"4.2\\\", \\\"2\\\", 2017], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"TAK-861 is a highly selective, orally bioavailable, and potent OX2R agonist.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"Rationale for the Proposed Study\\\", \\\"4.2\\\", \\\"2\\\", 2018], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Nonclinical pharmacology studies have demonstrated that TAK-861 produces arousal effects in hypersomnolent states both in animals with OX deficiency (mice) and in animals without OX deficiency (mice and cynomolgus monkeys).\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"Rationale for the Proposed Study\\\", \\\"4.2\\\", \\\"2\\\", 2019], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"The primary objective of this FIH study is to evaluate the safety, tolerability, and PK of single and multiple oral doses of TAK-861 in healthy adult, HE, and healthy non-Japanese subjects and in subjects with NT1.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"Rationale for the Proposed Study\\\", \\\"4.2\\\", \\\"2\\\", 2020], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"The available nonclinical pharmacology, PK, and toxicology studies support the proposed first escalating single and multiple dose study of TAK-861 in humans.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"Rationale for the Proposed Study\\\", \\\"4.2\\\", \\\"2\\\", 2021], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"The present study follows the Pharmaceuticals and\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"Rationale for the Proposed Study\\\", \\\"4.2\\\", \\\"2\\\", 2022], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Medical Devices Agency, European Medicines Agency, and Food and Drug Administration (~REDACTED~) FIH clinical study guidance to assess the safety, tolerability, and PK of TAK-861 administered orally in healthy subjects and subjects with narcolepsy.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"Rationale for the Proposed Study\\\", \\\"4.2\\\", \\\"2\\\", 2023], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"4.3 Benefit-Risk Profile\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading2\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"Benefit-Risk Profile\\\", \\\"4.3\\\", \\\"2\\\", 2024], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"To explore potential wake-promoting effects in humans, this FIH study will include safety/tolerability and PK evaluations in healthy adult and elderly subjects as well as safety/tolerability and efficacy evaluations in subjects with NT1 after single and multiple dose oral administration of TAK-861.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"Benefit-Risk Profile\\\", \\\"4.3\\\", \\\"2\\\", 2025], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Together, the safety, tolerability, PK, and PD information collected from this study will be used to inform the design and dosing regimen selection of subsequent clinical studies of TAK-861.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"Benefit-Risk Profile\\\", \\\"4.3\\\", \\\"2\\\", 2026], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Due to the limited treatment period of this study, little benefit is expected for subjects with NT1 in this study other than receiving medical examinations to obtain information about their overall health conditions, although nonclinical pharmacology studies suggested potential wake promoting effects as well as anticataplexy effect of TAK-861.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"Benefit-Risk Profile\\\", \\\"4.3\\\", \\\"2\\\", 2027], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"It is possible that the information obtained from the present study will become beneficial to patients with narcolepsy in the future.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"Benefit-Risk Profile\\\", \\\"4.3\\\", \\\"2\\\", 2028], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"There is no benefit for healthy subjects in this study.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"Benefit-Risk Profile\\\", \\\"4.3\\\", \\\"2\\\", 2029], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Safety data informing the risk profile for TAK-861 is limited to the mode of action, and data from nonclinical studies.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"Benefit-Risk Profile\\\", \\\"4.3\\\", \\\"2\\\", 2030], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Based on nonclinical safety pharmacology data, the primary potential risk is increased BP. A safety pharmacology study of TAK-861 in monkeys found mild to moderate degrees of transient elevated BP at all doses tested on initial dosing.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"Benefit-Risk Profile\\\", \\\"4.3\\\", \\\"2\\\", 2031], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"The cardiovascular effects noted in nonclinical models with OX2R agonists are considered potentially on-mechanism based on published literature [9].\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"Benefit-Risk Profile\\\", \\\"4.3\\\", \\\"2\\\", 2032], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"To mitigate this risk, BP will be measured frequently in this study; stopping rules for individual subjects, cohorts, and the overall study as well as the treatment of increased BP have been established and are noted in Section 6.5.5.1, Section 6.5.5.2, and Section 7.4.3.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"Benefit-Risk Profile\\\", \\\"4.3\\\", \\\"2\\\", 2033], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Other effects in nonclinical studies included vomiting at high doses.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"Benefit-Risk Profile\\\", \\\"4.3\\\", \\\"2\\\", 2034], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"These findings were considered nonadverse, and monitoring for these events is a standard part of phase 1 studies.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"Benefit-Risk Profile\\\", \\\"4.3\\\", \\\"2\\\", 2035], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"On the basis of these nonclinical data, potential risks include insomnia, BP increase, HR increase, etc.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"Benefit-Risk Profile\\\", \\\"4.3\\\", \\\"2\\\", 2036], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"The principal mitigation strategy for these risks includes appropriate selection of the study population; use of the inpatient ~REDACTED~ unit setting, which permits close monitoring and rapid institution of appropriate care as needed; appropriate specified monitoring procedures; and use of experienced staff trained in study procedures.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"Benefit-Risk Profile\\\", \\\"4.3\\\", \\\"2\\\", 2037], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"In addition, BP and pulse rate will be frequently monitored for all subjects.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"Benefit-Risk Profile\\\", \\\"4.3\\\", \\\"2\\\", 2038], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Cardiovascular effects will be evaluated in healthy subjects using time-matched BP and pulse rate assessments and Holter electrocardiogram (ECG) assessments.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"Benefit-Risk Profile\\\", \\\"4.3\\\", \\\"2\\\", 2039], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Stopping rules have also been created for severe or serious insomnia.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"Benefit-Risk Profile\\\", \\\"4.3\\\", \\\"2\\\", 2040], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Actigraphy, Holter ECG, and ambulatory blood pressure monitoring (ABPM) have been also included in the study to obtain continuous safety data in case these data needs to be referred for dose selection in subsequent cohorts.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"Benefit-Risk Profile\\\", \\\"4.3\\\", \\\"2\\\", 2041], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"On the basis of the emerging data from other compounds with the same mechanism of action showing a tendency of increased frequency of bladder-related adverse events (AEs), a checklist to collect bladder condition\\\\u2013related symptoms has been added to capture any bladder discomfort subjects may experience during this study.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"Benefit-Risk Profile\\\", \\\"4.3\\\", \\\"2\\\", 2042], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Because TAK-861 is a fluoride-containing molecule and defluorination via metabolism is thus of interest, plasma fluoride levels will also be assessed before dosing and at the end of dosing in selected study cohorts.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"Benefit-Risk Profile\\\", \\\"4.3\\\", \\\"2\\\", 2043], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Overall, there is minimal risk associated with the noninvasive procedures planned for this study.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"Benefit-Risk Profile\\\", \\\"4.3\\\", \\\"2\\\", 2044], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Potential risks relating to noninvasive study procedures include the following:\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"Benefit-Risk Profile\\\", \\\"4.3\\\", \\\"2\\\", 2045], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\\u2022 Acute hypersensitivity/anaphylactic reactions to new chemical entities are always a possible risk in any clinical study.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"Benefit-Risk Profile\\\", \\\"4.3\\\", \\\"2\\\", 2046], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Appropriate procedures will be used to manage such possible risks.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"Benefit-Risk Profile\\\", \\\"4.3\\\", \\\"2\\\", 2047], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\\u2022 Study procedure-specific risks include issues relating to blood collection for safety and PK assessments (eg, venipuncture may cause bruising).\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"Benefit-Risk Profile\\\", \\\"4.3\\\", \\\"2\\\", 2048], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"This study also includes continuous ~REDACTED~ collection, an invasive procedure.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"Benefit-Risk Profile\\\", \\\"4.3\\\", \\\"2\\\", 2049], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"This is an established procedure with the typical risks associated with lumbar puncture.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"Benefit-Risk Profile\\\", \\\"4.3\\\", \\\"2\\\", 2050], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"There is a very low risk of CNS infection.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"Benefit-Risk Profile\\\", \\\"4.3\\\", \\\"2\\\", 2051], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Subjects may experience low back pain during needle insertion and for a brief time after the procedure and postural headache after the procedure.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"Benefit-Risk Profile\\\", \\\"4.3\\\", \\\"2\\\", 2052], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Very rare risks include the risk of meningitis, nerve root injury, and hematoma resulting in spinal cord compression.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"Benefit-Risk Profile\\\", \\\"4.3\\\", \\\"2\\\", 2053], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"These risks will be detailed in the informed consent documentation.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"Benefit-Risk Profile\\\", \\\"4.3\\\", \\\"2\\\", 2054], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Review of available data supports a favorable benefit-risk ratio for this study of TAK-861.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"Benefit-Risk Profile\\\", \\\"4.3\\\", \\\"2\\\", 2055], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"To date, the observed nonclinical safety data for TAK-861, including mild and manageable AEs, are acceptable.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"Benefit-Risk Profile\\\", \\\"4.3\\\", \\\"2\\\", 2056], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Given the lack of reproductive toxicology data for TAK-861, women of childbearing potential will not be included for cohorts with healthy subjects.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"Benefit-Risk Profile\\\", \\\"4.3\\\", \\\"2\\\", 2057], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Considering NT1 is uncommon disease and limited number of patients with NT1 are available to participate in clinical studies, inclusion of women of childbearing potential may be considered for NT1 subject cohorts once reproductive toxicology study data for TAK-861 is available.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"Benefit-Risk Profile\\\", \\\"4.3\\\", \\\"2\\\", 2058], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"When the reproductive toxicology data become available, inclusion of women of childbearing potential in the NT1 cohorts in the study will be re-evaluated.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"Benefit-Risk Profile\\\", \\\"4.3\\\", \\\"2\\\", 2059], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"5.0 STUDY OBJECTIVES AND ENDPOINTS\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading1\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"STUDY OBJECTIVES AND ENDPOINTS\\\", \\\"5.0\\\", \\\"1\\\", 2060], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"5.1 Study Objectives\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading2\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"Study Objectives\\\", \\\"5.1\\\", \\\"2\\\", 2061], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"5.1.1 Study Primary Objective\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading4\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"Study Primary Objective\\\", \\\"5.1.1\\\", \\\"3\\\", 2062], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Segoe UI Symbol\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"Study Primary Objective\\\", \\\"5.1.1\\\", \\\"3\\\", 2063], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"To investigate the safety and tolerability of TAK-861 when single and/or multiple oral doses are administered to healthy adults, HE subjects, and subjects with NT1.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"Study Primary Objective\\\", \\\"5.1.1\\\", \\\"3\\\", 2064], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"5.1.2 Study Secondary Objectives\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading4\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"Study Secondary Objectives\\\", \\\"5.1.2\\\", \\\"3\\\", 2065], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"The secondary objectives of the study are:\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"Study Secondary Objectives\\\", \\\"5.1.2\\\", \\\"3\\\", 2066], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\\u2022 To investigate the PK of TAK-861 when single and/or multiple oral doses of suspension and/or tablet formulation are administered to healthy adults\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"Study Secondary Objectives\\\", \\\"5.1.2\\\", \\\"3\\\", 2067], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\\u2022 To investigate the PK of TAK-861 when multiple oral doses of tablet formulation are administered to HE subjects, and subjects with NT1.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"Study Secondary Objectives\\\", \\\"5.1.2\\\", \\\"3\\\", 2068], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\\u2022 To assess the effect of food on the PK of the TAK-861 tablet.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"Study Secondary Objectives\\\", \\\"5.1.2\\\", \\\"3\\\", 2069], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"5.1.3 Study Additional/Exploratory Objectives\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading4\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"Study Additional/Exploratory Objectives\\\", \\\"5.1.3\\\", \\\"3\\\", 2070], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Exploratory objectives of this study include:\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"Study Additional/Exploratory Objectives\\\", \\\"5.1.3\\\", \\\"3\\\", 2071], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\\u2022 To identify if subjects are experiencing any bladder related discomfort during the study period.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"Study Additional/Exploratory Objectives\\\", \\\"5.1.3\\\", \\\"3\\\", 2072], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\\u2022 To explore TAK-861 effects on concentrations of endogenous biomarkers (coproporphyrin [CP] I and CPIII) for OATP1B1 and OATP1B3 activities.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"Study Additional/Exploratory Objectives\\\", \\\"5.1.3\\\", \\\"3\\\", 2073], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\\u2022 To explore TAK-861 effects on 4\\\\u03b2-hydroxycholesterol/cholesterol ratio for CYP3A4/5 inductive activity.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"Study Additional/Exploratory Objectives\\\", \\\"5.1.3\\\", \\\"3\\\", 2074], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Exploratory objectives applicable to Parts B through F:\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"Study Additional/Exploratory Objectives\\\", \\\"5.1.3\\\", \\\"3\\\", 2075], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\\u2022 To evaluate accelerometry (actigraphy) for usefulness to evaluate daytime activity and sleep.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"Study Additional/Exploratory Objectives\\\", \\\"5.1.3\\\", \\\"3\\\", 2076], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\\u2022 To investigate the effect of TAK-861 on daytime sleepiness, as assessed by the Karolinska Sleepiness Scale (KSS).\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"Study Additional/Exploratory Objectives\\\", \\\"5.1.3\\\", \\\"3\\\", 2077], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Exploratory objectives applicable to Part D:\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"Study Additional/Exploratory Objectives\\\", \\\"5.1.3\\\", \\\"3\\\", 2078], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\\u2022 To investigate the PD of TAK-861, as assessed by Maintenance of Wakefulness Test (MWT).\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"Study Additional/Exploratory Objectives\\\", \\\"5.1.3\\\", \\\"3\\\", 2079], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\\u2022 To investigate the PD of TAK-861, as assessed by the Epworth Sleepiness Scale (ESS).\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"Study Additional/Exploratory Objectives\\\", \\\"5.1.3\\\", \\\"3\\\", 2080], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\\u2022 To investigate the PD of TAK-861, as assessed by weekly cataplexy rate (WCR).\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"Study Additional/Exploratory Objectives\\\", \\\"5.1.3\\\", \\\"3\\\", 2081], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\\u2022 To assess the effect of TAK-861 on daytime sleepiness, cataplexy, and overall narcolepsy symptoms as measured by Patient Global Impression of Improvement (PGI-I), Clinician Global Impression of Improvement (CGI-I), Patient Global Impression of Severity (PGI-S), and Clinician Global Impression of Severity (CGI-S) scales.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"Study Additional/Exploratory Objectives\\\", \\\"5.1.3\\\", \\\"3\\\", 2082], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\\u2022 To assess the effects of TAK-861 on REM sleep-related abnormalities, including hypnagogic/hypnopompic hallucination, sleep paralysis, and nocturnal awakenings, as reported by the subject.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"Study Additional/Exploratory Objectives\\\", \\\"5.1.3\\\", \\\"3\\\", 2083], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\\u2022 To assess the effects of TAK-861 on sleep ~REDACTED~ by polysomnography (PSG) measures and/or portable electroencephalography (EEG).\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"Study Additional/Exploratory Objectives\\\", \\\"5.1.3\\\", \\\"3\\\", 2084], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\\u2022 To assess the effects of TAK-861 on attention, vigilance, and memory, as measured by the cognitive tests (Sustained Attention to Response Test [SART] and ~REDACTED~ ~REDACTED~ Learning [CPAL]).\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"Study Additional/Exploratory Objectives\\\", \\\"5.1.3\\\", \\\"3\\\", 2085], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\\u2022 To investigate the impact of TAK-861 on overall narcolepsy symptoms and daily functioning of subjects, as assessed by the Pilot NT1 Items questionnaire.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"Study Additional/Exploratory Objectives\\\", \\\"5.1.3\\\", \\\"3\\\", 2086], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\\u2022 To investigate the impact of TAK-861 on quality of life (QOL) of subjects, as assessed by the EuroQoL-5 Dimensions-5 Levels (EQ-5D-5L) scale.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"Study Additional/Exploratory Objectives\\\", \\\"5.1.3\\\", \\\"3\\\", 2087], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\\u2022 To assess the PK-PD relationship of TAK-861 for selected efficacy measures in subjects with NT1.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"Study Additional/Exploratory Objectives\\\", \\\"5.1.3\\\", \\\"3\\\", 2088], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"The exploratory objectives applicable to Part F:\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"Study Additional/Exploratory Objectives\\\", \\\"5.1.3\\\", \\\"3\\\", 2089], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\\u2022 To assess OX levels.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"Study Additional/Exploratory Objectives\\\", \\\"5.1.3\\\", \\\"3\\\", 2090], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"The additional safety objectives:\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"Study Additional/Exploratory Objectives\\\", \\\"5.1.3\\\", \\\"3\\\", 2091], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\\u2022 To assess the effects of TAK-861 on BP, pulse rate, and ECG parameters (all parts).\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"Study Additional/Exploratory Objectives\\\", \\\"5.1.3\\\", \\\"3\\\", 2092], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\\u2022 To assess the effect of TAK-861 on Holter ECG parameters (only collected in Parts A, B, C, and E).\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"Study Additional/Exploratory Objectives\\\", \\\"5.1.3\\\", \\\"3\\\", 2093], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"5.2 Endpoints\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading2\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"Endpoints\\\", \\\"5.2\\\", \\\"2\\\", 2094], [\\\"3\\\", \\\"Primary Endpoint(s)\\\", \\\"header\\\", \\\"5.2.1 Primary Endpoint\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading4\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"Primary Endpoint\\\", \\\"5.2.1\\\", \\\"3\\\", 2095], [\\\"3\\\", \\\"Primary Endpoint(s)\\\", \\\"text\\\", \\\"The primary endpoints of the study are:\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"Primary Endpoint\\\", \\\"5.2.1\\\", \\\"3\\\", 2096], [\\\"3\\\", \\\"Primary Endpoint(s)\\\", \\\"text\\\", \\\"\\\\u2022 Number of subjects with at least 1 treatment-emergent adverse event (TEAE) postdose.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"Primary Endpoint\\\", \\\"5.2.1\\\", \\\"3\\\", 2097], [\\\"3\\\", \\\"Primary Endpoint(s)\\\", \\\"text\\\", \\\"\\\\u2022 Number of subjects with at least 1 markedly abnormal value (MAV) for laboratory assessments postdose.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"Primary Endpoint\\\", \\\"5.2.1\\\", \\\"3\\\", 2098], [\\\"3\\\", \\\"Primary Endpoint(s)\\\", \\\"text\\\", \\\"\\\\u2022 Number of subjects with at least 1 MAV for vital signs postdose.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"Primary Endpoint\\\", \\\"5.2.1\\\", \\\"3\\\", 2099], [\\\"3\\\", \\\"Primary Endpoint(s)\\\", \\\"text\\\", \\\"\\\\u2022 Number of subjects with at least 1 MAV for ECGs postdose.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"Primary Endpoint\\\", \\\"5.2.1\\\", \\\"3\\\", 2100], [\\\"3\\\", \\\"Secondary Endpoint(s)\\\", \\\"header\\\", \\\"5.2.2 Secondary Endpoints\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading4\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"Secondary Endpoints\\\", \\\"5.2.2\\\", \\\"3\\\", 2101], [\\\"3\\\", \\\"Secondary Endpoint(s)\\\", \\\"text\\\", \\\"Secondary endpoints include:\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"Secondary Endpoints\\\", \\\"5.2.2\\\", \\\"3\\\", 2102], [\\\"3\\\", \\\"Secondary Endpoint(s)\\\", \\\"text\\\", \\\"\\\\u2022 PK parameters of TAK-861 in healthy subjects (Parts A, B, C, E, and F) after a single dose (Day 1 [fasted] or Day 15 [fed]: C\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"Secondary Endpoints\\\", \\\"5.2.2\\\", \\\"3\\\", 2103], [\\\"3\\\", \\\"Secondary Endpoint(s)\\\", \\\"text\\\", \\\"max\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"subscript\\\"}, \\\"Introduction\\\", \\\"Secondary Endpoints\\\", \\\"5.2.2\\\", \\\"3\\\", 2104], [\\\"3\\\", \\\"Secondary Endpoint(s)\\\", \\\"text\\\", \\\"time of first occurrence of C\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"Secondary Endpoints\\\", \\\"5.2.2\\\", \\\"3\\\", 2105], [\\\"3\\\", \\\"Secondary Endpoint(s)\\\", \\\"text\\\", \\\"max\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"subscript\\\"}, \\\"Introduction\\\", \\\"Secondary Endpoints\\\", \\\"5.2.2\\\", \\\"3\\\", 2106], [\\\"3\\\", \\\"Secondary Endpoint(s)\\\", \\\"text\\\", \\\"[t\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"Secondary Endpoints\\\", \\\"5.2.2\\\", \\\"3\\\", 2107], [\\\"3\\\", \\\"Secondary Endpoint(s)\\\", \\\"text\\\", \\\"max\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"subscript\\\"}, \\\"Introduction\\\", \\\"Secondary Endpoints\\\", \\\"5.2.2\\\", \\\"3\\\", 2108], [\\\"3\\\", \\\"Secondary Endpoint(s)\\\", \\\"text\\\", \\\"], area under the plasma concentration-time from time 0 to time of the last quantifiable concentration [AUC\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"Secondary Endpoints\\\", \\\"5.2.2\\\", \\\"3\\\", 2109], [\\\"3\\\", \\\"Secondary Endpoint(s)\\\", \\\"text\\\", \\\"last\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"subscript\\\"}, \\\"Introduction\\\", \\\"Secondary Endpoints\\\", \\\"5.2.2\\\", \\\"3\\\", 2110], [\\\"3\\\", \\\"Secondary Endpoint(s)\\\", \\\"text\\\", \\\"], area under the plasma concentration-time curve from time 0 to infinity [AUC\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"Secondary Endpoints\\\", \\\"5.2.2\\\", \\\"3\\\", 2111], [\\\"3\\\", \\\"Secondary Endpoint(s)\\\", \\\"text\\\", \\\"\\\\u221e\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"subscript\\\"}, \\\"Introduction\\\", \\\"Secondary Endpoints\\\", \\\"5.2.2\\\", \\\"3\\\", 2112], [\\\"3\\\", \\\"Secondary Endpoint(s)\\\", \\\"text\\\", \\\"], and terminal disposition-phase half-life).\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"Secondary Endpoints\\\", \\\"5.2.2\\\", \\\"3\\\", 2113], [\\\"3\\\", \\\"Secondary Endpoint(s)\\\", \\\"text\\\", \\\"\\\\u2022 PK parameters of TAK-861 in healthy subjects (Parts B, C, E, and F) after multiple doses (Day 10 or Day 14 or Day 19: C\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"Secondary Endpoints\\\", \\\"5.2.2\\\", \\\"3\\\", 2114], [\\\"3\\\", \\\"Secondary Endpoint(s)\\\", \\\"text\\\", \\\"max\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"subscript\\\"}, \\\"Introduction\\\", \\\"Secondary Endpoints\\\", \\\"5.2.2\\\", \\\"3\\\", 2115], [\\\"3\\\", \\\"Secondary Endpoint(s)\\\", \\\"text\\\", \\\"t\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"Secondary Endpoints\\\", \\\"5.2.2\\\", \\\"3\\\", 2116], [\\\"3\\\", \\\"Secondary Endpoint(s)\\\", \\\"text\\\", \\\"max\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"subscript\\\"}, \\\"Introduction\\\", \\\"Secondary Endpoints\\\", \\\"5.2.2\\\", \\\"3\\\", 2117], [\\\"3\\\", \\\"Secondary Endpoint(s)\\\", \\\"text\\\", \\\"area under the plasma concentration-time curve during a dosing interval [AUC\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"Secondary Endpoints\\\", \\\"5.2.2\\\", \\\"3\\\", 2118], [\\\"3\\\", \\\"Secondary Endpoint(s)\\\", \\\"text\\\", \\\"\\\\u03c4\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"subscript\\\"}, \\\"Introduction\\\", \\\"Secondary Endpoints\\\", \\\"5.2.2\\\", \\\"3\\\", 2119], [\\\"3\\\", \\\"Secondary Endpoint(s)\\\", \\\"text\\\", \\\"], and accumulation ratio).\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"Secondary Endpoints\\\", \\\"5.2.2\\\", \\\"3\\\", 2120], [\\\"3\\\", \\\"Secondary Endpoint(s)\\\", \\\"text\\\", \\\"\\\\u2022 PK parameters of TAK-861 in subjects with NT1 (Part D) after a single dose (Day 1: C\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"Secondary Endpoints\\\", \\\"5.2.2\\\", \\\"3\\\", 2121], [\\\"3\\\", \\\"Secondary Endpoint(s)\\\", \\\"text\\\", \\\"max\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"subscript\\\"}, \\\"Introduction\\\", \\\"Secondary Endpoints\\\", \\\"5.2.2\\\", \\\"3\\\", 2122], [\\\"3\\\", \\\"Secondary Endpoint(s)\\\", \\\"text\\\", \\\"t\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"Secondary Endpoints\\\", \\\"5.2.2\\\", \\\"3\\\", 2123], [\\\"3\\\", \\\"Secondary Endpoint(s)\\\", \\\"text\\\", \\\"max\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"subscript\\\"}, \\\"Introduction\\\", \\\"Secondary Endpoints\\\", \\\"5.2.2\\\", \\\"3\\\", 2124], [\\\"3\\\", \\\"Secondary Endpoint(s)\\\", \\\"text\\\", \\\"AUC\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"Secondary Endpoints\\\", \\\"5.2.2\\\", \\\"3\\\", 2125], [\\\"3\\\", \\\"Secondary Endpoint(s)\\\", \\\"text\\\", \\\"last\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"subscript\\\"}, \\\"Introduction\\\", \\\"Secondary Endpoints\\\", \\\"5.2.2\\\", \\\"3\\\", 2126], [\\\"3\\\", \\\"Secondary Endpoint(s)\\\", \\\"text\\\", \\\") and multiple doses (Day 14: C\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"Secondary Endpoints\\\", \\\"5.2.2\\\", \\\"3\\\", 2127], [\\\"3\\\", \\\"Secondary Endpoint(s)\\\", \\\"text\\\", \\\"max\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"subscript\\\"}, \\\"Introduction\\\", \\\"Secondary Endpoints\\\", \\\"5.2.2\\\", \\\"3\\\", 2128], [\\\"3\\\", \\\"Secondary Endpoint(s)\\\", \\\"text\\\", \\\"t\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"Secondary Endpoints\\\", \\\"5.2.2\\\", \\\"3\\\", 2129], [\\\"3\\\", \\\"Secondary Endpoint(s)\\\", \\\"text\\\", \\\"max\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"subscript\\\"}, \\\"Introduction\\\", \\\"Secondary Endpoints\\\", \\\"5.2.2\\\", \\\"3\\\", 2130], [\\\"3\\\", \\\"Secondary Endpoint(s)\\\", \\\"text\\\", \\\"AUC\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"Secondary Endpoints\\\", \\\"5.2.2\\\", \\\"3\\\", 2131], [\\\"3\\\", \\\"Secondary Endpoint(s)\\\", \\\"text\\\", \\\"\\\\u03c4\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"subscript\\\"}, \\\"Introduction\\\", \\\"Secondary Endpoints\\\", \\\"5.2.2\\\", \\\"3\\\", 2132], [\\\"3\\\", \\\"Secondary Endpoint(s)\\\", \\\"text\\\", \\\").\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"Secondary Endpoints\\\", \\\"5.2.2\\\", \\\"3\\\", 2133], [\\\"3\\\", \\\"Tertiary/Exploratory Endpoint(s)\\\", \\\"header\\\", \\\"5.2.3 Additional/Exploratory Endpoints\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading4\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"Additional/Exploratory Endpoints\\\", \\\"5.2.3\\\", \\\"3\\\", 2134], [\\\"3\\\", \\\"Tertiary/Exploratory Endpoint(s)\\\", \\\"text\\\", \\\"Exploratory endpoints will be assessed through the following parameters:\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"Additional/Exploratory Endpoints\\\", \\\"5.2.3\\\", \\\"3\\\", 2135], [\\\"3\\\", \\\"Tertiary/Exploratory Endpoint(s)\\\", \\\"text\\\", \\\"\\\\u2022 Additional PK parameters of TAK-861 from plasma, urine, and ~REDACTED~.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"Additional/Exploratory Endpoints\\\", \\\"5.2.3\\\", \\\"3\\\", 2136], [\\\"3\\\", \\\"Tertiary/Exploratory Endpoint(s)\\\", \\\"text\\\", \\\"Change from baseline in overactive bladder\\\\u2013related symptom bother as evaluated by a checklist.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"Additional/Exploratory Endpoints\\\", \\\"5.2.3\\\", \\\"3\\\", 2137], [\\\"3\\\", \\\"Tertiary/Exploratory Endpoint(s)\\\", \\\"text\\\", \\\"For Parts B and E:\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"Additional/Exploratory Endpoints\\\", \\\"5.2.3\\\", \\\"3\\\", 2138], [\\\"3\\\", \\\"Tertiary/Exploratory Endpoint(s)\\\", \\\"text\\\", \\\"\\\\u2022 The concentration of CPI and CPIII and their PK parameters For Parts B through E:\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"Additional/Exploratory Endpoints\\\", \\\"5.2.3\\\", \\\"3\\\", 2139], [\\\"3\\\", \\\"Tertiary/Exploratory Endpoint(s)\\\", \\\"text\\\", \\\"\\\\u2022 The change of 4\\\\u03b2-hydroxycholesterol/cholesterol ratio after repeated dosing For Parts B through F:\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"Additional/Exploratory Endpoints\\\", \\\"5.2.3\\\", \\\"3\\\", 2140], [\\\"3\\\", \\\"Tertiary/Exploratory Endpoint(s)\\\", \\\"text\\\", \\\"\\\\u2022 Parameters on sleep and wakefulness from wearable devices used in the study.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"Additional/Exploratory Endpoints\\\", \\\"5.2.3\\\", \\\"3\\\", 2141], [\\\"3\\\", \\\"Tertiary/Exploratory Endpoint(s)\\\", \\\"text\\\", \\\"Parameters from continuous accelerometry (actigraphy) monitoring from screening through dosing period.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"Additional/Exploratory Endpoints\\\", \\\"5.2.3\\\", \\\"3\\\", 2142], [\\\"3\\\", \\\"Tertiary/Exploratory Endpoint(s)\\\", \\\"text\\\", \\\"\\\\u2022 Subjective daytime sleepiness using the KSS.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"Additional/Exploratory Endpoints\\\", \\\"5.2.3\\\", \\\"3\\\", 2143], [\\\"3\\\", \\\"Tertiary/Exploratory Endpoint(s)\\\", \\\"text\\\", \\\"For Part D only:\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"Additional/Exploratory Endpoints\\\", \\\"5.2.3\\\", \\\"3\\\", 2144], [\\\"3\\\", \\\"Tertiary/Exploratory Endpoint(s)\\\", \\\"text\\\", \\\"\\\\u2022 Change from baseline in mean sleep latency from 4 trials of MWT to Days 1 and 14.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"Additional/Exploratory Endpoints\\\", \\\"5.2.3\\\", \\\"3\\\", 2145], [\\\"3\\\", \\\"Tertiary/Exploratory Endpoint(s)\\\", \\\"text\\\", \\\"\\\\u2022 Change from baseline in the total score of subjective daytime sleepiness scale, ESS.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"Additional/Exploratory Endpoints\\\", \\\"5.2.3\\\", \\\"3\\\", 2146], [\\\"3\\\", \\\"Tertiary/Exploratory Endpoint(s)\\\", \\\"text\\\", \\\"\\\\u2022 Change from baseline in the WCR as reported in the patient-reported sleep diary.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"Additional/Exploratory Endpoints\\\", \\\"5.2.3\\\", \\\"3\\\", 2147], [\\\"3\\\", \\\"Tertiary/Exploratory Endpoint(s)\\\", \\\"text\\\", \\\"\\\\u2022 PGI-I and CGI-I scores.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"Additional/Exploratory Endpoints\\\", \\\"5.2.3\\\", \\\"3\\\", 2148], [\\\"3\\\", \\\"Tertiary/Exploratory Endpoint(s)\\\", \\\"text\\\", \\\"\\\\u2022 Change from baseline on scores of PGI-S and CGI-S scales.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"Additional/Exploratory Endpoints\\\", \\\"5.2.3\\\", \\\"3\\\", 2149], [\\\"3\\\", \\\"Tertiary/Exploratory Endpoint(s)\\\", \\\"text\\\", \\\"\\\\u2022 Change in weekly frequency of REM sleep-related abnormalities, including hypnagogic/hypnopompic hallucination, sleep paralysis, and nocturnal awakenings, from baseline as reported in the patient-reported daily sleep diary.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"Additional/Exploratory Endpoints\\\", \\\"5.2.3\\\", \\\"3\\\", 2150], [\\\"3\\\", \\\"Tertiary/Exploratory Endpoint(s)\\\", \\\"text\\\", \\\"\\\\u2022 Change in various sleep ~REDACTED~ obtained from nocturnal polysomnography (nPSG) and/or portable EEG, including nocturnal awakenings, from baseline.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"Additional/Exploratory Endpoints\\\", \\\"5.2.3\\\", \\\"3\\\", 2151], [\\\"3\\\", \\\"Tertiary/Exploratory Endpoint(s)\\\", \\\"text\\\", \\\"\\\\u2022 Change in various measures captured on cognitive tests (SART and CPAL), including attention, vigilance, and memory, from baseline.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"Additional/Exploratory Endpoints\\\", \\\"5.2.3\\\", \\\"3\\\", 2152], [\\\"3\\\", \\\"Tertiary/Exploratory Endpoint(s)\\\", \\\"text\\\", \\\"\\\\u2022 Change in scores from baseline to Day 15 on Pilot NT1 Items.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"Additional/Exploratory Endpoints\\\", \\\"5.2.3\\\", \\\"3\\\", 2153], [\\\"3\\\", \\\"Tertiary/Exploratory Endpoint(s)\\\", \\\"text\\\", \\\"\\\\u2022 Change in scores from baseline to Day 15 EQ-5D-5L scales.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"Additional/Exploratory Endpoints\\\", \\\"5.2.3\\\", \\\"3\\\", 2154], [\\\"3\\\", \\\"Tertiary/Exploratory Endpoint(s)\\\", \\\"text\\\", \\\"For Part F only:\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"Additional/Exploratory Endpoints\\\", \\\"5.2.3\\\", \\\"3\\\", 2155], [\\\"3\\\", \\\"Tertiary/Exploratory Endpoint(s)\\\", \\\"text\\\", \\\"\\\\u2022 OX levels in ~REDACTED~.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"Additional/Exploratory Endpoints\\\", \\\"5.2.3\\\", \\\"3\\\", 2156], [\\\"3\\\", \\\"Tertiary/Exploratory Endpoint(s)\\\", \\\"text\\\", \\\"The additional exploratory endpoints:\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"Additional/Exploratory Endpoints\\\", \\\"5.2.3\\\", \\\"3\\\", 2157], [\\\"3\\\", \\\"Tertiary/Exploratory Endpoint(s)\\\", \\\"text\\\", \\\"\\\\u2022 Time-matched change in clinic BP and pulse rate from baseline to postdose assessments on Days 1, 7, 10, or 14, in applicable study parts.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"Additional/Exploratory Endpoints\\\", \\\"5.2.3\\\", \\\"3\\\", 2158], [\\\"3\\\", \\\"Tertiary/Exploratory Endpoint(s)\\\", \\\"text\\\", \\\"\\\\u2022 Change in ambulatory BP and pulse rate parameters from baseline to the steady state, in applicable study parts.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"Additional/Exploratory Endpoints\\\", \\\"5.2.3\\\", \\\"3\\\", 2159], [\\\"3\\\", \\\"Tertiary/Exploratory Endpoint(s)\\\", \\\"text\\\", \\\"\\\\u2022 Holter ECG parameters for assessment of the effect of TAK-861 on QT intervals on Days 1 and 14 postdose, in applicable study parts.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"Additional/Exploratory Endpoints\\\", \\\"5.2.3\\\", \\\"3\\\", 2160], [\\\"3\\\", \\\"Tertiary/Exploratory Endpoint(s)\\\", \\\"text\\\", \\\"The safety endpoints of the study are:\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"Additional/Exploratory Endpoints\\\", \\\"5.2.3\\\", \\\"3\\\", 2161], [\\\"3\\\", \\\"Tertiary/Exploratory Endpoint(s)\\\", \\\"text\\\", \\\"\\\\u2022 Safety and tolerability: AEs, vital signs, 12-lead ECG, and clinical laboratory tests.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"Additional/Exploratory Endpoints\\\", \\\"5.2.3\\\", \\\"3\\\", 2162], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"6.0 STUDY DESIGN AND DESCRIPTION\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading1\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Introduction\\\", \\\"STUDY DESIGN AND DESCRIPTION\\\", \\\"6.0\\\", \\\"1\\\", 2163], [\\\"1\\\", \\\"Study Design\\\", \\\"header\\\", \\\"6.1 Study Design\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading2\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Study Design\\\", \\\"6.1\\\", \\\"2\\\", 2164], [\\\"1\\\", \\\"Study Design\\\", \\\"text\\\", \\\"This is a FIH, phase 1/1b, double-blind, safety, tolerability, PK, and PD study of single and multiple rising oral doses of TAK-861 in healthy non-Japanese and Japanese adult subjects and HE subjects.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Study Design\\\", \\\"6.1\\\", \\\"2\\\", 2165], [\\\"1\\\", \\\"Study Design\\\", \\\"text\\\", \\\"Subjects with NT1 will also be enrolled in Part D.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Study Design\\\", \\\"6.1\\\", \\\"2\\\", 2166], [\\\"1\\\", \\\"Study Design\\\", \\\"text\\\", \\\"In this study, TAK-861 or matching placebo will be administered orally as a suspension or tablet formulation and will be dispensed in a blinded fashion by qualified study site personnel.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Study Design\\\", \\\"6.1\\\", \\\"2\\\", 2167], [\\\"1\\\", \\\"Study Design\\\", \\\"text\\\", \\\"This study consists of 6 parts.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Study Design\\\", \\\"6.1\\\", \\\"2\\\", 2168], [\\\"1\\\", \\\"Study Design\\\", \\\"text\\\", \\\"\\\\u2022 Part A: a randomized, double-blind, placebo-controlled, single-rising dose (SRD) part to assess the safety, tolerability, and PK of TAK-861 administered orally as a suspension or tablet to healthy subjects.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Study Design\\\", \\\"6.1\\\", \\\"2\\\", 2169], [\\\"1\\\", \\\"Study Design\\\", \\\"text\\\", \\\"The effect of food on the PK of the TAK-861 tablet will also be evaluated.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Study Design\\\", \\\"6.1\\\", \\\"2\\\", 2170], [\\\"1\\\", \\\"Study Design\\\", \\\"text\\\", \\\"\\\\u2022 Part B: a randomized, double-blind, placebo-controlled, multiple-rising dose (MRD) part to assess the safety, tolerability, PK, and PD of TAK-861 administered orally to healthy subjects.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Study Design\\\", \\\"6.1\\\", \\\"2\\\", 2171], [\\\"1\\\", \\\"Study Design\\\", \\\"text\\\", \\\"\\\\u2022 Part C: a randomized, double-blind, placebo-controlled, MRD part to assess the safety, tolerability, PK, and PD of TAK-861 administered orally to HE subjects.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Study Design\\\", \\\"6.1\\\", \\\"2\\\", 2172], [\\\"1\\\", \\\"Study Design\\\", \\\"text\\\", \\\"\\\\u2022 Part D: a randomized, double-blind, placebo-controlled, MRD part to assess the safety, tolerability, PK, and PD of TAK-861 administered orally to subjects with NT1.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Study Design\\\", \\\"6.1\\\", \\\"2\\\", 2173], [\\\"1\\\", \\\"Study Design\\\", \\\"text\\\", \\\"\\\\u2022 Part E: a randomized, double-blind, placebo-controlled, SRD/MRD part to assess the safety, tolerability, PK and PD of TAK-861 administered orally to healthy subjects of non-Japanese origin.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Study Design\\\", \\\"6.1\\\", \\\"2\\\", 2174], [\\\"1\\\", \\\"Study Design\\\", \\\"text\\\", \\\"\\\\u2022 Part F: a randomized, double-blind, placebo-controlled, part to assess the PD and PK of TAK-861 in ~REDACTED~ in healthy subjects of non-Japanese origin.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Study Design\\\", \\\"6.1\\\", \\\"2\\\", 2175], [\\\"1\\\", \\\"Study Design\\\", \\\"text\\\", \\\"The study cohorts and the earliest initiation timings for each cohort are summarized in Figure 6.a.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Study Design\\\", \\\"6.1\\\", \\\"2\\\", 2176], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"Figure 6.a Overall Design and Planned Dose Levels of TAK-861\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading8\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Figure 6.a  Overall Design and Planned Dose Levels of TAK-861\\\", \\\"\\\", \\\"2\\\", 2177], [\\\"\\\", \\\"Unmapped\\\", \\\"table\\\", {\\\"Table\\\": \\\"<table border=\\\\\\\"1\\\\\\\" class=\\\\\\\"dataframe\\\\\\\">\\\\n  <thead>\\\\n    <tr style=\\\\\\\"text-align: right;\\\\\\\">\\\\n      <th></th>\\\\n      <th>1.0</th>\\\\n      <th>2.0</th>\\\\n      <th>3.0</th>\\\\n      <th>4.0</th>\\\\n      <th>5.0</th>\\\\n      <th>6.0</th>\\\\n      <th>7.0</th>\\\\n      <th>8.0</th>\\\\n    </tr>\\\\n  </thead>\\\\n  <tbody>\\\\n    <tr>\\\\n      <th>0</th>\\\\n      <td>Study Part/ Description</td>\\\\n      <td>Dosing Regimen</td>\\\\n      <td>Randomization</td>\\\\n      <td>Relative Timing of Planned Earliest Cohort Initiation and Planned Dose (Cohort Name)</td>\\\\n      <td>Relative Timing of Planned Earliest Cohort Initiation and Planned Dose (Cohort Name)</td>\\\\n      <td>Relative Timing of Planned Earliest Cohort Initiation and Planned Dose (Cohort Name)</td>\\\\n      <td>Relative Timing of Planned Earliest Cohort Initiation and Planned Dose (Cohort Name)</td>\\\\n      <td>Relative Timing of Planned Earliest Cohort Initiation and Planned Dose (Cohort Name)</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>1</th>\\\\n      <td>Part A/SRD HV Fasted</td>\\\\n      <td>Single dose</td>\\\\n      <td>6:2 to receive TAK-861 vs placebo</td>\\\\n      <td>1 mg (A1)</td>\\\\n      <td>TBD (A2)</td>\\\\n      <td>TBD (A3)</td>\\\\n      <td>TBD (A4-A10 <sup>a</sup> ) <sup>b</sup></td>\\\\n      <td>TBD (A4-A10 <sup>a</sup> ) <sup>b</sup></td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>2</th>\\\\n      <td>Part A/SRD HV Fed</td>\\\\n      <td>Single dose <sup>a</sup></td>\\\\n      <td>6:2 to receive TAK-861 vs placebo</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>TBD (A3)</td>\\\\n      <td>TBD (A10) <sup>b</sup></td>\\\\n      <td>TBD (A10) <sup>b</sup></td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>3</th>\\\\n      <td>Part B/MRD HV</td>\\\\n      <td>14 days of dosing (QD)</td>\\\\n      <td>6:2 to receive TAK-861 vs placebo</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>TBD <sup>c</sup> (B1)</td>\\\\n      <td>TBD <sup>c</sup> (B2), (B3-B6) <sup>b</sup></td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>4</th>\\\\n      <td>Part C/MRD-HE</td>\\\\n      <td>14 days of dosing (QD)</td>\\\\n      <td>6:2 to receive TAK-861 vs placebo</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>TBD <sup>d</sup> (C1)</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>5</th>\\\\n      <td>Part D/MRD-NT1</td>\\\\n      <td>14 days of dosing (QD)</td>\\\\n      <td>6:3 to receive TAK-861 vs placebo</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>TBD <sup>d</sup> (D1 <sup>e</sup> D2 <sup>d</sup> )</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>6</th>\\\\n      <td>Part E/ SRD/MRD non-Japanese cohorts</td>\\\\n      <td>Single dose and 14 days of dosing (QD)</td>\\\\n      <td>6:2 to receive TAK-861 vs placebo</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>TBD <sup>d</sup> (E1 <sup>b</sup> )</td>\\\\n      <td>TBD <sup>d</sup> (E2-E4) <sup>b</sup></td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>7</th>\\\\n      <td>Part F/ <span class=\\\\\\\"redact\\\\\\\"> ~REDACTED~ </span>  non-Japanese cohort</td>\\\\n      <td>10 days of dosing (QD)</td>\\\\n      <td>6:4 to receive TAK-861 vs placebo</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>TBD <sup>d</sup> (F1) b</td>\\\\n    </tr>\\\\n  </tbody>\\\\n</table>\\\", \\\"SectionHeaderPrintPage\\\": \\\"58\\\", \\\"TableIndex\\\": \\\"31\\\", \\\"TableName\\\": \\\"Figure\\\\u00a06.a Overall Design and Planned Dose Levels of TAK-861\\\", \\\"Header\\\": [0]}, {\\\"IsBold\\\": true, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Figure 6.a  Overall Design and Planned Dose Levels of TAK-861\\\", \\\"\\\", \\\"2\\\", 2178], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Figure 6.a  Overall Design and Planned Dose Levels of TAK-861\\\", \\\"\\\", \\\"2\\\", 2179], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Figure 6.a  Overall Design and Planned Dose Levels of TAK-861\\\", \\\"\\\", \\\"2\\\", 2180], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Figure 6.a  Overall Design and Planned Dose Levels of TAK-861\\\", \\\"\\\", \\\"2\\\", 2181], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Figure 6.a  Overall Design and Planned Dose Levels of TAK-861\\\", \\\"\\\", \\\"2\\\", 2182], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Figure 6.a  Overall Design and Planned Dose Levels of TAK-861\\\", \\\"\\\", \\\"2\\\", 2183], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Figure 6.a  Overall Design and Planned Dose Levels of TAK-861\\\", \\\"\\\", \\\"2\\\", 2184], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Figure 6.a  Overall Design and Planned Dose Levels of TAK-861\\\", \\\"\\\", \\\"2\\\", 2185], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Figure 6.a  Overall Design and Planned Dose Levels of TAK-861\\\", \\\"\\\", \\\"2\\\", 2186], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Figure 6.a  Overall Design and Planned Dose Levels of TAK-861\\\", \\\"\\\", \\\"2\\\", 2187], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Figure 6.a  Overall Design and Planned Dose Levels of TAK-861\\\", \\\"\\\", \\\"2\\\", 2188], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Figure 6.a  Overall Design and Planned Dose Levels of TAK-861\\\", \\\"\\\", \\\"2\\\", 2189], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Figure 6.a  Overall Design and Planned Dose Levels of TAK-861\\\", \\\"\\\", \\\"2\\\", 2190], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Figure 6.a  Overall Design and Planned Dose Levels of TAK-861\\\", \\\"\\\", \\\"2\\\", 2191], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Part E/\\\", \\\"3.4\\\", \\\"2\\\", 2192], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Part E/\\\", \\\"3.4\\\", \\\"2\\\", 2193], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Part E/\\\", \\\"3.4\\\", \\\"2\\\", 2194], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Part E/\\\", \\\"3.4\\\", \\\"2\\\", 2195], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Part E/\\\", \\\"3.4\\\", \\\"2\\\", 2196], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Part E/\\\", \\\"3.4\\\", \\\"2\\\", 2197], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Part E/\\\", \\\"3.4\\\", \\\"2\\\", 2198], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"~REDACTED~: cerebrospinal fluid; HE: healthy elderly; HV: healthy volunteers; MRD: multiple-rising dose; NT1: narcolepsy type 1; SRD:\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Part E/\\\", \\\"3.4\\\", \\\"2\\\", 2199], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"single-rising dose; TBD: to be determined; QD: once daily.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Part E/\\\", \\\"3.4\\\", \\\"2\\\", 2200], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"a\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 13, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 13, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Part E/\\\", \\\"3.4\\\", \\\"2\\\", 2201], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"For Cohort A3 (Cohort A3 may start later than other cohorts in Part A) and ~REDACTED~ (optional cohort) only, the dosing regimen consists of 2 single doses separated by a washout period.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Part E/\\\", \\\"3.4\\\", \\\"2\\\", 2202], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Cohort ~REDACTED~ may start earlier than other optional cohorts in Part A.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Part E/\\\", \\\"3.4\\\", \\\"2\\\", 2203], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"b\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"superscript\\\"}, \\\"Study Design\\\", \\\"Part E/\\\", \\\"3.4\\\", \\\"2\\\", 2204], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Optional cohort.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Part E/\\\", \\\"3.4\\\", \\\"2\\\", 2205], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"c\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"superscript\\\"}, \\\"Study Design\\\", \\\"Part E/\\\", \\\"3.4\\\", \\\"2\\\", 2206], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Dose based on SRD cohorts.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Part E/\\\", \\\"3.4\\\", \\\"2\\\", 2207], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"d\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"superscript\\\"}, \\\"Study Design\\\", \\\"Part E/\\\", \\\"3.4\\\", \\\"2\\\", 2208], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Dose and timing based on SRD and/or MRD cohorts.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Part E/\\\", \\\"3.4\\\", \\\"2\\\", 2209], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"e\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"superscript\\\"}, \\\"Study Design\\\", \\\"Part E/\\\", \\\"3.4\\\", \\\"2\\\", 2210], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Cohort D1 is anticipated to start once B1 is completed with pharmacokinetic and safety evaluation.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Part E/\\\", \\\"3.4\\\", \\\"2\\\", 2211], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"The timing of initiation for Part D may change based on the emerging data from precedent cohorts.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Part E/\\\", \\\"3.4\\\", \\\"2\\\", 2212], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Up to approximately 80 healthy adult Japanese subjects in Part A; 48 healthy adult Japanese subjects in Part B; 8 elderly Japanese subjects in Part C; 18 Japanese subjects with NT1 in Part D; 32 healthy adult non-Japanese subjects in Part E; and 10 healthy adult non-Japanese subjects in Part F will be enrolled.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Part E/\\\", \\\"3.4\\\", \\\"2\\\", 2213], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Parts A to D of this study will be conducted in Japan and Parts E and F will be conducted in the United States.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Part E/\\\", \\\"3.4\\\", \\\"2\\\", 2214], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"All cohorts will include serial blood sampling for TAK-861 PK.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Part E/\\\", \\\"3.4\\\", \\\"2\\\", 2215], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Urine PK samples will be collected from all cohorts except for Parts D, F and Part A fed portion of cohorts A3 and ~REDACTED~.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Part E/\\\", \\\"3.4\\\", \\\"2\\\", 2216], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Urine PK will be done in the fasted portion of A3 and ~REDACTED~.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Part E/\\\", \\\"3.4\\\", \\\"2\\\", 2217], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"The conduct of the ~REDACTED~ cohort is optional and will be determined on the basis of the PD results in subjects with NT1 in Part D.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Part E/\\\", \\\"3.4\\\", \\\"2\\\", 2218], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"In selected MRD study parts (ie, Parts B, C, D, and E only), additional 2 mL blood samples will be collected before dose on prespecified days for measurement of the\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Part E/\\\", \\\"3.4\\\", \\\"2\\\", 2219], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"4\\\\u03b2-hydroxycholesterol/cholesterol ratio to assess CYP3A4/5 activity.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Part E/\\\", \\\"3.4\\\", \\\"2\\\", 2220], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Separately, in selected MRD study parts (ie, B and E), additional blood samples will be collected at designated time points for measurement of CPI and CPIII to assess OATP1B1/3 activity.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Part E/\\\", \\\"3.4\\\", \\\"2\\\", 2221], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"6.1.1 Part A: SRD in Japanese Healthy Adults\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading4\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Part A: SRD in Japanese Healthy Adults\\\", \\\"6.1.1\\\", \\\"3\\\", 2222], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"The purpose of Part A is to assess safety and tolerability of TAK-861 in Japanese healthy adults.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Part A: SRD in Japanese Healthy Adults\\\", \\\"6.1.1\\\", \\\"3\\\", 2223], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"The FIH dosing of TAK-861 will be a single oral dose administered in Cohort A1.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Part A: SRD in Japanese Healthy Adults\\\", \\\"6.1.1\\\", \\\"3\\\", 2224], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Up to 10 cohorts will be dosed in the SRD part of the study.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Part A: SRD in Japanese Healthy Adults\\\", \\\"6.1.1\\\", \\\"3\\\", 2225], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Each cohort will consist of 8 healthy adult subjects who will be randomized 6:2 to receive a single dose of TAK-861 versus placebo.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Part A: SRD in Japanese Healthy Adults\\\", \\\"6.1.1\\\", \\\"3\\\", 2226], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Sentinel dosing consisting of 2 subjects (1 placebo and 1 active) will be conducted in the first 2 cohorts (A1 and A2 [sentinel dosing in Cohort A2 is optional pending data from the previous cohort]).\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Part A: SRD in Japanese Healthy Adults\\\", \\\"6.1.1\\\", \\\"3\\\", 2227], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Sentinel dosing may be executed in the following cohorts, if the sponsor and principal investigator agree, based on available PK and safety data from prior SRD cohorts.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Part A: SRD in Japanese Healthy Adults\\\", \\\"6.1.1\\\", \\\"3\\\", 2228], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"The remaining subjects may start dosing based on site investigator\\\\u2019s judgement at least 24 hours after sentinel cohort dosing.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Part A: SRD in Japanese Healthy Adults\\\", \\\"6.1.1\\\", \\\"3\\\", 2229], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Additional SRD cohorts (ie, Cohorts A3 to ~REDACTED~) will be used to study ascending single-dose level and dose escalation (based on emerging safety, tolerability, and PK data from the prior SRD cohorts) may continue until the maximum tolerated dose (MTD) or maximal allowed dose is reached, provided that the predicted mean steady-state exposure does not exceed limits set by nonclinical toxicology findings.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Part A: SRD in Japanese Healthy Adults\\\", \\\"6.1.1\\\", \\\"3\\\", 2230], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"A suspension formulation of TAK-861 could be used to initiate this part of the study based on the Sponsor\\\\u2019s discretion and therefore, when the tablet formulation is available to administer to subjects for the first time, PK, safety and tolerability data of previous cohorts will be carefully evaluated to support a dose level decision for the starting dose of the tablet formulation.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Part A: SRD in Japanese Healthy Adults\\\", \\\"6.1.1\\\", \\\"3\\\", 2231], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Starting dose level for tablet formulation will be the same or lower than the dose levels tested in previous cohorts with suspension formulation or will be 1 mg.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Part A: SRD in Japanese Healthy Adults\\\", \\\"6.1.1\\\", \\\"3\\\", 2232], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Cohorts A3 and ~REDACTED~ (~REDACTED~ is an optional cohort) will also evaluate the effect of food on the PK of the TAK-861 tablet formulation; therefore, subjects in these cohorts will return to the clinic at least after 5 days from initial discharge for dosing and assessment under fed conditions.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Part A: SRD in Japanese Healthy Adults\\\", \\\"6.1.1\\\", \\\"3\\\", 2233], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"An overview of the study schedule for Part A is provided in Table 6.a and Table 6.b (food effect cohorts).\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Part A: SRD in Japanese Healthy Adults\\\", \\\"6.1.1\\\", \\\"3\\\", 2234], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"The Schedules of Study Procedures are shown in Table 3.a and Table 3.b (food effect cohorts).\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Part A: SRD in Japanese Healthy Adults\\\", \\\"6.1.1\\\", \\\"3\\\", 2235], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Detailed timing for assessment collection is presented in Table 3.c and Table 3.d (food effect cohorts).\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Part A: SRD in Japanese Healthy Adults\\\", \\\"6.1.1\\\", \\\"3\\\", 2236], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"After the screening visit, eligible participants in Part A will check in on Day -2.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Part A: SRD in Japanese Healthy Adults\\\", \\\"6.1.1\\\", \\\"3\\\", 2237], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"On Day 1, eligible participants will be randomized and receive a single dose of blinded study drug (TAK-861 or placebo) orally in the morning after an overnight fast of at least 10 hours.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Part A: SRD in Japanese Healthy Adults\\\", \\\"6.1.1\\\", \\\"3\\\", 2238], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Subjects will be discharged on Day 6 and a follow-up visit will occur on Day 9\\\\u00b12 days.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Part A: SRD in Japanese Healthy Adults\\\", \\\"6.1.1\\\", \\\"3\\\", 2239], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"The test meal for Cohort A3 will consist of a standard ~REDACTED~ high-fat, high-calorie breakfast.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Part A: SRD in Japanese Healthy Adults\\\", \\\"6.1.1\\\", \\\"3\\\", 2240], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"On the basis of the emerging data from this cohort, the effect of a standard (non\\\\u2013high-fat) breakfast on TAK-861 PK may then be evaluated.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Part A: SRD in Japanese Healthy Adults\\\", \\\"6.1.1\\\", \\\"3\\\", 2241], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"Table 6.a Study Schedule: Part A\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading8\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"a  Study Schedule: Part A\\\", \\\"Table 6.\\\", \\\"2\\\", 2242], [\\\"\\\", \\\"Unmapped\\\", \\\"table\\\", {\\\"Table\\\": \\\"<table border=\\\\\\\"1\\\\\\\" class=\\\\\\\"dataframe\\\\\\\">\\\\n  <thead>\\\\n    <tr style=\\\\\\\"text-align: right;\\\\\\\">\\\\n      <th></th>\\\\n      <th>1.0</th>\\\\n      <th>2.0</th>\\\\n      <th>3.0</th>\\\\n      <th>4.0</th>\\\\n      <th>5.0</th>\\\\n    </tr>\\\\n  </thead>\\\\n  <tbody>\\\\n    <tr>\\\\n      <th>0</th>\\\\n      <td>Screening Periods</td>\\\\n      <td>Check-in and Baseline</td>\\\\n      <td>Treatment Period</td>\\\\n      <td>Treatment Period</td>\\\\n      <td>Follow-up Visit</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>1</th>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>Dose</td>\\\\n      <td>Sample Collection</td>\\\\n      <td></td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>2</th>\\\\n      <td>Days -28 to -2</td>\\\\n      <td>Day -2 to -1 Study assessments</td>\\\\n      <td>Day 1 Study drug administration</td>\\\\n      <td>Days 1 to 6 Study assessments</td>\\\\n      <td>Day 9\\\\u00b12 days</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>3</th>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>Confinement</td>\\\\n      <td>Confinement</td>\\\\n      <td></td>\\\\n    </tr>\\\\n  </tbody>\\\\n</table>\\\", \\\"SectionHeaderPrintPage\\\": \\\"60\\\", \\\"TableIndex\\\": \\\"32\\\", \\\"TableName\\\": \\\"Table 6.a Study Schedule: Part A\\\", \\\"Header\\\": [0, 1]}, {\\\"IsBold\\\": true, \\\"font_size\\\": 20, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 20, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"a  Study Schedule: Part A\\\", \\\"Table 6.\\\", \\\"2\\\", 2243], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"a  Study Schedule: Part A\\\", \\\"Table 6.\\\", \\\"2\\\", 2244], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"a  Study Schedule: Part A\\\", \\\"Table 6.\\\", \\\"2\\\", 2245], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"a  Study Schedule: Part A\\\", \\\"Table 6.\\\", \\\"2\\\", 2246], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"a  Study Schedule: Part A\\\", \\\"Table 6.\\\", \\\"2\\\", 2247], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"a  Study Schedule: Part A\\\", \\\"Table 6.\\\", \\\"2\\\", 2248], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"a  Study Schedule: Part A\\\", \\\"Table 6.\\\", \\\"2\\\", 2249], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"Table 6.b Study Schedule: Part A (Food Effect Cohorts)\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading8\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"b  Study Schedule: Part A (Food Effect Cohorts)\\\", \\\"Table 6.\\\", \\\"2\\\", 2250], [\\\"\\\", \\\"Unmapped\\\", \\\"table\\\", {\\\"Table\\\": \\\"<table border=\\\\\\\"1\\\\\\\" class=\\\\\\\"dataframe\\\\\\\">\\\\n  <thead>\\\\n    <tr style=\\\\\\\"text-align: right;\\\\\\\">\\\\n      <th></th>\\\\n      <th>1.0</th>\\\\n      <th>2.0</th>\\\\n      <th>3.0</th>\\\\n      <th>4.0</th>\\\\n      <th>5.0</th>\\\\n      <th>6.0</th>\\\\n      <th>7.0</th>\\\\n      <th>8.0</th>\\\\n      <th>9.0</th>\\\\n    </tr>\\\\n  </thead>\\\\n  <tbody>\\\\n    <tr>\\\\n      <th>0</th>\\\\n      <td>Screening Period</td>\\\\n      <td>Check-in and Baseline</td>\\\\n      <td>Treatment Period 1 (Fasted)</td>\\\\n      <td>Treatment Period 1 (Fasted)</td>\\\\n      <td>Washout</td>\\\\n      <td>Check-in</td>\\\\n      <td>Treatment Period 2 (Fed)</td>\\\\n      <td>Treatment Period 2 (Fed)</td>\\\\n      <td>Follow-up Visit</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>1</th>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>Dose</td>\\\\n      <td>Sample Collection</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>Dose</td>\\\\n      <td>Sample Collection</td>\\\\n      <td></td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>2</th>\\\\n      <td>Days -28 to -2</td>\\\\n      <td>Days -2 to -1 Study assessments</td>\\\\n      <td>Day 1 Study drug administration</td>\\\\n      <td>Days 1 to 6 Study assessments</td>\\\\n      <td>7 day \\\\u00b12 days</td>\\\\n      <td>Day 14 Study assessments</td>\\\\n      <td>Day 15 Study drug administration</td>\\\\n      <td>Day 15 to 20 Study assessments</td>\\\\n      <td>Day 23\\\\u00b12 days</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>3</th>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>Confinement</td>\\\\n      <td>Confinement</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>Confinement</td>\\\\n      <td>Confinement</td>\\\\n      <td></td>\\\\n    </tr>\\\\n  </tbody>\\\\n</table>\\\", \\\"SectionHeaderPrintPage\\\": \\\"60\\\", \\\"TableIndex\\\": \\\"33\\\", \\\"TableName\\\": \\\"Table 6.b Study Schedule: Part A (Food Effect Cohorts)\\\", \\\"Header\\\": [0, 1]}, {\\\"IsBold\\\": true, \\\"font_size\\\": 17, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 17, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"b  Study Schedule: Part A (Food Effect Cohorts)\\\", \\\"Table 6.\\\", \\\"2\\\", 2251], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"b  Study Schedule: Part A (Food Effect Cohorts)\\\", \\\"Table 6.\\\", \\\"2\\\", 2252], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"b  Study Schedule: Part A (Food Effect Cohorts)\\\", \\\"Table 6.\\\", \\\"2\\\", 2253], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"b  Study Schedule: Part A (Food Effect Cohorts)\\\", \\\"Table 6.\\\", \\\"2\\\", 2254], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"b  Study Schedule: Part A (Food Effect Cohorts)\\\", \\\"Table 6.\\\", \\\"2\\\", 2255], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"b  Study Schedule: Part A (Food Effect Cohorts)\\\", \\\"Table 6.\\\", \\\"2\\\", 2256], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"b  Study Schedule: Part A (Food Effect Cohorts)\\\", \\\"Table 6.\\\", \\\"2\\\", 2257], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"b  Study Schedule: Part A (Food Effect Cohorts)\\\", \\\"Table 6.\\\", \\\"2\\\", 2258], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"b  Study Schedule: Part A (Food Effect Cohorts)\\\", \\\"Table 6.\\\", \\\"2\\\", 2259], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"b  Study Schedule: Part A (Food Effect Cohorts)\\\", \\\"Table 6.\\\", \\\"2\\\", 2260], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"b  Study Schedule: Part A (Food Effect Cohorts)\\\", \\\"Table 6.\\\", \\\"2\\\", 2261], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"6.1.2 Part B: MRD in Japanese Healthy Adults\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading4\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Part B: MRD in Japanese Healthy Adults\\\", \\\"6.1.2\\\", \\\"3\\\", 2262], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"An overview of the study schedule for Part B is provided in Table 6.c.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Part B: MRD in Japanese Healthy Adults\\\", \\\"6.1.2\\\", \\\"3\\\", 2263], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Part B will be initiated after at least 3 cohorts from Part A and safety, tolerability, and PK data have been reviewed.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Part B: MRD in Japanese Healthy Adults\\\", \\\"6.1.2\\\", \\\"3\\\", 2264], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Subjects will receive once daily (QD) TAK-861 or matching placebo for 14 days.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Part B: MRD in Japanese Healthy Adults\\\", \\\"6.1.2\\\", \\\"3\\\", 2265], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Each cohort will consist of 8 healthy adult subjects who will be randomized 6:2 to receive TAK-861 versus placebo in a double-blinded fashion.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Part B: MRD in Japanese Healthy Adults\\\", \\\"6.1.2\\\", \\\"3\\\", 2266], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"After the screening visit, eligible participants will be asked to wear an accelerometer device throughout the study.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Part B: MRD in Japanese Healthy Adults\\\", \\\"6.1.2\\\", \\\"3\\\", 2267], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Enrollment in Cohort B1 will start at a dose that:\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Part B: MRD in Japanese Healthy Adults\\\", \\\"6.1.2\\\", \\\"3\\\", 2268], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"a) Results in predicted steady-state drug exposures that do not exceed the mean exposure of the highest single dose tested to date (ie, in the SRD cohorts in Part A, and at the earliest within the dose range tested in Cohort A3 as shown in Figure 6.a).\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Part B: MRD in Japanese Healthy Adults\\\", \\\"6.1.2\\\", \\\"3\\\", 2269], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"b) Was previously found to be safe and tolerable.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Part B: MRD in Japanese Healthy Adults\\\", \\\"6.1.2\\\", \\\"3\\\", 2270], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Dose escalation will be done following review of the emerging available safety, PK, and PD data from previous cohorts and may continue until the MTD or maximal allowed dose is reached, provided that the predicted mean steady-state exposure does not exceed limits set by nonclinical toxicology findings.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Part B: MRD in Japanese Healthy Adults\\\", \\\"6.1.2\\\", \\\"3\\\", 2271], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"6.1.3 Part C: Multiple Dose in Healthy Japanese Elderly Subjects\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading4\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Part C: Multiple Dose in Healthy Japanese Elderly Subjects\\\", \\\"6.1.3\\\", \\\"3\\\", 2272], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"The safety, tolerability, PK, and PD of TAK-861 will be evaluated in 1 cohort (Cohort C1) of healthy Japanese elderly subjects, with multiple oral administration of the same dose as or a lower dose than those previously studied in healthy younger subjects in Part B, and confirmed to be adequately safe and tolerable.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Part C: Multiple Dose in Healthy Japanese Elderly Subjects\\\", \\\"6.1.3\\\", \\\"3\\\", 2273], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"This cohort will consist of 8 healthy Japanese subjects (aged \\\\u226565 years), who will be randomized 6:2 to receive TAK-861 versus placebo in a double-blinded fashion.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Part C: Multiple Dose in Healthy Japanese Elderly Subjects\\\", \\\"6.1.3\\\", \\\"3\\\", 2274], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Subjects will receive QD dosing of TAK-861 or matching placebo for 14 days.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Part C: Multiple Dose in Healthy Japanese Elderly Subjects\\\", \\\"6.1.3\\\", \\\"3\\\", 2275], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"An overview of the schedule for Part B and Part C is provided in Table 6.c.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Part C: Multiple Dose in Healthy Japanese Elderly Subjects\\\", \\\"6.1.3\\\", \\\"3\\\", 2276], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"The Schedule of Study Procedures for Parts B and C is shown in Table 3.e.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Part C: Multiple Dose in Healthy Japanese Elderly Subjects\\\", \\\"6.1.3\\\", \\\"3\\\", 2277], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Detailed timing for assessment collection for Parts B and C is presented in Table 3.f.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Part C: Multiple Dose in Healthy Japanese Elderly Subjects\\\", \\\"6.1.3\\\", \\\"3\\\", 2278], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"Table 6.c Study Schedule: Part B and Part C\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading8\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"c  Study Schedule: Part B and Part C\\\", \\\"Table 6.\\\", \\\"2\\\", 2279], [\\\"\\\", \\\"Unmapped\\\", \\\"table\\\", {\\\"Table\\\": \\\"<table border=\\\\\\\"1\\\\\\\" class=\\\\\\\"dataframe\\\\\\\">\\\\n  <thead>\\\\n    <tr style=\\\\\\\"text-align: right;\\\\\\\">\\\\n      <th></th>\\\\n      <th>1.0</th>\\\\n      <th>2.0</th>\\\\n      <th>3.0</th>\\\\n      <th>4.0</th>\\\\n      <th>5.0</th>\\\\n    </tr>\\\\n  </thead>\\\\n  <tbody>\\\\n    <tr>\\\\n      <th>0</th>\\\\n      <td>Screening Period</td>\\\\n      <td>Check-in and Baseline</td>\\\\n      <td>Treatment Period</td>\\\\n      <td>Treatment Period</td>\\\\n      <td>Follow-up Visit</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>1</th>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>Dosing</td>\\\\n      <td>Sample Collection</td>\\\\n      <td></td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>2</th>\\\\n      <td>Days -28 to -2</td>\\\\n      <td>Days -2 to -1 Study assessments</td>\\\\n      <td>Day 1 to 14 Study drug administration (Dosing frequency once daily)</td>\\\\n      <td>Day 1 to 18 Study assessments</td>\\\\n      <td>Day 21\\\\u00b12 days</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>3</th>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>Confinement</td>\\\\n      <td>Confinement</td>\\\\n      <td></td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>4</th>\\\\n      <td>Days -45 to -3</td>\\\\n      <td>Days -2 to -1 Study assessments</td>\\\\n      <td>Day 1 to Day 14 Study drug administration</td>\\\\n      <td>Day 1 to 15 Study assessments</td>\\\\n      <td>Day 21\\\\u00b12 days</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>5</th>\\\\n      <td></td>\\\\n      <td>Confinement or outpatient per Schedule of Study Procedures</td>\\\\n      <td>Confinement or outpatient per Schedule of Study Procedures</td>\\\\n      <td>Confinement or outpatient per Schedule of Study Procedures</td>\\\\n      <td></td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>6</th>\\\\n      <td>Days -35 to -2</td>\\\\n      <td>Days -2 to -1 Study assessments</td>\\\\n      <td>Day 1; Days 6 to 19 (Dosing frequency once daily)</td>\\\\n      <td>Days 1 to 23 Study assessments</td>\\\\n      <td>Day 26\\\\u00b12 days</td>\\\\n    </tr>\\\\n  </tbody>\\\\n</table>\\\", \\\"SectionHeaderPrintPage\\\": \\\"61\\\", \\\"TableIndex\\\": \\\"34\\\", \\\"TableName\\\": \\\"Table 6.c Study Schedule: Part B and Part C\\\", \\\"Header\\\": [0, 1]}, {\\\"IsBold\\\": true, \\\"font_size\\\": 20, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 20, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"c  Study Schedule: Part B and Part C\\\", \\\"Table 6.\\\", \\\"2\\\", 2280], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"c  Study Schedule: Part B and Part C\\\", \\\"Table 6.\\\", \\\"2\\\", 2281], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"c  Study Schedule: Part B and Part C\\\", \\\"Table 6.\\\", \\\"2\\\", 2282], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"c  Study Schedule: Part B and Part C\\\", \\\"Table 6.\\\", \\\"2\\\", 2283], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"c  Study Schedule: Part B and Part C\\\", \\\"Table 6.\\\", \\\"2\\\", 2284], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"c  Study Schedule: Part B and Part C\\\", \\\"Table 6.\\\", \\\"2\\\", 2285], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"c  Study Schedule: Part B and Part C\\\", \\\"Table 6.\\\", \\\"2\\\", 2286], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"6.1.4 Part D: Japanese Subjects With NT1\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading4\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Part D: Japanese Subjects With NT1\\\", \\\"6.1.4\\\", \\\"3\\\", 2287], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Part D will be conducted in subjects with NT1 (aged <65 years), who will receive QD dosing of TAK-861 or matching placebo for 14 days so that TAK-861 effects on wakefulness will be assessed following acute and chronic dose administrations.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Part D: Japanese Subjects With NT1\\\", \\\"6.1.4\\\", \\\"3\\\", 2288], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Two cohorts are planned.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Part D: Japanese Subjects With NT1\\\", \\\"6.1.4\\\", \\\"3\\\", 2289], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Each cohort will recruit a minimum of 9 subjects with NT1 who will be randomized 6:3 to receive TAK-861 versus placebo in a double-blinded fashion.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Part D: Japanese Subjects With NT1\\\", \\\"6.1.4\\\", \\\"3\\\", 2290], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"The starting dose will be the same as or lower than those studied in Part B and be supported by the predicted range of pharmacologically active plasma exposure from animal studies.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Part D: Japanese Subjects With NT1\\\", \\\"6.1.4\\\", \\\"3\\\", 2291], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"PD measures include the MWT, accelerometry (actigraphy), nPSG, KSS, the ESS, electronic patient-reported outcome (ePRO) measures including cataplexy occurrence from which the WCR will be derived, the PGI-I, CGI-I, PGI-S, CGI-S, nighttime portable EEG (portable EEG assessment may not be done based on emerging clinical data), the cognitive tests, Pilot NT1 Items, and EQ-5D-5L scale.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Part D: Japanese Subjects With NT1\\\", \\\"6.1.4\\\", \\\"3\\\", 2292], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Subjects may undergo optional ~REDACTED~ sampling for OX assessment during screening.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Part D: Japanese Subjects With NT1\\\", \\\"6.1.4\\\", \\\"3\\\", 2293], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"An overview of the schedule for Part D is provided in Table 6.d and a schematic is provided in Figure 2.a.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Part D: Japanese Subjects With NT1\\\", \\\"6.1.4\\\", \\\"3\\\", 2294], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"The Schedules of Study Procedures are shown in Table 3.g.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Part D: Japanese Subjects With NT1\\\", \\\"6.1.4\\\", \\\"3\\\", 2295], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Detailed timing for assessment collection is presented in Table 3.h.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Part D: Japanese Subjects With NT1\\\", \\\"6.1.4\\\", \\\"3\\\", 2296], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"After screening, eligible subjects will be asked to wear an accelerometer throughout the study.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Part D: Japanese Subjects With NT1\\\", \\\"6.1.4\\\", \\\"3\\\", 2297], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Subjects should follow instructions listed in Section 7.3 for washout and adhere to the guidelines for excluded medications.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Part D: Japanese Subjects With NT1\\\", \\\"6.1.4\\\", \\\"3\\\", 2298], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Subjects with NT1 may undergo optional ~REDACTED~ sampling for OX assessment during screening.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Part D: Japanese Subjects With NT1\\\", \\\"6.1.4\\\", \\\"3\\\", 2299], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"In addition, ABPM, nPSG, MWT, and KSS will be conducted on the specified days per Schedule of Study Procedures (See Table 3.g, Table 3.h).\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Part D: Japanese Subjects With NT1\\\", \\\"6.1.4\\\", \\\"3\\\", 2300], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Subjects will complete a daily ePRO diary to record cataplexy, sleep paralysis, hypnagogic/hypnopompic hallucinations, self-reported sleep parameters (sleep onset, waking, and quality), and naps.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Part D: Japanese Subjects With NT1\\\", \\\"6.1.4\\\", \\\"3\\\", 2301], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Subjects will remain inpatient until Day 2; after completion of the scheduled test procedures on Day 2, they may be discharged to home.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Part D: Japanese Subjects With NT1\\\", \\\"6.1.4\\\", \\\"3\\\", 2302], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"The first 4 subjects in this part will be remained in the clinic until Day 7 and then be discharged on the basis of investigator\\\\u2019s discretion to ensure subject safety.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Part D: Japanese Subjects With NT1\\\", \\\"6.1.4\\\", \\\"3\\\", 2303], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Please refer to Section 7.4.1 for further dosing instructions.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Part D: Japanese Subjects With NT1\\\", \\\"6.1.4\\\", \\\"3\\\", 2304], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"While at home, subjects will take TAK-861 orally QD at approximately the same time each morning (approximately 24 hours apart) and continue to complete the daily ePRO diary.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Part D: Japanese Subjects With NT1\\\", \\\"6.1.4\\\", \\\"3\\\", 2305], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Subjects will be discharged on Day 15 after the completion of tests.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Part D: Japanese Subjects With NT1\\\", \\\"6.1.4\\\", \\\"3\\\", 2306], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"A follow-up visit will be done on Day 21\\\\u00b12 days, after which subjects may resume the use of their prior medication for the treatment of narcolepsy.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Part D: Japanese Subjects With NT1\\\", \\\"6.1.4\\\", \\\"3\\\", 2307], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"Table 6.d Study Schedule - Part D\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading8\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"d  Study Schedule - Part D\\\", \\\"Table 6.\\\", \\\"2\\\", 2308], [\\\"\\\", \\\"Unmapped\\\", \\\"table\\\", \\\"\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": 20, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 20, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"d  Study Schedule - Part D\\\", \\\"Table 6.\\\", \\\"2\\\", 2309], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"d  Study Schedule - Part D\\\", \\\"Table 6.\\\", \\\"2\\\", 2310], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"d  Study Schedule - Part D\\\", \\\"Table 6.\\\", \\\"2\\\", 2311], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"d  Study Schedule - Part D\\\", \\\"Table 6.\\\", \\\"2\\\", 2312], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"d  Study Schedule - Part D\\\", \\\"Table 6.\\\", \\\"2\\\", 2313], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"d  Study Schedule - Part D\\\", \\\"Table 6.\\\", \\\"2\\\", 2314], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"6.1.5 Part E: SRD/MRD in Healthy Non-Japanese Subjects\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading4\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Part E: SRD/MRD in Healthy Non-Japanese Subjects\\\", \\\"6.1.5\\\", \\\"3\\\", 2315], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"The purpose of Part E is to evaluate the safety, tolerability, and PK of TAK-861 following single and multiple oral administration in healthy adult subjects of non-Japanese origin.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Part E: SRD/MRD in Healthy Non-Japanese Subjects\\\", \\\"6.1.5\\\", \\\"3\\\", 2316], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"The starting dose in Part E will be the same as cohort B1 if cohort E1 and B1 will be run in parallel.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Part E: SRD/MRD in Healthy Non-Japanese Subjects\\\", \\\"6.1.5\\\", \\\"3\\\", 2317], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"If cohort E1 starts later than Part B, the starting dose in Part E will be the same or lower than those previously tested in healthy Japanese adult subjects in Part B.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Part E: SRD/MRD in Healthy Non-Japanese Subjects\\\", \\\"6.1.5\\\", \\\"3\\\", 2318], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Considering the purpose of this part, the Sponsor will enroll non-Japanese subjects only in this part.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Part E: SRD/MRD in Healthy Non-Japanese Subjects\\\", \\\"6.1.5\\\", \\\"3\\\", 2319], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"However, depending on the safety, tolerability, and PK results of the preceding parts or cohorts, the protocol will keep the option open to enroll healthy adult subjects from different ethnicities (eg, 4 non-Japanese and 4 Japanese) in some of the cohorts in Part E.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Part E: SRD/MRD in Healthy Non-Japanese Subjects\\\", \\\"6.1.5\\\", \\\"3\\\", 2320], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"This may be done only if the sponsor and principal investigator agree for the purpose of ethnobridging evaluation at certain dose levels and to potentially minimize the number of cohorts in the entire study to be conducted.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Part E: SRD/MRD in Healthy Non-Japanese Subjects\\\", \\\"6.1.5\\\", \\\"3\\\", 2321], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Up to 4 optional cohorts are planned.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Part E: SRD/MRD in Healthy Non-Japanese Subjects\\\", \\\"6.1.5\\\", \\\"3\\\", 2322], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Each cohort will consist of 8 healthy adult subjects each who will be randomized 6:2 to receive TAK-861 versus placebo in a double-blinded fashion.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Part E: SRD/MRD in Healthy Non-Japanese Subjects\\\", \\\"6.1.5\\\", \\\"3\\\", 2323], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"If different ethnic groups are to be included in each cohort, subjects in each ethnic group may be randomized with the same ratio for TAK-861 versus placebo (eg, 3:1 for TAK-861 vs placebo in each ethnic group).\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Part E: SRD/MRD in Healthy Non-Japanese Subjects\\\", \\\"6.1.5\\\", \\\"3\\\", 2324], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Subjects will receive QD dosing of TAK-861 or matching placebo for 1 day, followed by a washout period of 5 days; daily dosing will then resume on Day 6 and continue for an additional 14 days.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Part E: SRD/MRD in Healthy Non-Japanese Subjects\\\", \\\"6.1.5\\\", \\\"3\\\", 2325], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"An overview of the schedule for Part E is provided in Table 6.e.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Part E: SRD/MRD in Healthy Non-Japanese Subjects\\\", \\\"6.1.5\\\", \\\"3\\\", 2326], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"The Schedule of Study Procedures for Part E is shown in Table 3.i.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Part E: SRD/MRD in Healthy Non-Japanese Subjects\\\", \\\"6.1.5\\\", \\\"3\\\", 2327], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Detailed timing for assessment collection for Part E is presented in Table 3.j.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Part E: SRD/MRD in Healthy Non-Japanese Subjects\\\", \\\"6.1.5\\\", \\\"3\\\", 2328], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"After the screening visit, eligible participants will be asked to wear an accelerometer device throughout the study.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Part E: SRD/MRD in Healthy Non-Japanese Subjects\\\", \\\"6.1.5\\\", \\\"3\\\", 2329], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Subjects will check in on Day -2.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Part E: SRD/MRD in Healthy Non-Japanese Subjects\\\", \\\"6.1.5\\\", \\\"3\\\", 2330], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"In addition, a predose 24-hour ABPM with an ambulatory BP device will start in the morning of Day -2 and finish in the morning of Day -1.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Part E: SRD/MRD in Healthy Non-Japanese Subjects\\\", \\\"6.1.5\\\", \\\"3\\\", 2331], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"On Day 1, eligible participants will be randomized and receive a single dose of blinded study drug (TAK-861 or placebo) orally in the morning after an overnight fast of at least 10 hours, followed by safety and PK study assessments.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Part E: SRD/MRD in Healthy Non-Japanese Subjects\\\", \\\"6.1.5\\\", \\\"3\\\", 2332], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Study drug will then be administered QD from Days 6 through 19 followed by safety and PK study assessments.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Part E: SRD/MRD in Healthy Non-Japanese Subjects\\\", \\\"6.1.5\\\", \\\"3\\\", 2333], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"A follow-up visit will occur on Day 26\\\\u00b12 days.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Part E: SRD/MRD in Healthy Non-Japanese Subjects\\\", \\\"6.1.5\\\", \\\"3\\\", 2334], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"Table 6.e Study Schedule: Part E, Non-Japanese Cohort\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading8\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"e  Study Schedule: Part E, Non-Japanese Cohort\\\", \\\"Table 6.\\\", \\\"2\\\", 2335], [\\\"\\\", \\\"Unmapped\\\", \\\"table\\\", \\\"\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": 20, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 20, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"e  Study Schedule: Part E, Non-Japanese Cohort\\\", \\\"Table 6.\\\", \\\"2\\\", 2336], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"e  Study Schedule: Part E, Non-Japanese Cohort\\\", \\\"Table 6.\\\", \\\"2\\\", 2337], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"e  Study Schedule: Part E, Non-Japanese Cohort\\\", \\\"Table 6.\\\", \\\"2\\\", 2338], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"e  Study Schedule: Part E, Non-Japanese Cohort\\\", \\\"Table 6.\\\", \\\"2\\\", 2339], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"e  Study Schedule: Part E, Non-Japanese Cohort\\\", \\\"Table 6.\\\", \\\"2\\\", 2340], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"e  Study Schedule: Part E, Non-Japanese Cohort\\\", \\\"Table 6.\\\", \\\"2\\\", 2341], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"e  Study Schedule: Part E, Non-Japanese Cohort\\\", \\\"Table 6.\\\", \\\"2\\\", 2342], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"6.1.6 Part F: ~REDACTED~ and Biomarker Evaluation in Healthy Non-Japanese Subjects\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading4\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Part F: CSF-PK and Biomarker Evaluation in Healthy Non-Japanese Subjects\\\", \\\"6.1.6\\\", \\\"3\\\", 2343], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"CSF samples may be obtained to provide an indication of CNS penetration relative to plasma concentrations of TAK-861 and to characterize the time course of the compound and OX concentrations in the CSF.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Part F: CSF-PK and Biomarker Evaluation in Healthy Non-Japanese Subjects\\\", \\\"6.1.6\\\", \\\"3\\\", 2344], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"An optional cohort of healthy non-Japanese subjects is planned.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Part F: CSF-PK and Biomarker Evaluation in Healthy Non-Japanese Subjects\\\", \\\"6.1.6\\\", \\\"3\\\", 2345], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"The cohort will consist of 10 healthy adult subjects who will be randomized 6:4 to receive TAK-861 versus placebo in a double-blinded fashion.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Part F: CSF-PK and Biomarker Evaluation in Healthy Non-Japanese Subjects\\\", \\\"6.1.6\\\", \\\"3\\\", 2346], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"The starting dose will be the same as or lower than those studied in Part B or E.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Part F: CSF-PK and Biomarker Evaluation in Healthy Non-Japanese Subjects\\\", \\\"6.1.6\\\", \\\"3\\\", 2347], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"A placebo group was included in this part to enable the meaningful comparison of diurnal pattern of CSF exploratory biomarkers (ie, CSF OX) between the subjects who will be treated with active drug and placebo.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Part F: CSF-PK and Biomarker Evaluation in Healthy Non-Japanese Subjects\\\", \\\"6.1.6\\\", \\\"3\\\", 2348], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"In Part F, subjects will receive TAK-861 or matching placebo for 10 days, which is expected to be sufficient to achieve steady state PK of the compound.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Part F: CSF-PK and Biomarker Evaluation in Healthy Non-Japanese Subjects\\\", \\\"6.1.6\\\", \\\"3\\\", 2349], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"CSF samples will be collected on Day -1 and serial CSF samples may be collected at prespecified time points for 24 hours through an indwelling temporary catheter on Day 10 through 11.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Part F: CSF-PK and Biomarker Evaluation in Healthy Non-Japanese Subjects\\\", \\\"6.1.6\\\", \\\"3\\\", 2350], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"CSF may also be used to determine OX levels in healthy adults.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Part F: CSF-PK and Biomarker Evaluation in Healthy Non-Japanese Subjects\\\", \\\"6.1.6\\\", \\\"3\\\", 2351], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"An overview of the schedule for Part F is provided in Table 6.f.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Part F: CSF-PK and Biomarker Evaluation in Healthy Non-Japanese Subjects\\\", \\\"6.1.6\\\", \\\"3\\\", 2352], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"The Schedule of Study Procedures for Part F is shown in Table 3.k.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Part F: CSF-PK and Biomarker Evaluation in Healthy Non-Japanese Subjects\\\", \\\"6.1.6\\\", \\\"3\\\", 2353], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Detailed timing for assessment collection for Part F is presented in Table 3.l.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Part F: CSF-PK and Biomarker Evaluation in Healthy Non-Japanese Subjects\\\", \\\"6.1.6\\\", \\\"3\\\", 2354], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"After the screening visit, eligible participants will be asked to wear an accelerometer device throughout the study.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Part F: CSF-PK and Biomarker Evaluation in Healthy Non-Japanese Subjects\\\", \\\"6.1.6\\\", \\\"3\\\", 2355], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Subjects will check in on Day -2.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Part F: CSF-PK and Biomarker Evaluation in Healthy Non-Japanese Subjects\\\", \\\"6.1.6\\\", \\\"3\\\", 2356], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"On Day 1, eligible participants will be randomized and receive blinded study drug (TAK-861 or placebo) orally in the morning after an overnight fast of at least 10 hours; study drug will be administered QD from Days 1 through 10.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Part F: CSF-PK and Biomarker Evaluation in Healthy Non-Japanese Subjects\\\", \\\"6.1.6\\\", \\\"3\\\", 2357], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Intensive PK sampling, BP and HR assessments, and other study assessments will be performed on Days 1 through 6.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Part F: CSF-PK and Biomarker Evaluation in Healthy Non-Japanese Subjects\\\", \\\"6.1.6\\\", \\\"3\\\", 2358], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Subjects will be discharged on Day 14.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Part F: CSF-PK and Biomarker Evaluation in Healthy Non-Japanese Subjects\\\", \\\"6.1.6\\\", \\\"3\\\", 2359], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"A follow-up visit will occur on Day 17\\\\u00b12 days.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Part F: CSF-PK and Biomarker Evaluation in Healthy Non-Japanese Subjects\\\", \\\"6.1.6\\\", \\\"3\\\", 2360], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"Table 6.f Study Schedule: Part F, ~REDACTED~ Cohort\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading8\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"f  Study Schedule: Part F, CSF Cohort\\\", \\\"Table 6.\\\", \\\"2\\\", 2361], [\\\"\\\", \\\"Unmapped\\\", \\\"table\\\", {\\\"Table\\\": \\\"<table border=\\\\\\\"1\\\\\\\" class=\\\\\\\"dataframe\\\\\\\">\\\\n  <thead>\\\\n    <tr style=\\\\\\\"text-align: right;\\\\\\\">\\\\n      <th></th>\\\\n      <th>1.0</th>\\\\n      <th>2.0</th>\\\\n      <th>3.0</th>\\\\n      <th>4.0</th>\\\\n      <th>5.0</th>\\\\n    </tr>\\\\n  </thead>\\\\n  <tbody>\\\\n    <tr>\\\\n      <th>0</th>\\\\n      <td>Screening Period</td>\\\\n      <td>Check-in and Baseline</td>\\\\n      <td>Treatment Period  Dosing  Sample Collection</td>\\\\n      <td>Treatment Period  Dosing  Sample Collection</td>\\\\n      <td>Follow-up Visit</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>1</th>\\\\n      <td>Days -35 to -2</td>\\\\n      <td>Days -2 to -1 Study assessments</td>\\\\n      <td>Days 1 to 10 Study drug administration (Dosing frequency once daily)</td>\\\\n      <td>Days 1 to 14 Study assessments</td>\\\\n      <td>Day 17\\\\u00b12 days</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>2</th>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>Confinement</td>\\\\n      <td>Confinement</td>\\\\n      <td></td>\\\\n    </tr>\\\\n  </tbody>\\\\n</table>\\\", \\\"SectionHeaderPrintPage\\\": \\\"64\\\", \\\"TableIndex\\\": \\\"37\\\", \\\"TableName\\\": \\\"Table 6.f Study Schedule: Part F, CSF Cohort\\\", \\\"Header\\\": [0]}, {\\\"IsBold\\\": true, \\\"font_size\\\": 20, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 20, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"f  Study Schedule: Part F, CSF Cohort\\\", \\\"Table 6.\\\", \\\"2\\\", 2362], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"f  Study Schedule: Part F, CSF Cohort\\\", \\\"Table 6.\\\", \\\"2\\\", 2363], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"f  Study Schedule: Part F, CSF Cohort\\\", \\\"Table 6.\\\", \\\"2\\\", 2364], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"f  Study Schedule: Part F, CSF Cohort\\\", \\\"Table 6.\\\", \\\"2\\\", 2365], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"f  Study Schedule: Part F, CSF Cohort\\\", \\\"Table 6.\\\", \\\"2\\\", 2366], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"6.2 Dose Escalation\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading2\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Dose Escalation\\\", \\\"6.2\\\", \\\"2\\\", 2367], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"6.2.1 Dose Selection Rules\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading4\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Dose Selection Rules\\\", \\\"6.2.1\\\", \\\"3\\\", 2368], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"The proposed dose range(s) to be explored in this study is anticipated to achieve a range of plasma exposures with sufficient margins above the predicted pharmacologically active exposures under narcolepsy and normal OX conditions.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Dose Selection Rules\\\", \\\"6.2.1\\\", \\\"3\\\", 2369], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Doses shown in Table 6.g after single- and multiple dose administration are included for illustrative purposes only; the actual doses evaluated during the study will be determined on the basis of a full review of all available safety, tolerability, and PK data.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Dose Selection Rules\\\", \\\"6.2.1\\\", \\\"3\\\", 2370], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"Table 6.g Predicted TAK-861 Exposures in Humans and Calculated Safety Margins\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading8\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"g  Predicted TAK-861 Exposures in Humans and Calculated Safety Margins\\\", \\\"Table 6.\\\", \\\"2\\\", 2371], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"g  Predicted TAK-861 Exposures in Humans and Calculated Safety Margins\\\", \\\"Table 6.\\\", \\\"2\\\", 2372], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 22, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Calibri\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 22, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"g  Predicted TAK-861 Exposures in Humans and Calculated Safety Margins\\\", \\\"Table 6.\\\", \\\"2\\\", 2373], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Median\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"g  Predicted TAK-861 Exposures in Humans and Calculated Safety Margins\\\", \\\"Table 6.\\\", \\\"2\\\", 2374], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"g  Predicted TAK-861 Exposures in Humans and Calculated Safety Margins\\\", \\\"Table 6.\\\", \\\"2\\\", 2375], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Median\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"g  Predicted TAK-861 Exposures in Humans and Calculated Safety Margins\\\", \\\"Table 6.\\\", \\\"2\\\", 2376], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"g  Predicted TAK-861 Exposures in Humans and Calculated Safety Margins\\\", \\\"Table 6.\\\", \\\"2\\\", 2377], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Safety\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"g  Predicted TAK-861 Exposures in Humans and Calculated Safety Margins\\\", \\\"Table 6.\\\", \\\"2\\\", 2378], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"g  Predicted TAK-861 Exposures in Humans and Calculated Safety Margins\\\", \\\"Table 6.\\\", \\\"2\\\", 2379], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Safety\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"g  Predicted TAK-861 Exposures in Humans and Calculated Safety Margins\\\", \\\"Table 6.\\\", \\\"2\\\", 2380], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"g  Predicted TAK-861 Exposures in Humans and Calculated Safety Margins\\\", \\\"Table 6.\\\", \\\"2\\\", 2381], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Time Above Efficacy\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"g  Predicted TAK-861 Exposures in Humans and Calculated Safety Margins\\\", \\\"Table 6.\\\", \\\"2\\\", 2382], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"c\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": 12, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 12, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"g  Predicted TAK-861 Exposures in Humans and Calculated Safety Margins\\\", \\\"Table 6.\\\", \\\"2\\\", 2383], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 22, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Calibri\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 22, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"g  Predicted TAK-861 Exposures in Humans and Calculated Safety Margins\\\", \\\"Table 6.\\\", \\\"2\\\", 2384], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Dosing  C\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"g  Predicted TAK-861 Exposures in Humans and Calculated Safety Margins\\\", \\\"Table 6.\\\", \\\"2\\\", 2385], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"max a\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": 12, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 12, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"g  Predicted TAK-861 Exposures in Humans and Calculated Safety Margins\\\", \\\"Table 6.\\\", \\\"2\\\", 2386], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"AUC\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"g  Predicted TAK-861 Exposures in Humans and Calculated Safety Margins\\\", \\\"Table 6.\\\", \\\"2\\\", 2387], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\\u221e a\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": 12, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 12, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"g  Predicted TAK-861 Exposures in Humans and Calculated Safety Margins\\\", \\\"Table 6.\\\", \\\"2\\\", 2388], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Margin\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"g  Predicted TAK-861 Exposures in Humans and Calculated Safety Margins\\\", \\\"Table 6.\\\", \\\"2\\\", 2389], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"b\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": 12, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 12, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"g  Predicted TAK-861 Exposures in Humans and Calculated Safety Margins\\\", \\\"Table 6.\\\", \\\"2\\\", 2390], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Margin\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"g  Predicted TAK-861 Exposures in Humans and Calculated Safety Margins\\\", \\\"Table 6.\\\", \\\"2\\\", 2391], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"b\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": 12, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 12, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"g  Predicted TAK-861 Exposures in Humans and Calculated Safety Margins\\\", \\\"Table 6.\\\", \\\"2\\\", 2392], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Threshold (h)\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"g  Predicted TAK-861 Exposures in Humans and Calculated Safety Margins\\\", \\\"Table 6.\\\", \\\"2\\\", 2393], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Daily Dose Regimen (ng/mL) (ng*h/mL) C\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"g  Predicted TAK-861 Exposures in Humans and Calculated Safety Margins\\\", \\\"Table 6.\\\", \\\"2\\\", 2394], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"max\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"subscript\\\"}, \\\"Study Design\\\", \\\"g  Predicted TAK-861 Exposures in Humans and Calculated Safety Margins\\\", \\\"Table 6.\\\", \\\"2\\\", 2395], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"AUC\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"g  Predicted TAK-861 Exposures in Humans and Calculated Safety Margins\\\", \\\"Table 6.\\\", \\\"2\\\", 2396], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"24\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"subscript\\\"}, \\\"Study Design\\\", \\\"g  Predicted TAK-861 Exposures in Humans and Calculated Safety Margins\\\", \\\"Table 6.\\\", \\\"2\\\", 2397], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"NT1 Non-narcolepsy\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"g  Predicted TAK-861 Exposures in Humans and Calculated Safety Margins\\\", \\\"Table 6.\\\", \\\"2\\\", 2398], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"g  Predicted TAK-861 Exposures in Humans and Calculated Safety Margins\\\", \\\"Table 6.\\\", \\\"2\\\", 2399], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"0.5 mg SD 5.77 181 3362 1343 0 0\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"g  Predicted TAK-861 Exposures in Humans and Calculated Safety Margins\\\", \\\"Table 6.\\\", \\\"2\\\", 2400], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"1 mg\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"g  Predicted TAK-861 Exposures in Humans and Calculated Safety Margins\\\", \\\"Table 6.\\\", \\\"2\\\", 2401], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"g  Predicted TAK-861 Exposures in Humans and Calculated Safety Margins\\\", \\\"Table 6.\\\", \\\"2\\\", 2402], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"SD\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"g  Predicted TAK-861 Exposures in Humans and Calculated Safety Margins\\\", \\\"Table 6.\\\", \\\"2\\\", 2403], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"g  Predicted TAK-861 Exposures in Humans and Calculated Safety Margins\\\", \\\"Table 6.\\\", \\\"2\\\", 2404], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"11.5\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"g  Predicted TAK-861 Exposures in Humans and Calculated Safety Margins\\\", \\\"Table 6.\\\", \\\"2\\\", 2405], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"g  Predicted TAK-861 Exposures in Humans and Calculated Safety Margins\\\", \\\"Table 6.\\\", \\\"2\\\", 2406], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"362\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"g  Predicted TAK-861 Exposures in Humans and Calculated Safety Margins\\\", \\\"Table 6.\\\", \\\"2\\\", 2407], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"g  Predicted TAK-861 Exposures in Humans and Calculated Safety Margins\\\", \\\"Table 6.\\\", \\\"2\\\", 2408], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"1687\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"g  Predicted TAK-861 Exposures in Humans and Calculated Safety Margins\\\", \\\"Table 6.\\\", \\\"2\\\", 2409], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"g  Predicted TAK-861 Exposures in Humans and Calculated Safety Margins\\\", \\\"Table 6.\\\", \\\"2\\\", 2410], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"671\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"g  Predicted TAK-861 Exposures in Humans and Calculated Safety Margins\\\", \\\"Table 6.\\\", \\\"2\\\", 2411], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"g  Predicted TAK-861 Exposures in Humans and Calculated Safety Margins\\\", \\\"Table 6.\\\", \\\"2\\\", 2412], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"6\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"g  Predicted TAK-861 Exposures in Humans and Calculated Safety Margins\\\", \\\"Table 6.\\\", \\\"2\\\", 2413], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"g  Predicted TAK-861 Exposures in Humans and Calculated Safety Margins\\\", \\\"Table 6.\\\", \\\"2\\\", 2414], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"0\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"g  Predicted TAK-861 Exposures in Humans and Calculated Safety Margins\\\", \\\"Table 6.\\\", \\\"2\\\", 2415], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"1.5 mg SD 17.3 543 1121 448 14.5 0\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"g  Predicted TAK-861 Exposures in Humans and Calculated Safety Margins\\\", \\\"Table 6.\\\", \\\"2\\\", 2416], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"3 mg SD 34.6 1085 561 224 35.3 0\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"g  Predicted TAK-861 Exposures in Humans and Calculated Safety Margins\\\", \\\"Table 6.\\\", \\\"2\\\", 2417], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"10 mg SD 115 3617 169 67 >48 12\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"g  Predicted TAK-861 Exposures in Humans and Calculated Safety Margins\\\", \\\"Table 6.\\\", \\\"2\\\", 2418], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"28890426727>484211180176413504.5028890426727>484211180176413504.5025 mg\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"g  Predicted TAK-861 Exposures in Humans and Calculated Safety Margins\\\", \\\"Table 6.\\\", \\\"2\\\", 2419], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"g  Predicted TAK-861 Exposures in Humans and Calculated Safety Margins\\\", \\\"Table 6.\\\", \\\"2\\\", 2420], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"SD\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"g  Predicted TAK-861 Exposures in Humans and Calculated Safety Margins\\\", \\\"Table 6.\\\", \\\"2\\\", 2421], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"288\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"g  Predicted TAK-861 Exposures in Humans and Calculated Safety Margins\\\", \\\"Table 6.\\\", \\\"2\\\", 2422], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"9042\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"g  Predicted TAK-861 Exposures in Humans and Calculated Safety Margins\\\", \\\"Table 6.\\\", \\\"2\\\", 2423], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"67\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"g  Predicted TAK-861 Exposures in Humans and Calculated Safety Margins\\\", \\\"Table 6.\\\", \\\"2\\\", 2424], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"27\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"g  Predicted TAK-861 Exposures in Humans and Calculated Safety Margins\\\", \\\"Table 6.\\\", \\\"2\\\", 2425], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\">48\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"g  Predicted TAK-861 Exposures in Humans and Calculated Safety Margins\\\", \\\"Table 6.\\\", \\\"2\\\", 2426], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"42\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"g  Predicted TAK-861 Exposures in Humans and Calculated Safety Margins\\\", \\\"Table 6.\\\", \\\"2\\\", 2427], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"11\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"g  Predicted TAK-861 Exposures in Humans and Calculated Safety Margins\\\", \\\"Table 6.\\\", \\\"2\\\", 2428], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"180\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"g  Predicted TAK-861 Exposures in Humans and Calculated Safety Margins\\\", \\\"Table 6.\\\", \\\"2\\\", 2429], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"1764\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"g  Predicted TAK-861 Exposures in Humans and Calculated Safety Margins\\\", \\\"Table 6.\\\", \\\"2\\\", 2430], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"1350\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"g  Predicted TAK-861 Exposures in Humans and Calculated Safety Margins\\\", \\\"Table 6.\\\", \\\"2\\\", 2431], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"4.5\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"g  Predicted TAK-861 Exposures in Humans and Calculated Safety Margins\\\", \\\"Table 6.\\\", \\\"2\\\", 2432], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"0\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"g  Predicted TAK-861 Exposures in Humans and Calculated Safety Margins\\\", \\\"Table 6.\\\", \\\"2\\\", 2433], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"g  Predicted TAK-861 Exposures in Humans and Calculated Safety Margins\\\", \\\"Table 6.\\\", \\\"2\\\", 2434], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"g  Predicted TAK-861 Exposures in Humans and Calculated Safety Margins\\\", \\\"Table 6.\\\", \\\"2\\\", 2435], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"g  Predicted TAK-861 Exposures in Humans and Calculated Safety Margins\\\", \\\"Table 6.\\\", \\\"2\\\", 2436], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"g  Predicted TAK-861 Exposures in Humans and Calculated Safety Margins\\\", \\\"Table 6.\\\", \\\"2\\\", 2437], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"g  Predicted TAK-861 Exposures in Humans and Calculated Safety Margins\\\", \\\"Table 6.\\\", \\\"2\\\", 2438], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"g  Predicted TAK-861 Exposures in Humans and Calculated Safety Margins\\\", \\\"Table 6.\\\", \\\"2\\\", 2439], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"g  Predicted TAK-861 Exposures in Humans and Calculated Safety Margins\\\", \\\"Table 6.\\\", \\\"2\\\", 2440], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"g  Predicted TAK-861 Exposures in Humans and Calculated Safety Margins\\\", \\\"Table 6.\\\", \\\"2\\\", 2441], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"g  Predicted TAK-861 Exposures in Humans and Calculated Safety Margins\\\", \\\"Table 6.\\\", \\\"2\\\", 2442], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"g  Predicted TAK-861 Exposures in Humans and Calculated Safety Margins\\\", \\\"Table 6.\\\", \\\"2\\\", 2443], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"g  Predicted TAK-861 Exposures in Humans and Calculated Safety Margins\\\", \\\"Table 6.\\\", \\\"2\\\", 2444], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"g  Predicted TAK-861 Exposures in Humans and Calculated Safety Margins\\\", \\\"Table 6.\\\", \\\"2\\\", 2445], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"0.5 mg/day\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"g  Predicted TAK-861 Exposures in Humans and Calculated Safety Margins\\\", \\\"Table 6.\\\", \\\"2\\\", 2446], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"g  Predicted TAK-861 Exposures in Humans and Calculated Safety Margins\\\", \\\"Table 6.\\\", \\\"2\\\", 2447], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"QD\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"g  Predicted TAK-861 Exposures in Humans and Calculated Safety Margins\\\", \\\"Table 6.\\\", \\\"2\\\", 2448], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"1 mg/day QD 22 360 882 675 24 0\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"g  Predicted TAK-861 Exposures in Humans and Calculated Safety Margins\\\", \\\"Table 6.\\\", \\\"2\\\", 2449], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"5 mg/day\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"g  Predicted TAK-861 Exposures in Humans and Calculated Safety Margins\\\", \\\"Table 6.\\\", \\\"2\\\", 2450], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"g  Predicted TAK-861 Exposures in Humans and Calculated Safety Margins\\\", \\\"Table 6.\\\", \\\"2\\\", 2451], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"QD\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"g  Predicted TAK-861 Exposures in Humans and Calculated Safety Margins\\\", \\\"Table 6.\\\", \\\"2\\\", 2452], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"g  Predicted TAK-861 Exposures in Humans and Calculated Safety Margins\\\", \\\"Table 6.\\\", \\\"2\\\", 2453], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"1101798176135>24131101798176135>2413\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"g  Predicted TAK-861 Exposures in Humans and Calculated Safety Margins\\\", \\\"Table 6.\\\", \\\"2\\\", 2454], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"110\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"g  Predicted TAK-861 Exposures in Humans and Calculated Safety Margins\\\", \\\"Table 6.\\\", \\\"2\\\", 2455], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"1798\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"g  Predicted TAK-861 Exposures in Humans and Calculated Safety Margins\\\", \\\"Table 6.\\\", \\\"2\\\", 2456], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"176\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"g  Predicted TAK-861 Exposures in Humans and Calculated Safety Margins\\\", \\\"Table 6.\\\", \\\"2\\\", 2457], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"135\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"g  Predicted TAK-861 Exposures in Humans and Calculated Safety Margins\\\", \\\"Table 6.\\\", \\\"2\\\", 2458], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\">24\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"g  Predicted TAK-861 Exposures in Humans and Calculated Safety Margins\\\", \\\"Table 6.\\\", \\\"2\\\", 2459], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"13\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"g  Predicted TAK-861 Exposures in Humans and Calculated Safety Margins\\\", \\\"Table 6.\\\", \\\"2\\\", 2460], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"g  Predicted TAK-861 Exposures in Humans and Calculated Safety Margins\\\", \\\"Table 6.\\\", \\\"2\\\", 2461], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"g  Predicted TAK-861 Exposures in Humans and Calculated Safety Margins\\\", \\\"Table 6.\\\", \\\"2\\\", 2462], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"g  Predicted TAK-861 Exposures in Humans and Calculated Safety Margins\\\", \\\"Table 6.\\\", \\\"2\\\", 2463], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"g  Predicted TAK-861 Exposures in Humans and Calculated Safety Margins\\\", \\\"Table 6.\\\", \\\"2\\\", 2464], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"g  Predicted TAK-861 Exposures in Humans and Calculated Safety Margins\\\", \\\"Table 6.\\\", \\\"2\\\", 2465], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"g  Predicted TAK-861 Exposures in Humans and Calculated Safety Margins\\\", \\\"Table 6.\\\", \\\"2\\\", 2466], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"AUC\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"g  Predicted TAK-861 Exposures in Humans and Calculated Safety Margins\\\", \\\"Table 6.\\\", \\\"2\\\", 2467], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\\u221e\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"subscript\\\"}, \\\"Study Design\\\", \\\"g  Predicted TAK-861 Exposures in Humans and Calculated Safety Margins\\\", \\\"Table 6.\\\", \\\"2\\\", 2468], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\": area under the plasma concentration-time curve from time 0 to infinity; AUC\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"g  Predicted TAK-861 Exposures in Humans and Calculated Safety Margins\\\", \\\"Table 6.\\\", \\\"2\\\", 2469], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"24\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"subscript\\\"}, \\\"Study Design\\\", \\\"g  Predicted TAK-861 Exposures in Humans and Calculated Safety Margins\\\", \\\"Table 6.\\\", \\\"2\\\", 2470], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\": area under the plasma concentration-time curve from time 0 to 24 hours; CL: total clearance; C\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"g  Predicted TAK-861 Exposures in Humans and Calculated Safety Margins\\\", \\\"Table 6.\\\", \\\"2\\\", 2471], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"max\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"subscript\\\"}, \\\"Study Design\\\", \\\"g  Predicted TAK-861 Exposures in Humans and Calculated Safety Margins\\\", \\\"Table 6.\\\", \\\"2\\\", 2472], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\": maximum observed plasma concentration; EEG: electroencephalography; NOAEL: no-observed-adverse-effect level; NT1: narcolepsy type 1; PK: pharmacokinetic(s); QD: once daily; SD: single dose; V\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"g  Predicted TAK-861 Exposures in Humans and Calculated Safety Margins\\\", \\\"Table 6.\\\", \\\"2\\\", 2473], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"d\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"subscript\\\"}, \\\"Study Design\\\", \\\"g  Predicted TAK-861 Exposures in Humans and Calculated Safety Margins\\\", \\\"Table 6.\\\", \\\"2\\\", 2474], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\": volume of distribution.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"g  Predicted TAK-861 Exposures in Humans and Calculated Safety Margins\\\", \\\"Table 6.\\\", \\\"2\\\", 2475], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"a\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 12, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 12, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"g  Predicted TAK-861 Exposures in Humans and Calculated Safety Margins\\\", \\\"Table 6.\\\", \\\"2\\\", 2476], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Predicted human C\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"g  Predicted TAK-861 Exposures in Humans and Calculated Safety Margins\\\", \\\"Table 6.\\\", \\\"2\\\", 2477], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"max\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"subscript\\\"}, \\\"Study Design\\\", \\\"g  Predicted TAK-861 Exposures in Humans and Calculated Safety Margins\\\", \\\"Table 6.\\\", \\\"2\\\", 2478], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"and AUC\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"g  Predicted TAK-861 Exposures in Humans and Calculated Safety Margins\\\", \\\"Table 6.\\\", \\\"2\\\", 2479], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\\u221e\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"subscript\\\"}, \\\"Study Design\\\", \\\"g  Predicted TAK-861 Exposures in Humans and Calculated Safety Margins\\\", \\\"Table 6.\\\", \\\"2\\\", 2480], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"values using allometric scaling/physiologically-based PK modeling (CL = 2.45 L/h; V\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"g  Predicted TAK-861 Exposures in Humans and Calculated Safety Margins\\\", \\\"Table 6.\\\", \\\"2\\\", 2481], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"d\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"subscript\\\"}, \\\"Study Design\\\", \\\"g  Predicted TAK-861 Exposures in Humans and Calculated Safety Margins\\\", \\\"Table 6.\\\", \\\"2\\\", 2482], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"= 1.11 L/kg from IV dosing, F= 83%).\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"g  Predicted TAK-861 Exposures in Humans and Calculated Safety Margins\\\", \\\"Table 6.\\\", \\\"2\\\", 2483], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"b\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 12, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 12, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"g  Predicted TAK-861 Exposures in Humans and Calculated Safety Margins\\\", \\\"Table 6.\\\", \\\"2\\\", 2484], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Safety margins for C\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"g  Predicted TAK-861 Exposures in Humans and Calculated Safety Margins\\\", \\\"Table 6.\\\", \\\"2\\\", 2485], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"max\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"subscript\\\"}, \\\"Study Design\\\", \\\"g  Predicted TAK-861 Exposures in Humans and Calculated Safety Margins\\\", \\\"Table 6.\\\", \\\"2\\\", 2486], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"and AUC\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"g  Predicted TAK-861 Exposures in Humans and Calculated Safety Margins\\\", \\\"Table 6.\\\", \\\"2\\\", 2487], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\\u221e\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"subscript\\\"}, \\\"Study Design\\\", \\\"g  Predicted TAK-861 Exposures in Humans and Calculated Safety Margins\\\", \\\"Table 6.\\\", \\\"2\\\", 2488], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"were calculated using the exposure-limiting criteria (NOAEL in monkeys: Day 28 mean values for both sexes: C\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"g  Predicted TAK-861 Exposures in Humans and Calculated Safety Margins\\\", \\\"Table 6.\\\", \\\"2\\\", 2489], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"max\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"subscript\\\"}, \\\"Study Design\\\", \\\"g  Predicted TAK-861 Exposures in Humans and Calculated Safety Margins\\\", \\\"Table 6.\\\", \\\"2\\\", 2490], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"= 19,400 ng/mL ng/mL and AUC\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"g  Predicted TAK-861 Exposures in Humans and Calculated Safety Margins\\\", \\\"Table 6.\\\", \\\"2\\\", 2491], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"24\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"subscript\\\"}, \\\"Study Design\\\", \\\"g  Predicted TAK-861 Exposures in Humans and Calculated Safety Margins\\\", \\\"Table 6.\\\", \\\"2\\\", 2492], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"= 243,000 ng*h/mL).\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"g  Predicted TAK-861 Exposures in Humans and Calculated Safety Margins\\\", \\\"Table 6.\\\", \\\"2\\\", 2493], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"The area under the plasma concentration-time curve and C\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"g  Predicted TAK-861 Exposures in Humans and Calculated Safety Margins\\\", \\\"Table 6.\\\", \\\"2\\\", 2494], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"max\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"subscript\\\"}, \\\"Study Design\\\", \\\"g  Predicted TAK-861 Exposures in Humans and Calculated Safety Margins\\\", \\\"Table 6.\\\", \\\"2\\\", 2495], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"of the maximal dose will not exceed the mean AUC\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"g  Predicted TAK-861 Exposures in Humans and Calculated Safety Margins\\\", \\\"Table 6.\\\", \\\"2\\\", 2496], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"24\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"subscript\\\"}, \\\"Study Design\\\", \\\"g  Predicted TAK-861 Exposures in Humans and Calculated Safety Margins\\\", \\\"Table 6.\\\", \\\"2\\\", 2497], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"and C\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"g  Predicted TAK-861 Exposures in Humans and Calculated Safety Margins\\\", \\\"Table 6.\\\", \\\"2\\\", 2498], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"max\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"subscript\\\"}, \\\"Study Design\\\", \\\"g  Predicted TAK-861 Exposures in Humans and Calculated Safety Margins\\\", \\\"Table 6.\\\", \\\"2\\\", 2499], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"of the monkey NOAEL.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"g  Predicted TAK-861 Exposures in Humans and Calculated Safety Margins\\\", \\\"Table 6.\\\", \\\"2\\\", 2500], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"c\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 12, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 12, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"g  Predicted TAK-861 Exposures in Humans and Calculated Safety Margins\\\", \\\"Table 6.\\\", \\\"2\\\", 2501], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Efficacy threshold = 10 ng/mL (NT1) or 70 ng/mL (non-narcolepsy), predicted from monkey EEG studies.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"g  Predicted TAK-861 Exposures in Humans and Calculated Safety Margins\\\", \\\"Table 6.\\\", \\\"2\\\", 2502], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"In this study, dose escalation and subsequent dose levels will be selected on the basis of a review of available safety, tolerability, and PK data from the previous dosing cohorts and will only occur following agreement between the investigator and sponsor for dose selection (refer to Section 6.3.4).\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"g  Predicted TAK-861 Exposures in Humans and Calculated Safety Margins\\\", \\\"Table 6.\\\", \\\"2\\\", 2503], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Subsequent dose levels may be higher than, lower than, or the same as the preceding dose level.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"g  Predicted TAK-861 Exposures in Humans and Calculated Safety Margins\\\", \\\"Table 6.\\\", \\\"2\\\", 2504], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"In Part A, to determine the dose levels of Cohorts A2 up to ~REDACTED~, safety and available PK data from previous cohorts will be considered.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"g  Predicted TAK-861 Exposures in Humans and Calculated Safety Margins\\\", \\\"Table 6.\\\", \\\"2\\\", 2505], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"In Part B, dose levels in each cohort will be selected within the range of dose levels previously tested in Part A.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"g  Predicted TAK-861 Exposures in Humans and Calculated Safety Margins\\\", \\\"Table 6.\\\", \\\"2\\\", 2506], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Safety and PK data from all completed cohorts in Parts A and B will be considered.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"g  Predicted TAK-861 Exposures in Humans and Calculated Safety Margins\\\", \\\"Table 6.\\\", \\\"2\\\", 2507], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Parts C, E, and F may be conducted in parallel with Part B.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"g  Predicted TAK-861 Exposures in Humans and Calculated Safety Margins\\\", \\\"Table 6.\\\", \\\"2\\\", 2508], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"The starting doses in each part will be the same as or lower than those previously tested in this study.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"g  Predicted TAK-861 Exposures in Humans and Calculated Safety Margins\\\", \\\"Table 6.\\\", \\\"2\\\", 2509], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"In Part D, subjects with NT1 may start dosing once safety, tolerability, and PK data are available from Cohort B1.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"g  Predicted TAK-861 Exposures in Humans and Calculated Safety Margins\\\", \\\"Table 6.\\\", \\\"2\\\", 2510], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Dose levels for each cohort in Part D will be selected within the range of dose levels previously tested in Part B with adequate safety and tolerability confirmed, and dose selection will be supported by the predicted range of pharmacologically active plasma exposure from animal studies.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"g  Predicted TAK-861 Exposures in Humans and Calculated Safety Margins\\\", \\\"Table 6.\\\", \\\"2\\\", 2511], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"The dose level of the following cohort in Part D will be decided on the basis of available information including safety, tolerability, PK, and PD data in this study.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"g  Predicted TAK-861 Exposures in Humans and Calculated Safety Margins\\\", \\\"Table 6.\\\", \\\"2\\\", 2512], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"6.2.2 Data Review and Interim Analysis\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading4\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Data Review and Interim Analysis\\\", \\\"6.2.2\\\", \\\"3\\\", 2513], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Ongoing medical monitoring will occur during the study.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Data Review and Interim Analysis\\\", \\\"6.2.2\\\", \\\"3\\\", 2514], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Stopping rules are in Section 6.5.5 and Section 7.4.3.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Data Review and Interim Analysis\\\", \\\"6.2.2\\\", \\\"3\\\", 2515], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"The dose level chosen in each of the study parts after the first cohort and the decision whether to proceed to the next cohort or study part or to stop dosing may be evaluated by the sponsor\\\\u2019s unblinded team.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Data Review and Interim Analysis\\\", \\\"6.2.2\\\", \\\"3\\\", 2516], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Specifically, dose decision for specific cohorts including Cohorts A2, A3, B1, and D1 will be guided by unblind review of PK and safety data including BP and pulse rate.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Data Review and Interim Analysis\\\", \\\"6.2.2\\\", \\\"3\\\", 2517], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Dose decision for Cohort D2 will be guided by unblinded data review of available PK, PD, and safety data from previous cohorts.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Data Review and Interim Analysis\\\", \\\"6.2.2\\\", \\\"3\\\", 2518], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"The sponsor\\\\u2019s unblinded team will be comprised of individuals who do not have subject contact or involvement with the execution of the protocol at the site.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Data Review and Interim Analysis\\\", \\\"6.2.2\\\", \\\"3\\\", 2519], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"They will review unblinded data on safety and tolerability and any available PK results, and recommend the dose for the next cohort.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Data Review and Interim Analysis\\\", \\\"6.2.2\\\", \\\"3\\\", 2520], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"The interim analysis or cohort basis unblind may be done based on the sponsor\\\\u2019s decision.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Data Review and Interim Analysis\\\", \\\"6.2.2\\\", \\\"3\\\", 2521], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Also see Section 11.2 about the potential interim analysis.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Data Review and Interim Analysis\\\", \\\"6.2.2\\\", \\\"3\\\", 2522], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"6.3 Rationale for Study Design, Dose, and Endpoints\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading2\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Rationale for Study Design, Dose, and Endpoints\\\", \\\"6.3\\\", \\\"2\\\", 2523], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"6.3.1 Rationale for Study Population\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading4\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Rationale for Study Population\\\", \\\"6.3.1\\\", \\\"3\\\", 2524], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"6.3.1.1 Healthy Subjects\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading6\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Rationale for Study Population\\\", \\\"6.3.1\\\", \\\"3\\\", 2525], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"The subjects included in Part A, B, C, E, and F will be healthy, Japanese and non-Japanese adults and healthy Japanese elderly subjects who do not have any significant diseases, including significant cardiovascular or cerebrovascular health conditions.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Rationale for Study Population\\\", \\\"6.3.1\\\", \\\"3\\\", 2526], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"It will allow evaluation of the safety, tolerability, and PK profile of TAK-861 in a healthy population after single and repeated daily oral administration.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Rationale for Study Population\\\", \\\"6.3.1\\\", \\\"3\\\", 2527], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"These results will support the global clinical development of TAK-861 for the treatment of NT1 as well as other sleep disorder indications.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Rationale for Study Population\\\", \\\"6.3.1\\\", \\\"3\\\", 2528], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"In Part F, to minimize potential effect of inter- and intraindividual variability of sleep-wake cycles on ~REDACTED~ OX level, subjects who are maintaining a normal sleep-wake pattern evidenced by approximately 10-day actigraphy records associated with a sleep diary record during the screening period will be selected.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Rationale for Study Population\\\", \\\"6.3.1\\\", \\\"3\\\", 2529], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"6.3.1.2 Subjects With NT1\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading6\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Rationale for Study Population\\\", \\\"6.3.1\\\", \\\"3\\\", 2530], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Subjects with NT1 are deficient in OX and hence are the first candidates who would most benefit from treatment with an OX2R agonist.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Rationale for Study Population\\\", \\\"6.3.1\\\", \\\"3\\\", 2531], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Part D is designed as a repeat-dose study to evaluate the safety, tolerability, and PD effects of TAK-861 after repeat oral daily dosing in subjects with NT1.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Rationale for Study Population\\\", \\\"6.3.1\\\", \\\"3\\\", 2532], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"In nonclinical pharmacology studies, wake-promoting effects, as well as improvement of cataplexy-like syndrome by TAK-861, were observed in OX-deficient OX/ataxin-3 TG mice, a murine narcolepsy model.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Rationale for Study Population\\\", \\\"6.3.1\\\", \\\"3\\\", 2533], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"TAK-861 showed significant arousal effects in OX/ataxin-3 TG mice\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Rationale for Study Population\\\", \\\"6.3.1\\\", \\\"3\\\", 2534], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"(0.3 mg/kg, oral) during their sleep phase with an efficacious concentration that was approximately 7-fold lower than that in non-TG mice (3 mg/kg, oral), suggesting that there may be a difference in sensitivity to TAK-861 between subjects with narcolepsy and healthy subjects.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Rationale for Study Population\\\", \\\"6.3.1\\\", \\\"3\\\", 2535], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"6.3.2 Rationale of Study Design\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading4\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Rationale of Study Design\\\", \\\"6.3.2\\\", \\\"3\\\", 2536], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"The available nonclinical pharmacology, PK, and toxicology studies support the design of the proposed escalating single and multiple dose study of TAK-861 in humans, which will assess the safety, tolerability, PK, and PD of TAK-861 administered orally to healthy subjects and subjects with NT1.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Rationale of Study Design\\\", \\\"6.3.2\\\", \\\"3\\\", 2537], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Several key aspects were taken into consideration when designing the study, because the information generated will inform the design and dose selection for the late-phase development of TAK-861 as a potential treatment for NT1.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Rationale of Study Design\\\", \\\"6.3.2\\\", \\\"3\\\", 2538], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"This study may also support development of TAK-861 in other sleep disorder indications.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Rationale of Study Design\\\", \\\"6.3.2\\\", \\\"3\\\", 2539], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Study assessments are selected on the basis of data from nonclinical studies with TAK-861.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Rationale of Study Design\\\", \\\"6.3.2\\\", \\\"3\\\", 2540], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Because cardiovascular effects have been noted in nonclinical models with OX2R agonists and are thought to be on-target effects, monitoring for effects on BP and pulse will be conducted.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Rationale of Study Design\\\", \\\"6.3.2\\\", \\\"3\\\", 2541], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Cardiovascular effects will be evaluated in healthy subjects using time-matched BP and pulse assessments and Holter ECG assessments.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Rationale of Study Design\\\", \\\"6.3.2\\\", \\\"3\\\", 2542], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"In addition, ~REDACTED~ sampling may be collected to enable the characterization of TAK-861 exposure in the CNS, based on observed PD response.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Rationale of Study Design\\\", \\\"6.3.2\\\", \\\"3\\\", 2543], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"In Part D, subjects with NT1 will undergo close BP and pulse monitoring during confinement and will have outpatient ABPM at specific times.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Rationale of Study Design\\\", \\\"6.3.2\\\", \\\"3\\\", 2544], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Potential effects of TAK-861 on nighttime sleep will also be evaluated in healthy subjects by sleep questionnaires.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Rationale of Study Design\\\", \\\"6.3.2\\\", \\\"3\\\", 2545], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Because any adverse effects of TAK-861 on sleep in healthy subjects may not occur in subjects with NT1 (because they are OX deficient), multiple oral administration of TAK-861 will be evaluated in subjects with NT1 for safety and tolerability for 14 days.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Rationale of Study Design\\\", \\\"6.3.2\\\", \\\"3\\\", 2546], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Exploratory PD/efficacy measures in subjects with NT1 include the ESS, measurement of sleep latency on the MWT, and assessment of cataplexy frequency.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Rationale of Study Design\\\", \\\"6.3.2\\\", \\\"3\\\", 2547], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"The effects of TAK-861 repeat dosing on nighttime sleep architecture will also be assessed with nPSG in subjects with NT1.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Rationale of Study Design\\\", \\\"6.3.2\\\", \\\"3\\\", 2548], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"6.3.2.1 Parts A, B, C, E, and F\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading6\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Parts A, B, C, E, and F\\\", \\\"6.3.2.1\\\", \\\"4\\\", 2549], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Parts A, B, C, E, and F are randomized, double-blind, placebo-controlled design consisting of multiple SRD and MRD cohorts.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Parts A, B, C, E, and F\\\", \\\"6.3.2.1\\\", \\\"4\\\", 2550], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"This design is considered appropriate for the evaluation of TAK-861 in healthy subjects.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Parts A, B, C, E, and F\\\", \\\"6.3.2.1\\\", \\\"4\\\", 2551], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Parts A, B, C, E, and F are designed to support the late-phase development of TAK-861.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Parts A, B, C, E, and F\\\", \\\"6.3.2.1\\\", \\\"4\\\", 2552], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Cohort A3 and ~REDACTED~ (optional cohort), which evaluates the effect of food on TAK-861 PK, and Part B, which evaluates multiple repeated doses of TAK-861, are intended to support dosing administration in subjects with NT1 in an outpatient setting.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Parts A, B, C, E, and F\\\", \\\"6.3.2.1\\\", \\\"4\\\", 2553], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Part F, which incorporates ~REDACTED~ sampling to enable the characterization of TAK-861 exposure in the CNS and to understand the potential effect of TAK-861 on ~REDACTED~ OX diurnal variation.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Parts A, B, C, E, and F\\\", \\\"6.3.2.1\\\", \\\"4\\\", 2554], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Part C and Part E are intended to investigate age- and ethnicity-related differences, respectively, in the safety, tolerability, and/or PK of TAK-861.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Parts A, B, C, E, and F\\\", \\\"6.3.2.1\\\", \\\"4\\\", 2555], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Study assessments are selected based on nonclinical data from studies of TAK-861.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Parts A, B, C, E, and F\\\", \\\"6.3.2.1\\\", \\\"4\\\", 2556], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"In nonclinical studies of monkeys, increases in BP were observed after TAK-861 administration.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Parts A, B, C, E, and F\\\", \\\"6.3.2.1\\\", \\\"4\\\", 2557], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Therefore, Parts A, B, C, E, and F include close monitoring of cardiovascular parameters, including time-matched BP measurements before and after dosing to detect any changes and potential tolerance in BP following the administration of repeat doses.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Parts A, B, C, E, and F\\\", \\\"6.3.2.1\\\", \\\"4\\\", 2558], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Similarly, based on the potential effects of TAK-861 on nighttime sleep, Parts B, C, E and F also include evaluation of nighttime sleep in healthy subjects by sleep assessment questionnaire.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Parts A, B, C, E, and F\\\", \\\"6.3.2.1\\\", \\\"4\\\", 2559], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Part F is designed to provide an indication of CNS penetration relative to plasma concentrations of TAK-861.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Parts A, B, C, E, and F\\\", \\\"6.3.2.1\\\", \\\"4\\\", 2560], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Selected ~REDACTED~ samples will also be used for measuring OX levels.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Parts A, B, C, E, and F\\\", \\\"6.3.2.1\\\", \\\"4\\\", 2561], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Ten days of dosing should be sufficient to achieve steady state conditions based on the predicted TAK-861 half-life in human of 20 hours.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Parts A, B, C, E, and F\\\", \\\"6.3.2.1\\\", \\\"4\\\", 2562], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Subjects in Parts A, B, C, E, and F will be confined to an inpatient facility throughout the conduct of the study.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Parts A, B, C, E, and F\\\", \\\"6.3.2.1\\\", \\\"4\\\", 2563], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"This confinement ensures adherence to study procedures and permits monitoring of safety and tolerability.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Parts A, B, C, E, and F\\\", \\\"6.3.2.1\\\", \\\"4\\\", 2564], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"The duration of the dosing in Parts B through E is standard for MRD studies to allow evaluation of tolerability, safety, and PK.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Parts A, B, C, E, and F\\\", \\\"6.3.2.1\\\", \\\"4\\\", 2565], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"6.3.2.2 Part D\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading6\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Part D\\\", \\\"6.3.2.2\\\", \\\"4\\\", 2566], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Part D is a randomized, double-blind, placebo-controlled study consisting of MRD cohorts in subjects with NT1.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Part D\\\", \\\"6.3.2.2\\\", \\\"4\\\", 2567], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"The design is considered appropriate for subjects with narcolepsy due to the substantial length of treatment period (ie, 14 days) in this part of the study.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Part D\\\", \\\"6.3.2.2\\\", \\\"4\\\", 2568], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Part D is designed to begin enrollment after at least 1 MRD cohort in healthy subjects from Part B has completed at a dose that is within the predicted efficacious range to be initially tested in the first cohort of subjects with NT1 and dosing was found to be generally safe and tolerable.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Part D\\\", \\\"6.3.2.2\\\", \\\"4\\\", 2569], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Because there may be a difference in sensitivity to TAK-861 between healthy subjects and subjects with narcolepsy, a stepwise approach in which the drug is evaluated in healthy subjects before being administered to subjects with narcolepsy is considered appropriate for this part.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Part D\\\", \\\"6.3.2.2\\\", \\\"4\\\", 2570], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Unlike cohorts of healthy subjects that are typically dosed as a group, subjects with NT1 will be enrolled individually into Part D; this design is typical for studies recruiting subjects.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Part D\\\", \\\"6.3.2.2\\\", \\\"4\\\", 2571], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"The duration of the dosing in Part D allows evaluation of exploratory outcomes (eg, measurement of sleep latency on the MWT, exploratory assessment of cataplexy frequency, nPSG pattern) once the subjects have achieved steady-state.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Part D\\\", \\\"6.3.2.2\\\", \\\"4\\\", 2572], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Adverse effects of TAK-861 on sleep observed in healthy subjects may not occur in subjects with NT1 because they are OX deficient; therefore, Part D evaluates oral administration of multiple doses of TAK-861 in subjects with NT1 for 14 days.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Part D\\\", \\\"6.3.2.2\\\", \\\"4\\\", 2573], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Typically, if G protein\\\\u2013coupled receptor desensitization by a receptor agonist occurs, this desensitization happens within a short time frame of minutes (short reaction) or hours to days (longer reaction).\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Part D\\\", \\\"6.3.2.2\\\", \\\"4\\\", 2574], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Therefore, 14 days of dosing should be sufficient to evaluate the exploratory efficacy outcomes in Part D at the time when the steady state of TAK-861 PK is expected to be achieved.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Part D\\\", \\\"6.3.2.2\\\", \\\"4\\\", 2575], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"A completed 4-week Good Laboratory Practice (GLP) toxicity study supports the above dosing duration.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Part D\\\", \\\"6.3.2.2\\\", \\\"4\\\", 2576], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"The study population enrolled in these parts will be a medically healthy population other than having narcolepsy.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Part D\\\", \\\"6.3.2.2\\\", \\\"4\\\", 2577], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"6.3.3 Rationale for Dose\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading4\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Rationale for Dose\\\", \\\"6.3.3\\\", \\\"3\\\", 2578], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"6.3.3.1 Starting Dose for This Study\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading6\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Starting Dose for This Study\\\", \\\"6.3.3.1\\\", \\\"4\\\", 2579], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"6.3.3.1.1\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": true, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Healthy Subjects\\\", \\\"6.3.3.1.1\\\", \\\"5\\\", 2580], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": true, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Healthy Subjects\\\", \\\"6.3.3.1.1\\\", \\\"5\\\", 2581], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Healthy Subjects\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": true, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Healthy Subjects\\\", \\\"6.3.3.1.1\\\", \\\"5\\\", 2582], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"The starting dose of this study in Part A (Cohort A1) is 1 mg of TAK-861 administered as a single, oral dose.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Healthy Subjects\\\", \\\"6.3.3.1.1\\\", \\\"5\\\", 2583], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Although several drug-related findings were identified in the 4-week GLP toxicity studies in rats\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Healthy Subjects\\\", \\\"6.3.3.1.1\\\", \\\"5\\\", 2584], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"(20, 100, and 1000 mg/kg/day; n = 10 animals/sex/group) and monkeys (30, 100, and 300 mg/kg/day; n = 3 animals/sex/group) administered TAK-861 by oral gavage, none were considered adverse.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Healthy Subjects\\\", \\\"6.3.3.1.1\\\", \\\"5\\\", 2585], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"No animal deaths were also observed in these definitive 4-week studies and therefore, the NOAELs were determined to be 1000 mg/kg/day and 300 mg/kg/day in the rats and monkeys, respectively.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Healthy Subjects\\\", \\\"6.3.3.1.1\\\", \\\"5\\\", 2586], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"According to the ~REDACTED~ guidance in Initial Clinical Trials for Therapeutics in Adult Healthy Volunteers [11], the calculated human equivalent doses (HEDs) at the NOAELs from the 4-week, repeat-dose toxicity studies in rats and monkeys indicate that the lowest HED of 97 mg/kg/d was obtained from the monkey, based on body surface area.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Healthy Subjects\\\", \\\"6.3.3.1.1\\\", \\\"5\\\", 2587], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Multiplying the HED by 60 kg, a conservative estimate of human body weight, results in a total daily dose of 5806 mg/d.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Healthy Subjects\\\", \\\"6.3.3.1.1\\\", \\\"5\\\", 2588], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"By considering a 10-fold safety factor per ~REDACTED~ guidance, the maximum recommended starting dose is 581 mg/d.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Healthy Subjects\\\", \\\"6.3.3.1.1\\\", \\\"5\\\", 2589], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"In addition, the guidance recommends taking into consideration the projected pharmacologically active dose/exposure in humans.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Healthy Subjects\\\", \\\"6.3.3.1.1\\\", \\\"5\\\", 2590], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Using a PK/PD modeling approach, the efficacious plasma concentration of TAK-861 in monkeys (1 mg/kg, oral) associated with maintenance of wakefulness for 8 hours after drug administration, as measured by EEG, was estimated to be 100 ng/mL (based on actual measurements).\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Healthy Subjects\\\", \\\"6.3.3.1.1\\\", \\\"5\\\", 2591], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"In addition, TAK-861 showed significant arousal effects in OX/ataxin-3 TG mice (0.3 mg/kg, oral) during their sleep phase with an efficacious concentration that was approximately 7-fold lower than that in non-TG mice (3 mg/kg, oral).\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Healthy Subjects\\\", \\\"6.3.3.1.1\\\", \\\"5\\\", 2592], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Accounting for the cross-species difference in plasma protein binding and differential wake-promoting effects between narcolepsy and normal OX conditions, the efficacious concentration range of TAK-861 is projected to be 10 to 70 ng/mL in humans (based on prediction).\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Healthy Subjects\\\", \\\"6.3.3.1.1\\\", \\\"5\\\", 2593], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Predictions of the human PK profile of TAK-861 estimate an oral bioavailability of 83% and elimination half-life of 20.1 hours as well as an approximate 2-fold accumulation in plasma TAK-861 exposure with QD dosing.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Healthy Subjects\\\", \\\"6.3.3.1.1\\\", \\\"5\\\", 2594], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Using allometric scaling and physiologically-based PK modeling, these human efficacious exposures are expected to be achieved and sustained with daily doses of approximately 1 to 5 mg, respectively.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Healthy Subjects\\\", \\\"6.3.3.1.1\\\", \\\"5\\\", 2595], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Taking these data together, the proposed starting dose of 1 mg, with a predicted C\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Healthy Subjects\\\", \\\"6.3.3.1.1\\\", \\\"5\\\", 2596], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"max\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"subscript\\\"}, \\\"Study Design\\\", \\\"Healthy Subjects\\\", \\\"6.3.3.1.1\\\", \\\"5\\\", 2597], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"of\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Healthy Subjects\\\", \\\"6.3.3.1.1\\\", \\\"5\\\", 2598], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"11.5 ng/mL and AUC\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Healthy Subjects\\\", \\\"6.3.3.1.1\\\", \\\"5\\\", 2599], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\\u221e\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"subscript\\\"}, \\\"Study Design\\\", \\\"Healthy Subjects\\\", \\\"6.3.3.1.1\\\", \\\"5\\\", 2600], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"of 362 h*ng/mL, will produce TAK-861 systemic exposures approaching the predicted pharmacologically active concentration range and provide an estimated 1687- and 671-fold margin to the observed plasma exposures at the NOAEL of 300 mg/kg/day in monkeys (ie, Day 28 mean values for both sexes: C\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Healthy Subjects\\\", \\\"6.3.3.1.1\\\", \\\"5\\\", 2601], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"max\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"subscript\\\"}, \\\"Study Design\\\", \\\"Healthy Subjects\\\", \\\"6.3.3.1.1\\\", \\\"5\\\", 2602], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"= 19,400 ng/mL and AUC\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Healthy Subjects\\\", \\\"6.3.3.1.1\\\", \\\"5\\\", 2603], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"24\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"subscript\\\"}, \\\"Study Design\\\", \\\"Healthy Subjects\\\", \\\"6.3.3.1.1\\\", \\\"5\\\", 2604], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"= 243, 000 h*ng/mL).\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Healthy Subjects\\\", \\\"6.3.3.1.1\\\", \\\"5\\\", 2605], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"6.3.3.1.2\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": true, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Subjects With NT1\\\", \\\"6.3.3.1.2\\\", \\\"5\\\", 2606], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": true, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Subjects With NT1\\\", \\\"6.3.3.1.2\\\", \\\"5\\\", 2607], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Subjects With NT1\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": true, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Subjects With NT1\\\", \\\"6.3.3.1.2\\\", \\\"5\\\", 2608], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Part D will be initiated after at least 1 MRD healthy adult cohort from Part B has completed.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Subjects With NT1\\\", \\\"6.3.3.1.2\\\", \\\"5\\\", 2609], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"The starting dose will be the same as or lower than those studied in Part B and be supported by the predicted range of pharmacologically active plasma exposure from animal studies.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Subjects With NT1\\\", \\\"6.3.3.1.2\\\", \\\"5\\\", 2610], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"The cohorts of healthy subjects administered higher doses of TAK-861 will be enrolling and completing while the cohorts of subjects with NT1 in Part D are being evaluated.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Subjects With NT1\\\", \\\"6.3.3.1.2\\\", \\\"5\\\", 2611], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"6.3.4 Maximum Dose/Exposure for This Study\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading4\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Maximum Dose/Exposure for This Study\\\", \\\"6.3.4\\\", \\\"3\\\", 2612], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Dose escalation and subsequent dose levels after Cohort A1 will be selected based on a full review of all available safety, tolerability, and PK data from the previous dosing cohorts and will only occur following agreement between the investigator and ~REDACTED~ (Section 6.2.2).\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Maximum Dose/Exposure for This Study\\\", \\\"6.3.4\\\", \\\"3\\\", 2613], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Subsequent dose levels may be higher, lower, or the same as the preceding dose level.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Maximum Dose/Exposure for This Study\\\", \\\"6.3.4\\\", \\\"3\\\", 2614], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Maximum dose level that can be tested in this study will be 800 mg/d/man.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Maximum Dose/Exposure for This Study\\\", \\\"6.3.4\\\", \\\"3\\\", 2615], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"After Cohort A1, dose escalations will be limited to an escalated dose that is predicted to be no greater than approximately 3-fold in either the C\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Maximum Dose/Exposure for This Study\\\", \\\"6.3.4\\\", \\\"3\\\", 2616], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"max\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"subscript\\\"}, \\\"Study Design\\\", \\\"Maximum Dose/Exposure for This Study\\\", \\\"6.3.4\\\", \\\"3\\\", 2617], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"or area under the plasma concentration-time curve (AUC) of the immediate prior dose level.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Maximum Dose/Exposure for This Study\\\", \\\"6.3.4\\\", \\\"3\\\", 2618], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Changes in the planned dose levels will not constitute a protocol amendment, and dosing will continue as long as following conditions are met:\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Maximum Dose/Exposure for This Study\\\", \\\"6.3.4\\\", \\\"3\\\", 2619], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"1. The mean AUC and C\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Maximum Dose/Exposure for This Study\\\", \\\"6.3.4\\\", \\\"3\\\", 2620], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"max\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"subscript\\\"}, \\\"Study Design\\\", \\\"Maximum Dose/Exposure for This Study\\\", \\\"6.3.4\\\", \\\"3\\\", 2621], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"of the maximal dose is predicted not to exceed the mean AUC\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Maximum Dose/Exposure for This Study\\\", \\\"6.3.4\\\", \\\"3\\\", 2622], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"24\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"subscript\\\"}, \\\"Study Design\\\", \\\"Maximum Dose/Exposure for This Study\\\", \\\"6.3.4\\\", \\\"3\\\", 2623], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"and C\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Maximum Dose/Exposure for This Study\\\", \\\"6.3.4\\\", \\\"3\\\", 2624], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"max\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"subscript\\\"}, \\\"Study Design\\\", \\\"Maximum Dose/Exposure for This Study\\\", \\\"6.3.4\\\", \\\"3\\\", 2625], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"at the at the NOAEL of 300 mg/kg/day in monkeys (ie, Day 28 mean values for both sexes: C\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Maximum Dose/Exposure for This Study\\\", \\\"6.3.4\\\", \\\"3\\\", 2626], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"max\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"subscript\\\"}, \\\"Study Design\\\", \\\"Maximum Dose/Exposure for This Study\\\", \\\"6.3.4\\\", \\\"3\\\", 2627], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"= 19,400 ng/mL and AUC\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Maximum Dose/Exposure for This Study\\\", \\\"6.3.4\\\", \\\"3\\\", 2628], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"24\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"subscript\\\"}, \\\"Study Design\\\", \\\"Maximum Dose/Exposure for This Study\\\", \\\"6.3.4\\\", \\\"3\\\", 2629], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"= 243, 000 h*ng/mL).\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Maximum Dose/Exposure for This Study\\\", \\\"6.3.4\\\", \\\"3\\\", 2630], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"2. Adequate safety and tolerability are present.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Maximum Dose/Exposure for This Study\\\", \\\"6.3.4\\\", \\\"3\\\", 2631], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Specific criteria for cohort and study termination are provided in Section 6.5.5.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Maximum Dose/Exposure for This Study\\\", \\\"6.3.4\\\", \\\"3\\\", 2632], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"6.3.5 Rationale for Endpoints\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading4\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Rationale for Endpoints\\\", \\\"6.3.5\\\", \\\"3\\\", 2633], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"6.3.5.1 Safety Endpoints\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading6\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Safety Endpoints\\\", \\\"6.3.5.1\\\", \\\"4\\\", 2634], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Because this is an FIH single and multiple dosing study, standard safety endpoints (eg, TEAEs, physical examinations, vital signs [BP, HR, RR], 12-lead ECGs, clinical laboratory evaluations) will be included.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Safety Endpoints\\\", \\\"6.3.5.1\\\", \\\"4\\\", 2635], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"HE and non-Japanese subjects will be included to investigate any age- or ethnicity-related differences in the safety, tolerability, and/or PK of TAK-861.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Safety Endpoints\\\", \\\"6.3.5.1\\\", \\\"4\\\", 2636], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"In a safety pharmacology study of TAK-861 in monkeys, cardiovascular-related nonserious AE findings including mild to moderate degrees of transient elevated BP and HR were found at all dosages during initial dosing; these findings resolved on repeated dosing.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Safety Endpoints\\\", \\\"6.3.5.1\\\", \\\"4\\\", 2637], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"ABPM is also being obtained to assess BP in the outpatient setting in a rigorous manner.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Safety Endpoints\\\", \\\"6.3.5.1\\\", \\\"4\\\", 2638], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"The Columbia\\\\u2013Suicide Severity Rating Scale (C-SSRS) will be used as a standard tool for monitoring any signs of suicidal ideation or behavior.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Safety Endpoints\\\", \\\"6.3.5.1\\\", \\\"4\\\", 2639], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Liver function test (LFT) values (alanine aminotransferase [ALT] and aspartate aminotransferase\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Safety Endpoints\\\", \\\"6.3.5.1\\\", \\\"4\\\", 2640], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"[AST]) will be measured to monitor liver toxicity and plasma fluoride levels will be obtained because TAK-861 is a fluoride-containing molecule and defluorination via metabolism is thus of interest.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Safety Endpoints\\\", \\\"6.3.5.1\\\", \\\"4\\\", 2641], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"6.3.5.2 PK Endpoints\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading6\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"PK Endpoints\\\", \\\"6.3.5.2\\\", \\\"4\\\", 2642], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Standard noncompartmental PK analyses will provide measures of drug exposure in the plasma, ~REDACTED~, and urine following single and/or multiple oral dose administration of TAK-861 under fasted or fed conditions (see Section 5.2).\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"PK Endpoints\\\", \\\"6.3.5.2\\\", \\\"4\\\", 2643], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Metabolites may also be evaluated, as deemed appropriate.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"PK Endpoints\\\", \\\"6.3.5.2\\\", \\\"4\\\", 2644], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"The assessment of ~REDACTED~ concentrations of TAK-861 is intended to evaluate TAK-861 CNS penetration relative to systemic exposure pending the observed PD effects, as measured by MWT, in subjects with NT1.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"PK Endpoints\\\", \\\"6.3.5.2\\\", \\\"4\\\", 2645], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"6.3.5.3 PD Endpoints\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading6\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"PD Endpoints\\\", \\\"6.3.5.3\\\", \\\"4\\\", 2646], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"To evaluate the effect of TAK-861 on symptoms of narcolepsy after multiple dosing, this study includes well-established objective and subjective efficacy endpoints for narcolepsy symptom measures.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"PD Endpoints\\\", \\\"6.3.5.3\\\", \\\"4\\\", 2647], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Major narcolepsy symptoms include daytime sleepiness measured by objective endpoints such as sleep latency from the MWT procedure, and subjective endpoints such as ESS total score.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"PD Endpoints\\\", \\\"6.3.5.3\\\", \\\"4\\\", 2648], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"In addition, cataplexy (in subjects with NT1 only) and disturbance in nighttime sleep are also collected from a daily diary.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"PD Endpoints\\\", \\\"6.3.5.3\\\", \\\"4\\\", 2649], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Because of the short duration of this FIH study, these endpoints are considered PD endpoints.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"PD Endpoints\\\", \\\"6.3.5.3\\\", \\\"4\\\", 2650], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"In addition, several PD endpoints including parameters from nPSG, accelerometry/actigraphy, SART, and CPAL will also be evaluated.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"PD Endpoints\\\", \\\"6.3.5.3\\\", \\\"4\\\", 2651], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"6.3.6 Critical Procedures Based on Study Objectives: Timing of Procedures\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading4\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Critical Procedures Based on Study Objectives: Timing of Procedures\\\", \\\"6.3.6\\\", \\\"3\\\", 2652], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"For this study, assessments should be performed as close to the scheduled time as possible.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Critical Procedures Based on Study Objectives: Timing of Procedures\\\", \\\"6.3.6\\\", \\\"3\\\", 2653], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"In the event of conflicts between scheduled procedures, the following rules should be applied:\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Critical Procedures Based on Study Objectives: Timing of Procedures\\\", \\\"6.3.6\\\", \\\"3\\\", 2654], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\\u2022 ECGs and BP/vital signs assessments should be completed first, followed by PK and then PD assessments.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Critical Procedures Based on Study Objectives: Timing of Procedures\\\", \\\"6.3.6\\\", \\\"3\\\", 2655], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"In Part D, BP assessments should be completed first, followed by ECG and PK, then cognitive assessments.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Critical Procedures Based on Study Objectives: Timing of Procedures\\\", \\\"6.3.6\\\", \\\"3\\\", 2656], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"MWTs should be done at scheduled times and assessments staggered to occur before or after so as to not interfere with the conduct of the MWT.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Critical Procedures Based on Study Objectives: Timing of Procedures\\\", \\\"6.3.6\\\", \\\"3\\\", 2657], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\\u2022 Any nonscheduled procedures required for urgent evaluation of safety concerns take precedence over all routine scheduled procedures.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Critical Procedures Based on Study Objectives: Timing of Procedures\\\", \\\"6.3.6\\\", \\\"3\\\", 2658], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\\u2022 Blood sampling for PK evaluation should occur before the nominal time of standard meal, if scheduled together.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Critical Procedures Based on Study Objectives: Timing of Procedures\\\", \\\"6.3.6\\\", \\\"3\\\", 2659], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\\u2022 If the times for meals and the study procedures are conflicted, meals should be taken after all of the study procedures are completed.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Critical Procedures Based on Study Objectives: Timing of Procedures\\\", \\\"6.3.6\\\", \\\"3\\\", 2660], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\\u2022 The order of priority can be changed during the study with joint agreement of the investigator and the sponsor.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Critical Procedures Based on Study Objectives: Timing of Procedures\\\", \\\"6.3.6\\\", \\\"3\\\", 2661], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"6.4 Study Design/Dosing/Procedures Modifications Permitted Within Protocol\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading2\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Study Design/Dosing/Procedures Modifications Permitted Within Protocol\\\", \\\"6.4\\\", \\\"2\\\", 2662], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"Parameters\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading6\\\", \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": true, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Study Design/Dosing/Procedures Modifications Permitted Within Protocol\\\", \\\"6.4\\\", \\\"2\\\", 2663], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Modifications to the protocol currently outlined below may be required to achieve the scientific goals of the study objectives and/or to ensure appropriate safety monitoring of the study subjects.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Study Design/Dosing/Procedures Modifications Permitted Within Protocol\\\", \\\"6.4\\\", \\\"2\\\", 2664], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"The following minor modifications may be permitted based on newly available data:\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Study Design/Dosing/Procedures Modifications Permitted Within Protocol\\\", \\\"6.4\\\", \\\"2\\\", 2665], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\\u2022 Dose adjustments may be made based on the sentinel dosing results, and review of safety and tolerability data as described in Section 6.2.1.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Study Design/Dosing/Procedures Modifications Permitted Within Protocol\\\", \\\"6.4\\\", \\\"2\\\", 2666], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\\u2022 Not all cohorts may be run, and the doses in additional cohorts may be higher than, lower than, or the same as those of a prior cohort.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Study Design/Dosing/Procedures Modifications Permitted Within Protocol\\\", \\\"6.4\\\", \\\"2\\\", 2667], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Healthy adult cohorts and HE or NT1 cohorts that start following the initial cohort of the study may start at the sponsor\\\\u2019s discretion whenever possible, considering the dose to be used and the prior results from preceding cohorts.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Study Design/Dosing/Procedures Modifications Permitted Within Protocol\\\", \\\"6.4\\\", \\\"2\\\", 2668], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"In Part A, cohort A3 may start later than other cohorts in this part.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Study Design/Dosing/Procedures Modifications Permitted Within Protocol\\\", \\\"6.4\\\", \\\"2\\\", 2669], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Based on the sponsor\\\\u2019s discretion, the entire part(s) may not be run, or NT1 cohorts may close their recruitment earlier before reaching planned number of subjects.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Study Design/Dosing/Procedures Modifications Permitted Within Protocol\\\", \\\"6.4\\\", \\\"2\\\", 2670], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\\u2022 The method for collecting PK/PD sampling data currently described in the protocol may be modified on the basis of newly obtained PK or PD data during this study (eg, to obtain data at the time closer to the peak plasma concentration achieved).\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Study Design/Dosing/Procedures Modifications Permitted Within Protocol\\\", \\\"6.4\\\", \\\"2\\\", 2671], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Collected samples may be used in a study to explore metabolites and/or additional PD markers.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Study Design/Dosing/Procedures Modifications Permitted Within Protocol\\\", \\\"6.4\\\", \\\"2\\\", 2672], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"For PK blood draws, the timing of sampling collection may be changed without changing the total number of samples that will be taken.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Study Design/Dosing/Procedures Modifications Permitted Within Protocol\\\", \\\"6.4\\\", \\\"2\\\", 2673], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"The PK/PD sampling scheme may be modified during the study on the basis of newly available PK or PD data (eg, to obtain data closer to the tmax).\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Study Design/Dosing/Procedures Modifications Permitted Within Protocol\\\", \\\"6.4\\\", \\\"2\\\", 2674], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"If indicated, these collected samples may also be assayed in an exploratory manner for metabolites and/or additional PD markers.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Study Design/Dosing/Procedures Modifications Permitted Within Protocol\\\", \\\"6.4\\\", \\\"2\\\", 2675], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\\u2022 The timing of planned procedures for assessment of safety (eg, vital signs, ECG, safety laboratory tests) or PD currently outlined in the protocol may be modified during the study on the basis of newly available safety, tolerability, PK, or PD/biomarker data (eg, to obtain data closer to the time of peak plasma concentrations).\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Study Design/Dosing/Procedures Modifications Permitted Within Protocol\\\", \\\"6.4\\\", \\\"2\\\", 2676], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"These changes will not increase the number of study procedures for a given subject during their participation in the entire study.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Study Design/Dosing/Procedures Modifications Permitted Within Protocol\\\", \\\"6.4\\\", \\\"2\\\", 2677], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Additional laboratory safety tests may be added to blood samples previously drawn to obtain additional safety information (eg, adding creatine kinase to a serum chemistry panel that was already drawn).\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Study Design/Dosing/Procedures Modifications Permitted Within Protocol\\\", \\\"6.4\\\", \\\"2\\\", 2678], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\\u2022 The specified assessment time points of safety endpoints (eg, vital signs, ECG, laboratory tests) currently described in the protocol may be modified on the basis of the newly obtained safety, tolerability, PK or PD/biomarker data (eg, to collect data at the time closer to the peak plasma concentrations achieved).\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Study Design/Dosing/Procedures Modifications Permitted Within Protocol\\\", \\\"6.4\\\", \\\"2\\\", 2679], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"These changes will not result in an increase in the number of study procedures for subjects participating in the study.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Study Design/Dosing/Procedures Modifications Permitted Within Protocol\\\", \\\"6.4\\\", \\\"2\\\", 2680], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"It is understood that the current study may employ some or none of the alterations described above.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Study Design/Dosing/Procedures Modifications Permitted Within Protocol\\\", \\\"6.4\\\", \\\"2\\\", 2681], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Any alterations described above made to this protocol to meet the study objectives must be detailed by the sponsor in a letter to the Trial Master File and forwarded to the investigator for retention.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Study Design/Dosing/Procedures Modifications Permitted Within Protocol\\\", \\\"6.4\\\", \\\"2\\\", 2682], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"The letter will be forwarded to the institutional review board (IRB)/independent ethics committee (IEC).\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Study Design/Dosing/Procedures Modifications Permitted Within Protocol\\\", \\\"6.4\\\", \\\"2\\\", 2683], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"6.5 Study Beginning and End/Completion\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading2\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Study Beginning and End/Completion\\\", \\\"6.5\\\", \\\"2\\\", 2684], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"6.5.1 Definition of Beginning of the Study\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading4\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Definition of Beginning of the Study\\\", \\\"6.5.1\\\", \\\"3\\\", 2685], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"The overall study begins when the first subject signs the study informed consent form.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Definition of Beginning of the Study\\\", \\\"6.5.1\\\", \\\"3\\\", 2686], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"6.5.2 Definition of End of the Study\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading4\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Definition of End of the Study\\\", \\\"6.5.2\\\", \\\"3\\\", 2687], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"The overall study ends when the last subject completes the last planned or follow-up visit/interaction associated with a planned visit (this can be a phone contact), withdraws from the study, or is lost to follow-up (ie, the investigator is unable to contact the subject).\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Definition of End of the Study\\\", \\\"6.5.2\\\", \\\"3\\\", 2688], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"6.5.3 Definition of Study Completion\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading4\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Definition of Study Completion\\\", \\\"6.5.3\\\", \\\"3\\\", 2689], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"For an individual subject, study completion is defined as when the subject is examined after receiving all planned intervention/treatment to collect final data for all primary, secondary, and exploratory endpoints.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Definition of Study Completion\\\", \\\"6.5.3\\\", \\\"3\\\", 2690], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"6.5.4 Definition of Study Discontinuation\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading4\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Definition of Study Discontinuation\\\", \\\"6.5.4\\\", \\\"3\\\", 2691], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Study discontinuation is defined as cessation of the overall study due to nonsafety or safety reasons.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Definition of Study Discontinuation\\\", \\\"6.5.4\\\", \\\"3\\\", 2692], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\\u2022 For the overall study and individual cohorts, criteria and procedures for premature termination or suspension are described in Section 6.5.5.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Definition of Study Discontinuation\\\", \\\"6.5.4\\\", \\\"3\\\", 2693], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"For study sites, criteria and procedures for premature termination or suspension are described in Section 6.5.6.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Definition of Study Discontinuation\\\", \\\"6.5.4\\\", \\\"3\\\", 2694], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\\u2022 For individual subjects, criteria and procedures for discontinuation or withdrawal are described in Section 7.4.3 and Section 7.5, respectively.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Definition of Study Discontinuation\\\", \\\"6.5.4\\\", \\\"3\\\", 2695], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"6.5.5 Criteria for Premature Termination or Suspension of the Study\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading4\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Criteria for Premature Termination or Suspension of the Study\\\", \\\"6.5.5\\\", \\\"3\\\", 2696], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"6.5.5.1 Criteria for Premature Termination or Suspension of Study\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading6\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Criteria for Premature Termination or Suspension of Study\\\", \\\"6.5.5.1\\\", \\\"4\\\", 2697], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"The study will be completed as planned unless one or more of the following criteria are satisfied that require temporary suspension or early termination of a study cohort or the overall study:\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Criteria for Premature Termination or Suspension of Study\\\", \\\"6.5.5.1\\\", \\\"4\\\", 2698], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\\u2022 New information or other evaluation regarding the safety or efficacy of the study drug indicates a change in the known benefit-risk profile for the product, such that the benefit-risk is no longer acceptable for subjects participating in the study.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Criteria for Premature Termination or Suspension of Study\\\", \\\"6.5.5.1\\\", \\\"4\\\", 2699], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\\u2022 Significant violation of Good Clinical Practice (GCP) that compromises the ability to achieve the primary study objectives or compromises subject safety.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Criteria for Premature Termination or Suspension of Study\\\", \\\"6.5.5.1\\\", \\\"4\\\", 2700], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\\u2022 A finding (eg, PK, PD) from another nonclinical or clinical study using the study treatment results in the study being stopped for reasons unrelated to safety.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Criteria for Premature Termination or Suspension of Study\\\", \\\"6.5.5.1\\\", \\\"4\\\", 2701], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\\u2022 Data from drug(s) of the same class or methodology(ies) used in this study become available and result in the study being stopped for reasons unrelated to safety.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Criteria for Premature Termination or Suspension of Study\\\", \\\"6.5.5.1\\\", \\\"4\\\", 2702], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\\u2022 The study is stopped because of nonscientific and reasons unrelated to safety, such as slow enrollment.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Criteria for Premature Termination or Suspension of Study\\\", \\\"6.5.5.1\\\", \\\"4\\\", 2703], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\\u2022 Unanticipated concerns of safety to the study subjects arise from this clinical study or additional nonclinical or clinical studies with TAK-861 or drug(s) of the same class.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Criteria for Premature Termination or Suspension of Study\\\", \\\"6.5.5.1\\\", \\\"4\\\", 2704], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\\u2022 The sponsor terminates or suspends the study, or any study cohort, at any time for any other clinical or administrative reasons.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Criteria for Premature Termination or Suspension of Study\\\", \\\"6.5.5.1\\\", \\\"4\\\", 2705], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"6.5.5.2 Stopping Criteria for Individual Cohort\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading6\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Stopping Criteria for Individual Cohort\\\", \\\"6.5.5.2\\\", \\\"4\\\", 2706], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Study-specific stopping criteria for individual cohorts are below, based on review of unblinded data, which showed the number of subjects specified below in an active treatment group:\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Stopping Criteria for Individual Cohort\\\", \\\"6.5.5.2\\\", \\\"4\\\", 2707], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\\u2022 LFT: If 3 or more subjects in the same cohort meet the individual subject stopping criteria for abnormalities, as defined in Section 7.4.3, then further dosing in the cohort will be stopped.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Stopping Criteria for Individual Cohort\\\", \\\"6.5.5.2\\\", \\\"4\\\", 2708], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"No further dose escalation will occur.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Stopping Criteria for Individual Cohort\\\", \\\"6.5.5.2\\\", \\\"4\\\", 2709], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\\u2022 BP increase: If 4 or more subjects in the same cohort meet the individual subject stopping criteria for BP increases defined in Section 7.4.3, then further dosing in the cohort will be stopped.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Stopping Criteria for Individual Cohort\\\", \\\"6.5.5.2\\\", \\\"4\\\", 2710], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"In this case, no human dosing will be performed at this and any higher dose levels in this study.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Stopping Criteria for Individual Cohort\\\", \\\"6.5.5.2\\\", \\\"4\\\", 2711], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\\u2022 Insomnia: If 3 or more subjects in the same cohort meet the individual subject stopping criteria for serious or severe insomnia defined in Section 7.4.3, then further dosing in the cohort will be stopped.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Stopping Criteria for Individual Cohort\\\", \\\"6.5.5.2\\\", \\\"4\\\", 2712], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"No further dose escalation in the same part will occur.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Stopping Criteria for Individual Cohort\\\", \\\"6.5.5.2\\\", \\\"4\\\", 2713], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\\u2022 Serious adverse event (SAE): If 2 or more subjects in the same cohort meet the individual subject stopping criteria or 2 or more experience an SAE that is drug-related in investigator\\\\u2019s and sponsor\\\\u2019s opinions, then further dosing in the cohort will be stopped.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Stopping Criteria for Individual Cohort\\\", \\\"6.5.5.2\\\", \\\"4\\\", 2714], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"No further dose escalation will occur.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Stopping Criteria for Individual Cohort\\\", \\\"6.5.5.2\\\", \\\"4\\\", 2715], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\\u2022 One death will result in pause of the study for further evaluation.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Stopping Criteria for Individual Cohort\\\", \\\"6.5.5.2\\\", \\\"4\\\", 2716], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"6.5.5.3 Procedures for Premature Termination or Suspension of the Study\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading6\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Procedures for Premature Termination or Suspension of the Study\\\", \\\"6.5.5.3\\\", \\\"4\\\", 2717], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"If the sponsor, an IRB/IEC, or a regulatory authority elects to terminate or suspend the study, a study-specific procedure for early termination or suspension will be provided by the sponsor; the procedure will be followed by applicable investigational site(s) during the course of termination or study suspension.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Procedures for Premature Termination or Suspension of the Study\\\", \\\"6.5.5.3\\\", \\\"4\\\", 2718], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"6.5.6 Criteria for Premature Termination or Suspension of a Site\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading4\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Procedures for Premature Termination or Suspension of the Study\\\", \\\"6.5.5.3\\\", \\\"4\\\", 2719], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"6.5.6.1 Criteria for Premature Termination or Suspension of a Site\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading6\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Criteria for Premature Termination or Suspension of a Site\\\", \\\"6.5.6.1\\\", \\\"4\\\", 2720], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"A study site may be terminated prematurely or suspended if the site (including the investigator) is found in significant violation of GCP, the study protocol, or contractual agreement; if the site (including the investigator) is unable to ensure adequate performance of the study; or as otherwise permitted by the contractual agreement.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Criteria for Premature Termination or Suspension of a Site\\\", \\\"6.5.6.1\\\", \\\"4\\\", 2721], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"6.5.6.2 Procedures for Premature Termination or Suspension of a Site\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading6\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Procedures for Premature Termination or Suspension of a Site\\\", \\\"6.5.6.2\\\", \\\"4\\\", 2722], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"If the sponsor, an IRB/IEC, or a regulatory authority elects to terminate or suspend the participation of an investigational site, a study-specific procedure for early termination or suspension will be provided by the sponsor; the procedure will be followed by applicable investigational site(s) during the course of termination or study suspension.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Procedures for Premature Termination or Suspension of a Site\\\", \\\"6.5.6.2\\\", \\\"4\\\", 2723], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"If the site closure is due to coronavirus disease 2019 (COVID-19) or similar situation, this should be captured on the electronic case report form (eCRF).\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Procedures for Premature Termination or Suspension of a Site\\\", \\\"6.5.6.2\\\", \\\"4\\\", 2724], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"7.0 SELECTION AND DISCONTINUATION/WITHDRAWAL OF SUBJECTS\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading1\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"SELECTION AND DISCONTINUATION/WITHDRAWAL OF SUBJECTS\\\", \\\"7.0\\\", \\\"1\\\", 2725], [\\\"2\\\", \\\"Inclusion Criteria\\\", \\\"header\\\", \\\"7.1 Inclusion Criteria\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading2\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Inclusion Criteria\\\", \\\"7.1\\\", \\\"2\\\", 2726], [\\\"2\\\", \\\"Inclusion Criteria\\\", \\\"text\\\", \\\"To be eligible for study participation, subjects must:\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Inclusion Criteria\\\", \\\"7.1\\\", \\\"2\\\", 2727], [\\\"2\\\", \\\"Inclusion Criteria\\\", \\\"header\\\", \\\"All subjects\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading9\\\", \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"single\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Inclusion Criteria\\\", \\\"7.1\\\", \\\"2\\\", 2728], [\\\"2\\\", \\\"Inclusion Criteria\\\", \\\"text\\\", \\\"1. The subject must understand the study procedures and agree to participate by providing written informed consent.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Inclusion Criteria\\\", \\\"7.1\\\", \\\"2\\\", 2729], [\\\"2\\\", \\\"Inclusion Criteria\\\", \\\"text\\\", \\\"2. The subject must be willing and able to comply with all study procedures and restrictions.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Inclusion Criteria\\\", \\\"7.1\\\", \\\"2\\\", 2730], [\\\"2\\\", \\\"Inclusion Criteria\\\", \\\"text\\\", \\\"3. The subject must be judged to be in good health by the investigator to participate in the study, on the basis of clinical evaluations including laboratory safety tests, medical history, physical examination, 12-lead ECG, and vital sign measurements performed at the screening visit and before the first dose of study drug or first study assessment.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Inclusion Criteria\\\", \\\"7.1\\\", \\\"2\\\", 2731], [\\\"2\\\", \\\"Inclusion Criteria\\\", \\\"text\\\", \\\"\\\\u2013 Note: Screening laboratory assessments may be repeated for all parts; consultation with the sponsor or designee should occur for Part D.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Inclusion Criteria\\\", \\\"7.1\\\", \\\"2\\\", 2732], [\\\"2\\\", \\\"Inclusion Criteria\\\", \\\"text\\\", \\\"4. A male subject must meet the following requirements:\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Inclusion Criteria\\\", \\\"7.1\\\", \\\"2\\\", 2733], [\\\"2\\\", \\\"Inclusion Criteria\\\", \\\"text\\\", \\\"\\\\u2013 Is a male subject who is sterile.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Inclusion Criteria\\\", \\\"7.1\\\", \\\"2\\\", 2734], [\\\"2\\\", \\\"Inclusion Criteria\\\", \\\"text\\\", \\\"No restrictions are required for a vasectomized male subject, provided the subject is at least 1 year post\\\\u2013bilateral vasectomy procedure before the first dose of study drug.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Inclusion Criteria\\\", \\\"7.1\\\", \\\"2\\\", 2735], [\\\"2\\\", \\\"Inclusion Criteria\\\", \\\"text\\\", \\\"If vasectomy procedure was performed less than 1 year before the first dose of study drug, the male subject must follow the same restrictions as a nonvasectomized/nonsterilized man (below).\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Inclusion Criteria\\\", \\\"7.1\\\", \\\"2\\\", 2736], [\\\"2\\\", \\\"Inclusion Criteria\\\", \\\"text\\\", \\\"Appropriate documentation of surgical procedure should be provided.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Inclusion Criteria\\\", \\\"7.1\\\", \\\"2\\\", 2737], [\\\"2\\\", \\\"Inclusion Criteria\\\", \\\"text\\\", \\\"\\\\u2013 Is a male subject who is nonsterilized and sexually active with a female partner of childbearing potential and who agrees to use an appropriate method of contraception, including a condom with or without spermicidal cream or jelly, from the first dose of study drug until 5 half-lives plus 90 days after the last dose of study drug.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Inclusion Criteria\\\", \\\"7.1\\\", \\\"2\\\", 2738], [\\\"2\\\", \\\"Inclusion Criteria\\\", \\\"text\\\", \\\"\\\\u2013 Is a male subject who agrees to not donate sperm from the first dose of study drug until 5 half-lives plus 90 days after the last dose of study drug.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Inclusion Criteria\\\", \\\"7.1\\\", \\\"2\\\", 2739], [\\\"2\\\", \\\"Inclusion Criteria\\\", \\\"text\\\", \\\"Healthy Adult Subjects for Part A, B, C, E, and F\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"single\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Inclusion Criteria\\\", \\\"7.1\\\", \\\"2\\\", 2740], [\\\"2\\\", \\\"Inclusion Criteria\\\", \\\"text\\\", \\\"(inclusion criterion Number 5 will be also applicable for Part D until the decision is made by the sponsor to include women of childbearing potential; women of childbearing potential may be included in the study once reproductive toxicology results for TAK-861 are available)\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Inclusion Criteria\\\", \\\"7.1\\\", \\\"2\\\", 2741], [\\\"2\\\", \\\"Inclusion Criteria\\\", \\\"text\\\", \\\"5. If female, the subject must meet 1 of the following requirements:\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Inclusion Criteria\\\", \\\"7.1\\\", \\\"2\\\", 2742], [\\\"2\\\", \\\"Inclusion Criteria\\\", \\\"text\\\", \\\"\\\\u2013 Postmenopausal (defined as 6 months of spontaneous amenorrhea in women aged >45 years with serum ~REDACTED~ [FSH] levels >40 mIU/mL).\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Inclusion Criteria\\\", \\\"7.1\\\", \\\"2\\\", 2743], [\\\"2\\\", \\\"Inclusion Criteria\\\", \\\"text\\\", \\\"\\\\u2013 Surgically sterile by hysterectomy and/or bilateral oophorectomy with appropriate documentation of surgical procedure.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Inclusion Criteria\\\", \\\"7.1\\\", \\\"2\\\", 2744], [\\\"2\\\", \\\"Inclusion Criteria\\\", \\\"text\\\", \\\"\\\\u2013 Had a tubal ligation with appropriate documentation of surgical procedure.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Inclusion Criteria\\\", \\\"7.1\\\", \\\"2\\\", 2745], [\\\"2\\\", \\\"Inclusion Criteria\\\", \\\"text\\\", \\\"\\\\u2013 Has a congenital condition resulting in no uterus.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Inclusion Criteria\\\", \\\"7.1\\\", \\\"2\\\", 2746], [\\\"2\\\", \\\"Inclusion Criteria\\\", \\\"text\\\", \\\"6. The subject must be normotensive, with no history of hypertension or use of ~REDACTED~ medication.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Inclusion Criteria\\\", \\\"7.1\\\", \\\"2\\\", 2747], [\\\"2\\\", \\\"Inclusion Criteria\\\", \\\"text\\\", \\\"BP must be <140 mm Hg (systolic) and <90 mm Hg (diastolic) at screening and at Day -1.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Inclusion Criteria\\\", \\\"7.1\\\", \\\"2\\\", 2748], [\\\"2\\\", \\\"Inclusion Criteria\\\", \\\"text\\\", \\\"BP measures should be obtained after the subject has been resting for a minimum of 5 minutes and may be repeated 3 times in the event that the BP is slightly elevated above these parameters.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Inclusion Criteria\\\", \\\"7.1\\\", \\\"2\\\", 2749], [\\\"2\\\", \\\"Inclusion Criteria\\\", \\\"text\\\", \\\"The lowest BP obtained may be used.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Inclusion Criteria\\\", \\\"7.1\\\", \\\"2\\\", 2750], [\\\"2\\\", \\\"Inclusion Criteria\\\", \\\"text\\\", \\\"7. The subject must be a current nonsmoker who has not used ~REDACTED~ or nicotine-containing products (eg, ~REDACTED~) for at least 6 months before the first dose of study drug or first study assessment.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Inclusion Criteria\\\", \\\"7.1\\\", \\\"2\\\", 2751], [\\\"2\\\", \\\"Inclusion Criteria\\\", \\\"text\\\", \\\"8. The subject must have a body mass index (BMI) \\\\u226518.0 and \\\\u226430.0 kg/m\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Inclusion Criteria\\\", \\\"7.1\\\", \\\"2\\\", 2752], [\\\"2\\\", \\\"Inclusion Criteria\\\", \\\"text\\\", \\\"2\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"superscript\\\"}, \\\"Study Design\\\", \\\"Inclusion Criteria\\\", \\\"7.1\\\", \\\"2\\\", 2753], [\\\"2\\\", \\\"Inclusion Criteria\\\", \\\"text\\\", \\\"at the screening visit.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Inclusion Criteria\\\", \\\"7.1\\\", \\\"2\\\", 2754], [\\\"2\\\", \\\"Inclusion Criteria\\\", \\\"header\\\", \\\"Healthy Adult Subjects (Parts A, B, E, and F)\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading9\\\", \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"single\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Inclusion Criteria\\\", \\\"7.1\\\", \\\"2\\\", 2755], [\\\"2\\\", \\\"Inclusion Criteria\\\", \\\"text\\\", \\\"9. The subject must be aged 18 to 55 years, inclusive, at the screening visit.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Inclusion Criteria\\\", \\\"7.1\\\", \\\"2\\\", 2756], [\\\"2\\\", \\\"Inclusion Criteria\\\", \\\"text\\\", \\\"10. The subject must have a body weight \\\\u226550 kg at the screening visit.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Inclusion Criteria\\\", \\\"7.1\\\", \\\"2\\\", 2757], [\\\"2\\\", \\\"Inclusion Criteria\\\", \\\"header\\\", \\\"Healthy Adult Subjects (Part E and F)\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading9\\\", \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"single\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Inclusion Criteria\\\", \\\"7.1\\\", \\\"2\\\", 2758], [\\\"2\\\", \\\"Inclusion Criteria\\\", \\\"text\\\", \\\"11. The subject must be of non-Japanese origin.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Inclusion Criteria\\\", \\\"7.1\\\", \\\"2\\\", 2759], [\\\"2\\\", \\\"Inclusion Criteria\\\", \\\"text\\\", \\\"In the case that a subject of Japanese origin will be included in Part E, the criteria below will be applied:\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Inclusion Criteria\\\", \\\"7.1\\\", \\\"2\\\", 2760], [\\\"2\\\", \\\"Inclusion Criteria\\\", \\\"text\\\", \\\"\\\\u2013 The subject must have been born in Japan to a Japanese mother and father and have maternal and paternal Japanese grandparents.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Inclusion Criteria\\\", \\\"7.1\\\", \\\"2\\\", 2761], [\\\"2\\\", \\\"Inclusion Criteria\\\", \\\"text\\\", \\\"\\\\u2013 The subject must have not been away from Japan for more than 10 years at the screening visit.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Inclusion Criteria\\\", \\\"7.1\\\", \\\"2\\\", 2762], [\\\"2\\\", \\\"Inclusion Criteria\\\", \\\"text\\\", \\\"\\\\u2013 In the opinion of the investigator, the subject must have a lifestyle that has not changed significantly since relocation from Japan.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Inclusion Criteria\\\", \\\"7.1\\\", \\\"2\\\", 2763], [\\\"2\\\", \\\"Inclusion Criteria\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Inclusion Criteria\\\", \\\"7.1\\\", \\\"2\\\", 2764], [\\\"2\\\", \\\"Inclusion Criteria\\\", \\\"header\\\", \\\"Subjects With NT1 (Part D)\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading9\\\", \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"single\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Inclusion Criteria\\\", \\\"7.1\\\", \\\"2\\\", 2765], [\\\"2\\\", \\\"Inclusion Criteria\\\", \\\"text\\\", \\\"14. The subject must be aged 18 to 65 years, inclusive, at the time of informed consent.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Inclusion Criteria\\\", \\\"7.1\\\", \\\"2\\\", 2766], [\\\"2\\\", \\\"Inclusion Criteria\\\", \\\"text\\\", \\\"15. The subject must have a diagnosis of NT1 by PSG/multiple sleep latency test (MSLT) performed within the past 10 years meeting the minimal acceptable criteria for the proper performance of PSG/MSLT as outlined by the ICSD-3 criteria.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Inclusion Criteria\\\", \\\"7.1\\\", \\\"2\\\", 2767], [\\\"2\\\", \\\"Inclusion Criteria\\\", \\\"text\\\", \\\"Note: If there is a potential subject with NT1 whose diagnostic nPSG/MSLT was performed more than 10 years ago or is not available, special exemptions, that is, ability of the site to repeat the diagnostic PSG/MSLT, will be considered on a case-by-case basis after discussions between the investigator and the sponsor or designee.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Inclusion Criteria\\\", \\\"7.1\\\", \\\"2\\\", 2768], [\\\"2\\\", \\\"Inclusion Criteria\\\", \\\"text\\\", \\\"If the subject is diagnosed as having NT1 based on ICSD-3 criteria without nPSG/MSLT data but by ~REDACTED~ OX measurement, the subject may be enrolled with the sponsor or its designee\\\\u2019s agreement.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Inclusion Criteria\\\", \\\"7.1\\\", \\\"2\\\", 2769], [\\\"2\\\", \\\"Inclusion Criteria\\\", \\\"text\\\", \\\"Note: for subjects who present with results from a ~REDACTED~ test indicating an OX/hypocretin-1 concentration of \\\\u2264110 pg/mL, or less than one-third of the mean values obtained in normal subjects, with the same standardized assay, and the subject presents with cataplexy, the PSG/MSLT requirement may be waived after a discussion with the sponsor or designee.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Inclusion Criteria\\\", \\\"7.1\\\", \\\"2\\\", 2770], [\\\"2\\\", \\\"Inclusion Criteria\\\", \\\"text\\\", \\\"16. The subject\\\\u2019s ESS score must be \\\\u226510 at Day -1.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Inclusion Criteria\\\", \\\"7.1\\\", \\\"2\\\", 2771], [\\\"2\\\", \\\"Inclusion Criteria\\\", \\\"text\\\", \\\"17. The subject must be willing to discontinue all medications used for the treatment of NT1.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Inclusion Criteria\\\", \\\"7.1\\\", \\\"2\\\", 2772], [\\\"2\\\", \\\"Inclusion Criteria\\\", \\\"text\\\", \\\"See Section 7.3 for a complete list of medications that are exclusionary.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Inclusion Criteria\\\", \\\"7.1\\\", \\\"2\\\", 2773], [\\\"2\\\", \\\"Inclusion Criteria\\\", \\\"text\\\", \\\"5. The HLA genotype result should be positive for HLA-DQB1*06:02 (positive results for either homozygous or heterozygous alleles will be considered \\\\u201cpositive\\\\u201d and acceptable).Note: Subjects testing negative for HLA-DQB1*06:02 but who present with results from ~REDACTED~ testing indicating the subject\\\\u2019s ~REDACTED~ OX/hypocretin-1 concentration is <110 pg/mL, or less than one-third of the mean values obtained in normal subjects with the same standardized assay, may be considered for enrollment into Part D after a discussion with the sponsor or designee.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Inclusion Criteria\\\", \\\"7.1\\\", \\\"2\\\", 2774], [\\\"2\\\", \\\"Inclusion Criteria\\\", \\\"text\\\", \\\"6. During the screening period, the subject must have \\\\u22654 partial or complete episodes of cataplexy/week (WCR), averaged over 2 weeks (14 consecutive days) minimum.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Inclusion Criteria\\\", \\\"7.1\\\", \\\"2\\\", 2775], [\\\"2\\\", \\\"Inclusion Criteria\\\", \\\"text\\\", \\\"WCR recording between 7 days after washout of anticataplexy medications and Day -2 will be considered for study eligibility.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Inclusion Criteria\\\", \\\"7.1\\\", \\\"2\\\", 2776], [\\\"2\\\", \\\"Inclusion Criteria\\\", \\\"text\\\", \\\"Subjects must fill out self-reported cataplexy questions in the electronic diary for at least 11 out of 14 days, to be considered compliance.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Inclusion Criteria\\\", \\\"7.1\\\", \\\"2\\\", 2777], [\\\"2\\\", \\\"Inclusion Criteria\\\", \\\"text\\\", \\\"The eligibility criteria pertaining to WCR must be met prior to check in on Day -2.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Inclusion Criteria\\\", \\\"7.1\\\", \\\"2\\\", 2778], [\\\"2\\\", \\\"Inclusion Criteria\\\", \\\"text\\\", \\\"In cases where the ePRO diary becomes unavailable, the study site may employ alternative methods to collect these data with approval from the sponsor or designee.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Inclusion Criteria\\\", \\\"7.1\\\", \\\"2\\\", 2779], [\\\"2\\\", \\\"Inclusion Criteria\\\", \\\"text\\\", \\\"7. For a female subject of childbearing potential who is sexually active with a male partner who is not sterilized, the subject must agree to use highly effective methods of contraception from signing of informed consent until 5 half-lives of TAK-861 plus 30 days.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Inclusion Criteria\\\", \\\"7.1\\\", \\\"2\\\", 2780], [\\\"2\\\", \\\"Inclusion Criteria\\\", \\\"text\\\", \\\"Definitions and procedures for adequate contraception, pregnancy avoidance, and reporting responsibilities are defined in Appendix D.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Inclusion Criteria\\\", \\\"7.1\\\", \\\"2\\\", 2781], [\\\"2\\\", \\\"Inclusion Criteria\\\", \\\"text\\\", \\\"Note: inclusion criterion Number 20 will be only applicable for subjects once reproductive toxicological study results for TAK-861 are available and the sponsor has decided to apply this criterion for Part D.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Inclusion Criteria\\\", \\\"7.1\\\", \\\"2\\\", 2782], [\\\"2\\\", \\\"Inclusion Criteria\\\", \\\"text\\\", \\\"Before that, female subjects for Part D need to meet inclusion criterion Number 5.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Inclusion Criteria\\\", \\\"7.1\\\", \\\"2\\\", 2783], [\\\"2\\\", \\\"Inclusion Criteria\\\", \\\"text\\\", \\\"21. The subject must have a BMI \\\\u226518.0 and \\\\u226440 kg/m\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Inclusion Criteria\\\", \\\"7.1\\\", \\\"2\\\", 2784], [\\\"2\\\", \\\"Inclusion Criteria\\\", \\\"text\\\", \\\"2\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"superscript\\\"}, \\\"Study Design\\\", \\\"Inclusion Criteria\\\", \\\"7.1\\\", \\\"2\\\", 2785], [\\\"2\\\", \\\"Inclusion Criteria\\\", \\\"text\\\", \\\"at the screening visit.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Inclusion Criteria\\\", \\\"7.1\\\", \\\"2\\\", 2786], [\\\"2\\\", \\\"Inclusion Criteria\\\", \\\"text\\\", \\\"9. The subject must have BP <140 mm Hg (systolic) and <90 mm Hg (diastolic) at the screening visit and Day -2.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Inclusion Criteria\\\", \\\"7.1\\\", \\\"2\\\", 2787], [\\\"2\\\", \\\"Inclusion Criteria\\\", \\\"text\\\", \\\"The subject may have a history of hypertension and be receiving ~REDACTED~ medication treatment as long as the BP meets these criteria.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Inclusion Criteria\\\", \\\"7.1\\\", \\\"2\\\", 2788], [\\\"2\\\", \\\"Inclusion Criteria\\\", \\\"text\\\", \\\"BP measurements should be obtained after the subject has been resting for a minimum of 5 minutes and will be repeated 3 times.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Inclusion Criteria\\\", \\\"7.1\\\", \\\"2\\\", 2789], [\\\"2\\\", \\\"Inclusion Criteria\\\", \\\"text\\\", \\\"The median BP obtained will be used.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Inclusion Criteria\\\", \\\"7.1\\\", \\\"2\\\", 2790], [\\\"2\\\", \\\"Inclusion Criteria\\\", \\\"header\\\", \\\"Healthy Adult Subjects for Part F\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading9\\\", \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"single\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Inclusion Criteria\\\", \\\"7.1\\\", \\\"2\\\", 2791], [\\\"2\\\", \\\"Inclusion Criteria\\\", \\\"text\\\", \\\"23. The subject must have regular sleep-wake habits (eg, routinely spending 6.5 to 8 hours sleeping nightly, not oversleeping by more than 3 hours on weekends [ie, total sleep not more than 11 hours]) as determined by investigator interviews and confirmed in approximately 10-day actigraphy records with sleep diary record and the subject must regularly fall asleep between 9:30\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Inclusion Criteria\\\", \\\"7.1\\\", \\\"2\\\", 2792], [\\\"2\\\", \\\"Inclusion Criteria\\\", \\\"text\\\", \\\"PM\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 19, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 19, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Inclusion Criteria\\\", \\\"7.1\\\", \\\"2\\\", 2793], [\\\"2\\\", \\\"Inclusion Criteria\\\", \\\"text\\\", \\\"and 12:00\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Inclusion Criteria\\\", \\\"7.1\\\", \\\"2\\\", 2794], [\\\"2\\\", \\\"Inclusion Criteria\\\", \\\"text\\\", \\\"AM\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 19, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 19, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Inclusion Criteria\\\", \\\"7.1\\\", \\\"2\\\", 2795], [\\\"2\\\", \\\"Inclusion Criteria\\\", \\\"text\\\", \\\"and be willing to keep a similar sleep/wake pattern throughout the study period.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Inclusion Criteria\\\", \\\"7.1\\\", \\\"2\\\", 2796], [\\\"2\\\", \\\"Exclusion Criteria\\\", \\\"header\\\", \\\"7.2 Exclusion Criteria\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading2\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Exclusion Criteria\\\", \\\"7.2\\\", \\\"2\\\", 2797], [\\\"2\\\", \\\"Exclusion Criteria\\\", \\\"text\\\", \\\"The subject must be excluded from participating in the study if:\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Exclusion Criteria\\\", \\\"7.2\\\", \\\"2\\\", 2798], [\\\"2\\\", \\\"Exclusion Criteria\\\", \\\"header\\\", \\\"All Subjects\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading9\\\", \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"single\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Exclusion Criteria\\\", \\\"7.2\\\", \\\"2\\\", 2799], [\\\"2\\\", \\\"Exclusion Criteria\\\", \\\"text\\\", \\\"1. The subject has participated in another investigational study within 60 days (or based on local regulations) before the screening visit.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Exclusion Criteria\\\", \\\"7.2\\\", \\\"2\\\", 2800], [\\\"2\\\", \\\"Exclusion Criteria\\\", \\\"text\\\", \\\"The 60-day window will be derived from the date of the last study procedure and/or AE related to the study procedure in the previous study to the screening visit of the current study.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Exclusion Criteria\\\", \\\"7.2\\\", \\\"2\\\", 2801], [\\\"2\\\", \\\"Exclusion Criteria\\\", \\\"text\\\", \\\"Exceptions may be made for observational, natural history and nonintervention type studies with sponsor or designee approval.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Exclusion Criteria\\\", \\\"7.2\\\", \\\"2\\\", 2802], [\\\"2\\\", \\\"Exclusion Criteria\\\", \\\"text\\\", \\\"2. The subject is an employee of the sponsor or study site or an immediate family member (eg, spouse, parent, child, sibling) of an employee of the sponsor or study site who is directly involved in the conduct of the study.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Exclusion Criteria\\\", \\\"7.2\\\", \\\"2\\\", 2803], [\\\"2\\\", \\\"Exclusion Criteria\\\", \\\"text\\\", \\\"3. The subject has a history of cancer (does not apply to subjects with carcinoma in situ that has been resolved without further treatment or basal cell cancer; these subjects may be included after approval by the medical monitor).\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Exclusion Criteria\\\", \\\"7.2\\\", \\\"2\\\", 2804], [\\\"2\\\", \\\"Exclusion Criteria\\\", \\\"text\\\", \\\"4. The subject has a history of significant multiple and/or severe allergies (eg, food, drug, latex allergy) or has had an anaphylactic reaction or significant intolerance to prescription or nonprescription drugs or food.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Exclusion Criteria\\\", \\\"7.2\\\", \\\"2\\\", 2805], [\\\"2\\\", \\\"Exclusion Criteria\\\", \\\"text\\\", \\\"5. The subject has a known hypersensitivity to any component of the formulation of TAK 861 or related compounds.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Exclusion Criteria\\\", \\\"7.2\\\", \\\"2\\\", 2806], [\\\"2\\\", \\\"Exclusion Criteria\\\", \\\"text\\\", \\\"6. The subject has a positive test result for hepatitis B surface antigen, hepatitis C virus antibody, or HIV antibody/antigen at the screening visit.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Exclusion Criteria\\\", \\\"7.2\\\", \\\"2\\\", 2807], [\\\"2\\\", \\\"Exclusion Criteria\\\", \\\"text\\\", \\\"\\\\u2013 Note: Subjects with positive hepatitis B virus or hepatitis C virus serology may be enrolled if quantitative polymerase chain reaction for hepatitis B virus DNA or hepatitis C virus RNA is negative.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Exclusion Criteria\\\", \\\"7.2\\\", \\\"2\\\", 2808], [\\\"2\\\", \\\"Exclusion Criteria\\\", \\\"text\\\", \\\"7. The subject had major surgery or donated or lost 1 unit of blood (approximately 500 mL) within 4 weeks (in Part A, B, and C, 12 weeks for male subjects and 16 weeks for female subjects) before the screening visit.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Exclusion Criteria\\\", \\\"7.2\\\", \\\"2\\\", 2809], [\\\"2\\\", \\\"Exclusion Criteria\\\", \\\"text\\\", \\\"8. The subject is unable to refrain from or anticipates using excluded medications, including food products and grapefruit juice, beginning approximately 7 days before administration of the first dose of study drug or Day -2 (see prohibited medication Section 7.3), throughout the study (including washout intervals between treatment periods), and until the follow-up visit.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Exclusion Criteria\\\", \\\"7.2\\\", \\\"2\\\", 2810], [\\\"2\\\", \\\"Exclusion Criteria\\\", \\\"text\\\", \\\"9. The subject consumes excessive amounts, defined as greater than 6 servings (1 serving is approximately equivalent to 120 mg of ~REDACTED~), of coffee, tea, cola, energy drinks, or other caffeinated beverages per day.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Exclusion Criteria\\\", \\\"7.2\\\", \\\"2\\\", 2811], [\\\"2\\\", \\\"Exclusion Criteria\\\", \\\"text\\\", \\\"10. The subject has current or history of substance abuse disorder per the Diagnostic and Statistical Manual of Mental Disorders, 5th Edition criteria.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Exclusion Criteria\\\", \\\"7.2\\\", \\\"2\\\", 2812], [\\\"2\\\", \\\"Exclusion Criteria\\\", \\\"text\\\", \\\"For subjects with NT1 for Part D, history beyond 12 months before baseline may be allowed after consultation with the Medical Monitor.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Exclusion Criteria\\\", \\\"7.2\\\", \\\"2\\\", 2813], [\\\"2\\\", \\\"Exclusion Criteria\\\", \\\"text\\\", \\\"11. The subject\\\\u2019s renal creatinine clearance (Cockcroft-Gault Equation) is \\\\u226460 mL/min at screening.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Exclusion Criteria\\\", \\\"7.2\\\", \\\"2\\\", 2814], [\\\"2\\\", \\\"Exclusion Criteria\\\", \\\"text\\\", \\\"12. The subject has poor peripheral venous access, as assessed by the investigator.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Exclusion Criteria\\\", \\\"7.2\\\", \\\"2\\\", 2815], [\\\"2\\\", \\\"Exclusion Criteria\\\", \\\"text\\\", \\\"13. The subject has a risk of suicide according to endorsement of Item 4 or 5 of the screening/baseline visit C-SSRS or has made a suicide attempt in the previous 6 months.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Exclusion Criteria\\\", \\\"7.2\\\", \\\"2\\\", 2816], [\\\"2\\\", \\\"Exclusion Criteria\\\", \\\"text\\\", \\\"14. The subject has past or current epilepsy or seizure, tremor, or disorders of related symptoms.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Exclusion Criteria\\\", \\\"7.2\\\", \\\"2\\\", 2817], [\\\"2\\\", \\\"Exclusion Criteria\\\", \\\"text\\\", \\\"Subjects with a single febrile seizure episode in childhood will be allowed for Part D.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Exclusion Criteria\\\", \\\"7.2\\\", \\\"2\\\", 2818], [\\\"2\\\", \\\"Exclusion Criteria\\\", \\\"text\\\", \\\"15. The subject has a lifetime history of major psychiatric disorder, such as bipolar disorder or schizophrenia.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Exclusion Criteria\\\", \\\"7.2\\\", \\\"2\\\", 2819], [\\\"2\\\", \\\"Exclusion Criteria\\\", \\\"text\\\", \\\"Subjects who have history of major depressive disorder (MDD) may be included, but subjects who have current active MDD or who have had active MDD in the past 6 months are excluded.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Exclusion Criteria\\\", \\\"7.2\\\", \\\"2\\\", 2820], [\\\"2\\\", \\\"Exclusion Criteria\\\", \\\"text\\\", \\\"16. The subject has a clinically significant history of head injury or head trauma.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Exclusion Criteria\\\", \\\"7.2\\\", \\\"2\\\", 2821], [\\\"2\\\", \\\"Exclusion Criteria\\\", \\\"text\\\", \\\"17. The subject has a history of cerebral ischemia, transient ischemic attack, intracranial aneurysm, or arteriovenous malformation.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Exclusion Criteria\\\", \\\"7.2\\\", \\\"2\\\", 2822], [\\\"2\\\", \\\"Exclusion Criteria\\\", \\\"text\\\", \\\"18. The subject has known coronary artery disease, a history of myocardial infarction, angina, cardiac rhythm abnormality, or heart failure.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Exclusion Criteria\\\", \\\"7.2\\\", \\\"2\\\", 2823], [\\\"2\\\", \\\"Exclusion Criteria\\\", \\\"text\\\", \\\"19. The subject\\\\u2019s screening ECG reveals a QT interval with Fridericia correction method (QTcF) >450 ms (men) or >470 ms (women).\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Exclusion Criteria\\\", \\\"7.2\\\", \\\"2\\\", 2824], [\\\"2\\\", \\\"Exclusion Criteria\\\", \\\"text\\\", \\\"20. The subject has a resting HR outside of the range of 45 to 100 beats per minute at screening, confirmed on repeat testing within a maximum of 30 minutes.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Exclusion Criteria\\\", \\\"7.2\\\", \\\"2\\\", 2825], [\\\"2\\\", \\\"Exclusion Criteria\\\", \\\"text\\\", \\\"For subjects with NT1 for Part D, a range of 40 to 100 beats per minute at screening will be applied.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Exclusion Criteria\\\", \\\"7.2\\\", \\\"2\\\", 2826], [\\\"2\\\", \\\"Exclusion Criteria\\\", \\\"text\\\", \\\"21. The subject has a medical condition (other than narcolepsy for subjects with NT1 in Part D), such as medically significant unstable cardiovascular, pulmonary, hepatic, renal, or gastrointestinal disease, that would preclude enrollment in the view of the investigator.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Exclusion Criteria\\\", \\\"7.2\\\", \\\"2\\\", 2827], [\\\"2\\\", \\\"Exclusion Criteria\\\", \\\"text\\\", \\\"22. The subject has current or recent (within 6 months) gastrointestinal disease that is expected to influence the absorption of drugs (ie, a history of malabsorption, esophageal reflux, peptic ulcer disease, erosive esophagitis, frequent [more than once per week] occurrence of heartburn, or any surgical intervention).\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Exclusion Criteria\\\", \\\"7.2\\\", \\\"2\\\", 2828], [\\\"2\\\", \\\"Exclusion Criteria\\\", \\\"text\\\", \\\"Any history of Roux-en-Y gastric bypass is considered exclusionary and any other surgical intervention that may influence the absorption of drugs should be discussed and approved by the sponsor or designee before enrolling the subject.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Exclusion Criteria\\\", \\\"7.2\\\", \\\"2\\\", 2829], [\\\"2\\\", \\\"Exclusion Criteria\\\", \\\"text\\\", \\\"23. The subject has LFT values (ALT, AST) higher than 1.5 times the upper limit of normal (ULN) at screening.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Exclusion Criteria\\\", \\\"7.2\\\", \\\"2\\\", 2830], [\\\"2\\\", \\\"Exclusion Criteria\\\", \\\"text\\\", \\\"24. The subject has a positive pregnancy test or is a lactating/breastfeeding woman at screening or baseline.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Exclusion Criteria\\\", \\\"7.2\\\", \\\"2\\\", 2831], [\\\"2\\\", \\\"Exclusion Criteria\\\", \\\"text\\\", \\\"25. The subject has a positive urine screen for drugs of abuse and/or positive ~REDACTED~ test at screening and study baseline.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Exclusion Criteria\\\", \\\"7.2\\\", \\\"2\\\", 2832], [\\\"2\\\", \\\"Exclusion Criteria\\\", \\\"text\\\", \\\"An exception at screening is made for stimulants or other drugs that the subject with NT1 has been prescribed, but the drug screen must be negative at study baseline.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Exclusion Criteria\\\", \\\"7.2\\\", \\\"2\\\", 2833], [\\\"2\\\", \\\"Exclusion Criteria\\\", \\\"text\\\", \\\"26. The subject, in the opinion of the investigator or subinvestigator, is unlikely to comply with the protocol or is unsuitable for any other reason.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Exclusion Criteria\\\", \\\"7.2\\\", \\\"2\\\", 2834], [\\\"2\\\", \\\"Exclusion Criteria\\\", \\\"header\\\", \\\"Healthy Adult Subjects for Parts A, B, C, E, and F\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading9\\\", \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"single\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Exclusion Criteria\\\", \\\"7.2\\\", \\\"2\\\", 2835], [\\\"2\\\", \\\"Exclusion Criteria\\\", \\\"text\\\", \\\"1. The subject has a history of alcohol consumption exceeding 2 standard drinks per day on average (1 glass is approximately equivalent to the following: beer [354 mL/12 oz], wine [118 mL/4 oz], or distilled spirits [29.5 mL/1 oz] per day).\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Exclusion Criteria\\\", \\\"7.2\\\", \\\"2\\\", 2836], [\\\"2\\\", \\\"Exclusion Criteria\\\", \\\"text\\\", \\\"Healthy Adult Subjects in Cohorts A3 and ~REDACTED~\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"single\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Exclusion Criteria\\\", \\\"7.2\\\", \\\"2\\\", 2837], [\\\"2\\\", \\\"Exclusion Criteria\\\", \\\"text\\\", \\\"28. The subject is lactose intolerant.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Exclusion Criteria\\\", \\\"7.2\\\", \\\"2\\\", 2838], [\\\"2\\\", \\\"Exclusion Criteria\\\", \\\"header\\\", \\\"Subjects With NT1 for Part D\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading9\\\", \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"single\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Exclusion Criteria\\\", \\\"7.2\\\", \\\"2\\\", 2839], [\\\"2\\\", \\\"Exclusion Criteria\\\", \\\"text\\\", \\\"29. The subject has a history of drug or alcohol abuse within the 12 months before screening (Diagnostic and Statistical Manual of Mental Disorders, 5th Edition criteria).\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Exclusion Criteria\\\", \\\"7.2\\\", \\\"2\\\", 2840], [\\\"2\\\", \\\"Exclusion Criteria\\\", \\\"text\\\", \\\"30. The subject used NT1 medication within at least 7 days or 5 times the elimination half-lives, whichever is longer, as defined in Section 7.3.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Exclusion Criteria\\\", \\\"7.2\\\", \\\"2\\\", 2841], [\\\"2\\\", \\\"Exclusion Criteria\\\", \\\"text\\\", \\\"31. The subject is an excessive (>600 mg/day) ~REDACTED~ user 1 week before the study screening.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Exclusion Criteria\\\", \\\"7.2\\\", \\\"2\\\", 2842], [\\\"2\\\", \\\"Exclusion Criteria\\\", \\\"text\\\", \\\"4. The subject has a medical disorder, other than narcolepsy, associated with EDS.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Exclusion Criteria\\\", \\\"7.2\\\", \\\"2\\\", 2843], [\\\"2\\\", \\\"Exclusion Criteria\\\", \\\"text\\\", \\\"This includes clinically significant moderate to severe obstructive sleep apnea with or without treatment with mandibular advanced device hypoglossal nerve stimulation and/or positive airway pressure (PAP) therapy and/or restless legs syndrome (RLS)/periodic limb movement disorder that has a significant impact on daytime sleepiness.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Exclusion Criteria\\\", \\\"7.2\\\", \\\"2\\\", 2844], [\\\"2\\\", \\\"Exclusion Criteria\\\", \\\"text\\\", \\\"This is evidenced by a clinical history of sleep apnea syndrome (loud snoring with observed respiratory pauses in the absence of nPSG) and/or RLS causing historical sleep onset/maintenance insomnia with resultant insufficient\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Exclusion Criteria\\\", \\\"7.2\\\", \\\"2\\\", 2845], [\\\"2\\\", \\\"Exclusion Criteria\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Exclusion Criteria\\\", \\\"7.2\\\", \\\"2\\\", 2846], [\\\"2\\\", \\\"Exclusion Criteria\\\", \\\"text\\\", \\\"should be considered exclusionary unless, based on a clinical evaluation by the investigator, a meaningful change in clinical status has occurred that would not impact the results.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Exclusion Criteria\\\", \\\"7.2\\\", \\\"2\\\", 2847], [\\\"2\\\", \\\"Exclusion Criteria\\\", \\\"text\\\", \\\"Because nPSG data is obtained on Day -2, subjects may fail screening if criteria are not meet on the Day -2 nPSG.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Exclusion Criteria\\\", \\\"7.2\\\", \\\"2\\\", 2848], [\\\"2\\\", \\\"Exclusion Criteria\\\", \\\"text\\\", \\\"5. The subject has any other medical condition, such as anxiety, depression, heart disease, or significant hepatic, pulmonary, or renal disease, that requires the subject to take excluded medications (defined Section 7.3) or at the time of screening the subject is being treated with nasal/oro-nasal PAP for any reason.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Exclusion Criteria\\\", \\\"7.2\\\", \\\"2\\\", 2849], [\\\"2\\\", \\\"Exclusion Criteria\\\", \\\"text\\\", \\\"6. The subject is unwilling to abstain from driving and operating dangerous or hazardous machinery during study participation, starting from when narcolepsy medication is discontinued and extending until after the follow-up visit (21\\\\u00b12 days).\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Exclusion Criteria\\\", \\\"7.2\\\", \\\"2\\\", 2850], [\\\"2\\\", \\\"Exclusion Criteria\\\", \\\"text\\\", \\\"35. The subject has a usual bedtime later than 2400 (12:00\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Exclusion Criteria\\\", \\\"7.2\\\", \\\"2\\\", 2851], [\\\"2\\\", \\\"Exclusion Criteria\\\", \\\"text\\\", \\\"AM\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 19, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 19, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Exclusion Criteria\\\", \\\"7.2\\\", \\\"2\\\", 2852], [\\\"2\\\", \\\"Exclusion Criteria\\\", \\\"text\\\", \\\"midnight) or an occupation requiring nighttime shift work or variable shift work within the past 6 months or travel with significant jet lag within 14 days before Study Day -2.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Exclusion Criteria\\\", \\\"7.2\\\", \\\"2\\\", 2853], [\\\"2\\\", \\\"Exclusion Criteria\\\", \\\"text\\\", \\\"8. The subject has a ~REDACTED~ dependence that is likely to have an effect on sleep (eg, a subject who routinely awakens at night to smoke) and/or an unwillingness to discontinue all smoking and ~REDACTED~ use during the confinement portions of the study.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Exclusion Criteria\\\", \\\"7.2\\\", \\\"2\\\", 2854], [\\\"2\\\", \\\"Exclusion Criteria\\\", \\\"header\\\", \\\"Subjects Who Undergo ~REDACTED~ Sampling (Part D as Optional and Part F as Mandatory)\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading9\\\", \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"single\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Exclusion Criteria\\\", \\\"7.2\\\", \\\"2\\\", 2855], [\\\"2\\\", \\\"Exclusion Criteria\\\", \\\"text\\\", \\\"Note: For subjects in Part D, a subject who meets the criteria below can still participate in the study if the subject will not undergo optional ~REDACTED~ sampling.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Exclusion Criteria\\\", \\\"7.2\\\", \\\"2\\\", 2856], [\\\"2\\\", \\\"Exclusion Criteria\\\", \\\"text\\\", \\\"37. The subject has undergone ~REDACTED~ collection within 30 days before check-in.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Exclusion Criteria\\\", \\\"7.2\\\", \\\"2\\\", 2857], [\\\"2\\\", \\\"Exclusion Criteria\\\", \\\"text\\\", \\\"38. The subject has a known hypersensitivity to anesthesia/local ~REDACTED~, or its derivatives used during ~REDACTED~ collection or to any medication used to prepare the area of lumbar puncture.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Exclusion Criteria\\\", \\\"7.2\\\", \\\"2\\\", 2858], [\\\"2\\\", \\\"Exclusion Criteria\\\", \\\"text\\\", \\\"39. The subject has significant vertebral deformities (scoliosis or kyphosis) that, in the opinion of the investigator, may interfere with the lumbar puncture procedure.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Exclusion Criteria\\\", \\\"7.2\\\", \\\"2\\\", 2859], [\\\"2\\\", \\\"Exclusion Criteria\\\", \\\"text\\\", \\\"40. The subject has a history of major back (lumbar) surgery, clinically significant back pain, or injury, in the opinion of the investigator.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Exclusion Criteria\\\", \\\"7.2\\\", \\\"2\\\", 2860], [\\\"2\\\", \\\"Exclusion Criteria\\\", \\\"text\\\", \\\"41. The subject has a local infection at the puncture site.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Exclusion Criteria\\\", \\\"7.2\\\", \\\"2\\\", 2861], [\\\"2\\\", \\\"Exclusion Criteria\\\", \\\"text\\\", \\\"42. The subject has developed signs of lumbar radiculopathy, including lower extremity pain and paresthesia.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Exclusion Criteria\\\", \\\"7.2\\\", \\\"2\\\", 2862], [\\\"2\\\", \\\"Exclusion Criteria\\\", \\\"text\\\", \\\"43. The subject has any known focal neurological deficit that might suggest an increase in intracranial pressure.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Exclusion Criteria\\\", \\\"7.2\\\", \\\"2\\\", 2863], [\\\"2\\\", \\\"Exclusion Criteria\\\", \\\"text\\\", \\\"8. The subject has any abnormal findings on ophthalmological/fundoscopic assessment indicative of raised intracranial pressure (ie, optic disc swelling/edema or [uncontrolled] hypertension retinopathy).\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Exclusion Criteria\\\", \\\"7.2\\\", \\\"2\\\", 2864], [\\\"2\\\", \\\"Exclusion Criteria\\\", \\\"text\\\", \\\"45. The subject has a bleeding abnormality or history of bleeding abnormalities.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Exclusion Criteria\\\", \\\"7.2\\\", \\\"2\\\", 2865], [\\\"2\\\", \\\"Exclusion Criteria\\\", \\\"text\\\", \\\"The subject has thrombocytopenia or other suspected bleeding tendencies noted.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Exclusion Criteria\\\", \\\"7.2\\\", \\\"2\\\", 2866], [\\\"2\\\", \\\"Exclusion Criteria\\\", \\\"text\\\", \\\"10. The subject is taking an ~REDACTED~ or has abnormal coagulation tests (prothrombin time/international normalized ratio [INR], activated partial thromboplastin time) at screening (1 tablet per day of low dose ~REDACTED~ [81 mg] is allowed for subjects for Part D).\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Exclusion Criteria\\\", \\\"7.2\\\", \\\"2\\\", 2867], [\\\"2\\\", \\\"Exclusion Criteria\\\", \\\"header\\\", \\\"Healthy Adult Subjects for Part F\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading9\\\", \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"single\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Exclusion Criteria\\\", \\\"7.2\\\", \\\"2\\\", 2868], [\\\"2\\\", \\\"Exclusion Criteria\\\", \\\"text\\\", \\\"47. Have excessive sleepiness, defined by a self-reported ESS score at screening >10; irregular work hours; or routine night-shift work within 1 month before randomization.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Exclusion Criteria\\\", \\\"7.2\\\", \\\"2\\\", 2869], [\\\"2\\\", \\\"Exclusion Criteria\\\", \\\"text\\\", \\\"48. Have a history of or currently is experiencing any known/suspected sleep disorder (including obstructive sleep apnea and RLS), any disorder associated with EDS.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Exclusion Criteria\\\", \\\"7.2\\\", \\\"2\\\", 2870], [\\\"2\\\", \\\"Exclusion Criteria\\\", \\\"text\\\", \\\"49. At the time of screening, be receiving treatment with nasal/oronasal PAP for any reason.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Exclusion Criteria\\\", \\\"7.2\\\", \\\"2\\\", 2871], [\\\"2\\\", \\\"Exclusion Criteria\\\", \\\"text\\\", \\\"50. Have traveled across 2 or more time zones within the 2 weeks before screening.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Exclusion Criteria\\\", \\\"7.2\\\", \\\"2\\\", 2872], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"7.3 Excluded Medications, Supplements, Dietary Products\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading2\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Excluded Medications, Supplements, Dietary Products\\\", \\\"7.3\\\", \\\"2\\\", 2873], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Use of excluded medications applicable to healthy volunteer participants (Parts A, B, C, E, and F) is outline in Table 7.a.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Excluded Medications, Supplements, Dietary Products\\\", \\\"7.3\\\", \\\"2\\\", 2874], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Use of excluded medications applicable to subjects with NT1 (Part D) is outlined in Table 7.b.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Excluded Medications, Supplements, Dietary Products\\\", \\\"7.3\\\", \\\"2\\\", 2875], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Excluded Medications, Supplements, Dietary Products\\\", \\\"7.3\\\", \\\"2\\\", 2876], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"Table 7.a 7.a Excluded Medications, Supplements, and Dietary Products (Healthy Subjects)\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading8\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"a  Excluded Medications, Supplements, and Dietary Products (Healthy Subjects)\\\", \\\"7.\\\", \\\"2\\\", 2877], [\\\"\\\", \\\"Unmapped\\\", \\\"table\\\", {\\\"Table\\\": \\\"<table border=\\\\\\\"1\\\\\\\" class=\\\\\\\"dataframe\\\\\\\">\\\\n  <thead>\\\\n    <tr style=\\\\\\\"text-align: right;\\\\\\\">\\\\n      <th></th>\\\\n      <th>1.0</th>\\\\n      <th>2.0</th>\\\\n      <th>3.0</th>\\\\n    </tr>\\\\n  </thead>\\\\n  <tbody>\\\\n    <tr>\\\\n      <th>0</th>\\\\n      <td>Category</td>\\\\n      <td>Between Screening and Randomization (Day -28/35 to Predose on Day 1)</td>\\\\n      <td>After Randomization (Day 1 to Follow-up)</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>1</th>\\\\n      <td><span class=\\\\\\\"redact\\\\\\\"> ~REDACTED~ </span>  and nicotinecontaining products</td>\\\\n      <td>Completely restricted.</td>\\\\n      <td>Completely restricted.</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>2</th>\\\\n      <td>Cannabis products</td>\\\\n      <td>Completely restricted</td>\\\\n      <td>Completely restricted</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>3</th>\\\\n      <td><span class=\\\\\\\"redact\\\\\\\"> ~REDACTED~ </span></td>\\\\n      <td>Completely restricted starting from 7 days before dosing</td>\\\\n      <td>Completely restricted</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>4</th>\\\\n      <td>X<sup>anthine and/or  <span class=\\\\\\\"redact\\\\\\\"> ~REDACTED~ </span> </sup></td>\\\\n      <td>Completely restricted starting from 24 hours before dosing</td>\\\\n      <td>Completely restricted</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>5</th>\\\\n      <td>Medications <sup>a</sup></td>\\\\n      <td>Completely restricted starting from 7 days or 5 half-lives, whichever is longer, before dosing</td>\\\\n      <td>Completely restricted except treatments for AEs</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>6</th>\\\\n      <td>Food substance Grapefruit/grapefruit juice</td>\\\\n      <td>Completely restricted starting from 7 days before dosing</td>\\\\n      <td>Completely restricted</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>7</th>\\\\n      <td>Fruit juices</td>\\\\n      <td>No restriction</td>\\\\n      <td>Dosing will occur without consumption of fruit juice. Fruit juice is restricted up to 4 hours postdose and 12 hours before study drug on PK sampling days</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>8</th>\\\\n      <td><span class=\\\\\\\"redact\\\\\\\"> ~REDACTED~ </span>  green <sup>b</sup></td>\\\\n      <td>Completely restricted starting from 7 days before dosing</td>\\\\n      <td>Completely restricted</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>9</th>\\\\n      <td>Charbroiled meat</td>\\\\n      <td>Completely restricted starting from 7 days before dosing</td>\\\\n      <td>Completely restricted</td>\\\\n    </tr>\\\\n  </tbody>\\\\n</table>\\\", \\\"SectionHeaderPrintPage\\\": \\\"83\\\", \\\"TableIndex\\\": \\\"38\\\", \\\"TableName\\\": \\\"Table\\\\u00a07.a Excluded Medications, Supplements, and Dietary Products (Healthy Subjects)\\\", \\\"Header\\\": [0]}, {\\\"IsBold\\\": true, \\\"font_size\\\": 20, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 20, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"a  Excluded Medications, Supplements, and Dietary Products (Healthy Subjects)\\\", \\\"7.\\\", \\\"2\\\", 2878], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"AE: adverse event; CYP: cytochrome P450; OATP: organic anion transporting polypeptide.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 20, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 20, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"a  Excluded Medications, Supplements, and Dietary Products (Healthy Subjects)\\\", \\\"7.\\\", \\\"2\\\", 2879], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"a Medications are defined as prescription and over-the-counter drugs (including inhibitors/inducers of CYP3A and substrates of CYP3A and OATP1B1; see list in Appendix F), vaccines, supplements, nutraceuticals (eg, ~REDACTED~, ginseng, kava kava, ginkgo biloba, ~REDACTED~, and ~REDACTED~), and herbal preparations.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 20, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 20, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"a  Excluded Medications, Supplements, and Dietary Products (Healthy Subjects)\\\", \\\"7.\\\", \\\"2\\\", 2880], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"b ~REDACTED~ green family includes kale, broccoli, watercress, collard greens, kohlrabi, Brussel sprouts, and ~REDACTED~.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 20, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 20, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"a  Excluded Medications, Supplements, and Dietary Products (Healthy Subjects)\\\", \\\"7.\\\", \\\"2\\\", 2881], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"7.3.1 Subjects With NT1 (Part D)\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading4\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Subjects With NT1 (Part D)\\\", \\\"7.3.1\\\", \\\"3\\\", 2882], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Excluded medications and supplements are shown in Table 7.b.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Subjects With NT1 (Part D)\\\", \\\"7.3.1\\\", \\\"3\\\", 2883], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"For restrictions regarding fruit juice, ~REDACTED~, ~REDACTED~, and smoking please refer to Sections 7.3.3, 7.3.4, 7.3.5 and 7.3.6.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Subjects With NT1 (Part D)\\\", \\\"7.3.1\\\", \\\"3\\\", 2884], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Administration of any drugs used for the treatment of narcolepsy with cataplexy (NT1) must be discontinued as defined in Table 7.b.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Subjects With NT1 (Part D)\\\", \\\"7.3.1\\\", \\\"3\\\", 2885], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"The investigator will determine the schedule for tapering of ~REDACTED~ and stimulants.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Subjects With NT1 (Part D)\\\", \\\"7.3.1\\\", \\\"3\\\", 2886], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"7.b Excluded Medications and Supplements\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": 22, \\\"font_style\\\": \\\"Heading8\\\", \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Calibri\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 22, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Subjects With NT1 (Part D)\\\", \\\"7.3.1\\\", \\\"3\\\", 2887], [\\\"\\\", \\\"Unmapped\\\", \\\"table\\\", {\\\"Table\\\": \\\"<table border=\\\\\\\"1\\\\\\\" class=\\\\\\\"dataframe\\\\\\\">\\\\n  <thead>\\\\n    <tr style=\\\\\\\"text-align: right;\\\\\\\">\\\\n      <th></th>\\\\n      <th>1.0</th>\\\\n      <th>2.0</th>\\\\n    </tr>\\\\n  </thead>\\\\n  <tbody>\\\\n    <tr>\\\\n      <th>0</th>\\\\n      <td>Prohibited Drug Category</td>\\\\n      <td>Drugs Restricted From 7 Days or 5 Half-Lives <sup>a</sup> Before Dosing (Day 1) Until Follow-up (Unless Otherwise Specified)</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>1</th>\\\\n      <td>Any investigational drug</td>\\\\n      <td><60 days before screening or 5 half-lives, whichever is longer</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>2</th>\\\\n      <td>Psychostimulants</td>\\\\n      <td><span class=\\\\\\\"redact\\\\\\\"> ~REDACTED~ </span> ,  <span class=\\\\\\\"redact\\\\\\\"> ~REDACTED~ </span> ,  <span class=\\\\\\\"redact\\\\\\\"> ~REDACTED~ </span> ass=\\\\\\\"redact\\\\\\\"> ~REDACTED~ </span> ,  <span class=\\\\\\\"redact\\\\\\\"> ~REDACTED~ </span> ,  <span class=\\\\\\\"redact\\\\\\\"> ~REDACTED~ </span> , and  <span class=\\\\\\\"redact\\\\\\\"> ~REDACTED~ </span>  need to be restricted from 7 days or 5 half-lives before Day -2</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>3</th>\\\\n      <td><span class=\\\\\\\"redact\\\\\\\"> ~REDACTED~ </span></td>\\\\n      <td>Must be discontinued for medical reasons at a minimum of 4 weeks before baseline on Day -2 and only if necessitated by other medical reasons</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>4</th>\\\\n      <td>Antipsychotic drugs</td>\\\\n      <td>Not allowed</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>5</th>\\\\n      <td>Antianxiety/sleeping drugs (tranquilizers/sleeping medications)</td>\\\\n      <td>Including  <span class=\\\\\\\"redact\\\\\\\"> ~REDACTED~ </span> , nonbenzodiazepine drugs and melatoninergic agonists before Day -2</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>6</th>\\\\n      <td><span class=\\\\\\\"redact\\\\\\\"> ~REDACTED~ </span></td>\\\\n      <td>At screening, those on fluoxetine (any dose) or venlafaxine \\\\u2265300 mg/day will be excluded from the study. Stimulant medications must be discontinued for a minimum of 7 days or 5 half-lives before Day -2 check-in Anticataplexy medications (eg, tricyclic antidepressants,  <span class=\\\\\\\"redact\\\\\\\"> ~REDACTED~ </span> , and SNRI) must be discontinued for a minimum of 14 days or 5 half-lives, whichever is longer, before the Day -2 check-in.</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>7</th>\\\\n      <td>Mood stabilizers (such as  <span class=\\\\\\\"redact\\\\\\\"> ~REDACTED~ </span>  or  <span class=\\\\\\\"redact\\\\\\\"> ~REDACTED~ </span>  or other antipsychotic drugs)</td>\\\\n      <td>Not allowed</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>8</th>\\\\n      <td><span class=\\\\\\\"redact\\\\\\\"> ~REDACTED~ </span></td>\\\\n      <td>Not allowed</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>9</th>\\\\n      <td>Sleeping pills</td>\\\\n      <td>Including Chinese medicine ( Yokukansan, Yokukansankachinpihange ) used for insomnia discontinue before Day -2</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>10</th>\\\\n      <td>Anti-Parkinson disease drugs (completely excluded)</td>\\\\n      <td>Not allowed</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>11</th>\\\\n      <td>Adrenocorticosteroids (excluded except for inhaled and topical)</td>\\\\n      <td>Systemic administration would only occur during the study to treat an AE</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>12</th>\\\\n      <td>Interferon, interleukin-formulation (excluded)</td>\\\\n      <td>Not allowed</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>13</th>\\\\n      <td>Muscle-relaxant drug</td>\\\\n      <td>eg,  <span class=\\\\\\\"redact\\\\\\\"> ~REDACTED~ </span></td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>14</th>\\\\n      <td>Antihistamines</td>\\\\n      <td>OTC drugs and pharmaceutic adjuvants are also included Only centrally acting antihistamines are prohibited, including  <span class=\\\\\\\"redact\\\\\\\"> ~REDACTED~ </span> .</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>15</th>\\\\n      <td><span class=\\\\\\\"redact\\\\\\\"> ~REDACTED~ </span>  with CNS action</td>\\\\n      <td>Not allowed</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>16</th>\\\\n      <td><span class=\\\\\\\"redact\\\\\\\"> ~REDACTED~ </span>  with CNS action</td>\\\\n      <td>Not allowed</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>17</th>\\\\n      <td>Narcotic  <span class=\\\\\\\"redact\\\\\\\"> ~REDACTED~ </span>  and nonnarcotic  <span class=\\\\\\\"redact\\\\\\\"> ~REDACTED~ </span> ,  <span class=\\\\\\\"redact\\\\\\\"> ~REDACTED~ </span>  ( <span class=\\\\\\\"redact\\\\\\\"> ~REDACTED~ </span> )</td>\\\\n      <td>Use of OTC pain medications ( <span class=\\\\\\\"redact\\\\\\\"> ~REDACTED~ </span> ; excluding occasional use of  <span class=\\\\\\\"redact\\\\\\\"> ~REDACTED~ </span> ,  <span class=\\\\\\\"redact\\\\\\\"> ~REDACTED~ </span> , and  <span class=\\\\\\\"redact\\\\\\\"> ~REDACTED~ </span> ) is prohibited unless otherwise approved by the principal investigator after consultation with the sponsor or designee (ie, Medical Monitor)</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>18</th>\\\\n      <td><span class=\\\\\\\"redact\\\\\\\"> ~REDACTED~ </span> , health foods containing  <span class=\\\\\\\"redact\\\\\\\"> ~REDACTED~ </span></td>\\\\n      <td>Not allowed</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>19</th>\\\\n      <td>The list of known moderate and strong CYP3A inhibitors or inducers can be found in Appendix F. The list of known CYP3A substrates with narrow therapeutic range can be found in Appendix F.</td>\\\\n      <td>Not allowed</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>20</th>\\\\n      <td>The list of known sensitive OATP1B1 substrates can be found in Appendix F.</td>\\\\n      <td></td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>21</th>\\\\n      <td>Chinese herbal medicine</td>\\\\n      <td>Only topical use is allowed</td>\\\\n    </tr>\\\\n  </tbody>\\\\n</table>\\\", \\\"SectionHeaderPrintPage\\\": \\\"83\\\", \\\"TableIndex\\\": \\\"39\\\", \\\"TableName\\\": \\\"7.3.1 Subjects With NT1 (Part D)\\\", \\\"Header\\\": [0]}, {\\\"IsBold\\\": true, \\\"font_size\\\": 20, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 20, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Subjects With NT1 (Part D)\\\", \\\"7.3.1\\\", \\\"3\\\", 2888], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"7.b Excluded Medications and Supplements\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": 22, \\\"font_style\\\": \\\"Heading8\\\", \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Calibri\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 22, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"b  Excluded Medications and Supplements\\\", \\\"7.\\\", \\\"2\\\", 2889], [\\\"\\\", \\\"Unmapped\\\", \\\"table\\\", \\\"\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": 20, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 20, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"b  Excluded Medications and Supplements\\\", \\\"7.\\\", \\\"2\\\", 2890], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"b  Excluded Medications and Supplements\\\", \\\"7.\\\", \\\"2\\\", 2891], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"AE: adverse event; CNS: central nervous system; CYP: cytochrome P450; OATP: organic anion transporting polypeptide; OTC: over-the-counter; SNRI: serotonin and ~REDACTED~ reuptake inhibitor; ~REDACTED~: ~REDACTED~.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 20, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 20, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"b  Excluded Medications and Supplements\\\", \\\"7.\\\", \\\"2\\\", 2892], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"If medications are required to treat an AE, certain medications, including supplements, may be allowed after discussion and agreement between the sponsor or designee and principal investigator, unless the investigator or investigator\\\\u2019s designee considers immediate administration necessary.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 20, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 20, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"b  Excluded Medications and Supplements\\\", \\\"7.\\\", \\\"2\\\", 2893], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"a\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 20, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 20, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"superscript\\\"}, \\\"Study Design\\\", \\\"b  Excluded Medications and Supplements\\\", \\\"7.\\\", \\\"2\\\", 2894], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Whichever is longer.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 20, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 20, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"b  Excluded Medications and Supplements\\\", \\\"7.\\\", \\\"2\\\", 2895], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"7.3.2 Concomitant Medications\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading4\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Concomitant Medications\\\", \\\"7.3.2\\\", \\\"3\\\", 2896], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"Healthy Subjects\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading9\\\", \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"single\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Concomitant Medications\\\", \\\"7.3.2\\\", \\\"3\\\", 2897], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"The use of concomitant medications starting from 7 days or 5 half-lives (whichever is longer) before administration of the first dose of study drug, throughout the study (including the washout interval between treatment periods for food effect cohorts), and until the follow-up visit is not permitted.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Concomitant Medications\\\", \\\"7.3.2\\\", \\\"3\\\", 2898], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Subjects must be instructed not to take any medications without first consulting with the investigator.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Concomitant Medications\\\", \\\"7.3.2\\\", \\\"3\\\", 2899], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Any concomitant medication use must first be discussed with the sponsor, unless the investigator or designee considers immediate administration necessary.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Concomitant Medications\\\", \\\"7.3.2\\\", \\\"3\\\", 2900], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"The occasional use of ~REDACTED~ (approximately <1 g/d) is allowed.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Concomitant Medications\\\", \\\"7.3.2\\\", \\\"3\\\", 2901], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"The use of any investigational drug other than TAK-861 is not permitted throughout all study participation periods.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Concomitant Medications\\\", \\\"7.3.2\\\", \\\"3\\\", 2902], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"Subjects With NT1\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading9\\\", \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"single\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Concomitant Medications\\\", \\\"7.3.2\\\", \\\"3\\\", 2903], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Subjects may take any medication that is not prohibited as listed in Section 7.3.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Concomitant Medications\\\", \\\"7.3.2\\\", \\\"3\\\", 2904], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"The investigators or the subinvestigators will review concomitant medication use at screening and determine the time of discontinuation, keeping in mind that some medications will need to be tapered.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Concomitant Medications\\\", \\\"7.3.2\\\", \\\"3\\\", 2905], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"The investigator or subinvestigator will consult with the sponsor or designee (ie, Medical Monitor)\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Concomitant Medications\\\", \\\"7.3.2\\\", \\\"3\\\", 2906], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Concomitant Medications\\\", \\\"7.3.2\\\", \\\"3\\\", 2907], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"before allowing any concomitant medication during the study.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Concomitant Medications\\\", \\\"7.3.2\\\", \\\"3\\\", 2908], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Subjects will also be instructed not to take any medications, including over-the-counter drugs, without prior consultation with the investigator or subinvestigator.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Concomitant Medications\\\", \\\"7.3.2\\\", \\\"3\\\", 2909], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"The use of any investigational drug other than TAK-861 is not permitted throughout any study participation period.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Concomitant Medications\\\", \\\"7.3.2\\\", \\\"3\\\", 2910], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"7.3.3 Fruit Juice\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading4\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Fruit Juice\\\", \\\"7.3.3\\\", \\\"3\\\", 2911], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"Healthy Subjects\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading9\\\", \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"single\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Fruit Juice\\\", \\\"7.3.3\\\", \\\"3\\\", 2912], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Subjects will refrain from consuming grapefruit juice, grapefruits, and products containing grapefruit beginning approximately 7 days before administration of the first dose of study drug, throughout the study (including the food effect cohorts), and until the follow-up visit.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Fruit Juice\\\", \\\"7.3.3\\\", \\\"3\\\", 2913], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Subjects will also refrain from consuming all juices from approximately 12 hours before administration of each dose of study drug on PK sampling days (see the Schedules of Study Procedures in Section 3.0) until 4 hours postdose.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Fruit Juice\\\", \\\"7.3.3\\\", \\\"3\\\", 2914], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Consumption of all fruits other than grapefruit is allowed on all other days of the study.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Fruit Juice\\\", \\\"7.3.3\\\", \\\"3\\\", 2915], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"Subjects With NT1\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading9\\\", \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"single\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Fruit Juice\\\", \\\"7.3.3\\\", \\\"3\\\", 2916], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Consumption of all fruit juices and fruit other than grapefruit fruit and grapefruit juice is allowed on all days of the study.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Fruit Juice\\\", \\\"7.3.3\\\", \\\"3\\\", 2917], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"7.3.4 ~REDACTED~\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading4\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Alcohol\\\", \\\"7.3.4\\\", \\\"3\\\", 2918], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"Healthy Subjects and Subjects With NT 1\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading9\\\", \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"single\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Alcohol\\\", \\\"7.3.4\\\", \\\"3\\\", 2919], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Subjects will refrain from consuming alcohol starting from 7 days before dosing and until the follow-up visit.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Alcohol\\\", \\\"7.3.4\\\", \\\"3\\\", 2920], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"During the washout interval between treatment periods for food effect cohorts, alcohol consumption is limited to no more than approximately 2 alcoholic beverages or equivalent (1 alcoholic beverage is approximately equivalent to beer [354 mL/12 oz], wine [118 mL/4 oz], or distilled spirits [29.5 mL/1 oz]) per day.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Alcohol\\\", \\\"7.3.4\\\", \\\"3\\\", 2921], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"7.3.5 ~REDACTED~\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading4\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Caffeine\\\", \\\"7.3.5\\\", \\\"3\\\", 2922], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"Healthy Subjects\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading9\\\", \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"single\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Caffeine\\\", \\\"7.3.5\\\", \\\"3\\\", 2923], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Subjects will refrain from consuming caffeinated beverages starting from 24 hours before dosing and until the follow-up visit.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Caffeine\\\", \\\"7.3.5\\\", \\\"3\\\", 2924], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"During the washout interval between treatment periods for food effect cohorts, caffeinated beverages or xanthine-containing products will be limited to amounts of no more than 6 units per day (1 unit is 120 mg of caffeine).\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Caffeine\\\", \\\"7.3.5\\\", \\\"3\\\", 2925], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"Subjects With NT1\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading9\\\", \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"single\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Caffeine\\\", \\\"7.3.5\\\", \\\"3\\\", 2926], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"On days of PSG and MWT assessments (Section 3.0), caffeine will not be allowed; subjects will follow the PSG/MWT manual.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Caffeine\\\", \\\"7.3.5\\\", \\\"3\\\", 2927], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"At all other times, caffeinated beverages (including caffeinated tea) or xanthine-containing products will be limited to amounts of no more than 600 mg per day.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Caffeine\\\", \\\"7.3.5\\\", \\\"3\\\", 2928], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"7.3.6 Smoking\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading4\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Smoking\\\", \\\"7.3.6\\\", \\\"3\\\", 2929], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Healthy Subjects\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"single\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Smoking\\\", \\\"7.3.6\\\", \\\"3\\\", 2930], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Smoking and consumption of ~REDACTED~ foods are not permitted during the study.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Smoking\\\", \\\"7.3.6\\\", \\\"3\\\", 2931], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"Subjects With NT1\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading9\\\", \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"single\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Smoking\\\", \\\"7.3.6\\\", \\\"3\\\", 2932], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Subjects will follow the PSG/MWT manual.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Smoking\\\", \\\"7.3.6\\\", \\\"3\\\", 2933], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Subjects must be willing to abstain from smoking and use of nicotine-related products during the period of confinement in the inpatient or in-laboratory sleep center.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Smoking\\\", \\\"7.3.6\\\", \\\"3\\\", 2934], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"7.4 Dosing Instructions and Activity\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading2\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Dosing Instructions and Activity\\\", \\\"7.4\\\", \\\"2\\\", 2935], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"7.4.1 Diet and Fluid\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading4\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Diet and Fluid\\\", \\\"7.4.1\\\", \\\"3\\\", 2936], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"For the initial cohort(s), the TAK-861 oral suspension will be administered followed by a large glass of rinsing water (total volume of suspension and the rinse volume should be approximately 240 mL).\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Diet and Fluid\\\", \\\"7.4.1\\\", \\\"3\\\", 2937], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Subjects may then consume water ad libitum with the exception of 1 hour before and 1 hour after drug administration.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Diet and Fluid\\\", \\\"7.4.1\\\", \\\"3\\\", 2938], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"In all study parts except for food effects cohorts and Part D, subjects will be administered TAK-861 or matched placebo after an overnight fast of at least 10 hours and will continue to fast for an additional 4 hours postdose on serial PK collection days or 2 hours after dosing on nonintense PK collection days.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Diet and Fluid\\\", \\\"7.4.1\\\", \\\"3\\\", 2939], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"The dose will be taken in the morning on awakening, as close to 8\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Diet and Fluid\\\", \\\"7.4.1\\\", \\\"3\\\", 2940], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"AM\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 19, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 19, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Diet and Fluid\\\", \\\"7.4.1\\\", \\\"3\\\", 2941], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"as possible (after completion of predose assessments in the unit) and a dosing window of up to as close to 9\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Diet and Fluid\\\", \\\"7.4.1\\\", \\\"3\\\", 2942], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"AM\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 19, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 19, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Diet and Fluid\\\", \\\"7.4.1\\\", \\\"3\\\", 2943], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"as possible can be allowed in healthy subject cohorts where multiple dosing may happen at once.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Diet and Fluid\\\", \\\"7.4.1\\\", \\\"3\\\", 2944], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Subjects may consume water ad libitum except for 1 hour before and 1 hour after study drug administration.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Diet and Fluid\\\", \\\"7.4.1\\\", \\\"3\\\", 2945], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"During confinement in the SRD portions of Part A and Part E (Days 1 through 5), breakfast will not be served on Day 1 (except for Cohorts A3 and ~REDACTED~, fed condition).\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Diet and Fluid\\\", \\\"7.4.1\\\", \\\"3\\\", 2946], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Subjects will be given 2 standardized meals (lunch and dinner) and an evening snack, each containing approximately 30% fat (relative to total calories).\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Diet and Fluid\\\", \\\"7.4.1\\\", \\\"3\\\", 2947], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"On other non-dosing days, subjects will be given 3 standardized meals and an evening snack each containing approximately 30% fat (relative to the total calories).\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Diet and Fluid\\\", \\\"7.4.1\\\", \\\"3\\\", 2948], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"For Cohort A3 only, on Day 15 (ie, dosing in the fed regimen), subjects will receive a high-fat\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Diet and Fluid\\\", \\\"7.4.1\\\", \\\"3\\\", 2949], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"(approximately 50% of total caloric content of the meal) and high-calorie (approximately 800 to 1000 calories) breakfast after an overnight fast of at least 10 hours as recommended in 2019 ~REDACTED~ food-effect guidance[12].\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Diet and Fluid\\\", \\\"7.4.1\\\", \\\"3\\\", 2950], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"For Cohort ~REDACTED~ only, on Day 15 (ie, dosing in the fed regimen), subjects will be served a standardized non\\\\u2013high-fat breakfast after an overnight fast of at least 10 hours.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Diet and Fluid\\\", \\\"7.4.1\\\", \\\"3\\\", 2951], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"The breakdown of caloric composition of this breakfast should be approximately 55% to 60% carbohydrate, 30% fat, and 10% to 15% protein.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Diet and Fluid\\\", \\\"7.4.1\\\", \\\"3\\\", 2952], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"For the cohorts, the meal must be consumed within 30 minutes.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Diet and Fluid\\\", \\\"7.4.1\\\", \\\"3\\\", 2953], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Within 5 minutes after the end of the meal, subjects will be administered TAK-861 (as tablets) by mouth with 240 mL of water.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Diet and Fluid\\\", \\\"7.4.1\\\", \\\"3\\\", 2954], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Lunch will be served following the 4-hour postdose PK blood collection.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Diet and Fluid\\\", \\\"7.4.1\\\", \\\"3\\\", 2955], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Subjects may consume water ad libitum, except for 1 hour before and 1 hour after study drug administration.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Diet and Fluid\\\", \\\"7.4.1\\\", \\\"3\\\", 2956], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"The caloric breakdown of the test meal, meal start and stop times, and the amount consumed will be recorded in the source document and appropriate eCRF page.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Diet and Fluid\\\", \\\"7.4.1\\\", \\\"3\\\", 2957], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"10.2.9.2 During confinement in the MRD portions of Parts B, C, E (Days 6 through 19), and F, subjects will be given 2 standardized meals (lunch and dinner) and an evening snack, each containing approximately 30% fat (relative to total calories).\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Diet and Fluid\\\", \\\"7.4.1\\\", \\\"3\\\", 2958], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"For QD dosing, subjects will receive TAK-861/matched placebo by mouth with 240 mL of water after an overnight fast of at least 10 hours and will continue to fast for an additional 4 hours postdose.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Diet and Fluid\\\", \\\"7.4.1\\\", \\\"3\\\", 2959], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"If a subject is unable to continue fasting for 4 hours postdose, a light snack/very light meal may be provided no earlier than 2 hours postdose on nonintense PK collection days.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Diet and Fluid\\\", \\\"7.4.1\\\", \\\"3\\\", 2960], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Lunch will be served following the 4-hour postdose collection.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Diet and Fluid\\\", \\\"7.4.1\\\", \\\"3\\\", 2961], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"The meals served on dosing days should be similar in composition and caloric content for each cohort in the study.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Diet and Fluid\\\", \\\"7.4.1\\\", \\\"3\\\", 2962], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Whether the standardized meals were fully consumed (100%) or, if not, the percentage consumed (0, 25%, 50%, 75%) will be recorded on these days.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Diet and Fluid\\\", \\\"7.4.1\\\", \\\"3\\\", 2963], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Japanese subjects may continue with a Japanese diet, provided it contains approximately 30% fat (relative to total calories).\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Diet and Fluid\\\", \\\"7.4.1\\\", \\\"3\\\", 2964], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"For Part D only, during confinement, subjects will administer TAK-861 or matched placebo after an overnight fast of at least 8 hours.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Diet and Fluid\\\", \\\"7.4.1\\\", \\\"3\\\", 2965], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Subjects will then be allowed to have a morning meal approximately half an hour to 1 hour after study drug administration.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Diet and Fluid\\\", \\\"7.4.1\\\", \\\"3\\\", 2966], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Lunch will be served approximately 5 hours after dosing time after the 4 hours postdose MWT procedure.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Diet and Fluid\\\", \\\"7.4.1\\\", \\\"3\\\", 2967], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"In addition, standardized meals for subjects on Day -1 in Part D should be the same as those on study PK collection days (Days 1 and 14).\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Diet and Fluid\\\", \\\"7.4.1\\\", \\\"3\\\", 2968], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"At home, subject will be instructed to take TAK-861 or matched placebo on arising in the morning and have breakfast approximately half an hour to 1 hour after study drug intake whenever possible.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Diet and Fluid\\\", \\\"7.4.1\\\", \\\"3\\\", 2969], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Instructions on whether to take TAK-861 with or without food and/or drink may be modified during the study based on newly available data.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Diet and Fluid\\\", \\\"7.4.1\\\", \\\"3\\\", 2970], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Subjects will be provided written instructions by the site on how to take study drug (dosing and mealtimes) at home.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Diet and Fluid\\\", \\\"7.4.1\\\", \\\"3\\\", 2971], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Tablets should be taken with a large glass of water (approximately 240 mL total).\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Diet and Fluid\\\", \\\"7.4.1\\\", \\\"3\\\", 2972], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Subjects should swallow the tablet whole and not chew it or manipulate it in any way before swallowing.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Diet and Fluid\\\", \\\"7.4.1\\\", \\\"3\\\", 2973], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"For subjects with suspension formulation, dose administration will be followed by two rinses of 80 mL of water each (total volume of rinse water =160ml.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Diet and Fluid\\\", \\\"7.4.1\\\", \\\"3\\\", 2974], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"It is included in total 240 mL water).\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Diet and Fluid\\\", \\\"7.4.1\\\", \\\"3\\\", 2975], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Subjects should be instructed to take not more than the prescribed dose at any time.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Diet and Fluid\\\", \\\"7.4.1\\\", \\\"3\\\", 2976], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"In Part D, at home, if a subject fails to take the TAK 861 or matched placebo dose within the time frame specified, they should be instructed to take it before noon (approximately 12\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Diet and Fluid\\\", \\\"7.4.1\\\", \\\"3\\\", 2977], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"PM\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 19, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 19, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Diet and Fluid\\\", \\\"7.4.1\\\", \\\"3\\\", 2978], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\") at least 30 minutes before the next scheduled meal.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Diet and Fluid\\\", \\\"7.4.1\\\", \\\"3\\\", 2979], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"If the subject failed to administer the study drug before noon, the drug administration will be skipped on that day.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Diet and Fluid\\\", \\\"7.4.1\\\", \\\"3\\\", 2980], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Under no circumstance should a subject repeat a dose or double-up doses.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Diet and Fluid\\\", \\\"7.4.1\\\", \\\"3\\\", 2981], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Subjects will be instructed to record their dose of TAK 861 or matched placebo each day, or any skipped or mistimed doses, in their electronic dosing diary (see the study manual for details).\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Diet and Fluid\\\", \\\"7.4.1\\\", \\\"3\\\", 2982], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"In cases where the ePRO diary becomes unavailable, the study site may employ alternative methods to collect these data with approval from the sponsor or designee.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Diet and Fluid\\\", \\\"7.4.1\\\", \\\"3\\\", 2983], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Subjects will adhere to the medication and dietary restrictions described in Section 7.3.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Diet and Fluid\\\", \\\"7.4.1\\\", \\\"3\\\", 2984], [\\\"3\\\", \\\"Activity\\\", \\\"header\\\", \\\"7.4.2 Activity\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading4\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Activity\\\", \\\"7.4.2\\\", \\\"3\\\", 2985], [\\\"3\\\", \\\"Activity\\\", \\\"text\\\", \\\"During confinement, subjects should remain upright (seated, standing, or ambulatory) for 4 hours as feasible, following dose administration, except as necessitated by the occurrence of an AE or study procedure (eg, obtaining 12-lead ECG).\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Activity\\\", \\\"7.4.2\\\", \\\"3\\\", 2986], [\\\"3\\\", \\\"Activity\\\", \\\"text\\\", \\\"Please follow specific instructions for study assessments (eg, MWT).\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Activity\\\", \\\"7.4.2\\\", \\\"3\\\", 2987], [\\\"3\\\", \\\"Activity\\\", \\\"text\\\", \\\"Subjects should refrain from strenuous physical activity (eg, weightlifting, running, bicycling) from 72 hours before check-in until checkout for scheduled study visits.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Activity\\\", \\\"7.4.2\\\", \\\"3\\\", 2988], [\\\"3\\\", \\\"Activity\\\", \\\"text\\\", \\\"Subjects may engage in usual activities at other times with the exception of driving or operating hazardous machinery.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Activity\\\", \\\"7.4.2\\\", \\\"3\\\", 2989], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"7.4.3 Criteria for Discontinuation or Withdrawal of a Subject\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading4\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Criteria for Discontinuation or Withdrawal of a Subject\\\", \\\"7.4.3\\\", \\\"3\\\", 2990], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"The primary reason for discontinuation or withdrawal of a subject from the study or study drug should be recorded in the eCRF using the following categories:\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Criteria for Discontinuation or Withdrawal of a Subject\\\", \\\"7.4.3\\\", \\\"3\\\", 2991], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"1. Pretreatment event (PTE) or AE.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Criteria for Discontinuation or Withdrawal of a Subject\\\", \\\"7.4.3\\\", \\\"3\\\", 2992], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"The subject has experienced a PTE or AE that requires early termination because continued participation imposes an unacceptable risk to the subject\\\\u2019s health or the subject is unwilling to continue because of the PTE or AE.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Criteria for Discontinuation or Withdrawal of a Subject\\\", \\\"7.4.3\\\", \\\"3\\\", 2993], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\\u2013 LFT abnormalities: Study drug should be discontinued immediately with appropriate clinical follow-up (including repeat laboratory tests until a subject\\\\u2019s laboratory profile has returned to normal/baseline status, see Section 6.5.5.2), if the following circumstances occur at any time during the study drug treatment:\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Criteria for Discontinuation or Withdrawal of a Subject\\\", \\\"7.4.3\\\", \\\"3\\\", 2994], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"ALT or AST >5 \\\\u00d7 ULN.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Criteria for Discontinuation or Withdrawal of a Subject\\\", \\\"7.4.3\\\", \\\"3\\\", 2995], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"ALT or AST >3 \\\\u00d7 ULN in conjunction with elevated bilirubin >2 \\\\u00d7 ULN or INR >1.5.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Criteria for Discontinuation or Withdrawal of a Subject\\\", \\\"7.4.3\\\", \\\"3\\\", 2996], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"ALT or AST >3 \\\\u00d7 ULN with appearance of fatigue, nausea, vomiting, right upper quadrant pain or tenderness, fever, rash, and/or eosinophilia (>5%).\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Criteria for Discontinuation or Withdrawal of a Subject\\\", \\\"7.4.3\\\", \\\"3\\\", 2997], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"ALT >3 \\\\u00d7 ULN twice consecutively at least 24 to 48 hours apart.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Criteria for Discontinuation or Withdrawal of a Subject\\\", \\\"7.4.3\\\", \\\"3\\\", 2998], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\\u2013 BP increase: Study drug should be discontinued immediately if the median of 3 in-clinic BP measurements (at least 10 minutes apart) meets any of the following criteria:\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Criteria for Discontinuation or Withdrawal of a Subject\\\", \\\"7.4.3\\\", \\\"3\\\", 2999], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"o\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Courier New\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Criteria for Discontinuation or Withdrawal of a Subject\\\", \\\"7.4.3\\\", \\\"3\\\", 3000], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Systolic BP \\\\u2265160 mm Hg and/or diastolic BP \\\\u2265100 mm Hg.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Criteria for Discontinuation or Withdrawal of a Subject\\\", \\\"7.4.3\\\", \\\"3\\\", 3001], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"o\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Courier New\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Criteria for Discontinuation or Withdrawal of a Subject\\\", \\\"7.4.3\\\", \\\"3\\\", 3002], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Neurologic or cardiac findings associated with increases in BP.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Criteria for Discontinuation or Withdrawal of a Subject\\\", \\\"7.4.3\\\", \\\"3\\\", 3003], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"In the event of BP values meeting the criteria above, the subject will be treated for elevated BP according to the best judgment of the investigator and in accordance with good medical practice, and, if needed, further emergency medical evaluation sought.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Criteria for Discontinuation or Withdrawal of a Subject\\\", \\\"7.4.3\\\", \\\"3\\\", 3004], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"If the drug is discontinued in any subject due to a BP increase, the subject will not be rechallenged with TAK-861.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Criteria for Discontinuation or Withdrawal of a Subject\\\", \\\"7.4.3\\\", \\\"3\\\", 3005], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Any subject found to have significantly elevated BP as an outpatient should be treated per standard to care to obtain BP lowering.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Criteria for Discontinuation or Withdrawal of a Subject\\\", \\\"7.4.3\\\", \\\"3\\\", 3006], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"The sponsor or designee (ie, Medical Monitor) should be notified and consulted.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Criteria for Discontinuation or Withdrawal of a Subject\\\", \\\"7.4.3\\\", \\\"3\\\", 3007], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\\u2013 HR (or pulse rate) increase: sustained HR >100 beats per minute measured during the in-clinic visit will result in stopping treatment per the investigator\\\\u2019s clinical judgment.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Criteria for Discontinuation or Withdrawal of a Subject\\\", \\\"7.4.3\\\", \\\"3\\\", 3008], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\\u2013 Suicidality: Study drug should be discontinued immediately for subjects at imminent risk of suicide per the C-SSRS (score of 5) or per the investigator\\\\u2019s clinical judgment.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Criteria for Discontinuation or Withdrawal of a Subject\\\", \\\"7.4.3\\\", \\\"3\\\", 3009], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\\u2013 Insomnia: Study drug should be discontinued for subjects with sustained severe or serious insomnia as determined by the principal investigator after consultation with the sponsor or designee (ie, Medical Monitor).\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Criteria for Discontinuation or Withdrawal of a Subject\\\", \\\"7.4.3\\\", \\\"3\\\", 3010], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"2. Significant protocol deviation: The discovery postrandomization that the subject failed to meet protocol entry criteria or did not adhere to protocol requirements, and continued participation poses an unacceptable risk to the subject\\\\u2019s health.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Criteria for Discontinuation or Withdrawal of a Subject\\\", \\\"7.4.3\\\", \\\"3\\\", 3011], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"3. Lost to follow-up: The subject did not return to the clinic and 3 attempts to contact the subject were unsuccessful.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Criteria for Discontinuation or Withdrawal of a Subject\\\", \\\"7.4.3\\\", \\\"3\\\", 3012], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Attempts to contact the subject must be documented in the subject\\\\u2019s source documents.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Criteria for Discontinuation or Withdrawal of a Subject\\\", \\\"7.4.3\\\", \\\"3\\\", 3013], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"A certified letter can be sent as a last attempt.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Criteria for Discontinuation or Withdrawal of a Subject\\\", \\\"7.4.3\\\", \\\"3\\\", 3014], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"4. Voluntary withdrawal: The subject wishes to withdraw from the study.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Criteria for Discontinuation or Withdrawal of a Subject\\\", \\\"7.4.3\\\", \\\"3\\\", 3015], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"The reason for withdrawal, if provided, should be recorded in the eCRF.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Criteria for Discontinuation or Withdrawal of a Subject\\\", \\\"7.4.3\\\", \\\"3\\\", 3016], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Note: All attempts should be made to determine the underlying reason for the withdrawal and, where possible, the primary underlying reason should be recorded (ie, withdrawal due to an AE should not be recorded in the \\\\u201cvoluntary withdrawal\\\\u201d category).\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Criteria for Discontinuation or Withdrawal of a Subject\\\", \\\"7.4.3\\\", \\\"3\\\", 3017], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"If a subject chooses to withdraw from study participation due to personal concerns related to the COVID-19 pandemic (other than a COVID-19\\\\u2013related AE), this should be specified as the reason for subject withdrawal in the eCRF.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Criteria for Discontinuation or Withdrawal of a Subject\\\", \\\"7.4.3\\\", \\\"3\\\", 3018], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"5. Pregnancy, as described in Appendix D.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Criteria for Discontinuation or Withdrawal of a Subject\\\", \\\"7.4.3\\\", \\\"3\\\", 3019], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"6. Other: The reason for discontinuation should be entered into the eCRF, including unavoidable circumstances such as the COVID-19 pandemic.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Criteria for Discontinuation or Withdrawal of a Subject\\\", \\\"7.4.3\\\", \\\"3\\\", 3020], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Subjects may withdraw from the study at any time at the discretion of the investigator or sponsor for safety reasons, which should be entered into the eCRF.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Criteria for Discontinuation or Withdrawal of a Subject\\\", \\\"7.4.3\\\", \\\"3\\\", 3021], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"7. Study termination: The sponsor, IRB, IEC, or regulatory agency terminates the study.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Criteria for Discontinuation or Withdrawal of a Subject\\\", \\\"7.4.3\\\", \\\"3\\\", 3022], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Criteria for premature cohort and/or study termination are provided in Section 6.5.5.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Criteria for Discontinuation or Withdrawal of a Subject\\\", \\\"7.4.3\\\", \\\"3\\\", 3023], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"7.5 Procedures for Discontinuation or Withdrawal of a Subject\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading2\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Procedures for Discontinuation or Withdrawal of a Subject\\\", \\\"7.5\\\", \\\"2\\\", 3024], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"The investigator may discontinue a subject\\\\u2019s study participation at any time during the study when the subject meets the study termination criteria described in Section 7.4.3.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Procedures for Discontinuation or Withdrawal of a Subject\\\", \\\"7.5\\\", \\\"2\\\", 3025], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"In addition, a subject may discontinue his or her participation without giving a reason at any time during the study.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Procedures for Discontinuation or Withdrawal of a Subject\\\", \\\"7.5\\\", \\\"2\\\", 3026], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Should a subject\\\\u2019s participation be discontinued, the primary criterion for termination must be recorded by the investigator.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Procedures for Discontinuation or Withdrawal of a Subject\\\", \\\"7.5\\\", \\\"2\\\", 3027], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"In addition, efforts should be made to perform all procedures scheduled for the early termination visit.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Procedures for Discontinuation or Withdrawal of a Subject\\\", \\\"7.5\\\", \\\"2\\\", 3028], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"The investigator should consult with the sponsor or designee (ie, Medical Monitor) before subject discontinuation whenever possible.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Procedures for Discontinuation or Withdrawal of a Subject\\\", \\\"7.5\\\", \\\"2\\\", 3029], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"7.6 Subject Replacement\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading2\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Subject Replacement\\\", \\\"7.6\\\", \\\"2\\\", 3030], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Because of the risk of screen failures and subject withdrawals, replacement of a subject may be allowed or more subjects may be enrolled than planned for each cohort.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Subject Replacement\\\", \\\"7.6\\\", \\\"2\\\", 3031], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"If a subject withdraws from the study, a replacement subject may be enrolled, if deemed appropriate by the investigator and sponsor.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Subject Replacement\\\", \\\"7.6\\\", \\\"2\\\", 3032], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"The study site should contact the sponsor for the replacement of a subject\\\\u2019s treatment assignment and allocation number.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Subject Replacement\\\", \\\"7.6\\\", \\\"2\\\", 3033], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"8.0 CLINICAL STUDY MATERIAL MANAGEMENT\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading1\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"CLINICAL STUDY MATERIAL MANAGEMENT\\\", \\\"8.0\\\", \\\"1\\\", 3034], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"8.1 Clinical Study Drug\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading2\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Clinical Study Drug\\\", \\\"8.1\\\", \\\"2\\\", 3035], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"On occasion in unavoidable circumstances, such as the COVID-19 pandemic, additional drug supply may be provided to subjects (either at an in-person visit or delivered to subject\\\\u2019s residence) to cover extended periods between on-site visits.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Clinical Study Drug\\\", \\\"8.1\\\", \\\"2\\\", 3036], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Any additional re-supply must be reviewed and approved in advance by the sponsor or designee.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Clinical Study Drug\\\", \\\"8.1\\\", \\\"2\\\", 3037], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"8.1.1 Suspension Formulation\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading4\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Clinical Study Drug\\\", \\\"8.1\\\", \\\"2\\\", 3038], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"TAK-861 Oral Suspension, 0.2-5 mg/mL, is formulated as an aqueous oral suspension and will be compounded at the clinical site per the compounding worksheet or similar document.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Clinical Study Drug\\\", \\\"8.1\\\", \\\"2\\\", 3039], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"TAK-861 Oral Suspension components include TAK-861 drug substance suspended in a ~REDACTED~ and sterile water for injection vehicle.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Clinical Study Drug\\\", \\\"8.1\\\", \\\"2\\\", 3040], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"The TAK-861 Placebo Suspension contains all the same components of the active TAK-861 Oral Suspension, with exception of the TAK-861 drug substance, which is replaced with microcrystalline cellulose.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Clinical Study Drug\\\", \\\"8.1\\\", \\\"2\\\", 3041], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"See investigator's brochure for additional details.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Clinical Study Drug\\\", \\\"8.1\\\", \\\"2\\\", 3042], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"8.1.2 Tablet Formulation\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading4\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Clinical Study Drug\\\", \\\"8.1\\\", \\\"2\\\", 3043], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"TAK-861 drug product is formulated as pale yellow-red film-coated tablets in dosage strengths of 0.5, 1, 5, and 25 mg with matching placebos.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Clinical Study Drug\\\", \\\"8.1\\\", \\\"2\\\", 3044], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Details regarding the dosage form description and strengths of the active drug and matching placebo can be found in the pharmacy manual.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Clinical Study Drug\\\", \\\"8.1\\\", \\\"2\\\", 3045], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Study drug will be packaged to support enrollment and replacement subjects as required.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Clinical Study Drug\\\", \\\"8.1\\\", \\\"2\\\", 3046], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"8.1.3 Clinical Study Drug Labeling\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading4\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Clinical Study Drug Labeling\\\", \\\"8.1.3\\\", \\\"3\\\", 3047], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"8.1.3.1 Suspension Formulation\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading6\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Suspension Formulation\\\", \\\"8.1.3.1\\\", \\\"4\\\", 3048], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"TAK-861 Oral Suspension and placebo are contained in glass dosing bottles with polyethylene-lined cap and may be covered with the blinding sleeves for administration.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Suspension Formulation\\\", \\\"8.1.3.1\\\", \\\"4\\\", 3049], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"See investigator's brochure for additional details.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Suspension Formulation\\\", \\\"8.1.3.1\\\", \\\"4\\\", 3050], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"8.1.3.2 Tablet Formulation\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading6\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Tablet Formulation\\\", \\\"8.1.3.2\\\", \\\"4\\\", 3051], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"TAK-861 tablets are packaged in glass bottles with non\\\\u2013child resistant, metal screw cap closures with a polyethylene liner or in high-density polyethylene bottles with child-resistant closures.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Tablet Formulation\\\", \\\"8.1.3.2\\\", \\\"4\\\", 3052], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Study drug containers will be affixed with a clinical label in accordance with local regulatory requirements.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Tablet Formulation\\\", \\\"8.1.3.2\\\", \\\"4\\\", 3053], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"8.1.4 Clinical Study Drug Inventory and Storage\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading4\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Clinical Study Drug Inventory and Storage\\\", \\\"8.1.4\\\", \\\"3\\\", 3054], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Study drug at the sites must be stored in a secure, limited-access location under the storage conditions specified on the label and remain in the original container until dispensed.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Clinical Study Drug Inventory and Storage\\\", \\\"8.1.4\\\", \\\"3\\\", 3055], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"The temperature excursion information can be found in the pharmacy manual.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Clinical Study Drug Inventory and Storage\\\", \\\"8.1.4\\\", \\\"3\\\", 3056], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Receipt and dispensing of study drug at the study site must be recorded by authorized personnel.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Clinical Study Drug Inventory and Storage\\\", \\\"8.1.4\\\", \\\"3\\\", 3057], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"8.1.5 Clinical Study Drug Blinding\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading4\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Clinical Study Drug Blinding\\\", \\\"8.1.5\\\", \\\"3\\\", 3058], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"This is a double-blind study; the investigator and subjects are blinded to treatment assignment.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Clinical Study Drug Blinding\\\", \\\"8.1.5\\\", \\\"3\\\", 3059], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Treatment identity (name and strength or potency) will be included on the study drug container label; emergency randomization code access will be made available through the interactive response technology (IRT) system in accordance with the standard operating procedures of the clinical site.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Clinical Study Drug Blinding\\\", \\\"8.1.5\\\", \\\"3\\\", 3060], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"If needed, the unblinded study drug supply may be provided to an unblinded pharmacist or other qualified study site personnel, who will blind the study drug supplies.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Clinical Study Drug Blinding\\\", \\\"8.1.5\\\", \\\"3\\\", 3061], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Details on determination of study drug doses and cohort initiation are provided in Section 6.1.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Clinical Study Drug Blinding\\\", \\\"8.1.5\\\", \\\"3\\\", 3062], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"8.1.6 Randomization Code Creation and Storage\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading4\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Randomization Code Creation and Storage\\\", \\\"8.1.6\\\", \\\"3\\\", 3063], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Randomization personnel of the sponsor or designee will generate the randomization schedule.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Randomization Code Creation and Storage\\\", \\\"8.1.6\\\", \\\"3\\\", 3064], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"All randomization information will be stored in a secured area, accessible only by authorized personnel.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Randomization Code Creation and Storage\\\", \\\"8.1.6\\\", \\\"3\\\", 3065], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"8.1.7 Clinical Study Blind Maintenance/Unblinding Procedure\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading4\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Clinical Study Blind Maintenance/Unblinding Procedure\\\", \\\"8.1.7\\\", \\\"3\\\", 3066], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"The study drug blind will be maintained through a randomization schedule held by the unblinded pharmacist at the study site or sponsor or its designee.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Clinical Study Blind Maintenance/Unblinding Procedure\\\", \\\"8.1.7\\\", \\\"3\\\", 3067], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"The study drug blind shall not be broken by the investigator unless information concerning the study drug is necessary for the medical treatment of the subject.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Clinical Study Blind Maintenance/Unblinding Procedure\\\", \\\"8.1.7\\\", \\\"3\\\", 3068], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"If possible, the medical monitor should be contacted before the blind is broken.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Clinical Study Blind Maintenance/Unblinding Procedure\\\", \\\"8.1.7\\\", \\\"3\\\", 3069], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Unblinding will be performed per the standard operating procedures of the study site.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Clinical Study Blind Maintenance/Unblinding Procedure\\\", \\\"8.1.7\\\", \\\"3\\\", 3070], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Unblinding of a particular cohort may be done at the sponsor\\\\u2019s discretion for analysis purposes, but the study drug blind at the study site shall be maintained.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Clinical Study Blind Maintenance/Unblinding Procedure\\\", \\\"8.1.7\\\", \\\"3\\\", 3071], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"8.1.8 Accountability and Destruction of Sponsor-Supplied Drugs\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading4\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Accountability and Destruction of Sponsor-Supplied Drugs\\\", \\\"8.1.8\\\", \\\"3\\\", 3072], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"The investigator is responsible for keeping accurate records of the study drug received from the sponsor or designee, the amount dispensed to and returned by the subjects, and the amount remaining at the end of the study.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Accountability and Destruction of Sponsor-Supplied Drugs\\\", \\\"8.1.8\\\", \\\"3\\\", 3073], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"For all study sites, the local country sponsor personnel or designee will provide appropriate documentation that must be completed for study drug accountability, return, and destruction.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Accountability and Destruction of Sponsor-Supplied Drugs\\\", \\\"8.1.8\\\", \\\"3\\\", 3074], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"9.0 STUDY PROCEDURES\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading1\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"STUDY PROCEDURES\\\", \\\"9.0\\\", \\\"1\\\", 3075], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"The following sections describe the study procedures to be performed and data to be collected as indicated in the Schedules of Study Procedures (Section 3.0).\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"STUDY PROCEDURES\\\", \\\"9.0\\\", \\\"1\\\", 3076], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"9.1 Administrative Procedures\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading2\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Administrative Procedures\\\", \\\"9.1\\\", \\\"2\\\", 3077], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"9.1.1 Alternative Approaches to Study Procedures and Data Collection Due to\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading4\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Alternative Approaches to Study Procedures and Data Collection Due to\\\", \\\"9.1.1\\\", \\\"3\\\", 3078], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"COVID-19 or Other Unavoidable Circumstances\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading7\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Alternative Approaches to Study Procedures and Data Collection Due to\\\", \\\"9.1.1\\\", \\\"3\\\", 3079], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"In unavoidable circumstances (eg, a widespread disease outbreak or natural disaster) that impact the study site\\\\u2019s ability to conduct study procedures according to the Schedule of Study Procedures (Section 3.0), contingency measures may be implemented.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Alternative Approaches to Study Procedures and Data Collection Due to\\\", \\\"9.1.1\\\", \\\"3\\\", 3080], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"In acknowledgement of study site, hospital, local, state and national restrictions established in response to circumstances like COVID-19, the following measures are being taken for the current study:\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Alternative Approaches to Study Procedures and Data Collection Due to\\\", \\\"9.1.1\\\", \\\"3\\\", 3081], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\\u2022 For subjects active in the study, all attempts should be made to perform the assessments with the subject present at the site using the visit windows.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Alternative Approaches to Study Procedures and Data Collection Due to\\\", \\\"9.1.1\\\", \\\"3\\\", 3082], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Exceptions may be granted for alternative approaches to study procedures and data collection through approval by the sponsor or designee.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Alternative Approaches to Study Procedures and Data Collection Due to\\\", \\\"9.1.1\\\", \\\"3\\\", 3083], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Such instances must be documented in the study records and may include the following:\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Alternative Approaches to Study Procedures and Data Collection Due to\\\", \\\"9.1.1\\\", \\\"3\\\", 3084], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\\u2013 Sites impacted by the COVID-19 pandemic or similar unavoidable circumstances, must contact the sponsor or designee to discuss individual subject and site circumstances to obtain approval for use of alternative approaches to study procedures and data collection due to COVID-19 or other unavoidable circumstances.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Alternative Approaches to Study Procedures and Data Collection Due to\\\", \\\"9.1.1\\\", \\\"3\\\", 3085], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\\u2013 Sites may seek approval from the sponsor or designee to continue subjects in the study despite departures from the Schedule of Study Procedures.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Alternative Approaches to Study Procedures and Data Collection Due to\\\", \\\"9.1.1\\\", \\\"3\\\", 3086], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"The principal investigator is expected to evaluate the impact to the safety of the study participants and site personnel for subjects to continue.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Alternative Approaches to Study Procedures and Data Collection Due to\\\", \\\"9.1.1\\\", \\\"3\\\", 3087], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"In evaluating such requests, the sponsor or designee will give the highest priority to the safety and welfare of the subjects.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Alternative Approaches to Study Procedures and Data Collection Due to\\\", \\\"9.1.1\\\", \\\"3\\\", 3088], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Subjects must be willing and able to continue taking study medication and remain compliant with the protocol.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Alternative Approaches to Study Procedures and Data Collection Due to\\\", \\\"9.1.1\\\", \\\"3\\\", 3089], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\\u2013 Other than discharge visits, alternative methods for conducting subject visits (eg, video conferencing, telephone visits, or in-home study visits conducted by study site personnel or designated medical personnel, contingent on local regulations) may be used per approval by the sponsor or designee:\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Alternative Approaches to Study Procedures and Data Collection Due to\\\", \\\"9.1.1\\\", \\\"3\\\", 3090], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"o Under these circumstances, collection of certain study assessments may be omitted and visit windows may be extended.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Alternative Approaches to Study Procedures and Data Collection Due to\\\", \\\"9.1.1\\\", \\\"3\\\", 3091], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"o When approval is given for a subject to miss an in-person study visit, a study site physician will speak directly with the subject by telephone or other medium (eg, a computer-based video communication) during each visit window to assess subject safety and overall clinical status.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Alternative Approaches to Study Procedures and Data Collection Due to\\\", \\\"9.1.1\\\", \\\"3\\\", 3092], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"o The study site physician or other qualified site personnel should conduct the following assessments within specified visit window time frames: AE assessments, documentation of concomitant medication, administration of C-SSRS (at applicable visits), and an assessment of clinical symptoms.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Alternative Approaches to Study Procedures and Data Collection Due to\\\", \\\"9.1.1\\\", \\\"3\\\", 3093], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"o For this study, home nurses or other qualified clinical personnel may be deployed at the request of the site, when appropriate.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Alternative Approaches to Study Procedures and Data Collection Due to\\\", \\\"9.1.1\\\", \\\"3\\\", 3094], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Advance approval from the sponsor or designee should be obtained.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Alternative Approaches to Study Procedures and Data Collection Due to\\\", \\\"9.1.1\\\", \\\"3\\\", 3095], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"o Other study assessments may be collected using an alternative method as feasible, and may involve audio or video recording where allowed by local regulation.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Alternative Approaches to Study Procedures and Data Collection Due to\\\", \\\"9.1.1\\\", \\\"3\\\", 3096], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"This will be documented in the study records.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Alternative Approaches to Study Procedures and Data Collection Due to\\\", \\\"9.1.1\\\", \\\"3\\\", 3097], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"o In some instances, sites may need to split visits or sites may only be able to perform a few procedures on site and some procedures may need to be performed remotely.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Alternative Approaches to Study Procedures and Data Collection Due to\\\", \\\"9.1.1\\\", \\\"3\\\", 3098], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Sites should inform sponsor or designee when this occurs.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Alternative Approaches to Study Procedures and Data Collection Due to\\\", \\\"9.1.1\\\", \\\"3\\\", 3099], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"o Sites may seek approval to extend a visit window to conduct an on-site visit.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Alternative Approaches to Study Procedures and Data Collection Due to\\\", \\\"9.1.1\\\", \\\"3\\\", 3100], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Assessments that cannot be completed during the protocol-specified window or within the visit window granted by the sponsor or designee will be considered missing data and such departures will be recorded in the study records.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Alternative Approaches to Study Procedures and Data Collection Due to\\\", \\\"9.1.1\\\", \\\"3\\\", 3101], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"o There will be no interval longer than 2 weeks between successive visits at which clinical laboratory tests are performed and vital signs are measured.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Alternative Approaches to Study Procedures and Data Collection Due to\\\", \\\"9.1.1\\\", \\\"3\\\", 3102], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Should the period of 2 weeks be met for a particular subject, the site should reach out to the sponsor or designee to discuss withdrawal of the subject.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Alternative Approaches to Study Procedures and Data Collection Due to\\\", \\\"9.1.1\\\", \\\"3\\\", 3103], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"o Study site personnel may dispense additional investigational product to subjects at a visit to allow for potentially longer intervals between visits than originally planned per protocol, or investigational product may be supplied to subjects via delivery by site personnel or by courier.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Alternative Approaches to Study Procedures and Data Collection Due to\\\", \\\"9.1.1\\\", \\\"3\\\", 3104], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"o Early termination visits should be performed in person.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Alternative Approaches to Study Procedures and Data Collection Due to\\\", \\\"9.1.1\\\", \\\"3\\\", 3105], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"When it is not possible for the subject to come to the study site and the protocol specified visit window cannot be extended further, the preferred alternative for the early termination visit is for qualified study site personnel or designated clinical personnel to go to the subject\\\\u2019s residence and conduct the protocol-specified procedures in that location.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Alternative Approaches to Study Procedures and Data Collection Due to\\\", \\\"9.1.1\\\", \\\"3\\\", 3106], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Assessments collected at a subject\\\\u2019s residence should comply with applicable local regulations.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Alternative Approaches to Study Procedures and Data Collection Due to\\\", \\\"9.1.1\\\", \\\"3\\\", 3107], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"If neither option is available with sponsor or designee approval, sites may conduct early termination procedures remotely as is feasible.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Alternative Approaches to Study Procedures and Data Collection Due to\\\", \\\"9.1.1\\\", \\\"3\\\", 3108], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\\u2022 Testing of COVID-19 during the screening period is not mandatory for this study and requirement of COVID-19 testing may be decided by site investigator(s) on the basis of standard screening procedure at the site and local regulation and/or requirement.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Alternative Approaches to Study Procedures and Data Collection Due to\\\", \\\"9.1.1\\\", \\\"3\\\", 3109], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"If the site investigator(s) decided to do the testing, extension of the screening period window may be allowed depending on the situation of availability of testing results at the site if the sponsor or designee approved.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Alternative Approaches to Study Procedures and Data Collection Due to\\\", \\\"9.1.1\\\", \\\"3\\\", 3110], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Confirmed cases of COVID-19 should be treated and handled on the basis of applicable local regulation and procedures at the site.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Alternative Approaches to Study Procedures and Data Collection Due to\\\", \\\"9.1.1\\\", \\\"3\\\", 3111], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"All subject discontinuations and alternative approaches to study procedures (ie, procedures not conducted per the Schedule of Study Procedures) due to the COVID-19 pandemic must be documented in the study records.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Alternative Approaches to Study Procedures and Data Collection Due to\\\", \\\"9.1.1\\\", \\\"3\\\", 3112], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Data collected using alternative methods may be handled differently in the final data analyses.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Alternative Approaches to Study Procedures and Data Collection Due to\\\", \\\"9.1.1\\\", \\\"3\\\", 3113], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"This will be documented in the statistical analysis plan (SAP).\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Alternative Approaches to Study Procedures and Data Collection Due to\\\", \\\"9.1.1\\\", \\\"3\\\", 3114], [\\\"3\\\", \\\"Informed Consent Process\\\", \\\"header\\\", \\\"9.1.2 Informed Consent Procedure\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading4\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Informed Consent Procedure\\\", \\\"9.1.2\\\", \\\"3\\\", 3115], [\\\"3\\\", \\\"Informed Consent Process\\\", \\\"text\\\", \\\"Informed consent must be obtained before the subject enters the study and before any protocol-directed procedures are performed.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Informed Consent Procedure\\\", \\\"9.1.2\\\", \\\"3\\\", 3116], [\\\"3\\\", \\\"Informed Consent Process\\\", \\\"text\\\", \\\"The requirements of informed consent (and e-consent, if applicable) are described in Appendix B.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Informed Consent Procedure\\\", \\\"9.1.2\\\", \\\"3\\\", 3117], [\\\"3\\\", \\\"Informed Consent Process\\\", \\\"text\\\", \\\"When subjects aged under 20 years join the study in Japan, Informed consent of the subject\\\\u2019s parent or the subject\\\\u2019s legal ~REDACTED~ must be obtained before the subject enters into the study, and before any protocol-directed procedures are performed.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Informed Consent Procedure\\\", \\\"9.1.2\\\", \\\"3\\\", 3118], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"9.1.2.1 Assignment of Subject Numbers\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading6\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Assignment of Subject Numbers\\\", \\\"9.1.2.1\\\", \\\"4\\\", 3119], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"All consented subjects will be given a unique subject number (site number plus a unique sequential number) through an IRT system that will be used to identify the subject for all procedures that occur during the study.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Assignment of Subject Numbers\\\", \\\"9.1.2.1\\\", \\\"4\\\", 3120], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Each subject will be assigned only 1 subject number except in the event of rescreens authorized by the sponsor.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Assignment of Subject Numbers\\\", \\\"9.1.2.1\\\", \\\"4\\\", 3121], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Subject numbers must not be reused for different subjects.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Assignment of Subject Numbers\\\", \\\"9.1.2.1\\\", \\\"4\\\", 3122], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Rescreening may be allowed once for any one subject participating in Part D.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Assignment of Subject Numbers\\\", \\\"9.1.2.1\\\", \\\"4\\\", 3123], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Multiple screening may be allowed for healthy volunteer participants.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Assignment of Subject Numbers\\\", \\\"9.1.2.1\\\", \\\"4\\\", 3124], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Additional rescreening may be allowed for COVID-19\\\\u2013related factors.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Assignment of Subject Numbers\\\", \\\"9.1.2.1\\\", \\\"4\\\", 3125], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Rescreening of any subject must be reviewed with the sponsor or designee.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Assignment of Subject Numbers\\\", \\\"9.1.2.1\\\", \\\"4\\\", 3126], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Any subject who is screened more than once will be assigned a new subject number for each screening event.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Assignment of Subject Numbers\\\", \\\"9.1.2.1\\\", \\\"4\\\", 3127], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"9.1.2.2 Study Drug Assignment and Randomization Number\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading6\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Study Drug Assignment and Randomization Number\\\", \\\"9.1.2.2\\\", \\\"4\\\", 3128], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"On Day 1, subjects will be assigned a randomization number through the IRT system at the clinical site.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Study Drug Assignment and Randomization Number\\\", \\\"9.1.2.2\\\", \\\"4\\\", 3129], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"The randomization number encodes the subject treatment assignment according to the randomization schedule generated before the study.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Study Drug Assignment and Randomization Number\\\", \\\"9.1.2.2\\\", \\\"4\\\", 3130], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"The randomization number will be recorded on the eCRF.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Study Drug Assignment and Randomization Number\\\", \\\"9.1.2.2\\\", \\\"4\\\", 3131], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Each subject will be dispensed blinded study drug assigned by the IRT system throughout the study.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Study Drug Assignment and Randomization Number\\\", \\\"9.1.2.2\\\", \\\"4\\\", 3132], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"9.1.3 Inclusion and Exclusion\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading4\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Inclusion and Exclusion\\\", \\\"9.1.3\\\", \\\"3\\\", 3133], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Each subject will be assessed through randomization, according to the eligibility criteria provided in Section 7.0, which includes confirmation of primary disease (narcolepsy) status such as EDS or cataplexy episodes for subjects with NT1.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Inclusion and Exclusion\\\", \\\"9.1.3\\\", \\\"3\\\", 3134], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"9.1.4 Medical History/Demography\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading4\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Medical History/Demography\\\", \\\"9.1.4\\\", \\\"3\\\", 3135], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Qualified site personnel will collect subject significant medical history (past and concurrent medical conditions), per the site\\\\u2019s standard of care and appropriate clinical judgment, along with subject demographics (eg, date of birth, sex, race [reported by the subject], ~REDACTED~ consumption, alcohol consumption, smoking status).\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Medical History/Demography\\\", \\\"9.1.4\\\", \\\"3\\\", 3136], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"For subjects in Part D, information on the primary disease (narcolepsy) will also be collected including age of onset and year of diagnosis.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Medical History/Demography\\\", \\\"9.1.4\\\", \\\"3\\\", 3137], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"The details about cataplexy symptoms of the subject may be also confirmed.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Medical History/Demography\\\", \\\"9.1.4\\\", \\\"3\\\", 3138], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"If test results are available, OX concentration data, and past MSLT data including the mean sleep latency and the number of SOREM period will be also collected.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Medical History/Demography\\\", \\\"9.1.4\\\", \\\"3\\\", 3139], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"9.1.5 Concomitant Medications\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading4\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Concomitant Medications\\\", \\\"9.1.5\\\", \\\"3\\\", 3140], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Qualified site personnel will review subject\\\\u2019s prior and concomitant medication use.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Concomitant Medications\\\", \\\"9.1.5\\\", \\\"3\\\", 3141], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Medications are defined as prescription and over-the-counter drugs, vaccines, supplements, nutraceuticals, and herbal preparations.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Concomitant Medications\\\", \\\"9.1.5\\\", \\\"3\\\", 3142], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Subjects will be asked whether they have taken any medications other than the study drug (during a period from the signing of informed consent through the end of the study), and all medications used by a subject must be recorded in each subject\\\\u2019s eCRF.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Concomitant Medications\\\", \\\"9.1.5\\\", \\\"3\\\", 3143], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"The nonproprietary name, route of administration, dates of initial and final administrations, and reasons for use must also be recorded.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Concomitant Medications\\\", \\\"9.1.5\\\", \\\"3\\\", 3144], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"9.2 Clinical Procedures and Assessments\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading2\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Clinical Procedures and Assessments\\\", \\\"9.2\\\", \\\"2\\\", 3145], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Assessments will be done in applicable parts and/or cohorts only (please refer Section 3.0 Schedule of Study Procedures for details).\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Clinical Procedures and Assessments\\\", \\\"9.2\\\", \\\"2\\\", 3146], [\\\"3\\\", \\\"Physical Examinations\\\", \\\"header\\\", \\\"9.2.1 Physical Examination\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading4\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Physical Examination\\\", \\\"9.2.1\\\", \\\"3\\\", 3147], [\\\"3\\\", \\\"Physical Examinations\\\", \\\"text\\\", \\\"Qualified site personnel will conduct full physical examinations (including neurological examination) at screening and final visit (final discharge)/early termination.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Physical Examination\\\", \\\"9.2.1\\\", \\\"3\\\", 3148], [\\\"3\\\", \\\"Physical Examinations\\\", \\\"text\\\", \\\"On all other time points, an abbreviated physical examination will be done.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Physical Examination\\\", \\\"9.2.1\\\", \\\"3\\\", 3149], [\\\"3\\\", \\\"Physical Examinations\\\", \\\"text\\\", \\\"Subjects undergoing ~REDACTED~ sampling will undergo ophthalmological assessment of the retina (fundoscopy), a nondilated ophthalmoscopy examination to evaluate for any evidence of increased intracranial pressure.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Physical Examination\\\", \\\"9.2.1\\\", \\\"3\\\", 3150], [\\\"3\\\", \\\"Physical Examinations\\\", \\\"text\\\", \\\"If needed, a dilated examination for fundoscopy may be performed by a trained person (optometrist, ophthalmologist, or neurologist) after dilatation of the pupil in both eyes by administration of ~REDACTED~ 0.4 or 0.5% eye drops.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Physical Examination\\\", \\\"9.2.1\\\", \\\"3\\\", 3151], [\\\"3\\\", \\\"Physical Examinations\\\", \\\"text\\\", \\\"After pupil dilatation, subjects will be advised to wear sunglasses for the next 4 to 6 hours and avoid operating a car.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Physical Examination\\\", \\\"9.2.1\\\", \\\"3\\\", 3152], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"9.2.2 Height and Weight\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading4\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Height and Weight\\\", \\\"9.2.2\\\", \\\"3\\\", 3153], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Body weight and height will be obtained with the subject\\\\u2019s shoes off and jacket or coat removed at the times indicated in the Schedule of Study Procedures (Section 3.0).\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Height and Weight\\\", \\\"9.2.2\\\", \\\"3\\\", 3154], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"9.2.3 BMI\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading3\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"BMI\\\", \\\"9.2.3\\\", \\\"3\\\", 3155], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"BMI is defined as a subject\\\\u2019s weight (in kilograms) divided by height (in meters) squared (BMI = kg/m\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"BMI\\\", \\\"9.2.3\\\", \\\"3\\\", 3156], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"2\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"superscript\\\"}, \\\"Study Design\\\", \\\"BMI\\\", \\\"9.2.3\\\", \\\"3\\\", 3157], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\").\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"BMI\\\", \\\"9.2.3\\\", \\\"3\\\", 3158], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"BMI will be calculated at the times indicated in the Schedules of Study Procedures (Section 3.0).\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"BMI\\\", \\\"9.2.3\\\", \\\"3\\\", 3159], [\\\"3\\\", \\\"Vital Signs\\\", \\\"header\\\", \\\"9.2.4 Vital Signs\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading3\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Vital Signs\\\", \\\"9.2.4\\\", \\\"3\\\", 3160], [\\\"3\\\", \\\"Vital Signs\\\", \\\"text\\\", \\\"Vital signs, including pulse rate, systolic and diastolic BP, RR, and body temperature, will be obtained at the times indicated in the Schedule of Study Procedures (Section 3.0).\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Vital Signs\\\", \\\"9.2.4\\\", \\\"3\\\", 3161], [\\\"3\\\", \\\"Vital Signs\\\", \\\"text\\\", \\\"When assessed in the clinic, BP will be checked (single measurement) with the subject lying in a bed resting for a minimum of 5 minutes with the head of the bed at 30 degrees.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Vital Signs\\\", \\\"9.2.4\\\", \\\"3\\\", 3162], [\\\"3\\\", \\\"Vital Signs\\\", \\\"text\\\", \\\"See Section 7.0 for more details to assess eligibility of subjects.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Vital Signs\\\", \\\"9.2.4\\\", \\\"3\\\", 3163], [\\\"3\\\", \\\"Vital Signs\\\", \\\"text\\\", \\\"Orthostatic BP and pulse rate will be assessed with the subject standing for 1 minute and 5 minutes.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Vital Signs\\\", \\\"9.2.4\\\", \\\"3\\\", 3164], [\\\"3\\\", \\\"Vital Signs\\\", \\\"text\\\", \\\"In the event of conflicts between scheduled BP assessment and PK blood draw times, BP assessments should be taken first.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Vital Signs\\\", \\\"9.2.4\\\", \\\"3\\\", 3165], [\\\"3\\\", \\\"Vital Signs\\\", \\\"text\\\", \\\"See Section 9.2.6 for further details on wearable devices that will also collect similar assessments.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Vital Signs\\\", \\\"9.2.4\\\", \\\"3\\\", 3166], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"9.2.5 ECGs\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading3\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"ECGs\\\", \\\"9.2.5\\\", \\\"3\\\", 3167], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"9.2.5.1 12-Lead ECG\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading5\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"-Lead ECG\\\", \\\"9.2.5.1  12\\\", \\\"4\\\", 3168], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"ECG monitoring will be obtained according to the Schedule of Study Procedures (Section 3.0).\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"-Lead ECG\\\", \\\"9.2.5.1  12\\\", \\\"4\\\", 3169], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Special care must be taken for proper lead placement by qualified personnel.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"-Lead ECG\\\", \\\"9.2.5.1  12\\\", \\\"4\\\", 3170], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Skin should be clean and dry before lead placement.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"-Lead ECG\\\", \\\"9.2.5.1  12\\\", \\\"4\\\", 3171], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Subjects may need to be shaved to ensure proper lead placement.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"-Lead ECG\\\", \\\"9.2.5.1  12\\\", \\\"4\\\", 3172], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Subjects should be resting in a semirecumbent position for at least 5 minutes before each ECG measurement.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"-Lead ECG\\\", \\\"9.2.5.1  12\\\", \\\"4\\\", 3173], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"The principal investigator should arrange to have a study cardiologist available as needed to review ECG tracings with abnormalities.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"-Lead ECG\\\", \\\"9.2.5.1  12\\\", \\\"4\\\", 3174], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"If a subject demonstrates an increase in QTcF interval \\\\u226540 milliseconds compared with a baseline measurement, the ECG will be repeated within 5 minutes.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"-Lead ECG\\\", \\\"9.2.5.1  12\\\", \\\"4\\\", 3175], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"The average value of the QTcF interval from the 2 ECGs will represent the value at that time point.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"-Lead ECG\\\", \\\"9.2.5.1  12\\\", \\\"4\\\", 3176], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"If the average QTcF interval increase from baseline for any postdose time point is \\\\u226540 milliseconds, the subject will continue to be monitored by repeat 12-lead ECGs every 60 minutes for at least 4 hours or until the QTcF interval is within 40 milliseconds of the baseline value.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"-Lead ECG\\\", \\\"9.2.5.1  12\\\", \\\"4\\\", 3177], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"If prolongation of the QTcF interval\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"-Lead ECG\\\", \\\"9.2.5.1  12\\\", \\\"4\\\", 3178], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\\u226540 milliseconds persists, a consultation with a study cardiologist may be appropriate and the sponsor should be notified.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"-Lead ECG\\\", \\\"9.2.5.1  12\\\", \\\"4\\\", 3179], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"If the QTcF interval is \\\\u2265500 milliseconds, the sponsor should be notified and the ECGs should be reviewed by a cardiologist.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"-Lead ECG\\\", \\\"9.2.5.1  12\\\", \\\"4\\\", 3180], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"The subject should be considered for transfer to a location where closer monitoring is available.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"-Lead ECG\\\", \\\"9.2.5.1  12\\\", \\\"4\\\", 3181], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"If the subject has unstable hemodynamics, or has any clinically significant dysrhythmias noted by telemetry, the subject should be immediately transferred to an acute care setting for definitive therapy.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"-Lead ECG\\\", \\\"9.2.5.1  12\\\", \\\"4\\\", 3182], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"If repeat ECGs are required, the clinical site will decide whether to leave the electrodes in place or mark the position of the electrodes for subsequent ECGs.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"-Lead ECG\\\", \\\"9.2.5.1  12\\\", \\\"4\\\", 3183], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"To mark the position of the electrodes, 12-lead electrode sites will be marked on the skin of each subject with an ECG skin marker pen to ensure reproducible electrode placement.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"-Lead ECG\\\", \\\"9.2.5.1  12\\\", \\\"4\\\", 3184], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"The following ECG parameters will be recorded: heart rate, PR interval, QRS interval, QT interval, QTcF interval, and the interpretation of the ECG profile by the principal investigator.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"-Lead ECG\\\", \\\"9.2.5.1  12\\\", \\\"4\\\", 3185], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"9.2.5.2 Holter ECGs\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading5\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Holter ECGs\\\", \\\"9.2.5.2\\\", \\\"4\\\", 3186], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Holter monitoring is done in healthy subjects.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Holter ECGs\\\", \\\"9.2.5.2\\\", \\\"4\\\", 3187], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"This monitoring will be obtained according to the Schedules of Study Procedures.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Holter ECGs\\\", \\\"9.2.5.2\\\", \\\"4\\\", 3188], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Details regarding Holter ECG collection are provided in the study procedure manual.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Holter ECGs\\\", \\\"9.2.5.2\\\", \\\"4\\\", 3189], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"ECGs derived from Holter monitoring are not intended to be analyzed for real-time safety monitoring but will be used for future retrospective ECG analyses, unless an earlier analysis is warranted by emerging safety information.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Holter ECGs\\\", \\\"9.2.5.2\\\", \\\"4\\\", 3190], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"9.2.6 ABPM\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading3\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"ABPM\\\", \\\"9.2.6\\\", \\\"3\\\", 3191], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"The ABPM device is a portable monitor connected to a BP cuff that automatically inflates at regular intervals and records many BP readings over a 24-hour period.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"ABPM\\\", \\\"9.2.6\\\", \\\"3\\\", 3192], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"ABPM recording should be obtained over an approximately 24-hour period.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"ABPM\\\", \\\"9.2.6\\\", \\\"3\\\", 3193], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"The ABPM monitoring should not occur during nights immediately before a PSG night.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"ABPM\\\", \\\"9.2.6\\\", \\\"3\\\", 3194], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"The baseline ABPM recording should be started on the basis of the predicted time of the morning dosing during the double-blind period (for example: 8\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"ABPM\\\", \\\"9.2.6\\\", \\\"3\\\", 3195], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"AM\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 19, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 19, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"ABPM\\\", \\\"9.2.6\\\", \\\"3\\\", 3196], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\").\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"ABPM\\\", \\\"9.2.6\\\", \\\"3\\\", 3197], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"In the double-blind treatment period, the ABPM device should be fitted and the reading should start before the\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"ABPM\\\", \\\"9.2.6\\\", \\\"3\\\", 3198], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"AM\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 19, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 19, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"ABPM\\\", \\\"9.2.6\\\", \\\"3\\\", 3199], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"dose is administered on specific days per the Schedule of Study Procedures.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"ABPM\\\", \\\"9.2.6\\\", \\\"3\\\", 3200], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"After the 24-hour reading, the device can be taken off for downloading the readings, and recharged for next use.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"ABPM\\\", \\\"9.2.6\\\", \\\"3\\\", 3201], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Subjects will be trained on the use of the device.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"ABPM\\\", \\\"9.2.6\\\", \\\"3\\\", 3202], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Study sites should ensure that all readings meet the minimum threshold of acceptability.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"ABPM\\\", \\\"9.2.6\\\", \\\"3\\\", 3203], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"If a reading does not meet this threshold the site should collect a new reading within the protocol-specified time frame (avoiding nights immediately before a PSG).\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"ABPM\\\", \\\"9.2.6\\\", \\\"3\\\", 3204], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"9.2.7 C-SSRS\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading3\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"C-SSRS\\\", \\\"9.2.7\\\", \\\"3\\\", 3205], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Suicidal ideation will be assessed using the C-SSRS at the times stipulated in the Schedules of\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"C-SSRS\\\", \\\"9.2.7\\\", \\\"3\\\", 3206], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Study Procedures.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"C-SSRS\\\", \\\"9.2.7\\\", \\\"3\\\", 3207], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Two versions of the C-SSRS will be used in this study: the Screening/Baseline C-SSRS Lifetime and the Since-Last-Visit C-SSRS.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"C-SSRS\\\", \\\"9.2.7\\\", \\\"3\\\", 3208], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Any suicidal ideation or suicidal behavior during the study periods detected by the C-SSRS will be recorded as an AE.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"C-SSRS\\\", \\\"9.2.7\\\", \\\"3\\\", 3209], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"The investigator will ensure that any suicidal ideation or behavior is medically addressed, including assessment and treatment by qualified medical personnel.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"C-SSRS\\\", \\\"9.2.7\\\", \\\"3\\\", 3210], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"9.2.8 Overactive Bladder Condition\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading3\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Overactive Bladder Condition\\\", \\\"9.2.8\\\", \\\"3\\\", 3211], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Subjects will be asked to fill out some questions related to any bladder symptoms at baseline (after eligibility is confirmed) and throughout the study (as indicated in the schedule of assessments) to monitor any bladder-related symptoms they might be experiencing.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Overactive Bladder Condition\\\", \\\"9.2.8\\\", \\\"3\\\", 3212], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"More detailed instruction for implementation of the questionnaires can be found in study manual.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Overactive Bladder Condition\\\", \\\"9.2.8\\\", \\\"3\\\", 3213], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"9.2.9 Study Drug Administration\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading3\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Study Drug Administration\\\", \\\"9.2.9\\\", \\\"3\\\", 3214], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Study drug (TAK-861 at the subject\\\\u2019s specified dose or placebo) will be administered as described in Section 7.4.1 and the Schedule of Study Procedures (Section 3.0).\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Study Drug Administration\\\", \\\"9.2.9\\\", \\\"3\\\", 3215], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Study Drug Administration\\\", \\\"9.2.9\\\", \\\"3\\\", 3216], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"9.2.10 Urine Input/Output Collection\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading3\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Urine Input/Output Collection\\\", \\\"9.2.10\\\", \\\"3\\\", 3217], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Water intake and output will be recorded on the scheduled days (Section 3.0).\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Urine Input/Output Collection\\\", \\\"9.2.10\\\", \\\"3\\\", 3218], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Subject and/or site staffs will record when subject intakes water or other beverages and has urine output.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Urine Input/Output Collection\\\", \\\"9.2.10\\\", \\\"3\\\", 3219], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"The time when each event occurred and volume of each time will be recorded.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Urine Input/Output Collection\\\", \\\"9.2.10\\\", \\\"3\\\", 3220], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"9.2.11 AE Monitoring\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading3\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"AE Monitoring\\\", \\\"9.2.11\\\", \\\"3\\\", 3221], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"AE monitoring begins after signing of the informed consent form.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"AE Monitoring\\\", \\\"9.2.11\\\", \\\"3\\\", 3222], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Changes in subject health status from the baseline assessment until study drug administration should be captured in the subject\\\\u2019s medical history.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"AE Monitoring\\\", \\\"9.2.11\\\", \\\"3\\\", 3223], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"A complete description of AE collection procedures is provided in Section 10.0.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"AE Monitoring\\\", \\\"9.2.11\\\", \\\"3\\\", 3224], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"9.2.12 Laboratory Procedures and Assessments\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading3\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Laboratory Procedures and Assessments\\\", \\\"9.2.12\\\", \\\"3\\\", 3225], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Laboratory samples will be collected in accordance with acceptable laboratory procedures.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Laboratory Procedures and Assessments\\\", \\\"9.2.12\\\", \\\"3\\\", 3226], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"A discussion between the investigator and the sponsor or designee will take place to consider additional laboratory assessments or rescreening.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Laboratory Procedures and Assessments\\\", \\\"9.2.12\\\", \\\"3\\\", 3227], [\\\"2\\\", \\\"Appendix 2: Clinical Laboratory Tests\\\", \\\"header\\\", \\\"9.2.12.1 Clinical Laboratory Tests\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading5\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Clinical Laboratory Tests\\\", \\\"9.2.12.1\\\", \\\"4\\\", 3228], [\\\"2\\\", \\\"Appendix 2: Clinical Laboratory Tests\\\", \\\"text\\\", \\\"Samples for assessment of hematology, chemistry, and urinalysis will be taken as indicated in the Schedule of Study Procedures (Section 3.0).\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Clinical Laboratory Tests\\\", \\\"9.2.12.1\\\", \\\"4\\\", 3229], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"9.2.12.1.1\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": true, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Hematology\\\", \\\"9.2.12.1.1\\\", \\\"5\\\", 3230], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": true, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Hematology\\\", \\\"9.2.12.1.1\\\", \\\"5\\\", 3231], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Hematology\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": true, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Hematology\\\", \\\"9.2.12.1.1\\\", \\\"5\\\", 3232], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Hematology will consist of the following tests:\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Hematology\\\", \\\"9.2.12.1.1\\\", \\\"5\\\", 3233], [\\\"\\\", \\\"Unmapped\\\", \\\"table\\\", {\\\"Table\\\": \\\"<table border=\\\\\\\"1\\\\\\\" class=\\\\\\\"dataframe\\\\\\\">\\\\n  <thead>\\\\n    <tr style=\\\\\\\"text-align: right;\\\\\\\">\\\\n      <th></th>\\\\n      <th>1.0</th>\\\\n      <th>2.0</th>\\\\n    </tr>\\\\n  </thead>\\\\n  <tbody>\\\\n    <tr>\\\\n      <th>0</th>\\\\n      <td>Erythrocytes (red blood cell count)</td>\\\\n      <td>PT/INR, aPTT <sup>a</sup></td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>1</th>\\\\n      <td>Hematocrit</td>\\\\n      <td>Leukocytes (white blood cell count) with absolute differential</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>2</th>\\\\n      <td>Hemoglobin</td>\\\\n      <td>Platelets</td>\\\\n    </tr>\\\\n  </tbody>\\\\n</table>\\\", \\\"SectionHeaderPrintPage\\\": \\\"99\\\", \\\"TableIndex\\\": \\\"41\\\", \\\"TableName\\\": \\\"9.2.12.1.1 Hematology\\\", \\\"Header\\\": []}, {\\\"IsBold\\\": false, \\\"font_size\\\": 20, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 20, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Hematology\\\", \\\"9.2.12.1.1\\\", \\\"5\\\", 3234], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"aPTT: activated partial thromboplastin time; ~REDACTED~: cerebrospinal fluid; INR: international normalized ratio; PT: prothrombin time.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 20, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 20, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Hematology\\\", \\\"9.2.12.1.1\\\", \\\"5\\\", 3235], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"a\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 20, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 20, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"superscript\\\"}, \\\"Study Design\\\", \\\"Hematology\\\", \\\"9.2.12.1.1\\\", \\\"5\\\", 3236], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"For subjects undergoing ~REDACTED~ collection only.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 20, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 20, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Hematology\\\", \\\"9.2.12.1.1\\\", \\\"5\\\", 3237], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"9.2.12.1.2\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": true, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Chemistry\\\", \\\"9.2.12.1.2\\\", \\\"5\\\", 3238], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": true, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Chemistry\\\", \\\"9.2.12.1.2\\\", \\\"5\\\", 3239], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Chemistry\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": true, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Chemistry\\\", \\\"9.2.12.1.2\\\", \\\"5\\\", 3240], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Chemistry evaluations will consist of the following standard chemistry panel:\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Chemistry\\\", \\\"9.2.12.1.2\\\", \\\"5\\\", 3241], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Chemistry\\\", \\\"9.2.12.1.2\\\", \\\"5\\\", 3242], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Albumin\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 20, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 20, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Chemistry\\\", \\\"9.2.12.1.2\\\", \\\"5\\\", 3243], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 20, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 20, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Chemistry\\\", \\\"9.2.12.1.2\\\", \\\"5\\\", 3244], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Chloride\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 20, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 20, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Chemistry\\\", \\\"9.2.12.1.2\\\", \\\"5\\\", 3245], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Alkaline phosphatase\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 20, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 20, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Chemistry\\\", \\\"9.2.12.1.2\\\", \\\"5\\\", 3246], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 20, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 20, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Chemistry\\\", \\\"9.2.12.1.2\\\", \\\"5\\\", 3247], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Creatinine\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 20, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 20, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Chemistry\\\", \\\"9.2.12.1.2\\\", \\\"5\\\", 3248], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"ALT\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 20, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 20, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Chemistry\\\", \\\"9.2.12.1.2\\\", \\\"5\\\", 3249], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 20, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 20, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Chemistry\\\", \\\"9.2.12.1.2\\\", \\\"5\\\", 3250], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\\u03b3-glutamyltransferase\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 20, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 20, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Chemistry\\\", \\\"9.2.12.1.2\\\", \\\"5\\\", 3251], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"AST\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 20, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 20, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Chemistry\\\", \\\"9.2.12.1.2\\\", \\\"5\\\", 3252], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 20, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 20, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Chemistry\\\", \\\"9.2.12.1.2\\\", \\\"5\\\", 3253], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Glucose\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 20, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 20, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Chemistry\\\", \\\"9.2.12.1.2\\\", \\\"5\\\", 3254], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Bilirubin (total), if above ULN total bilirubin will be\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 20, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 20, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Chemistry\\\", \\\"9.2.12.1.2\\\", \\\"5\\\", 3255], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 20, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 20, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Chemistry\\\", \\\"9.2.12.1.2\\\", \\\"5\\\", 3256], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"FSH\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 20, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 20, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Chemistry\\\", \\\"9.2.12.1.2\\\", \\\"5\\\", 3257], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"a\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 20, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 20, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"superscript\\\"}, \\\"Study Design\\\", \\\"Chemistry\\\", \\\"9.2.12.1.2\\\", \\\"5\\\", 3258], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"fractionated\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 20, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 20, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Chemistry\\\", \\\"9.2.12.1.2\\\", \\\"5\\\", 3259], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Blood urea nitrogen\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 20, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 20, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Chemistry\\\", \\\"9.2.12.1.2\\\", \\\"5\\\", 3260], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 20, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 20, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Chemistry\\\", \\\"9.2.12.1.2\\\", \\\"5\\\", 3261], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"GLDH\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 20, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 20, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Chemistry\\\", \\\"9.2.12.1.2\\\", \\\"5\\\", 3262], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Calcium\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 20, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 20, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Chemistry\\\", \\\"9.2.12.1.2\\\", \\\"5\\\", 3263], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 20, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 20, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Chemistry\\\", \\\"9.2.12.1.2\\\", \\\"5\\\", 3264], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Potassium\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 20, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 20, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Chemistry\\\", \\\"9.2.12.1.2\\\", \\\"5\\\", 3265], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Carbon dioxide\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 20, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 20, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Chemistry\\\", \\\"9.2.12.1.2\\\", \\\"5\\\", 3266], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 20, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 20, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Chemistry\\\", \\\"9.2.12.1.2\\\", \\\"5\\\", 3267], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Protein (total)\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 20, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 20, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Chemistry\\\", \\\"9.2.12.1.2\\\", \\\"5\\\", 3268], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Triglycerides\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 20, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 20, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Chemistry\\\", \\\"9.2.12.1.2\\\", \\\"5\\\", 3269], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 20, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 20, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Chemistry\\\", \\\"9.2.12.1.2\\\", \\\"5\\\", 3270], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Sodium\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 20, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 20, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Chemistry\\\", \\\"9.2.12.1.2\\\", \\\"5\\\", 3271], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Lipid panel (HDL, LDL, total cholesterol)\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 20, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 20, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Chemistry\\\", \\\"9.2.12.1.2\\\", \\\"5\\\", 3272], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 20, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 20, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Chemistry\\\", \\\"9.2.12.1.2\\\", \\\"5\\\", 3273], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Fluoride (in applicable part)\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 20, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 20, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Chemistry\\\", \\\"9.2.12.1.2\\\", \\\"5\\\", 3274], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"b\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 20, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 20, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"superscript\\\"}, \\\"Study Design\\\", \\\"Chemistry\\\", \\\"9.2.12.1.2\\\", \\\"5\\\", 3275], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Chemistry\\\", \\\"9.2.12.1.2\\\", \\\"5\\\", 3276], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"ALT: alanine aminotransferase; AST: aspartate aminotransferase; FSH: ~REDACTED~; GLDH: glutamate dehydrogenase; HDL: high density lipoproteins; LDL: low density lipoproteins; ULN: upper limit of normal.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 20, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 20, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Chemistry\\\", \\\"9.2.12.1.2\\\", \\\"5\\\", 3277], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"a\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 13, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 13, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Chemistry\\\", \\\"9.2.12.1.2\\\", \\\"5\\\", 3278], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Optional; for postmenopausal women only.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 20, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 20, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Chemistry\\\", \\\"9.2.12.1.2\\\", \\\"5\\\", 3279], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"b\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 13, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 13, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Chemistry\\\", \\\"9.2.12.1.2\\\", \\\"5\\\", 3280], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Part B to E only.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 20, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 20, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Chemistry\\\", \\\"9.2.12.1.2\\\", \\\"5\\\", 3281], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"See details for schedule of events.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 20, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 20, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Chemistry\\\", \\\"9.2.12.1.2\\\", \\\"5\\\", 3282], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"In Part D, fluoride testing is planned at all planned clinical laboratory assessments except screening visit.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 20, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 20, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Chemistry\\\", \\\"9.2.12.1.2\\\", \\\"5\\\", 3283], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"If subjects experience ALT or AST >3 \\\\u00d7 ULN, follow-up laboratory tests (at a minimum, serum alkaline phosphatase, ALT, AST, total bilirubin, \\\\u03b3-glutamyltransferase, and INR) should be performed within 24 to 48 hours after the abnormality is noted.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Chemistry\\\", \\\"9.2.12.1.2\\\", \\\"5\\\", 3284], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"As detailed in Section 7.4.3, subjects with 2 consecutive ALT elevation >3 \\\\u00d7 ULN should be withdrawn from the study.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Chemistry\\\", \\\"9.2.12.1.2\\\", \\\"5\\\", 3285], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"For subjects with an ALT or AST elevated >3 \\\\u00d7 ULN at any occasion, the investigator must contact the sponsor or designee for consideration of additional testing, close monitoring, possible discontinuation of study drug, and discussion of the relevant subject details and possible alternative etiologies.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Chemistry\\\", \\\"9.2.12.1.2\\\", \\\"5\\\", 3286], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"The abnormality should be recorded as an AE.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Chemistry\\\", \\\"9.2.12.1.2\\\", \\\"5\\\", 3287], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Please refer to Section 7.4.3 for subject discontinuation criteria regarding abnormal LFTs and Section 10.2.9.4 for guidance on reporting abnormal LFTs.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Chemistry\\\", \\\"9.2.12.1.2\\\", \\\"5\\\", 3288], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Urinalysis will consist of the following tests:\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Chemistry\\\", \\\"9.2.12.1.2\\\", \\\"5\\\", 3289], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"BloodNitriteGlucoseProteinBloodNitriteGlucoseProtein\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 20, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 20, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Chemistry\\\", \\\"9.2.12.1.2\\\", \\\"5\\\", 3290], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Blood\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 20, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 20, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Chemistry\\\", \\\"9.2.12.1.2\\\", \\\"5\\\", 3291], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Nitrite\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 20, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 20, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Chemistry\\\", \\\"9.2.12.1.2\\\", \\\"5\\\", 3292], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Glucose\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 20, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 20, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Chemistry\\\", \\\"9.2.12.1.2\\\", \\\"5\\\", 3293], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Protein\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 20, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 20, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Chemistry\\\", \\\"9.2.12.1.2\\\", \\\"5\\\", 3294], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Chemistry\\\", \\\"9.2.12.1.2\\\", \\\"5\\\", 3295], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Chemistry\\\", \\\"9.2.12.1.2\\\", \\\"5\\\", 3296], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Chemistry\\\", \\\"9.2.12.1.2\\\", \\\"5\\\", 3297], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Chemistry\\\", \\\"9.2.12.1.2\\\", \\\"5\\\", 3298], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"In addition, additional urinalysis assessments (eg, 24-hour urine input/output collection, specific gravity assessments) as noted in the Schedule of Study Procedures for each study part (Section 3.0), when applicable.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Chemistry\\\", \\\"9.2.12.1.2\\\", \\\"5\\\", 3299], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Urine microscopy will be performed if urinalysis is abnormal.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Chemistry\\\", \\\"9.2.12.1.2\\\", \\\"5\\\", 3300], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Microscopy consists of red blood cell count/high-power field, white blood cell count/high-power field, and casts.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Chemistry\\\", \\\"9.2.12.1.2\\\", \\\"5\\\", 3301], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"9.2.12.2 Diagnostic Screening\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading5\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Diagnostic Screening\\\", \\\"9.2.12.2\\\", \\\"4\\\", 3302], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Samples for serum screening, ~REDACTED~ screening, and urine drug screening will be taken as indicated in the Schedule of Study Procedures for each study part (Section 3.0).\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Diagnostic Screening\\\", \\\"9.2.12.2\\\", \\\"4\\\", 3303], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"9.2.12.2.1\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": true, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Serum\\\", \\\"9.2.12.2.1\\\", \\\"5\\\", 3304], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": true, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Serum\\\", \\\"9.2.12.2.1\\\", \\\"5\\\", 3305], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Serum\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": true, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Serum\\\", \\\"9.2.12.2.1\\\", \\\"5\\\", 3306], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"The serum diagnostic screening assessment will include the following tests:\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Serum\\\", \\\"9.2.12.2.1\\\", \\\"5\\\", 3307], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"HIV\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 20, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 20, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Serum\\\", \\\"9.2.12.2.1\\\", \\\"5\\\", 3308], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 20, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 20, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Serum\\\", \\\"9.2.12.2.1\\\", \\\"5\\\", 3309], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Hepatitis screen (hepatitis B surface antigen, hepatitis C virus)\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 20, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 20, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Serum\\\", \\\"9.2.12.2.1\\\", \\\"5\\\", 3310], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Additional serum diagnostic screening assessments may be executed with the investigator\\\\u2019s discretion after consultation with the sponsor or designee.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 20, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 20, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Serum\\\", \\\"9.2.12.2.1\\\", \\\"5\\\", 3311], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"9.2.12.2.2\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": true, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Alcohol Screen\\\", \\\"9.2.12.2.2\\\", \\\"5\\\", 3312], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": true, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Alcohol Screen\\\", \\\"9.2.12.2.2\\\", \\\"5\\\", 3313], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"~REDACTED~ Screen\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": true, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Alcohol Screen\\\", \\\"9.2.12.2.2\\\", \\\"5\\\", 3314], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"At the screening visit, alcohol screening will be done initially with a breathalyzer and if positive, a serum ethanol level will be obtained.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Alcohol Screen\\\", \\\"9.2.12.2.2\\\", \\\"5\\\", 3315], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"For all other time points a breathalyzer will be done at check-in.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Alcohol Screen\\\", \\\"9.2.12.2.2\\\", \\\"5\\\", 3316], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"A urine alcohol test may be performed at the discretion of the investigator.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Alcohol Screen\\\", \\\"9.2.12.2.2\\\", \\\"5\\\", 3317], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"9.2.12.2.3\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": true, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Urine Drug Screen\\\", \\\"9.2.12.2.3\\\", \\\"5\\\", 3318], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": true, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Urine Drug Screen\\\", \\\"9.2.12.2.3\\\", \\\"5\\\", 3319], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Urine Drug Screen\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": true, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Urine Drug Screen\\\", \\\"9.2.12.2.3\\\", \\\"5\\\", 3320], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"The urine drug screening assessment will include the following tests:\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Urine Drug Screen\\\", \\\"9.2.12.2.3\\\", \\\"5\\\", 3321], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Urine Drug Screen\\\", \\\"9.2.12.2.3\\\", \\\"5\\\", 3322], [\\\"\\\", \\\"Unmapped\\\", \\\"table\\\", {\\\"Table\\\": \\\"<table border=\\\\\\\"1\\\\\\\" class=\\\\\\\"dataframe\\\\\\\">\\\\n  <thead>\\\\n    <tr style=\\\\\\\"text-align: right;\\\\\\\">\\\\n      <th></th>\\\\n      <th>1.0</th>\\\\n      <th>2.0</th>\\\\n    </tr>\\\\n  </thead>\\\\n  <tbody>\\\\n    <tr>\\\\n      <th>0</th>\\\\n      <td>Amphetamines</td>\\\\n      <td><span class=\\\\\\\"redact\\\\\\\"> ~REDACTED~ </span>  ( <span class=\\\\\\\"redact\\\\\\\"> ~REDACTED~ </span> )</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>1</th>\\\\n      <td>Barbiturates</td>\\\\n      <td><span class=\\\\\\\"redact\\\\\\\"> ~REDACTED~ </span> /metabolite</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>2</th>\\\\n      <td><span class=\\\\\\\"redact\\\\\\\"> ~REDACTED~ </span></td>\\\\n      <td>Opiates</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>3</th>\\\\n      <td><span class=\\\\\\\"redact\\\\\\\"> ~REDACTED~ </span> /metabolite <sup>a</sup></td>\\\\n      <td><span class=\\\\\\\"redact\\\\\\\"> ~REDACTED~ </span> / <span class=\\\\\\\"redact\\\\\\\"> ~REDACTED~ </span></td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>4</th>\\\\n      <td>Cannabinoids</td>\\\\n      <td><span class=\\\\\\\"redact\\\\\\\"> ~REDACTED~ </span></td>\\\\n    </tr>\\\\n  </tbody>\\\\n</table>\\\", \\\"SectionHeaderPrintPage\\\": \\\"101\\\", \\\"TableIndex\\\": \\\"42\\\", \\\"TableName\\\": \\\"9.2.12.2.3 Urine Drug Screen\\\", \\\"Header\\\": []}, {\\\"IsBold\\\": false, \\\"font_size\\\": 20, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 20, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Urine Drug Screen\\\", \\\"9.2.12.2.3\\\", \\\"5\\\", 3323], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"~REDACTED~/metabolites\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 20, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 20, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Urine Drug Screen\\\", \\\"9.2.12.2.3\\\", \\\"5\\\", 3324], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Urine Drug Screen\\\", \\\"9.2.12.2.3\\\", \\\"5\\\", 3325], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Urine drug screen: See clinical laboratory reference document for details.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 20, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 20, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Urine Drug Screen\\\", \\\"9.2.12.2.3\\\", \\\"5\\\", 3326], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"a\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 20, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 20, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"superscript\\\"}, \\\"Study Design\\\", \\\"Urine Drug Screen\\\", \\\"9.2.12.2.3\\\", \\\"5\\\", 3327], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"In some regions confirmatory testing for this substance may not be available.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 20, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 20, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Urine Drug Screen\\\", \\\"9.2.12.2.3\\\", \\\"5\\\", 3328], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"9.2.12.2.4\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": true, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"HLA Genotyping\\\", \\\"9.2.12.2.4\\\", \\\"5\\\", 3329], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": true, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"HLA Genotyping\\\", \\\"9.2.12.2.4\\\", \\\"5\\\", 3330], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"HLA Genotyping\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": true, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"HLA Genotyping\\\", \\\"9.2.12.2.4\\\", \\\"5\\\", 3331], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"HLA DQB1*06:02 typing will be obtained from subjects in specified parts of the study according to the Schedules of Study Procedures in Section 3.0.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"HLA Genotyping\\\", \\\"9.2.12.2.4\\\", \\\"5\\\", 3332], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"If done previously, a copy of the prior test results must be filed in the source documents, too.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"HLA Genotyping\\\", \\\"9.2.12.2.4\\\", \\\"5\\\", 3333], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Almost all patients with NT1 who experience cataplectic attacks have this HLA genotype (heterozygous or homozygous expression), which has been found to correlate with low OX concentrations in the ~REDACTED~.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"HLA Genotyping\\\", \\\"9.2.12.2.4\\\", \\\"5\\\", 3334], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Therefore, this genotype is viewed as a surrogate biomarker in the right clinical setting.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"HLA Genotyping\\\", \\\"9.2.12.2.4\\\", \\\"5\\\", 3335], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"The HLA genotype will be determined only at screening.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"HLA Genotyping\\\", \\\"9.2.12.2.4\\\", \\\"5\\\", 3336], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Prescreening for HLA is allowed per the protocol and will require a separate informed consent.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"HLA Genotyping\\\", \\\"9.2.12.2.4\\\", \\\"5\\\", 3337], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Dependent on local regulations, informed consent for HLA testing may be administered through e-consent or be administered over-the-phone for participants who may not live close to the site.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"HLA Genotyping\\\", \\\"9.2.12.2.4\\\", \\\"5\\\", 3338], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"In these cases, home nurses or other qualified clinical personnel may be deployed by the site to the subject\\\\u2019s residence to collect prescreening HLA sample.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"HLA Genotyping\\\", \\\"9.2.12.2.4\\\", \\\"5\\\", 3339], [\\\"3\\\", \\\"Pregnancy Testing\\\", \\\"header\\\", \\\"9.2.12.2.5\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": true, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Pregnancy Testing\\\", \\\"9.2.12.2.5\\\", \\\"5\\\", 3340], [\\\"3\\\", \\\"Pregnancy Testing\\\", \\\"header\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": true, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Pregnancy Testing\\\", \\\"9.2.12.2.5\\\", \\\"5\\\", 3341], [\\\"3\\\", \\\"Pregnancy Testing\\\", \\\"header\\\", \\\"Pregnancy Testing\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": true, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Pregnancy Testing\\\", \\\"9.2.12.2.5\\\", \\\"5\\\", 3342], [\\\"3\\\", \\\"Pregnancy Testing\\\", \\\"text\\\", \\\"Women of childbearing potential will undergo urine or serum pregnancy testing on the days indicated in the Schedules of Study Procedures (see Section 3.0 for details).\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Pregnancy Testing\\\", \\\"9.2.12.2.5\\\", \\\"5\\\", 3343], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"9.3 Biomarker, PK, PD, and Pharmacogenomics Samples\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading1\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Biomarker, PK, PD, and Pharmacogenomics Samples\\\", \\\"9.3\\\", \\\"2\\\", 3344], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Primary specimen collection parameters are provided in Table 9.a.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Biomarker, PK, PD, and Pharmacogenomics Samples\\\", \\\"9.3\\\", \\\"2\\\", 3345], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"The standard total blood draw volume in this study is expected to be maximum approximately 339 mL (without pregnancy tests).\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Biomarker, PK, PD, and Pharmacogenomics Samples\\\", \\\"9.3\\\", \\\"2\\\", 3346], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"Table 9.a Primary Specimen Collections\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading8\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"a  Primary Specimen Collections\\\", \\\"Table 9.\\\", \\\"2\\\", 3347], [\\\"\\\", \\\"Unmapped\\\", \\\"table\\\", {\\\"Table\\\": \\\"<table border=\\\\\\\"1\\\\\\\" class=\\\\\\\"dataframe\\\\\\\">\\\\n  <thead>\\\\n    <tr style=\\\\\\\"text-align: right;\\\\\\\">\\\\n      <th></th>\\\\n      <th>1.0</th>\\\\n      <th>2.0</th>\\\\n      <th>3.0</th>\\\\n      <th>4.0</th>\\\\n      <th>5.0</th>\\\\n    </tr>\\\\n  </thead>\\\\n  <tbody>\\\\n    <tr>\\\\n      <th>0</th>\\\\n      <td>Specimen Name</td>\\\\n      <td>Primary Specimen</td>\\\\n      <td>Primary Specimen Derivative</td>\\\\n      <td>Description of Intended Use</td>\\\\n      <td>Sample Collection</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>1</th>\\\\n      <td>Blood sample for TAK-861 PK</td>\\\\n      <td>Plasma</td>\\\\n      <td></td>\\\\n      <td>Plasma sample for PK analysis</td>\\\\n      <td>Mandatory (all parts)</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>2</th>\\\\n      <td>Urine sample for TAK-861 PK <sup>b</sup></td>\\\\n      <td>Urine</td>\\\\n      <td>NA</td>\\\\n      <td>Urine sample for PK analysis</td>\\\\n      <td>Mandatory (Parts A[ f asted portion of A3 and  <span class=\\\\\\\"redact\\\\\\\"> ~REDACTED~ </span> ], B, C and E)</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>3</th>\\\\n      <td><span class=\\\\\\\"redact\\\\\\\"> ~REDACTED~ </span>  sample for TAK-861 PK assessment <sup>b</sup></td>\\\\n      <td><span class=\\\\\\\"redact\\\\\\\"> ~REDACTED~ </span></td>\\\\n      <td>NA</td>\\\\n      <td><span class=\\\\\\\"redact\\\\\\\"> ~REDACTED~ </span>  sample for TAK-861 PK assessment</td>\\\\n      <td>Mandatory (Part F)</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>4</th>\\\\n      <td>Blood sample for CYP3A4/5 <sup>b</sup></td>\\\\n      <td>Plasma</td>\\\\n      <td>NA</td>\\\\n      <td>Plasma sample for 4\\\\u03b2-hydroxycholesterol/c holesterol ratio</td>\\\\n      <td>Mandatory (Parts B-E)</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>5</th>\\\\n      <td>Blood sample for OATP1B1/3 activity <sup>b</sup></td>\\\\n      <td>Plasma</td>\\\\n      <td>NA</td>\\\\n      <td>Plasma sample for CPI and CPIII</td>\\\\n      <td>Mandatory (Parts B and E)</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>6</th>\\\\n      <td><span class=\\\\\\\"redact\\\\\\\"> ~REDACTED~ </span>  sample for OX assessment <sup>b</sup></td>\\\\n      <td><span class=\\\\\\\"redact\\\\\\\"> ~REDACTED~ </span></td>\\\\n      <td>NA</td>\\\\n      <td><span class=\\\\\\\"redact\\\\\\\"> ~REDACTED~ </span>  sample for OX assessment</td>\\\\n      <td>Optional (Part D) Mandatory (Part F)</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>7</th>\\\\n      <td>Blood sample for exosome research <sup>b</sup></td>\\\\n      <td>Plasma</td>\\\\n      <td>NA</td>\\\\n      <td>Plasma sample for exosome research</td>\\\\n      <td>Mandatory (Parts B-F)</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>8</th>\\\\n      <td>Blood sample for pharmacogenomics a</td>\\\\n      <td>Blood</td>\\\\n      <td>DNA</td>\\\\n      <td>DNA measurements</td>\\\\n      <td>Optional (all parts)</td>\\\\n    </tr>\\\\n  </tbody>\\\\n</table>\\\", \\\"SectionHeaderPrintPage\\\": \\\"102\\\", \\\"TableIndex\\\": \\\"43\\\", \\\"TableName\\\": \\\"Table 9.a Primary Specimen Collections\\\", \\\"Header\\\": [0]}, {\\\"IsBold\\\": true, \\\"font_size\\\": 20, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 20, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"a  Primary Specimen Collections\\\", \\\"Table 9.\\\", \\\"2\\\", 3348], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"a  Primary Specimen Collections\\\", \\\"Table 9.\\\", \\\"2\\\", 3349], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"CP: coproporphyrin; ~REDACTED~: cerebrospinal fluid; CYP: cytochrome P450; HLA: human leukocyte antigen; NA: not applicable; OX: orexin; PK: pharmacokinetic(s).\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 20, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 20, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"a  Primary Specimen Collections\\\", \\\"Table 9.\\\", \\\"2\\\", 3350], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"a\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 13, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 13, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"a  Primary Specimen Collections\\\", \\\"Table 9.\\\", \\\"2\\\", 3351], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"This testing is separate from HLA genotyping.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 20, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 20, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"a  Primary Specimen Collections\\\", \\\"Table 9.\\\", \\\"2\\\", 3352], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"b\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 13, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 13, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"a  Primary Specimen Collections\\\", \\\"Table 9.\\\", \\\"2\\\", 3353], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Specified parts/cohorts only.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 20, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 20, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"a  Primary Specimen Collections\\\", \\\"Table 9.\\\", \\\"2\\\", 3354], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"9.3.1 PK Measurements\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading3\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"PK Measurements\\\", \\\"9.3.1\\\", \\\"3\\\", 3355], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Standard noncompartmental PK analyses will provide measures of drug exposure in the plasma, ~REDACTED~, and urine following single and/or multiple oral dose administration of TAK-861 under fasted or fed conditions.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"PK Measurements\\\", \\\"9.3.1\\\", \\\"3\\\", 3356], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Metabolites may also be evaluated, as deemed appropriate.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"PK Measurements\\\", \\\"9.3.1\\\", \\\"3\\\", 3357], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"The assessment of ~REDACTED~ concentrations of TAK-861 is intended to evaluate TAK-861 CNS penetration relative to systemic exposure pending the observed PD effects, as measured by MWT, in subjects with NT1.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"PK Measurements\\\", \\\"9.3.1\\\", \\\"3\\\", 3358], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"The following PK parameters will be calculated from plasma, ~REDACTED~, and urine concentrations of TAK-861, as data permit:\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"PK Measurements\\\", \\\"9.3.1\\\", \\\"3\\\", 3359], [\\\"\\\", \\\"Unmapped\\\", \\\"table\\\", {\\\"Table\\\": \\\"<table border=\\\\\\\"1\\\\\\\" class=\\\\\\\"dataframe\\\\\\\">\\\\n  <thead>\\\\n    <tr style=\\\\\\\"text-align: right;\\\\\\\">\\\\n      <th></th>\\\\n      <th>1.0</th>\\\\n      <th>2.0</th>\\\\n    </tr>\\\\n  </thead>\\\\n  <tbody>\\\\n    <tr>\\\\n      <th>0</th>\\\\n      <td>Symbol/Term</td>\\\\n      <td>Definition</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>1</th>\\\\n      <td>Plasma</td>\\\\n      <td></td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>2</th>\\\\n      <td>AUC \\\\u03c4</td>\\\\n      <td>Area under the concentration-time curve during a dosing interval, where \\\\u03c4 is the length of the dosing interval</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>3</th>\\\\n      <td>AUC last</td>\\\\n      <td>Area under the concentration-time curve from time 0 to time of the last quantifiable concentration</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>4</th>\\\\n      <td>AUC \\\\u221e</td>\\\\n      <td>Area under the concentration-time curve from time 0 to infinity</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>5</th>\\\\n      <td>AUC 24</td>\\\\n      <td>Area under the concentration-time curve from time 0 to 24 hours</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>6</th>\\\\n      <td>C av,ss</td>\\\\n      <td>Average plasma concentration during a dosing interval, at steady state, calculated as AUC \\\\u03c4 /\\\\u03c4</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>7</th>\\\\n      <td>CL/F</td>\\\\n      <td>Apparent clearance after extravascular administration, calculated using the observed value of the last quantifiable concentration</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>8</th>\\\\n      <td>C max</td>\\\\n      <td>Maximum observed concentration</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>9</th>\\\\n      <td>C max,ss</td>\\\\n      <td>Maximum observed concentration during a dosing interval, at steady state</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>10</th>\\\\n      <td>C trough</td>\\\\n      <td>Trough plasma concentration at steady state (observed concentration at the end of a dosing interval measured directly before the next study drug administration)</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>11</th>\\\\n      <td>\\\\u03bb z</td>\\\\n      <td>Terminal disposition phase rate constant</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>12</th>\\\\n      <td>R ac(AUC)</td>\\\\n      <td>Accumulation ratio based on AUC \\\\u03c4</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>13</th>\\\\n      <td>R ac(Cmax)</td>\\\\n      <td>Accumulation ratio based on C max</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>14</th>\\\\n      <td>t 1/2z</td>\\\\n      <td>Terminal disposition phase half-life</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>15</th>\\\\n      <td>t max</td>\\\\n      <td>Time of first occurrence of C max</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>16</th>\\\\n      <td>V z /F</td>\\\\n      <td>Apparent volume of distribution during the terminal disposition phase after extravascular administration, calculated using the observed value of the last quantifiable concentration</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>17</th>\\\\n      <td>Urine</td>\\\\n      <td></td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>18</th>\\\\n      <td>Ae t</td>\\\\n      <td>Total amount of drug excreted in urine from time 0 to time t</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>19</th>\\\\n      <td>Ae \\\\u03c4</td>\\\\n      <td>Amount of drug excreted in urine during a dosing interval at steady state</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>20</th>\\\\n      <td>CL R</td>\\\\n      <td>Renal clearance</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>21</th>\\\\n      <td>f e</td>\\\\n      <td>Fraction of administered dose of drug excreted in urine</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>22</th>\\\\n      <td><span class=\\\\\\\"redact\\\\\\\"> ~REDACTED~ </span></td>\\\\n      <td></td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>23</th>\\\\n      <td>Ratio CSF/ <span class=\\\\\\\"redact\\\\\\\"> ~REDACTED~ </span></td>\\\\n      <td>Ratio of the  <span class=\\\\\\\"redact\\\\\\\"> ~REDACTED~ </span>  to plasma AUC 24 values</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>24</th>\\\\n      <td>AUC \\\\u03c4,CSF</td>\\\\n      <td>Area under the  <span class=\\\\\\\"redact\\\\\\\"> ~REDACTED~ </span>  concentration-time curve during a dosing interval</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>25</th>\\\\n      <td>C max,CSF</td>\\\\n      <td>Maximum observed  <span class=\\\\\\\"redact\\\\\\\"> ~REDACTED~ </span>  concentration</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>26</th>\\\\n      <td>t max,CSF</td>\\\\n      <td>Time to reach C max,CSF</td>\\\\n    </tr>\\\\n  </tbody>\\\\n</table>\\\", \\\"SectionHeaderPrintPage\\\": \\\"102\\\", \\\"TableIndex\\\": \\\"44\\\", \\\"TableName\\\": \\\"9.3.1 PK Measurements\\\", \\\"Header\\\": [0, 1]}, {\\\"IsBold\\\": true, \\\"font_size\\\": 20, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 20, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"PK Measurements\\\", \\\"9.3.1\\\", \\\"3\\\", 3360], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"PK Measurements\\\", \\\"9.3.1\\\", \\\"3\\\", 3361], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"PK Measurements\\\", \\\"9.3.1\\\", \\\"3\\\", 3362], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"PK Measurements\\\", \\\"9.3.1\\\", \\\"3\\\", 3363], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Additional PK parameters may be calculated as appropriate.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"PK Measurements\\\", \\\"9.3.1\\\", \\\"3\\\", 3364], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"A detailed PK analysis plan will be prepared before PK parameter computation.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"PK Measurements\\\", \\\"9.3.1\\\", \\\"3\\\", 3365], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"9.3.1.1 Plasma for PK Measurements\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading5\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Plasma for PK Measurements\\\", \\\"9.3.1.1\\\", \\\"4\\\", 3366], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Blood samples (one 4 mL sample per scheduled time) for PK analysis of TAK-861 will be collected according to the Schedule of Study Procedures in Section 3.0.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Plasma for PK Measurements\\\", \\\"9.3.1.1\\\", \\\"4\\\", 3367], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"In selected MRD study parts (ie, Parts B, C, D, and E only), 3 additional 2 mL blood samples should be collected predose on the days specified in the Schedules of Study Procedures for measurement of the 4\\\\u03b2-hydroxycholesterol/cholesterol ratio to assess CYP3A4/5 activity.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Plasma for PK Measurements\\\", \\\"9.3.1.1\\\", \\\"4\\\", 3368], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"In MRD study parts (Parts B and E), Blood specimens (one 2 mL sample per scheduled time) for the assessment of CPI and CPIII will be collected as outlined in the Schedule of Study Procedures (Section 3.0) to measure OATP1B1/3 activities.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Plasma for PK Measurements\\\", \\\"9.3.1.1\\\", \\\"4\\\", 3369], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"The following parameters will be calculated for CPI and CPIII, as appropriate: AUC\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Plasma for PK Measurements\\\", \\\"9.3.1.1\\\", \\\"4\\\", 3370], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"last\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"subscript\\\"}, \\\"Study Design\\\", \\\"Plasma for PK Measurements\\\", \\\"9.3.1.1\\\", \\\"4\\\", 3371], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"and C\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Plasma for PK Measurements\\\", \\\"9.3.1.1\\\", \\\"4\\\", 3372], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"max\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"subscript\\\"}, \\\"Study Design\\\", \\\"Plasma for PK Measurements\\\", \\\"9.3.1.1\\\", \\\"4\\\", 3373], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\".\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Plasma for PK Measurements\\\", \\\"9.3.1.1\\\", \\\"4\\\", 3374], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"The actual time of sample collection will be recorded on the source document and eCRF.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Plasma for PK Measurements\\\", \\\"9.3.1.1\\\", \\\"4\\\", 3375], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Sampling time points may be adjusted based on the preliminary emerging concentration data collected from prior subject(s), but the total number of samples collected per subject should not exceed the planned number.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Plasma for PK Measurements\\\", \\\"9.3.1.1\\\", \\\"4\\\", 3376], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Instructions for collecting, processing, and shipping of PK samples are provided in the Laboratory Manual.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Plasma for PK Measurements\\\", \\\"9.3.1.1\\\", \\\"4\\\", 3377], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"9.3.1.2 Urine for PK Measurements\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading5\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Urine for PK Measurements\\\", \\\"9.3.1.2\\\", \\\"4\\\", 3378], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Urine samples for PK analysis of TAK-861 will be collected according to the schedules in Section 3.0.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Urine for PK Measurements\\\", \\\"9.3.1.2\\\", \\\"4\\\", 3379], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Instructions for collecting, processing, and shipping of urine PK samples are provided in the Laboratory Manual.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Urine for PK Measurements\\\", \\\"9.3.1.2\\\", \\\"4\\\", 3380], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"9.3.1.3 ~REDACTED~ for PK Measurement\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading5\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"CSF for PK Measurement\\\", \\\"9.3.1.3\\\", \\\"4\\\", 3381], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Serial CSF samples for PK analysis of TAK-861 will be collected from subjects in specified parts of the study according to the Schedules of Study Procedures in Section 3.0 using an indwelling spinal catheter inserted into the lower spinal canal by trained personnel at the clinical site per the standard operating procedure.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"CSF for PK Measurement\\\", \\\"9.3.1.3\\\", \\\"4\\\", 3382], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"The actual time of sample collection will be recorded on the source document and eCRF.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"CSF for PK Measurement\\\", \\\"9.3.1.3\\\", \\\"4\\\", 3383], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Sampling time points may be adjusted based on the preliminary emerging concentration data collected from prior subject(s), but the total number of samples collected per subject should not exceed the planned number.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"CSF for PK Measurement\\\", \\\"9.3.1.3\\\", \\\"4\\\", 3384], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Instructions for collecting, processing, and shipping of CSF samples are provided in the Laboratory Manual.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"CSF for PK Measurement\\\", \\\"9.3.1.3\\\", \\\"4\\\", 3385], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"9.3.1.4 PK Sample Analysis\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading5\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"PK Sample Analysis\\\", \\\"9.3.1.4\\\", \\\"4\\\", 3386], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Plasma, ~REDACTED~, and urine concentrations of TAK-861 and plasma concentrations of 4\\\\u03b2-hydroxycholesterol, cholesterol, CPI, and CPIII will be measured by validated high-performance liquid chromatography with tandem mass spectrometry assays.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"PK Sample Analysis\\\", \\\"9.3.1.4\\\", \\\"4\\\", 3387], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Part of the archival plasma, ~REDACTED~, and urine samples may be used for potential analysis of unknown metabolite characterization, if appropriate.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"PK Sample Analysis\\\", \\\"9.3.1.4\\\", \\\"4\\\", 3388], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"9.3.2 PD Measurements\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading3\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"PD Measurements\\\", \\\"9.3.2\\\", \\\"3\\\", 3389], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"PD and/or efficacy assessments will be performed according to the Schedules of Study Procedures as described in Section 3.0.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"PD Measurements\\\", \\\"9.3.2\\\", \\\"3\\\", 3390], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Key PD assessment procedures are summarized below, and additional details may be found in the study procedure manual or respective vendor manual.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"PD Measurements\\\", \\\"9.3.2\\\", \\\"3\\\", 3391], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Qualification, certification, and training processes for site staff administering these assessments or procedures will be provided in the study manual or respective vendor manuals if applicable.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"PD Measurements\\\", \\\"9.3.2\\\", \\\"3\\\", 3392], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"9.3.2.1 MWT\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading5\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"MWT\\\", \\\"9.3.2.1\\\", \\\"4\\\", 3393], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"The MWT is a validated, objective measure that evaluates a person\\\\u2019s ability to remain awake under soporific conditions for a defined period of time.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"MWT\\\", \\\"9.3.2.1\\\", \\\"4\\\", 3394], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Because there is no biological measure of wakefulness, wakefulness is measured indirectly by the inability or delayed tendency to fall asleep.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"MWT\\\", \\\"9.3.2.1\\\", \\\"4\\\", 3395], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"This tendency to fall asleep is measured via EEG-derived sleep latency in the MWT.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"MWT\\\", \\\"9.3.2.1\\\", \\\"4\\\", 3396], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"One session, that includes four 40-minute MWTs, will be done on each day specified in the Schedules of Study Procedures.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"MWT\\\", \\\"9.3.2.1\\\", \\\"4\\\", 3397], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Sleep latency in each session will be recorded.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"MWT\\\", \\\"9.3.2.1\\\", \\\"4\\\", 3398], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Subjects will be required to stay awake in between the 4 MWT tests in each session.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"MWT\\\", \\\"9.3.2.1\\\", \\\"4\\\", 3399], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"9.3.2.2 ESS\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading5\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"ESS\\\", \\\"9.3.2.2\\\", \\\"4\\\", 3400], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"The ESS is a subjective, self-administered scale that has been validated and used extensively as a key endpoint in studies in patients with narcolepsy to measure EDS.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"ESS\\\", \\\"9.3.2.2\\\", \\\"4\\\", 3401], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"The ESS provides individuals with 8 different situations of daily life and asks them how likely they are to fall asleep in those situations (scored 0 to 3) over the past 5 to 7 days and to try to imagine their likelihood of dozing even if they have not actually been in the identical situation; the scores are summed to give an overall score of 0 to 24.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"ESS\\\", \\\"9.3.2.2\\\", \\\"4\\\", 3402], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Higher scores indicate stronger subjective daytime sleepiness, and scores below 10 are considered to be within the reference range.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"ESS\\\", \\\"9.3.2.2\\\", \\\"4\\\", 3403], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"In this study, the ESS will be administered to assess sleep propensity on selected days after TAK-861 administration.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"ESS\\\", \\\"9.3.2.2\\\", \\\"4\\\", 3404], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Subjects will be asked to evaluate their subjective sleepiness based on recalling their most recent daily life experiences.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"ESS\\\", \\\"9.3.2.2\\\", \\\"4\\\", 3405], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"The change in the ESS score from baseline will be evaluated at specified times as an exploratory.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"ESS\\\", \\\"9.3.2.2\\\", \\\"4\\\", 3406], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"In addition, in Part F the ESS will be administered to confirm subject eligibility to participate in the study at screening.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"ESS\\\", \\\"9.3.2.2\\\", \\\"4\\\", 3407], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"9.3.2.3 Clinical Global Impression Scales (CGI-S and CGI-I)\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading5\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Clinical Global Impression Scales (CGI-S and CGI-I)\\\", \\\"9.3.2.3\\\", \\\"4\\\", 3408], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"The Clinical Global Impression Scale provides an overall clinician-determined summary measure of a subject\\\\u2019s treatment experience that takes into account all available information, including knowledge of the subject\\\\u2019s history, psychosocial circumstances, symptoms, behavior, and the impact of the symptoms on the subject\\\\u2019s ability to function.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Clinical Global Impression Scales (CGI-S and CGI-I)\\\", \\\"9.3.2.3\\\", \\\"4\\\", 3409], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"The assessment consists of 2 subscales, the CGI-S and the CGI-I, which assess severity and improvement of symptoms, respectively.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Clinical Global Impression Scales (CGI-S and CGI-I)\\\", \\\"9.3.2.3\\\", \\\"4\\\", 3410], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"The CGI-S will assess severity of EDS, cataplexy and overall narcolepsy symptoms.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Clinical Global Impression Scales (CGI-S and CGI-I)\\\", \\\"9.3.2.3\\\", \\\"4\\\", 3411], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"It uses a 7-point Likert-type scale ranging from \\\\u201cnormal, not at all ill\\\\u201d to \\\\u201camong the most extremely ill patients.\\\\u201d CGI-S will be administered at baseline and according to the Schedule of Study Procedures.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Clinical Global Impression Scales (CGI-S and CGI-I)\\\", \\\"9.3.2.3\\\", \\\"4\\\", 3412], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"The CGI-I asks clinicians to rate the extent to which their patients\\\\u2019 current overall narcolepsy symptoms and specifically EDS and cataplexy are improved (compared with the start of the study).\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Clinical Global Impression Scales (CGI-S and CGI-I)\\\", \\\"9.3.2.3\\\", \\\"4\\\", 3413], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"This assessment uses a 7-point Likert-type scale ranging from 1 (\\\\u201cVery much improved\\\\u201d) to 7 (\\\\u201cVery much worse\\\\u201d).\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Clinical Global Impression Scales (CGI-S and CGI-I)\\\", \\\"9.3.2.3\\\", \\\"4\\\", 3414], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Improvements on the CGI-I will be defined by responses reflecting minimally, much, or very much improved.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Clinical Global Impression Scales (CGI-S and CGI-I)\\\", \\\"9.3.2.3\\\", \\\"4\\\", 3415], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Clinicians will be trained on what aspects to take into consideration when rating the CGI-I to ensure consistency of responses.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Clinical Global Impression Scales (CGI-S and CGI-I)\\\", \\\"9.3.2.3\\\", \\\"4\\\", 3416], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"CGI-I will be administered at various time points according to the Schedule of Study Procedures.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Clinical Global Impression Scales (CGI-S and CGI-I)\\\", \\\"9.3.2.3\\\", \\\"4\\\", 3417], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"It is strongly recommended that the same clinician administers the CGI-S and then the CGI-I at every visit for the same subject.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Clinical Global Impression Scales (CGI-S and CGI-I)\\\", \\\"9.3.2.3\\\", \\\"4\\\", 3418], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"9.3.2.4 Patient Global Impression Scales (PGI-I and PGI-S)\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading5\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Patient Global Impression Scales (PGI-I and PGI-S)\\\", \\\"9.3.2.4\\\", \\\"4\\\", 3419], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"The Patient Global Impression rating scales capture global effect of TAK-861 on daytime sleepiness, cataplexy, and overall narcolepsy symptoms as perceived by the subject and provide \\\\u201canchors\\\\u201d to determine clinically relevant effects.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Patient Global Impression Scales (PGI-I and PGI-S)\\\", \\\"9.3.2.4\\\", \\\"4\\\", 3420], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"The PGI-S requires the subject to rate his/her disease severity at the time of assessment on a 4-point scale ranging from \\\\u201cnormal\\\\u201d to \\\\u201csevere.\\\\u201d\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Patient Global Impression Scales (PGI-I and PGI-S)\\\", \\\"9.3.2.4\\\", \\\"4\\\", 3421], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"The PGI-I measures improvement due to treatment relative to baseline on a 7-point scale ranging from 1 (very much improved) to 7 (very much worse).\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Patient Global Impression Scales (PGI-I and PGI-S)\\\", \\\"9.3.2.4\\\", \\\"4\\\", 3422], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"In this study, the PGI-S will be administered to assess the severity of overall narcolepsy symptoms and PGI-I will be administered to assess improvement in overall narcolepsy symptoms.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Patient Global Impression Scales (PGI-I and PGI-S)\\\", \\\"9.3.2.4\\\", \\\"4\\\", 3423], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Instructions will be provided to the subject to help ensure consistency in the tests.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Patient Global Impression Scales (PGI-I and PGI-S)\\\", \\\"9.3.2.4\\\", \\\"4\\\", 3424], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"The PGI-S and the PGI-I will be administered similarly to the CGI-S and CGI-I.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Patient Global Impression Scales (PGI-I and PGI-S)\\\", \\\"9.3.2.4\\\", \\\"4\\\", 3425], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"9.3.2.5 nPSG\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading5\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"nPSG\\\", \\\"9.3.2.5\\\", \\\"4\\\", 3426], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"nPSG is a standardized procedure used to assess various sleep parameters, including sleep latency and sleep architecture.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"nPSG\\\", \\\"9.3.2.5\\\", \\\"4\\\", 3427], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"In this study, nPSG will be performed to evaluate the effects of TAK-861 on nighttime sleep architecture.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"nPSG\\\", \\\"9.3.2.5\\\", \\\"4\\\", 3428], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Subjects with narcolepsy have disrupted nighttime sleep, with frequent awakenings and shorter REM latency that may cause sleep paralysis and hypnagogic/hypnopompic hallucinations.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"nPSG\\\", \\\"9.3.2.5\\\", \\\"4\\\", 3429], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"In this study, there will be exploratory evaluation for changes in nighttime sleep ~REDACTED~ following TAK-861 multiple dosing.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"nPSG\\\", \\\"9.3.2.5\\\", \\\"4\\\", 3430], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"The standard sleep parameters will be captured.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"nPSG\\\", \\\"9.3.2.5\\\", \\\"4\\\", 3431], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"9.3.2.6 Wearable EEG Device\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading5\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Wearable EEG Device\\\", \\\"9.3.2.6\\\", \\\"4\\\", 3432], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Collecting EEG data during the night while subjects\\\\u2019 sleep is considered to be useful to understand the effect of TAK-861 on nighttime sleep disturbance of subjects with NT1.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Wearable EEG Device\\\", \\\"9.3.2.6\\\", \\\"4\\\", 3433], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Although nPSG will be implemented during inpatient days in this study in NT1, EEG data will be also collected using portable devices as specified in the Schedule of Study Procedures from subjects with NT1 to collect EEG data during outpatient days.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Wearable EEG Device\\\", \\\"9.3.2.6\\\", \\\"4\\\", 3434], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Subjects will be trained on the use of the devices before they start recording portable EEG.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Wearable EEG Device\\\", \\\"9.3.2.6\\\", \\\"4\\\", 3435], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"The devices will be used throughout the study as described in the Schedule of Study Procedures.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Wearable EEG Device\\\", \\\"9.3.2.6\\\", \\\"4\\\", 3436], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Based on emerging data from other studies, portable EEG may not be done.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Wearable EEG Device\\\", \\\"9.3.2.6\\\", \\\"4\\\", 3437], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"9.3.2.7 Accelerometry (Actigraphy)\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading5\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Accelerometry (Actigraphy)\\\", \\\"9.3.2.7\\\", \\\"4\\\", 3438], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"In specified parts or cohorts, subjects will wear portable accelerometry devices as specified in the Schedule of Study Procedures.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Accelerometry (Actigraphy)\\\", \\\"9.3.2.7\\\", \\\"4\\\", 3439], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"These devices are worn on the wrist, are noninvasive, and do not interfere with normal activity, showering, or bathing.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Accelerometry (Actigraphy)\\\", \\\"9.3.2.7\\\", \\\"4\\\", 3440], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"An accelerometry device will capture data on subject activity level during daytime and intensity of movement during rest and sleep, for exploratory purposes.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Accelerometry (Actigraphy)\\\", \\\"9.3.2.7\\\", \\\"4\\\", 3441], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"The data are not intended to be analyzed for real-time safety monitoring and will not be used for clinical management purposes during the study but may be used in exploratory analyses to evaluate the utility of measuring activity during wakefulness and sleep during the study.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Accelerometry (Actigraphy)\\\", \\\"9.3.2.7\\\", \\\"4\\\", 3442], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Continuous accelerometry will be used to correlate with HR obtained during standard nPSG during baseline and as indicated in the Schedule of Study Procedures (Section 3.0).\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Accelerometry (Actigraphy)\\\", \\\"9.3.2.7\\\", \\\"4\\\", 3443], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"9.3.2.8 Assessment of Cataplexy and Other Narcolepsy Symptoms\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading5\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Assessment of Cataplexy and Other Narcolepsy Symptoms\\\", \\\"9.3.2.8\\\", \\\"4\\\", 3444], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Subjects with narcolepsy will complete a daily ePRO diary to record self-reported narcolepsy symptoms.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Assessment of Cataplexy and Other Narcolepsy Symptoms\\\", \\\"9.3.2.8\\\", \\\"4\\\", 3445], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"In cases where ePRO diary becomes unavailable, site may employ alternative methods to collect these data with approval from sponsor or designee.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Assessment of Cataplexy and Other Narcolepsy Symptoms\\\", \\\"9.3.2.8\\\", \\\"4\\\", 3446], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Episodes of cataplexy will be reported by the subject via an ePRO diary.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Assessment of Cataplexy and Other Narcolepsy Symptoms\\\", \\\"9.3.2.8\\\", \\\"4\\\", 3447], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"The time of event, severity of the cataplexy attack (including body location of the attack), duration, and time to recovery after the attack will be collected.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Assessment of Cataplexy and Other Narcolepsy Symptoms\\\", \\\"9.3.2.8\\\", \\\"4\\\", 3448], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"The total number of events/week will be calculated, and the additional parameters collected will be analyzed.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Assessment of Cataplexy and Other Narcolepsy Symptoms\\\", \\\"9.3.2.8\\\", \\\"4\\\", 3449], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Subjects will record partial or complete episodes of cataplexy, including the time of occurrence, severity (including body location), and other aspects, in the diary (if applicable, ie, subjects with NT1).\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Assessment of Cataplexy and Other Narcolepsy Symptoms\\\", \\\"9.3.2.8\\\", \\\"4\\\", 3450], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Subjects may begin recording partial and complete episodes at any time after the screening visit at the investigator\\\\u2019s discretion.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Assessment of Cataplexy and Other Narcolepsy Symptoms\\\", \\\"9.3.2.8\\\", \\\"4\\\", 3451], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Cataplexy events recorded for 14 consecutive days, starting after 7-day washout of anticataplexy medications and completed before day -2, will be considered for WCR study entry criterion.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Assessment of Cataplexy and Other Narcolepsy Symptoms\\\", \\\"9.3.2.8\\\", \\\"4\\\", 3452], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"The total number of events/week will be calculated based on the number of cataplexy episodes as averaged over 2 weeks (14 consecutive days) minimum.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Assessment of Cataplexy and Other Narcolepsy Symptoms\\\", \\\"9.3.2.8\\\", \\\"4\\\", 3453], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Subjects must fill out self-reported cataplexy questions in the electronic diary for at least 11 out of 14 days, to be considered compliance.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Assessment of Cataplexy and Other Narcolepsy Symptoms\\\", \\\"9.3.2.8\\\", \\\"4\\\", 3454], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"The eligibility criteria pertaining to WCR must be met prior to check in on Day -2.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Assessment of Cataplexy and Other Narcolepsy Symptoms\\\", \\\"9.3.2.8\\\", \\\"4\\\", 3455], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Other narcolepsy symptoms, including sleep paralysis and hypnopompic/hypnogogic hallucinations, will be self-reported by subjects in a diary.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Assessment of Cataplexy and Other Narcolepsy Symptoms\\\", \\\"9.3.2.8\\\", \\\"4\\\", 3456], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Information on nocturnal awakenings, total sleep time, and naps during the day will also be reported by the subjects in a diary.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Assessment of Cataplexy and Other Narcolepsy Symptoms\\\", \\\"9.3.2.8\\\", \\\"4\\\", 3457], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"9.3.2.9 KSS\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading5\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"KSS\\\", \\\"9.3.2.9\\\", \\\"4\\\", 3458], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"The KSS is a self-reported tool for assessing changes in situational sleepiness in response to the effects of drugs.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"KSS\\\", \\\"9.3.2.9\\\", \\\"4\\\", 3459], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"It is sensitive to fluctuations and has been used in studies of shift work, jetlag, driving abilities, and attention and performance as well as in clinical settings.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"KSS\\\", \\\"9.3.2.9\\\", \\\"4\\\", 3460], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"The KSS can also assess changes in response to environmental factors and circadian rhythm.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"KSS\\\", \\\"9.3.2.9\\\", \\\"4\\\", 3461], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"In prior studies investigating the validity of the KSS, KSS scores were highly correlated to EEG and behavioral variables, indicating high validity for this measure.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"KSS\\\", \\\"9.3.2.9\\\", \\\"4\\\", 3462], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"KSS can be skipped if the subject has already fallen asleep.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"KSS\\\", \\\"9.3.2.9\\\", \\\"4\\\", 3463], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"If the subject is sleeping, site staff will rate KSS as 9 associated with applicable flag or comments (ie, the subject was sleeping).\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"KSS\\\", \\\"9.3.2.9\\\", \\\"4\\\", 3464], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"9.3.2.10 Cognitive Assessments\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading5\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Cognitive Assessments\\\", \\\"9.3.2.10\\\", \\\"4\\\", 3465], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"9.3.2.10.1\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": true, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"SART\\\", \\\"9.3.2.10.1\\\", \\\"5\\\", 3466], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": true, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"SART\\\", \\\"9.3.2.10.1\\\", \\\"5\\\", 3467], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"SART\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": true, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"SART\\\", \\\"9.3.2.10.1\\\", \\\"5\\\", 3468], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"The SART provides a measure of vigilance and sustained attention.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"SART\\\", \\\"9.3.2.10.1\\\", \\\"5\\\", 3469], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"A number ranging from 1 to 9 is presented on screen.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"SART\\\", \\\"9.3.2.10.1\\\", \\\"5\\\", 3470], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"The subject must press a predetermined button as soon as the number is presented, except when the number is a 3.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"SART\\\", \\\"9.3.2.10.1\\\", \\\"5\\\", 3471], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"The number 3 is the default number (no-go stimulus) for which a response should be inhibited, and the subject should not press the predetermined button.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"SART\\\", \\\"9.3.2.10.1\\\", \\\"5\\\", 3472], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"The no-go stimulus can be configured to be a number other than 3.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"SART\\\", \\\"9.3.2.10.1\\\", \\\"5\\\", 3473], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Performance is measured by calculating the number of errors made during the test over the course of 225 trials.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"SART\\\", \\\"9.3.2.10.1\\\", \\\"5\\\", 3474], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Performance is measured by calculating the error score, which is the sum of trials where a response was provided when a 3 was presented and trials where no response was provided when a number other than 3 was presented.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"SART\\\", \\\"9.3.2.10.1\\\", \\\"5\\\", 3475], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"The duration of the test is 5 minutes 30 seconds.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"SART\\\", \\\"9.3.2.10.1\\\", \\\"5\\\", 3476], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"9.3.2.10.2\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": true, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"CPAL\\\", \\\"9.3.2.10.2\\\", \\\"5\\\", 3477], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": true, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"CPAL\\\", \\\"9.3.2.10.2\\\", \\\"5\\\", 3478], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"CPAL\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"CPAL\\\", \\\"9.3.2.10.2\\\", \\\"5\\\", 3479], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"The CPAL test is a measure of visual associate memory and uses a well-validated paired associate learning paradigm in which the subject must learn the locations of a number of amoeba-like shapes on the computer screen.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"CPAL\\\", \\\"9.3.2.10.2\\\", \\\"5\\\", 3480], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"This test consists of a single amoeboid shape displayed in the center of the screen surrounded by a number of blue-filled circles.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"CPAL\\\", \\\"9.3.2.10.2\\\", \\\"5\\\", 3481], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"In the exposure phase of the test all of the to-be-remembered pattern-location associations are presented on the computer screen simultaneously.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"CPAL\\\", \\\"9.3.2.10.2\\\", \\\"5\\\", 3482], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"After a 5 second delay, a pattern is shown in the central location and this signals that the subject should touch the location in the periphery that contains the same pattern.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"CPAL\\\", \\\"9.3.2.10.2\\\", \\\"5\\\", 3483], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"This process continues until the participant has acknowledged all of the pattern-location associations.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"CPAL\\\", \\\"9.3.2.10.2\\\", \\\"5\\\", 3484], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"The learning phase begins with the same test display presented during the exposure phase except that now all of the peripheral locations are shown as blue spheres.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"CPAL\\\", \\\"9.3.2.10.2\\\", \\\"5\\\", 3485], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"One of the patterns presented in the exposure phase is presented in the center location.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"CPAL\\\", \\\"9.3.2.10.2\\\", \\\"5\\\", 3486], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"With the presentation of this pattern, the subject is required to select the peripheral location where an identical pattern is hidden beneath the blue sphere.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"CPAL\\\", \\\"9.3.2.10.2\\\", \\\"5\\\", 3487], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"This process continues until the correct location of each pattern is found. Finding the correct location for all patterns in the set is defined as a learning trial.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"CPAL\\\", \\\"9.3.2.10.2\\\", \\\"5\\\", 3488], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"The software records each move as an error or as a correct move.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"CPAL\\\", \\\"9.3.2.10.2\\\", \\\"5\\\", 3489], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Duration of Test: 7 minutes.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"CPAL\\\", \\\"9.3.2.10.2\\\", \\\"5\\\", 3490], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"9.3.2.11 Pilot NT1 Items\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading5\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Pilot NT1 Items\\\", \\\"9.3.2.11\\\", \\\"4\\\", 3491], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"The Pilot NT1 Items are self-reported assessments, comprised of questions that evaluate symptoms and impacts on daily functioning.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Pilot NT1 Items\\\", \\\"9.3.2.11\\\", \\\"4\\\", 3492], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"These include the NT1 \\\\u2018pentad\\\\u2019 of symptoms (EDS, cataplexy, DNS, hypnagogic hallucinations, and sleep paralysis); fatigue and the impact of fatigue on daily function; subjective cognitive symptoms and impacts; and, impact on work/school, social relationships, physical activities, and emotions.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Pilot NT1 Items\\\", \\\"9.3.2.11\\\", \\\"4\\\", 3493], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Items assessing fatigue are from the\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Pilot NT1 Items\\\", \\\"9.3.2.11\\\", \\\"4\\\", 3494], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Patient-Reported Outcomes Measurement Information System (PROMIS) Fatigue Item Bank\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Pilot NT1 Items\\\", \\\"9.3.2.11\\\", \\\"4\\\", 3495], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"[13,14]; all other items are de novo, based on qualitative research with subjects with NT1.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Pilot NT1 Items\\\", \\\"9.3.2.11\\\", \\\"4\\\", 3496], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"The Pilot NT1 Items will be used to help inform the development and validation of a new NT1 patient reported outcome scale.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Pilot NT1 Items\\\", \\\"9.3.2.11\\\", \\\"4\\\", 3497], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Only PROMIS fatigue items are culturally validated for languages other than English, all other de novo items are not validated for other languages.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Pilot NT1 Items\\\", \\\"9.3.2.11\\\", \\\"4\\\", 3498], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Hence, only PROMIS fatigue items will be administered to non-English speaking subjects, as applicable.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Pilot NT1 Items\\\", \\\"9.3.2.11\\\", \\\"4\\\", 3499], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Once appropriate steps such as translation and cultural validation completes and items are available, those items may be added accordingly in the respective countries.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Pilot NT1 Items\\\", \\\"9.3.2.11\\\", \\\"4\\\", 3500], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Only PROMIS fatigue items will be administered for the remaining countries, as applicable.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Pilot NT1 Items\\\", \\\"9.3.2.11\\\", \\\"4\\\", 3501], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"9.3.2.12 EQ-5D-5L Health-Related QOL Utility Scale\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading5\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"EQ-5D-5L Health-Related QOL Utility Scale\\\", \\\"9.3.2.12\\\", \\\"4\\\", 3502], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"The EQ-5D-5L is a brief 5-item participant-completed visual analog scale (VAS) that provides standardized health economic evaluation data relevant to treatment response.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"EQ-5D-5L Health-Related QOL Utility Scale\\\", \\\"9.3.2.12\\\", \\\"4\\\", 3503], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"EQ-5D-5L is an instrument developed by the EuroQol Group as a measure of health-related QOL that has been used in a wide range of health conditions and treatments[15], [16].\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"EQ-5D-5L Health-Related QOL Utility Scale\\\", \\\"9.3.2.12\\\", \\\"4\\\", 3504], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"The EQ-5D-5L consists of a descriptive system and the EuroQoL Visual Analogue Scale (EQ VAS).\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"EQ-5D-5L Health-Related QOL Utility Scale\\\", \\\"9.3.2.12\\\", \\\"4\\\", 3505], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"The descriptive system comprises 5 dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"EQ-5D-5L Health-Related QOL Utility Scale\\\", \\\"9.3.2.12\\\", \\\"4\\\", 3506], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"The EQ VAS records the subject\\\\u2019s self-rated health on a vertical VAS.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"EQ-5D-5L Health-Related QOL Utility Scale\\\", \\\"9.3.2.12\\\", \\\"4\\\", 3507], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"This can be used as a quantitative measure of health outcome that reflects the subject\\\\u2019s own judgment.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"EQ-5D-5L Health-Related QOL Utility Scale\\\", \\\"9.3.2.12\\\", \\\"4\\\", 3508], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"The scores on these 5 dimensions can be presented as a health profile or can be converted to a single summary index number (utility) reflecting preferability compared with other health profiles.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"EQ-5D-5L Health-Related QOL Utility Scale\\\", \\\"9.3.2.12\\\", \\\"4\\\", 3509], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"9.3.3 Exploratory Biomarker Research\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading3\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Exploratory Biomarker Research\\\", \\\"9.3.3\\\", \\\"3\\\", 3510], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"9.3.3.1 Exploratory Plasma Biomarker Research\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading5\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Exploratory Plasma Biomarker Research\\\", \\\"9.3.3.1\\\", \\\"4\\\", 3511], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Exploratory biomarkers for the assessment of OX-related biomarkers in plasma neuronally derived exosomes may be assessed in healthy subjects and subjects with NT1.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Exploratory Plasma Biomarker Research\\\", \\\"9.3.3.1\\\", \\\"4\\\", 3512], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Neuronally derived exosomes will be isolated and enriched from plasma samples in all cohorts involving repeated multiple dosing.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Exploratory Plasma Biomarker Research\\\", \\\"9.3.3.1\\\", \\\"4\\\", 3513], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"OX messenger RNA (mRNA) and protein levels as well as OX2R and OX1R mRNA expression levels may be quantified in lysates from the neuronally derived exosomes.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Exploratory Plasma Biomarker Research\\\", \\\"9.3.3.1\\\", \\\"4\\\", 3514], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"After the conclusion of the study, the relationship between OX and OX receptor expression levels and efficacy may be evaluated.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Exploratory Plasma Biomarker Research\\\", \\\"9.3.3.1\\\", \\\"4\\\", 3515], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"9.3.3.2 ~REDACTED~ OX Measurements\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading6\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"CSF OX Measurements\\\", \\\"9.3.3.2\\\", \\\"4\\\", 3516], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"In addition, OX levels over the course of the day will also be measured in the CSF of healthy adults (Part F) and subjects with NT1 (Part D) to obtain a greater understanding of the circadian variation in OX levels as well as the potential effect of TAK-861 on this diurnal variation.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"CSF OX Measurements\\\", \\\"9.3.3.2\\\", \\\"4\\\", 3517], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Samples will be collected by trained personnel at the clinical site per their standard operating procedure.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"CSF OX Measurements\\\", \\\"9.3.3.2\\\", \\\"4\\\", 3518], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"9.3.3.3 Future Biomedical Research (Unplanned Exploratory Biomarker Research)\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading6\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Future Biomedical Research (Unplanned Exploratory Biomarker Research)\\\", \\\"9.3.3.3\\\", \\\"4\\\", 3519], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"The retained materials of measurement samples may be used for exploratory use (eg, metabolite scouting) and measured if needed in the case of unidentified metabolites and for the purpose of exploratory biomarkers.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Future Biomedical Research (Unplanned Exploratory Biomarker Research)\\\", \\\"9.3.3.3\\\", \\\"4\\\", 3520], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"9.3.3.4 DNA Analysis Measurements\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading6\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"DNA Analysis Measurements\\\", \\\"9.3.3.4\\\", \\\"4\\\", 3521], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Blood samples for DNA will be collected to identify biomarkers that are predictive of efficacy, resistance to and or safety of treatment with TAK-861 and for genotyping variations in genes encoding drug metabolizing enzymes or drug transporters that might be implicated in TAK-861 disposition.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"DNA Analysis Measurements\\\", \\\"9.3.3.4\\\", \\\"4\\\", 3522], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"9.3.4 Confinement\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading4\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Confinement\\\", \\\"9.3.4\\\", \\\"3\\\", 3523], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Subjects in each study part will report to the clinical site at check-in and will leave after completion of all study-related procedures on the days specified in the relevant Schedule of Study Procedures (Section 3.0).\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Confinement\\\", \\\"9.3.4\\\", \\\"3\\\", 3524], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"At the discretion of the investigator, subjects may be requested to remain in the clinical site longer.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Confinement\\\", \\\"9.3.4\\\", \\\"3\\\", 3525], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Subjects may check-in earlier than scheduled depending on each subject availability for timing of study assessments.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Confinement\\\", \\\"9.3.4\\\", \\\"3\\\", 3526], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Considering the nature of this study that has scheduled confinement period, above possible extension of the confinement period in the study sites may occur by the investigator\\\\u2019s discretion and this extension will be considered as a part of planned confinement period of the study.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Confinement\\\", \\\"9.3.4\\\", \\\"3\\\", 3527], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"In Part D, as needed subjects may be allowed to be confined either from earlier than planned or to stay longer than the Schedule of Study Procedure requires (eg, entire treatment period of the study), to ensure the subject safety throughout the study period including the washout period based on investigator\\\\u2019s discretion.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Confinement\\\", \\\"9.3.4\\\", \\\"3\\\", 3528], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"For the first 4 subjects of the first cohort who will be enrolled in Part D, subjects need to stay in clinic from Day -2 to Day 7.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Confinement\\\", \\\"9.3.4\\\", \\\"3\\\", 3529], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"10.0 ADVERSE EVENTS\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading1\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"ADVERSE EVENTS\\\", \\\"10.0\\\", \\\"1\\\", 3530], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"10.1 Definitions and Elements of AEs\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading2\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Definitions and Elements of AEs\\\", \\\"10.1\\\", \\\"2\\\", 3531], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"An AE is defined as any untoward medical occurrence in a clinical investigation subject who has signed informed consent to participate in a study; it does not necessarily have to have a causal relationship with the treatment.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Definitions and Elements of AEs\\\", \\\"10.1\\\", \\\"2\\\", 3532], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"An AE can therefore be any unfavorable and unintended sign (eg, a clinically significant abnormal laboratory finding), symptom, or disease temporally associated with the use of a drug, whether or not it is considered related to the drug.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Definitions and Elements of AEs\\\", \\\"10.1\\\", \\\"2\\\", 3533], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"An untoward finding generally may:\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Definitions and Elements of AEs\\\", \\\"10.1\\\", \\\"2\\\", 3534], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\\u2022 Indicate a new diagnosis or unexpected worsening of a preexisting condition.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Definitions and Elements of AEs\\\", \\\"10.1\\\", \\\"2\\\", 3535], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"(Intermittent events for pre-existing conditions or underlying disease should not be considered AEs.)\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Definitions and Elements of AEs\\\", \\\"10.1\\\", \\\"2\\\", 3536], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Segoe UI Symbol\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Definitions and Elements of AEs\\\", \\\"10.1\\\", \\\"2\\\", 3537], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Necessitate therapeutic intervention.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Definitions and Elements of AEs\\\", \\\"10.1\\\", \\\"2\\\", 3538], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\\u2022 Require an invasive diagnostic procedure.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Definitions and Elements of AEs\\\", \\\"10.1\\\", \\\"2\\\", 3539], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\\u2022 Require discontinuation or a change in dose of study medication or a concomitant medication.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Definitions and Elements of AEs\\\", \\\"10.1\\\", \\\"2\\\", 3540], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\\u2022 Be considered unfavorable by the investigator for any reason.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Definitions and Elements of AEs\\\", \\\"10.1\\\", \\\"2\\\", 3541], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Diagnoses versus signs and symptoms:\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Definitions and Elements of AEs\\\", \\\"10.1\\\", \\\"2\\\", 3542], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\\u2022 Each event should be recorded to represent a single diagnosis.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Definitions and Elements of AEs\\\", \\\"10.1\\\", \\\"2\\\", 3543], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Accompanying signs (including abnormal laboratory values or ECG findings) or symptoms should NOT be recorded as additional AEs.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Definitions and Elements of AEs\\\", \\\"10.1\\\", \\\"2\\\", 3544], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"If a diagnosis is unknown, sign(s) or symptom(s) should be recorded appropriately as an AE(s).\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Definitions and Elements of AEs\\\", \\\"10.1\\\", \\\"2\\\", 3545], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Laboratory values and ECG findings:\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Definitions and Elements of AEs\\\", \\\"10.1\\\", \\\"2\\\", 3546], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\\u2022 Changes in laboratory values or ECG parameters maybe considered AEs if they are judged to be clinically significant (ie, if some action or intervention is required or if the investigator judges the change to be beyond the range of normal physiologic fluctuation).\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Definitions and Elements of AEs\\\", \\\"10.1\\\", \\\"2\\\", 3547], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"A laboratory re-test and/or continued monitoring of an abnormal value are not considered an intervention.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Definitions and Elements of AEs\\\", \\\"10.1\\\", \\\"2\\\", 3548], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"In addition, repeated or additional noninvasive testing for verification, evaluation or monitoring of an abnormality is not considered an intervention.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Definitions and Elements of AEs\\\", \\\"10.1\\\", \\\"2\\\", 3549], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\\u2022 If abnormal laboratory values or ECG findings are the result of pathology for which there is an overall diagnosis (eg, increased creatinine in renal failure), the diagnosis only should be reported appropriately as an AE.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Definitions and Elements of AEs\\\", \\\"10.1\\\", \\\"2\\\", 3550], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Pre-existing conditions:\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Definitions and Elements of AEs\\\", \\\"10.1\\\", \\\"2\\\", 3551], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\\u2022 A pre-existing condition (present at the time of signing of informed consent) is considered a concurrent medical history condition and should NOT be recorded as an AE.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Definitions and Elements of AEs\\\", \\\"10.1\\\", \\\"2\\\", 3552], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"A baseline evaluation (eg, laboratory test, ECG, x-ray) should NOT be recorded as an AE unless related to a study procedure.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Definitions and Elements of AEs\\\", \\\"10.1\\\", \\\"2\\\", 3553], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"However, if the subject experiences a worsening or complication of such a concurrent medical history condition, the worsening or complication should be recorded appropriately as an AE (worsening or complication occurs after informed consent is signed).\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Definitions and Elements of AEs\\\", \\\"10.1\\\", \\\"2\\\", 3554], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Investigators should ensure that the event term recorded captures the change in the condition (eg, \\\\u201cworsening of\\\\u2026\\\\u201d).\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Definitions and Elements of AEs\\\", \\\"10.1\\\", \\\"2\\\", 3555], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\\u2022 If a subject has a pre-existing episodic condition (eg, asthma, epilepsy), any occurrence of an episode should only be captured as an AE if the episodes become more frequent, serious, or severe in nature, that is, investigators should ensure that the AE term recorded captures the change from baseline in the condition (eg \\\\u201cworsening of\\\\u2026\\\\u201d).\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Definitions and Elements of AEs\\\", \\\"10.1\\\", \\\"2\\\", 3556], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\\u2022 If a subject has a degenerative concurrent condition (eg, cataracts, rheumatoid arthritis), worsening of the condition should only be captured as an AE if occurring to a greater extent to that which would be expected.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Definitions and Elements of AEs\\\", \\\"10.1\\\", \\\"2\\\", 3557], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Again, investigators should ensure that the AE term recorded captures the change in the condition (eg, \\\\u201cworsening of\\\\u2026\\\\u201d).\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Definitions and Elements of AEs\\\", \\\"10.1\\\", \\\"2\\\", 3558], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Worsening of AEs:\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Definitions and Elements of AEs\\\", \\\"10.1\\\", \\\"2\\\", 3559], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\\u2022 If the subject experiences a worsening or complication of an AE after the first administration of study medication or after any change in study medication, the worsening or complication should be recorded as a new AE.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Definitions and Elements of AEs\\\", \\\"10.1\\\", \\\"2\\\", 3560], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Investigators should ensure that the AE term recorded captures the change in the condition (eg, \\\\u201cworsening of\\\\u2026\\\\u201d).\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Definitions and Elements of AEs\\\", \\\"10.1\\\", \\\"2\\\", 3561], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Changes in severity of AEs:\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Definitions and Elements of AEs\\\", \\\"10.1\\\", \\\"2\\\", 3562], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\\u2022 If the subject experiences a change in the severity of an AE that is not associated with a change in study medication, the event should be captured once with the maximum severity recorded.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Definitions and Elements of AEs\\\", \\\"10.1\\\", \\\"2\\\", 3563], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Preplanned surgeries or procedures:\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Definitions and Elements of AEs\\\", \\\"10.1\\\", \\\"2\\\", 3564], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\\u2022 Preplanned procedures (surgeries or therapies) that were scheduled before signing of informed consent are not considered AEs.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Definitions and Elements of AEs\\\", \\\"10.1\\\", \\\"2\\\", 3565], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"However, if a preplanned procedure is performed early (eg, as an emergency) due to a worsening of the pre-existing condition, the worsening of the condition should be captured appropriately as an AE.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Definitions and Elements of AEs\\\", \\\"10.1\\\", \\\"2\\\", 3566], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Complications resulting from any planned surgery should be reported as AEs.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Definitions and Elements of AEs\\\", \\\"10.1\\\", \\\"2\\\", 3567], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Elective surgeries or procedures:\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Definitions and Elements of AEs\\\", \\\"10.1\\\", \\\"2\\\", 3568], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\\u2022 Elective procedures performed where there is no change in the subject\\\\u2019s medical condition should not be recorded as AEs but should be documented in the subject\\\\u2019s source documents.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Definitions and Elements of AEs\\\", \\\"10.1\\\", \\\"2\\\", 3569], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Complications resulting from an elective surgery should be reported as AEs.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Definitions and Elements of AEs\\\", \\\"10.1\\\", \\\"2\\\", 3570], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Overdose:\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Definitions and Elements of AEs\\\", \\\"10.1\\\", \\\"2\\\", 3571], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\\u2022 An overdose is defined as a known deliberate or accidental administration of investigational drug, to or by a study subject, at a dose above that which is assigned to that individual subject according to the study protocol.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Definitions and Elements of AEs\\\", \\\"10.1\\\", \\\"2\\\", 3572], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"It is up to the investigator or the reporting physician to decide whether a dose is to be considered an overdose, in consultation with the sponsor.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Definitions and Elements of AEs\\\", \\\"10.1\\\", \\\"2\\\", 3573], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\\u2022 All cases of overdose (with or without associated AEs) will be documented on an Overdose page of the eCRF, to capture this important safety information consistently in the database.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Definitions and Elements of AEs\\\", \\\"10.1\\\", \\\"2\\\", 3574], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"AEs associated with an overdose will be documented on AE CRF(s) according to Section 10.0.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Definitions and Elements of AEs\\\", \\\"10.1\\\", \\\"2\\\", 3575], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\\u2022 SAEs of overdose should be reported according to the procedure outlined in Section 10.2.9.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Definitions and Elements of AEs\\\", \\\"10.1\\\", \\\"2\\\", 3576], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\\u2022 In the event of drug overdose, the subject should be treated symptomatically.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Definitions and Elements of AEs\\\", \\\"10.1\\\", \\\"2\\\", 3577], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"10.1.1 SAEs\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading4\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"SAEs\\\", \\\"10.1.1\\\", \\\"3\\\", 3578], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"An SAE is defined as any untoward medical occurrence that at any dose:\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"SAEs\\\", \\\"10.1.1\\\", \\\"3\\\", 3579], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"1. Results in DEATH.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"SAEs\\\", \\\"10.1.1\\\", \\\"3\\\", 3580], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"2. Is LIFE THREATENING.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"SAEs\\\", \\\"10.1.1\\\", \\\"3\\\", 3581], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\\u2022 The term \\\\u201clife threatening\\\\u201d refers to an event in which the subject was at risk of death at the time of the event; it does not refer to an event that hypothetically might have caused death if it were more severe.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"SAEs\\\", \\\"10.1.1\\\", \\\"3\\\", 3582], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"3. Requires inpatient HOSPITALIZATION or prolongation of existing hospitalization.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"SAEs\\\", \\\"10.1.1\\\", \\\"3\\\", 3583], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"4. Results in persistent or significant DISABILITY/INCAPACITY.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"SAEs\\\", \\\"10.1.1\\\", \\\"3\\\", 3584], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"5. Is a CONGENITAL ANOMALY/BIRTH DEFECT.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"SAEs\\\", \\\"10.1.1\\\", \\\"3\\\", 3585], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"6. Is an IMPORTANT MEDICAL EVENT that satisfies any of the following:\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"SAEs\\\", \\\"10.1.1\\\", \\\"3\\\", 3586], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\\u2022 May require intervention to prevent items 1 through 5 above.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"SAEs\\\", \\\"10.1.1\\\", \\\"3\\\", 3587], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\\u2022 May expose the subject to danger, even though the event is not immediately life threatening or fatal or does not result in hospitalization.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"SAEs\\\", \\\"10.1.1\\\", \\\"3\\\", 3588], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\\u2022 Includes any event or synonym described in the ~REDACTED~ Medically Significant AE List (Table 10.a).\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"SAEs\\\", \\\"10.1.1\\\", \\\"3\\\", 3589], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"Table 10.a ~REDACTED~ Medically Significant AE List\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading8\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"a  Takeda Medically Significant AE List\\\", \\\"Table 10.\\\", \\\"2\\\", 3590], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"a  Takeda Medically Significant AE List\\\", \\\"Table 10.\\\", \\\"2\\\", 3591], [\\\"\\\", \\\"Unmapped\\\", \\\"table\\\", {\\\"Table\\\": \\\"<table border=\\\\\\\"1\\\\\\\" class=\\\\\\\"dataframe\\\\\\\">\\\\n  <thead>\\\\n    <tr style=\\\\\\\"text-align: right;\\\\\\\">\\\\n      <th></th>\\\\n      <th>1.0</th>\\\\n      <th>2.0</th>\\\\n    </tr>\\\\n  </thead>\\\\n  <tbody>\\\\n    <tr>\\\\n      <th>0</th>\\\\n      <td></td>\\\\n      <td>Term</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>1</th>\\\\n      <td>Acute respiratory failure/acute respiratory distress syndrome</td>\\\\n      <td>Hepatic necrosis Acute liver failure</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>2</th>\\\\n      <td>Torsade de pointes/ventricular fibrillation/ ventricular tachycardia</td>\\\\n      <td>Anaphylactic shock Acute renal failure</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>3</th>\\\\n      <td>Malignant hypertension</td>\\\\n      <td>Pulmonary hypertension</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>4</th>\\\\n      <td>Convulsive seizures</td>\\\\n      <td>Pulmonary fibrosis</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>5</th>\\\\n      <td>Agranulocytosis</td>\\\\n      <td>Confirmed or suspected endotoxin shock</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>6</th>\\\\n      <td>Aplastic anemia</td>\\\\n      <td>Confirmed or suspected transmission of infectious agent by</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>7</th>\\\\n      <td>Toxic epidermal necrolysis/</td>\\\\n      <td>a medicinal product</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>8</th>\\\\n      <td>Stevens-Johnson syndrome</td>\\\\n      <td>Neuroleptic malignant syndrome/malignant hyperthermia Spontaneous abortion/stillbirth and fetal death</td>\\\\n    </tr>\\\\n  </tbody>\\\\n</table>\\\", \\\"SectionHeaderPrintPage\\\": \\\"113\\\", \\\"TableIndex\\\": \\\"45\\\", \\\"TableName\\\": \\\"Table\\\\u00a010.a Takeda Medically Significant AE List\\\", \\\"Header\\\": [0]}, {\\\"IsBold\\\": true, \\\"font_size\\\": 20, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 20, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"a  Takeda Medically Significant AE List\\\", \\\"Table 10.\\\", \\\"2\\\", 3592], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"AEs that fulfill 1 or more of the serious criteria above are to be considered SAEs and should be reported and followed up in the same manner (see Sections 10.1 and 10.1.1).\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"a  Takeda Medically Significant AE List\\\", \\\"Table 10.\\\", \\\"2\\\", 3593], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"10.1.2 Special Interest AEs\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading4\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Special Interest AEs\\\", \\\"10.1.2\\\", \\\"3\\\", 3594], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"The special interest AEs has not been defined for this study.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Special Interest AEs\\\", \\\"10.1.2\\\", \\\"3\\\", 3595], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"10.2 AE Procedures\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading2\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"AE Procedures\\\", \\\"10.2\\\", \\\"2\\\", 3596], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"10.2.1 Assigning Severity/Intensity of AEs\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading4\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Assigning Severity/Intensity of AEs\\\", \\\"10.2.1\\\", \\\"3\\\", 3597], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"The different categories of severity/intensity are:\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Assigning Severity/Intensity of AEs\\\", \\\"10.2.1\\\", \\\"3\\\", 3598], [\\\"\\\", \\\"Unmapped\\\", \\\"table\\\", {\\\"Table\\\": \\\"<table border=\\\\\\\"1\\\\\\\" class=\\\\\\\"dataframe\\\\\\\">\\\\n  <thead>\\\\n    <tr style=\\\\\\\"text-align: right;\\\\\\\">\\\\n      <th></th>\\\\n      <th>1.0</th>\\\\n      <th>2.0</th>\\\\n    </tr>\\\\n  </thead>\\\\n  <tbody>\\\\n    <tr>\\\\n      <th>0</th>\\\\n      <td>Mild:</td>\\\\n      <td>An AE that is usually transient and may require only minimal treatment or therapeutic intervention. The event does not generally interfere with usual activities of daily living.</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>1</th>\\\\n      <td>Moderate:</td>\\\\n      <td>An AE that is usually alleviated with additional specific therapeutic intervention. The event interferes with usual activities of daily living, causing discomfort but poses no significant or permanent risk of harm to the research participant.</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>2</th>\\\\n      <td>Severe:</td>\\\\n      <td>An AE that interrupts usual activities of daily living, or significantly affects clinical status, or may require intensive therapeutic intervention.</td>\\\\n    </tr>\\\\n  </tbody>\\\\n</table>\\\", \\\"SectionHeaderPrintPage\\\": \\\"114\\\", \\\"TableIndex\\\": \\\"46\\\", \\\"TableName\\\": \\\"10.2.1 Assigning Severity/Intensity of AEs\\\", \\\"Header\\\": []}, {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Assigning Severity/Intensity of AEs\\\", \\\"10.2.1\\\", \\\"3\\\", 3599], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"10.2.2 Assigning Causality of AEs\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading4\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Assigning Causality of AEs\\\", \\\"10.2.2\\\", \\\"3\\\", 3600], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"The relationship of each AE to study medication(s) will be assessed using the following categories:\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Assigning Causality of AEs\\\", \\\"10.2.2\\\", \\\"3\\\", 3601], [\\\"\\\", \\\"Unmapped\\\", \\\"table\\\", {\\\"Table\\\": \\\"<table border=\\\\\\\"1\\\\\\\" class=\\\\\\\"dataframe\\\\\\\">\\\\n  <thead>\\\\n    <tr style=\\\\\\\"text-align: right;\\\\\\\">\\\\n      <th></th>\\\\n      <th>1.0</th>\\\\n      <th>2.0</th>\\\\n    </tr>\\\\n  </thead>\\\\n  <tbody>\\\\n    <tr>\\\\n      <th>0</th>\\\\n      <td>Related:</td>\\\\n      <td>An AE that follows a reasonable temporal sequence from administration of a drug (including the course after withdrawal of the drug), or for which a causal relationship is at least a reasonable possibility, ie, the relationship cannot be ruled out, although factors other than the drug, such as underlying diseases, complications, concomitant drugs and concurrent treatments, may also be responsible.</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>1</th>\\\\n      <td>Not Related:</td>\\\\n      <td>An AE that does not follow a reasonable temporal sequence from administration of a drug and/or that can reasonably be explained by other factors, such as underlying diseases, complications, concomitant medications and concurrent treatments.</td>\\\\n    </tr>\\\\n  </tbody>\\\\n</table>\\\", \\\"SectionHeaderPrintPage\\\": \\\"114\\\", \\\"TableIndex\\\": \\\"47\\\", \\\"TableName\\\": \\\"10.2.2 Assigning Causality of AEs\\\", \\\"Header\\\": []}, {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Assigning Causality of AEs\\\", \\\"10.2.2\\\", \\\"3\\\", 3602], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"10.2.3 Assigning Causality of AEs to Study Procedure\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading4\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Assigning Causality of AEs to Study Procedure\\\", \\\"10.2.3\\\", \\\"3\\\", 3603], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"The causality of each AE to study procedures will be assessed.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Assigning Causality of AEs to Study Procedure\\\", \\\"10.2.3\\\", \\\"3\\\", 3604], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"The causality should be assessed as related if the investigator or subinvestigator considers that there is a reasonable possibility that an event is due to a study procedure.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Assigning Causality of AEs to Study Procedure\\\", \\\"10.2.3\\\", \\\"3\\\", 3605], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Otherwise, the causality should be assessed as not related.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Assigning Causality of AEs to Study Procedure\\\", \\\"10.2.3\\\", \\\"3\\\", 3606], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"10.2.4 Start Date\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading4\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Start Date\\\", \\\"10.2.4\\\", \\\"3\\\", 3607], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"The start date of the AE is the date that the first signs/symptoms were noted by the subject and/or investigator.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Start Date\\\", \\\"10.2.4\\\", \\\"3\\\", 3608], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"10.2.5 End Date\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading4\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"End Date\\\", \\\"10.2.5\\\", \\\"3\\\", 3609], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"The end date of the AE is the date at which the subject recovered, the event resolved but with sequelae, or the subject died.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"End Date\\\", \\\"10.2.5\\\", \\\"3\\\", 3610], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"10.2.6 Pattern of AE (Frequency)\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading4\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"End Date\\\", \\\"10.2.5\\\", \\\"3\\\", 3611], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Episodic AEs (eg, headache) or those that occur repeatedly over a period of consecutive days are intermittent.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"End Date\\\", \\\"10.2.5\\\", \\\"3\\\", 3612], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"All other events are continuous.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"End Date\\\", \\\"10.2.5\\\", \\\"3\\\", 3613], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"10.2.7 Action Taken With Study Treatment\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading4\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Action Taken With Study Treatment\\\", \\\"10.2.7\\\", \\\"3\\\", 3614], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\\u2022 Drug withdrawn: a study medication is stopped due to the particular AE.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Action Taken With Study Treatment\\\", \\\"10.2.7\\\", \\\"3\\\", 3615], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\\u2022 Dose not changed: the particular AE did not require stopping a study medication.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Action Taken With Study Treatment\\\", \\\"10.2.7\\\", \\\"3\\\", 3616], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\\u2022 Unknown: only to be used if it has not been possible to determine what action has been taken.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Action Taken With Study Treatment\\\", \\\"10.2.7\\\", \\\"3\\\", 3617], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\\u2022 Not applicable: a study medication was stopped for a reason other than the particular AE, for example, the study has been terminated, the subject died, dosing with study medication had not yet started or dosing with study medication was already stopped before the onset of the AE.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Action Taken With Study Treatment\\\", \\\"10.2.7\\\", \\\"3\\\", 3618], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\\u2022 Dose reduced: the dose was reduced due to the particular AE.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Action Taken With Study Treatment\\\", \\\"10.2.7\\\", \\\"3\\\", 3619], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\\u2022 Dose increased: the dose was increased due to the particular AE.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Action Taken With Study Treatment\\\", \\\"10.2.7\\\", \\\"3\\\", 3620], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\\u2022 Drug interrupted: the dose was interrupted due to the particular AE.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Action Taken With Study Treatment\\\", \\\"10.2.7\\\", \\\"3\\\", 3621], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"10.2.8 Outcome\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading4\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Outcome\\\", \\\"10.2.8\\\", \\\"3\\\", 3622], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\\u2022 Recovered/resolved: subject returned to first assessment status with respect to the AE.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Outcome\\\", \\\"10.2.8\\\", \\\"3\\\", 3623], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\\u2022 Recovering/resolving: the intensity is lowered by one or more stages: the diagnosis has or signs/symptoms have almost disappeared; the abnormal laboratory value improved, but has not returned to the reference range or to the baseline value; the subject died from a cause other than the particular AE with the condition remaining \\\\u201crecovering/resolving.\\\\u201d\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Outcome\\\", \\\"10.2.8\\\", \\\"3\\\", 3624], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\\u2022 Not recovered/not resolved: there is no change in the diagnosis, signs or symptoms; the intensity of the diagnosis, signs/symptoms or laboratory value on the last day of the observed study period has become worse than when it started; is an irreversible congenital anomaly; the subject died from another cause with the particular AE state remaining \\\\u201cNot recovered/not resolved.\\\\u201d\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Outcome\\\", \\\"10.2.8\\\", \\\"3\\\", 3625], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\\u2022 Recovered/resolved with sequelae: the subject recovered from an acute AE but was left with permanent/significant impairment (eg, recovered from a cardiovascular accident but with some persisting paresis).\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Outcome\\\", \\\"10.2.8\\\", \\\"3\\\", 3626], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\\u2022 Fatal: an AE that is considered as the cause of death.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Outcome\\\", \\\"10.2.8\\\", \\\"3\\\", 3627], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\\u2022 Unknown: the course of the AE cannot be followed up due to hospital change or residence change at the end of the subject\\\\u2019s participation in the study.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Outcome\\\", \\\"10.2.8\\\", \\\"3\\\", 3628], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"10.2.9 Collection and Reporting of AEs, SAEs, Special Interest AEs, and Abnormal LFTs\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading4\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Collection and Reporting of AEs, SAEs, Special Interest AEs, and Abnormal LFTs\\\", \\\"10.2.9\\\", \\\"3\\\", 3629], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"10.2.9.1 Collection Period\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading6\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Collection Period\\\", \\\"10.2.9.1\\\", \\\"4\\\", 3630], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Collection of AEs (ie, AEs, SAEs, special interest AEs, and abnormal LFTs) will commence at the time the subject signs the informed consent.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Collection Period\\\", \\\"10.2.9.1\\\", \\\"4\\\", 3631], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Routine collection of AEs will continue until approximately 30 days after the last dose of investigational product or follow-up visit or early termination visit whenever appropriate.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Collection Period\\\", \\\"10.2.9.1\\\", \\\"4\\\", 3632], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"For subjects who discontinue before the administration of study medication, AEs will be followed until the subject discontinues study participation.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Collection Period\\\", \\\"10.2.9.1\\\", \\\"4\\\", 3633], [\\\"3\\\", \\\"Reporting of SAEs\\\", \\\"header\\\", \\\"10.2.9.2 Reporting AEs\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading6\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Reporting AEs\\\", \\\"10.2.9.2\\\", \\\"4\\\", 3634], [\\\"3\\\", \\\"Reporting of SAEs\\\", \\\"text\\\", \\\"At each study visit, the investigator will assess whether any subjective AEs have occurred.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Reporting AEs\\\", \\\"10.2.9.2\\\", \\\"4\\\", 3635], [\\\"3\\\", \\\"Reporting of SAEs\\\", \\\"text\\\", \\\"A neutral question, such as \\\\u201cHow have you been feeling since your last visit?\\\\u201d may be asked.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Reporting AEs\\\", \\\"10.2.9.2\\\", \\\"4\\\", 3636], [\\\"3\\\", \\\"Reporting of SAEs\\\", \\\"text\\\", \\\"Subjects may report AEs occurring at any other time during the study.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Reporting AEs\\\", \\\"10.2.9.2\\\", \\\"4\\\", 3637], [\\\"3\\\", \\\"Reporting of SAEs\\\", \\\"text\\\", \\\"Subjects experiencing an SAE before the first exposure to investigational product must be monitored until the symptoms subside and any clinically relevant changes in laboratory values have returned to baseline or there is a satisfactory explanation for the change.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Reporting AEs\\\", \\\"10.2.9.2\\\", \\\"4\\\", 3638], [\\\"3\\\", \\\"Reporting of SAEs\\\", \\\"text\\\", \\\"Nonserious AEs that begin before the first exposure to investigational product, related or unrelated to the study procedure, need not be followed-up for the purposes of the protocol.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Reporting AEs\\\", \\\"10.2.9.2\\\", \\\"4\\\", 3639], [\\\"3\\\", \\\"Reporting of SAEs\\\", \\\"text\\\", \\\"All subjects experiencing AEs, whether considered associated with the use of the study medication or not, must be monitored until the symptoms subside and any clinically relevant changes in laboratory values have returned to baseline or until there is a satisfactory explanation for the changes observed.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Reporting AEs\\\", \\\"10.2.9.2\\\", \\\"4\\\", 3640], [\\\"3\\\", \\\"Reporting of SAEs\\\", \\\"text\\\", \\\"All AEs will be documented in the AE page of the eCRF, whether or not the investigator concludes that the event is related to the drug treatment.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Reporting AEs\\\", \\\"10.2.9.2\\\", \\\"4\\\", 3641], [\\\"3\\\", \\\"Reporting of SAEs\\\", \\\"text\\\", \\\"The following information will be documented for each event:\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Reporting AEs\\\", \\\"10.2.9.2\\\", \\\"4\\\", 3642], [\\\"3\\\", \\\"Reporting of SAEs\\\", \\\"text\\\", \\\"\\\\u2022 Event term.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Reporting AEs\\\", \\\"10.2.9.2\\\", \\\"4\\\", 3643], [\\\"3\\\", \\\"Reporting of SAEs\\\", \\\"text\\\", \\\"\\\\u2022 Start and end date and time.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Reporting AEs\\\", \\\"10.2.9.2\\\", \\\"4\\\", 3644], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\\u2022 Pattern of AE (frequency).\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Pattern of AE (frequency).\\\", \\\"10.2.6\\\", \\\"3\\\", 3645], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\\u2022 Severity/intensity.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Pattern of AE (frequency).\\\", \\\"10.2.6\\\", \\\"3\\\", 3646], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\\u2022 Causality (investigator\\\\u2019s opinion of the causal relationship between the event and administration of study ~REDACTED~).\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Pattern of AE (frequency).\\\", \\\"10.2.6\\\", \\\"3\\\", 3647], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\\u2022 Investigators\\\\u2019 opinion of the causal relationship between the event and the study procedure(s) (The details of study procedure(s) that may cause the event should also be provided; see Section 10.2.3).\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Pattern of AE (frequency).\\\", \\\"10.2.6\\\", \\\"3\\\", 3648], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\\u2022 Action taken with study drug.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Pattern of AE (frequency).\\\", \\\"10.2.6\\\", \\\"3\\\", 3649], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\\u2022 Outcome of event.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Pattern of AE (frequency).\\\", \\\"10.2.6\\\", \\\"3\\\", 3650], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\\u2022 Seriousness.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Pattern of AE (frequency).\\\", \\\"10.2.6\\\", \\\"3\\\", 3651], [\\\"3\\\", \\\"Reporting of SAEs\\\", \\\"header\\\", \\\"10.2.9.3 Reporting SAEs\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading6\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Reporting SAEs\\\", \\\"10.2.9.3\\\", \\\"4\\\", 3652], [\\\"3\\\", \\\"Reporting of SAEs\\\", \\\"text\\\", \\\"When an SAE occurs through the AE collection period it should be reported according to the procedure outlined below:\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Reporting SAEs\\\", \\\"10.2.9.3\\\", \\\"4\\\", 3653], [\\\"3\\\", \\\"Reporting of SAEs\\\", \\\"text\\\", \\\"A ~REDACTED~ SAE form must be completed, in English and signed by the investigator immediately or within 24 hours of first onset or notification of the event.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Reporting SAEs\\\", \\\"10.2.9.3\\\", \\\"4\\\", 3654], [\\\"3\\\", \\\"Reporting of SAEs\\\", \\\"text\\\", \\\"The information should be completed as fully as possible but contain, at a minimum:\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Reporting SAEs\\\", \\\"10.2.9.3\\\", \\\"4\\\", 3655], [\\\"3\\\", \\\"Reporting of SAEs\\\", \\\"text\\\", \\\"\\\\u2022 A short description of the event and the reason why the event is categorized as serious.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Reporting SAEs\\\", \\\"10.2.9.3\\\", \\\"4\\\", 3656], [\\\"3\\\", \\\"Reporting of SAEs\\\", \\\"text\\\", \\\"\\\\u2022 Subject identification number.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Reporting SAEs\\\", \\\"10.2.9.3\\\", \\\"4\\\", 3657], [\\\"3\\\", \\\"Reporting of SAEs\\\", \\\"text\\\", \\\"\\\\u2022 Investigator\\\\u2019s name.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Reporting SAEs\\\", \\\"10.2.9.3\\\", \\\"4\\\", 3658], [\\\"3\\\", \\\"Reporting of SAEs\\\", \\\"text\\\", \\\"\\\\u2022 Name of the study medication(s).\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Reporting SAEs\\\", \\\"10.2.9.3\\\", \\\"4\\\", 3659], [\\\"3\\\", \\\"Reporting of SAEs\\\", \\\"text\\\", \\\"\\\\u2022 Causality assessment.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Reporting SAEs\\\", \\\"10.2.9.3\\\", \\\"4\\\", 3660], [\\\"3\\\", \\\"Reporting of SAEs\\\", \\\"text\\\", \\\"The SAE form should be transmitted within 24 hours to the attention of the contact listed in Appendix 14.1.1.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Reporting SAEs\\\", \\\"10.2.9.3\\\", \\\"4\\\", 3661], [\\\"3\\\", \\\"Reporting of SAEs\\\", \\\"text\\\", \\\"Any SAE spontaneously reported to the investigator following the AE collection period should be reported to the sponsor if considered related to study participation.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Reporting SAEs\\\", \\\"10.2.9.3\\\", \\\"4\\\", 3662], [\\\"3\\\", \\\"Reporting of SAEs\\\", \\\"text\\\", \\\"Reporting of SAEs that begin before first administration of investigational product will follow the same procedure for SAEs occurring on treatment.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Reporting SAEs\\\", \\\"10.2.9.3\\\", \\\"4\\\", 3663], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"10.2.9.3.1\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": true, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"SAE Follow-up\\\", \\\"10.2.9.3.1\\\", \\\"5\\\", 3664], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": true, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"SAE Follow-up\\\", \\\"10.2.9.3.1\\\", \\\"5\\\", 3665], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"SAE Follow-up\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": true, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"SAE Follow-up\\\", \\\"10.2.9.3.1\\\", \\\"5\\\", 3666], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"If information is not available at the time of the first report becomes available at a later date, the investigator should complete a follow-up SAE form or provide other written documentation and fax it immediately within 24 hours of receipt.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"SAE Follow-up\\\", \\\"10.2.9.3.1\\\", \\\"5\\\", 3667], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Copies of any relevant data from the hospital notes (eg, ECGs, laboratory tests, discharge summary, postmortem results) should be sent to the addressee, if requested.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"SAE Follow-up\\\", \\\"10.2.9.3.1\\\", \\\"5\\\", 3668], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"All SAEs should be followed up until resolution or permanent outcome of the event.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"SAE Follow-up\\\", \\\"10.2.9.3.1\\\", \\\"5\\\", 3669], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"The timelines and procedure for follow-up reports are the same as those for the initial report.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"SAE Follow-up\\\", \\\"10.2.9.3.1\\\", \\\"5\\\", 3670], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"10.2.9.4 Reporting of Abnormal LFTs\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading6\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Reporting of Abnormal LFTs\\\", \\\"10.2.9.4\\\", \\\"4\\\", 3671], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"If a subject is noted to have ALT or AST elevated >3 \\\\u00d7 ULN on 2 consecutive occasions, the abnormality should be recorded as an AE.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Reporting of Abnormal LFTs\\\", \\\"10.2.9.4\\\", \\\"4\\\", 3672], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"In addition, an LFT Increases eCRF must be completed providing additional information on relevant recent history, risk factors, clinical signs and symptoms, and results of any additional diagnostic tests performed.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Reporting of Abnormal LFTs\\\", \\\"10.2.9.4\\\", \\\"4\\\", 3673], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"If a subject is noted to have ALT or AST >3 \\\\u00d7 ULN and total bilirubin >2 \\\\u00d7 ULN for which an alternative etiology has not been identified, the event should be recorded as an SAE and reported per Section 10.2.9.3.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Reporting of Abnormal LFTs\\\", \\\"10.2.9.4\\\", \\\"4\\\", 3674], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"The investigator must contact the Medical Monitor for discussion of the relevant subject details and possible alternative etiologies, such as acute viral hepatitis A or B or other acute liver disease.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Reporting of Abnormal LFTs\\\", \\\"10.2.9.4\\\", \\\"4\\\", 3675], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Follow-up laboratory tests as described in Section 9.2.12 must also be performed.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Reporting of Abnormal LFTs\\\", \\\"10.2.9.4\\\", \\\"4\\\", 3676], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"In addition, an LFT Increases eCRF must be completed and transmitted with the ~REDACTED~ SAE form (per Section 10.2.10).\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Reporting of Abnormal LFTs\\\", \\\"10.2.9.4\\\", \\\"4\\\", 3677], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"10.2.10 Safety Reporting to Investigators, IRBs or IECs, and Regulatory Authorities\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading4\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Safety Reporting to Investigators, IRBs or IECs, and Regulatory Authorities\\\", \\\"10.2.10\\\", \\\"3\\\", 3678], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"The sponsor will be responsible for reporting all suspected unexpected serious adverse reactions\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Safety Reporting to Investigators, IRBs or IECs, and Regulatory Authorities\\\", \\\"10.2.10\\\", \\\"3\\\", 3679], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"(SUSARs) and any other applicable SAEs to regulatory authorities, investigators and IRBs or IECs, as applicable, in accordance with national regulations in the countries where the study is conducted.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Safety Reporting to Investigators, IRBs or IECs, and Regulatory Authorities\\\", \\\"10.2.10\\\", \\\"3\\\", 3680], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Relative to the first awareness of the event by/or further provision to the sponsor or sponsor\\\\u2019s designee, SUSARs will be submitted within 7 days for fatal and life-threatening events and 15 days for other serious events, unless otherwise required by national regulations.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Safety Reporting to Investigators, IRBs or IECs, and Regulatory Authorities\\\", \\\"10.2.10\\\", \\\"3\\\", 3681], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"The sponsor will also prepare an expedited report for other safety issues where these might materially alter the current benefit-risk assessment of an investigational medicinal product or that would be sufficient to consider changes in the investigational medicinal products administration or in the overall conduct of the study.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Safety Reporting to Investigators, IRBs or IECs, and Regulatory Authorities\\\", \\\"10.2.10\\\", \\\"3\\\", 3682], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"The investigational site also will forward a copy of all expedited reports to his or her IRB or IEC in accordance with national regulations.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Safety Reporting to Investigators, IRBs or IECs, and Regulatory Authorities\\\", \\\"10.2.10\\\", \\\"3\\\", 3683], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"11.0 STATISTICAL METHODS\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading1\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"STATISTICAL METHODS\\\", \\\"11.0\\\", \\\"1\\\", 3684], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"11.1 Statistical and Analytical Plans\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading2\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Statistical and Analytical Plans\\\", \\\"11.1\\\", \\\"2\\\", 3685], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"A SAP will be prepared and finalized before the first unblinded data review occurs.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Statistical and Analytical Plans\\\", \\\"11.1\\\", \\\"2\\\", 3686], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"This document will provide further details regarding the definition of analysis variables and analysis methodology to address all study objectives.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Statistical and Analytical Plans\\\", \\\"11.1\\\", \\\"2\\\", 3687], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"A blinded data review will be conducted before database lock.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Statistical and Analytical Plans\\\", \\\"11.1\\\", \\\"2\\\", 3688], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"This review will assess the accuracy and completeness of the study database, subject evaluability, and appropriateness of the planned statistical methods.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Statistical and Analytical Plans\\\", \\\"11.1\\\", \\\"2\\\", 3689], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"The planned analyses are described below.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Statistical and Analytical Plans\\\", \\\"11.1\\\", \\\"2\\\", 3690], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Details will be described in the SAP.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Statistical and Analytical Plans\\\", \\\"11.1\\\", \\\"2\\\", 3691], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"The analysis for actigraphy will be described in the biomarker analysis plan.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Statistical and Analytical Plans\\\", \\\"11.1\\\", \\\"2\\\", 3692], [\\\"2\\\", \\\"Analysis Sets\\\", \\\"header\\\", \\\"11.1.1 Analysis Sets\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading4\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Analysis Sets\\\", \\\"11.1.1\\\", \\\"3\\\", 3693], [\\\"2\\\", \\\"Analysis Sets\\\", \\\"text\\\", \\\"The analysis sets defined below are for Part A through Part F.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Analysis Sets\\\", \\\"11.1.1\\\", \\\"3\\\", 3694], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"11.1.1.1 Safety Set\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading6\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Safety Set\\\", \\\"11.1.1.1\\\", \\\"4\\\", 3695], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"The safety set will consist of all subjects who were enrolled and received at least 1 dose of study drug.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Safety Set\\\", \\\"11.1.1.1\\\", \\\"4\\\", 3696], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Subjects in this analysis set will be used for demographic, baseline characteristics, and safety summaries.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Safety Set\\\", \\\"11.1.1.1\\\", \\\"4\\\", 3697], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"11.1.1.2 PK Set\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading6\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"PK Set\\\", \\\"11.1.1.2\\\", \\\"4\\\", 3698], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"The PK analysis set will consist of all subjects who received at least 1 dose of TAK-861 and have at least 1 measurable plasma concentration.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"PK Set\\\", \\\"11.1.1.2\\\", \\\"4\\\", 3699], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"11.1.1.3 PD Set\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading6\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"PD Set\\\", \\\"11.1.1.3\\\", \\\"4\\\", 3700], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"The PD analysis set will consist of all subjects who received at least 1 dose of study drug and have at least 1 evaluable PD endpoint.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"PD Set\\\", \\\"11.1.1.3\\\", \\\"4\\\", 3701], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"11.1.1.4 Full Analysis Set\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading6\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Full Analysis Set\\\", \\\"11.1.1.4\\\", \\\"4\\\", 3702], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"A full analysis set will be used for the analysis of primary endpoints.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Full Analysis Set\\\", \\\"11.1.1.4\\\", \\\"4\\\", 3703], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"11.1.2 Analysis of Demography and Other Baseline Characteristics\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading4\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Analysis of Demography and Other Baseline Characteristics\\\", \\\"11.1.2\\\", \\\"3\\\", 3704], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Demography and other baseline characteristics will be summarized by treatment groups and will be listed.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Analysis of Demography and Other Baseline Characteristics\\\", \\\"11.1.2\\\", \\\"3\\\", 3705], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Data from subjects receiving placebo will be pooled across cohorts.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Analysis of Demography and Other Baseline Characteristics\\\", \\\"11.1.2\\\", \\\"3\\\", 3706], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Descriptive statistics will be used to summarize data for continuous variables like age and weight (N, mean, median, SD, minimum, and maximum) and for categorical variables like sex, ethnicity, and race (number and percentage of subjects within each category).\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Analysis of Demography and Other Baseline Characteristics\\\", \\\"11.1.2\\\", \\\"3\\\", 3707], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Medical history and medication history will be listed by subject.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Analysis of Demography and Other Baseline Characteristics\\\", \\\"11.1.2\\\", \\\"3\\\", 3708], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"11.1.3 PK Analysis\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading4\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"PK Analysis\\\", \\\"11.1.3\\\", \\\"3\\\", 3709], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Individual concentrations of TAK-861 in the plasma and ~REDACTED~ will be presented in a data listing and summarized by study part, dose level and dosage form, day, and nominal sampling time point using descriptive statistics (arithmetic mean, SD, coefficient of variation, median, minimum, maximum, geometric mean, and coefficient variation for geometric mean), as deemed appropriate.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"PK Analysis\\\", \\\"11.1.3\\\", \\\"3\\\", 3710], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Dose proportionality of each formulation will be assessed graphically, and by dosage form if data permit (dose-normalized C\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"PK Analysis\\\", \\\"11.1.3\\\", \\\"3\\\", 3711], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"max\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"subscript\\\"}, \\\"Study Design\\\", \\\"PK Analysis\\\", \\\"11.1.3\\\", \\\"3\\\", 3712], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"and AUC vs dose).\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"PK Analysis\\\", \\\"11.1.3\\\", \\\"3\\\", 3713], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"To assess dose proportionality after single and multiple dosing, a power model or analysis of variance (ANOVA) model will be used.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"PK Analysis\\\", \\\"11.1.3\\\", \\\"3\\\", 3714], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Trough plasma concentrations measured in the MRD part will be summarized to assess steady state.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"PK Analysis\\\", \\\"11.1.3\\\", \\\"3\\\", 3715], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"For the food effect cohorts in Part A, concentrations of TAK-861 in the plasma will be summarized by regimen (fasted or fed) and nominal sampling time using descriptive statistics.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"PK Analysis\\\", \\\"11.1.3\\\", \\\"3\\\", 3716], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"The plasma PK parameters will be summarized for the fasting and fed (standard meal, high-fat meal) conditions.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"PK Analysis\\\", \\\"11.1.3\\\", \\\"3\\\", 3717], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Additionally, exposure parameters (C\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"PK Analysis\\\", \\\"11.1.3\\\", \\\"3\\\", 3718], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"max\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"subscript\\\"}, \\\"Study Design\\\", \\\"PK Analysis\\\", \\\"11.1.3\\\", \\\"3\\\", 3719], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"and AUC) may be dose-normalized as deemed necessary.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"PK Analysis\\\", \\\"11.1.3\\\", \\\"3\\\", 3720], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Individual concentration data and PK parameters will be presented in data listings.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"PK Analysis\\\", \\\"11.1.3\\\", \\\"3\\\", 3721], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"A 1-way ANOVA will be performed on the natural logarithms of TAK-861 C\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"PK Analysis\\\", \\\"11.1.3\\\", \\\"3\\\", 3722], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"max\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"subscript\\\"}, \\\"Study Design\\\", \\\"PK Analysis\\\", \\\"11.1.3\\\", \\\"3\\\", 3723], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"and AUC\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"PK Analysis\\\", \\\"11.1.3\\\", \\\"3\\\", 3724], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\\u221e\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"subscript\\\"}, \\\"Study Design\\\", \\\"PK Analysis\\\", \\\"11.1.3\\\", \\\"3\\\", 3725], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"with values normalized to dose if deemed necessary.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"PK Analysis\\\", \\\"11.1.3\\\", \\\"3\\\", 3726], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"The effect of food on the TAK-861 tablet formulation will be evaluated by the ratio and 90% CI of TAK-861 exposure in the fed versus fasted state.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"PK Analysis\\\", \\\"11.1.3\\\", \\\"3\\\", 3727], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"For the multiple dose parts, an ANOVA model may be used to assess time dependency in the kinetics of plasma TAK-861 after single and 7 to 14 days of dosing.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"PK Analysis\\\", \\\"11.1.3\\\", \\\"3\\\", 3728], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"As data permit, time invariance will be assessed by comparing the AUC\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"PK Analysis\\\", \\\"11.1.3\\\", \\\"3\\\", 3729], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\\u03c4\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"subscript\\\"}, \\\"Study Design\\\", \\\"PK Analysis\\\", \\\"11.1.3\\\", \\\"3\\\", 3730], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"after 7 to 14 days of dosing with the AUC\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"PK Analysis\\\", \\\"11.1.3\\\", \\\"3\\\", 3731], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\\u221e\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"subscript\\\"}, \\\"Study Design\\\", \\\"PK Analysis\\\", \\\"11.1.3\\\", \\\"3\\\", 3732], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"for Day 1, separately for each study part and dose level.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"PK Analysis\\\", \\\"11.1.3\\\", \\\"3\\\", 3733], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"The model will include dose, day, and the interaction of dose level by day as factors with the natural logarithmic AUCs as the response.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"PK Analysis\\\", \\\"11.1.3\\\", \\\"3\\\", 3734], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"For Parts B through E, the intrinsic CYP3A4/5 activity will be evaluated by the ratio of\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"PK Analysis\\\", \\\"11.1.3\\\", \\\"3\\\", 3735], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"4\\\\u03b2-hydroxycholesterol versus cholesterol concentrations.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"PK Analysis\\\", \\\"11.1.3\\\", \\\"3\\\", 3736], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"The observed ratio of hydroxycholesterol over cholesterol and its change from baseline will be summarized by dose and day.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"PK Analysis\\\", \\\"11.1.3\\\", \\\"3\\\", 3737], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"For Parts B and E, the intrinsic OATP1B1/3 activity will be evaluated by the C\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"PK Analysis\\\", \\\"11.1.3\\\", \\\"3\\\", 3738], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"max\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"subscript\\\"}, \\\"Study Design\\\", \\\"PK Analysis\\\", \\\"11.1.3\\\", \\\"3\\\", 3739], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"and AUC\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"PK Analysis\\\", \\\"11.1.3\\\", \\\"3\\\", 3740], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"last\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"subscript\\\"}, \\\"Study Design\\\", \\\"PK Analysis\\\", \\\"11.1.3\\\", \\\"3\\\", 3741], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"of CPI or CPIII.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"PK Analysis\\\", \\\"11.1.3\\\", \\\"3\\\", 3742], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Individual concentration of CPI and CPIII in the plasma will be presented in a data listing and summarized by study part, dose level, day, and nominal sampling time pointing using descriptive statistics, as deemed appropriate.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"PK Analysis\\\", \\\"11.1.3\\\", \\\"3\\\", 3743], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"The calculated C\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"PK Analysis\\\", \\\"11.1.3\\\", \\\"3\\\", 3744], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"max\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"subscript\\\"}, \\\"Study Design\\\", \\\"PK Analysis\\\", \\\"11.1.3\\\", \\\"3\\\", 3745], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"and AUC\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"PK Analysis\\\", \\\"11.1.3\\\", \\\"3\\\", 3746], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"last\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"subscript\\\"}, \\\"Study Design\\\", \\\"PK Analysis\\\", \\\"11.1.3\\\", \\\"3\\\", 3747], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"and their changes from baseline will be summarized by dose and day in each part.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"PK Analysis\\\", \\\"11.1.3\\\", \\\"3\\\", 3748], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Individual TAK-861 urinary excretion data by collection interval will be presented in a data listing.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"PK Analysis\\\", \\\"11.1.3\\\", \\\"3\\\", 3749], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"The amount of TAK-861 excreted in urine will be summarized by dose level at each scheduled sampling interval using descriptive statistics.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"PK Analysis\\\", \\\"11.1.3\\\", \\\"3\\\", 3750], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Urine PK parameters will be tabulated and summarized descriptively.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"PK Analysis\\\", \\\"11.1.3\\\", \\\"3\\\", 3751], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"11.1.4 PD Analysis\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading4\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"PD Analysis\\\", \\\"11.1.4\\\", \\\"3\\\", 3752], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"For Part D, observed MWT, KSS, ESS, WCR, and other PD endpoints, and change from baseline (or shift tables) will be summarized by treatment and overall.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"PD Analysis\\\", \\\"11.1.4\\\", \\\"3\\\", 3753], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Placebo subjects from different cohorts will be pooled together as 1 placebo group.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"PD Analysis\\\", \\\"11.1.4\\\", \\\"3\\\", 3754], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Change from baseline in MWT and ESS scores will be analyzed using linear mixed-effect models for repeated measures.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"PD Analysis\\\", \\\"11.1.4\\\", \\\"3\\\", 3755], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Baseline will be included as a covariate, treatment, time, and treatment by time interaction will be included as fixed factors.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"PD Analysis\\\", \\\"11.1.4\\\", \\\"3\\\", 3756], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Other PD measures will use a similar model if deemed appropriate for the type of data.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"PD Analysis\\\", \\\"11.1.4\\\", \\\"3\\\", 3757], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Bayesian posterior probability of the true drug effect on MWT of >8 minutes, on ESS of >4 points reduction will be calculated given the data from Part D.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"PD Analysis\\\", \\\"11.1.4\\\", \\\"3\\\", 3758], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"11.1.5 PK/PD Analysis\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading4\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"PK/PD Analysis\\\", \\\"11.1.5\\\", \\\"3\\\", 3759], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Exploratory PK/PD analyses may be carried out to assess the relationship between TAK-861 exposure and various PD and safety endpoints.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"PK/PD Analysis\\\", \\\"11.1.5\\\", \\\"3\\\", 3760], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"The PD endpoints include, but not limited to, MWT, KSS, ESS, WCR, and NSF Sleep Diary\\\\u2013Morning.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"PK/PD Analysis\\\", \\\"11.1.5\\\", \\\"3\\\", 3761], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"The safety endpoints include, but not limited to, BP, pulse rate, and Holter ECG parameters.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"PK/PD Analysis\\\", \\\"11.1.5\\\", \\\"3\\\", 3762], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"The exposure metric (eg, instantaneous concentration or cumulative exposure, like AUC) will be appropriately selected based on visual inspection of the relationship as well as the underlying pharmacology.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"PK/PD Analysis\\\", \\\"11.1.5\\\", \\\"3\\\", 3763], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Holter ECG parameters will be extracted, and a separate concentration-QTcF modeling plan will be prepared for further analysis, as data permit.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"PK/PD Analysis\\\", \\\"11.1.5\\\", \\\"3\\\", 3764], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"The results of this analysis will be reported in a stand-alone report.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"PK/PD Analysis\\\", \\\"11.1.5\\\", \\\"3\\\", 3765], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"11.1.6 Safety Analyses\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading4\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Safety Analyses\\\", \\\"11.1.6\\\", \\\"3\\\", 3766], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"All data analyses and summaries will be performed separately for each study part.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Safety Analyses\\\", \\\"11.1.6\\\", \\\"3\\\", 3767], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"All AEs will be coded by System Organ Class and Preferred Term using the Medical Dictionary for Regulatory Activities (MedDRA).\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Safety Analyses\\\", \\\"11.1.6\\\", \\\"3\\\", 3768], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"TEAEs will be summarized in each study part by treatment, for TAK-861 overall, and for each study part, the placebo subjects from each cohort will be pooled together in summary statistics and data analysis.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Safety Analyses\\\", \\\"11.1.6\\\", \\\"3\\\", 3769], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Where appropriate, safety laboratory assessments, vital signs, ECGs, and Holter ECG parameters\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Safety Analyses\\\", \\\"11.1.6\\\", \\\"3\\\", 3770], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"(N, mean, SD, median, minimum, and maximum) will be summarized for baseline, postdose, and change from baseline (or change from time-matched baseline to postdose, if appropriate) by treatment.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Safety Analyses\\\", \\\"11.1.6\\\", \\\"3\\\", 3771], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Subjects meeting markedly abnormal criteria will be listed and summarized.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Safety Analyses\\\", \\\"11.1.6\\\", \\\"3\\\", 3772], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Linear mixed-effect models for the repeated measures will be performed to evaluate the drug effect on clinic BP and pulse rate.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Safety Analyses\\\", \\\"11.1.6\\\", \\\"3\\\", 3773], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"In these analyses, change from time-matched baseline will be the response and baseline, treatment, time point, and the treatment by time point interaction will be the fixed effects.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Safety Analyses\\\", \\\"11.1.6\\\", \\\"3\\\", 3774], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"The relationships between TAK-861 exposure and selected safety measures will be explored graphically, as data permit.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Safety Analyses\\\", \\\"11.1.6\\\", \\\"3\\\", 3775], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Ambulatory BP parameters will be summarized at baseline and scheduled postdose days.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Safety Analyses\\\", \\\"11.1.6\\\", \\\"3\\\", 3776], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Change from baseline will also be summarized.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Safety Analyses\\\", \\\"11.1.6\\\", \\\"3\\\", 3777], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Analysis of covariance or linear mixed-effect model for repeated measures will be used to analyze the drug effect on change from baseline in the ambulatory BP parameters.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Safety Analyses\\\", \\\"11.1.6\\\", \\\"3\\\", 3778], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Unless stated otherwise, baseline for safety parameters is defined as the last measurement collected before study drug administration, and summary statistics will be performed by treatments for observed values and change from baseline if deemed appropriate.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Safety Analyses\\\", \\\"11.1.6\\\", \\\"3\\\", 3779], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Data from subjects receiving placebo will be pooled across cohorts.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Safety Analyses\\\", \\\"11.1.6\\\", \\\"3\\\", 3780], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Shift tables may be provided for appropriate safety assessment.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Safety Analyses\\\", \\\"11.1.6\\\", \\\"3\\\", 3781], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"11.1.6.1 Clinical Laboratory Evaluation\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading6\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Clinical Laboratory Evaluation\\\", \\\"11.1.6.1\\\", \\\"4\\\", 3782], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Safety clinical laboratory evaluation data will be summarized by treatment group, and for TAK-861 overall.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Clinical Laboratory Evaluation\\\", \\\"11.1.6.1\\\", \\\"4\\\", 3783], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Subjects meeting markedly abnormal criteria for safety clinical laboratory assessments will be listed and summarized.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Clinical Laboratory Evaluation\\\", \\\"11.1.6.1\\\", \\\"4\\\", 3784], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"The MAV criteria will be defined in the SAP.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Clinical Laboratory Evaluation\\\", \\\"11.1.6.1\\\", \\\"4\\\", 3785], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"11.1.6.2 Vital Signs and ECG\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading6\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Vital Signs and ECG\\\", \\\"11.1.6.2\\\", \\\"4\\\", 3786], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Where appropriate, BP and safety ECG parameters will be summarized (N, mean, SD, median, minimum, and maximum) for baseline, postdose, and change from baseline (or change from time-matched baseline to postdose, if appropriate) by treatment.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Vital Signs and ECG\\\", \\\"11.1.6.2\\\", \\\"4\\\", 3787], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Linear mixed-effect models for the repeated measures will be performed to evaluate the drug effect on BP using data from inpatient and ABPM.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Vital Signs and ECG\\\", \\\"11.1.6.2\\\", \\\"4\\\", 3788], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"In these analyses, change from time-matched baseline will be the response and baseline, treatment, time point, and the treatment by time point interaction will be the fixed effects.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Vital Signs and ECG\\\", \\\"11.1.6.2\\\", \\\"4\\\", 3789], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"For Part B, D, and E, 24-hour ABPM mean profiles will be plotted at baseline and postdose days by treatment groups.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Vital Signs and ECG\\\", \\\"11.1.6.2\\\", \\\"4\\\", 3790], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"ABPM parameters will be derived from 24-hour ABPM monitoring at baseline and postdose days, such as mean 24-hour BP, day, and nighttime mean BP. Observed values and change from baseline in these parameters will be summarized by treatment groups.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Vital Signs and ECG\\\", \\\"11.1.6.2\\\", \\\"4\\\", 3791], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Change from baseline in these parameters to postdose days will be analyzed using analysis of covariance or linear mixed effect models for repeated measures, as appropriate (details will be described in the SAP).\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Vital Signs and ECG\\\", \\\"11.1.6.2\\\", \\\"4\\\", 3792], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"The effect of TAK-861 on these ABPM parameters will be evaluated through estimates of difference between TAK-861 treatment groups and placebo and 95% CIs.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Vital Signs and ECG\\\", \\\"11.1.6.2\\\", \\\"4\\\", 3793], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"The relationships between TAK-861 exposure and selected safety measures (such as change from baseline in systolic and diastolic BP and HR) will be explored graphically, as data permit.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Vital Signs and ECG\\\", \\\"11.1.6.2\\\", \\\"4\\\", 3794], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Details will be described in the SAP.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Vital Signs and ECG\\\", \\\"11.1.6.2\\\", \\\"4\\\", 3795], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"All other vital signs will be summarized for baseline (predose on Day 1), postdose, and change from baseline by treatment and time, if deemed appropriate.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Vital Signs and ECG\\\", \\\"11.1.6.2\\\", \\\"4\\\", 3796], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"11.1.6.3 Holter ECG\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading6\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Holter ECG\\\", \\\"11.1.6.3\\\", \\\"4\\\", 3797], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Holter ECG monitoring will be obtained according to the Schedule of Study Procedures for applicable study part (Section 3.0).\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Holter ECG\\\", \\\"11.1.6.3\\\", \\\"4\\\", 3798], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Details regarding Holter ECG collection are provided in the Study Procedure Manual.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Holter ECG\\\", \\\"11.1.6.3\\\", \\\"4\\\", 3799], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"ECGs derived from Holter monitoring are not intended to be analyzed for real-time safety monitoring but will be used for future retrospective ECG analyses, unless an earlier analysis is warranted by emerging safety information.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Holter ECG\\\", \\\"11.1.6.3\\\", \\\"4\\\", 3800], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"11.1.6.4 Other Safety Parameters\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading6\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Other Safety Parameters\\\", \\\"11.1.6.4\\\", \\\"4\\\", 3801], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Physical examination findings and C-SSRS data will be presented in the data listings.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Other Safety Parameters\\\", \\\"11.1.6.4\\\", \\\"4\\\", 3802], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"11.1.7 Pharmacogenomics (DNA) Measurement\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading4\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Pharmacogenomics (DNA) Measurement\\\", \\\"11.1.7\\\", \\\"3\\\", 3803], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"The exploratory assay for exosome research may include plasma sampling for exploratory assessment of OX expression in the plasma (exosome research) in all parts except part A.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Pharmacogenomics (DNA) Measurement\\\", \\\"11.1.7\\\", \\\"3\\\", 3804], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"11.2 Interim Analysis and Criteria for Early Termination\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading2\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Interim Analysis and Criteria for Early Termination\\\", \\\"11.2\\\", \\\"2\\\", 3805], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Unblinded analyses may be performed after completion of each Study Part (A, B, C, E, and F) and after each cohort in Part D to evaluate safety and PD of TAK-861 in those parts/cohorts.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Interim Analysis and Criteria for Early Termination\\\", \\\"11.2\\\", \\\"2\\\", 3806], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"The objectives of these analyses are to support further clinical development of the program and to support timely regulatory communication.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Interim Analysis and Criteria for Early Termination\\\", \\\"11.2\\\", \\\"2\\\", 3807], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"11.3 Determination of Sample Size\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading2\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Determination of Sample Size\\\", \\\"11.3\\\", \\\"2\\\", 3808], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"The sample size for each cohort (for Parts A, B, C, E, and F; 8-10 subjects per cohort: 6 active and 2-4 placebo) is typical for FIH SRD/MRD studies investigating safety, tolerability, PK, and PD in healthy subjects.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Determination of Sample Size\\\", \\\"11.3\\\", \\\"2\\\", 3809], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"For Part D, 9 subjects each in Cohorts D1 and D2 will be enrolled to evaluate the safety, tolerability, PK, and PD effects of TAK-861 when multiple doses of TAK-861 are administered orally to subjects with NT1.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Determination of Sample Size\\\", \\\"11.3\\\", \\\"2\\\", 3810], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"These sample sizes are not based on any effect size or obtained by the MWT statistical evidence.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Determination of Sample Size\\\", \\\"11.3\\\", \\\"2\\\", 3811], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"12.0 QUALITY CONTROL AND QUALITY ASSURANCE\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading1\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"QUALITY CONTROL AND QUALITY ASSURANCE\\\", \\\"12.0\\\", \\\"1\\\", 3812], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"12.1 Study-Site Monitoring Visits\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading2\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Study-Site Monitoring Visits\\\", \\\"12.1\\\", \\\"2\\\", 3813], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Monitoring visits to the study site will be made periodically during the study to ensure that all aspects of the protocol are followed.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Study-Site Monitoring Visits\\\", \\\"12.1\\\", \\\"2\\\", 3814], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Source documents will be reviewed for verification of data recorded on the eCRFs.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Study-Site Monitoring Visits\\\", \\\"12.1\\\", \\\"2\\\", 3815], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Source documents are defined as original documents, data, and records.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Study-Site Monitoring Visits\\\", \\\"12.1\\\", \\\"2\\\", 3816], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"The investigator and study site guarantee access to source documents by the sponsor or its designee (contract research organization) and by the IRB or IEC.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Study-Site Monitoring Visits\\\", \\\"12.1\\\", \\\"2\\\", 3817], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"All aspects of the study and its documentation will be subject to review by the sponsor or the sponsor\\\\u2019s designee (as long as blinding is not jeopardized), including but not limited to the Investigator\\\\u2019s Binder, study drug, subject medical records, informed consent documentation, and review of eCRFs and associated source documents.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Study-Site Monitoring Visits\\\", \\\"12.1\\\", \\\"2\\\", 3818], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"It is important that the investigator and other study personnel are available during the monitoring visits and that sufficient time is devoted to the process.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Study-Site Monitoring Visits\\\", \\\"12.1\\\", \\\"2\\\", 3819], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"12.2 Protocol Deviations\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading2\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Protocol Deviations\\\", \\\"12.2\\\", \\\"2\\\", 3820], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"The investigator should not deviate from the protocol, except where necessary to eliminate an immediate hazard to study subjects.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Protocol Deviations\\\", \\\"12.2\\\", \\\"2\\\", 3821], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Should other unexpected circumstances arise that will require deviation from protocol-specified procedures, the investigator should consult with the sponsor or designee (and IRB or IEC, as required) to determine the appropriate course of action.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Protocol Deviations\\\", \\\"12.2\\\", \\\"2\\\", 3822], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"There will be no exemptions (a prospectively approved deviation) from the inclusion or exclusion criteria.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Protocol Deviations\\\", \\\"12.2\\\", \\\"2\\\", 3823], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Significant deviations include, but are not limited to, those that involve fraud or misconduct, increase the health risk to the subject, or confound interpretation of primary study assessment.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Protocol Deviations\\\", \\\"12.2\\\", \\\"2\\\", 3824], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"12.3 Quality Assurance Audits and Regulatory Agency Inspections\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading2\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Quality Assurance Audits and Regulatory Agency Inspections\\\", \\\"12.3\\\", \\\"2\\\", 3825], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"The study site also may be subject to quality assurance audits by the sponsor or designees.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Quality Assurance Audits and Regulatory Agency Inspections\\\", \\\"12.3\\\", \\\"2\\\", 3826], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"In this circumstance, the sponsor-designated auditor will contact the site in advance to arrange an auditing visit.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Quality Assurance Audits and Regulatory Agency Inspections\\\", \\\"12.3\\\", \\\"2\\\", 3827], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"The auditor may ask to visit the facilities where laboratory samples are collected, where the medication is stored and prepared, and any other facility used during the study.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Quality Assurance Audits and Regulatory Agency Inspections\\\", \\\"12.3\\\", \\\"2\\\", 3828], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"In addition, there is the possibility that this study may be inspected by regulatory agencies, including those of foreign governments (eg, the ~REDACTED~, the United Kingdom Medicines and Healthcare products Regulatory Agency, the Pharmaceuticals and Medical Devices Agency of Japan).\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Quality Assurance Audits and Regulatory Agency Inspections\\\", \\\"12.3\\\", \\\"2\\\", 3829], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"If the study site is contacted for an inspection by a regulatory body, the Sponsor should be notified immediately.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Quality Assurance Audits and Regulatory Agency Inspections\\\", \\\"12.3\\\", \\\"2\\\", 3830], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"The investigator guarantees access for quality assurance auditors to all study documents as described in Section 12.1.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Quality Assurance Audits and Regulatory Agency Inspections\\\", \\\"12.3\\\", \\\"2\\\", 3831], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"13.0 ETHICAL ASPECTS OF THE STUDY\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading1\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"ETHICAL ASPECTS OF THE STUDY\\\", \\\"13.0\\\", \\\"1\\\", 3832], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"This study will be conducted with the highest respect for the individual participants (ie, subjects) according to the protocol, the ethical principles that have their origin in the Declaration of Helsinki, and the International Council for Harmonisation (ICH) Harmonised Tripartite Guideline for GCP.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"ETHICAL ASPECTS OF THE STUDY\\\", \\\"13.0\\\", \\\"1\\\", 3833], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Each investigator will conduct the study according to applicable local or regional regulatory requirements and align his or her conduct in accordance with the \\\\u201cResponsibilities of the Investigator\\\\u201d that are listed in Appendix A.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"ETHICAL ASPECTS OF THE STUDY\\\", \\\"13.0\\\", \\\"1\\\", 3834], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"The principles of Helsinki are addressed through the protocol and through appendices containing requirements for informed consent and investigator responsibilities.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"ETHICAL ASPECTS OF THE STUDY\\\", \\\"13.0\\\", \\\"1\\\", 3835], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"13.1 IRB and/or IEC Approval\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading2\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"IRB and/or IEC Approval\\\", \\\"13.1\\\", \\\"2\\\", 3836], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"IRBs and IECs must be constituted according to the applicable state and federal/local requirements of each participating region.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"IRB and/or IEC Approval\\\", \\\"13.1\\\", \\\"2\\\", 3837], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"The sponsor or designee will require documentation noting all names and titles of members who make up the respective IRB or IEC.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"IRB and/or IEC Approval\\\", \\\"13.1\\\", \\\"2\\\", 3838], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"If any member of the IRB or IEC has direct participation in this study, written notification regarding his or her abstinence from voting must also be obtained.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"IRB and/or IEC Approval\\\", \\\"13.1\\\", \\\"2\\\", 3839], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Those Americas sites unwilling to provide names and titles of all members due to privacy and conflict of interest concerns should instead provide a Federal Wide Assurance Number or comparable number assigned by the ~REDACTED~\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"IRB and/or IEC Approval\\\", \\\"13.1\\\", \\\"2\\\", 3840], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"The sponsor or designee will supply relevant documents for submission to the respective IRB or IEC for the protocol\\\\u2019s review and approval.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"IRB and/or IEC Approval\\\", \\\"13.1\\\", \\\"2\\\", 3841], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"This protocol, the Investigator\\\\u2019s Brochure, a copy of the informed consent form, and, if applicable, subject recruitment materials and/or advertisements and other documents required by all applicable laws and regulations, must be submitted to a central or local IRB or IEC for approval.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"IRB and/or IEC Approval\\\", \\\"13.1\\\", \\\"2\\\", 3842], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"The IRB\\\\u2019s or IEC\\\\u2019s written approval of the protocol and subject informed consent must be obtained and submitted to the sponsor or designee before commencement of the study (ie, before shipment of the sponsor-supplied drug or study specific screening activity).\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"IRB and/or IEC Approval\\\", \\\"13.1\\\", \\\"2\\\", 3843], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"The IRB or IEC approval must refer to the study by exact protocol title, number, and version date; identify versions of other documents (eg, informed consent form) reviewed; and state the approval date.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"IRB and/or IEC Approval\\\", \\\"13.1\\\", \\\"2\\\", 3844], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"The sponsor will ship drug/notify site once the sponsor has confirmed the adequacy of site regulatory documentation and, when applicable, the sponsor has received permission from competent authority to begin the study.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"IRB and/or IEC Approval\\\", \\\"13.1\\\", \\\"2\\\", 3845], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Until the site receives drug/notification no protocol activities, including screening, may occur.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"IRB and/or IEC Approval\\\", \\\"13.1\\\", \\\"2\\\", 3846], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Sites must adhere to all requirements stipulated by their respective IRB or IEC.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"IRB and/or IEC Approval\\\", \\\"13.1\\\", \\\"2\\\", 3847], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"This may include notification to the IRB or IEC regarding protocol amendments, updates to the informed consent form, recruitment materials intended for viewing by subjects, local safety reporting requirements, reports and updates regarding the ongoing review of the study at intervals specified by the respective IRB or IEC, and submission of the investigator\\\\u2019s final status report to IRB or IEC.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"IRB and/or IEC Approval\\\", \\\"13.1\\\", \\\"2\\\", 3848], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"All IRB and IEC approvals and relevant documentation for these items must be provided to the sponsor or its designee.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"IRB and/or IEC Approval\\\", \\\"13.1\\\", \\\"2\\\", 3849], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Subject incentives should not exert undue influence for participation.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"IRB and/or IEC Approval\\\", \\\"13.1\\\", \\\"2\\\", 3850], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Payments to subjects must be approved by the IRB or IEC and sponsor.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"IRB and/or IEC Approval\\\", \\\"13.1\\\", \\\"2\\\", 3851], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"13.2 Subject Information, Informed Consent, and Subject Authorization\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading2\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Subject Information, Informed Consent, and Subject Authorization\\\", \\\"13.2\\\", \\\"2\\\", 3852], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Written consent documents will embody the elements of informed consent as described in the Declaration of Helsinki and the ICH Guidelines for GCP and will be in accordance with all applicable laws and regulations.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Subject Information, Informed Consent, and Subject Authorization\\\", \\\"13.2\\\", \\\"2\\\", 3853], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"The informed consent form, subject authorization form (if applicable), and subject information sheet (if applicable) describe the planned and permitted uses, transfers, and disclosures of the subject\\\\u2019s personal and personal health information for purposes of conducting the study.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Subject Information, Informed Consent, and Subject Authorization\\\", \\\"13.2\\\", \\\"2\\\", 3854], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"The informed consent form and the subject information sheet (if applicable) further explain the nature of the study, its objectives, and potential risks and benefits, as well as the date informed consent is given.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Subject Information, Informed Consent, and Subject Authorization\\\", \\\"13.2\\\", \\\"2\\\", 3855], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"The informed consent form will detail the requirements of the participant and the fact that he or she is free to withdraw at any time without giving a reason and without prejudice to his or her further medical care.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Subject Information, Informed Consent, and Subject Authorization\\\", \\\"13.2\\\", \\\"2\\\", 3856], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"The investigator is responsible for the preparation, content, and IRB or IEC approval of the informed consent form and, if applicable, the subject authorization form.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Subject Information, Informed Consent, and Subject Authorization\\\", \\\"13.2\\\", \\\"2\\\", 3857], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"The informed consent form, subject authorization form (if applicable), and subject information sheet (if applicable) must be approved by both the IRB or IEC and the sponsor before use.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Subject Information, Informed Consent, and Subject Authorization\\\", \\\"13.2\\\", \\\"2\\\", 3858], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"The informed consent form, subject authorization form (if applicable), and subject information sheet (if applicable) must be written in a language fully comprehensible to the prospective subject.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Subject Information, Informed Consent, and Subject Authorization\\\", \\\"13.2\\\", \\\"2\\\", 3859], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"It is the responsibility of the investigator to explain the detailed elements of the informed consent form, subject authorization form (if applicable), and subject information sheet (if applicable) to the subject.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Subject Information, Informed Consent, and Subject Authorization\\\", \\\"13.2\\\", \\\"2\\\", 3860], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Information should be given in both oral and written form whenever possible and in the manner deemed appropriate by the IRB or IEC.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Subject Information, Informed Consent, and Subject Authorization\\\", \\\"13.2\\\", \\\"2\\\", 3861], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"In the event the subject is not capable of rendering adequate written informed consent, then the subject\\\\u2019s legally acceptable representative may provide such consent for the subject in accordance with applicable laws and regulations.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Subject Information, Informed Consent, and Subject Authorization\\\", \\\"13.2\\\", \\\"2\\\", 3862], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"The subject, or the subject\\\\u2019s legally acceptable representative, must be given ample opportunity to: (1) inquire about details of the study, and (2) decide whether or not to participate in the study.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Subject Information, Informed Consent, and Subject Authorization\\\", \\\"13.2\\\", \\\"2\\\", 3863], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"If the subject, or the subject\\\\u2019s legally acceptable representative, determines he or she will participate in the study, then the informed consent form and subject authorization form (if applicable) must be signed and dated by the subject, or the subject\\\\u2019s legally acceptable representative, at the time of consent and before the subject entering into the study.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Subject Information, Informed Consent, and Subject Authorization\\\", \\\"13.2\\\", \\\"2\\\", 3864], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"The subject or the subject\\\\u2019s legally acceptable representative should be instructed to sign using their legal names, not nicknames, using blue or black ballpoint ink.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Subject Information, Informed Consent, and Subject Authorization\\\", \\\"13.2\\\", \\\"2\\\", 3865], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"The investigator must also sign and date the informed consent form and subject authorization (if applicable) at the time of consent and before subject entering into the study; however, the sponsor may allow a designee of the investigator to sign to the extent permitted by applicable law.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Subject Information, Informed Consent, and Subject Authorization\\\", \\\"13.2\\\", \\\"2\\\", 3866], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Once signed, the original informed consent form, subject authorization form (if applicable), and subject information sheet (if applicable) will be stored in the investigator\\\\u2019s site file.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Subject Information, Informed Consent, and Subject Authorization\\\", \\\"13.2\\\", \\\"2\\\", 3867], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"The investigator must document the date the subject signs the informed consent in the subject\\\\u2019s medical record.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Subject Information, Informed Consent, and Subject Authorization\\\", \\\"13.2\\\", \\\"2\\\", 3868], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Copies of the signed informed consent form, the signed subject authorization form (if applicable), and subject information sheet (if applicable) shall be given to the subject.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Subject Information, Informed Consent, and Subject Authorization\\\", \\\"13.2\\\", \\\"2\\\", 3869], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"All revised informed consent forms must be reviewed and signed by relevant subjects or the relevant subject\\\\u2019s legally acceptable representative in the same manner as the original informed consent.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Subject Information, Informed Consent, and Subject Authorization\\\", \\\"13.2\\\", \\\"2\\\", 3870], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"The date the revised consent was obtained should be recorded in the subject\\\\u2019s medical record, and the subject should receive a copy of the revised informed consent form.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Subject Information, Informed Consent, and Subject Authorization\\\", \\\"13.2\\\", \\\"2\\\", 3871], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Subjects who consented and provided a pharmacogenomics sample for DNA and RNA analysis can withdraw their consent and request disposal of a stored sample at any time before analysis.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Subject Information, Informed Consent, and Subject Authorization\\\", \\\"13.2\\\", \\\"2\\\", 3872], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Notify sponsor of consent withdrawal.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Subject Information, Informed Consent, and Subject Authorization\\\", \\\"13.2\\\", \\\"2\\\", 3873], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"13.3 Subject Confidentiality\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading2\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Subject Confidentiality\\\", \\\"13.3\\\", \\\"2\\\", 3874], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"The sponsor and designees affirm and uphold the principle of the subject\\\\u2019s right to protection against invasion of privacy.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Subject Confidentiality\\\", \\\"13.3\\\", \\\"2\\\", 3875], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Throughout this study, a subject\\\\u2019s source data will only be linked to the sponsor\\\\u2019s clinical study database or documentation via a unique identification number.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Subject Confidentiality\\\", \\\"13.3\\\", \\\"2\\\", 3876], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"As permitted by all applicable laws and regulations, limited subject attributes, such as sex, age, or date of birth, and subject initials may be used to verify the subject and accuracy of the subject\\\\u2019s unique identification number.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Subject Confidentiality\\\", \\\"13.3\\\", \\\"2\\\", 3877], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"To comply with ICH Guidelines for GCP and to verify compliance with this protocol, the sponsor requires the investigator to permit its monitor or designee\\\\u2019s monitor, representatives from any regulatory authority (eg, ~REDACTED~, Medicines and Healthcare products ~REDACTED~ and Medical Devices Agency), the sponsor\\\\u2019s designated auditors, and the appropriate IRBs and IECs to review the subject\\\\u2019s original medical records (source data or documents), including, but not limited to, laboratory test result reports, ECG reports, admission and discharge summaries for hospital admissions occurring during a subject\\\\u2019s study participation, and autopsy reports.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Subject Confidentiality\\\", \\\"13.3\\\", \\\"2\\\", 3878], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Access to a subject\\\\u2019s original medical records requires the specific authorization of the subject as part of the informed consent process (see Section 13.2).\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Subject Confidentiality\\\", \\\"13.3\\\", \\\"2\\\", 3879], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Copies of any subject source documents that are provided to the sponsor must have certain personally identifiable information removed (ie, subject name, address, and other identifier fields not collected on the subject\\\\u2019s eCRF).\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Subject Confidentiality\\\", \\\"13.3\\\", \\\"2\\\", 3880], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"13.4 Publication, Disclosure, and Clinical Study Registration Policy\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading2\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Publication, Disclosure, and Clinical Study Registration Policy\\\", \\\"13.4\\\", \\\"2\\\", 3881], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"13.4.1 Publication and Disclosure\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading4\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Publication and Disclosure\\\", \\\"13.4.1\\\", \\\"3\\\", 3882], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"The investigator is obliged to provide the sponsor with complete test results and all data derived by the investigator from the study.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Publication and Disclosure\\\", \\\"13.4.1\\\", \\\"3\\\", 3883], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"During and after the study, only the sponsor may make study information available to other study investigators or to regulatory agencies, except as required by law or regulation.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Publication and Disclosure\\\", \\\"13.4.1\\\", \\\"3\\\", 3884], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Except as otherwise allowable in the clinical study site agreement, any public disclosure (including publicly accessible websites) related to the protocol or study results, other than study recruitment materials and/or advertisements, is the sole responsibility of the sponsor.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Publication and Disclosure\\\", \\\"13.4.1\\\", \\\"3\\\", 3885], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"The sponsor may publish any data and information from the study (including data and information generated by the investigator) without the consent of the investigator.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Publication and Disclosure\\\", \\\"13.4.1\\\", \\\"3\\\", 3886], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Manuscript authorship for any peer-reviewed publication will appropriately reflect contributions to the production and review of the document.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Publication and Disclosure\\\", \\\"13.4.1\\\", \\\"3\\\", 3887], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"All publications and presentations must be prepared in accordance with this section and the Clinical Study Site Agreement.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Publication and Disclosure\\\", \\\"13.4.1\\\", \\\"3\\\", 3888], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"In the event of any discrepancy between the protocol and the Clinical Study Site Agreement, the Clinical Study Site Agreement will prevail.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Publication and Disclosure\\\", \\\"13.4.1\\\", \\\"3\\\", 3889], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"13.4.2 Clinical Study Registration\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading4\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Clinical Study Registration\\\", \\\"13.4.2\\\", \\\"3\\\", 3890], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"To ensure that information on clinical studies reaches the public in a timely manner and to comply with applicable laws, regulations and guidance, ~REDACTED~ will, at a minimum register all interventional clinical studies it sponsors anywhere in the world on ClinicalTrials.gov and/or other publicly accessible websites before start of study, as defined in ~REDACTED~ Policy/Standard.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Clinical Study Registration\\\", \\\"13.4.2\\\", \\\"3\\\", 3891], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"~REDACTED~ contact information, along with facility name, investigator\\\\u2019s city, state (for Americas investigators), country, and recruiting status will be registered and available for public viewing.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Clinical Study Registration\\\", \\\"13.4.2\\\", \\\"3\\\", 3892], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"For some registries, ~REDACTED~ will assist callers in locating study sites closest to their homes by providing the investigator name, address, and phone number to the callers requesting study information.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Clinical Study Registration\\\", \\\"13.4.2\\\", \\\"3\\\", 3893], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Once subjects receive investigator contact information, they may call the site requesting enrollment into the study.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Clinical Study Registration\\\", \\\"13.4.2\\\", \\\"3\\\", 3894], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"The investigative sites are encouraged to handle the study inquiries according to their established subject screening process.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Clinical Study Registration\\\", \\\"13.4.2\\\", \\\"3\\\", 3895], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"If the caller asks additional questions beyond the topic of study enrollment, they should be referred to the sponsor.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Clinical Study Registration\\\", \\\"13.4.2\\\", \\\"3\\\", 3896], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Any investigator who objects to the sponsor providing this information to callers must provide the sponsor with a written notice requesting that their information not be listed on the registry site.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Clinical Study Registration\\\", \\\"13.4.2\\\", \\\"3\\\", 3897], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"13.4.3 Clinical Study Results Disclosure\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading4\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Clinical Study Results Disclosure\\\", \\\"13.4.3\\\", \\\"3\\\", 3898], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"~REDACTED~ will post the results of clinical studies on ClinicalTrials.gov or other publicly accessible websites, as required by ~REDACTED~ Policy/Standard, applicable laws and/or regulations.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Clinical Study Results Disclosure\\\", \\\"13.4.3\\\", \\\"3\\\", 3899], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"13.5 Insurance and Compensation for Injury\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading2\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Insurance and Compensation for Injury\\\", \\\"13.5\\\", \\\"2\\\", 3900], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Each subject in the study must be insured in accordance with the regulations applicable to the site where the subject is participating.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Insurance and Compensation for Injury\\\", \\\"13.5\\\", \\\"2\\\", 3901], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"If a local underwriter is required, then the sponsor or sponsor\\\\u2019s designee will obtain clinical study insurance against the risk of injury to study subjects.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Insurance and Compensation for Injury\\\", \\\"13.5\\\", \\\"2\\\", 3902], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Refer to the study site agreement regarding the sponsor\\\\u2019s policy on subject compensation and treatment for injury.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Insurance and Compensation for Injury\\\", \\\"13.5\\\", \\\"2\\\", 3903], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"If the investigator has questions regarding this policy, he or she should contact the sponsor or sponsor\\\\u2019s designee.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Insurance and Compensation for Injury\\\", \\\"13.5\\\", \\\"2\\\", 3904], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"14.0 ADMINISTRATIVE AND REFERENCE INFORMATION\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading1\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"ADMINISTRATIVE AND REFERENCE INFORMATION\\\", \\\"14.0\\\", \\\"1\\\", 3905], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"14.1 Administrative Information\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading2\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Administrative Information\\\", \\\"14.1\\\", \\\"2\\\", 3906], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"14.1.1 Study Contact Information\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading4\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Study Contact Information\\\", \\\"14.1.1\\\", \\\"3\\\", 3907], [\\\"\\\", \\\"Unmapped\\\", \\\"table\\\", {\\\"Table\\\": \\\"<table border=\\\\\\\"1\\\\\\\" class=\\\\\\\"dataframe\\\\\\\">\\\\n  <thead>\\\\n    <tr style=\\\\\\\"text-align: right;\\\\\\\">\\\\n      <th></th>\\\\n      <th>1.0</th>\\\\n      <th>2.0</th>\\\\n    </tr>\\\\n  </thead>\\\\n  <tbody>\\\\n    <tr>\\\\n      <th>0</th>\\\\n      <td>Contact Type / Role</td>\\\\n      <td>Contact</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>1</th>\\\\n      <td>Serious adverse event and pregnancy reporting for the United States</td>\\\\n      <td>Pharmacovigilance Takeda Development Center Americas, Inc.  <span class=\\\\\\\"redact\\\\\\\"> ~REDACTED~ </span> EDACTED~ </span> .</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>2</th>\\\\n      <td><span class=\\\\\\\"redact\\\\\\\"> ~REDACTED~ </span>  class=\\\\\\\"redact\\\\\\\"> ~REDACTED~ </span>  Study Physician</td>\\\\n      <td>X<sup>inlu Du, MD. Medical Director, Clinical Science, Takeda Development Center Asia. 29 F, Wheelock Square, 1717 Nanjing West Road, Jing\\\\u2019an District, Shanghai, 200040, China Tel: +86 21 2225 2968</sup></td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>3</th>\\\\n      <td>Contact information for Japan</td>\\\\n      <td>Please refer protocol annex information.</td>\\\\n    </tr>\\\\n  </tbody>\\\\n</table>\\\", \\\"SectionHeaderPrintPage\\\": \\\"128\\\", \\\"TableIndex\\\": \\\"48\\\", \\\"TableName\\\": \\\"14.1.1 Study Contact Information\\\", \\\"Header\\\": [0]}, {\\\"IsBold\\\": true, \\\"font_size\\\": 20, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 20, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Study Contact Information\\\", \\\"14.1.1\\\", \\\"3\\\", 3908], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Study Contact Information\\\", \\\"14.1.1\\\", \\\"3\\\", 3909], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"14.1.2 INVESTIGATOR AGREEMENT\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading4\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"INVESTIGATOR AGREEMENT\\\", \\\"14.1.2\\\", \\\"3\\\", 3910], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"I confirm that I have read and that I understand this protocol, the Investigator\\\\u2019s Brochure, package insert and any other product information provided by the sponsor.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"INVESTIGATOR AGREEMENT\\\", \\\"14.1.2\\\", \\\"3\\\", 3911], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"I agree to conduct this study in accordance with the requirements of this protocol and also to protect the rights, safety, privacy, and well-being of study subjects in accordance with the following:\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"INVESTIGATOR AGREEMENT\\\", \\\"14.1.2\\\", \\\"3\\\", 3912], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\\u2022 The ethical principles that have their origin in the Declaration of Helsinki.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"INVESTIGATOR AGREEMENT\\\", \\\"14.1.2\\\", \\\"3\\\", 3913], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\\u2022 ICH, E6 GCP: Consolidated Guideline.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"INVESTIGATOR AGREEMENT\\\", \\\"14.1.2\\\", \\\"3\\\", 3914], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\\u2022 All applicable laws and regulations, including, without limitation, data privacy laws and regulations.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"INVESTIGATOR AGREEMENT\\\", \\\"14.1.2\\\", \\\"3\\\", 3915], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\\u2022 Regulatory requirements for reporting SAEs defined in Section 10.2.10 of this protocol.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"INVESTIGATOR AGREEMENT\\\", \\\"14.1.2\\\", \\\"3\\\", 3916], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\\u2022 Terms outlined in the study site agreement.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"INVESTIGATOR AGREEMENT\\\", \\\"14.1.2\\\", \\\"3\\\", 3917], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\\u2022 Responsibilities of the Investigator (Appendix B).\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"INVESTIGATOR AGREEMENT\\\", \\\"14.1.2\\\", \\\"3\\\", 3918], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"I further authorize that my personal information may be processed and transferred in accordance with the uses contemplated in Appendix C of this protocol.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"INVESTIGATOR AGREEMENT\\\", \\\"14.1.2\\\", \\\"3\\\", 3919], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"INVESTIGATOR AGREEMENT\\\", \\\"14.1.2\\\", \\\"3\\\", 3920], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Signature of Investigator\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"INVESTIGATOR AGREEMENT\\\", \\\"14.1.2\\\", \\\"3\\\", 3921], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"INVESTIGATOR AGREEMENT\\\", \\\"14.1.2\\\", \\\"3\\\", 3922], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Date\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"INVESTIGATOR AGREEMENT\\\", \\\"14.1.2\\\", \\\"3\\\", 3923], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"INVESTIGATOR AGREEMENT\\\", \\\"14.1.2\\\", \\\"3\\\", 3924], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Investigator Name (print or type)\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"INVESTIGATOR AGREEMENT\\\", \\\"14.1.2\\\", \\\"3\\\", 3925], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"INVESTIGATOR AGREEMENT\\\", \\\"14.1.2\\\", \\\"3\\\", 3926], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Investigator\\\\u2019s Title\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"INVESTIGATOR AGREEMENT\\\", \\\"14.1.2\\\", \\\"3\\\", 3927], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"INVESTIGATOR AGREEMENT\\\", \\\"14.1.2\\\", \\\"3\\\", 3928], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Location of Facility (City, State/Province)\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"INVESTIGATOR AGREEMENT\\\", \\\"14.1.2\\\", \\\"3\\\", 3929], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"INVESTIGATOR AGREEMENT\\\", \\\"14.1.2\\\", \\\"3\\\", 3930], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Location of Facility (Country)\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"INVESTIGATOR AGREEMENT\\\", \\\"14.1.2\\\", \\\"3\\\", 3931], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"14.1.3 Study-Related Responsibilities\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading4\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Study-Related Responsibilities\\\", \\\"14.1.3\\\", \\\"3\\\", 3932], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"The sponsor will perform all study-related activities with the exception of those identified in the Study-Related Responsibilities template.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Study-Related Responsibilities\\\", \\\"14.1.3\\\", \\\"3\\\", 3933], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"The vendors identified for specific study-related activities will perform these activities in full or in partnership with the sponsor.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Study-Related Responsibilities\\\", \\\"14.1.3\\\", \\\"3\\\", 3934], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"14.1.4 List of Abbreviations\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading4\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"List of Abbreviations\\\", \\\"14.1.4\\\", \\\"3\\\", 3935], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"ABPM\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 20, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 20, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"List of Abbreviations\\\", \\\"14.1.4\\\", \\\"3\\\", 3936], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 20, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 20, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"List of Abbreviations\\\", \\\"14.1.4\\\", \\\"3\\\", 3937], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"ambulatory blood pressure monitoring\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 20, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 20, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"List of Abbreviations\\\", \\\"14.1.4\\\", \\\"3\\\", 3938], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"AE\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 20, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 20, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"List of Abbreviations\\\", \\\"14.1.4\\\", \\\"3\\\", 3939], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 20, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 20, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"List of Abbreviations\\\", \\\"14.1.4\\\", \\\"3\\\", 3940], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"adverse event\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 20, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 20, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"List of Abbreviations\\\", \\\"14.1.4\\\", \\\"3\\\", 3941], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"ALT\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 20, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 20, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"List of Abbreviations\\\", \\\"14.1.4\\\", \\\"3\\\", 3942], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 20, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 20, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"List of Abbreviations\\\", \\\"14.1.4\\\", \\\"3\\\", 3943], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"alanine aminotransferase\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 20, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 20, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"List of Abbreviations\\\", \\\"14.1.4\\\", \\\"3\\\", 3944], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"ANOVA\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 20, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 20, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"List of Abbreviations\\\", \\\"14.1.4\\\", \\\"3\\\", 3945], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 20, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 20, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"List of Abbreviations\\\", \\\"14.1.4\\\", \\\"3\\\", 3946], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"analysis of variance\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 20, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 20, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"List of Abbreviations\\\", \\\"14.1.4\\\", \\\"3\\\", 3947], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"AST\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 20, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 20, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"List of Abbreviations\\\", \\\"14.1.4\\\", \\\"3\\\", 3948], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 20, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 20, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"List of Abbreviations\\\", \\\"14.1.4\\\", \\\"3\\\", 3949], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"aspartate aminotransferase\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 20, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 20, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"List of Abbreviations\\\", \\\"14.1.4\\\", \\\"3\\\", 3950], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"AUC\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 20, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 20, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"List of Abbreviations\\\", \\\"14.1.4\\\", \\\"3\\\", 3951], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 20, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 20, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"List of Abbreviations\\\", \\\"14.1.4\\\", \\\"3\\\", 3952], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"area under the plasma concentration-time curve\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 20, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 20, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"List of Abbreviations\\\", \\\"14.1.4\\\", \\\"3\\\", 3953], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"AUC\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 20, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 20, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"List of Abbreviations\\\", \\\"14.1.4\\\", \\\"3\\\", 3954], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\\u221e\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 10, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"SimSun\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 10, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"List of Abbreviations\\\", \\\"14.1.4\\\", \\\"3\\\", 3955], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 10, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"SimSun\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 10, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"List of Abbreviations\\\", \\\"14.1.4\\\", \\\"3\\\", 3956], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"area under the plasma concentration-time curve from time 0 to infinity\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 20, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 20, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"List of Abbreviations\\\", \\\"14.1.4\\\", \\\"3\\\", 3957], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"AUC\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 20, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 20, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"List of Abbreviations\\\", \\\"14.1.4\\\", \\\"3\\\", 3958], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"24\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 20, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 20, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"subscript\\\"}, \\\"Study Design\\\", \\\"List of Abbreviations\\\", \\\"14.1.4\\\", \\\"3\\\", 3959], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 20, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 20, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"subscript\\\"}, \\\"Study Design\\\", \\\"List of Abbreviations\\\", \\\"14.1.4\\\", \\\"3\\\", 3960], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"area under the plasma concentration-time curve from time 0 to 24 hours\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 20, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 20, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"List of Abbreviations\\\", \\\"14.1.4\\\", \\\"3\\\", 3961], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"AUC\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 20, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 20, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"List of Abbreviations\\\", \\\"14.1.4\\\", \\\"3\\\", 3962], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"last\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 20, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 20, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"subscript\\\"}, \\\"Study Design\\\", \\\"List of Abbreviations\\\", \\\"14.1.4\\\", \\\"3\\\", 3963], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 20, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 20, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"subscript\\\"}, \\\"Study Design\\\", \\\"List of Abbreviations\\\", \\\"14.1.4\\\", \\\"3\\\", 3964], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"area under the plasma concentration-time from time 0 to time of the last quantifiable concentration\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 20, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 20, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"List of Abbreviations\\\", \\\"14.1.4\\\", \\\"3\\\", 3965], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"AUC\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 20, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 20, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"List of Abbreviations\\\", \\\"14.1.4\\\", \\\"3\\\", 3966], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\\u03c4\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 20, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 20, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"subscript\\\"}, \\\"Study Design\\\", \\\"List of Abbreviations\\\", \\\"14.1.4\\\", \\\"3\\\", 3967], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 20, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 20, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"subscript\\\"}, \\\"Study Design\\\", \\\"List of Abbreviations\\\", \\\"14.1.4\\\", \\\"3\\\", 3968], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"area under plasma the concentration-time curve during a dosing interval\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 20, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 20, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"List of Abbreviations\\\", \\\"14.1.4\\\", \\\"3\\\", 3969], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"BMI\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 20, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 20, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"List of Abbreviations\\\", \\\"14.1.4\\\", \\\"3\\\", 3970], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 20, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 20, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"List of Abbreviations\\\", \\\"14.1.4\\\", \\\"3\\\", 3971], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"body mass index\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 20, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 20, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"List of Abbreviations\\\", \\\"14.1.4\\\", \\\"3\\\", 3972], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"BP\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 20, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 20, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"List of Abbreviations\\\", \\\"14.1.4\\\", \\\"3\\\", 3973], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 20, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 20, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"List of Abbreviations\\\", \\\"14.1.4\\\", \\\"3\\\", 3974], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"blood pressure\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 20, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 20, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"List of Abbreviations\\\", \\\"14.1.4\\\", \\\"3\\\", 3975], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"~REDACTED~\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 20, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 20, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"List of Abbreviations\\\", \\\"14.1.4\\\", \\\"3\\\", 3976], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 20, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 20, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"List of Abbreviations\\\", \\\"14.1.4\\\", \\\"3\\\", 3977], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Code of Federal Regulations\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 20, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 20, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"List of Abbreviations\\\", \\\"14.1.4\\\", \\\"3\\\", 3978], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"CGI-I\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 20, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 20, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"List of Abbreviations\\\", \\\"14.1.4\\\", \\\"3\\\", 3979], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 20, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 20, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"List of Abbreviations\\\", \\\"14.1.4\\\", \\\"3\\\", 3980], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Clinical Global Impression of Improvement\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 20, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 20, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"List of Abbreviations\\\", \\\"14.1.4\\\", \\\"3\\\", 3981], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"CGI-S\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 20, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 20, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"List of Abbreviations\\\", \\\"14.1.4\\\", \\\"3\\\", 3982], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 20, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 20, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"List of Abbreviations\\\", \\\"14.1.4\\\", \\\"3\\\", 3983], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Clinical Global Impression of Severity\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 20, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 20, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"List of Abbreviations\\\", \\\"14.1.4\\\", \\\"3\\\", 3984], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"CHO\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 20, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 20, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"List of Abbreviations\\\", \\\"14.1.4\\\", \\\"3\\\", 3985], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 20, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 20, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"List of Abbreviations\\\", \\\"14.1.4\\\", \\\"3\\\", 3986], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Chinese hamster ovary\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 20, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 20, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"List of Abbreviations\\\", \\\"14.1.4\\\", \\\"3\\\", 3987], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"C\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 20, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 20, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"List of Abbreviations\\\", \\\"14.1.4\\\", \\\"3\\\", 3988], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"max\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 20, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 20, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"subscript\\\"}, \\\"Study Design\\\", \\\"List of Abbreviations\\\", \\\"14.1.4\\\", \\\"3\\\", 3989], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 20, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 20, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"subscript\\\"}, \\\"Study Design\\\", \\\"List of Abbreviations\\\", \\\"14.1.4\\\", \\\"3\\\", 3990], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"maximum observed plasma concentration\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 20, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 20, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"List of Abbreviations\\\", \\\"14.1.4\\\", \\\"3\\\", 3991], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"CNS\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 20, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 20, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"List of Abbreviations\\\", \\\"14.1.4\\\", \\\"3\\\", 3992], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 20, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 20, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"List of Abbreviations\\\", \\\"14.1.4\\\", \\\"3\\\", 3993], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"central nervous system\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 20, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 20, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"List of Abbreviations\\\", \\\"14.1.4\\\", \\\"3\\\", 3994], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"COVID-19\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 20, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 20, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"List of Abbreviations\\\", \\\"14.1.4\\\", \\\"3\\\", 3995], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 20, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 20, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"List of Abbreviations\\\", \\\"14.1.4\\\", \\\"3\\\", 3996], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"coronavirus disease 2019\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 20, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 20, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"List of Abbreviations\\\", \\\"14.1.4\\\", \\\"3\\\", 3997], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"CP\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 20, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 20, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"List of Abbreviations\\\", \\\"14.1.4\\\", \\\"3\\\", 3998], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 20, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 20, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"List of Abbreviations\\\", \\\"14.1.4\\\", \\\"3\\\", 3999], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"coproporphyrin\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 20, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 20, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"List of Abbreviations\\\", \\\"14.1.4\\\", \\\"3\\\", 4000], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"CPAL\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 20, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 20, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"List of Abbreviations\\\", \\\"14.1.4\\\", \\\"3\\\", 4001], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 20, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 20, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"List of Abbreviations\\\", \\\"14.1.4\\\", \\\"3\\\", 4002], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Continuous Paired ~REDACTED~ Learning\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 20, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 20, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"List of Abbreviations\\\", \\\"14.1.4\\\", \\\"3\\\", 4003], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"~REDACTED~\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 20, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 20, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"List of Abbreviations\\\", \\\"14.1.4\\\", \\\"3\\\", 4004], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 20, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 20, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"List of Abbreviations\\\", \\\"14.1.4\\\", \\\"3\\\", 4005], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"cerebrospinal fluid\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 20, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 20, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"List of Abbreviations\\\", \\\"14.1.4\\\", \\\"3\\\", 4006], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"C-SSRS\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 20, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 20, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"List of Abbreviations\\\", \\\"14.1.4\\\", \\\"3\\\", 4007], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 20, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 20, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"List of Abbreviations\\\", \\\"14.1.4\\\", \\\"3\\\", 4008], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Columbia\\\\u2013Suicide Severity Rating Scale\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 20, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 20, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"List of Abbreviations\\\", \\\"14.1.4\\\", \\\"3\\\", 4009], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"CYP\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 20, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 20, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"List of Abbreviations\\\", \\\"14.1.4\\\", \\\"3\\\", 4010], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 20, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 20, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"List of Abbreviations\\\", \\\"14.1.4\\\", \\\"3\\\", 4011], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"cytochrome P450\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 20, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 20, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"List of Abbreviations\\\", \\\"14.1.4\\\", \\\"3\\\", 4012], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"DDI\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 20, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 20, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"List of Abbreviations\\\", \\\"14.1.4\\\", \\\"3\\\", 4013], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 20, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 20, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"List of Abbreviations\\\", \\\"14.1.4\\\", \\\"3\\\", 4014], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"drug-drug interaction\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 20, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 20, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"List of Abbreviations\\\", \\\"14.1.4\\\", \\\"3\\\", 4015], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"DNS\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 20, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 20, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"List of Abbreviations\\\", \\\"14.1.4\\\", \\\"3\\\", 4016], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 20, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 20, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"List of Abbreviations\\\", \\\"14.1.4\\\", \\\"3\\\", 4017], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"disturbed nighttime sleep\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 20, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 20, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"List of Abbreviations\\\", \\\"14.1.4\\\", \\\"3\\\", 4018], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"EC\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 20, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 20, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"List of Abbreviations\\\", \\\"14.1.4\\\", \\\"3\\\", 4019], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"50\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 20, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 20, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"subscript\\\"}, \\\"Study Design\\\", \\\"List of Abbreviations\\\", \\\"14.1.4\\\", \\\"3\\\", 4020], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 20, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 20, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"subscript\\\"}, \\\"Study Design\\\", \\\"List of Abbreviations\\\", \\\"14.1.4\\\", \\\"3\\\", 4021], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"half-maximal effective concentration\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 20, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 20, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"List of Abbreviations\\\", \\\"14.1.4\\\", \\\"3\\\", 4022], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"ECG\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 20, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 20, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"List of Abbreviations\\\", \\\"14.1.4\\\", \\\"3\\\", 4023], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 20, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 20, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"List of Abbreviations\\\", \\\"14.1.4\\\", \\\"3\\\", 4024], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"electrocardiogram\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 20, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 20, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"List of Abbreviations\\\", \\\"14.1.4\\\", \\\"3\\\", 4025], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"eCRF\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 20, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 20, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"List of Abbreviations\\\", \\\"14.1.4\\\", \\\"3\\\", 4026], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 20, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 20, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"List of Abbreviations\\\", \\\"14.1.4\\\", \\\"3\\\", 4027], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"electronic case report form EDS\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 20, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 20, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"List of Abbreviations\\\", \\\"14.1.4\\\", \\\"3\\\", 4028], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 20, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 20, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"List of Abbreviations\\\", \\\"14.1.4\\\", \\\"3\\\", 4029], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"excessive daytime sleepiness EEG\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 20, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 20, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"List of Abbreviations\\\", \\\"14.1.4\\\", \\\"3\\\", 4030], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 20, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 20, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"List of Abbreviations\\\", \\\"14.1.4\\\", \\\"3\\\", 4031], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"electroencephalography\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 20, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 20, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"List of Abbreviations\\\", \\\"14.1.4\\\", \\\"3\\\", 4032], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"ePRO electronic patient-reported outcome EQ-5D-5L EuroQoL-5 Dimensions-5 Levels\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 20, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 20, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"List of Abbreviations\\\", \\\"14.1.4\\\", \\\"3\\\", 4033], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"List of Abbreviations\\\", \\\"14.1.4\\\", \\\"3\\\", 4034], [\\\"\\\", \\\"Unmapped\\\", \\\"table\\\", {\\\"Table\\\": \\\"<table border=\\\\\\\"1\\\\\\\" class=\\\\\\\"dataframe\\\\\\\">\\\\n  <thead>\\\\n    <tr style=\\\\\\\"text-align: right;\\\\\\\">\\\\n      <th></th>\\\\n      <th>1.0</th>\\\\n      <th>2.0</th>\\\\n    </tr>\\\\n  </thead>\\\\n  <tbody>\\\\n    <tr>\\\\n      <th>0</th>\\\\n      <td>EQ VAS</td>\\\\n      <td>EuroQoL Visual Analogue Scale</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>1</th>\\\\n      <td>ESS</td>\\\\n      <td>Epworth Sleepiness Scale</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>2</th>\\\\n      <td><span class=\\\\\\\"redact\\\\\\\"> ~REDACTED~ </span></td>\\\\n      <td>Food and Drug Administration</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>3</th>\\\\n      <td>FIH</td>\\\\n      <td>first-in-human</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>4</th>\\\\n      <td>FSH</td>\\\\n      <td><span class=\\\\\\\"redact\\\\\\\"> ~REDACTED~ </span></td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>5</th>\\\\n      <td>GCP</td>\\\\n      <td>Good Clinical Practice</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>6</th>\\\\n      <td>GLP</td>\\\\n      <td>Good Laboratory Practice</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>7</th>\\\\n      <td><span class=\\\\\\\"redact\\\\\\\"> ~REDACTED~ </span></td>\\\\n      <td><span class=\\\\\\\"redact\\\\\\\"> ~REDACTED~ </span></td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>8</th>\\\\n      <td>HE</td>\\\\n      <td>healthy elderly</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>9</th>\\\\n      <td>HED</td>\\\\n      <td>human equivalent dose</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>10</th>\\\\n      <td>HLA</td>\\\\n      <td>human leukocyte antigen</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>11</th>\\\\n      <td>HR</td>\\\\n      <td>heart rate</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>12</th>\\\\n      <td>IC 50</td>\\\\n      <td>50% inhibitory concentration</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>13</th>\\\\n      <td>ICH</td>\\\\n      <td>International Council for Harmonisation</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>14</th>\\\\n      <td>ICSD-3</td>\\\\n      <td>International Classification of Sleep Disorders, 3rd edition</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>15</th>\\\\n      <td>IEC</td>\\\\n      <td>independent ethics committee</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>16</th>\\\\n      <td>INR</td>\\\\n      <td>international normalized ratio</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>17</th>\\\\n      <td>IRB</td>\\\\n      <td>institutional review board</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>18</th>\\\\n      <td>IRT</td>\\\\n      <td>interactive response technology</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>19</th>\\\\n      <td>k inact</td>\\\\n      <td>maximal inactivation rate constant</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>20</th>\\\\n      <td>KSS</td>\\\\n      <td>Karolinska Sleepiness Scale</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>21</th>\\\\n      <td>LFT</td>\\\\n      <td>liver function test</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>22</th>\\\\n      <td>LV dP/dt max</td>\\\\n      <td>maximal left ventricular pressure rise</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>23</th>\\\\n      <td>MAV</td>\\\\n      <td>markedly abnormal value</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>24</th>\\\\n      <td>MDD</td>\\\\n      <td>major depressive disorder</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>25</th>\\\\n      <td>MedDRA</td>\\\\n      <td>Medical Dictionary for Regulatory Activities</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>26</th>\\\\n      <td>MRD</td>\\\\n      <td>multiple-rising dose</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>27</th>\\\\n      <td>MSLT</td>\\\\n      <td>multiple sleep latency test</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>28</th>\\\\n      <td>MTD</td>\\\\n      <td>maximum tolerated dose</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>29</th>\\\\n      <td>MV</td>\\\\n      <td>minute volume</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>30</th>\\\\n      <td>MWT</td>\\\\n      <td>Maintenance of Wakefulness Test</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>31</th>\\\\n      <td>NOAEL</td>\\\\n      <td>no-observed-adverse-effect level</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>32</th>\\\\n      <td>NOEL</td>\\\\n      <td>no-observed-effect level</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>33</th>\\\\n      <td>nPSG</td>\\\\n      <td>nocturnal polysomnography</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>34</th>\\\\n      <td>NSF</td>\\\\n      <td><span class=\\\\\\\"redact\\\\\\\"> ~REDACTED~ </span></td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>35</th>\\\\n      <td>NT1</td>\\\\n      <td>narcolepsy type 1 (narcolepsy with cataplexy)</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>36</th>\\\\n      <td>OATP</td>\\\\n      <td>organic anion transporting polypeptide</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>37</th>\\\\n      <td>OX</td>\\\\n      <td>orexin</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>38</th>\\\\n      <td>OX1R</td>\\\\n      <td>orexin type-1 receptor</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>39</th>\\\\n      <td>OX2R</td>\\\\n      <td>orexin type-2 receptor</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>40</th>\\\\n      <td>PAP</td>\\\\n      <td>positive airway pressure</td>\\\\n    </tr>\\\\n  </tbody>\\\\n</table>\\\", \\\"SectionHeaderPrintPage\\\": \\\"130\\\", \\\"TableIndex\\\": \\\"49\\\", \\\"TableName\\\": \\\"14.1.4 List of Abbreviations\\\", \\\"Header\\\": []}, {\\\"IsBold\\\": false, \\\"font_size\\\": 20, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 20, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"List of Abbreviations\\\", \\\"14.1.4\\\", \\\"3\\\", 4035], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"List of Abbreviations\\\", \\\"14.1.4\\\", \\\"3\\\", 4036], [\\\"\\\", \\\"Unmapped\\\", \\\"table\\\", {\\\"Table\\\": \\\"<table border=\\\\\\\"1\\\\\\\" class=\\\\\\\"dataframe\\\\\\\">\\\\n  <thead>\\\\n    <tr style=\\\\\\\"text-align: right;\\\\\\\">\\\\n      <th></th>\\\\n      <th>1.0</th>\\\\n      <th>2.0</th>\\\\n    </tr>\\\\n  </thead>\\\\n  <tbody>\\\\n    <tr>\\\\n      <th>0</th>\\\\n      <td>PD</td>\\\\n      <td>pharmacodynamic(s)</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>1</th>\\\\n      <td>PGI-I</td>\\\\n      <td>Patient Global Impression of Improvement</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>2</th>\\\\n      <td>PGI-S</td>\\\\n      <td>Patient Global Impression of Severity</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>3</th>\\\\n      <td>PK</td>\\\\n      <td>pharmacokinetic(s)</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>4</th>\\\\n      <td>PROMIS</td>\\\\n      <td>Patient-Reported Outcomes Measurement Information System</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>5</th>\\\\n      <td>PSG</td>\\\\n      <td>polysomnography</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>6</th>\\\\n      <td>PTE</td>\\\\n      <td>pretreatment event</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>7</th>\\\\n      <td>QD</td>\\\\n      <td>once daily</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>8</th>\\\\n      <td>QOL</td>\\\\n      <td>quality of life</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>9</th>\\\\n      <td>QTcF</td>\\\\n      <td>QT interval with Fridericia correction method</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>10</th>\\\\n      <td>REM</td>\\\\n      <td>rapid eye movement</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>11</th>\\\\n      <td>RLS</td>\\\\n      <td>restless leg syndrome</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>12</th>\\\\n      <td>RR</td>\\\\n      <td>respiratory rate</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>13</th>\\\\n      <td>SAE</td>\\\\n      <td>serious adverse event</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>14</th>\\\\n      <td>SAP</td>\\\\n      <td>statistical analysis plan</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>15</th>\\\\n      <td>SART</td>\\\\n      <td>Sustained Attention to Response Test</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>16</th>\\\\n      <td>SOREMP</td>\\\\n      <td>sleep onset REM period</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>17</th>\\\\n      <td>SRD</td>\\\\n      <td>single-rising dose</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>18</th>\\\\n      <td>SUSAR</td>\\\\n      <td>suspected unexpected serious adverse reaction</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>19</th>\\\\n      <td>TEAE</td>\\\\n      <td>treatment-emergent adverse event</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>20</th>\\\\n      <td>TG</td>\\\\n      <td>transgenic</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>21</th>\\\\n      <td>t max</td>\\\\n      <td>time of first occurrence of C max</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>22</th>\\\\n      <td>ULN</td>\\\\n      <td>upper limit of normal</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>23</th>\\\\n      <td>VAS</td>\\\\n      <td>visual analog scale</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>24</th>\\\\n      <td>WCR</td>\\\\n      <td>weekly cataplexy rate</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>25</th>\\\\n      <td>WT</td>\\\\n      <td>wild type</td>\\\\n    </tr>\\\\n  </tbody>\\\\n</table>\\\", \\\"SectionHeaderPrintPage\\\": \\\"130\\\", \\\"TableIndex\\\": \\\"50\\\", \\\"TableName\\\": \\\"14.1.4 List of Abbreviations\\\", \\\"Header\\\": []}, {\\\"IsBold\\\": false, \\\"font_size\\\": 20, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 20, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"List of Abbreviations\\\", \\\"14.1.4\\\", \\\"3\\\", 4037], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"15.0 DATA HANDLING AND RECORDKEEPING\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading1\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"DATA HANDLING AND RECORDKEEPING\\\", \\\"15.0\\\", \\\"1\\\", 4038], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"The full details of procedures for data handling will be documented in the Data Management Plan.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"DATA HANDLING AND RECORDKEEPING\\\", \\\"15.0\\\", \\\"1\\\", 4039], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"AEs, medical history, and concurrent conditions will be coded using the MedDRA.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"DATA HANDLING AND RECORDKEEPING\\\", \\\"15.0\\\", \\\"1\\\", 4040], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Drugs will be coded using the ~REDACTED~ Drug Dictionary.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"DATA HANDLING AND RECORDKEEPING\\\", \\\"15.0\\\", \\\"1\\\", 4041], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"15.1 eCRFs\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading2\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"eCRFs\\\", \\\"15.1\\\", \\\"2\\\", 4042], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Completed eCRFs are required for each subject who signs an informed consent.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"eCRFs\\\", \\\"15.1\\\", \\\"2\\\", 4043], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"The sponsor or its designee will supply investigative sites with access to eCRFs.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"eCRFs\\\", \\\"15.1\\\", \\\"2\\\", 4044], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"The sponsor will make arrangements to train appropriate site staff in the use of the eCRF.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"eCRFs\\\", \\\"15.1\\\", \\\"2\\\", 4045], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"These forms are used to transmit the information collected in the performance of this study to the sponsor and regulatory authorities.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"eCRFs\\\", \\\"15.1\\\", \\\"2\\\", 4046], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"eCRFs must be completed in English.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"eCRFs\\\", \\\"15.1\\\", \\\"2\\\", 4047], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Data are transcribed directly onto eCRFs.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"eCRFs\\\", \\\"15.1\\\", \\\"2\\\", 4048], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"After completion of the entry process, computer logic checks will be run to identify items, such as inconsistent dates, missing data, and questionable values.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"eCRFs\\\", \\\"15.1\\\", \\\"2\\\", 4049], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Queries may be issued by ~REDACTED~ personnel (or designees) and will be answered by the site.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"eCRFs\\\", \\\"15.1\\\", \\\"2\\\", 4050], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Corrections are recorded in an audit trail that captures the old information, the new information, identification of the person making the correction, the date the correction was made, and the reason for change.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"eCRFs\\\", \\\"15.1\\\", \\\"2\\\", 4051], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Reasons for significant corrections should additionally be included.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"eCRFs\\\", \\\"15.1\\\", \\\"2\\\", 4052], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"The principal investigator must review the eCRFs for completeness and accuracy and must sign and date the appropriate eCRFs as indicated.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"eCRFs\\\", \\\"15.1\\\", \\\"2\\\", 4053], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Furthermore, the investigator must retain full responsibility for the accuracy and authenticity of all data entered on the eCRFs\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"eCRFs\\\", \\\"15.1\\\", \\\"2\\\", 4054], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\".\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 20, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 20, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"eCRFs\\\", \\\"15.1\\\", \\\"2\\\", 4055], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"After the lock of the clinical study database, any change of, modification of, or addition to the data on the eCRFs should be made by the investigator with use of change and modification records of the eCRFs.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"eCRFs\\\", \\\"15.1\\\", \\\"2\\\", 4056], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"The principal investigator must review the data change for completeness and accuracy, and must sign and date.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"eCRFs\\\", \\\"15.1\\\", \\\"2\\\", 4057], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"eCRFs will be reviewed for completeness and acceptability at the study site during periodic visits by study monitors.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"eCRFs\\\", \\\"15.1\\\", \\\"2\\\", 4058], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"The sponsor or its designee will be permitted to review the subject\\\\u2019s medical and hospital records pertinent to the study to ensure accuracy of the eCRFs.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"eCRFs\\\", \\\"15.1\\\", \\\"2\\\", 4059], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"The completed eCRFs are the sole property of the sponsor and should not be made available in any form to third parties, except for authorized representatives of appropriate governmental health or regulatory authorities, without written permission of the sponsor.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"eCRFs\\\", \\\"15.1\\\", \\\"2\\\", 4060], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"15.2 Record Retention\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading2\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Record Retention\\\", \\\"15.2\\\", \\\"2\\\", 4061], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"The investigator agrees to keep the records stipulated in Section 15.1 and those documents that include (but are not limited to) the study-specific documents, the identification log of all participating subjects, medical records, temporary media such as thermal sensitive paper, source worksheets, all original signed and dated informed consent forms, subject authorization forms regarding the use of personal health information (if separate from the informed consent forms), electronic copy of eCRFs, including the audit trail, and detailed records of drug disposition to enable evaluations or audits from regulatory authorities, the sponsor or its designees.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Record Retention\\\", \\\"15.2\\\", \\\"2\\\", 4062], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Any source documentation printed on degradable thermal sensitive paper should be photocopied by the site and filed with the original in the subject\\\\u2019s chart to ensure long-term legibility.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Record Retention\\\", \\\"15.2\\\", \\\"2\\\", 4063], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Furthermore, ICH E6 Section 4.9.5 requires the investigator to retain essential documents specified in ICH E6 (Section 8) until at least 2 years after the last approval of a marketing application for a specified drug indication being investigated or, if an application is not approved, until at least 2 years after the investigation is discontinued and regulatory authorities are notified.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Record Retention\\\", \\\"15.2\\\", \\\"2\\\", 4064], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"In addition, ICH E6 Section 4.9.5 states that the study records should be retained until an amount of time specified by applicable regulatory requirements or for a time specified in the Clinical Study Site Agreement between the investigator and sponsor.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Record Retention\\\", \\\"15.2\\\", \\\"2\\\", 4065], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Refer to the Clinical Study Site Agreement for the sponsor\\\\u2019s requirements on record retention.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Record Retention\\\", \\\"15.2\\\", \\\"2\\\", 4066], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"The investigator and the head of the institution should contact and receive written approval from the sponsor before disposing of any such documents.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Study Design\\\", \\\"Record Retention\\\", \\\"15.2\\\", \\\"2\\\", 4067], [\\\"1\\\", \\\"References\\\", \\\"header\\\", \\\"16.0 REFERENCES\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading1\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"REFERENCES\\\", \\\"16.0\\\", \\\"1\\\", 4068], [\\\"1\\\", \\\"References\\\", \\\"text\\\", \\\"1. Ohno Y, Matsumoto K, Hirose A, Nakamura M.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"REFERENCES\\\", \\\"16.0\\\", \\\"1\\\", 4069], [\\\"1\\\", \\\"References\\\", \\\"text\\\", \\\"Effects of ~REDACTED~ hydrochloride, a novel antipsychotic agent, on EEG in rabbits and spinal reflex in cats.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"REFERENCES\\\", \\\"16.0\\\", \\\"1\\\", 4070], [\\\"1\\\", \\\"References\\\", \\\"text\\\", \\\"Clinical Report 1997;31(2):879-92.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"REFERENCES\\\", \\\"16.0\\\", \\\"1\\\", 4071], [\\\"1\\\", \\\"References\\\", \\\"text\\\", \\\"2. Scammell TE, Winrow CJ.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"REFERENCES\\\", \\\"16.0\\\", \\\"1\\\", 4072], [\\\"1\\\", \\\"References\\\", \\\"text\\\", \\\"Orexin receptors: pharmacology and therapeutic opportunities.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"REFERENCES\\\", \\\"16.0\\\", \\\"1\\\", 4073], [\\\"1\\\", \\\"References\\\", \\\"text\\\", \\\"Annu Rev Pharmacol Toxicol 2011;51:243-66.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"REFERENCES\\\", \\\"16.0\\\", \\\"1\\\", 4074], [\\\"1\\\", \\\"References\\\", \\\"text\\\", \\\"3. ~REDACTED~\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"REFERENCES\\\", \\\"16.0\\\", \\\"1\\\", 4075], [\\\"1\\\", \\\"References\\\", \\\"text\\\", \\\"International classification of sleep disorders.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"REFERENCES\\\", \\\"16.0\\\", \\\"1\\\", 4076], [\\\"1\\\", \\\"References\\\", \\\"text\\\", \\\"3rd ed. (ICSD-3).\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"REFERENCES\\\", \\\"16.0\\\", \\\"1\\\", 4077], [\\\"1\\\", \\\"References\\\", \\\"text\\\", \\\"Rochester, MN: ~REDACTED~; 2014.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"REFERENCES\\\", \\\"16.0\\\", \\\"1\\\", 4078], [\\\"1\\\", \\\"References\\\", \\\"text\\\", \\\"4. Krahn LE, Pankratz VS, Oliver L, Boeve BF, Silber MH.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"REFERENCES\\\", \\\"16.0\\\", \\\"1\\\", 4079], [\\\"1\\\", \\\"References\\\", \\\"text\\\", \\\"Hypocretin (orexin) levels in cerebrospinal fluid of patients with narcolepsy: relationship to cataplexy and HLA DQB1*0602 status.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"REFERENCES\\\", \\\"16.0\\\", \\\"1\\\", 4080], [\\\"1\\\", \\\"References\\\", \\\"text\\\", \\\"Sleep 2002;25(7):733-6.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"REFERENCES\\\", \\\"16.0\\\", \\\"1\\\", 4081], [\\\"1\\\", \\\"References\\\", \\\"text\\\", \\\"5. De la Herran-Arita AK, Garcia-Garcia F.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"REFERENCES\\\", \\\"16.0\\\", \\\"1\\\", 4082], [\\\"1\\\", \\\"References\\\", \\\"text\\\", \\\"Narcolepsy as an immune-mediated disease.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"REFERENCES\\\", \\\"16.0\\\", \\\"1\\\", 4083], [\\\"1\\\", \\\"References\\\", \\\"text\\\", \\\"Sleep Disord 2014;2014:792687.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"REFERENCES\\\", \\\"16.0\\\", \\\"1\\\", 4084], [\\\"1\\\", \\\"References\\\", \\\"text\\\", \\\"6. Szekely M, Petervari E, Balasko M, Hernadi I, Uzsoki B.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"REFERENCES\\\", \\\"16.0\\\", \\\"1\\\", 4085], [\\\"1\\\", \\\"References\\\", \\\"text\\\", \\\"Effects of orexins on energy balance and thermoregulation.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"REFERENCES\\\", \\\"16.0\\\", \\\"1\\\", 4086], [\\\"1\\\", \\\"References\\\", \\\"text\\\", \\\"Regul Pept 2002;104(1-3):47-53.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"REFERENCES\\\", \\\"16.0\\\", \\\"1\\\", 4087], [\\\"1\\\", \\\"References\\\", \\\"text\\\", \\\"7. Samson WK, Bagley SL, Ferguson AV, White MM.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"REFERENCES\\\", \\\"16.0\\\", \\\"1\\\", 4088], [\\\"1\\\", \\\"References\\\", \\\"text\\\", \\\"Orexin receptor subtype activation and locomotor behaviour in the rat.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"REFERENCES\\\", \\\"16.0\\\", \\\"1\\\", 4089], [\\\"1\\\", \\\"References\\\", \\\"text\\\", \\\"Acta ~REDACTED~ (Oxf) 2010;198(3):313-24.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"REFERENCES\\\", \\\"16.0\\\", \\\"1\\\", 4090], [\\\"1\\\", \\\"References\\\", \\\"text\\\", \\\"8. Sakurai T, Amemiya A, Ishii M, Matsuzaki I, Chemelli RM, Tanaka H, et al.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"REFERENCES\\\", \\\"16.0\\\", \\\"1\\\", 4091], [\\\"1\\\", \\\"References\\\", \\\"text\\\", \\\"Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"REFERENCES\\\", \\\"16.0\\\", \\\"1\\\", 4092], [\\\"1\\\", \\\"References\\\", \\\"text\\\", \\\"Cell 1998;92(4):573-85.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"REFERENCES\\\", \\\"16.0\\\", \\\"1\\\", 4093], [\\\"1\\\", \\\"References\\\", \\\"text\\\", \\\"9. Huang SC, Dai YW, Lee YH, Chiou LC, Hwang LL. Orexins depolarize rostral ventrolateral medulla neurons and increase arterial pressure and heart rate in rats mainly via orexin 2 receptors.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"REFERENCES\\\", \\\"16.0\\\", \\\"1\\\", 4094], [\\\"1\\\", \\\"References\\\", \\\"text\\\", \\\"J Pharmacol Exp Ther 2010;334(2):522-9.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"REFERENCES\\\", \\\"16.0\\\", \\\"1\\\", 4095], [\\\"1\\\", \\\"References\\\", \\\"text\\\", \\\"10. Zhang W, Fukuda Y, Kuwaki T.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"REFERENCES\\\", \\\"16.0\\\", \\\"1\\\", 4096], [\\\"1\\\", \\\"References\\\", \\\"text\\\", \\\"Respiratory and cardiovascular actions of orexin-A in mice.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"REFERENCES\\\", \\\"16.0\\\", \\\"1\\\", 4097], [\\\"1\\\", \\\"References\\\", \\\"text\\\", \\\"Neurosci Lett 2005;385(2):131-6.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"REFERENCES\\\", \\\"16.0\\\", \\\"1\\\", 4098], [\\\"1\\\", \\\"References\\\", \\\"text\\\", \\\"11. Guidance for Industry: Estimating the Maximum Safe Starting Dose in Initial Clinical Trials for Therapeutics in Adult Healthy Volunteers.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"REFERENCES\\\", \\\"16.0\\\", \\\"1\\\", 4099], [\\\"1\\\", \\\"References\\\", \\\"text\\\", \\\"~REDACTED~, Food and Drug Administration, ~REDACTED~ (CDER).\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"REFERENCES\\\", \\\"16.0\\\", \\\"1\\\", 4100], [\\\"1\\\", \\\"References\\\", \\\"text\\\", \\\"July 2005.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"REFERENCES\\\", \\\"16.0\\\", \\\"1\\\", 4101], [\\\"1\\\", \\\"References\\\", \\\"text\\\", \\\"12. Guidance for Industry: Assessing the Effects of Food on Drugs in INDs and NDAs \\\\u2014 Clinical Pharmacology Considerations (Draft Guidance).\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"REFERENCES\\\", \\\"16.0\\\", \\\"1\\\", 4102], [\\\"1\\\", \\\"References\\\", \\\"text\\\", \\\"~REDACTED~, Food and Drug Administration, ~REDACTED~ (CDER).\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"REFERENCES\\\", \\\"16.0\\\", \\\"1\\\", 4103], [\\\"1\\\", \\\"References\\\", \\\"text\\\", \\\"February 2019.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"REFERENCES\\\", \\\"16.0\\\", \\\"1\\\", 4104], [\\\"1\\\", \\\"References\\\", \\\"text\\\", \\\"13. Cella D, Lai JS, Jensen SE, Christodoulou C, Junghaenel DU, Reeve BB, et al.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"REFERENCES\\\", \\\"16.0\\\", \\\"1\\\", 4105], [\\\"1\\\", \\\"References\\\", \\\"text\\\", \\\"PROMIS fatigue item bank had clinical validity across diverse chronic conditions.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"REFERENCES\\\", \\\"16.0\\\", \\\"1\\\", 4106], [\\\"1\\\", \\\"References\\\", \\\"text\\\", \\\"J Clin Epidemiol 2016;73:128-34.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"REFERENCES\\\", \\\"16.0\\\", \\\"1\\\", 4107], [\\\"1\\\", \\\"References\\\", \\\"text\\\", \\\"14. Cook KF, Jensen SE, Schalet BD, Beaumont JL, Amtmann D, Czajkowski S, et al.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"REFERENCES\\\", \\\"16.0\\\", \\\"1\\\", 4108], [\\\"1\\\", \\\"References\\\", \\\"text\\\", \\\"PROMIS measures of pain, fatigue, negative affect, physical function, and social function demonstrated clinical validity across a range of chronic conditions.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"REFERENCES\\\", \\\"16.0\\\", \\\"1\\\", 4109], [\\\"1\\\", \\\"References\\\", \\\"text\\\", \\\"J Clin Epidemiol 2016;73:89-102.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"REFERENCES\\\", \\\"16.0\\\", \\\"1\\\", 4110], [\\\"1\\\", \\\"References\\\", \\\"text\\\", \\\"15. Herdman M, Gudex C, Lloyd A, ~REDACTED~ M, Kind P, Parkin D, et al.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"REFERENCES\\\", \\\"16.0\\\", \\\"1\\\", 4111], [\\\"1\\\", \\\"References\\\", \\\"text\\\", \\\"Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L).\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"REFERENCES\\\", \\\"16.0\\\", \\\"1\\\", 4112], [\\\"1\\\", \\\"References\\\", \\\"text\\\", \\\"Qual Life Res 2011;20(10):1727-36.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"REFERENCES\\\", \\\"16.0\\\", \\\"1\\\", 4113], [\\\"1\\\", \\\"References\\\", \\\"text\\\", \\\"16. ~REDACTED~ MF, Pickard AS, Golicki D, Gudex C, Niewada M, Scalone L, et al.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"REFERENCES\\\", \\\"16.0\\\", \\\"1\\\", 4114], [\\\"1\\\", \\\"References\\\", \\\"text\\\", \\\"Measurement properties of the EQ-5D-5L compared to the EQ-5D-3L across eight patient groups: a multi-country study.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"REFERENCES\\\", \\\"16.0\\\", \\\"1\\\", 4115], [\\\"1\\\", \\\"References\\\", \\\"text\\\", \\\"Qual Life Res 2013;22(7):1717-27.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"REFERENCES\\\", \\\"16.0\\\", \\\"1\\\", 4116], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"17.0 APPENDICES\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading1\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"APPENDICES\\\", \\\"17.0\\\", \\\"1\\\", 4117], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"Appendix A Responsibilities of the Investigator\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading8\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix A  Responsibilities of the Investigator\\\", \\\"\\\", \\\"2\\\", 4118], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"~REDACTED~ studies sponsored by the sponsor are subject to ICH GCP and all the applicable local laws and regulations.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix A  Responsibilities of the Investigator\\\", \\\"\\\", \\\"2\\\", 4119], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"The responsibilities imposed on investigators by the ~REDACTED~ are summarized in the \\\\u201cStatement of Investigator\\\\u201d (Form ~REDACTED~ 1572), which must be completed and signed before the investigator may participate in this study.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix A  Responsibilities of the Investigator\\\", \\\"\\\", \\\"2\\\", 4120], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"The investigator agrees to assume the following responsibilities by signing a Form ~REDACTED~ 1572:\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix A  Responsibilities of the Investigator\\\", \\\"\\\", \\\"2\\\", 4121], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"1. Conduct the study in accordance with the protocol.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix A  Responsibilities of the Investigator\\\", \\\"\\\", \\\"2\\\", 4122], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"2. Personally conduct or supervise the staff that will assist in the protocol.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix A  Responsibilities of the Investigator\\\", \\\"\\\", \\\"2\\\", 4123], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"3. If the investigator/institution retains the services of any individual or party to perform study-related duties and functions, the investigator/institution should ensure that this individual or party is qualified to perform those study-related duties and functions and should implement procedures to ensure the integrity of the study-related duties and functions performed and any data generated.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix A  Responsibilities of the Investigator\\\", \\\"\\\", \\\"2\\\", 4124], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"4. Ensure that study related procedures, including study specific (nonroutine/nonstandard panel) screening assessments are NOT performed on potential subjects, before the receipt of written approval from relevant governing bodies/authorities.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix A  Responsibilities of the Investigator\\\", \\\"\\\", \\\"2\\\", 4125], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"5. Ensure that all colleagues and employees assisting in the conduct of the study are informed of these obligations.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix A  Responsibilities of the Investigator\\\", \\\"\\\", \\\"2\\\", 4126], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"6. Secure prior approval of the study and any changes by an appropriate IRB/IEC that conform to 21 Code of Federal Regulations (~REDACTED~) Part 56, ICH, and local regulatory requirements.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix A  Responsibilities of the Investigator\\\", \\\"\\\", \\\"2\\\", 4127], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"7. Ensure that the IRB/IEC will be responsible for initial review, continuing review, and approval of the protocol.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix A  Responsibilities of the Investigator\\\", \\\"\\\", \\\"2\\\", 4128], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Promptly report to the IRB/IEC all changes in research activity and all anticipated risks to subjects.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix A  Responsibilities of the Investigator\\\", \\\"\\\", \\\"2\\\", 4129], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Make at least yearly reports on the progress of the study to the IRB/IEC, and issue a final report within 3 months of study completion.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix A  Responsibilities of the Investigator\\\", \\\"\\\", \\\"2\\\", 4130], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"8. Ensure that requirements for informed consent, as outlined in 21 ~REDACTED~ Part 50, ICH and local regulations, are met.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix A  Responsibilities of the Investigator\\\", \\\"\\\", \\\"2\\\", 4131], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"9. Obtain valid informed consent from each subject who participates in the study, and document the date of consent in the subject\\\\u2019s medical chart.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix A  Responsibilities of the Investigator\\\", \\\"\\\", \\\"2\\\", 4132], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Valid informed consent is the most current version approved by the IRB/IEC.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix A  Responsibilities of the Investigator\\\", \\\"\\\", \\\"2\\\", 4133], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Each informed consent form should contain a subject authorization section that describes the uses and disclosures of a subject\\\\u2019s personal information (including personal health information) that will take place in connection with the study.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix A  Responsibilities of the Investigator\\\", \\\"\\\", \\\"2\\\", 4134], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"If an informed consent form does not include such a subject authorization, then the investigator must obtain a separate subject authorization form from each subject or the subject\\\\u2019s legally acceptable representative.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix A  Responsibilities of the Investigator\\\", \\\"\\\", \\\"2\\\", 4135], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"10. Prepare and maintain adequate case histories of all persons entered into the study, including eCRFs, hospital records, laboratory results, etc, and maintain these data for a minimum of\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix A  Responsibilities of the Investigator\\\", \\\"\\\", \\\"2\\\", 4136], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"2 years following notification by the sponsor that all investigations have been discontinued or that the regulatory authority has approved the marketing application.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix A  Responsibilities of the Investigator\\\", \\\"\\\", \\\"2\\\", 4137], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"The investigator should contact and receive written approval from the sponsor before disposing of any such documents.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix A  Responsibilities of the Investigator\\\", \\\"\\\", \\\"2\\\", 4138], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"11. Allow possible inspection and copying by the regulatory authority of GCP-specified essential documents.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix A  Responsibilities of the Investigator\\\", \\\"\\\", \\\"2\\\", 4139], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"12. Maintain current records of the receipt, administration, and disposition of sponsor-supplied drugs, and return all unused sponsor-supplied drugs to the sponsor.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix A  Responsibilities of the Investigator\\\", \\\"\\\", \\\"2\\\", 4140], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Report adverse reactions to the sponsor promptly.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix A  Responsibilities of the Investigator\\\", \\\"\\\", \\\"2\\\", 4141], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"In the event of an SAE, notify the sponsor within 24 hours.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix A  Responsibilities of the Investigator\\\", \\\"\\\", \\\"2\\\", 4142], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix A  Responsibilities of the Investigator\\\", \\\"\\\", \\\"2\\\", 4143], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"Appendix B Elements of the Subject Informed Consent\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading8\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix B  Elements of the Subject Informed Consent\\\", \\\"\\\", \\\"2\\\", 4144], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"In seeking informed consent, the following information shall be provided to each subject:\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix B  Elements of the Subject Informed Consent\\\", \\\"\\\", \\\"2\\\", 4145], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"1. A statement that the study involves research.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix B  Elements of the Subject Informed Consent\\\", \\\"\\\", \\\"2\\\", 4146], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"2. An explanation of the purposes of the research.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix B  Elements of the Subject Informed Consent\\\", \\\"\\\", \\\"2\\\", 4147], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"3. The expected duration of the subject\\\\u2019s participation.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix B  Elements of the Subject Informed Consent\\\", \\\"\\\", \\\"2\\\", 4148], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"4. A description of the procedures to be followed, including invasive procedures.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix B  Elements of the Subject Informed Consent\\\", \\\"\\\", \\\"2\\\", 4149], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"5. The identification of any procedures that are experimental.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix B  Elements of the Subject Informed Consent\\\", \\\"\\\", \\\"2\\\", 4150], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"6. The estimated number of subjects involved in the study.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix B  Elements of the Subject Informed Consent\\\", \\\"\\\", \\\"2\\\", 4151], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"7. A description of the subject\\\\u2019s responsibilities.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix B  Elements of the Subject Informed Consent\\\", \\\"\\\", \\\"2\\\", 4152], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"8. A description of the conduct of the study.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix B  Elements of the Subject Informed Consent\\\", \\\"\\\", \\\"2\\\", 4153], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"9. A statement describing the treatment(s) and the probability for random assignment to each treatment.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix B  Elements of the Subject Informed Consent\\\", \\\"\\\", \\\"2\\\", 4154], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"10. A description of the possible side effects of the treatment that the subject may receive.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix B  Elements of the Subject Informed Consent\\\", \\\"\\\", \\\"2\\\", 4155], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"11. A description of any reasonably foreseeable risks or discomforts to the subject and, when applicable, to an embryo, fetus, or nursing infant.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix B  Elements of the Subject Informed Consent\\\", \\\"\\\", \\\"2\\\", 4156], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"12. A description of any benefits to the subject or to others that reasonably may be expected from the research.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix B  Elements of the Subject Informed Consent\\\", \\\"\\\", \\\"2\\\", 4157], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"When there is no intended clinical benefit to the subject, the subject should be made aware of this.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix B  Elements of the Subject Informed Consent\\\", \\\"\\\", \\\"2\\\", 4158], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"13. Disclosures of appropriate alternative procedures or courses of treatment, if any, that might be advantageous to the subject and their important potential risks and benefits.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix B  Elements of the Subject Informed Consent\\\", \\\"\\\", \\\"2\\\", 4159], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"14. A statement describing the extent to which confidentiality of records identifying the subject will be maintained, and a note of the possibility that regulatory agencies, auditor(s), IRB/IEC, and the monitor may inspect the records.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix B  Elements of the Subject Informed Consent\\\", \\\"\\\", \\\"2\\\", 4160], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"By signing a written informed consent form, the subject or the subject\\\\u2019s legally acceptable representative is authorizing such access.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix B  Elements of the Subject Informed Consent\\\", \\\"\\\", \\\"2\\\", 4161], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"15. For research involving more than minimal risk, an explanation as to whether any compensation and an explanation as to whether any medical treatments are available if injury occurs and, if so, what they consist of or where further information may be obtained.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix B  Elements of the Subject Informed Consent\\\", \\\"\\\", \\\"2\\\", 4162], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"16. The anticipated prorated payment(s), if any, to the subject for participating in the study.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix B  Elements of the Subject Informed Consent\\\", \\\"\\\", \\\"2\\\", 4163], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"17. The anticipated expenses, if any, to the subject for participating in the study.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix B  Elements of the Subject Informed Consent\\\", \\\"\\\", \\\"2\\\", 4164], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"18. An explanation of whom to contact for answers to pertinent questions about the research (investigator), subject\\\\u2019s rights, and IRB/IEC and whom to contact in the event of a research-related injury to the subject.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix B  Elements of the Subject Informed Consent\\\", \\\"\\\", \\\"2\\\", 4165], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"19. A statement that participation is voluntary, that refusal to participate will involve no penalty or loss of benefits to which the subject otherwise is entitled, and that the subject or the subject\\\\u2019s legally acceptable representative may discontinue participation at any time without penalty or loss of benefits to which the subject is otherwise entitled.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix B  Elements of the Subject Informed Consent\\\", \\\"\\\", \\\"2\\\", 4166], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"20. The consequences of a subject\\\\u2019s decision to withdraw from the research and procedures for orderly termination of participation by the subject.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix B  Elements of the Subject Informed Consent\\\", \\\"\\\", \\\"2\\\", 4167], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"21. A statement that the subject or the subject\\\\u2019s legally acceptable representative will be informed in a timely manner if information becomes available that may be relevant to the subject\\\\u2019s willingness to continue participation in the study.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix B  Elements of the Subject Informed Consent\\\", \\\"\\\", \\\"2\\\", 4168], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"22. A statement that results of pharmacogenomics analysis will not be disclosed to an individual, unless prevailing laws require the sponsor to do so.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix B  Elements of the Subject Informed Consent\\\", \\\"\\\", \\\"2\\\", 4169], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"23. The foreseeable circumstances or reasons under which the subject\\\\u2019s participation in the study may be terminated.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix B  Elements of the Subject Informed Consent\\\", \\\"\\\", \\\"2\\\", 4170], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"24. A written subject authorization (either contained within the informed consent form or provided as a separate document) describing to the subject the contemplated and permissible uses and disclosures of the subject\\\\u2019s personal information (including personal health information) for purposes of conducting the study.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix B  Elements of the Subject Informed Consent\\\", \\\"\\\", \\\"2\\\", 4171], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"The subject authorization must contain the following statements regarding the uses and disclosures of the subject\\\\u2019s personal information:\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix B  Elements of the Subject Informed Consent\\\", \\\"\\\", \\\"2\\\", 4172], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"that personal information (including personal health information) may be processed by or transferred to other parties in other countries for ~REDACTED~ and safety reporting purposes, including, without limitation, to the following: (1) ~REDACTED~, its affiliates, and licensing partners; (2) business partners assisting ~REDACTED~, its affiliates, and licensing partners; (3) regulatory agencies and other health authorities; and (4) IRBs/IECs;\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix B  Elements of the Subject Informed Consent\\\", \\\"\\\", \\\"2\\\", 4173], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"b) it is possible that personal information (including personal health information) may be processed and transferred to countries that do not have data protection laws that offer subjects the same level of protection as the data protection laws within this country; however, ~REDACTED~ will make every effort to keep your personal information confidential, and your name will not be disclosed outside the clinic unless required by law;\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix B  Elements of the Subject Informed Consent\\\", \\\"\\\", \\\"2\\\", 4174], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"that personal information (including personal health information) may be added to ~REDACTED~\\\\u2019s research databases for purposes of developing a better understanding of the safety and effectiveness of the study medication(s), studying other therapies for patients, developing a better understanding of disease, and improving the efficiency of future clinical studies;\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix B  Elements of the Subject Informed Consent\\\", \\\"\\\", \\\"2\\\", 4175], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"d) that subjects agree not to restrict the use and disclosure of their personal information (including personal health information) on withdrawal from the study to the extent that the restricted use or disclosure of such information may impact the scientific integrity of the research; and\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix B  Elements of the Subject Informed Consent\\\", \\\"\\\", \\\"2\\\", 4176], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"e) that the subject\\\\u2019s identity will remain confidential in the event that study results are published.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix B  Elements of the Subject Informed Consent\\\", \\\"\\\", \\\"2\\\", 4177], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"25. Female subjects of childbearing potential (eg, nonsterilized, premenopausal female subjects) who are sexually active must use highly effective contraception (as defined in the informed consent) from signing the informed consent and throughout the duration of the study, and for 5 half-lives PLUS 30 days after the last dose of study drug.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix B  Elements of the Subject Informed Consent\\\", \\\"\\\", \\\"2\\\", 4178], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Regular pregnancy tests will be performed throughout the study for all female subjects of childbearing potential.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix B  Elements of the Subject Informed Consent\\\", \\\"\\\", \\\"2\\\", 4179], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"If a subject is found to be pregnant during study, study drug will be discontinued and the investigator will offer the subject the choice to receive unblinded treatment information.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix B  Elements of the Subject Informed Consent\\\", \\\"\\\", \\\"2\\\", 4180], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"26. Male subjects must use highly effective contraception (as defined in the informed consent) from signing the informed consent throughout the duration of the study and for 5 half-lives PLUS 90 days after the last dose of study drug.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix B  Elements of the Subject Informed Consent\\\", \\\"\\\", \\\"2\\\", 4181], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"If the partner or wife of the subject is found to be pregnant during the study, the investigator will offer the subject the choice to receive unblinded treatment information.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix B  Elements of the Subject Informed Consent\\\", \\\"\\\", \\\"2\\\", 4182], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"A statement that clinical study information from this study will be publicly disclosed in a publicly accessible website, such as ClinicalTrials.gov.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix B  Elements of the Subject Informed Consent\\\", \\\"\\\", \\\"2\\\", 4183], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix B  Elements of the Subject Informed Consent\\\", \\\"\\\", \\\"2\\\", 4184], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"Appendix C Investigator Consent to the Use of Personal Information\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading8\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix C  Investigator Consent to the Use of Personal Information\\\", \\\"\\\", \\\"2\\\", 4185], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"~REDACTED~ will collect and retain personal information of investigator, including his or her name, address, and other personally identifiable information.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix C  Investigator Consent to the Use of Personal Information\\\", \\\"\\\", \\\"2\\\", 4186], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"In addition, investigator\\\\u2019s personal information may be transferred to other parties located in countries throughout the world (eg, the United Kingdom, United States, and Japan), including the following:\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix C  Investigator Consent to the Use of Personal Information\\\", \\\"\\\", \\\"2\\\", 4187], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\\u2022 ~REDACTED~, its affiliates, and licensing partners.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix C  Investigator Consent to the Use of Personal Information\\\", \\\"\\\", \\\"2\\\", 4188], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\\u2022 Business partners assisting ~REDACTED~, its affiliates, and licensing partners.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix C  Investigator Consent to the Use of Personal Information\\\", \\\"\\\", \\\"2\\\", 4189], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\\u2022 Regulatory agencies and other health authorities.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix C  Investigator Consent to the Use of Personal Information\\\", \\\"\\\", \\\"2\\\", 4190], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\\u2022 IRBs and IECs.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix C  Investigator Consent to the Use of Personal Information\\\", \\\"\\\", \\\"2\\\", 4191], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Investigator\\\\u2019s personal information may be retained, processed, and transferred by ~REDACTED~ and these other parties for research purposes including the following:\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix C  Investigator Consent to the Use of Personal Information\\\", \\\"\\\", \\\"2\\\", 4192], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\\u2022 Assessment of the suitability of investigator for the study and/or other clinical studies.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix C  Investigator Consent to the Use of Personal Information\\\", \\\"\\\", \\\"2\\\", 4193], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\\u2022 Management, monitoring, inspection, and audit of the study.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix C  Investigator Consent to the Use of Personal Information\\\", \\\"\\\", \\\"2\\\", 4194], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\\u2022 Analysis, review, and verification of the study results.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix C  Investigator Consent to the Use of Personal Information\\\", \\\"\\\", \\\"2\\\", 4195], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\\u2022 Safety reporting and pharmacovigilance relating to the study.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix C  Investigator Consent to the Use of Personal Information\\\", \\\"\\\", \\\"2\\\", 4196], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\\u2022 Preparation and submission of regulatory filings, correspondence, and communications to regulatory agencies relating to the study.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix C  Investigator Consent to the Use of Personal Information\\\", \\\"\\\", \\\"2\\\", 4197], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\\u2022 Preparation and submission of regulatory filings, correspondence, and communications to regulatory agencies relating to other medications used in other clinical studies that may contain the same chemical compound present in the study medication.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix C  Investigator Consent to the Use of Personal Information\\\", \\\"\\\", \\\"2\\\", 4198], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\\u2022 Inspections and investigations by regulatory authorities relating to the study.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix C  Investigator Consent to the Use of Personal Information\\\", \\\"\\\", \\\"2\\\", 4199], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\\u2022 Self-inspection and internal audit within ~REDACTED~, its affiliates, and licensing partners.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix C  Investigator Consent to the Use of Personal Information\\\", \\\"\\\", \\\"2\\\", 4200], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\\u2022 Archiving and audit of study records.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix C  Investigator Consent to the Use of Personal Information\\\", \\\"\\\", \\\"2\\\", 4201], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\\u2022 Posting investigator site contact information, study details and results on publicly accessible clinical trial registries, databases, and websites.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix C  Investigator Consent to the Use of Personal Information\\\", \\\"\\\", \\\"2\\\", 4202], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Investigator\\\\u2019s personal information may be transferred to other countries that do not have data protection laws that offer the same level of protection as data protection laws in investigator\\\\u2019s own country.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix C  Investigator Consent to the Use of Personal Information\\\", \\\"\\\", \\\"2\\\", 4203], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Investigator acknowledges and consents to the use of his or her personal information by ~REDACTED~ and other parties for the purposes described above.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix C  Investigator Consent to the Use of Personal Information\\\", \\\"\\\", \\\"2\\\", 4204], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"Appendix D Pregnancy and Contraception Contraception and Pregnancy Avoidance Procedure\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading8\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix D  Pregnancy and Contraception Contraception and Pregnancy Avoidance Procedure\\\", \\\"\\\", \\\"2\\\", 4205], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Male Subjects and Their Female Partners\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": true, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix D  Pregnancy and Contraception Contraception and Pregnancy Avoidance Procedure\\\", \\\"\\\", \\\"2\\\", 4206], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Throughout the duration of the study, and for 5 half-lives PLUS 90 days after last dose of study drug, nonsterilized** male subjects who are sexually active with a female partner of childbearing potential* must use barrier contraception (eg, condom with or without spermicidal cream or jelly).\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix D  Pregnancy and Contraception Contraception and Pregnancy Avoidance Procedure\\\", \\\"\\\", \\\"2\\\", 4207], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"In addition, they must be advised not to donate sperm during this period.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix D  Pregnancy and Contraception Contraception and Pregnancy Avoidance Procedure\\\", \\\"\\\", \\\"2\\\", 4208], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Females of childbearing potential who are partners of male subjects are also advised to use additional contraception as shown in the list containing highly effective/effective contraception below.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix D  Pregnancy and Contraception Contraception and Pregnancy Avoidance Procedure\\\", \\\"\\\", \\\"2\\\", 4209], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Female Subjects and Their Male Partners\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": true, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix D  Pregnancy and Contraception Contraception and Pregnancy Avoidance Procedure\\\", \\\"\\\", \\\"2\\\", 4210], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"From signing of informed consent, throughout the duration of the study, and for 5 half-lives PLUS 30 days after last dose of study drug, female subjects of childbearing potential* who are sexually active with a nonsterilized male partner** must use:\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix D  Pregnancy and Contraception Contraception and Pregnancy Avoidance Procedure\\\", \\\"\\\", \\\"2\\\", 4211], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Two highly effective methods of contraception (from the list below).\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix D  Pregnancy and Contraception Contraception and Pregnancy Avoidance Procedure\\\", \\\"\\\", \\\"2\\\", 4212], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"In addition, they must be advised not to donate ova during this period.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix D  Pregnancy and Contraception Contraception and Pregnancy Avoidance Procedure\\\", \\\"\\\", \\\"2\\\", 4213], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Definitions and Procedures for Contraception and Pregnancy Avoidance\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": true, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix D  Pregnancy and Contraception Contraception and Pregnancy Avoidance Procedure\\\", \\\"\\\", \\\"2\\\", 4214], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"The following definitions apply for contraception and pregnancy avoidance procedures.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"single\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix D  Pregnancy and Contraception Contraception and Pregnancy Avoidance Procedure\\\", \\\"\\\", \\\"2\\\", 4215], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"* A woman is considered a woman of childbearing potential, that is, fertile, following menarche and until becoming postmenopausal unless permanently sterile.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix D  Pregnancy and Contraception Contraception and Pregnancy Avoidance Procedure\\\", \\\"\\\", \\\"2\\\", 4216], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Permanent sterilization methods include hysterectomy and bilateral oophorectomy.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix D  Pregnancy and Contraception Contraception and Pregnancy Avoidance Procedure\\\", \\\"\\\", \\\"2\\\", 4217], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"A postmenopausal state is defined as no menses for 12 months without an alternative medical cause.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix D  Pregnancy and Contraception Contraception and Pregnancy Avoidance Procedure\\\", \\\"\\\", \\\"2\\\", 4218], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"A high FSH level in the postmenopausal range (FSH >40 IU/L) may be used to confirm a postmenopausal state in younger women (eg, those aged <45 years) or women who are not using hormonal contraception or hormonal replacement therapy.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix D  Pregnancy and Contraception Contraception and Pregnancy Avoidance Procedure\\\", \\\"\\\", \\\"2\\\", 4219], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"However, in the absence of 12 months of amenorrhea, a single FSH measurement is insufficient.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix D  Pregnancy and Contraception Contraception and Pregnancy Avoidance Procedure\\\", \\\"\\\", \\\"2\\\", 4220], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"** Sterilized males should be at least 1 year post\\\\u2013bilateral vasectomy and have confirmed that they have obtained documentation of the absence of sperm in the ejaculate or have had bilateral orchidectomy.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix D  Pregnancy and Contraception Contraception and Pregnancy Avoidance Procedure\\\", \\\"\\\", \\\"2\\\", 4221], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"The following procedures apply for contraception and pregnancy avoidance.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": true, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"single\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix D  Pregnancy and Contraception Contraception and Pregnancy Avoidance Procedure\\\", \\\"\\\", \\\"2\\\", 4222], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"1. Highly effective methods of contraception are defined as those, alone or in combination, that result in a low failure rate (ie, less than 1% failure rate per year when used consistently and correctly).\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix D  Pregnancy and Contraception Contraception and Pregnancy Avoidance Procedure\\\", \\\"\\\", \\\"2\\\", 4223], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"In this study, where medications and devices containing hormones are included, the only acceptable methods of contraception are:\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix D  Pregnancy and Contraception Contraception and Pregnancy Avoidance Procedure\\\", \\\"\\\", \\\"2\\\", 4224], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\\u2022 Nonhormonal methods:\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix D  Pregnancy and Contraception Contraception and Pregnancy Avoidance Procedure\\\", \\\"\\\", \\\"2\\\", 4225], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\\u2013 Intrauterine device.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix D  Pregnancy and Contraception Contraception and Pregnancy Avoidance Procedure\\\", \\\"\\\", \\\"2\\\", 4226], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\\u2013 Bilateral tubal occlusion.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix D  Pregnancy and Contraception Contraception and Pregnancy Avoidance Procedure\\\", \\\"\\\", \\\"2\\\", 4227], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\\u2013 Vasectomized partner, provided that partner is the sole sexual partner of the study participant and that the vasectomized partner has received medical assessment of the surgical success.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix D  Pregnancy and Contraception Contraception and Pregnancy Avoidance Procedure\\\", \\\"\\\", \\\"2\\\", 4228], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\\u2013 True sexual abstinence, only if this is in line with the preferred and usual lifestyle of the subject.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix D  Pregnancy and Contraception Contraception and Pregnancy Avoidance Procedure\\\", \\\"\\\", \\\"2\\\", 4229], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"True abstinence is defined as refraining from heterosexual intercourse during the entire period of the study, from 1 month before the first dose until 5 half-lives PLUS 30 days after last dose.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix D  Pregnancy and Contraception Contraception and Pregnancy Avoidance Procedure\\\", \\\"\\\", \\\"2\\\", 4230], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\\u2022 Hormonal methods: Hormonal contraception may be susceptible to interaction with the investigative compound, comparator, concomitant medications, which may reduce the efficacy of the contraception method.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix D  Pregnancy and Contraception Contraception and Pregnancy Avoidance Procedure\\\", \\\"\\\", \\\"2\\\", 4231], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\\u2013 Combined (estrogen and progestogen) hormonal contraception associated with inhibition of ovulation.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix D  Pregnancy and Contraception Contraception and Pregnancy Avoidance Procedure\\\", \\\"\\\", \\\"2\\\", 4232], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Contraception must be initiated at least 3 months before the first dose of study drug.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix D  Pregnancy and Contraception Contraception and Pregnancy Avoidance Procedure\\\", \\\"\\\", \\\"2\\\", 4233], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"If female subjects have been taking progestogen-only hormonal contraception for less than 3 months before the first dose of study drug, female subjects must also (or partners of male subjects are advised to) employ a barrier method (male condom, female condom or diaphragm) until she has been on contraceptive for 3 months.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix D  Pregnancy and Contraception Contraception and Pregnancy Avoidance Procedure\\\", \\\"\\\", \\\"2\\\", 4234], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"The options below are included in the category of progestogen-only hormonal contraception;\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix D  Pregnancy and Contraception Contraception and Pregnancy Avoidance Procedure\\\", \\\"\\\", \\\"2\\\", 4235], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Segoe UI Symbol\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix D  Pregnancy and Contraception Contraception and Pregnancy Avoidance Procedure\\\", \\\"\\\", \\\"2\\\", 4236], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Oral \\\\u2020.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix D  Pregnancy and Contraception Contraception and Pregnancy Avoidance Procedure\\\", \\\"\\\", \\\"2\\\", 4237], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\\u2022 Intravaginal \\\\u2020 (eg, ring).\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix D  Pregnancy and Contraception Contraception and Pregnancy Avoidance Procedure\\\", \\\"\\\", \\\"2\\\", 4238], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\\u2022 transdermal \\\\u2020.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix D  Pregnancy and Contraception Contraception and Pregnancy Avoidance Procedure\\\", \\\"\\\", \\\"2\\\", 4239], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\\u2013 Progestogen-only hormonal contraception associated with inhibition of ovulation.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix D  Pregnancy and Contraception Contraception and Pregnancy Avoidance Procedure\\\", \\\"\\\", \\\"2\\\", 4240], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Important: Progestogen-only hormonal contraception must be initiated at least 3 months before the first dose of study drug.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix D  Pregnancy and Contraception Contraception and Pregnancy Avoidance Procedure\\\", \\\"\\\", \\\"2\\\", 4241], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"If female subjects have been taking progestogen-only hormonal contraception for less than 3 months before the first dose of study drug, female subjects must also (or partners of male subjects are advised to) employ a barrier method (male condom, female condom or diaphragm) until she has been on contraceptive for 3 months.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix D  Pregnancy and Contraception Contraception and Pregnancy Avoidance Procedure\\\", \\\"\\\", \\\"2\\\", 4242], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"The options below are included in the category of progestogen-only hormonal contraception:\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix D  Pregnancy and Contraception Contraception and Pregnancy Avoidance Procedure\\\", \\\"\\\", \\\"2\\\", 4243], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\\u2022 Oral \\\\u2020.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix D  Pregnancy and Contraception Contraception and Pregnancy Avoidance Procedure\\\", \\\"\\\", \\\"2\\\", 4244], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\\u2022 Injectable.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix D  Pregnancy and Contraception Contraception and Pregnancy Avoidance Procedure\\\", \\\"\\\", \\\"2\\\", 4245], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\\u2022 Implantable.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix D  Pregnancy and Contraception Contraception and Pregnancy Avoidance Procedure\\\", \\\"\\\", \\\"2\\\", 4246], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Among the examples of contraception methods shown above, methods available in Japan are listed below.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix D  Pregnancy and Contraception Contraception and Pregnancy Avoidance Procedure\\\", \\\"\\\", \\\"2\\\", 4247], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Male Subjects and Their Female Partners\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix D  Pregnancy and Contraception Contraception and Pregnancy Avoidance Procedure\\\", \\\"\\\", \\\"2\\\", 4248], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Segoe UI Symbol\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix D  Pregnancy and Contraception Contraception and Pregnancy Avoidance Procedure\\\", \\\"\\\", \\\"2\\\", 4249], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Intrauterine device.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix D  Pregnancy and Contraception Contraception and Pregnancy Avoidance Procedure\\\", \\\"\\\", \\\"2\\\", 4250], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\\u2022 Bilateral tubal occlusion.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix D  Pregnancy and Contraception Contraception and Pregnancy Avoidance Procedure\\\", \\\"\\\", \\\"2\\\", 4251], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\\u2022 Vasectomized partner (provided that partner is the sole sexual partner of the study participant and that the vasectomized partner has received medical assessment of the surgical success).\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix D  Pregnancy and Contraception Contraception and Pregnancy Avoidance Procedure\\\", \\\"\\\", \\\"2\\\", 4252], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\\u2022 Combined (estrogen and progestogen) hormonal contraception associated with inhibition of ovulation.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix D  Pregnancy and Contraception Contraception and Pregnancy Avoidance Procedure\\\", \\\"\\\", \\\"2\\\", 4253], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Female Subjects and Their Male Partners\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix D  Pregnancy and Contraception Contraception and Pregnancy Avoidance Procedure\\\", \\\"\\\", \\\"2\\\", 4254], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Segoe UI Symbol\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix D  Pregnancy and Contraception Contraception and Pregnancy Avoidance Procedure\\\", \\\"\\\", \\\"2\\\", 4255], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Intrauterine device.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix D  Pregnancy and Contraception Contraception and Pregnancy Avoidance Procedure\\\", \\\"\\\", \\\"2\\\", 4256], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\\u2022 Bilateral tubal occlusion.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix D  Pregnancy and Contraception Contraception and Pregnancy Avoidance Procedure\\\", \\\"\\\", \\\"2\\\", 4257], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\\u2022 Vasectomized partner (provided that partner is the sole sexual partner of the study participant and that the vasectomized partner has received medical assessment of the surgical success).\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix D  Pregnancy and Contraception Contraception and Pregnancy Avoidance Procedure\\\", \\\"\\\", \\\"2\\\", 4258], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\\u2022 Combined (estrogen and progestogen) hormonal contraception associated with inhibition of ovulation.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix D  Pregnancy and Contraception Contraception and Pregnancy Avoidance Procedure\\\", \\\"\\\", \\\"2\\\", 4259], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Male partners who are sexually active use condom.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix D  Pregnancy and Contraception Contraception and Pregnancy Avoidance Procedure\\\", \\\"\\\", \\\"2\\\", 4260], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"2. If genotoxicity/teratogenicity/embryotoxicity is unlikely to be caused by the investigational drug, comparator, background therapy or standard of care medications effective methods of contraception (there may be a higher than 1% failure rate) are:\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix D  Pregnancy and Contraception Contraception and Pregnancy Avoidance Procedure\\\", \\\"\\\", \\\"2\\\", 4261], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\\u2022 Double-barrier method (contraceptive sponge, diaphragm or cervical cap with spermicidal jellies or creams PLUS male condom).\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix D  Pregnancy and Contraception Contraception and Pregnancy Avoidance Procedure\\\", \\\"\\\", \\\"2\\\", 4262], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\\u2022 Progestogen only hormonal contraception, where inhibition of ovulation is not the primary mode of action PLUS condom with or without spermicide.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix D  Pregnancy and Contraception Contraception and Pregnancy Avoidance Procedure\\\", \\\"\\\", \\\"2\\\", 4263], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"3. Unacceptable methods of contraception are:\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix D  Pregnancy and Contraception Contraception and Pregnancy Avoidance Procedure\\\", \\\"\\\", \\\"2\\\", 4264], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\\u2022 Periodic abstinence (eg, calendar, ovulation, symptothermal, post-ovulation methods).\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix D  Pregnancy and Contraception Contraception and Pregnancy Avoidance Procedure\\\", \\\"\\\", \\\"2\\\", 4265], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\\u2022 Spermicides only.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix D  Pregnancy and Contraception Contraception and Pregnancy Avoidance Procedure\\\", \\\"\\\", \\\"2\\\", 4266], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\\u2022 Withdrawal.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix D  Pregnancy and Contraception Contraception and Pregnancy Avoidance Procedure\\\", \\\"\\\", \\\"2\\\", 4267], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\\u2022 No method at all.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix D  Pregnancy and Contraception Contraception and Pregnancy Avoidance Procedure\\\", \\\"\\\", \\\"2\\\", 4268], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\\u2022 Use of female and male condoms together.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix D  Pregnancy and Contraception Contraception and Pregnancy Avoidance Procedure\\\", \\\"\\\", \\\"2\\\", 4269], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\\u2022 Cap/diaphragm/sponge without spermicide and without condom.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix D  Pregnancy and Contraception Contraception and Pregnancy Avoidance Procedure\\\", \\\"\\\", \\\"2\\\", 4270], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\\u2022 Sexual abstinence is NOT an acceptable method of contraception (unless approved by the investigator).\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix D  Pregnancy and Contraception Contraception and Pregnancy Avoidance Procedure\\\", \\\"\\\", \\\"2\\\", 4271], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"4. Subjects will be provided with information on highly effective/effective methods of contraception as part of the subject informed consent process and will be asked to sign a consent form stating that they understand the requirements for avoidance of pregnancy, donation of ova, and sperm donation during the course of the study.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix D  Pregnancy and Contraception Contraception and Pregnancy Avoidance Procedure\\\", \\\"\\\", \\\"2\\\", 4272], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"5. During the course of the study, regular serum/urine ~REDACTED~ (~REDACTED~) pregnancy tests will be performed only for women of childbearing potential and all subjects (male and female) will receive continued guidance with respect to the avoidance of pregnancy and sperm donation as part of the study procedures.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix D  Pregnancy and Contraception Contraception and Pregnancy Avoidance Procedure\\\", \\\"\\\", \\\"2\\\", 4273], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Such guidance should include a reminder of the following:\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix D  Pregnancy and Contraception Contraception and Pregnancy Avoidance Procedure\\\", \\\"\\\", \\\"2\\\", 4274], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"a) Contraceptive requirements of the study.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix D  Pregnancy and Contraception Contraception and Pregnancy Avoidance Procedure\\\", \\\"\\\", \\\"2\\\", 4275], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"b) Reasons for use of barrier methods (ie, condom) in males with pregnant partners.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix D  Pregnancy and Contraception Contraception and Pregnancy Avoidance Procedure\\\", \\\"\\\", \\\"2\\\", 4276], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"c) Assessment of subject compliance through questions such as:\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix D  Pregnancy and Contraception Contraception and Pregnancy Avoidance Procedure\\\", \\\"\\\", \\\"2\\\", 4277], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"i. Have you used the contraception consistently and correctly since the last visit?\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix D  Pregnancy and Contraception Contraception and Pregnancy Avoidance Procedure\\\", \\\"\\\", \\\"2\\\", 4278], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"ii. Have you forgotten to use contraception since the last visit?\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix D  Pregnancy and Contraception Contraception and Pregnancy Avoidance Procedure\\\", \\\"\\\", \\\"2\\\", 4279], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"iii. Are your menses late (even in women with irregular or infrequent menstrual cycles a pregnancy test must be performed if the answer is \\\\u201cyes\\\\u201d).\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix D  Pregnancy and Contraception Contraception and Pregnancy Avoidance Procedure\\\", \\\"\\\", \\\"2\\\", 4280], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"iv. Is there a chance you could be pregnant?\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix D  Pregnancy and Contraception Contraception and Pregnancy Avoidance Procedure\\\", \\\"\\\", \\\"2\\\", 4281], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"1. In addition to a negative ~REDACTED~ pregnancy test at screening, female subjects of childbearing potential must also have confirmed menses in the month before first dosing (no delayed menses), a negative ~REDACTED~ pregnancy test before receiving any dose of study medication.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix D  Pregnancy and Contraception Contraception and Pregnancy Avoidance Procedure\\\", \\\"\\\", \\\"2\\\", 4282], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"In addition, subjects must also have a negative ~REDACTED~ pregnancy test before receiving first dose of investigational drug as close as possible and before first dose of investigational drug, preferably on the same day.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix D  Pregnancy and Contraception Contraception and Pregnancy Avoidance Procedure\\\", \\\"\\\", \\\"2\\\", 4283], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"General Guidance With Respect to the Avoidance of Pregnancy\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": true, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix D  Pregnancy and Contraception Contraception and Pregnancy Avoidance Procedure\\\", \\\"\\\", \\\"2\\\", 4284], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Such guidance should include a reminder of the following:\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix D  Pregnancy and Contraception Contraception and Pregnancy Avoidance Procedure\\\", \\\"\\\", \\\"2\\\", 4285], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\\u2022 Contraceptive requirements of the study.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix D  Pregnancy and Contraception Contraception and Pregnancy Avoidance Procedure\\\", \\\"\\\", \\\"2\\\", 4286], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\\u2022 Reasons for use of barrier methods (ie, condom) in males with pregnant partners.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix D  Pregnancy and Contraception Contraception and Pregnancy Avoidance Procedure\\\", \\\"\\\", \\\"2\\\", 4287], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\\u2022 Assessment of subject compliance through questions such as:\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix D  Pregnancy and Contraception Contraception and Pregnancy Avoidance Procedure\\\", \\\"\\\", \\\"2\\\", 4288], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\\u2013 Have you used the contraception consistently and correctly since the last visit?\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix D  Pregnancy and Contraception Contraception and Pregnancy Avoidance Procedure\\\", \\\"\\\", \\\"2\\\", 4289], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\\u2013 Have you forgotten to use contraception since the last visit?\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix D  Pregnancy and Contraception Contraception and Pregnancy Avoidance Procedure\\\", \\\"\\\", \\\"2\\\", 4290], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\\u2013 Are your menses late (even in women with irregular or infrequent menstrual cycles a pregnancy test must be performed if the answer is \\\\u201cyes\\\\u201d).\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix D  Pregnancy and Contraception Contraception and Pregnancy Avoidance Procedure\\\", \\\"\\\", \\\"2\\\", 4291], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\\u2013 Is there a chance you could be pregnant?\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix D  Pregnancy and Contraception Contraception and Pregnancy Avoidance Procedure\\\", \\\"\\\", \\\"2\\\", 4292], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"Pregnancy/Suspected Pregnancy\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading8\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix D  Pregnancy and Contraception Contraception and Pregnancy Avoidance Procedure\\\", \\\"\\\", \\\"2\\\", 4293], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"If any subject is found to be pregnant during the study, she should be withdrawn and any sponsor-supplied drug should be immediately discontinued.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix D  Pregnancy and Contraception Contraception and Pregnancy Avoidance Procedure\\\", \\\"\\\", \\\"2\\\", 4294], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"In addition, any pregnancies in the partner of a male subject during the study or for 5 half-lives PLUS 90 days after the last dose, should also be recorded following authorization from the subject\\\\u2019s partner.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix D  Pregnancy and Contraception Contraception and Pregnancy Avoidance Procedure\\\", \\\"\\\", \\\"2\\\", 4295], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Should the pregnancy occur during or after administration of blinded drug, the investigator must inform the subject of their right to receive treatment information.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix D  Pregnancy and Contraception Contraception and Pregnancy Avoidance Procedure\\\", \\\"\\\", \\\"2\\\", 4296], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"If the subject chooses to receive unblinded treatment information, the individual blind should be broken by the investigator.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix D  Pregnancy and Contraception Contraception and Pregnancy Avoidance Procedure\\\", \\\"\\\", \\\"2\\\", 4297], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Subjects randomized to placebo need not be followed.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix D  Pregnancy and Contraception Contraception and Pregnancy Avoidance Procedure\\\", \\\"\\\", \\\"2\\\", 4298], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"If the female subject or female partner of a male subject agrees to the primary care physician being informed, the investigator should notify the primary care physician that the female subject or female partner of the subject was participating in a clinical study at the time she became pregnant and provide details of the study drug the subject received (blinded or unblinded, as applicable).\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix D  Pregnancy and Contraception Contraception and Pregnancy Avoidance Procedure\\\", \\\"\\\", \\\"2\\\", 4299], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"All pregnancies, including female partners of male subjects, in subjects on active study drug (including comparator, if applicable) will be followed up to final outcome, using the pregnancy form.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix D  Pregnancy and Contraception Contraception and Pregnancy Avoidance Procedure\\\", \\\"\\\", \\\"2\\\", 4300], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Pregnancies will remain blinded to the study team.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix D  Pregnancy and Contraception Contraception and Pregnancy Avoidance Procedure\\\", \\\"\\\", \\\"2\\\", 4301], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"The outcome, including any premature termination, must be reported to the sponsor.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix D  Pregnancy and Contraception Contraception and Pregnancy Avoidance Procedure\\\", \\\"\\\", \\\"2\\\", 4302], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"An evaluation after the birth of the child will also be conducted.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix D  Pregnancy and Contraception Contraception and Pregnancy Avoidance Procedure\\\", \\\"\\\", \\\"2\\\", 4303], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix D  Pregnancy and Contraception Contraception and Pregnancy Avoidance Procedure\\\", \\\"\\\", \\\"2\\\", 4304], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Appendix E\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix E  ICSD-3 Diagnostic Criteria for NT1 Criteria A and B must be met:\\\", \\\"\\\", \\\"2\\\", 4305], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix E  ICSD-3 Diagnostic Criteria for NT1 Criteria A and B must be met:\\\", \\\"\\\", \\\"2\\\", 4306], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"ICSD-3 Diagnostic Criteria for NT1\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix E  ICSD-3 Diagnostic Criteria for NT1 Criteria A and B must be met:\\\", \\\"\\\", \\\"2\\\", 4307], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Criteria A and B must be met:\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix E  ICSD-3 Diagnostic Criteria for NT1 Criteria A and B must be met:\\\", \\\"\\\", \\\"2\\\", 4308], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"A. The patient has daily periods of irrepressible need to sleep or daytime lapses into sleep occurring for at least 3 months.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix E  ICSD-3 Diagnostic Criteria for NT1 Criteria A and B must be met:\\\", \\\"\\\", \\\"2\\\", 4309], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"B. The presence of one or both of the following:\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix E  ICSD-3 Diagnostic Criteria for NT1 Criteria A and B must be met:\\\", \\\"\\\", \\\"2\\\", 4310], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"1. Cataplexy (as defined under essential features) and a mean sleep latency of \\\\u22648 minutes and 2 or more sleep onset REM periods (SOREMPs) on an MSLT performed according to standard techniques.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix E  ICSD-3 Diagnostic Criteria for NT1 Criteria A and B must be met:\\\", \\\"\\\", \\\"2\\\", 4311], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"A SOREMP (within 15 minutes of sleep onset) on the preceding nocturnal polysomnogram may replace one of the SOREMPs on the MSLT.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix E  ICSD-3 Diagnostic Criteria for NT1 Criteria A and B must be met:\\\", \\\"\\\", \\\"2\\\", 4312], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"~REDACTED~ hypocretin-1 concentration, measured by immunoreactivity, is either \\\\u2264110 pg/mL or less than one-third of mean values obtained in normal subjects with the same standardized assay.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix E  ICSD-3 Diagnostic Criteria for NT1 Criteria A and B must be met:\\\", \\\"\\\", \\\"2\\\", 4313], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix E  ICSD-3 Diagnostic Criteria for NT1 Criteria A and B must be met:\\\", \\\"\\\", \\\"2\\\", 4314], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"Appendix F List of Inhibitors and Inducers of CYP3A and the Substrates of CYP3A4 and OATP1B1\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading8\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix F  List of Inhibitors and Inducers of CYP3A and the Substrates of CYP3A4 and OATP1B1\\\", \\\"\\\", \\\"2\\\", 4315], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Known moderate and strong CYP3A inhibitors or inducers and listed below:\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix F  List of Inhibitors and Inducers of CYP3A and the Substrates of CYP3A4 and OATP1B1\\\", \\\"\\\", \\\"2\\\", 4316], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Strong CYP3A inhibitors:\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"single\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix F  List of Inhibitors and Inducers of CYP3A and the Substrates of CYP3A4 and OATP1B1\\\", \\\"\\\", \\\"2\\\", 4317], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"~REDACTED~, ~REDACTED~, ~REDACTED~, ~REDACTED~, ~REDACTED~, danoprevir, ~REDACTED~, ~REDACTED~, ~REDACTED~, ~REDACTED~, ~REDACTED~, ~REDACTED~, ~REDACTED~, ~REDACTED~, ~REDACTED~, ~REDACTED~, ~REDACTED~, ~REDACTED~, ~REDACTED~, ~REDACTED~, ~REDACTED~, ~REDACTED~, ~REDACTED~.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix F  List of Inhibitors and Inducers of CYP3A and the Substrates of CYP3A4 and OATP1B1\\\", \\\"\\\", \\\"2\\\", 4318], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Moderate CYP3A inhibitors:\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"single\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix F  List of Inhibitors and Inducers of CYP3A and the Substrates of CYP3A4 and OATP1B1\\\", \\\"\\\", \\\"2\\\", 4319], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"~REDACTED~, ~REDACTED~, ~REDACTED~, ~REDACTED~, ~REDACTED~, ~REDACTED~, ~REDACTED~, ~REDACTED~, ~REDACTED~, ~REDACTED~, ~REDACTED~, ~REDACTED~, ~REDACTED~, fos~REDACTED~, ~REDACTED~, ~REDACTED~, ~REDACTED~, ~REDACTED~, ~REDACTED~, ~REDACTED~.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix F  List of Inhibitors and Inducers of CYP3A and the Substrates of CYP3A4 and OATP1B1\\\", \\\"\\\", \\\"2\\\", 4320], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Strong CYP3A inducers:\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"single\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix F  List of Inhibitors and Inducers of CYP3A and the Substrates of CYP3A4 and OATP1B1\\\", \\\"\\\", \\\"2\\\", 4321], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"~REDACTED~, ~REDACTED~, ~REDACTED~, ~REDACTED~, ~REDACTED~, ~REDACTED~, ~REDACTED~.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix F  List of Inhibitors and Inducers of CYP3A and the Substrates of CYP3A4 and OATP1B1\\\", \\\"\\\", \\\"2\\\", 4322], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Moderate CYP3A inducers:\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"single\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix F  List of Inhibitors and Inducers of CYP3A and the Substrates of CYP3A4 and OATP1B1\\\", \\\"\\\", \\\"2\\\", 4323], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"~REDACTED~, ~REDACTED~, ~REDACTED~, ~REDACTED~.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix F  List of Inhibitors and Inducers of CYP3A and the Substrates of CYP3A4 and OATP1B1\\\", \\\"\\\", \\\"2\\\", 4324], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Known CYP3A substrates with narrow therapeutic range including but not limited to ergot alkaloids, ~REDACTED~, ~REDACTED~, ~REDACTED~, ~REDACTED~, systemic ~REDACTED~ (dose equivalent to \\\\u226510 mg ~REDACTED~ per day), ~REDACTED~, ~REDACTED~, ~REDACTED~, ~REDACTED~, ~REDACTED~, ~REDACTED~, ~REDACTED~, ~REDACTED~, ~REDACTED~, ~REDACTED~, ~REDACTED~, ~REDACTED~, ~REDACTED~, ~REDACTED~, ~REDACTED~, and ~REDACTED~.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix F  List of Inhibitors and Inducers of CYP3A and the Substrates of CYP3A4 and OATP1B1\\\", \\\"\\\", \\\"2\\\", 4325], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Known sensitive OATP1B1 substrates including but not limited to ~REDACTED~, ~REDACTED~, ~REDACTED~, ~REDACTED~, ~REDACTED~, ~REDACTED~, ~REDACTED~.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix F  List of Inhibitors and Inducers of CYP3A and the Substrates of CYP3A4 and OATP1B1\\\", \\\"\\\", \\\"2\\\", 4326], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix F  List of Inhibitors and Inducers of CYP3A and the Substrates of CYP3A4 and OATP1B1\\\", \\\"\\\", \\\"2\\\", 4327], [\\\"\\\", \\\"Unmapped\\\", \\\"table\\\", {\\\"Table\\\": \\\"<table border=\\\\\\\"1\\\\\\\" class=\\\\\\\"dataframe\\\\\\\">\\\\n  <thead>\\\\n    <tr style=\\\\\\\"text-align: right;\\\\\\\">\\\\n      <th></th>\\\\n      <th>1.0</th>\\\\n      <th>2.0</th>\\\\n    </tr>\\\\n  </thead>\\\\n  <tbody>\\\\n    <tr>\\\\n      <th>0</th>\\\\n      <td>Study No. TAK-861-1001</td>\\\\n      <td>Page 150 of 151</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>1</th>\\\\n      <td>Protocol Incorporating Amendment No. 2</td>\\\\n      <td>16 March 2021</td>\\\\n    </tr>\\\\n  </tbody>\\\\n</table>\\\", \\\"SectionHeaderPrintPage\\\": \\\"148\\\", \\\"TableIndex\\\": \\\"51\\\", \\\"TableName\\\": \\\"Appendix\\\\u00a0F List of Inhibitors and Inducers of CYP3A and the Substrates of CYP3A4 and OATP1B1\\\", \\\"Header\\\": [0, 1]}, {\\\"IsBold\\\": true, \\\"font_size\\\": 20, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 20, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix F  List of Inhibitors and Inducers of CYP3A and the Substrates of CYP3A4 and OATP1B1\\\", \\\"\\\", \\\"2\\\", 4328], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix F  List of Inhibitors and Inducers of CYP3A and the Substrates of CYP3A4 and OATP1B1\\\", \\\"\\\", \\\"2\\\", 4329], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\"Appendix G Protocol History\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading8\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix G  Protocol History\\\", \\\"\\\", \\\"2\\\", 4330], [\\\"\\\", \\\"Unmapped\\\", \\\"table\\\", {\\\"Table\\\": \\\"<table border=\\\\\\\"1\\\\\\\" class=\\\\\\\"dataframe\\\\\\\">\\\\n  <thead>\\\\n    <tr style=\\\\\\\"text-align: right;\\\\\\\">\\\\n      <th></th>\\\\n      <th>1.0</th>\\\\n      <th>2.0</th>\\\\n      <th>3.0</th>\\\\n    </tr>\\\\n  </thead>\\\\n  <tbody>\\\\n    <tr>\\\\n      <th>0</th>\\\\n      <td>Date</td>\\\\n      <td>Amendment Number</td>\\\\n      <td>Region</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>1</th>\\\\n      <td>16 March 2021</td>\\\\n      <td>Amendment 2</td>\\\\n      <td>Global</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>2</th>\\\\n      <td>12 February 2021</td>\\\\n      <td>Amendment 1</td>\\\\n      <td>Global</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>3</th>\\\\n      <td>15 December 2020</td>\\\\n      <td>Initial version</td>\\\\n      <td>Global</td>\\\\n    </tr>\\\\n  </tbody>\\\\n</table>\\\", \\\"SectionHeaderPrintPage\\\": \\\"149\\\", \\\"TableIndex\\\": \\\"52\\\", \\\"TableName\\\": \\\"\\\", \\\"Header\\\": [0]}, {\\\"IsBold\\\": true, \\\"font_size\\\": 20, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 20, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix G  Protocol History\\\", \\\"\\\", \\\"2\\\", 4331], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Protocol Amendment 1 Summary and Rationale:\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix G  Protocol History\\\", \\\"\\\", \\\"2\\\", 4332], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"This section describes the changes in reference to the protocol incorporating Amendment 1.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix G  Protocol History\\\", \\\"\\\", \\\"2\\\", 4333], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"The primary reasons for this amendment were to:\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix G  Protocol History\\\", \\\"\\\", \\\"2\\\", 4334], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\\u2022 update study drug formulation section.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix G  Protocol History\\\", \\\"\\\", \\\"2\\\", 4335], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\\u2022 update blood volume.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix G  Protocol History\\\", \\\"\\\", \\\"2\\\", 4336], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\\u2022 specify ECG parameters.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix G  Protocol History\\\", \\\"\\\", \\\"2\\\", 4337], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"In this amendment, minor grammatical, editorial, formatting, and administrative changes not affecting the conduct of the study are included for clarification and administrative purposes only.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix G  Protocol History\\\", \\\"\\\", \\\"2\\\", 4338], [\\\"\\\", \\\"Unmapped\\\", \\\"table\\\", {\\\"Table\\\": \\\"<table border=\\\\\\\"1\\\\\\\" class=\\\\\\\"dataframe\\\\\\\">\\\\n  <thead>\\\\n    <tr style=\\\\\\\"text-align: right;\\\\\\\">\\\\n      <th></th>\\\\n      <th>1.0</th>\\\\n      <th>2.0</th>\\\\n      <th>3.0</th>\\\\n      <th>4.0</th>\\\\n    </tr>\\\\n  </thead>\\\\n  <tbody>\\\\n    <tr>\\\\n      <th>0</th>\\\\n      <td>Protocol Amendment 1</td>\\\\n      <td>Protocol Amendment 1</td>\\\\n      <td>Protocol Amendment 1</td>\\\\n      <td>Protocol Amendment 1</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>1</th>\\\\n      <td>Summary of Changes Since the Last Version of the Approved Protocol</td>\\\\n      <td>Summary of Changes Since the Last Version of the Approved Protocol</td>\\\\n      <td>Summary of Changes Since the Last Version of the Approved Protocol</td>\\\\n      <td>Summary of Changes Since the Last Version of the Approved Protocol</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>2</th>\\\\n      <td>Change Number</td>\\\\n      <td>Sections Affected by Change</td>\\\\n      <td>Description of Each Change and Rationale</td>\\\\n      <td>Description of Each Change and Rationale</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>3</th>\\\\n      <td></td>\\\\n      <td>Location</td>\\\\n      <td>Description</td>\\\\n      <td>Rationale</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>4</th>\\\\n      <td>1</td>\\\\n      <td>Section 3.0 Schedule of Study Procedures</td>\\\\n      <td>It has been clarified that only blood pressure and pulse rate will be taken in supine position. For 24-hour assessments, \\\\\\\"X\\\\\\\"s have been added to indicate both days. Timepoints have been specified in footnotes. For Part E, baseline ABPM footnote has been revised.</td>\\\\n      <td>Clarification</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>5</th>\\\\n      <td>2</td>\\\\n      <td>Section 7.4.1 Diet and Fluid Section 8.1.1 Suspension Formulation Section 8.1.3.1 Suspension Formulation</td>\\\\n      <td>Text has been added for TAK-861 suspension formulation.</td>\\\\n      <td>Information has been added for suspension formulation.</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>6</th>\\\\n      <td>3</td>\\\\n      <td>Section 9.1.2.1 Assignment of Subject Numbers</td>\\\\n      <td>Text has been added to reflect that multiple screening is allowed for the healthy volunteer participants.</td>\\\\n      <td>Updated information regarding rescreening.</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>7</th>\\\\n      <td>4</td>\\\\n      <td>Section 9.2.5.1 12-Lead ECG</td>\\\\n      <td>Text has been added to specify ECG criteria that will be recorded.</td>\\\\n      <td>Clarification.</td>\\\\n    </tr>\\\\n  </tbody>\\\\n</table>\\\", \\\"SectionHeaderPrintPage\\\": \\\"149\\\", \\\"TableIndex\\\": \\\"53\\\", \\\"TableName\\\": \\\"\\\", \\\"Header\\\": [0, 1, 2, 3]}, {\\\"IsBold\\\": true, \\\"font_size\\\": 20, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 20, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix G  Protocol History\\\", \\\"\\\", \\\"2\\\", 4339], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix G  Protocol History\\\", \\\"\\\", \\\"2\\\", 4340], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix G  Protocol History\\\", \\\"\\\", \\\"2\\\", 4341], [\\\"\\\", \\\"Unmapped\\\", \\\"table\\\", {\\\"Table\\\": \\\"<table border=\\\\\\\"1\\\\\\\" class=\\\\\\\"dataframe\\\\\\\">\\\\n  <thead>\\\\n    <tr style=\\\\\\\"text-align: right;\\\\\\\">\\\\n      <th></th>\\\\n      <th>1.0</th>\\\\n      <th>2.0</th>\\\\n    </tr>\\\\n  </thead>\\\\n  <tbody>\\\\n    <tr>\\\\n      <th>0</th>\\\\n      <td>Study No. TAK-861-1001</td>\\\\n      <td>Page 151 of 151</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>1</th>\\\\n      <td>Protocol Incorporating Amendment No. 2</td>\\\\n      <td>16 March 2021</td>\\\\n    </tr>\\\\n  </tbody>\\\\n</table>\\\", \\\"SectionHeaderPrintPage\\\": \\\"149\\\", \\\"TableIndex\\\": \\\"54\\\", \\\"TableName\\\": \\\"\\\", \\\"Header\\\": [0, 1]}, {\\\"IsBold\\\": true, \\\"font_size\\\": 20, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 20, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix G  Protocol History\\\", \\\"\\\", \\\"2\\\", 4342], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix G  Protocol History\\\", \\\"\\\", \\\"2\\\", 4343], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix G  Protocol History\\\", \\\"\\\", \\\"2\\\", 4344], [\\\"\\\", \\\"Unmapped\\\", \\\"table\\\", {\\\"Table\\\": \\\"<table border=\\\\\\\"1\\\\\\\" class=\\\\\\\"dataframe\\\\\\\">\\\\n  <thead>\\\\n    <tr style=\\\\\\\"text-align: right;\\\\\\\">\\\\n      <th></th>\\\\n      <th>1.0</th>\\\\n      <th>2.0</th>\\\\n      <th>3.0</th>\\\\n      <th>4.0</th>\\\\n    </tr>\\\\n  </thead>\\\\n  <tbody>\\\\n    <tr>\\\\n      <th>0</th>\\\\n      <td></td>\\\\n      <td>Protocol Amendment 1</td>\\\\n      <td>Protocol Amendment 1</td>\\\\n      <td>Protocol Amendment 1</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>1</th>\\\\n      <td></td>\\\\n      <td>Summary of Changes Since the Last Version of the Approved Protocol</td>\\\\n      <td>Summary of Changes Since the Last Version of the Approved Protocol</td>\\\\n      <td>Summary of Changes Since the Last Version of the Approved Protocol</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>2</th>\\\\n      <td>Change Number</td>\\\\n      <td>Sections Affected by Change</td>\\\\n      <td>Description of Each Change and Rationale</td>\\\\n      <td>Description of Each Change and Rationale</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>3</th>\\\\n      <td></td>\\\\n      <td>Location</td>\\\\n      <td>Description</td>\\\\n      <td>Rationale</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>4</th>\\\\n      <td>5</td>\\\\n      <td>Section 9.3 Biomarker, PK, PD, and Pharmacogenomics Samples</td>\\\\n      <td>Maximum blood draw volume has been updated.</td>\\\\n      <td>Update.</td>\\\\n    </tr>\\\\n  </tbody>\\\\n</table>\\\", \\\"SectionHeaderPrintPage\\\": \\\"149\\\", \\\"TableIndex\\\": \\\"55\\\", \\\"TableName\\\": \\\"\\\", \\\"Header\\\": [0, 1, 2, 3]}, {\\\"IsBold\\\": true, \\\"font_size\\\": 20, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 20, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix G  Protocol History\\\", \\\"\\\", \\\"2\\\", 4345], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix G  Protocol History\\\", \\\"\\\", \\\"2\\\", 4346], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix G  Protocol History\\\", \\\"\\\", \\\"2\\\", 4347], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix G  Protocol History\\\", \\\"\\\", \\\"2\\\", 4348], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Amendment 02 to A Randomized, Double-blind, Placebo-Controlled Study to Assess the Safety, Tolerability,\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 20, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"MS UI Gothic\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 20, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix G  Protocol History\\\", \\\"\\\", \\\"2\\\", 4349], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Pharmacokinetics, and Pharmacodynamics of Single and Multiple Doses of TAK-861 in Healthy Adult and Elderly\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 20, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"MS UI Gothic\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 20, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix G  Protocol History\\\", \\\"\\\", \\\"2\\\", 4350], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Subjects and Subjects With Narcolepsy Type 1\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 20, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"MS UI Gothic\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 20, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix G  Protocol History\\\", \\\"\\\", \\\"2\\\", 4351], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix G  Protocol History\\\", \\\"\\\", \\\"2\\\", 4352], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix G  Protocol History\\\", \\\"\\\", \\\"2\\\", 4353], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix G  Protocol History\\\", \\\"\\\", \\\"2\\\", 4354], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix G  Protocol History\\\", \\\"\\\", \\\"2\\\", 4355], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix G  Protocol History\\\", \\\"\\\", \\\"2\\\", 4356], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"E\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 28, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 28, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix G  Protocol History\\\", \\\"\\\", \\\"2\\\", 4357], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"LECTRONIC\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 22, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 22, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix G  Protocol History\\\", \\\"\\\", \\\"2\\\", 4358], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"S\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 28, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 28, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix G  Protocol History\\\", \\\"\\\", \\\"2\\\", 4359], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"IGNATURES\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 22, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 22, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix G  Protocol History\\\", \\\"\\\", \\\"2\\\", 4360], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 28, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 28, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix G  Protocol History\\\", \\\"\\\", \\\"2\\\", 4361], [\\\"\\\", \\\"Unmapped\\\", \\\"table\\\", {\\\"Table\\\": \\\"<table border=\\\\\\\"1\\\\\\\" class=\\\\\\\"dataframe\\\\\\\">\\\\n  <thead>\\\\n    <tr style=\\\\\\\"text-align: right;\\\\\\\">\\\\n      <th></th>\\\\n      <th>1.0</th>\\\\n      <th>2.0</th>\\\\n      <th>3.0</th>\\\\n    </tr>\\\\n  </thead>\\\\n  <tbody>\\\\n    <tr>\\\\n      <th>0</th>\\\\n      <td>Signed by</td>\\\\n      <td>Meaning of Signature</td>\\\\n      <td>Server Date (dd-MMM-yyyy HH:mm \\\\u2018UTC\\\\u2019)</td>\\\\n    </tr>\\\\n  </tbody>\\\\n</table>\\\", \\\"SectionHeaderPrintPage\\\": \\\"149\\\", \\\"TableIndex\\\": \\\"56\\\", \\\"TableName\\\": \\\"\\\", \\\"Header\\\": [0]}, {\\\"IsBold\\\": true, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"entity\\\": [], \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix G  Protocol History\\\", \\\"\\\", \\\"2\\\", 4362], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Sugiura, Kenkichi\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix G  Protocol History\\\", \\\"\\\", \\\"2\\\", 4363], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix G  Protocol History\\\", \\\"\\\", \\\"2\\\", 4364], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix G  Protocol History\\\", \\\"\\\", \\\"2\\\", 4365], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Biostatistics Approval\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix G  Protocol History\\\", \\\"\\\", \\\"2\\\", 4366], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix G  Protocol History\\\", \\\"\\\", \\\"2\\\", 4367], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"17-Mar-2021 00:11 UTC\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix G  Protocol History\\\", \\\"\\\", \\\"2\\\", 4368], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix G  Protocol History\\\", \\\"\\\", \\\"2\\\", 4369], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix G  Protocol History\\\", \\\"\\\", \\\"2\\\", 4370], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": 6, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 6, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix G  Protocol History\\\", \\\"\\\", \\\"2\\\", 4371], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": 6, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 6, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix G  Protocol History\\\", \\\"\\\", \\\"2\\\", 4372], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Xu, Lin\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix G  Protocol History\\\", \\\"\\\", \\\"2\\\", 4373], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix G  Protocol History\\\", \\\"\\\", \\\"2\\\", 4374], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix G  Protocol History\\\", \\\"\\\", \\\"2\\\", 4375], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Clinical Pharmacology Approval\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix G  Protocol History\\\", \\\"\\\", \\\"2\\\", 4376], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix G  Protocol History\\\", \\\"\\\", \\\"2\\\", 4377], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"17-Mar-2021 00:20 UTC\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix G  Protocol History\\\", \\\"\\\", \\\"2\\\", 4378], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix G  Protocol History\\\", \\\"\\\", \\\"2\\\", 4379], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix G  Protocol History\\\", \\\"\\\", \\\"2\\\", 4380], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": 6, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 6, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix G  Protocol History\\\", \\\"\\\", \\\"2\\\", 4381], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": 6, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 6, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix G  Protocol History\\\", \\\"\\\", \\\"2\\\", 4382], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Von Hehn, Christian\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix G  Protocol History\\\", \\\"\\\", \\\"2\\\", 4383], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix G  Protocol History\\\", \\\"\\\", \\\"2\\\", 4384], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Clinical Science Approval\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix G  Protocol History\\\", \\\"\\\", \\\"2\\\", 4385], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix G  Protocol History\\\", \\\"\\\", \\\"2\\\", 4386], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"17-Mar-2021 14:03 UTC\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix G  Protocol History\\\", \\\"\\\", \\\"2\\\", 4387], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix G  Protocol History\\\", \\\"\\\", \\\"2\\\", 4388], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix G  Protocol History\\\", \\\"\\\", \\\"2\\\", 4389], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": 6, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 6, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix G  Protocol History\\\", \\\"\\\", \\\"2\\\", 4390], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": 6, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 6, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix G  Protocol History\\\", \\\"\\\", \\\"2\\\", 4391], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix G  Protocol History\\\", \\\"\\\", \\\"2\\\", 4392], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix G  Protocol History\\\", \\\"\\\", \\\"2\\\", 4393], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix G  Protocol History\\\", \\\"\\\", \\\"2\\\", 4394], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": 6, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 6, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix G  Protocol History\\\", \\\"\\\", \\\"2\\\", 4395], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": 6, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 6, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix G  Protocol History\\\", \\\"\\\", \\\"2\\\", 4396], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix G  Protocol History\\\", \\\"\\\", \\\"2\\\", 4397], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix G  Protocol History\\\", \\\"\\\", \\\"2\\\", 4398], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix G  Protocol History\\\", \\\"\\\", \\\"2\\\", 4399], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": 6, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 6, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix G  Protocol History\\\", \\\"\\\", \\\"2\\\", 4400], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": 6, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 6, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix G  Protocol History\\\", \\\"\\\", \\\"2\\\", 4401], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix G  Protocol History\\\", \\\"\\\", \\\"2\\\", 4402], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix G  Protocol History\\\", \\\"\\\", \\\"2\\\", 4403], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix G  Protocol History\\\", \\\"\\\", \\\"2\\\", 4404], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": 6, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 6, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix G  Protocol History\\\", \\\"\\\", \\\"2\\\", 4405], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": 6, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 6, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix G  Protocol History\\\", \\\"\\\", \\\"2\\\", 4406], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix G  Protocol History\\\", \\\"\\\", \\\"2\\\", 4407], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix G  Protocol History\\\", \\\"\\\", \\\"2\\\", 4408], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix G  Protocol History\\\", \\\"\\\", \\\"2\\\", 4409], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": 6, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 6, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix G  Protocol History\\\", \\\"\\\", \\\"2\\\", 4410], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": 6, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 6, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix G  Protocol History\\\", \\\"\\\", \\\"2\\\", 4411], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix G  Protocol History\\\", \\\"\\\", \\\"2\\\", 4412], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix G  Protocol History\\\", \\\"\\\", \\\"2\\\", 4413], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix G  Protocol History\\\", \\\"\\\", \\\"2\\\", 4414], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": 6, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 6, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix G  Protocol History\\\", \\\"\\\", \\\"2\\\", 4415], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": 6, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 6, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix G  Protocol History\\\", \\\"\\\", \\\"2\\\", 4416], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix G  Protocol History\\\", \\\"\\\", \\\"2\\\", 4417], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix G  Protocol History\\\", \\\"\\\", \\\"2\\\", 4418], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix G  Protocol History\\\", \\\"\\\", \\\"2\\\", 4419], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": 6, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 6, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix G  Protocol History\\\", \\\"\\\", \\\"2\\\", 4420], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": 6, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 6, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix G  Protocol History\\\", \\\"\\\", \\\"2\\\", 4421], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix G  Protocol History\\\", \\\"\\\", \\\"2\\\", 4422], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix G  Protocol History\\\", \\\"\\\", \\\"2\\\", 4423], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix G  Protocol History\\\", \\\"\\\", \\\"2\\\", 4424], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": 6, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 6, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix G  Protocol History\\\", \\\"\\\", \\\"2\\\", 4425], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": 6, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 6, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix G  Protocol History\\\", \\\"\\\", \\\"2\\\", 4426], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix G  Protocol History\\\", \\\"\\\", \\\"2\\\", 4427], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix G  Protocol History\\\", \\\"\\\", \\\"2\\\", 4428], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix G  Protocol History\\\", \\\"\\\", \\\"2\\\", 4429], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": 6, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 6, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix G  Protocol History\\\", \\\"\\\", \\\"2\\\", 4430], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": 6, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 6, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix G  Protocol History\\\", \\\"\\\", \\\"2\\\", 4431], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix G  Protocol History\\\", \\\"\\\", \\\"2\\\", 4432], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix G  Protocol History\\\", \\\"\\\", \\\"2\\\", 4433], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix G  Protocol History\\\", \\\"\\\", \\\"2\\\", 4434], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": 6, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 6, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix G  Protocol History\\\", \\\"\\\", \\\"2\\\", 4435], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": 6, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 6, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix G  Protocol History\\\", \\\"\\\", \\\"2\\\", 4436], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix G  Protocol History\\\", \\\"\\\", \\\"2\\\", 4437], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix G  Protocol History\\\", \\\"\\\", \\\"2\\\", 4438], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix G  Protocol History\\\", \\\"\\\", \\\"2\\\", 4439], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": 6, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 6, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix G  Protocol History\\\", \\\"\\\", \\\"2\\\", 4440], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": 6, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 6, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix G  Protocol History\\\", \\\"\\\", \\\"2\\\", 4441], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix G  Protocol History\\\", \\\"\\\", \\\"2\\\", 4442], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix G  Protocol History\\\", \\\"\\\", \\\"2\\\", 4443], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix G  Protocol History\\\", \\\"\\\", \\\"2\\\", 4444], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": 6, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 6, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix G  Protocol History\\\", \\\"\\\", \\\"2\\\", 4445], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": 6, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 6, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix G  Protocol History\\\", \\\"\\\", \\\"2\\\", 4446], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix G  Protocol History\\\", \\\"\\\", \\\"2\\\", 4447], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix G  Protocol History\\\", \\\"\\\", \\\"2\\\", 4448], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix G  Protocol History\\\", \\\"\\\", \\\"2\\\", 4449], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": 6, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 6, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix G  Protocol History\\\", \\\"\\\", \\\"2\\\", 4450], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": 6, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 6, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix G  Protocol History\\\", \\\"\\\", \\\"2\\\", 4451], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix G  Protocol History\\\", \\\"\\\", \\\"2\\\", 4452], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix G  Protocol History\\\", \\\"\\\", \\\"2\\\", 4453], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix G  Protocol History\\\", \\\"\\\", \\\"2\\\", 4454], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": 6, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 6, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix G  Protocol History\\\", \\\"\\\", \\\"2\\\", 4455], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": 6, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 6, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix G  Protocol History\\\", \\\"\\\", \\\"2\\\", 4456], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix G  Protocol History\\\", \\\"\\\", \\\"2\\\", 4457], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix G  Protocol History\\\", \\\"\\\", \\\"2\\\", 4458], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix G  Protocol History\\\", \\\"\\\", \\\"2\\\", 4459], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": 6, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 6, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix G  Protocol History\\\", \\\"\\\", \\\"2\\\", 4460], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": 6, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 6, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix G  Protocol History\\\", \\\"\\\", \\\"2\\\", 4461], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix G  Protocol History\\\", \\\"\\\", \\\"2\\\", 4462], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix G  Protocol History\\\", \\\"\\\", \\\"2\\\", 4463], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix G  Protocol History\\\", \\\"\\\", \\\"2\\\", 4464], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": 6, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 6, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix G  Protocol History\\\", \\\"\\\", \\\"2\\\", 4465], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": 6, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 6, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix G  Protocol History\\\", \\\"\\\", \\\"2\\\", 4466], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix G  Protocol History\\\", \\\"\\\", \\\"2\\\", 4467], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix G  Protocol History\\\", \\\"\\\", \\\"2\\\", 4468], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix G  Protocol History\\\", \\\"\\\", \\\"2\\\", 4469], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": 6, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 6, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix G  Protocol History\\\", \\\"\\\", \\\"2\\\", 4470], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": 6, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 6, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix G  Protocol History\\\", \\\"\\\", \\\"2\\\", 4471], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix G  Protocol History\\\", \\\"\\\", \\\"2\\\", 4472], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix G  Protocol History\\\", \\\"\\\", \\\"2\\\", 4473], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix G  Protocol History\\\", \\\"\\\", \\\"2\\\", 4474], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix G  Protocol History\\\", \\\"\\\", \\\"2\\\", 4475], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 20, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 20, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix G  Protocol History\\\", \\\"\\\", \\\"2\\\", 4476], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"090101d68100716c\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 20, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 20, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix G  Protocol History\\\", \\\"\\\", \\\"2\\\", 4477], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 20, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 20, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"References\\\", \\\"Appendix G  Protocol History\\\", \\\"\\\", \\\"2\\\", 4478]], \\\"metadata\\\": {\\\"protocol_title\\\": \\\"A Randomized, Double-blind, Placebo-Controlled Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Doses of TAK-861 in Healthy Adult and Elderly Subjects and Subjects With Narcolepsy Type 1\\\", \\\"protocol_title_short\\\": \\\"\\\", \\\"amendment_number\\\": \\\"1\\\", \\\"is_amendment\\\": \\\"Y\\\", \\\"trial_phase\\\": \\\"\\\", \\\"sponsor\\\": \\\"redaction\\\", \\\"sponsor_address\\\": \\\"\\\", \\\"drug\\\": \\\"\\\", \\\"approval_date\\\": \\\"20210316\\\", \\\"version_number\\\": \\\"1\\\", \\\"version_date\\\": \\\"\\\", \\\"blinded\\\": \\\"DOUBLE-BLIND\\\", \\\"compound_number\\\": \\\"\\\", \\\"control\\\": \\\"\\\", \\\"investigator\\\": \\\"\\\", \\\"study_id\\\": \\\"\\\", \\\"number_of_subjects\\\": \\\"196\\\", \\\"participant_age\\\": \\\"adult elderly\\\", \\\"participant_sex\\\": \\\"FEMALE\\\", \\\"exclusion_criteria\\\": \\\"Each subject will be assessed through randomization, according to the eligibility criteria provided in Section 7.0, which includes confirmation of primary disease (narcolepsy) status such as EDS or cataplexy episodes for subjects with NT1.\\\", \\\"inclusion_criteria\\\": \\\"Each subject will be assessed through randomization, according to the eligibility criteria provided in Section 7.0, which includes confirmation of primary disease (narcolepsy) status such as EDS or cataplexy episodes for subjects with NT1.\\\", \\\"indication\\\": \\\"test\\\", \\\"objectives_section\\\": \\\"\\\\u2022 The order of priority can be changed during the study with joint agreement of the investigator and the sponsor.\\\", \\\"study_population\\\": \\\"patient, subject, ad.. ( ), treated with diagnosis of entity: basic, word .. Diseases and Symptom.. and Diseases and Sym.. showing symptoms of ..\\\", \\\"entities_in_assessments\\\": \\\"\\\", \\\"soa_epochs\\\": \\\"\\\", \\\"assessment_footnote\\\": \\\"\\\", \\\"upload_date\\\": \\\"20210928113924\\\", \\\"protocol_number\\\": \\\"TAK-861-1001\\\", \\\"study_status\\\": \\\"final\\\", \\\"molecule_device\\\": \\\"test\\\", \\\"accuracy\\\": \\\"\\\"}}\"", "iqvdataSoa": "\"[[{\\\"Table\\\": \\\"<table border=\\\\\\\"1\\\\\\\" class=\\\\\\\"dataframe\\\\\\\">\\\\n  <thead>\\\\n    <tr style=\\\\\\\"text-align: right;\\\\\\\">\\\\n      <th></th>\\\\n      <th>1.0</th>\\\\n      <th>2.0</th>\\\\n      <th>3.0</th>\\\\n      <th>4.0</th>\\\\n      <th>5.0</th>\\\\n      <th>6.0</th>\\\\n      <th>7.0</th>\\\\n      <th>8.0</th>\\\\n      <th>9.0</th>\\\\n      <th>10.0</th>\\\\n    </tr>\\\\n  </thead>\\\\n  <tbody>\\\\n    <tr>\\\\n      <th>0</th>\\\\n      <td>Procedures</td>\\\\n      <td>Screening Days -28 to -2</td>\\\\n      <td>Day -1</td>\\\\n      <td>Predose Day 1</td>\\\\n      <td>Postdose Day 1</td>\\\\n      <td>Day 2</td>\\\\n      <td>Day 3 to 5</td>\\\\n      <td>Day 6 <sup>i</sup> Discharge</td>\\\\n      <td>ET</td>\\\\n      <td>Day 9\\\\u00b12 Follow-up Visit</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>1</th>\\\\n      <td>Administrative Procedures</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>2</th>\\\\n      <td>Informed consent</td>\\\\n      <td>X</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>3</th>\\\\n      <td>Inclusion/exclusion criteria</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>4</th>\\\\n      <td>Medical history/demographics</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>5</th>\\\\n      <td>Prior and concomitant medication review (continuous review)</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>6</th>\\\\n      <td>Clinical Procedures/Assessments</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>7</th>\\\\n      <td>Full physical examination</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>8</th>\\\\n      <td>Height, body mass index calculation</td>\\\\n      <td>X</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>9</th>\\\\n      <td>Weight</td>\\\\n      <td>X</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td></td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>10</th>\\\\n      <td>Vital signs (BP [supine], PR [supine], RR, and BT) (see Table 3.c) <sup>a</sup></td>\\\\n      <td>X</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>11</th>\\\\n      <td>Orthostatic BP and pulse rate measurements (see Table 3.c) <sup>b</sup></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>12</th>\\\\n      <td>12-lead ECG standard (see Table 3.c)</td>\\\\n      <td>X</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>13</th>\\\\n      <td>Holter ECG <sup>c</sup></td>\\\\n      <td></td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>14</th>\\\\n      <td>C-SSRS</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td></td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>15</th>\\\\n      <td>Bladder condition checklist</td>\\\\n      <td>X</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>X</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>16</th>\\\\n      <td>TAK-861/placebo administration <sup>d</sup></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>X</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>17</th>\\\\n      <td>AE monitoring (continuous monitoring)</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n    </tr>\\\\n  </tbody>\\\\n</table>\\\", \\\"SectionHeaderPrintPage\\\": \\\"20\\\", \\\"TableIndex\\\": \\\"16\\\", \\\"TableName\\\": \\\"3.1 Part A(Schedule of Assessment)\\\", \\\"Header\\\": [0, 1]}, {\\\"Table\\\": \\\"<table border=\\\\\\\"1\\\\\\\" class=\\\\\\\"dataframe\\\\\\\">\\\\n  <thead>\\\\n    <tr style=\\\\\\\"text-align: right;\\\\\\\">\\\\n      <th></th>\\\\n      <th>1.0</th>\\\\n      <th>2.0</th>\\\\n      <th>3.0</th>\\\\n      <th>4.0</th>\\\\n      <th>5.0</th>\\\\n      <th>6.0</th>\\\\n      <th>7.0</th>\\\\n      <th>8.0</th>\\\\n      <th>9.0</th>\\\\n      <th>10.0</th>\\\\n      <th>11.0</th>\\\\n    </tr>\\\\n  </thead>\\\\n  <tbody>\\\\n    <tr>\\\\n      <th>0</th>\\\\n      <td>Procedures</td>\\\\n      <td>Screening Days -28 to -2</td>\\\\n      <td>Day -1</td>\\\\n      <td></td>\\\\n      <td>Predose Day 1</td>\\\\n      <td>Postdose Day 1</td>\\\\n      <td>Day 2</td>\\\\n      <td>Day 3 to 5</td>\\\\n      <td>Day 6 <sup>i</sup> Discharge</td>\\\\n      <td>ET</td>\\\\n      <td>Day 9\\\\u00b12 Follow-up Visit</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>1</th>\\\\n      <td>Laboratory Procedures/Assessments</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>2</th>\\\\n      <td>Hematology and blood chemistry <sup>e</sup></td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td></td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>3</th>\\\\n      <td>FSH assessment (optional; for postmenopausal women) <sup>f</sup></td>\\\\n      <td>X</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>4</th>\\\\n      <td>Urinalysis</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>X</td>\\\\n      <td></td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>5</th>\\\\n      <td><span class=\\\\\\\"redact\\\\\\\"> ~REDACTED~ </span>  screening and urine drug screen</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>6</th>\\\\n      <td>Hepatitis and HIV screen</td>\\\\n      <td>X</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>7</th>\\\\n      <td>Blood for retained samples and pharmacogenomics <sup>g</sup></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>8</th>\\\\n      <td>PK Evaluations</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>9</th>\\\\n      <td>Blood sample for PK TAK-861 (See Table 3.c)</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>10</th>\\\\n      <td>Urine sample for PK TAK-861 (See Table 3.c)</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>11</th>\\\\n      <td>Other</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>12</th>\\\\n      <td>Check-in <sup>h</sup></td>\\\\n      <td>X</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>13</th>\\\\n      <td>Confinement</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td></td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td></td>\\\\n    </tr>\\\\n  </tbody>\\\\n</table>\\\", \\\"SectionHeaderPrintPage\\\": \\\"20\\\", \\\"TableIndex\\\": \\\"17\\\", \\\"TableName\\\": \\\"Table 3.a Schedule of Study Procedures for Part A (SRD in Healthy Adults)(Schedule of Assessment)\\\", \\\"AttachmentEntities\\\": [{\\\"content\\\": \\\"Administrative Procedures Informed consent X\\\", \\\"entities\\\": []}, {\\\"content\\\": \\\"Clinical Procedures/Assessments\\\", \\\"entities\\\": []}, {\\\"content\\\": \\\"Height, body mass index calculation X\\\", \\\"entities\\\": []}, {\\\"content\\\": \\\"Vital signs (BP [supine], PR [supine], RR, and BT) (see X Table 3.c) a\\\", \\\"entities\\\": []}, {\\\"content\\\": \\\"Orthostatic BP and pulse rate measurements (see Table 3.c) b\\\", \\\"entities\\\": []}, {\\\"content\\\": \\\"12-lead ECG standard (see Table 3.c) X\\\", \\\"entities\\\": []}, {\\\"content\\\": \\\"TAK-861/placebo administration d X\\\", \\\"entities\\\": []}, {\\\"content\\\": \\\"AE: adverse event; BP: blood pressure; BT: body temperature; C-SSRS: ColumbiaSuicide Severity Rating Scale; ECG: electrocardiogram; ET: early termination; FSH:\\\", \\\"entities\\\": []}, {\\\"content\\\": \\\"follicle-stimulating hormone; PK: pharmacokinetic(s); PR: pulse rate; RR: respiratory rate; SRD: single-rising dose.\\\", \\\"entities\\\": [{\\\"start_idx\\\": 0, \\\"end_idx\\\": 27, \\\"standard_entity_name\\\": \\\"Molecule\\\", \\\"subcategory\\\": \\\"Molecule\\\", \\\"confidence\\\": 87.0, \\\"text\\\": \\\"follicle-stimulating hormone\\\"}]}, {\\\"content\\\": \\\"a BP will be checked (single measurement) with the subject resting for a minimum of 5 minutes lying in a bed with the head of the bed at 30 degrees.\\\", \\\"entities\\\": []}, {\\\"content\\\": \\\"b Orthostatic BP and pulse rate will also be checked, with the subject standing for 1 minute and 5 minutes.\\\", \\\"entities\\\": []}, {\\\"content\\\": \\\"c 12-lead, 24-h continuous Holter monitoring. Additional details may be found in the training manual.\\\", \\\"entities\\\": []}, {\\\"content\\\": \\\"d Drug administration on Day 1 after an overnight fast of at least 10 h; subjects must remain fasted until 4 h postdose. Detailed guidance of drug administration with diet and fluid\\\", \\\"entities\\\": []}, {\\\"content\\\": \\\"requirements can be found in Section 7.4.1.\\\", \\\"entities\\\": []}, {\\\"content\\\": \\\"e Hematology (complete blood count) and blood chemistry on Day 1 will be done at 8 h postdose; on all other days, blood draws will be done at the relative Day 1 predose time.\\\", \\\"entities\\\": []}, {\\\"content\\\": \\\"f FSH is mandatory for postmenopausal subjects.\\\", \\\"entities\\\": []}, {\\\"content\\\": \\\"g Blood samples for pharmacogenomics are collected before the initiation of study drug administration on Day 1. Will be performed once only in each subject during the study period.\\\", \\\"entities\\\": []}, {\\\"content\\\": \\\"h Subjects are to check in in the afternoon or evening of Day -2 at the latest. Some of the assessments (eg, C-SSRS and alcohol and drug screen) can be done at check-in time.\\\", \\\"entities\\\": [{\\\"start_idx\\\": 118, \\\"end_idx\\\": 124, \\\"standard_entity_name\\\": \\\"Molecule\\\", \\\"subcategory\\\": \\\"Molecule\\\", \\\"confidence\\\": 75.0, \\\"text\\\": \\\"alcohol\\\"}]}, {\\\"content\\\": \\\"i Some of the Day 6 study assessments may not be performed based on the emerging data from initial cohorts.\\\", \\\"entities\\\": []}], \\\"FootnoteText_0\\\": \\\" Administrative Procedures Informed consent X\\\", \\\"FootnoteText_1\\\": \\\" Clinical Procedures/Assessments\\\", \\\"FootnoteText_2\\\": \\\" Height, body mass index calculation X\\\", \\\"FootnoteText_3\\\": \\\" Vital signs (BP [supine], PR [supine], RR, and BT) (see X Table 3.c) a\\\", \\\"FootnoteText_4\\\": \\\" Orthostatic BP and pulse rate measurements (see Table 3.c) b\\\", \\\"FootnoteText_5\\\": \\\" 12-lead ECG standard (see Table 3.c) X\\\", \\\"FootnoteText_6\\\": \\\" TAK-861/placebo administration d X\\\", \\\"FootnoteText_7\\\": \\\" AE: adverse event; BP: blood pressure; BT: body temperature; C-SSRS: ColumbiaSuicide Severity Rating Scale; ECG: electrocardiogram; ET: early termination; FSH:\\\", \\\"FootnoteText_8\\\": \\\" follicle-stimulating hormone; PK: pharmacokinetic(s); PR: pulse rate; RR: respiratory rate; SRD: single-rising dose.\\\", \\\"FootnoteText_9\\\": \\\"a BP will be checked (single measurement) with the subject resting for a minimum of 5 minutes lying in a bed with the head of the bed at 30 degrees.\\\", \\\"FootnoteText_10\\\": \\\"b Orthostatic BP and pulse rate will also be checked, with the subject standing for 1 minute and 5 minutes.\\\", \\\"FootnoteText_11\\\": \\\"c 12-lead, 24-h continuous Holter monitoring. Additional details may be found in the training manual.\\\", \\\"FootnoteText_12\\\": \\\"d Drug administration on Day 1 after an overnight fast of at least 10 h; subjects must remain fasted until 4 h postdose. Detailed guidance of drug administration with diet and fluid\\\", \\\"FootnoteText_13\\\": \\\" requirements can be found in Section 7.4.1.\\\", \\\"FootnoteText_14\\\": \\\"e Hematology (complete blood count) and blood chemistry on Day 1 will be done at 8 h postdose; on all other days, blood draws will be done at the relative Day 1 predose time.\\\", \\\"FootnoteText_15\\\": \\\"f FSH is mandatory for postmenopausal subjects.\\\", \\\"FootnoteText_16\\\": \\\"g Blood samples for pharmacogenomics are collected before the initiation of study drug administration on Day 1. Will be performed once only in each subject during the study period.\\\", \\\"FootnoteText_17\\\": \\\"h Subjects are to check in in the afternoon or evening of Day -2 at the latest. Some of the assessments (eg, C-SSRS and alcohol and drug screen) can be done at check-in time.\\\", \\\"FootnoteText_18\\\": \\\"i Some of the Day 6 study assessments may not be performed based on the emerging data from initial cohorts.\\\", \\\"Header\\\": [0, 1]}, {\\\"Table\\\": \\\"<table border=\\\\\\\"1\\\\\\\" class=\\\\\\\"dataframe\\\\\\\">\\\\n  <thead>\\\\n    <tr style=\\\\\\\"text-align: right;\\\\\\\">\\\\n      <th></th>\\\\n      <th>1.0</th>\\\\n      <th>2.0</th>\\\\n      <th>3.0</th>\\\\n      <th>4.0</th>\\\\n      <th>5.0</th>\\\\n      <th>6.0</th>\\\\n      <th>7.0</th>\\\\n      <th>8.0</th>\\\\n      <th>9.0</th>\\\\n      <th>10.0</th>\\\\n      <th>11.0</th>\\\\n    </tr>\\\\n  </thead>\\\\n  <tbody>\\\\n    <tr>\\\\n      <th>0</th>\\\\n      <td>Procedure</td>\\\\n      <td>Predose</td>\\\\n      <td>Predose</td>\\\\n      <td>Dosing</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>Postdose</td>\\\\n      <td>Postdose</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>Follow-up</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>1</th>\\\\n      <td>Day</td>\\\\n      <td>-1</td>\\\\n      <td>1</td>\\\\n      <td>1</td>\\\\n      <td>2</td>\\\\n      <td>3</td>\\\\n      <td>4</td>\\\\n      <td>5</td>\\\\n      <td>6 <sup>a</sup> Discharge</td>\\\\n      <td>ET</td>\\\\n      <td>9 (\\\\u00b12 days)</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>2</th>\\\\n      <td>Blood sample for TAK-861 PK</td>\\\\n      <td></td>\\\\n      <td>Pre</td>\\\\n      <td>0.25, 0.5, 1, 2, 3, 4, 6, 8, and 12 h Post</td>\\\\n      <td>24 and 36 h Post</td>\\\\n      <td>48 h Post</td>\\\\n      <td>72 h Post</td>\\\\n      <td>96 h Post</td>\\\\n      <td>120 h Post</td>\\\\n      <td>X <sup>b</sup></td>\\\\n      <td></td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>3</th>\\\\n      <td>Urine sample for TAK-861 PK <sup>c</sup></td>\\\\n      <td></td>\\\\n      <td>Spot: Pre</td>\\\\n      <td>Pooled: 0-6 and 6-12 h Post</td>\\\\n      <td>Pooled: 12-24 h Post</td>\\\\n      <td>Pooled: 24-48 h Post</td>\\\\n      <td>Pooled: 48-72 h Post</td>\\\\n      <td>Pooled: 72-96 h Post</td>\\\\n      <td>Pooled: 96-120 h Post</td>\\\\n      <td>X<sup> c</sup></td>\\\\n      <td></td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>4</th>\\\\n      <td>Supine BP and pulse rate measurements</td>\\\\n      <td>Approximately 0700 and then at 0.5, 1, 2, 3, 4, 6, 8, and 12 h later relative to the initial measurement (matched to the time assessment schedule of Day 1)</td>\\\\n      <td>Pre</td>\\\\n      <td>0.5, 1, 2, 3, 4, 6, 8, and 12 h Post</td>\\\\n      <td>24 and 36 h Post</td>\\\\n      <td>48 h Post</td>\\\\n      <td>72 h Post <sup>e</sup></td>\\\\n      <td>96 h Post</td>\\\\n      <td>120 h Post</td>\\\\n      <td>X <sup>d</sup></td>\\\\n      <td>X</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>5</th>\\\\n      <td>Orthostatic BP and pulse rate measurements</td>\\\\n      <td></td>\\\\n      <td>Pre</td>\\\\n      <td>1, 2, and 6 h Post</td>\\\\n      <td>24 h Post</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>X<sup> d, e</sup></td>\\\\n      <td></td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>6</th>\\\\n      <td>Respiratory rate and body temperature</td>\\\\n      <td></td>\\\\n      <td>1 h Pre</td>\\\\n      <td>1, 2, 4, and 6 h Post</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>120 h Post</td>\\\\n      <td>X<sup> d</sup></td>\\\\n      <td>X</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>7</th>\\\\n      <td>Standard 12-lead ECGs</td>\\\\n      <td>X</td>\\\\n      <td>Pre</td>\\\\n      <td>1, 2, 4, 6, and 12 h Post</td>\\\\n      <td>24 h Post</td>\\\\n      <td>48 h Post</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>120 h Post</td>\\\\n      <td>X<sup> d</sup></td>\\\\n      <td>X</td>\\\\n    </tr>\\\\n  </tbody>\\\\n</table>\\\", \\\"SectionHeaderPrintPage\\\": \\\"24\\\", \\\"TableIndex\\\": \\\"18\\\", \\\"TableName\\\": \\\"Table 3.c Detailed Schedule for Part A(Schedule of Assessment)\\\", \\\"Header\\\": [0, 1]}, {\\\"Table\\\": \\\"<table border=\\\\\\\"1\\\\\\\" class=\\\\\\\"dataframe\\\\\\\">\\\\n  <thead>\\\\n    <tr style=\\\\\\\"text-align: right;\\\\\\\">\\\\n      <th></th>\\\\n      <th>1.0</th>\\\\n      <th>2.0</th>\\\\n      <th>3.0</th>\\\\n      <th>4.0</th>\\\\n      <th>5.0</th>\\\\n      <th>6.0</th>\\\\n      <th>7.0</th>\\\\n      <th>8.0</th>\\\\n      <th>9.0</th>\\\\n      <th>10.0</th>\\\\n      <th>11.0</th>\\\\n      <th>12.0</th>\\\\n      <th>13.0</th>\\\\n      <th>14.0</th>\\\\n      <th>15.0</th>\\\\n      <th>16.0</th>\\\\n    </tr>\\\\n  </thead>\\\\n  <tbody>\\\\n    <tr>\\\\n      <th>0</th>\\\\n      <td>Procedure</td>\\\\n      <td>Predose</td>\\\\n      <td>Predose</td>\\\\n      <td>Postdose</td>\\\\n      <td>Postdose</td>\\\\n      <td>Postdose</td>\\\\n      <td>Postdose</td>\\\\n      <td>Washout (7\\\\u00b12 days)</td>\\\\n      <td>Predose</td>\\\\n      <td>Predose</td>\\\\n      <td></td>\\\\n      <td>Postdose</td>\\\\n      <td>Postdose</td>\\\\n      <td>Postdose</td>\\\\n      <td>Postdose</td>\\\\n      <td>Follow-up</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>1</th>\\\\n      <td>Day</td>\\\\n      <td>-1</td>\\\\n      <td>1</td>\\\\n      <td>1</td>\\\\n      <td>2</td>\\\\n      <td>3-5</td>\\\\n      <td>6 <sup>d</sup></td>\\\\n      <td></td>\\\\n      <td>14</td>\\\\n      <td>15</td>\\\\n      <td>15</td>\\\\n      <td>16</td>\\\\n      <td>17-19</td>\\\\n      <td>20 <sup>a</sup></td>\\\\n      <td>ET</td>\\\\n      <td>23 (\\\\u00b12 days)</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>2</th>\\\\n      <td>Blood sample for TAK-861 PK</td>\\\\n      <td></td>\\\\n      <td>Pre</td>\\\\n      <td>0.25, 0.5, 1, 2, 3, 4, 6, 8, and 12 h Post</td>\\\\n      <td>24 and 36 h Post</td>\\\\n      <td>48, 72, and 96 h Post</td>\\\\n      <td>120 h Post</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>Pre</td>\\\\n      <td>0.25, 0.5, 1, 2, 3, 4, 6, 8, and 12 h Post</td>\\\\n      <td>24 and 36 h Post</td>\\\\n      <td>48, 72, and 96 h Post</td>\\\\n      <td>120 h Post</td>\\\\n      <td>X <sup>b</sup></td>\\\\n      <td></td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>3</th>\\\\n      <td>Urine sample for TAK-861 PK</td>\\\\n      <td></td>\\\\n      <td>Spot: Pre</td>\\\\n      <td>Pooled: 0-6 and 6-12 h Post</td>\\\\n      <td>Pooled: 12-24 h Post</td>\\\\n      <td>Pooled: 24-48, 48-72, 72-96 h Post</td>\\\\n      <td>Pooled: 96-120 h Post</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>4</th>\\\\n      <td>Supine BP and pulse rate measurements</td>\\\\n      <td>At approximately 0700 and at 0.5, 1, 2, 3, 4, 6, 8, and 12 h later relative to initial measurement (matched to Day 1 assessment schedule)</td>\\\\n      <td>Pre</td>\\\\n      <td>0.5, 1, 2, 3, 4, 6, 8, and 12 h Post</td>\\\\n      <td>24 and 36 h Post</td>\\\\n      <td>48, 72 and 96 h Post</td>\\\\n      <td>120 h Post</td>\\\\n      <td></td>\\\\n      <td>X</td>\\\\n      <td>Pre</td>\\\\n      <td>0.5, 1, 2, 3, 4, 6, 8, and 12 h Post</td>\\\\n      <td>24 and 36 h Post</td>\\\\n      <td>48, 72, and 96 h Post</td>\\\\n      <td>120 h Post</td>\\\\n      <td>X <sup>c</sup></td>\\\\n      <td>X</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>5</th>\\\\n      <td>Orthostatic BP and pulse rate measurements</td>\\\\n      <td></td>\\\\n      <td>Pre</td>\\\\n      <td>1, 2, and 6 h Post</td>\\\\n      <td>24 h Post</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>Pre</td>\\\\n      <td>1, 2, and 6 h Post</td>\\\\n      <td>24 h Post</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>X<sup> c, d</sup></td>\\\\n      <td></td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>6</th>\\\\n      <td>Respiratory rate and body temperature</td>\\\\n      <td></td>\\\\n      <td>1 h Pre</td>\\\\n      <td>1, 2, 4, and 6 h Post</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>120 h Post</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>1 h Pre</td>\\\\n      <td>1, 2, 4, and 6 h Post</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>120 h Post</td>\\\\n      <td>X <sup>c</sup></td>\\\\n      <td>X</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>7</th>\\\\n      <td>Standard 12-lead ECGs</td>\\\\n      <td>X</td>\\\\n      <td>Pre</td>\\\\n      <td>1, 2, 4, 6, and 12 h Post</td>\\\\n      <td>24 h Post</td>\\\\n      <td>48 h Post</td>\\\\n      <td>120 h Post</td>\\\\n      <td></td>\\\\n      <td>X</td>\\\\n      <td>Pre</td>\\\\n      <td>1, 2, 4, 6, and 12 h Post</td>\\\\n      <td>24 h Post</td>\\\\n      <td>48 h Post</td>\\\\n      <td>120 h Post</td>\\\\n      <td>X <sup>c</sup></td>\\\\n      <td>X</td>\\\\n    </tr>\\\\n  </tbody>\\\\n</table>\\\", \\\"SectionHeaderPrintPage\\\": \\\"25\\\", \\\"TableIndex\\\": \\\"19\\\", \\\"TableName\\\": \\\"Table 3.d Detailed Schedule for Cohorts A3 and A10 (SRD Food Effect)(Schedule of Assessment)\\\", \\\"AttachmentEntities\\\": [{\\\"content\\\": \\\"BP: blood pressure; ECG: electrocardiogram; ET: early termination; PK: pharmacokinetic(s); Post: postdose; Pre: predose; SRD: single-rising dose.\\\", \\\"entities\\\": []}, {\\\"content\\\": \\\"a All or some of the Day 6 or Day 20 study assessments may not be performed based on the emerging data from initial cohorts.\\\", \\\"entities\\\": []}, {\\\"content\\\": \\\"b At ET visit, blood sample for TAK-861 PK to be collected at the time of subject discontinuation (before discharge).\\\", \\\"entities\\\": []}, {\\\"content\\\": \\\"c Assessment at ET visit to be conducted before discharge.\\\", \\\"entities\\\": []}, {\\\"content\\\": \\\"d If ET occurs later than 24 h postdose, this assessment is not required.\\\", \\\"entities\\\": []}], \\\"FootnoteText_0\\\": \\\" BP: blood pressure; ECG: electrocardiogram; ET: early termination; PK: pharmacokinetic(s); Post: postdose; Pre: predose; SRD: single-rising dose.\\\", \\\"FootnoteText_1\\\": \\\"a All or some of the Day 6 or Day 20 study assessments may not be performed based on the emerging data from initial cohorts.\\\", \\\"FootnoteText_2\\\": \\\"b At ET visit, blood sample for TAK-861 PK to be collected at the time of subject discontinuation (before discharge).\\\", \\\"FootnoteText_3\\\": \\\"c Assessment at ET visit to be conducted before discharge.\\\", \\\"FootnoteText_4\\\": \\\"d If ET occurs later than 24 h postdose, this assessment is not required.\\\", \\\"Header\\\": [0, 1]}, {\\\"Table\\\": \\\"<table border=\\\\\\\"1\\\\\\\" class=\\\\\\\"dataframe\\\\\\\">\\\\n  <thead>\\\\n    <tr style=\\\\\\\"text-align: right;\\\\\\\">\\\\n      <th></th>\\\\n      <th>1.0</th>\\\\n      <th>2.0</th>\\\\n      <th>3.0</th>\\\\n      <th>4.0</th>\\\\n      <th>5.0</th>\\\\n      <th>6.0</th>\\\\n      <th>7.0</th>\\\\n      <th>8.0</th>\\\\n      <th>9.0</th>\\\\n      <th>10.0</th>\\\\n      <th>11.0</th>\\\\n      <th>12.0</th>\\\\n      <th>13.0</th>\\\\n      <th>14.0</th>\\\\n      <th>15.0</th>\\\\n      <th>16.0</th>\\\\n      <th>17.0</th>\\\\n      <th>18.0</th>\\\\n      <th>19.0</th>\\\\n      <th>20.0</th>\\\\n      <th>21.0</th>\\\\n      <th>22.0</th>\\\\n      <th>23.0</th>\\\\n    </tr>\\\\n  </thead>\\\\n  <tbody>\\\\n    <tr>\\\\n      <th>0</th>\\\\n      <td>Day</td>\\\\n      <td>Screening Days -28 to -2</td>\\\\n      <td>Day -1</td>\\\\n      <td>Predose Day 1</td>\\\\n      <td>1</td>\\\\n      <td>2</td>\\\\n      <td>3</td>\\\\n      <td>4</td>\\\\n      <td>5</td>\\\\n      <td>6</td>\\\\n      <td>7</td>\\\\n      <td>8</td>\\\\n      <td>9</td>\\\\n      <td>10</td>\\\\n      <td>11</td>\\\\n      <td>12</td>\\\\n      <td>13</td>\\\\n      <td>14</td>\\\\n      <td>15</td>\\\\n      <td>16, 17</td>\\\\n      <td>Day 18 <sup>m</sup> Discharge</td>\\\\n      <td>ET</td>\\\\n      <td>Day 21\\\\u00b12 Follow-up Visit</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>1</th>\\\\n      <td>Administrative Procedures</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>2</th>\\\\n      <td>Informed consent</td>\\\\n      <td>X</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>3</th>\\\\n      <td>Inclusion/exclusion criteria</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>4</th>\\\\n      <td>Medical history/demographics</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>5</th>\\\\n      <td>Prior and concomitant medication review (continuous review)</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>6</th>\\\\n      <td>Clinical Procedures/ Assessments</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>7</th>\\\\n      <td>Full physical examination</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>8</th>\\\\n      <td>Height, BMI calculation</td>\\\\n      <td>X</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>9</th>\\\\n      <td>Weight</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td></td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>10</th>\\\\n      <td>Vital signs BP [ supine] PR [ supine] RR, and BT) (see Table a 3.f)</td>\\\\n      <td>X</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>11</th>\\\\n      <td>Orthostatic BP, pulse rate <sup>b</sup> (see Table 3.f)</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>12</th>\\\\n      <td>ABPM (Part B only) <sup>c</sup></td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td></td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td></td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>13</th>\\\\n      <td>12-lead ECG standard(see Table 3.f)</td>\\\\n      <td>X</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>14</th>\\\\n      <td>Holter ECG <sup>d</sup></td>\\\\n      <td></td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>15</th>\\\\n      <td>C-SSRS</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>X</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>X</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>X</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>X</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>X</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>16</th>\\\\n      <td>Bladder condition checklist</td>\\\\n      <td>X</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>X</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>X</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>X</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>X</td>\\\\n      <td></td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>17</th>\\\\n      <td>NSF Sleep Diary\\\\u2013Morning</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td></td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>18</th>\\\\n      <td>KSS <sup>e</sup> (See Table 3.f)</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>19</th>\\\\n      <td>Accelerometry <sup>f</sup></td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>20</th>\\\\n      <td>TAK-861/placebo administration <sup>g</sup></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>21</th>\\\\n      <td>AE monitoring (continuous monitoring)</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>22</th>\\\\n      <td>Hematology and blood chemistry <sup>h</sup></td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td></td>\\\\n      <td>X</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>X</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>X</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>X</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>X</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>23</th>\\\\n      <td>Plasma fluoride (see Table 3.f)</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>24</th>\\\\n      <td>FSH assessment (optional; for postmenopausal women) <sup>i</sup></td>\\\\n      <td>X</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>25</th>\\\\n      <td>Urinalysis</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>X</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>X</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>26</th>\\\\n      <td>24-hour urine input/output collection</td>\\\\n      <td></td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>27</th>\\\\n      <td><span class=\\\\\\\"redact\\\\\\\"> ~REDACTED~ </span>  screening and urine drug screen</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>28</th>\\\\n      <td>Hepatitis and HIV screen</td>\\\\n      <td>X</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>29</th>\\\\n      <td>Blood for retained samples and pharmacogenomics <sup>j</sup></td>\\\\n      <td></td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>30</th>\\\\n      <td>Blood sample for CYP3A4/5 activity (see Table 3.f)</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>31</th>\\\\n      <td>Blood samples for OATP1B1/3 activity, Part B (see Table 3.f)</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>32</th>\\\\n      <td>Blood for exosome research <sup>k</sup></td>\\\\n      <td></td>\\\\n      <td>X</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>X</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>X</td>\\\\n      <td></td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>33</th>\\\\n      <td>PK Evaluations</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>34</th>\\\\n      <td>Blood sample for PK TAK-861 (See Table 3.f)</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>35</th>\\\\n      <td>Urine sample for PK TAK-861 (See Table 3.f)</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>36</th>\\\\n      <td>Check-in <sup>l</sup></td>\\\\n      <td>X</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>37</th>\\\\n      <td>Confinement</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td></td>\\\\n    </tr>\\\\n  </tbody>\\\\n</table>\\\", \\\"SectionHeaderPrintPage\\\": \\\"26\\\", \\\"TableIndex\\\": \\\"20\\\", \\\"TableName\\\": \\\"3.2 Part B and Part C(Schedule of Assessment)\\\", \\\"AttachmentEntities\\\": [{\\\"content\\\": \\\"Administrative Procedures Informed consent X\\\", \\\"entities\\\": []}, {\\\"content\\\": \\\"review (continuous review) Clinical Procedures/\\\", \\\"entities\\\": []}, {\\\"content\\\": \\\"Height, BMI calculation X\\\", \\\"entities\\\": []}, {\\\"content\\\": \\\"Vital signs BP [ supine] , PR X\\\", \\\"entities\\\": []}, {\\\"content\\\": \\\"[ supine] , RR, and BT) (see Table 3.f) a\\\", \\\"entities\\\": []}, {\\\"content\\\": \\\"Orthostatic BP, pulse rate b (see Table 3.f)\\\", \\\"entities\\\": []}, {\\\"content\\\": \\\"12-lead ECG standard (see X Table 3.f)\\\", \\\"entities\\\": []}, {\\\"content\\\": \\\"KSS e (See Table 3.f)\\\", \\\"entities\\\": []}, {\\\"content\\\": \\\"(continuous monitoring)\\\", \\\"entities\\\": []}, {\\\"content\\\": \\\"Laboratory Procedures/\\\", \\\"entities\\\": []}, {\\\"content\\\": \\\"Plasma fluoride (see Table 3.f)\\\", \\\"entities\\\": []}, {\\\"content\\\": \\\"FSH assessment (optional; for X\\\", \\\"entities\\\": []}, {\\\"content\\\": \\\"postmenopausal women) i\\\", \\\"entities\\\": []}, {\\\"content\\\": \\\"Hepatitis and HIV screen X\\\", \\\"entities\\\": []}, {\\\"content\\\": \\\"Blood for retained samples and X pharmacogenomics j X\\\", \\\"entities\\\": []}, {\\\"content\\\": \\\"activity (see Table 3.f)\\\", \\\"entities\\\": []}, {\\\"content\\\": \\\"ABPM: ambulatory blood pressure monitoring; AE: adverse event; BMI: body mass index; BP: blood pressure; BT: body temperature; C-SSRS: ColumbiaSuicide Severity Rating Scale; CYP:\\\", \\\"entities\\\": []}, {\\\"content\\\": \\\"cytochrome P450; ECG: electrocardiogram; ET: early termination; FSH: follicle-stimulating hormone; KSS: Karolinska Sleepiness Scale; MRD: multiple-rising dose; NSF: National Sleep\\\", \\\"entities\\\": [{\\\"start_idx\\\": 69, \\\"end_idx\\\": 96, \\\"standard_entity_name\\\": \\\"Molecule\\\", \\\"subcategory\\\": \\\"Molecule\\\", \\\"confidence\\\": 87.0, \\\"text\\\": \\\"follicle-stimulating hormone\\\"}]}, {\\\"content\\\": \\\"Foundation; OATP: organic anion transporting polypeptide; PK: pharmacokinetic(s); PR: pulse rate; RR: respiratory rate.\\\", \\\"entities\\\": []}, {\\\"content\\\": \\\"a BP will be checked (single measurement) with the subject resting for a minimum of 5 minutes lying in a bed with the head of the bed at 30 degrees.\\\", \\\"entities\\\": []}, {\\\"content\\\": \\\"b Orthostatic BP and pulse rate will also be checked, with the subject standing for 1 minute and 5 minutes.\\\", \\\"entities\\\": []}, {\\\"content\\\": \\\"c Twenty-four hour ABPM starts on Days -2, 3, 6, 10 and 13 in the morning before dosing time of the day.\\\", \\\"entities\\\": []}, {\\\"content\\\": \\\"d 12-lead, 24-h continuous Holter monitoring. Additional details may be found in the training manual.\\\", \\\"entities\\\": []}, {\\\"content\\\": \\\"e If subject is sleeping, please refer to Section 9.3.2.9 regarding how to rate KSS.\\\", \\\"entities\\\": []}, {\\\"content\\\": \\\"f Subjects will wear accelerometer for approximately 10 consecutive days during the screening period and throughout the study.\\\", \\\"entities\\\": []}, {\\\"content\\\": \\\"g Drug will be administered as a single dose after an overnight fast of at least 10 h. Subjects will continue to fast for an additional 4 h after dosing on serial PK collection days or 2 h after dosing\\\", \\\"entities\\\": []}, {\\\"content\\\": \\\"on nonintense PK collection days. Detailed guidance of drug administration with diet and fluid requirements can be found in Section 7.4.1.\\\", \\\"entities\\\": []}, {\\\"content\\\": \\\"h Hematology (complete blood count) and blood chemistry on Day 1 will be done at 8 h postdose. On all other days, blood draws are predose or at the relative Day 1 predose time.\\\", \\\"entities\\\": []}, {\\\"content\\\": \\\"i FSH is mandatory for postmenopausal subjects.\\\", \\\"entities\\\": []}, {\\\"content\\\": \\\"j Blood samples for pharmacogenomics are collected before the initiation of study drug administration on Day 1. Will be performed once only in each subject during the study period.\\\", \\\"entities\\\": []}, {\\\"content\\\": \\\"k The exploratory assay may include exploratory assessment of orexin-related biomarkers in plasma neuronally derived exosomes (exosome research).\\\", \\\"entities\\\": []}, {\\\"content\\\": \\\"l Subjects to check in in the afternoon or evening of Day -2 at the latest. For Part B, subjects may need to check in on Day -3 evening time to start ABPM in the morning time of Day -2. Some\\\", \\\"entities\\\": []}, {\\\"content\\\": \\\"of the assessments (eg. C-SSRS, alcohol, and drug screen) can be done at check-in time.\\\", \\\"entities\\\": [{\\\"start_idx\\\": 32, \\\"end_idx\\\": 38, \\\"standard_entity_name\\\": \\\"Molecule\\\", \\\"subcategory\\\": \\\"Molecule\\\", \\\"confidence\\\": 75.0, \\\"text\\\": \\\"alcohol\\\"}]}, {\\\"content\\\": \\\"m Day 18 study assessments may not be performed based on the emerging data from initial cohorts.\\\", \\\"entities\\\": []}], \\\"FootnoteText_0\\\": \\\" Administrative Procedures Informed consent X\\\", \\\"FootnoteText_1\\\": \\\" review (continuous review) Clinical Procedures/\\\", \\\"FootnoteText_2\\\": \\\" Height, BMI calculation X\\\", \\\"FootnoteText_3\\\": \\\" Vital signs BP [ supine] , PR X\\\", \\\"FootnoteText_4\\\": \\\"[ supine] , RR, and BT) (see Table 3.f) a\\\", \\\"FootnoteText_5\\\": \\\" Orthostatic BP, pulse rate b (see Table 3.f)\\\", \\\"FootnoteText_6\\\": \\\" 12-lead ECG standard (see X Table 3.f)\\\", \\\"FootnoteText_7\\\": \\\"KSS e (See Table 3.f)\\\", \\\"FootnoteText_8\\\": \\\" (continuous monitoring)\\\", \\\"FootnoteText_9\\\": \\\" Laboratory Procedures/\\\", \\\"FootnoteText_10\\\": \\\" Plasma fluoride (see Table 3.f)\\\", \\\"FootnoteText_11\\\": \\\" FSH assessment (optional; for X\\\", \\\"FootnoteText_12\\\": \\\" postmenopausal women) i\\\", \\\"FootnoteText_13\\\": \\\" Hepatitis and HIV screen X\\\", \\\"FootnoteText_14\\\": \\\" Blood for retained samples and X pharmacogenomics j X\\\", \\\"FootnoteText_15\\\": \\\" activity (see Table 3.f)\\\", \\\"FootnoteText_16\\\": \\\" ABPM: ambulatory blood pressure monitoring; AE: adverse event; BMI: body mass index; BP: blood pressure; BT: body temperature; C-SSRS: ColumbiaSuicide Severity Rating Scale; CYP:\\\", \\\"FootnoteText_17\\\": \\\" cytochrome P450; ECG: electrocardiogram; ET: early termination; FSH: follicle-stimulating hormone; KSS: Karolinska Sleepiness Scale; MRD: multiple-rising dose; NSF: National Sleep\\\", \\\"FootnoteText_18\\\": \\\" Foundation; OATP: organic anion transporting polypeptide; PK: pharmacokinetic(s); PR: pulse rate; RR: respiratory rate.\\\", \\\"FootnoteText_19\\\": \\\"a BP will be checked (single measurement) with the subject resting for a minimum of 5 minutes lying in a bed with the head of the bed at 30 degrees.\\\", \\\"FootnoteText_20\\\": \\\"b Orthostatic BP and pulse rate will also be checked, with the subject standing for 1 minute and 5 minutes.\\\", \\\"FootnoteText_21\\\": \\\"c Twenty-four hour ABPM starts on Days -2, 3, 6, 10 and 13 in the morning before dosing time of the day.\\\", \\\"FootnoteText_22\\\": \\\"d 12-lead, 24-h continuous Holter monitoring. Additional details may be found in the training manual.\\\", \\\"FootnoteText_23\\\": \\\"e If subject is sleeping, please refer to Section 9.3.2.9 regarding how to rate KSS.\\\", \\\"FootnoteText_24\\\": \\\"f Subjects will wear accelerometer for approximately 10 consecutive days during the screening period and throughout the study.\\\", \\\"FootnoteText_25\\\": \\\"g Drug will be administered as a single dose after an overnight fast of at least 10 h. Subjects will continue to fast for an additional 4 h after dosing on serial PK collection days or 2 h after dosing\\\", \\\"FootnoteText_26\\\": \\\" on nonintense PK collection days. Detailed guidance of drug administration with diet and fluid requirements can be found in Section 7.4.1.\\\", \\\"FootnoteText_27\\\": \\\"h Hematology (complete blood count) and blood chemistry on Day 1 will be done at 8 h postdose. On all other days, blood draws are predose or at the relative Day 1 predose time.\\\", \\\"FootnoteText_28\\\": \\\"i FSH is mandatory for postmenopausal subjects.\\\", \\\"FootnoteText_29\\\": \\\"j Blood samples for pharmacogenomics are collected before the initiation of study drug administration on Day 1. Will be performed once only in each subject during the study period.\\\", \\\"FootnoteText_30\\\": \\\"k The exploratory assay may include exploratory assessment of orexin-related biomarkers in plasma neuronally derived exosomes (exosome research).\\\", \\\"FootnoteText_31\\\": \\\"l Subjects to check in in the afternoon or evening of Day -2 at the latest. For Part B, subjects may need to check in on Day -3 evening time to start ABPM in the morning time of Day -2. Some\\\", \\\"FootnoteText_32\\\": \\\" of the assessments (eg. C-SSRS, alcohol, and drug screen) can be done at check-in time.\\\", \\\"FootnoteText_33\\\": \\\"m Day 18 study assessments may not be performed based on the emerging data from initial cohorts.\\\", \\\"Header\\\": [0, 1, 0]}, {\\\"Table\\\": \\\"<table border=\\\\\\\"1\\\\\\\" class=\\\\\\\"dataframe\\\\\\\">\\\\n  <thead>\\\\n    <tr style=\\\\\\\"text-align: right;\\\\\\\">\\\\n      <th></th>\\\\n      <th>1.0</th>\\\\n      <th>2.0</th>\\\\n      <th>3.0</th>\\\\n      <th>4.0</th>\\\\n      <th>5.0</th>\\\\n      <th>6.0</th>\\\\n      <th>7.0</th>\\\\n      <th>8.0</th>\\\\n      <th>9.0</th>\\\\n      <th>10.0</th>\\\\n      <th>11.0</th>\\\\n      <th>12.0</th>\\\\n      <th>13.0</th>\\\\n      <th>14.0</th>\\\\n      <th>15.0</th>\\\\n      <th>16.0</th>\\\\n      <th>17.0</th>\\\\n      <th>18.0</th>\\\\n      <th>19.0</th>\\\\n    </tr>\\\\n  </thead>\\\\n  <tbody>\\\\n    <tr>\\\\n      <th>0</th>\\\\n      <td>Procedure</td>\\\\n      <td>Predose</td>\\\\n      <td>Treatment Period</td>\\\\n      <td>Treatment Period</td>\\\\n      <td>Treatment Period</td>\\\\n      <td>Treatment Period</td>\\\\n      <td>Treatment Period</td>\\\\n      <td>Treatment Period</td>\\\\n      <td>Treatment Period</td>\\\\n      <td>Treatment Period</td>\\\\n      <td>Treatment Period</td>\\\\n      <td>Treatment Period</td>\\\\n      <td>Treatment Period</td>\\\\n      <td>Treatment Period</td>\\\\n      <td>Treatment Period</td>\\\\n      <td>Treatment Period</td>\\\\n      <td>Postdose/Follow-up</td>\\\\n      <td>Postdose/Follow-up</td>\\\\n      <td>Postdose/Follow-up</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>1</th>\\\\n      <td>Day</td>\\\\n      <td>-1</td>\\\\n      <td>1</td>\\\\n      <td>2</td>\\\\n      <td>3</td>\\\\n      <td>4</td>\\\\n      <td>5</td>\\\\n      <td>6</td>\\\\n      <td>7</td>\\\\n      <td>8</td>\\\\n      <td>9</td>\\\\n      <td>10</td>\\\\n      <td>11</td>\\\\n      <td>12</td>\\\\n      <td>13</td>\\\\n      <td>14-17</td>\\\\n      <td>18 <sup>a</sup></td>\\\\n      <td>ET</td>\\\\n      <td>21 (\\\\u00b12 days)</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>2</th>\\\\n      <td>Blood sample for TAK-861 PK</td>\\\\n      <td></td>\\\\n      <td>Pre and 0.25, 0.5, 1, 2, 3, 4, 6, 8, and 12 h Post</td>\\\\n      <td>24 h after Day 1  dose (must be collected before Day 2 dose)</td>\\\\n      <td></td>\\\\n      <td>Pre</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>Pre</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>Pre</td>\\\\n      <td></td>\\\\n      <td>Pre</td>\\\\n      <td>Pre and 0.25, 0.5, 1, 2, 3, 4, 6, 8 12, 24, 36, 48, and 72 h after Day 14 dose</td>\\\\n      <td>96 h after Day 14 dose</td>\\\\n      <td>X <sup>b</sup></td>\\\\n      <td></td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>3</th>\\\\n      <td>Blood sample for CYP3A4/5 activity</td>\\\\n      <td></td>\\\\n      <td>Pre</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>Pre</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>Predose on Day 14</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>4</th>\\\\n      <td>Blood sample for OATP1B1/3 activity, Part B only</td>\\\\n      <td></td>\\\\n      <td>Pre, 1, 2, 6, and 12 h</td>\\\\n      <td>Pre</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>Pre, 1, 2, 6, 12, 24 h after Day 14 dose</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>5</th>\\\\n      <td>Blood sample for plasma fluoride</td>\\\\n      <td></td>\\\\n      <td>Pre</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>2 and 12 h after Day 14 dose</td>\\\\n      <td>96 h after Day 14 dose</td>\\\\n      <td>X <sup>b</sup></td>\\\\n      <td></td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>6</th>\\\\n      <td>Urine sample for TAK-861 PK (selected cohorts only)</td>\\\\n      <td></td>\\\\n      <td>Spot: Pre Pooled: 0-6 and 6-12 h Post</td>\\\\n      <td>Pooled: 12-24 h after Day 1 dose</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>Pooled: 0-6, 6-12, and 12-24 h after Day 14 dose</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>7</th>\\\\n      <td>Supine BP and pulse rate measurements</td>\\\\n      <td>Approximately before morning dose time on Day 1 and 0.5, 1, 2, 3, 4, 6, 8, and 12 h later relative to initial measurement (matched to the time assessment schedule of Day 1)</td>\\\\n      <td>Pre and 0.5, 1, 2, 3, 4, 6, 8, and 12 h Post</td>\\\\n      <td>24 h after Day 1 dose</td>\\\\n      <td>Pre</td>\\\\n      <td>Pre</td>\\\\n      <td>Pre</td>\\\\n      <td>Pre</td>\\\\n      <td>Pre and 3, 6, and 12 h Post</td>\\\\n      <td>Pre</td>\\\\n      <td>Pre</td>\\\\n      <td>Pre</td>\\\\n      <td>Pre</td>\\\\n      <td>Pre</td>\\\\n      <td>Pre</td>\\\\n      <td>Pre and 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 36, 48, and 72 h after Day 14 dose</td>\\\\n      <td>96 h after Day 14 dose <sup>c</sup></td>\\\\n      <td>X <sup>c</sup></td>\\\\n      <td>X</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>8</th>\\\\n      <td>Orthostatic BP and pulse rate measurements</td>\\\\n      <td>X<sup> (relative Pre time)</sup></td>\\\\n      <td>Pre, 1, 2, and 6 h Post</td>\\\\n      <td>24 h Post</td>\\\\n      <td></td>\\\\n      <td>Pre</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>Pre</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>Pre</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>Pre, 1, 2, and 6 h after Day 14 dose</td>\\\\n      <td>96 h after Day 14 dose</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>9</th>\\\\n      <td>Respiratory rate</td>\\\\n      <td></td>\\\\n      <td>Pre and 1, 2, 4, and 6 h Post</td>\\\\n      <td>Pre</td>\\\\n      <td></td>\\\\n      <td>Pre</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>Pre</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>Pre</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>Pre dose on Day 14</td>\\\\n      <td>96 h after Day 14 dose</td>\\\\n      <td>X<sup> c</sup></td>\\\\n      <td>X</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>10</th>\\\\n      <td>Body temperature</td>\\\\n      <td></td>\\\\n      <td>Pre</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>Pre</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>Pre</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>Pre</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>Pre dose on Day 14</td>\\\\n      <td>96 h after Day 14 dose</td>\\\\n      <td>X<sup> c</sup></td>\\\\n      <td>X</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>11</th>\\\\n      <td>Standard 12-lead ECGs</td>\\\\n      <td>X</td>\\\\n      <td>Pre and 1, 2, 4, 6, and 12 h Post</td>\\\\n      <td>Pre</td>\\\\n      <td></td>\\\\n      <td>Pre</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>Pre</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>Pre</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>Pre dose on Day 14</td>\\\\n      <td>96 h after Day 14 dose</td>\\\\n      <td>X<sup> c</sup></td>\\\\n      <td>X</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>12</th>\\\\n      <td>KSS <sup>d</sup></td>\\\\n      <td>Pre (relative to planned Day 1 dose time) and 1, 2, 4, 8, 12, and 14 h relative to initial measurement</td>\\\\n      <td>16 and 24 h after initial  Day -1 measurement</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>Pre and 1, 2, 4, 8, 12, and 14 h Post</td>\\\\n      <td>16 and 24 h after Day 7 dose</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>Pre and 1, 2, 4, 8, 12, 16, and 24 h after Day 14 dose</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n    </tr>\\\\n  </tbody>\\\\n</table>\\\", \\\"SectionHeaderPrintPage\\\": \\\"26\\\", \\\"TableIndex\\\": \\\"23\\\", \\\"TableName\\\": \\\"Table 3.e Schedule of Study Procedures for Part B and Part C (MRD in Healthy Adults/Elderly)(Schedule of Assessment)\\\", \\\"AttachmentEntities\\\": [{\\\"content\\\": \\\"activity, Part B (see Table 3.f)\\\", \\\"entities\\\": []}, {\\\"content\\\": \\\"Blood sample for PK TAK-861 (See Table 3.f)\\\", \\\"entities\\\": []}, {\\\"content\\\": \\\"TAK-861 (See Table 3.f)\\\", \\\"entities\\\": []}], \\\"FootnoteText_0\\\": \\\" activity, Part B (see Table 3.f)\\\", \\\"FootnoteText_1\\\": \\\" Blood sample for PK TAK-861 (See Table 3.f)\\\", \\\"FootnoteText_2\\\": \\\" TAK-861 (See Table 3.f)\\\", \\\"Header\\\": [0, 1]}, {\\\"Table\\\": \\\"<table border=\\\\\\\"1\\\\\\\" class=\\\\\\\"dataframe\\\\\\\">\\\\n  <thead>\\\\n    <tr style=\\\\\\\"text-align: right;\\\\\\\">\\\\n      <th></th>\\\\n      <th>1.0</th>\\\\n      <th>2.0</th>\\\\n      <th>3.0</th>\\\\n      <th>4.0</th>\\\\n      <th>5.0</th>\\\\n      <th>6.0</th>\\\\n      <th>7.0</th>\\\\n      <th>8.0</th>\\\\n      <th>9.0</th>\\\\n      <th>10.0</th>\\\\n      <th>11.0</th>\\\\n      <th>12.0</th>\\\\n      <th>13.0</th>\\\\n      <th>14.0</th>\\\\n      <th>15.0</th>\\\\n      <th>16.0</th>\\\\n    </tr>\\\\n  </thead>\\\\n  <tbody>\\\\n    <tr>\\\\n      <th>0</th>\\\\n      <td>Day</td>\\\\n      <td>Screening -45 to -3</td>\\\\n      <td>Check-in/ Baseline -2</td>\\\\n      <td>Baseline -1</td>\\\\n      <td>1 Predose</td>\\\\n      <td>1 Postdose</td>\\\\n      <td>2</td>\\\\n      <td>3-5 Outpatient</td>\\\\n      <td>6</td>\\\\n      <td>7</td>\\\\n      <td>8-12 Outpatient</td>\\\\n      <td>13</td>\\\\n      <td>14</td>\\\\n      <td>15 Discharge</td>\\\\n      <td>ET</td>\\\\n      <td>Day 21 \\\\u00b12 Follow-up Visit</td>\\\\n    </tr>\\\\n  </tbody>\\\\n</table>\\\", \\\"SectionHeaderPrintPage\\\": \\\"31\\\", \\\"TableIndex\\\": \\\"25\\\", \\\"TableName\\\": \\\"Table 3.g Schedule of Study Procedures for Part D (Subjects With NT1)\\\", \\\"Header\\\": [0]}, {\\\"Table\\\": \\\"<table border=\\\\\\\"1\\\\\\\" class=\\\\\\\"dataframe\\\\\\\">\\\\n  <thead>\\\\n    <tr style=\\\\\\\"text-align: right;\\\\\\\">\\\\n      <th></th>\\\\n      <th>1.0</th>\\\\n      <th>2.0</th>\\\\n      <th>3.0</th>\\\\n      <th>4.0</th>\\\\n      <th>5.0</th>\\\\n      <th>6.0</th>\\\\n      <th>7.0</th>\\\\n      <th>8.0</th>\\\\n      <th>9.0</th>\\\\n      <th>10.0</th>\\\\n      <th>11.0</th>\\\\n      <th>12.0</th>\\\\n      <th>13.0</th>\\\\n      <th>14.0</th>\\\\n      <th>15.0</th>\\\\n      <th>16.0</th>\\\\n      <th>17.0</th>\\\\n      <th>18.0</th>\\\\n      <th>19.0</th>\\\\n      <th>20.0</th>\\\\n    </tr>\\\\n  </thead>\\\\n  <tbody>\\\\n    <tr>\\\\n      <th>0</th>\\\\n      <td>Procedures</td>\\\\n      <td>Predose</td>\\\\n      <td>Predose</td>\\\\n      <td>Dosing</td>\\\\n      <td>After First Dose and Before MRD Dosing</td>\\\\n      <td>After First Dose and Before MRD Dosing</td>\\\\n      <td>MRD Dosing</td>\\\\n      <td>MRD Dosing</td>\\\\n      <td>MRD Dosing</td>\\\\n      <td>MRD Dosing</td>\\\\n      <td>MRD Dosing</td>\\\\n      <td>MRD Dosing</td>\\\\n      <td>MRD Dosing</td>\\\\n      <td>MRD Dosing</td>\\\\n      <td>MRD Dosing</td>\\\\n      <td>MRD Dosing</td>\\\\n      <td>MRD Dosing</td>\\\\n      <td>Discharge/ ET</td>\\\\n      <td>Discharge/ ET</td>\\\\n      <td>Follow-up</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>1</th>\\\\n      <td>Day</td>\\\\n      <td>-1</td>\\\\n      <td>1</td>\\\\n      <td>1</td>\\\\n      <td>2-5</td>\\\\n      <td>6</td>\\\\n      <td>6</td>\\\\n      <td>7</td>\\\\n      <td>8</td>\\\\n      <td>9</td>\\\\n      <td>10-11</td>\\\\n      <td>12</td>\\\\n      <td>13-15</td>\\\\n      <td>16</td>\\\\n      <td>17</td>\\\\n      <td>18</td>\\\\n      <td>19-22</td>\\\\n      <td>23 <sup>b</sup></td>\\\\n      <td>E T</td>\\\\n      <td>26 (\\\\u00b12 days)</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>2</th>\\\\n      <td>Blood sample for TAK-861 PK</td>\\\\n      <td></td>\\\\n      <td>Pre</td>\\\\n      <td>0.25, 0.5, 1, 2, 3, 4, 6, 8, and 12 h Post</td>\\\\n      <td>24, 36, 48, 72, and 96 h after Day 1 dose</td>\\\\n      <td>120 h after Day 1 dose (before Day 6 dose)</td>\\\\n      <td>0.25, 0.5, 1, 2, 3, 4, 6, 8, and 12 h Post</td>\\\\n      <td>24 h after Day 6 dose</td>\\\\n      <td></td>\\\\n      <td>Pre</td>\\\\n      <td></td>\\\\n      <td>Pre</td>\\\\n      <td></td>\\\\n      <td>Pre</td>\\\\n      <td></td>\\\\n      <td>Pre</td>\\\\n      <td>Pre and 0.25, 0.5, 1, 2, 3, 4, 6, 8 12, 24, 36, 48, and 72 h after Day 19 dose</td>\\\\n      <td>96 h after Day 19 dose <sup>c</sup></td>\\\\n      <td>X <sup>a</sup></td>\\\\n      <td></td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>3</th>\\\\n      <td>Urine sample for TAK-861 PK</td>\\\\n      <td></td>\\\\n      <td>Spot: Pre</td>\\\\n      <td>Pooled: 0-6 and 6-12 h Post</td>\\\\n      <td>Pooled: 12-24, 24-48, 48-72, and 72-96 h after Day 1 dose</td>\\\\n      <td>Pooled: 96-120 h after Day 1 dose (or to before Day 6 dose)</td>\\\\n      <td>Pooled: 0-6 and 6-12 h Post</td>\\\\n      <td>Pooled: 12-24 h after Day 6 dose</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>Pooled: 0-6, 6-12, and 12-24 h after Day 19 dose</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>4</th>\\\\n      <td>Blood sample for OATP1B1/3 activity</td>\\\\n      <td></td>\\\\n      <td>Pre</td>\\\\n      <td>1, 2, 6, and 12 h</td>\\\\n      <td>Pre on Day 2</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>Pre, 1, 2, 6, 12, 24 h after Day 19 dose</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>5</th>\\\\n      <td>Blood sample for CYP3A4/5 activity</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>Pre</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>Pre</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>Pre</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>6</th>\\\\n      <td>Blood sample for plasma fluoride</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>Pre</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>2 and 12 h postdose</td>\\\\n      <td>72 h after Day 19 dose</td>\\\\n      <td>X <sup>a</sup></td>\\\\n      <td></td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>7</th>\\\\n      <td>BP and pulse rate measurements</td>\\\\n      <td>Approximately 0700 and then at 0.5, 1, 2, 3, 4, 6, 8, and 12 h later relative to the initial measurement (matched to the time assessment schedule of Day 1)</td>\\\\n      <td>Pre</td>\\\\n      <td>0.5, 1, 2, 3, 4, 6, 8, and 12 h Post</td>\\\\n      <td>24, 36, 48, 72 and 96 h after Day 1 dose</td>\\\\n      <td>Before Day 6 dose</td>\\\\n      <td>0.5, 1, 2, 3, 4, 6, 8, and 12 h Post</td>\\\\n      <td>24 h after Day 6 dose</td>\\\\n      <td>Pre</td>\\\\n      <td>Pre</td>\\\\n      <td>Pre</td>\\\\n      <td>Pre and 3, 6, and 12 h Post</td>\\\\n      <td>Pre</td>\\\\n      <td>Pre</td>\\\\n      <td>Pre</td>\\\\n      <td>Pre</td>\\\\n      <td>Pre and 0.5, 1, 2, 3, 4, 6, 8 12, 24, 36, 48, and 72 h after Day 19 dose</td>\\\\n      <td>96 h after Day 19 dose</td>\\\\n      <td>X <sup>c</sup></td>\\\\n      <td>X</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>8</th>\\\\n      <td>Orthostatic BP and pulse rate measurements</td>\\\\n      <td></td>\\\\n      <td>Pre</td>\\\\n      <td>1, 2, and 6 h Post</td>\\\\n      <td>24 h Post</td>\\\\n      <td>Pre</td>\\\\n      <td>1, 2, and 6 h Post</td>\\\\n      <td>24 h Post</td>\\\\n      <td></td>\\\\n      <td>Pre</td>\\\\n      <td></td>\\\\n      <td>Pre</td>\\\\n      <td></td>\\\\n      <td>Pre</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>Pre, 1, 2, and 6 h Post</td>\\\\n      <td>96 h after Day 19 dose</td>\\\\n      <td>X <sup>c</sup></td>\\\\n      <td></td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>9</th>\\\\n      <td>Respiratory rate</td>\\\\n      <td></td>\\\\n      <td>1 h Pre</td>\\\\n      <td>1, 2, 4, and 6 h Post</td>\\\\n      <td></td>\\\\n      <td>Pre</td>\\\\n      <td>1, 2, 4, and 6 h Post</td>\\\\n      <td>Pre</td>\\\\n      <td></td>\\\\n      <td>Pre</td>\\\\n      <td></td>\\\\n      <td>Pre</td>\\\\n      <td></td>\\\\n      <td>Pre</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>Pre</td>\\\\n      <td>96 h after Day 19 dose</td>\\\\n      <td>X<sup> c</sup></td>\\\\n      <td>X</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>10</th>\\\\n      <td>Body temperature</td>\\\\n      <td></td>\\\\n      <td>1 h Pre</td>\\\\n      <td>1, 2, 4, and 6 h Post</td>\\\\n      <td></td>\\\\n      <td>Pre</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>Pre</td>\\\\n      <td></td>\\\\n      <td>Pre</td>\\\\n      <td></td>\\\\n      <td>Pre</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>Pre</td>\\\\n      <td>96 h after Day 19 dose</td>\\\\n      <td>X<sup> c</sup></td>\\\\n      <td>X</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>11</th>\\\\n      <td>Standard 12-lead ECGs</td>\\\\n      <td>X</td>\\\\n      <td>Pre</td>\\\\n      <td>1, 2, 4, 6, and 12 h Post</td>\\\\n      <td>24 and 48 h Post</td>\\\\n      <td>Pre</td>\\\\n      <td>1, 2, 4, 6, and 12 h Post</td>\\\\n      <td>Pre</td>\\\\n      <td></td>\\\\n      <td>Pre</td>\\\\n      <td></td>\\\\n      <td>Pre</td>\\\\n      <td></td>\\\\n      <td>Pre</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>Pre</td>\\\\n      <td>96 h after Day 19 dose</td>\\\\n      <td>X<sup> c</sup></td>\\\\n      <td>X</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>12</th>\\\\n      <td>KSS <sup>d</sup></td>\\\\n      <td>Pre (relative to planned Day 1 dose time) and 1, 2, 4, 8, 12, 14, 16, and 24 h relative to initial measurement</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>Pre and 1, 2, 4, 8, 12, 14, 16, and 24 h Post</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n    </tr>\\\\n  </tbody>\\\\n</table>\\\", \\\"SectionHeaderPrintPage\\\": \\\"37\\\", \\\"TableIndex\\\": \\\"26\\\", \\\"TableName\\\": \\\"Table 3.i Schedule of Study Procedures for Part E: Non-Japanese Cohort\\\", \\\"AttachmentEntities\\\": [{\\\"content\\\": \\\"Administrative Procedures Informed consent X\\\", \\\"entities\\\": []}, {\\\"content\\\": \\\"Height, BMI calculation X\\\", \\\"entities\\\": []}, {\\\"content\\\": \\\"Vital signs (BP [ supine] , PR X\\\", \\\"entities\\\": []}, {\\\"content\\\": \\\"[ supine] , RR, and BT) a (see Table 3.j)\\\", \\\"entities\\\": []}, {\\\"content\\\": \\\"Orthostatic BP and rate b (see Table 3.j)\\\", \\\"entities\\\": []}, {\\\"content\\\": \\\"12-lead ECG standard (see X Table 3.j)\\\", \\\"entities\\\": []}, {\\\"content\\\": \\\"Laboratory Procedures/\\\", \\\"entities\\\": []}, {\\\"content\\\": \\\"Plasma fluoride (see Table 3.j)\\\", \\\"entities\\\": []}, {\\\"content\\\": \\\"FSH assessment (optional; for X\\\", \\\"entities\\\": []}, {\\\"content\\\": \\\"postmenopausal women) g\\\", \\\"entities\\\": []}, {\\\"content\\\": \\\"Hepatitis and HIV screen X\\\", \\\"entities\\\": []}, {\\\"content\\\": \\\"Blood for retained samples and X pharmacogenomics h\\\", \\\"entities\\\": []}, {\\\"content\\\": \\\"activity (see Table 3.j)\\\", \\\"entities\\\": []}, {\\\"content\\\": \\\"Blood samples for OATP1B1/3\\\", \\\"entities\\\": []}, {\\\"content\\\": \\\"Blood sample for PK TAK-861 (see Table 3.j)\\\", \\\"entities\\\": []}, {\\\"content\\\": \\\"Urine sample for PK TAK-861 (see Table 3.j)\\\", \\\"entities\\\": []}, {\\\"content\\\": \\\"ABPM: ambulatory blood pressure monitoring; AE: adverse event; BMI: body mass index; BP: blood pressure; BT: body temperature; C-SSRS: ColumbiaSuicide Severity Rating Scale; CYP:\\\", \\\"entities\\\": []}, {\\\"content\\\": \\\"cytochrome P450; ECG: electrocardiogram; ET: early termination; FSH: follicle-stimulating hormone; KSS: Karolinska Sleepiness Scale; NSF: National Sleep Foundation; OATP: organic anion\\\", \\\"entities\\\": [{\\\"start_idx\\\": 138, \\\"end_idx\\\": 162, \\\"standard_entity_name\\\": \\\"ANY: Organization\\\", \\\"subcategory\\\": \\\"ANY: Organization\\\", \\\"confidence\\\": 87.0, \\\"text\\\": \\\"National Sleep Foundation\\\"}, {\\\"start_idx\\\": 69, \\\"end_idx\\\": 96, \\\"standard_entity_name\\\": \\\"Molecule\\\", \\\"subcategory\\\": \\\"Molecule\\\", \\\"confidence\\\": 87.0, \\\"text\\\": \\\"follicle-stimulating hormone\\\"}]}, {\\\"content\\\": \\\"transporting polypeptide; PK: pharmacokinetic(s); PR: pulse rate; RR: respiratory rate.\\\", \\\"entities\\\": []}, {\\\"content\\\": \\\"a BP will be checked (single measurement) with the subject resting for a minimum of 5 minutes lying in a bed with the head of the bed at 30 degrees.\\\", \\\"entities\\\": []}, {\\\"content\\\": \\\"b Orthostatic BP and pulse rate will also be checked, with the subject standing for 1 minute and 5 minutes.\\\", \\\"entities\\\": []}, {\\\"content\\\": \\\"c T wenty-four hour ABPM starts on Days -2, 8, 11, 15 and 18 in the morning before dosing time of the day. Refer to Section 9.2.6 for further details.\\\", \\\"entities\\\": []}, {\\\"content\\\": \\\"d 12-lead, 24-h continuous Holter monitoring. Additional details may be found in the training manual.\\\", \\\"entities\\\": []}, {\\\"content\\\": \\\"e Drug will be administered as a single dose after an overnight fast of at least 10 h on Day 1, followed by a washout period through Day 5. On Day 6, study drug will be administered in the morning after a\\\", \\\"entities\\\": []}, {\\\"content\\\": \\\"fast of at least 10 h. Subjects will continue to fast for an additional 4 h after dosing on serial PK collection days or 2 h after dosing on nonintense PK collection days. Detailed guidance of drug administration\\\", \\\"entities\\\": []}, {\\\"content\\\": \\\"with diet and fluid requirements can be found in Section 7.4.1.\\\", \\\"entities\\\": []}, {\\\"content\\\": \\\"f Hematology (complete blood count) and blood chemistry on Day 1 will be done at 8 h postdose. On all other days, blood draws are predose or at the relative Day 1 predose time.\\\", \\\"entities\\\": []}, {\\\"content\\\": \\\"g FSH is mandatory for postmenopausal subjects.\\\", \\\"entities\\\": []}, {\\\"content\\\": \\\"h Blood samples for pharmacogenomics are collected before the initiation of study drug administration on Day 1. Will be performed once only in each subject during the study period.\\\", \\\"entities\\\": []}, {\\\"content\\\": \\\"i The exploratory assay may include exploratory assessment of OX-related biomarkers in the plasma (exosome research).\\\", \\\"entities\\\": []}, {\\\"content\\\": \\\"j Subjects may need to check in on Day -3 evening time to start ABPM in the morning time of Day -2.\\\", \\\"entities\\\": []}, {\\\"content\\\": \\\"k Day 23 study assessments may not be performed based on the emerging data from initial cohorts.\\\", \\\"entities\\\": []}], \\\"FootnoteText_0\\\": \\\" Administrative Procedures Informed consent X\\\", \\\"FootnoteText_1\\\": \\\" Height, BMI calculation X\\\", \\\"FootnoteText_2\\\": \\\" Vital signs (BP [ supine] , PR X\\\", \\\"FootnoteText_3\\\": \\\"[ supine] , RR, and BT) a (see Table 3.j)\\\", \\\"FootnoteText_4\\\": \\\" Orthostatic BP and rate b (see Table 3.j)\\\", \\\"FootnoteText_5\\\": \\\" 12-lead ECG standard (see X Table 3.j)\\\", \\\"FootnoteText_6\\\": \\\" Laboratory Procedures/\\\", \\\"FootnoteText_7\\\": \\\" Plasma fluoride (see Table 3.j)\\\", \\\"FootnoteText_8\\\": \\\" FSH assessment (optional; for X\\\", \\\"FootnoteText_9\\\": \\\" postmenopausal women) g\\\", \\\"FootnoteText_10\\\": \\\" Hepatitis and HIV screen X\\\", \\\"FootnoteText_11\\\": \\\" Blood for retained samples and X pharmacogenomics h\\\", \\\"FootnoteText_12\\\": \\\" activity (see Table 3.j)\\\", \\\"FootnoteText_13\\\": \\\" Blood samples for OATP1B1/3\\\", \\\"FootnoteText_14\\\": \\\" Blood sample for PK TAK-861 (see Table 3.j)\\\", \\\"FootnoteText_15\\\": \\\" Urine sample for PK TAK-861 (see Table 3.j)\\\", \\\"FootnoteText_16\\\": \\\" ABPM: ambulatory blood pressure monitoring; AE: adverse event; BMI: body mass index; BP: blood pressure; BT: body temperature; C-SSRS: ColumbiaSuicide Severity Rating Scale; CYP:\\\", \\\"FootnoteText_17\\\": \\\" cytochrome P450; ECG: electrocardiogram; ET: early termination; FSH: follicle-stimulating hormone; KSS: Karolinska Sleepiness Scale; NSF: National Sleep Foundation; OATP: organic anion\\\", \\\"FootnoteText_18\\\": \\\" transporting polypeptide; PK: pharmacokinetic(s); PR: pulse rate; RR: respiratory rate.\\\", \\\"FootnoteText_19\\\": \\\"a BP will be checked (single measurement) with the subject resting for a minimum of 5 minutes lying in a bed with the head of the bed at 30 degrees.\\\", \\\"FootnoteText_20\\\": \\\"b Orthostatic BP and pulse rate will also be checked, with the subject standing for 1 minute and 5 minutes.\\\", \\\"FootnoteText_21\\\": \\\"c T wenty-four hour ABPM starts on Days -2, 8, 11, 15 and 18 in the morning before dosing time of the day. Refer to Section 9.2.6 for further details.\\\", \\\"FootnoteText_22\\\": \\\"d 12-lead, 24-h continuous Holter monitoring. Additional details may be found in the training manual.\\\", \\\"FootnoteText_23\\\": \\\"e Drug will be administered as a single dose after an overnight fast of at least 10 h on Day 1, followed by a washout period through Day 5. On Day 6, study drug will be administered in the morning after a\\\", \\\"FootnoteText_24\\\": \\\" fast of at least 10 h. Subjects will continue to fast for an additional 4 h after dosing on serial PK collection days or 2 h after dosing on nonintense PK collection days. Detailed guidance of drug administration\\\", \\\"FootnoteText_25\\\": \\\" with diet and fluid requirements can be found in Section 7.4.1.\\\", \\\"FootnoteText_26\\\": \\\"f Hematology (complete blood count) and blood chemistry on Day 1 will be done at 8 h postdose. On all other days, blood draws are predose or at the relative Day 1 predose time.\\\", \\\"FootnoteText_27\\\": \\\"g FSH is mandatory for postmenopausal subjects.\\\", \\\"FootnoteText_28\\\": \\\"h Blood samples for pharmacogenomics are collected before the initiation of study drug administration on Day 1. Will be performed once only in each subject during the study period.\\\", \\\"FootnoteText_29\\\": \\\"i The exploratory assay may include exploratory assessment of OX-related biomarkers in the plasma (exosome research).\\\", \\\"FootnoteText_30\\\": \\\"j Subjects may need to check in on Day -3 evening time to start ABPM in the morning time of Day -2.\\\", \\\"FootnoteText_31\\\": \\\"k Day 23 study assessments may not be performed based on the emerging data from initial cohorts.\\\", \\\"Header\\\": [0, 1]}, {\\\"Table\\\": \\\"<table border=\\\\\\\"1\\\\\\\" class=\\\\\\\"dataframe\\\\\\\">\\\\n  <thead>\\\\n    <tr style=\\\\\\\"text-align: right;\\\\\\\">\\\\n      <th></th>\\\\n      <th>1.0</th>\\\\n      <th>2.0</th>\\\\n      <th>3.0</th>\\\\n      <th>4.0</th>\\\\n      <th>5.0</th>\\\\n      <th>6.0</th>\\\\n      <th>7.0</th>\\\\n      <th>8.0</th>\\\\n      <th>9.0</th>\\\\n      <th>10.0</th>\\\\n      <th>11.0</th>\\\\n      <th>12.0</th>\\\\n      <th>13.0</th>\\\\n      <th>14.0</th>\\\\n      <th>15.0</th>\\\\n      <th>16.0</th>\\\\n      <th>17.0</th>\\\\n      <th>18.0</th>\\\\n    </tr>\\\\n  </thead>\\\\n  <tbody>\\\\n    <tr>\\\\n      <th>0</th>\\\\n      <td>Day</td>\\\\n      <td>Screening Days -35 to -2</td>\\\\n      <td>Baseline Day -1</td>\\\\n      <td>Day 1 Pre</td>\\\\n      <td>Day 1</td>\\\\n      <td>Day 2</td>\\\\n      <td>Day 3</td>\\\\n      <td>Day 4</td>\\\\n      <td>Day 5</td>\\\\n      <td>Day 6</td>\\\\n      <td>Day 7</td>\\\\n      <td>Day 8</td>\\\\n      <td>Day 9</td>\\\\n      <td>Day 10</td>\\\\n      <td>Day 11</td>\\\\n      <td>Day 12 -13</td>\\\\n      <td>Day 14 Discharge/ ET <sup>j</sup></td>\\\\n      <td>Day 17\\\\u00b12 Follow-up Visit</td>\\\\n    </tr>\\\\n  </tbody>\\\\n</table>\\\", \\\"SectionHeaderPrintPage\\\": \\\"42\\\", \\\"TableIndex\\\": \\\"28\\\", \\\"TableName\\\": \\\"Table 3.k Schedule of Study Procedures for Part F: CSF Cohorts\\\", \\\"Header\\\": [0]}, {\\\"Table\\\": \\\"<table border=\\\\\\\"1\\\\\\\" class=\\\\\\\"dataframe\\\\\\\">\\\\n  <thead>\\\\n    <tr style=\\\\\\\"text-align: right;\\\\\\\">\\\\n      <th></th>\\\\n      <th>1.0</th>\\\\n      <th>2.0</th>\\\\n      <th>3.0</th>\\\\n      <th>4.0</th>\\\\n      <th>5.0</th>\\\\n      <th>6.0</th>\\\\n      <th>7.0</th>\\\\n      <th>8.0</th>\\\\n      <th>9.0</th>\\\\n      <th>10.0</th>\\\\n      <th>11.0</th>\\\\n      <th>12.0</th>\\\\n      <th>13.0</th>\\\\n    </tr>\\\\n  </thead>\\\\n  <tbody>\\\\n    <tr>\\\\n      <th>0</th>\\\\n      <td>Procedures</td>\\\\n      <td>Baseline</td>\\\\n      <td>Treatment Period</td>\\\\n      <td>Treatment Period</td>\\\\n      <td>Treatment Period</td>\\\\n      <td>Treatment Period</td>\\\\n      <td>Treatment Period</td>\\\\n      <td>Treatment Period</td>\\\\n      <td>Treatment Period</td>\\\\n      <td>Treatment Period</td>\\\\n      <td>Postdose/Follow-up</td>\\\\n      <td>Postdose/Follow-up</td>\\\\n      <td>Postdose/Follow-up</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>1</th>\\\\n      <td>Day</td>\\\\n      <td>-1</td>\\\\n      <td>1</td>\\\\n      <td>2</td>\\\\n      <td>3</td>\\\\n      <td>4</td>\\\\n      <td>5-6</td>\\\\n      <td>7</td>\\\\n      <td>8-9</td>\\\\n      <td>10-13</td>\\\\n      <td>14 <sup>c</sup></td>\\\\n      <td>ET</td>\\\\n      <td>17 (\\\\u00b12 days)</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>2</th>\\\\n      <td>Blood sample for TAK-861 PK</td>\\\\n      <td></td>\\\\n      <td>Pre and 0.25, 0.5, 1, 2, 3, 4, 6, 8, and 12 h Post</td>\\\\n      <td>24 h after Day 1 dose</td>\\\\n      <td></td>\\\\n      <td>Pre</td>\\\\n      <td></td>\\\\n      <td>Pre</td>\\\\n      <td></td>\\\\n      <td>Pre on Day 10 and 0.25, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 36, 48, and 72 h after last dose</td>\\\\n      <td>96 h after last dose</td>\\\\n      <td>X <sup>a</sup></td>\\\\n      <td></td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>3</th>\\\\n      <td><span class=\\\\\\\"redact\\\\\\\"> ~REDACTED~ </span>  sample for TAK-861 PK</td>\\\\n      <td>X<sup> (relative 1 hour postdose time when Day 10 dose may happen)</sup></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>Pre on Day 10 and 1, 2, 4, 8, 12, 16, 20, and 24 h after last dose</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>4</th>\\\\n      <td>CSF sample for TAK-861 orexin levels</td>\\\\n      <td>X<sup> (relative 1 hour postdose time when Day 10 dose may happen)</sup></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>Pre on Day 10 and 1, 2, 4, 8, 12, 16, 20, and 24 h after last dose</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>5</th>\\\\n      <td>Supine BP and supine pulse rate measurements</td>\\\\n      <td>Approximately before morning dose on Day 1 and 0.5, 1, 2, 3, 4, 6, 8, and 12 h later relative to initial measurement (matched to the time assessment schedule of Day 1)</td>\\\\n      <td>Pre and 0.5, 1, 2, 3, 4, 6, 8, and 12 h Post</td>\\\\n      <td>24 h after Day 1 dose</td>\\\\n      <td>Pre</td>\\\\n      <td>Pre</td>\\\\n      <td>Pre</td>\\\\n      <td>Pre and 3, 6, and 12 h Post</td>\\\\n      <td>Pre</td>\\\\n      <td>Pre and 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 36, 48, and 72 h after last dose</td>\\\\n      <td>96 h after last dose</td>\\\\n      <td>X <sup>b</sup></td>\\\\n      <td>X</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>6</th>\\\\n      <td>Standing Orthostatic BP and pulse rate measurements</td>\\\\n      <td>X<sup> (relative Pre)</sup></td>\\\\n      <td>Pre, 1, 2, and 6 h Post</td>\\\\n      <td>24 h after Day 1 dose</td>\\\\n      <td></td>\\\\n      <td>Pre</td>\\\\n      <td></td>\\\\n      <td>Pre</td>\\\\n      <td></td>\\\\n      <td>Pre, 1, 2, and 6 h Post</td>\\\\n      <td>96 h after last dose</td>\\\\n      <td>X <sup>b</sup></td>\\\\n      <td></td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>7</th>\\\\n      <td>Respiratory rate</td>\\\\n      <td></td>\\\\n      <td>Pre and 1, 2, 4, and 6 h Post</td>\\\\n      <td>Pre</td>\\\\n      <td></td>\\\\n      <td>Pre</td>\\\\n      <td></td>\\\\n      <td>Pre</td>\\\\n      <td></td>\\\\n      <td>Pre</td>\\\\n      <td>96 h after last dose</td>\\\\n      <td>X <sup>b</sup></td>\\\\n      <td>X</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>8</th>\\\\n      <td>Body temperature</td>\\\\n      <td></td>\\\\n      <td>Pre</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>Pre</td>\\\\n      <td></td>\\\\n      <td>Pre</td>\\\\n      <td></td>\\\\n      <td>Pre</td>\\\\n      <td>96 h after last dose <sup>c</sup></td>\\\\n      <td>X <sup>b</sup></td>\\\\n      <td>X</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>9</th>\\\\n      <td>Standard 12-lead ECGs</td>\\\\n      <td>X</td>\\\\n      <td>Pre and 1, 2, 4, 6, and 12 h Post</td>\\\\n      <td>Pre</td>\\\\n      <td></td>\\\\n      <td>Pre</td>\\\\n      <td></td>\\\\n      <td>Pre</td>\\\\n      <td></td>\\\\n      <td>Pre</td>\\\\n      <td>96 h after last dose <sup>c</sup></td>\\\\n      <td>X <sup>b</sup></td>\\\\n      <td>X</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>10</th>\\\\n      <td>KSS</td>\\\\n      <td>Pre (relative to planned Day 1 dose) and 1, 2, 4, 8, 12, 14 and 15, 16, 24 h relative to initial measurement <sup>d</sup></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>Pre and 1, 2, 4, 8, 12, 14, 15, 16, and 24 h Post</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n    </tr>\\\\n  </tbody>\\\\n</table>\\\", \\\"SectionHeaderPrintPage\\\": \\\"42\\\", \\\"TableIndex\\\": \\\"29\\\", \\\"TableName\\\": \\\"Table 3.k Schedule of Study Procedures for Part F: CSF Cohorts(Schedule of Assessment)\\\", \\\"AttachmentEntities\\\": [{\\\"content\\\": \\\"Administrative Procedures Informed consent X\\\", \\\"entities\\\": []}, {\\\"content\\\": \\\"medication review (continuous review)\\\", \\\"entities\\\": []}, {\\\"content\\\": \\\"Procedures/Assessments\\\", \\\"entities\\\": []}, {\\\"content\\\": \\\"Height, BMI calculation X\\\", \\\"entities\\\": []}, {\\\"content\\\": \\\"Vital signs a, b (see Table 3.l) X\\\", \\\"entities\\\": []}, {\\\"content\\\": \\\"12-lead ECG standard (See X Table 3.l)\\\", \\\"entities\\\": []}, {\\\"content\\\": \\\"(continuous monitoring)\\\", \\\"entities\\\": []}, {\\\"content\\\": \\\"Laboratory Procedures/\\\", \\\"entities\\\": []}, {\\\"content\\\": \\\"count) and blood chemistry e FSH assessment f X\\\", \\\"entities\\\": []}, {\\\"content\\\": \\\"Hepatitis and HIV screen X\\\", \\\"entities\\\": []}, {\\\"content\\\": \\\"Blood for retained samples and X pharmacogenomics g\\\", \\\"entities\\\": []}, {\\\"content\\\": \\\"Blood sample for PK TAK-861 (See Table 3.l)\\\", \\\"entities\\\": []}, {\\\"content\\\": \\\"CSF sample for PK and OX (see Table 3.l)\\\", \\\"entities\\\": [{\\\"start_idx\\\": 0, \\\"end_idx\\\": 2, \\\"standard_entity_name\\\": \\\"Molecule\\\", \\\"subcategory\\\": \\\"Molecule\\\", \\\"confidence\\\": 37.0, \\\"text\\\": \\\"CSF\\\"}]}, {\\\"content\\\": \\\"ESS (only for determining X eligibility)\\\", \\\"entities\\\": []}, {\\\"content\\\": \\\"AE: adverse event; aPTT: activated partial thromboplastin time; BMI: body mass index; BP: blood pressure; CSF: cerebrospinal fluid; C-SSRS: ColumbiaSuicide\\\", \\\"entities\\\": [{\\\"start_idx\\\": 106, \\\"end_idx\\\": 108, \\\"standard_entity_name\\\": \\\"Molecule\\\", \\\"subcategory\\\": \\\"Molecule\\\", \\\"confidence\\\": 37.0, \\\"text\\\": \\\"CSF\\\"}]}, {\\\"content\\\": \\\"Severity Rating Scale; ECG: electrocardiogram; ESS: Epworth Sleepiness Scale; ET: early termination; FSH: follicle-stimulating hormone; INR: international\\\", \\\"entities\\\": [{\\\"start_idx\\\": 106, \\\"end_idx\\\": 133, \\\"standard_entity_name\\\": \\\"Molecule\\\", \\\"subcategory\\\": \\\"Molecule\\\", \\\"confidence\\\": 87.0, \\\"text\\\": \\\"follicle-stimulating hormone\\\"}]}, {\\\"content\\\": \\\"normalized ratio; KSS: Karolinska Sleepiness Scale; NSF: National Sleep Foundation; PK: pharmacokinetic(s); PT: prothrombin time.\\\", \\\"entities\\\": [{\\\"start_idx\\\": 57, \\\"end_idx\\\": 81, \\\"standard_entity_name\\\": \\\"ANY: Organization\\\", \\\"subcategory\\\": \\\"ANY: Organization\\\", \\\"confidence\\\": 87.0, \\\"text\\\": \\\"National Sleep Foundation\\\"}]}, {\\\"content\\\": \\\"a BP will be checked (single measurement) with the subject resting for a minimum of 5 minutes lying in a bed with the head of the bed at 30 degrees.\\\", \\\"entities\\\": []}, {\\\"content\\\": \\\"b Orthostatic BP and pulse rate will also be checked, with the subject standing for 1 minute and 5 minutes.\\\", \\\"entities\\\": []}, {\\\"content\\\": \\\"c Subject will start recording sleep diary and start wearing accelerometry on Day -11 and subject will continue wearing accelerometry until discharge. Additional subject behavior\\\", \\\"entities\\\": []}, {\\\"content\\\": \\\"information collecting system may be also collected during Day -11 through discharge.\\\", \\\"entities\\\": []}, {\\\"content\\\": \\\"d Drug will be administered as a single dose after an overnight fast of at least 10 h. Subjects will continue to fast for an additional 4 h after dosing on serial PK collection days or 2 h\\\", \\\"entities\\\": []}, {\\\"content\\\": \\\"after dosing on nonintense PK collection days. Detailed guidance of drug administration with diet and fluid requirements can be found in Section 7.4.1.\\\", \\\"entities\\\": []}, {\\\"content\\\": \\\"e Hematology (complete blood count) and blood chemistry on Day 1 will be done at 8 h postdose. On all other days, blood draws are predose or at the relative Day 1 predose time.\\\", \\\"entities\\\": []}, {\\\"content\\\": \\\"f FSH is mandatory for postmenopausal subjects.\\\", \\\"entities\\\": []}, {\\\"content\\\": \\\"g Blood samples for pharmacogenomics are collected before the initiation of study drug administration on Day1. Will be performed once only in each subject during the study period.\\\", \\\"entities\\\": []}, {\\\"content\\\": \\\"h The exploratory assay may include exploratory assessment of OX-related biomarkers in plasma neuronally derived exosomes (exosome research).\\\", \\\"entities\\\": []}, {\\\"content\\\": \\\"i Subjects to check in in the afternoon or evening of Day -2 at the latest.\\\", \\\"entities\\\": []}, {\\\"content\\\": \\\"j Day 12 study assessments may not be performed based on the emerging data from initial cohorts.\\\", \\\"entities\\\": []}, {\\\"content\\\": \\\"6, 8, and 12 h 36, 48, and 72 h after last Post dose\\\", \\\"entities\\\": []}, {\\\"content\\\": \\\"initial measurement (matched to Post\\\", \\\"entities\\\": []}, {\\\"content\\\": \\\"the time assessment schedule of Day 1)\\\", \\\"entities\\\": []}, {\\\"content\\\": \\\"temperature last dose c\\\", \\\"entities\\\": []}, {\\\"content\\\": \\\"dose) and 1, 2, 4, 8, 12, 14 and 15, 16, and 24 h Post\\\", \\\"entities\\\": []}, {\\\"content\\\": \\\"15, 16, 24 h relative to initial measurement d\\\", \\\"entities\\\": []}, {\\\"content\\\": \\\"BP: blood pressure; CSF: cerebrospinal fluid; ECG: electrocardiogram; KSS: Karolinska Sleepiness Scale; MRD: multiple-rising dose; PK: pharmacokinetic(s); Post: postdose; Pre: predose.\\\", \\\"entities\\\": [{\\\"start_idx\\\": 20, \\\"end_idx\\\": 22, \\\"standard_entity_name\\\": \\\"Molecule\\\", \\\"subcategory\\\": \\\"Molecule\\\", \\\"confidence\\\": 37.0, \\\"text\\\": \\\"CSF\\\"}]}, {\\\"content\\\": \\\"a At ET, blood sample to be collected at the time of subject discontinuation (before discharge).\\\", \\\"entities\\\": []}, {\\\"content\\\": \\\"b ET assessment to be conducted before discharge.\\\", \\\"entities\\\": []}, {\\\"content\\\": \\\"c All or some of the Day 14 study assessments may not be performed based on the emerging data from initial cohorts.\\\", \\\"entities\\\": []}, {\\\"content\\\": \\\"d If subject is sleeping, please refer to Section 9.3.2.9 regarding how to rate KSS.\\\", \\\"entities\\\": []}], \\\"FootnoteText_0\\\": \\\" Administrative Procedures Informed consent X\\\", \\\"FootnoteText_1\\\": \\\" medication review (continuous review)\\\", \\\"FootnoteText_2\\\": \\\" Procedures/Assessments\\\", \\\"FootnoteText_3\\\": \\\" Height, BMI calculation X\\\", \\\"FootnoteText_4\\\": \\\" Vital signs a, b (see Table 3.l) X\\\", \\\"FootnoteText_5\\\": \\\" 12-lead ECG standard (See X Table 3.l)\\\", \\\"FootnoteText_6\\\": \\\" (continuous monitoring)\\\", \\\"FootnoteText_7\\\": \\\" Laboratory Procedures/\\\", \\\"FootnoteText_8\\\": \\\" count) and blood chemistry e FSH assessment f X\\\", \\\"FootnoteText_9\\\": \\\" Hepatitis and HIV screen X\\\", \\\"FootnoteText_10\\\": \\\" Blood for retained samples and X pharmacogenomics g\\\", \\\"FootnoteText_11\\\": \\\" Blood sample for PK TAK-861 (See Table 3.l)\\\", \\\"FootnoteText_12\\\": \\\" CSF sample for PK and OX (see Table 3.l)\\\", \\\"FootnoteText_13\\\": \\\" ESS (only for determining X eligibility)\\\", \\\"FootnoteText_14\\\": \\\" AE: adverse event; aPTT: activated partial thromboplastin time; BMI: body mass index; BP: blood pressure; CSF: cerebrospinal fluid; C-SSRS: ColumbiaSuicide\\\", \\\"FootnoteText_15\\\": \\\" Severity Rating Scale; ECG: electrocardiogram; ESS: Epworth Sleepiness Scale; ET: early termination; FSH: follicle-stimulating hormone; INR: international\\\", \\\"FootnoteText_16\\\": \\\" normalized ratio; KSS: Karolinska Sleepiness Scale; NSF: National Sleep Foundation; PK: pharmacokinetic(s); PT: prothrombin time.\\\", \\\"FootnoteText_17\\\": \\\"a BP will be checked (single measurement) with the subject resting for a minimum of 5 minutes lying in a bed with the head of the bed at 30 degrees.\\\", \\\"FootnoteText_18\\\": \\\"b Orthostatic BP and pulse rate will also be checked, with the subject standing for 1 minute and 5 minutes.\\\", \\\"FootnoteText_19\\\": \\\"c Subject will start recording sleep diary and start wearing accelerometry on Day -11 and subject will continue wearing accelerometry until discharge. Additional subject behavior\\\", \\\"FootnoteText_20\\\": \\\" information collecting system may be also collected during Day -11 through discharge.\\\", \\\"FootnoteText_21\\\": \\\"d Drug will be administered as a single dose after an overnight fast of at least 10 h. Subjects will continue to fast for an additional 4 h after dosing on serial PK collection days or 2 h\\\", \\\"FootnoteText_22\\\": \\\" after dosing on nonintense PK collection days. Detailed guidance of drug administration with diet and fluid requirements can be found in Section 7.4.1.\\\", \\\"FootnoteText_23\\\": \\\"e Hematology (complete blood count) and blood chemistry on Day 1 will be done at 8 h postdose. On all other days, blood draws are predose or at the relative Day 1 predose time.\\\", \\\"FootnoteText_24\\\": \\\"f FSH is mandatory for postmenopausal subjects.\\\", \\\"FootnoteText_25\\\": \\\"g Blood samples for pharmacogenomics are collected before the initiation of study drug administration on Day1. Will be performed once only in each subject during the study period.\\\", \\\"FootnoteText_26\\\": \\\"h The exploratory assay may include exploratory assessment of OX-related biomarkers in plasma neuronally derived exosomes (exosome research).\\\", \\\"FootnoteText_27\\\": \\\"i Subjects to check in in the afternoon or evening of Day -2 at the latest.\\\", \\\"FootnoteText_28\\\": \\\"j Day 12 study assessments may not be performed based on the emerging data from initial cohorts.\\\", \\\"FootnoteText_29\\\": \\\" 6, 8, and 12 h 36, 48, and 72 h after last Post dose\\\", \\\"FootnoteText_30\\\": \\\" initial measurement (matched to Post\\\", \\\"FootnoteText_31\\\": \\\" the time assessment schedule of Day 1)\\\", \\\"FootnoteText_32\\\": \\\" temperature last dose c\\\", \\\"FootnoteText_33\\\": \\\" dose) and 1, 2, 4, 8, 12, 14 and 15, 16, and 24 h Post\\\", \\\"FootnoteText_34\\\": \\\" 15, 16, 24 h relative to initial measurement d\\\", \\\"FootnoteText_35\\\": \\\" BP: blood pressure; CSF: cerebrospinal fluid; ECG: electrocardiogram; KSS: Karolinska Sleepiness Scale; MRD: multiple-rising dose; PK: pharmacokinetic(s); Post: postdose; Pre: predose.\\\", \\\"FootnoteText_36\\\": \\\"a At ET, blood sample to be collected at the time of subject discontinuation (before discharge).\\\", \\\"FootnoteText_37\\\": \\\"b ET assessment to be conducted before discharge.\\\", \\\"FootnoteText_38\\\": \\\"c All or some of the Day 14 study assessments may not be performed based on the emerging data from initial cohorts.\\\", \\\"FootnoteText_39\\\": \\\"d If subject is sleeping, please refer to Section 9.3.2.9 regarding how to rate KSS.\\\", \\\"Header\\\": [0, 1]}, {\\\"Table\\\": \\\"<table border=\\\\\\\"1\\\\\\\" class=\\\\\\\"dataframe\\\\\\\">\\\\n  <thead>\\\\n    <tr style=\\\\\\\"text-align: right;\\\\\\\">\\\\n      <th></th>\\\\n      <th>1.0</th>\\\\n      <th>2.0</th>\\\\n      <th>3.0</th>\\\\n      <th>4.0</th>\\\\n      <th>5.0</th>\\\\n    </tr>\\\\n  </thead>\\\\n  <tbody>\\\\n    <tr>\\\\n      <th>0</th>\\\\n      <td>Screening Periods</td>\\\\n      <td>Check-in and Baseline</td>\\\\n      <td>Treatment Period</td>\\\\n      <td>Treatment Period</td>\\\\n      <td>Follow-up Visit</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>1</th>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>Dose</td>\\\\n      <td>Sample Collection</td>\\\\n      <td></td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>2</th>\\\\n      <td>Days -28 to -2</td>\\\\n      <td>Day -2 to -1 Study assessments</td>\\\\n      <td>Day 1 Study drug administration</td>\\\\n      <td>Days 1 to 6 Study assessments</td>\\\\n      <td>Day 9\\\\u00b12 days</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>3</th>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>Confinement</td>\\\\n      <td>Confinement</td>\\\\n      <td></td>\\\\n    </tr>\\\\n  </tbody>\\\\n</table>\\\", \\\"SectionHeaderPrintPage\\\": \\\"60\\\", \\\"TableIndex\\\": \\\"32\\\", \\\"TableName\\\": \\\"Table 6.a Study Schedule: Part A\\\", \\\"Header\\\": [0, 1]}, {\\\"Table\\\": \\\"<table border=\\\\\\\"1\\\\\\\" class=\\\\\\\"dataframe\\\\\\\">\\\\n  <thead>\\\\n    <tr style=\\\\\\\"text-align: right;\\\\\\\">\\\\n      <th></th>\\\\n      <th>1.0</th>\\\\n      <th>2.0</th>\\\\n      <th>3.0</th>\\\\n      <th>4.0</th>\\\\n      <th>5.0</th>\\\\n      <th>6.0</th>\\\\n      <th>7.0</th>\\\\n      <th>8.0</th>\\\\n      <th>9.0</th>\\\\n    </tr>\\\\n  </thead>\\\\n  <tbody>\\\\n    <tr>\\\\n      <th>0</th>\\\\n      <td>Screening Period</td>\\\\n      <td>Check-in and Baseline</td>\\\\n      <td>Treatment Period 1 (Fasted)</td>\\\\n      <td>Treatment Period 1 (Fasted)</td>\\\\n      <td>Washout</td>\\\\n      <td>Check-in</td>\\\\n      <td>Treatment Period 2 (Fed)</td>\\\\n      <td>Treatment Period 2 (Fed)</td>\\\\n      <td>Follow-up Visit</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>1</th>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>Dose</td>\\\\n      <td>Sample Collection</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>Dose</td>\\\\n      <td>Sample Collection</td>\\\\n      <td></td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>2</th>\\\\n      <td>Days -28 to -2</td>\\\\n      <td>Days -2 to -1 Study assessments</td>\\\\n      <td>Day 1 Study drug administration</td>\\\\n      <td>Days 1 to 6 Study assessments</td>\\\\n      <td>7 day \\\\u00b12 days</td>\\\\n      <td>Day 14 Study assessments</td>\\\\n      <td>Day 15 Study drug administration</td>\\\\n      <td>Day 15 to 20 Study assessments</td>\\\\n      <td>Day 23\\\\u00b12 days</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>3</th>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>Confinement</td>\\\\n      <td>Confinement</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>Confinement</td>\\\\n      <td>Confinement</td>\\\\n      <td></td>\\\\n    </tr>\\\\n  </tbody>\\\\n</table>\\\", \\\"SectionHeaderPrintPage\\\": \\\"60\\\", \\\"TableIndex\\\": \\\"33\\\", \\\"TableName\\\": \\\"Table 6.b Study Schedule: Part A (Food Effect Cohorts)\\\", \\\"Header\\\": [0, 1]}, {\\\"Table\\\": \\\"<table border=\\\\\\\"1\\\\\\\" class=\\\\\\\"dataframe\\\\\\\">\\\\n  <thead>\\\\n    <tr style=\\\\\\\"text-align: right;\\\\\\\">\\\\n      <th></th>\\\\n      <th>1.0</th>\\\\n      <th>2.0</th>\\\\n      <th>3.0</th>\\\\n      <th>4.0</th>\\\\n      <th>5.0</th>\\\\n    </tr>\\\\n  </thead>\\\\n  <tbody>\\\\n    <tr>\\\\n      <th>0</th>\\\\n      <td>Screening Period</td>\\\\n      <td>Check-in and Baseline</td>\\\\n      <td>Treatment Period</td>\\\\n      <td>Treatment Period</td>\\\\n      <td>Follow-up Visit</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>1</th>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>Dosing</td>\\\\n      <td>Sample Collection</td>\\\\n      <td></td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>2</th>\\\\n      <td>Days -28 to -2</td>\\\\n      <td>Days -2 to -1 Study assessments</td>\\\\n      <td>Day 1 to 14 Study drug administration (Dosing frequency once daily)</td>\\\\n      <td>Day 1 to 18 Study assessments</td>\\\\n      <td>Day 21\\\\u00b12 days</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>3</th>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>Confinement</td>\\\\n      <td>Confinement</td>\\\\n      <td></td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>4</th>\\\\n      <td>Days -45 to -3</td>\\\\n      <td>Days -2 to -1 Study assessments</td>\\\\n      <td>Day 1 to Day 14 Study drug administration</td>\\\\n      <td>Day 1 to 15 Study assessments</td>\\\\n      <td>Day 21\\\\u00b12 days</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>5</th>\\\\n      <td></td>\\\\n      <td>Confinement or outpatient per Schedule of Study Procedures</td>\\\\n      <td>Confinement or outpatient per Schedule of Study Procedures</td>\\\\n      <td>Confinement or outpatient per Schedule of Study Procedures</td>\\\\n      <td></td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>6</th>\\\\n      <td>Days -35 to -2</td>\\\\n      <td>Days -2 to -1 Study assessments</td>\\\\n      <td>Day 1; Days 6 to 19 (Dosing frequency once daily)</td>\\\\n      <td>Days 1 to 23 Study assessments</td>\\\\n      <td>Day 26\\\\u00b12 days</td>\\\\n    </tr>\\\\n  </tbody>\\\\n</table>\\\", \\\"SectionHeaderPrintPage\\\": \\\"61\\\", \\\"TableIndex\\\": \\\"34\\\", \\\"TableName\\\": \\\"Table 6.c Study Schedule: Part B and Part C\\\", \\\"Header\\\": [0, 1]}, {\\\"Table\\\": \\\"<table border=\\\\\\\"1\\\\\\\" class=\\\\\\\"dataframe\\\\\\\">\\\\n  <thead>\\\\n    <tr style=\\\\\\\"text-align: right;\\\\\\\">\\\\n      <th></th>\\\\n      <th>1.0</th>\\\\n      <th>2.0</th>\\\\n      <th>3.0</th>\\\\n      <th>4.0</th>\\\\n      <th>5.0</th>\\\\n    </tr>\\\\n  </thead>\\\\n  <tbody>\\\\n    <tr>\\\\n      <th>0</th>\\\\n      <td>Screening Period</td>\\\\n      <td>Check-in and Baseline</td>\\\\n      <td>Treatment Period  Dosing  Sample Collection</td>\\\\n      <td>Treatment Period  Dosing  Sample Collection</td>\\\\n      <td>Follow-up Visit</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>1</th>\\\\n      <td>Days -35 to -2</td>\\\\n      <td>Days -2 to -1 Study assessments</td>\\\\n      <td>Days 1 to 10 Study drug administration (Dosing frequency once daily)</td>\\\\n      <td>Days 1 to 14 Study assessments</td>\\\\n      <td>Day 17\\\\u00b12 days</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>2</th>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>Confinement</td>\\\\n      <td>Confinement</td>\\\\n      <td></td>\\\\n    </tr>\\\\n  </tbody>\\\\n</table>\\\", \\\"SectionHeaderPrintPage\\\": \\\"64\\\", \\\"TableIndex\\\": \\\"37\\\", \\\"TableName\\\": \\\"Table 6.f Study Schedule: Part F, CSF Cohort\\\", \\\"Header\\\": [0]}], 5]\""}